<SEC-DOCUMENT>0001520138-24-000324.txt : 20240930
<SEC-HEADER>0001520138-24-000324.hdr.sgml : 20240930
<ACCEPTANCE-DATETIME>20240930170837
ACCESSION NUMBER:		0001520138-24-000324
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		80
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240930
DATE AS OF CHANGE:		20240930

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOVIE INC.
		CENTRAL INDEX KEY:			0001580149
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				462510769
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39015
		FILM NUMBER:		241340317

	BUSINESS ADDRESS:	
		STREET 1:		680 W NYE LANE
		STREET 2:		SUITE 201
		CITY:			CARSON CITY
		STATE:			NV
		ZIP:			89703
		BUSINESS PHONE:		775-888-3162

	MAIL ADDRESS:	
		STREET 1:		680 W NYE LANE
		STREET 2:		SUITE 201
		CITY:			CARSON CITY
		STATE:			NV
		ZIP:			89703

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NANOANTIBIOTICS, INC.
		DATE OF NAME CHANGE:	20130625
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>bivi-20240630_10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:us-roles="http://fasb.org/us-roles/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:bivi="http://bioviepharma.com/20240630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2024%2D(with%2DECD) -->
<!-- Field: Set; Name: xdx; ID: xdx_038_bivi_bioviepharma.com_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_042_20230701_20240630 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05A_edei%2D%2DDocumentFiscalPeriodFocus_FY -->
<!-- Field: Set; Name: xdx; ID: xdx_052_edei%2D%2DDocumentFiscalYearFocus_2024 -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001580149 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000004" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000005" name="dei:DocumentFiscalYearFocus">2024</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000006" name="dei:EntityCentralIndexKey">0001580149</ix:nonNumeric>
  <ix:nonFraction name="bivi:InvestmentsInU.s.TreasuryBills" contextRef="AsOf2024-06-30" id="xdx2ixbrl0059" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2024-06-30" id="xdx2ixbrl0089" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" contextRef="AsOf2024-06-30" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2024-06-30" id="xdx2ixbrl0114" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2024-06-30" id="xdx2ixbrl0130" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2023-06-30" id="xdx2ixbrl0131" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2024-06-30" id="xdx2ixbrl0171" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DividendsSharebasedCompensationStock" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0223" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:UnrealizedGainOnInvestmentsForAvailableforsale" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl0252" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0256" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0266" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0267" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0272" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0276" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0295" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0299" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfOptions" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0303" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfOptions" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfOptions" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfOptions" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfWarrants" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0310" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfWarrants" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfWarrants" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfWarrants" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfWarrants" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:CashlessExerciseOfWarrants" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0321" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0323" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0338" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0339" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0340" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:UnrealizedGainOnAvailableforsaleInvestments" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0345" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:UnrealizedGainOnAvailableforsaleInvestments" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:UnrealizedGainOnAvailableforsaleInvestments" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0347" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:UnrealizedGainOnAvailableforsaleInvestments" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0349" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0353" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0354" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0370" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0375" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0377" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0378" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0379" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0382" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0383" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0397" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl0399" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0406" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0407" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0408" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0412" unitRef="Shares" xs:nil="true"/>
  <ix:nonFraction name="bivi:DeemedDividendForRatchetAdjustmentToWarrants" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0414" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:DeemedDividendForRatchetAdjustmentToWarrants" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0416" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:DeemedDividendForRatchetAdjustmentToWarrants" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:DeemedDividendForRatchetAdjustmentToWarrants" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl0419" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0422" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0423" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0425" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0428" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0431" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0432" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl0433" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0437" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0440" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0447" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:RealizedGainOnMaturityOfAvailableforSale" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0491" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0530" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:NetProceedsFromIssuanceOfCommonStockRelatedParty" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:RightOfUseAssetsObtainedInExchangeForLeaseObligations" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:UnrealizedGainOnU.s.TreasuryBills" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0566" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:DeemedDividendOfRatchetAdjustmentsToWarrants" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:GrossUnrealizedLoss" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:NotesPayableNoncurrent" contextRef="AsOf2024-06-30" id="xdx2ixbrl0771" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:LongtermDebtFinancingCosts" contextRef="AsOf2024-06-30" id="xdx2ixbrl0774" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" contextRef="AsOf2024-06-30" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:LongTermAccretionOfLoanPremiums" contextRef="AsOf2024-06-30" id="xdx2ixbrl0780" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="bivi:LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" contextRef="AsOf2024-06-30" id="xdx2ixbrl0783" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0804" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0806" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0812" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0814" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0816" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember" id="xdx2ixbrl0818" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0822" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0828" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0830" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0836" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0838" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0844" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0846" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0858" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0860" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0866" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0868" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0874" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0876" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0882" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0884" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0888" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0914" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0922" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0924" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0930" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0932" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0938" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0940" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0946" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0948" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0954" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0956" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0962" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0964" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2022-06-30_custom_StockOptionsMember" id="xdx2ixbrl1020" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="xdx2ixbrl1070" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2022-06-30_us-gaap_WarrantMember" id="xdx2ixbrl1249" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2024-06-30_us-gaap_WarrantMember" id="xdx2ixbrl1289" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2024-06-30" id="xdx2ixbrl1388" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="AsOf2023-06-30" id="xdx2ixbrl1389" unitRef="USD" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2023-07-01to2024-06-30" id="xdx2ixbrl1409" unitRef="Pure" xs:nil="true"/>
  <ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="From2022-07-012023-06-30" id="xdx2ixbrl1410" unitRef="Pure" xs:nil="true"/>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="bivi-20240630.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-07-01to2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_TreasuryStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_TreasuryStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_TreasuryStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_TreasuryStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_TreasuryStocksMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_NotespayableConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bivi:NotespayableConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_NotespayableConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bivi:NotespayableConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-07-15_custom_AcuitasGroupHoldingsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bivi:AcuitasGroupHoldingsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-07-15</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_UnearnedDiscountMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bivi:UnearnedDiscountMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FinanceReceivablesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_LoanAccretionPremiumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bivi:LoanAccretionPremiumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_CashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_CashMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bivi:USTreasuryBillSecurities1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bivi:USTreasuryBillSecurities1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bivi:USTreasuryBillSecurities1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bivi:USTreasuryBillSecurities1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bivi:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bivi:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-03-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-06_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-03-012024-03-06_custom_CommonWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:CommonWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-03-01</xbrli:startDate>
        <xbrli:endDate>2024-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-04-012023-04-06_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-04-01</xbrli:startDate>
        <xbrli:endDate>2023-04-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-04-06_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-04-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-05-012024-05-10_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-05-01</xbrli:startDate>
        <xbrli:endDate>2024-05-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-05-10_custom_VendorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:VendorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-05-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-06-012022-06-21_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-01</xbrli:startDate>
        <xbrli:endDate>2022-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:FourDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_ThreeDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:ThreeDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:FourDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_TwoDirectorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:TwoDirectorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-11-01</xbrli:startDate>
        <xbrli:endDate>2023-11-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:FourDirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-12-012022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-12-01</xbrli:startDate>
        <xbrli:endDate>2022-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-11-012022-11-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-11-01</xbrli:startDate>
        <xbrli:endDate>2022-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-11-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-10-012022-10-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-10-01</xbrli:startDate>
        <xbrli:endDate>2022-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-10-31_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-05-012023-05-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-05-01</xbrli:startDate>
        <xbrli:endDate>2023-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-05-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_CertainEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:CertainEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-07</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-10-01</xbrli:startDate>
        <xbrli:endDate>2023-10-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-06-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2022-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2022-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-012023-06-30_us-gaap_WarrantMember53646031">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-01</xbrli:startDate>
        <xbrli:endDate>2023-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2023-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2023-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-012024-06-30_us-gaap_WarrantMember53646062">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-01</xbrli:startDate>
        <xbrli:endDate>2024-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-02-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-02-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-25_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bivi:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-25_custom_CommonWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bivi:CommonWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2024-09-012024-09-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2024-09-01</xbrli:startDate>
        <xbrli:endDate>2024-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2024-09-25_custom_PlacementAgentsWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001580149</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2024-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 3pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->
<p style="font: 7pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</b></span><br/>
Washington, D.C. 20549</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM <span id="xdx_909_edei--DocumentType_c20230701__20240630_zi4fUk1vLE01"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000012" name="dei:DocumentType">10-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Mark One)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--DocumentAnnualReport_c20230701__20240630_zRjGuIo2CCx9"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleantrue" id="Fact000013" name="dei:DocumentAnnualReport">&#9746;</ix:nonNumeric></span></span>
<b>ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FOR THE FISCAL YEAR ENDED <span id="xdx_90A_edei--DocumentPeriodEndDate_c20230701__20240630_zl2NHgdrMj37"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:datemonthdayyearen" id="Fact000014" name="dei:DocumentPeriodEndDate"><span id="xdx_900_edei--CurrentFiscalYearEndDate_c20230701__20240630_zWQq8B3coUc4"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:datemonthdayen" id="Fact000015" name="dei:CurrentFiscalYearEndDate">JUNE 30</ix:nonNumeric></span>, 2024</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--DocumentTransitionReport_c20230701__20240630_zljBcDk2TUDe"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000016" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span></span>
<b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the transition period from ____________to _____________</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number: <b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityFileNumber_c20230701__20240630_zdM9xriIsgVb"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000017" name="dei:EntityFileNumber">001-39015</ix:nonNumeric></span></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-size: 14pt"><b><span style="text-decoration: underline"><span id="xdx_90A_edei--EntityRegistrantName_c20230701__20240630_zEoF5MEGqtjc"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000018" name="dei:EntityRegistrantName">BIOVIE INC.</ix:nonNumeric></span></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>(Exact name of registrant as specified in its charter)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><b><span id="xdx_90C_edei--EntityIncorporationStateCountryCode_c20230701__20240630_z2jrEtfhm5V2"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt-sec:stateprovnameen" id="Fact000019" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><b><span id="xdx_905_edei--EntityTaxIdentificationNumber_c20230701__20240630_z7mgb3fThoYd"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000020" name="dei:EntityTaxIdentificationNumber">46-2510769</ix:nonNumeric></span></b></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><i>(State or other jurisdiction of</i> <i>incorporation or organization)</i></td>
    <td>&#160;</td>
    <td style="text-align: center"><i>(I.R.S. Employer Identification Number)</i></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="vertical-align: top; width: 17%; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; width: 67%; text-align: center"><b><span id="xdx_90E_edei--EntityAddressAddressLine1_c20230701__20240630_zoc19R9oAD8g"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000021" name="dei:EntityAddressAddressLine1">680 W Nye Lane Suite 204</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top; width: 16%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><b><span id="xdx_903_edei--EntityAddressCityOrTown_c20230701__20240630_zTb4GehjRhHk"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000022" name="dei:EntityAddressCityOrTown">Carson City</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20230701__20240630_zIr2JvrXB8ff"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000023" name="dei:EntityAddressStateOrProvince">NV</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20230701__20240630_zeJjFgDdwxY7"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000024" name="dei:EntityAddressPostalZipCode">89703</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><i>(Address of principal executive offices, Zip Code)</i></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><b><span id="xdx_90A_edei--CityAreaCode_c20230701__20240630_zhZRjbSCwIj5"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000025" name="dei:CityAreaCode">(775)</ix:nonNumeric></span>-<span id="xdx_906_edei--LocalPhoneNumber_c20230701__20240630_zwVOvn9K36Ll"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000026" name="dei:LocalPhoneNumber">888-3162</ix:nonNumeric></span></b></td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><i>(Registrant&#8217;s telephone number, including area code)</i></td>
    <td style="vertical-align: top">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Securities registered pursuant to Section 12(b) of
the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border: black 1.5pt solid; width: 45%; text-align: center">Title of each class</td>
    <td style="border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; width: 20%; text-align: center">Trading Symbol(s)</td>
    <td style="border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; width: 35%; text-align: center">Name of each exchange on which registered</td></tr>
  <tr style="vertical-align: top">
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; text-align: center"><span id="xdx_90D_edei--Security12bTitle_c20230701__20240630_z8rPAcqAXKI2"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000027" name="dei:Security12bTitle">Class A Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center"><span id="xdx_904_edei--TradingSymbol_c20230701__20240630_zCeuGJ7BtFP3"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000028" name="dei:TradingSymbol">BIVI</ix:nonNumeric></span></td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; text-align: center">The <span id="xdx_90C_edei--SecurityExchangeName_c20230701__20240630_zMwP8O5PCjYi"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt-sec:exchnameen" id="Fact000029" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market, LLC</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Securities registered pursuant to Section 12(g)
of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">None</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span id="xdx_90A_edei--EntityWellKnownSeasonedIssuer_c20230701__20240630_zdRKpWI0y6H5"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000030" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant is not required
to file reports pursuant to Section 13 or Section 15(d) of the Act&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span id="xdx_90A_edei--EntityVoluntaryFilers_c20230701__20240630_zoppnmpmSjf8"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000031" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant (1)
has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter
period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_907_edei--EntityCurrentReportingStatus_c20230701__20240630_z6W9frKe1yPk"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000032" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="xdx_90C_edei--EntityInteractiveDataCurrent_c20230701__20240630_z77CsvonjRmd"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000033" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is a
large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See
the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and
&#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 42%">Large Accelerated Filer</td>
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td>
    <td style="width: 38%">Accelerated Filer</td>
    <td style="width: 10%"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span id="xdx_90A_edei--EntityFilerCategory_c20230701__20240630_zcu2Jafuve5l"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt-sec:entityfilercategoryen" id="Fact000034" name="dei:EntityFilerCategory">Non-Accelerated Filer</ix:nonNumeric></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td>
    <td>Smaller reporting company</td>
    <td><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_905_edei--EntitySmallBusiness_c20230701__20240630_zclME8hGH915"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleantrue" id="Fact000035" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr>
    <td style="vertical-align: top">Emerging growth company</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_90E_edei--EntityEmergingGrowthCompany_c20230701__20240630_zbFbz2FHeRz1"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000036" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></td>
    <td colspan="2">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark if the registrant has filed
a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7362(b)) by the registered public accounting firm that prepared or issued its
audit report.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
No <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If securities are registered pursuant to Section 12(b)
of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of
an error to previously issued financial statements.&#160;<span style="font-family: Times New Roman, Times, Serif"><span id="xdx_908_edei--DocumentFinStmtErrorCorrectionFlag_c20230701__20240630_zTg9kQpjIFJ5"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000037" name="dei:DocumentFinStmtErrorCorrectionFlag">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s
executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).&#160;<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Indicate by check mark whether the registrant is
a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;
<span id="xdx_908_edei--EntityShellCompany_c20230701__20240630_zAp4GoVEbn17"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000038" name="dei:EntityShellCompany">No</ix:nonNumeric></span> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The aggregate market value of the voting and non-voting
common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid
and asked price of such common equity, as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter
was $<span id="xdx_900_edei--EntityPublicFloat_iI_c20230630_zxtiHEzQaNWi"><ix:nonFraction name="dei:EntityPublicFloat" contextRef="AsOf2023-06-30" id="Fact000039" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,590,705</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were <span id="xdx_909_edei--EntityCommonStockSharesOutstanding_iI_c20240925_zWNyNWWZDfMf"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2024-09-25" id="Fact000040" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,956,660</ix:nonFraction>
</span>shares of the Registrant&#8217;s Class A Common Stock, $0.0001 par value per share, outstanding as of September 25, 2024</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p id="xdx_985_edei--DocumentsIncorporatedByReferenceTextBlock_c20230701__20240630_zapJxILGmbB2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000041" name="dei:DocumentsIncorporatedByReferenceTextBlock">Portions of the Registrant&#8217;s definitive proxy
statement relating to its 2024 annual meeting of stockholders (the &#8220;2024 Proxy Statement&#8221;) are incorporated by reference into
Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement was filed with the U.S. Securities and Exchange
Commission on September 27, 2024.</ix:nonNumeric></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 3.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">&#160;</td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BIOVIE INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>FORM 10-K INDEX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_001"><b>PART I </b></a></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 10%"><a href="#a_002">Item 1.</a></td>
    <td style="width: 85%"><a href="#a_002">Business</a></td>
    <td style="vertical-align: bottom; width: 5%; text-align: right">1</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_003">Item 1A.</a></td>
    <td><a href="#a_003">Risk Factors</a></td>
    <td style="vertical-align: bottom; text-align: right">12</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_004">Item 1B.&#160;</a></td>
    <td><a href="#a_004">Unresolved Staff Comments</a></td>
    <td style="vertical-align: bottom; text-align: right">38</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_008">Item 1C.</a></td>
    <td><a href="#a_008">Cybersecurity </a></td>
    <td style="vertical-align: bottom; text-align: right">38</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_005">Item 2.</a></td>
    <td><a href="#a_005">Properties</a></td>
    <td style="vertical-align: bottom; text-align: right">38</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_006">Item 3.</a></td>
    <td><a href="#a_006">Legal Proceedings</a></td>
    <td style="vertical-align: bottom; text-align: right">39</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_007">Item 4.</a></td>
    <td><a href="#a_007">Mine Safety Disclosures</a></td>
    <td style="vertical-align: bottom; text-align: right">39</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_009"><b>PART II </b></a></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_010">Item 5.</a></td>
    <td><a href="#a_010">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></td>
    <td style="vertical-align: bottom; text-align: right">40</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_011">Item 6.</a></td>
    <td><a href="#a_011">[Reserved]</a></td>
    <td style="vertical-align: bottom; text-align: right">40</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_012">Item 7.</a></td>
    <td><a href="#a_012">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></td>
    <td style="vertical-align: bottom; text-align: right">40</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_013">Item 7A.</a></td>
    <td><a href="#a_013">Quantitative and Qualitative Disclosures About Market Risk</a></td>
    <td style="vertical-align: bottom; text-align: right">44</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_014">Item 8.</a></td>
    <td><a href="#a_014">Financial Statements and Supplementary Data</a></td>
    <td style="vertical-align: bottom; text-align: right">44</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_015">Item 9.</a></td>
    <td><a href="#a_015">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></td>
    <td style="vertical-align: bottom; text-align: right">44</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_016">Item 9A</a></td>
    <td><a href="#a_016">Controls and Procedures</a></td>
    <td style="vertical-align: bottom; text-align: right">44</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_017">Item 9B.</a></td>
    <td><a href="#a_017">Other Information</a></td>
    <td style="vertical-align: bottom; text-align: right">45</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_018">Item 9C.</a></td>
    <td><a href="#a_018">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections&#8239;</a></td>
    <td style="vertical-align: bottom; text-align: right">45</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_019"><b>PART III</b></a></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_020">Item 10.</a></td>
    <td><a href="#a_020">Directors, Executive Officers and Corporate Governance</a></td>
    <td style="vertical-align: bottom; text-align: right">46</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_021">Item 11.</a></td>
    <td><a href="#a_021">Executive Compensation</a></td>
    <td style="vertical-align: bottom; text-align: right">46</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_022">Item 12.</a></td>
    <td><a href="#a_022">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></td>
    <td style="vertical-align: bottom; text-align: right">46</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><a href="#a_023">Item 13.</a></td>
    <td><a href="#a_023">Certain Relationships and Related Transactions, and Director Independence</a></td>
    <td style="vertical-align: bottom; text-align: right">46</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_024">Item 14.</a></td>
    <td><a href="#a_024">Principal Accountant Fees and Services</a></td>
    <td style="vertical-align: bottom; text-align: right">46</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2"><a href="#a_025"><b>PART IV</b></a></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td colspan="2">&#160;</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_026">Item 15.</a></td>
    <td><a href="#a_026">Exhibits and Financial Statement Schedules</a></td>
    <td style="vertical-align: bottom; text-align: right">47</td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>Item 16.</td>
    <td>Form 10-K Summary</td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">(<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence -->)</td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>BIOVIE INC.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>FORWARD-LOOKING STATEMENTS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This report contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934, and Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities
Act&#8221;). Any statements contained in this report that are not statements of historical fact may be forward-looking statements. When
we use the words &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continues,&#8221;
&#8220;anticipates,&#8221; &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;should,&#8221; &#8220;could,&#8221;
&#8220;may,&#8221; &#8220;will&#8221; or the negative of these terms or other comparable terminology, we are identifying forward-looking
statements. Forward-looking statements involve risks and uncertainties, which may cause our actual results, performance or achievements
to be materially different from those expressed or implied by forward-looking statements. These factors include our research and development
activities, distributor channel; compliance with regulatory impositions; and our capital needs. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as may be required by applicable law, we do
not undertake or intend to update or revise our forward-looking statements, and we assume no obligation to update any forward-looking
statements contained in this report as a result of new information or future events or developments. Thus, you should not assume that
our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should
carefully review and consider the various disclosures we make in this report and our other reports filed with the Securities and Exchange
Commission (the &#8220;Commission&#8221;) that attempt to advise interested parties of the risks, uncertainties and other factors that
may affect our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All statements other than statements of historical
fact are statements that could be deemed forward-looking statements. The Company assumes no obligation and does not intend to update these
forward-looking statements, except as required by law. When used in this report, the terms &#8220;BioVie&#8221;, &#8220;Company&#8221;,
&#8220;we&#8221;, &#8220;our&#8221;, and &#8220;us&#8221; refer to BioVie, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">(<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence -->)</td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_001"></span>PART I</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_002"></span><b>ITEM 1.</b></td>
    <td style="width: 90%"><b>BUSINESS </b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;
or &#8220;our&#8221;) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative
disorders and advanced liver disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Neurodegenerative Disease Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acquired the biopharmaceutical assets
of NeurMedix, Inc. (&#8220;NeurMedix&#8221;) a privately held clinical-stage pharmaceutical company and a related party in June 2021<i>.</i>
The acquired assets included NE3107. In April 2024, the Company announced that the United States Adopted Names Council, and the World
Health Organization International Nonproprietary Names expert committee had approved &#8220;bezisterim&#8221; as the non-proprietary (generic)
name for NE3107. Bezisterim (NE3107) is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven
insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus
that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer&#8217;s disease (&#8220;AD&#8221;)
and Parkinson&#8217;s disease (&#8220;PD&#8221;), and bezisterim (NE3107) could, if approved by U.S. Food and Drug Administration (&#8220;FDA&#8221;),
represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering
from AD and 1 million Americans suffering from PD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In neurodegenerative disease, bezisterim (NE3107)
inhibits activation of inflammatory extracellular signal-regulated kinase (&#8220;ERK&#8221;) and nuclear factor kappa-light-chain-enhancer
of activated B cells (&#8220;NF&#954;B&#8221;) (including interactions with tumor necrosis factor (&#8220;TNF&#8221;) signaling and other
relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. Bezisterim (NE3107) does not interfere with their
homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of
AD and PD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>About Inflammation and Bezisterim&#8217;s (NE3107&#8217;s)
Mechanism of Action</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Neuroinflammation, insulin resistance, and oxidative
stress are common features in the major neurodegenerative diseases, including AD, PD frontotemporal lobar dementia, and Amyotrophic lateral
sclerosis (&#8220;ALS&#8221;). Bezisterim (NE3107) is an orally bioavailable, blood-brain permeable, small molecule, with potential anti-inflammatory,
insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NF&#954;B- and TNF-stimulated inflammation.
Bezisterim&#8217;s (NE3107&#8217;s) potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company&#8217;s
work testing the molecule in AD and PD patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parallels exist between AD and PD, among them activated
microglia driving inflammation, involvement of TNF&#945;, oxidative stress, protein misfolding, mitochondrial dysfunction, and insulin
resistance. In preclinical and clinical studies, bezisterim (NE3107) reduced inflammation and enhanced insulin sensitivity, both of which
are important to PD pathology. Preclinical studies in marmoset monkeys have shown bezisterim (NE3107) administered alone to be as pro-motoric
as levodopa, underscoring the apparently critical role of inflammation in expression of PD motor symptoms. When bezisterim (NE3107) was
administered with levodopa, the combination improved motor control better than either drug alone. Furthermore, in the marmoset study,
bezisterim (NE3107) reduced the severity of levodopa induced dyskinesia (&#8220;LID&#8221;) concurrent with pro-motoric benefit and decreased
neurodegeneration, preserving twice as many dopaminergic neurons compared to control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Alzheimer&#8217;s Disease</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>AD Pathophysiology and Bezisterim (NE3107) Treatment
Rationale</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alzheimer&#8217;s disease, which affects an estimated
6 million Americans, is a neuroinflammatory and neurodegenerative condition characterized by progressive deterioration of cognitive function
and loss of short-term memory and executive function. Cognitive tests quantifying AD severity have been exhaustively developed. Formal
diagnosis of AD has historically been dependent on the presence of extraneuronal amyloid beta (&#8220;A&#946;&#8221;) plaques, which can
only be observed at autopsy or with the aid of sophisticated radioimaging techniques. However, diagnostic methods have recently been approved
that quantify A&#946; in peripheral blood and correlate well with imaging results. A&#946; plaques can also be found in people without
apparent AD symptoms, which has cast doubt about the role of A&#946; as the central mediator of disease pathology.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Scientific investigations in the past twenty years
have provided strong evidence that inflammation, type 2 diabetes (&#8220;T2D&#8221;), and inflammation-driven insulin resistance are drivers
of AD through interplay with the major inflammation signaling node, NFkB, and the cytokine, TNF, the activities of which are modulated
by bezisterim (NE3107). The link between inflammation, T2D, and inflammation-driven insulin resistance and cognitive impairment are described
by relatively new terms, type 3 diabetes and metabolic-cognitive syndrome.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Inflammation, insulin resistance, and associated metabolic
dysregulation in the brain contribute to A&#946; oligomerization and aggregation, phospho-tau formation, reduced neuron survival stimulus,
and a forward-feeding cycle of neuronal energy deficit and oxidative stress, causing neuronal dysfunction (cognitive impairment) and neurodegeneration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Insulin has a major role in metabolic regulation and
neuron survival, while insulin resistance and T2D are closely linked to AD pathology. Insulin signaling is involved in synaptic plasticity,
learning, and memory. Exogenous insulin enhances cognition in normal and cognitively impaired subjects. Insulin resistance is linked to
cognitive impairment and senescence in the central nervous system (&#8220;CNS&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Systemic inflammation from inflamed adipose tissue
and associated mononuclear cells promotes CNS inflammation and is linked to cognitive decline and neurodegeneration. In addition to the
afore mentioned factors contributing to AD pathophysiology, there is an extensive literature on the complex role of adipose tissue inflammation
in systemic inflammation, insulin resistance, hypothalamus-pituitary-adrenal axis (&#8220;HPA&#8221;) dysregulation and chronic cortisol
excess in cognitive impairment in AD. Obesity and inflammation are closely linked in expanding adipose tissue, where the production of
inflammatory cytokines and increased cortisol are driven though up-regulation of 11&#946;-hydroxysteroid dehydrogenase type 1 and adipocyte
mineralocorticoid receptor activation. Inflamed adipose tissue interacts with the HPA axis and hippocampus to increase systemic cortisol,
and promote hippocampal inflammation through chronically elevated cortisol, which freely penetrates the blood-brain barrier. Hyperglycemia
(secondary to insulin resistance) exacerbates adrenal cortisol production and promotes forward feeding of inflammation and HPA-hippocampal
dysregulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bezisterim (NE3107) is believed to inhibit ERK/NFkB
activation and TNF production stimulated by inflammatory stimuli, which includes oxidative stress. Inhibition of NFkB activation and TNF
production from this type of stimulation has broad potential implications for reduction of pathological peripheral and CNS inflammatory
signaling in AD, which includes reduction of inflammation-driven insulin resistance, decreased inflammatory cell infiltration into the
CNS, and decreased microglia activation. Reduction of systemic inflammation and inflammation-driven insulin resistance are also predicted
to have beneficial effects on HPA axis dysregulation and hippocampal dysregulation of cortisol secretion that are consequences of adipose
inflammation and insulin resistance, and as described above, are known to promote cognitive impairment and forward-feeding insulin resistance.
We believe bezisterim&#8217;s (NE3107&#8217;s) combination of anti-inflammatory and insulin sensitizing activity has the potential to
disrupt this forward-feeding cycle of AD pathology. The multifactorial influence of insulin signaling on neuron survival and cognition
suggests that correction of insulin signaling deficits with bezisterim (NE3107) in the target population may provide significant benefits
on both cognition and disease progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Company&#8217;s Progress with Alzheimer&#8217;s
Disease Clinical Trial</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 29, 2023, the Company announced topline
efficacy data from its Phase 3 clinical trial (NCT04669028) of bezisterim (NE3107) in the treatment of mild to moderate AD. The study
had co-primary endpoints looking at cognition using the Alzheimer&#8217;s Disease Assessment Scale-Cognitive Scale (ADAS-Cog 12) and function
using the Clinical Dementia Rating-Sum of Boxes. Patients were randomly assigned, 1:1 versus placebo, to receive sequentially 5 mg of
bezisterim (NE3107) orally twice a day for 14 days, then 10 mg orally twice a day for 14 days, followed by 26 weeks of 20 mg orally twice
daily.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon trial completion, as the Company began the process
of analyzing the trial data, the Company found significant deviation from protocol and current good clinical practices (&#8220;cGCPs&#8221;)
violations at 15 study sites (virtually all of which were from one geographic area). This highly unusual level of suspected improprieties
led the Company to exclude all patients from these sites and to refer the sites to the FDA&#8217;s Office of Scientific Investigations
(&#8220;OSI&#8221;) for potential action.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the patient exclusions, 81 patients remained
in the Modified Intent-to-Treat population, 57 of whom were in the Per-Protocol population which included those who completed the trial
and were verified to take study drug based on pharmacokinetic data. The trial was originally designed to be 80% powered with 125 patients
in each of the treatment and placebo arms. The unplanned exclusion of so many patients left the trial underpowered for its primary endpoints.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the Per-Protocol population, which includes those
patients who completed the trial and who were further verified to have taken the study drug (based on pharmacokinetics data), an observed
but not statistically significant change from baseline appeared to suggest a slowing of cognitive loss; these same patients experienced
an advantage in age deceleration vs. placebo as measured by deoxyribonucleic acid (&#8220;DNA&#8221;) epigenetic change. Age deceleration
is used by longevity researchers to measure the difference between the patient&#8217;s biological age, in this case as measured by the
Horvath DNA methylation Skin Blood Clock, relative to the patient&#8217;s actual chronological age. This test was a non-primary/secondary
endpoint, other-outcome measure, done via blood test collected at week 30 (end of study).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on the efficacy signal seen in this trial, the
Company is exploring (1) a discussion with the FDA to potentially employ the adaptive trial feature of the protocol to continue enrolling
patients to achieve statistical significance; and/or (2) the design of a new Phase 3 study of bezisterim (NE3107) that leverages the most
recent data and understanding of the potential effects bezisterim (NE3107) may have in persons with AD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Parkinson&#8217;s Disease </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parkinson&#8217;s disease (PD), which affects an estimated
1 million Americans, is driven in large part by neuroinflammation and activation of brain microglia, leading to increased proinflammatory
cytokines (particularly TNF). Multiple daily administrations of levodopa (converted to dopamine in the brain) is the current standard
of care treatment for this movement disorder, but levodopa effectiveness diminishes over time necessitating increased dosage and prolonged
daily administration leads to side effects of uncontrolled movements called levodopa-induced dyskinesia, commonly referred to as LID,
which is exacerbated by high dose levodopa. Although levodopa provides symptomatic benefit, it does not slow PD progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s Phase 2 study of bezisterim (NE3107)
for the treatment of PD (NCT05083260), completed in January 2023, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics
study in PD participants treated with carbidopa/levodopa and NE3107. Forty-five patients with a defined L-dopa &#8220;off state&#8221;
were randomized 1:1 to placebo or bezisterim (NE3107) 20 mg twice daily for 28 days. This trial was launched with two design objectives:
(1) the primary objective was safety and drug-drug interaction, as requested by the FDA, to assess the potential for adverse interactions
between bezisterim (NE3107) and carbidopa/ levodopa; and (2) the secondary objective was to determine if preclinical indications of promotoric
activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met. Results of the study include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 18pt">&#160;</td>
    <td style="width: 18pt; text-align: justify">&#9679;</td>
    <td style="text-align: justify">Five (26%) of the 19 patients treated with NE3107 vs zero of 19 placebo treated patients, experienced a morning ON state prior to receiving their initial morning C/L medications at the end of the study (day 28); this difference was statistically significant (p=0.046).</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">Patients treated with NE3107 + C/L experienced greater improvements in their Motor Disease Society- Unified Parkinson&#8217;s Disease Rating Scale (MDS UPDRS) Part III score than patients treated with placebo + C/L at the 2- and 3-hour marks after administration of the first daily dose of C/L.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">Patients &lt;70 years old treated with NE3107 + C/L experienced improvements that were ~6 points better than those who received placebo + C/L.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">The study met its endpoints; investigators concluded that NE3107 + C/L combination treatment was associated with clinically meaningful and superior improvements (3+ points) on the motor examination part (Part III) of the MDS UPDRS.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#9679;</td>
    <td style="text-align: justify">NE3107 produced statistically significant improvements in nonmotor symptoms scale assessments (NMSS) for fatigue (Q4) p=0.02, urge to move legs (Q6) p=0.0036, and saliva dribbling (Q19) p= 0.0395.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To extend this Phase 2 data in progressed patients,
the Company has designed a new Phase 2 study of bezisterim (NE3107) as a potential first line therapy to treat patients with new onset
PD. In July 2024, the Company submitted the protocol for this new study to the FDA for regulatory review.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bezisterim (NE3107) may have the potential to become
a non-dopaminergic alternative to PD patients. There are numerous scientific reports that support the critical role of inflammation in
the manifestation of PD symptoms in addition to the essential role of inflammation in driving disease progression. We have shown in a
mouse model of PD that bezisterim (NE3107) decreases inflammation and TNF in the brain and increases neuron survival (Nicoletti, 2012
Parkinson&#8217;s Disease 969418). In this neurotoxin induced model, bezisterim (NE3107) decreased clinical signs of disease and neuronal
death compared to placebo treated mice. An unpublished study of a neurotoxin induced marmoset model of PD reported that administration
of bezisterim (NE3107) decreased movement abnormalities that are the clinical signs of the disease. In the same study, bezisterim (NE3107)
in combination with levodopa had a stronger effect on clinical signs of disease than levodopa or bezisterim (NE3107) alone, while marmosets
treated with bezisterim (NE3107) developed less LID. Bezisterim (NE3107)-treated monkeys also exhibited neuroprotective activity that
promoted the survival of twice as many neurons in the substantia nigra (primary region of the brain that degenerates to cause parkinsonism)
as monkeys treated with placebo. The results from the marmoset study suggest that bezisterim (NE3107) may decrease clinical signs of disease
in humans (improve motor function), which if true could enable a straightforward clinical development strategy to test bezisterim (NE3107)
in PD patients needing promotoric therapy. If approved as a promotoric agent, NE3107 would provide a non-dopaminergic alternative to Parkinson&#8217;s
patients, and an opportunity to significantly delay the need to start levodopa therapy. This could represent a first step toward supplanting
levodopa as the primary PD therapy, and in addition to delaying the emergence of LID, could also slow disease progression, the most important
and still unmet objective of PD drug development.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Long COVID Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2024, the Company announced the grant of a clinical trial award of up to $13.1 million from the U.S. Department of Defense (&#8220;DOD&#8221;),
awarded through the Peer Reviewed Medical Research Program of the Congressionally Directed Medical Research Programs. In August 2024,
U.S. Army Medical Research and Development Command, Office of Human Research Oversight (&#8220;OHRO&#8221;) approved the Company&#8217;s
plan to evaluate bezisterim (NE3107) for the treatment of neurological symptoms that are associated with long COVID. The FDA
had previously reviewed and approved the study as &#8220;Safe to Proceed&#8221; in August 2024. The approval form OHRO is the last scientific
review milestone needed for the Company to receive the additional $12.6 million of the aggregate $13.1 million in grant funding from the
DOD. The award can provide up to 2 years of non-dilutive funding for a Phase 2 clinical trial that will assess bezisterim (NE3107) for
the treatment of neurological symptoms that are associated with long COVID. The Company anticipates the trial to commence by early 2025.
The study protocol was finalized and submitted to the FDA for regulatory review in July 2024 and on August 22, 2024 the FDA authorized
our IND application for Bezisterim (NE3107) allowing us to study a novel, anti-inflammatory approach or the treatment of the debilitating
neurocognitive symptoms associated with long covid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long COVID is a condition in which symptoms of COVID-19,
the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more.
The Centers for Disease Control recently reported that 6.8% of adults in the United States (more than 17 million individuals) currently
or previously had long COVID. Symptoms, which include fatigue, cognitive dysfunction and sleep disturbances, are debilitating. The loss
in quality of life and earnings and increased medical costs has an enormous economic impact estimated to be 3.7 trillion dollars. To date
there are no therapies proven effective for treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chronic inflammation is one of the main hypotheses
that researchers have proposed to explain the persistence of symptoms in long COVID. Specifically in individuals with &#8220;brain fog,&#8221;
sustained systemic inflammation and persistent localized blood-brain-barrier (&#8220;BBB&#8221;) dysfunction are key physiological features.
Bezisterim (NE3107) permeates the BBB and has been shown to modulate inflammation via the inhibition of NF-kB activation, thus representing
a novel oral treatment targeting an underlying cause of long COVID symptoms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chronic neuroinflammation, insulin resistance, and
oxidative stress are common features in the major neurodegenerative diseases, including AD, PD, frontotemporal lobar dementia, and ALS.
Bezisterim (NE3107) is an investigational oral small molecule, blood-brain permeable, compound with potential anti-inflammatory, insulin
sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NF&#954;B- and TNF-stimulated inflammation. Bezisterim&#8217;s
(NE3107) potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company&#8217;s work testing the molecule
in AD, PD, and long COVID patients. Bezisterim (NE3107) is patented in the United States, Australia, Canada, Europe and South Korea.<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liver Cirrhosis Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In liver disease, our investigational drug candidate
BIV201 (continuous infusion terlipressin), which has been granted both FDA Fast Track designation status and FDA Orphan Drug status, is
being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing for the treatment
of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Ascites is a common complication of advanced liver
cirrhosis involving the accumulation of large volumes of fluid in the abdomen, often exceeding five liters, due to liver and kidney dysfunction.
The FDA has never approved a drug to treat ascites, and once patients reach the refractory stage the estimated one-year survival rate
is only approximately 50%<sup>[10]</sup>. BIV201 is a continuous infusion of terlipressin, a drug used in over 40 countries to treat related
complications of liver cirrhosis (Type 1 hepatorenal syndrome and bleeding esophageal varices) that was recently approved in the U.S.
but is not approved in Japan. With the novel room temperature stable formulation in a pre-filled syringe, BIV201 could potentially provide
a superior terlipressin drug delivery system throughout the world. The goal of BIV201 therapy is to interrupt the ascites disease pathway,
thereby halting the cycle of accelerated fluid generation in ascites patients.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2021, the Company initiated a Phase 2 study
(NCT04112199) designed to evaluate the efficacy of BIV201 (terlipressin, administered by continuous infusion for two 28-day treatment
cycles) combined with standard-of-care (&#8220;SOC&#8221;), compared to SOC alone, for the treatment of refractory ascites. The primary
endpoints of the study are the incidence of ascites-related complications and change in ascites fluid accumulation during treatment compared
to a pre-treatment period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, the Company announced enrollment was
paused and that data from the first 15 patients treated with BIV201 plus SOC appeared to show at least a 30% reduction in ascites fluid
during the 28 days after treatment initiation compared to the 28 days prior to treatment. The change in ascites volume was significantly
different from those patients receiving SOC treatment. Patients who completed the treatment with BIV201 experienced a 53% reduction in
ascites fluid, which was sustained (43% reduction) during the three months after treatment initiation as compared to the three-month pre-treatment
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2023, the Company requested and subsequently
received guidance from the FDA regarding the design and endpoints for definitive clinical testing of BIV201 for the treatment of ascites
due to chronic liver cirrhosis. The Company is currently finalizing protocol designs for the Phase 3 study of BIV201 for the treatment
of ascites due to chronic liver cirrhosis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While the active agent, terlipressin, is approved
in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, treatment of ascites is not included in these
authorizations. Patients with refractory ascites suffer from frequent life-threatening complications, generate more than $5 billion in
annual treatment costs, and have an estimated 50% mortality rate within 6 to 12 months. The FDA has not approved any drug to treat refractory
ascites.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our proprietary novel liquid formulation of terlipressin
is designed to improve convenience for outpatient administration and avoid potential formulation errors when pharmacists reconstitute
the current powder version of terlipressin. To date, analytical testing results have confirmed room temperature stability of the prefilled
syringe in storage for 18 months, with the potential for up two years stability. Room temperature storage presents a key product differentiation
versus terlipressin products in countries where the drug is approved. To the best of the Company&#8217;s knowledge, all other terlipressin
products sold globally must be stored under refrigeration and there is no prefilled syringe format of terlipressin available for treating
patients in these countries. BioVie has also filed a Patent Cooperation Treaty (&#8220;PCT&#8221;) application covering our novel liquid
formulations of terlipressin (international patent application PCT/US2020/034269, published as WO2020/237170) and we are seeking patent
protection in at least the U.S., Europe, China, Japan and other jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 (continuous infusion terlipressin) has the
potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis,
nonalcoholic steatohepatitis, and alcoholism. The FDA has granted Fast-Track status and Orphan Drug designation for the most common of
these complications, ascites, which represents a significant unmet medical need. Patients with cirrhosis and ascites account for an estimated
116,000 U.S. hospital discharges annually, with frequent early readmissions. According to the HCUP Nationwide Readmissions Database 2016,
those requiring paracentesis (removal of ascites fluid) experience an average hospital stay lasting eight days incurring over $86,000
in medical costs. This translates into a total potentially addressable ascites market size for BIV201 therapy exceeding $650 million based
on Company estimates. The FDA has never approved any drug specifically for treating ascites. For patients with refractory ascites the
mean one-year survival rate is only 50% (Bureau et al. 2017<i>).</i> BIV201 has also received Orphan Drug designation for hepatorenal
syndrome (&#8220;HRS&#8221;). Patients with refractory ascites often progress to HRS which is the onset of kidney failure and requires
emergency hospitalization.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BIV201 development program began at LAT Pharma
LLC. On April 11, 2016, we acquired LAT Pharma LLC and the rights to its BIV201 development program and currently own all development
and marketing rights to the product candidate. We and PharmaIN, LAT Pharma&#8217;s former partner focused on the development of new modified
product candidates in the same therapeutic field but not including BIV201, have agreed to pay royalties equal to less than 1% of future
net sales of each company&#8217;s ascites drug development programs, or if such program is licensed to a third party, less than 5% of
each company&#8217;s net license revenues. On December 24, 2018, we returned our partial ownership rights to the PharmaIN modified terlipressin
development program and simultaneously paid the remaining balance due on a related debt. PharmaIN&#8217;s rights to our program remain
unchanged.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0%; text-align: justify"><sup></sup></td>
    <td style="width: 0.25in"><sup>10</sup></td>
    <td style="text-align: justify">Bureau et al. 2017</td></tr>
  </table>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>About Ascites and Liver Cirrhosis</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cirrhosis is a leading cause of death in the U.S.
The condition results primarily from hepatitis, alcoholism, and fatty liver disease linked to obesity. Ascites is a common complication
of advanced liver cirrhosis, involving kidney dysfunction and the accumulation of large amounts of fluid in the abdominal cavity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The Need for an Ascites Therapy</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With no medications approved by the FDA specifically
for treating ascites, an estimated 40% of patients die within two years of diagnosis. Certain drugs approved for other uses such as diuretics
may provide initial relief, but patients may fail to respond to treatment as ascites worsens. This represents a critical unmet medical
need, reflected by the Fast Track designation granted to BIV201 by the FDA as a treatment for ascites refractory to or intolerant of diuretic
therapy. U.S. treatment costs for liver cirrhosis, including ascites and other complications, are estimated at more than $5 billion annually.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>The Ascites Development Pathway&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><img src="image_01.jpg" alt=""/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Most experts agree that ascites develops through a
sequence of events illustrated by the above diagram. High blood pressure in the vein that supplies blood to the liver, called &#8220;portal
hypertension,&#8221; occurs as increasing liver damage (fibrosis) impedes blood flow through the liver.&#160;This causes vasodilation
and blood pooling in the central or &#8220;splanchnic&#8221; region of the body and low blood volume in the arteries. The decrease in
effective blood volume activates a signaling pathway (&#8220;neurohormonal systems&#8221;) which tells the kidneys to retain large amounts
of salt and water in an effort to increase blood volume. Ultimately the retention of excess sodium and water leads to the formation of
ascites as these substances &#8220;weep&#8221; from the liver and lymph system and collect in the patient&#8217;s abdomen.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>The BIV201 Proposed Mechanism of Action</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 is being developed with the goal of alleviating
portal hypertension and correcting splanchnic vasodilation, thereby increasing effective blood volume and&#160;reducing the&#160;signals
to the kidneys to retain excess salt and water. If successful, BIV201 could halt the cycle of accelerating fluid generation in ascites
patients and reduce the need for the frequent and painful paracentesis procedures many of these patients currently require.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Future Possible BIV201 Indications</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Based on international investigative studies of the
active agent in BIV201, terlipressin, we believe our drug candidate has potential future applications in other life-threatening conditions
due to liver cirrhosis. Securing marketing approvals for any of these new uses will require well-controlled clinical trials to satisfy
the FDA and/or other countries&#8217; regulatory requirements, none of which have commenced at this time. The Company continues to evaluate
other indications for the use of terlipressin continuous infusion. BioVie will discuss such indications if and when selected for testing.<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>BIV201</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie relies on a combination of patent, trade secret,
other intellectual property laws (such as FDA data exclusivity), nondisclosure agreements, and other measures to protect our proposed
products. We require our employees, consultants, and advisors to execute confidentiality agreements and to agree to disclose and assign
to us all inventions conceived during the workday, using our property, or which relate to our business. Despite any measures taken to
protect our intellectual property (IP), unauthorized parties may attempt to copy aspects of our products or to obtain and use information
that we regard as proprietary.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 was awarded Orphan Drug Designations in the
U.S. for the treatment of hepatorenal syndrome on November 21, 2018 and treatment of ascites due to all etiologies except cancer on September
8, 2016. We also filed a PCT application covering our novel liquid formulations of terlipressin (international patent application PCT/US2020/034269,
published as WO2020/237170) and are seeking patent protection in U.S., Europe, China, Japan and other jurisdictions. To date patents have
been granted in India (Patent No. 540813) and Chile (Patent No. 68965). Also, we own U.S. Patent 11,364,277, and European patent EP3347032,
which is directed to a method of treating ascites with BIV201, and we are pursuing additional patent coverage in U.S., Japan, Europe,
and China.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Bezisterim (NE3107) and related compounds</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of August 15, 2024, we have twelve (12) issued U.S. patents, six (6)
pending U.S. patent applications, three (3) pending U.S. PCT applications, six (6) issued foreign patents, and six (6) pending foreign
patent applications directed to protecting NE3107 and related compounds and methods of making and using thereof. The U.S. patents and
pending patent applications and their projected expiration dates are provided below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; font-weight: bold">Title</td><td style="font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">Patent Application<br/> Number</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Patent <br/> Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="white-space: nowrap; font-weight: bold; text-align: center">Expiration<br/> Date</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 61%; text-align: left">Unsaturated Steroid Compounds</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">13/030,326</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">8,586,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 12%; text-align: center">6/2/2026</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Solid State Forms of a Pharmaceutical</td><td>&#160;</td>
    <td style="text-align: center">12/418,559</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,252,947</td><td style="white-space: nowrap; text-align: left">*</td><td>&#160;</td>
    <td style="text-align: center">4/18/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: left">Crystalline Anhydrate Forms of a Pharmaceutical</td><td>&#160;</td>
    <td style="text-align: center">14/459,528<br/> 15/348,107<br/> 16/598,694<br/> 17/240,728</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,555,046<br/> 9,850,271<br/> 10,995,112<br/> pending</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/3/2029<br/> 4/3/2029<br/> 4/3/2029<br/> &#8212;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Pharmaceutical Solid State Forms</td><td>&#160;</td>
    <td style="text-align: center">12/370,510</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,518,922</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">9/24/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Methods of Preparing Pharmaceutical Solid State Forms</td><td>&#160;</td>
    <td style="text-align: center">13/919,593</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,314,471</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/28/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Steroid Tetrol Solid State Forms</td><td>&#160;</td>
    <td style="text-align: center">12/272,767</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,486,926</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">1/10/2030</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Drug Identification and Treatment Method</td><td>&#160;</td>
    <td style="text-align: center">11/941,936</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,354,396</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">7/7/2031</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="vertical-align: top; text-align: left">Method For Preparing Substituted 3,7-Dihydroxy Steroids</td><td>&#160;</td>
    <td style="text-align: center">13/664,304<br/> 14/886,738</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,163,059**<br/> 9,994,608</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/5/2029<br/> 6/5/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Treatment Methods Using Pharmaceutical Solid State Forms</td><td>&#160;</td>
    <td style="text-align: center">14/459,493</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9,877,972</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/3/2029</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Compositions for Treatment of Neurodegenerative Conditions</td><td>&#160;</td>
    <td style="text-align: center">18/511,027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">pending</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#8212;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Methods of Treating Long COVID</td><td>&#160;</td>
    <td style="text-align: center">63/621,280</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">pending</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#8212;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Modified C19 Steroids and Methods of Using the Same</td><td>&#160;</td>
    <td style="text-align: center">63/610,915</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">pending</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#8212;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Compositions and Methods for the Treatment of Diseases and Conditions Associated with Amyloid Beta Peptides</td><td>&#160;</td>
    <td style="text-align: center">63/592,364</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">pending</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#8212;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Methods for the Treatment of Biological Aging</td><td>&#160;</td>
    <td style="text-align: center">63/561,157</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">pending</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#8212;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify">*</td>
    <td style="text-align: justify">Foreign counterparts issued in Australia, Canada, Europe and South Korea projected to expire 4/3/2029.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in; text-align: justify">&#160;</td>
    <td style="width: 0.25in; text-align: justify">**</td>
    <td style="text-align: justify">Foreign counterparts issued in Europe and Japan projected to expire 6/5/2029.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Government Regulation</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Government authorities in the United States, at the
federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture,
quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring
and reporting, marketing and export and import of products such as those we are developing. Any pharmaceutical candidate that we develop
must be approved by the FDA before it may be legally marketed in the United States and by the appropriate foreign regulatory agency before
it may be legally marketed in foreign countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>United States Drug Development Process</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the United States, the FDA regulates drugs under
the Federal Food, Drug and Cosmetic Act (&#8220;FDCA&#8221;), and implements regulations. Drugs are also subject to other federal, state
and local statutes and regulations. Biologics are subject to regulation by the FDA under the FDCA, the Public Health Service Act (the
&#8220;PHSA&#8221;), and related regulations, and other federal, state and local statutes and regulations. Biological products include,
among other things, viruses, therapeutic serums, vaccines and most protein products. The process of obtaining regulatory approvals and
the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial
time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development
process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include
refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures,
total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement
or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The process required by the FDA before a drug or biological
product may be marketed in the United States generally involves the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify">Completion of preclinical laboratory tests, animal studies and formulation studies according to Good Laboratory Practices or other applicable regulations;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify">Submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify">Performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s GCPs, to establish the safety and efficacy of the proposed drug or biologic for its intended use;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify">Submission to the FDA of a New Drug Application (an &#8220;NDA&#8221;), for a new drug product, or a Biologics License Application (a &#8220;BLA&#8221;), for a new biological product;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the drug or biologic is to be produced to assess compliance with the FDA&#8217;s current good manufacturing practice standards, or cGMP, to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s or biologic&#8217;s identity, strength, quality and purity;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify">Potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the NDA or BLA; and</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify">FDA review and approval of the NDA or BLA.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The lengthy process of seeking required approvals
and the continuing need for compliance with applicable statutes and regulations require the expenditure of substantial resources. There
can be no certainty that approvals will be granted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Clinical trials involve the administration of the
drug or biological candidate to healthy volunteers or patients having the disease being studied under the supervision of qualified investigators,
generally physicians not employed by or under the trial sponsor&#8217;s control. Clinical trials are conducted under protocols detailing,
among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters
to be used to monitor subject safety. Each protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted
in accordance with the FDA&#8217;s cGCP requirements. Further, each clinical trial must be reviewed and approved by an independent institutional
review board (&#8220;IRB&#8221;), at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with
protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in
the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form
that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until it is
completed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Human clinical trials prior to approval are typically
conducted in three sequential phases that may overlap or be combined:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify"><i>Phase&#160;1.</i>&#160;&#160;The drug or biologic is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients having the specific disease.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify"><i>Phase&#160;2.&#160;&#160;</i>The drug or biologic is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine&#160;&#160;optimal dosage and dosing schedule for patients having the specific disease.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 29px; text-align: justify">&#160;</td>
    <td style="width: 29px; text-align: justify"><i>&#9679;</i></td>
    <td style="text-align: justify"><i>Phase&#160;3.</i>&#160;&#160;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials, which usually involve more subjects than earlier trials, are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. Generally, two adequate and well-controlled Phase&#160;3 clinical trials are required by the FDA for approval of an NDA or BLA.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Post-approval studies, or Phase&#160;4 clinical trials,
may be conducted after initial marketing approval. These studies are used to gain additional experience from the treatment of patients
in the intended therapeutic indication and may be required by the FDA as part of the approval process.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Progress reports detailing the results of the clinical
trials must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA by the investigators
for serious and unexpected adverse events or any finding from tests in laboratory animals that suggests a significant risk for human subjects.
Phase&#160;1, Phase&#160;2 and Phase&#160;3 clinical trials may not be completed successfully within any specified period, if at all.
The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding
that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval
of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or
if the drug or biologic has been associated with unexpected serious harm to patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Concurrent with clinical trials, companies usually
complete additional animal studies and develop additional information about the chemistry and physical characteristics of the drug or
biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The
manufacturing process must be capable of consistently producing quality batches of the drug or biological candidate and, among other things,
must include methods for testing the identity, strength, quality and purity of the final drug or biologic. Additionally, appropriate packaging
must be selected and tested and stability studies must be conducted to demonstrate that the drug or biological candidate does not undergo
unacceptable deterioration over its shelf life.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>U.S. Review and Approval Processes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The results of product development, preclinical studies
and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug or
biologic, proposed labeling and other relevant information are submitted to the FDA as part of an NDA or BLA requesting approval to market
the product. The submission of an NDA or BLA is subject to the payment of substantial user fees; a waiver of such fees may be obtained
under certain limited circumstances.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA reviews all NDAs and BLAs submitted before
it accepts them for filing and may request additional information rather than accepting an NDA or BLA for filing. Once the submission
is accepted for filing, the FDA begins an in-depth review of the NDA or BLA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">After the NDA or BLA submission is accepted for filing,
the FDA reviews the NDA to determine, among other things, whether the proposed product is safe and effective for its intended use, and
whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#8217;s identity, strength, quality
and purity. The FDA reviews a BLA to determine, among other things, whether the product is safe, pure and potent and the facility in which
it is manufactured, processed, packaged or held meets standards designed to assure the product&#8217;s continued safety, purity and potency.
In addition to its own review, the FDA may refer applications for novel drug or biological products or drug or biological products which
present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts,
for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not
bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the
approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe
use of the drug or biologic. If the FDA concludes that a REMS is needed, the sponsor of the NDA or BLA must submit a proposed REMS; the
FDA will not approve the NDA or BLA without a REMS, if required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Before approving an NDA or BLA, the FDA will inspect
the facilities at which the product is to be manufactured. The FDA will not approve the product unless it determines that the manufacturing
processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required
specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect one or more clinical sites to assure compliance
with cGMP. If the FDA determines the application, manufacturing process or manufacturing facilities are not acceptable it will outline
the deficiencies in the submission and often will request additional testing or information.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The NDA or BLA review and approval process is lengthy
and difficult and the FDA may refuse to approve an NDA or BLA if the applicable regulatory criteria are not satisfied or may require additional
clinical data or other information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA or BLA
does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and may be susceptible to varying
interpretations, which could delay, limit or prevent regulatory approval. The FDA will issue a &#8220;complete response&#8221; letter
if the agency decides not to approve the NDA or BLA. The complete response letter describes all of the specific deficiencies in the NDA
or BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example,
requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might
take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit
the NDA or BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a product receives regulatory approval, the approval
may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial
value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product
labeling. In addition, the FDA may require Phase&#160;4 testing which involves clinical trials designed to further assess a product&#8217;s
safety and effectiveness and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Orphan Drug Designation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the Orphan Drug Act, the FDA may grant orphan
designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that
affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there
is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this
type of disease or condition will be recovered from sales of the product. Orphan product designation must be requested before submitting
an NDA or BLA. After the FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are
disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review
and approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If a product that has Orphan designation subsequently
receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product
exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same
indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity.
Competitors, however, may receive approval of different products for the indication for which the Orphan product has exclusivity or obtain
approval for the same product but for a different indication for which the Orphan product has exclusivity. Orphan product exclusivity
also could block the approval of one of our products for seven years if a competitor obtains approval of the same drug or biological product
as defined by the FDA or if our drug or biological candidate is determined to be contained within the competitor&#8217;s product for the
same indication or disease. If a drug or biological product designated as an orphan product receives marketing approval for an indication
broader than what is designated, it may not be entitled to orphan product exclusivity. Orphan Drug status in the European Union has similar
but not identical benefits in the European Union.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Expedited Development and Review Programs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA has a Fast Track program that is intended
to expedite or facilitate the process for reviewing new drug and biological products that meet certain criteria. Specifically, new drug
and biological products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition
and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the
product and the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may consider for review sections
of the NDA or BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission
of the sections of the NDA or BLA, the FDA agrees to accept sections of the NDA or BLA and determines that the schedule is acceptable,
and the sponsor pays any required user fees upon submission of the first section of the NDA or BLA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any product submitted to the FDA for marketing approval,
including those submitted to a Fast Track program, may also be eligible for other types of FDA programs intended to expedite development
and review, such as priority review and accelerated approval. Any product is eligible for priority review if it has the potential to provide
safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or
prevention of a disease compared with marketed products. The FDA will attempt to direct additional resources to the evaluation of an application
for a new drug or biological product designated for priority review in an effort to facilitate the review. Additionally, a product may
be eligible for accelerated approval. Drug or biological products studied for their safety and effectiveness in treating serious or life-threatening
illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval, which means that
they may be approved on the basis of adequate and well-controlled clinical studies establishing that the product has an effect on a surrogate
endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival
or irreversible morbidity. As a condition of approval, the FDA generally requires that a sponsor of a drug or biological product receiving
accelerated approval perform adequate and well-controlled post-marketing clinical studies to establish safety and efficacy for the approved
indication. Failure to conduct such studies or conducting such studies that do not establish the required safety and efficacy may result
in revocation of the original approval. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of
promotional materials, which could adversely impact the timing of the commercial launch or subsequent marketing of the product. Fast Track
designation, priority review and accelerated approval do not change the standards for approval but may expedite the development or approval
process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Post-Approval Requirements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any drug or biological products for which we receive
FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of
adverse experiences with the product, providing the FDA with updated safety and efficacy information on an annual basis or as required
more frequently for specific events, product sampling and distribution requirements, complying with certain electronic records and signature
requirements and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer
advertising, prohibitions against promoting drugs and biologics for uses or in patient populations that are not described in the drug&#8217;s
or biologic&#8217;s approved labeling (known as &#8220;off-label use&#8221;), rules for conducting industry-sponsored scientific and educational
activities, and promotional activities involving the internet. Failure to comply with FDA requirements can have negative consequences,
including the immediate discontinuation of noncomplying materials, adverse publicity, enforcement letters from the FDA, mandated corrective
advertising or communications with doctors, and civil or criminal penalties. Although physicians may prescribe legally available drugs
and biologics for off-label uses, manufacturers may not market or promote such off-label uses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We will need to rely on third parties for the production
of our product candidates. Manufacturers of our product candidates are required to comply with applicable FDA manufacturing requirements
contained in the FDA&#8217;s cGMP regulations. cGMP regulations require among other things, quality control and quality assurance as well
as the corresponding maintenance of comprehensive records and documentation. Drug and biologic manufacturers and other entities involved
in the manufacture and distribution of approved drugs and biologics are also required to register their establishments and list any products
made there with the FDA and comply with related requirements in certain states, and are subject to periodic unannounced inspections by
the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money
and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval
may result in serious and extensive restrictions on a product, manufacturer, or holder of an approved NDA or BLA, including suspension
of a product until the FDA is assured that quality standards can be met, continuing oversight of manufacturing by the FDA under a &#8220;consent
decree,&#8221; which frequently includes the imposition of costs and continuing inspections over a period of many years, and possible
withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before
being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are
also subject to further FDA review and approval.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA also may require post-marketing testing, known
as Phase&#160;4 testing, risk minimization action plans and surveillance to monitor the effects of an approved product or place conditions
on an approval that could otherwise restrict the distribution or use of the product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Employees</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business is managed by our officers who consist
of Mr. Cuong Do, Chief Executive Officer &amp; President; Dr. Joseph M Columbo, Executive Vice President -Chief Medical Officer; and Wendy
Kim, our Chief Financial Officer and Corporate Secretary. These individuals devote their full-time efforts to the Company activities.
The Company has 14 employees which are all full time. We also rely on a team of highly experienced scientific, medical, and regulatory
consultants to conduct product development activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_003"></span>ITEM 1A.</b></td>
    <td style="width: 90%; text-align: justify"><b>RISK FACTORS</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business, financial condition, operating results
and prospects are subject to the following risks. Additional risks and uncertainties not presently foreseeable to us may also impair our
business operations. If any of the following risks or the risks described elsewhere in this report actually occurs, our business, financial
condition or operating results could be materially adversely affected. In such case, the trading price of our Company&#8217;s Class A
Common Stock, par value $0.0001 (&#8220;Common Stock&#8221;) Common Stock could decline, and our stockholders may lose all or part of
their investment in the shares of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Form 10-K contains forward-looking statements
that involve risks and uncertainties. These statements can be identified by the use of forward-looking terminology such as &#8220;believes,&#8221;
&#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;predict&#8221;
or &#8220;anticipation&#8221; or the negative thereof or other variations thereon or comparable terminology. Actual results could differ
materially from those discussed in the forward- looking statements as a result of certain factors, including those set forth below and
elsewhere in this Form 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risk Factor Summary</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our business operations are subject to numerous risks,
factors and uncertainties, including those outside of our control, which could cause our actual results to be harmed, including risks
regarding the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Relating to Our Business and Industry</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>If these third parties contractors do not successfully carry out their contractual duties or meet expected deadlines or do not successfully
perform and comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize our product candidates.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Successful development of biopharmaceuticals is highly uncertain and is dependent on numerous factors, many of which are beyond our
control.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>The concentration of our assets within certain financial institutions could have a material adverse effect on its business, financial
condition and results of operations.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We are currently subject to securities class action litigation and may be subject to similar or other litigation in the future, which
may have a material adverse effect on our business.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We have no products approved for commercial sale, have never generated any revenues, and may never achieve revenues or profitability,
which could cause us to cease operations.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We are a development stage company with a limited operating history, making it difficult for you to evaluate our business and your
investment.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>If the FDA or comparable foreign regulatory authorities approve generic versions of any of our product candidates that receive marketing
approval, or such authorities do not grant our products sufficient, or any, periods of exclusivity before approving generic versions of
our products, the sales of our products could be adversely affected.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>If we fail to obtain or maintain Orphan Drug exclusivity for BIV201, we will have to rely on other potential marketing exclusivity
and on our intellectual property rights.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We will need to raise substantial additional capital in the future to fund our operations, which could have a materially adverse effect
on our business.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We have limited experience in drug development and may not be able to successfully develop any drugs, which would cause us to cease
operations.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Development of pharmaceutical products is a time-consuming process, subject to a number of risks, many of which are outside of our
control.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may expend our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates
or indications that may be more profitable or for which there is a greater likelihood of success.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We have no manufacturing experience, and the failure to comply with all applicable manufacturing regulations and requirements could
have a materially adverse effect on our business.&#160;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We do not currently have the sales and marketing personnel necessary to sell products, and the failure to hire and retain such staff
could have a materially adverse effect on our business.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Even if we were to successfully develop approvable drugs, we will not be able to sell these drugs if we or our third-party manufacturers
fail to comply with manufacturing regulations.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We must comply with significant and complex government regulations, compliance with which may delay or prevent the commercialization
of our product candidates.&#160;&#160;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may face business disruption and related risks if there is another pandemic.&#160;</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>The loss or unavailability of our management could put us at a competitive disadvantage.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may not be able to attract and retain highly skilled personnel.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may be unable to compete with enterprises in the highly competitive biotechnology and biopharmaceutical industries and those equipped
with more substantial resources than us.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>There may be conflicts of interest among our officers, directors and stockholders.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We indemnify our officers and directors against liability to us and our security holders, and such indemnification could increase
our operating costs.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-indent: 0in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Relating to Our Intellectual Property</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may be unable to obtain or protect intellectual property rights relating to our product candidates.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>If we fail to comply with our obligations in the licensing and collaboration agreements, our competitive position, business, financial
condition, results of operations and prospects could be harmed.&#160;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Compliance with federal regulations such as &#8220;march-in&#8221; rights may limit our exclusive rights and our ability to contract
with non-U.S. manufacturers.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Patent terms may be inadequate to establish our competitive position on our drug candidates for an adequate amount of time.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may not be able to protect our intellectual property rights throughout the world. &#160;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Changes in patent law could diminish the value of our patents and impair our ability to protect our drug candidate.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may be involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time-consuming
and unsuccessful, and our patents could be found invalid or unenforceable.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Our failure to identify relevant third-party patents or correctly interpret the relevance, scope or expiration of patents, we may
be subject to infringement claims or may not be able to develop our drug candidates.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual
property rights.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may be subject to claims by third parties asserting that we or our employees have infringed, misappropriated or otherwise violated
their intellectual property rights, or claiming ownership of what we regard as our own intellectual property.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We may be subject to claims challenging the inventorship of our patents and other intellectual property.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Intellectual property rights do not necessarily address all potential threats.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of shares
of our Common Stock to decline.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Risks Relating to Our Common Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Our stock price is and may continue to be volatile and you may not be able to resell our Common Stock at or above the price you paid.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>You may experience future dilution as a result of future equity offerings or if we issue shares subject to options, warrants, stock
awards or other arrangements.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Certain stockholder of the Company may have significant control over our Company.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>The reverse stock split effected on August 6, 2024 may not result in positive outcomes.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>The market price and trading volume of our Common Stock may be volatile.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>The large number of restricted shares outstanding may reduce the market price of our Common Stock.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Any failure to maintain effective internal control over financial reporting could harm us.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Limited trading market for our Common Stock could make it difficult to liquidate an investment.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>The lack of public company experience of our management team could negatively affect our business.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Investors may be less attracted to our Common Stock because we are as a smaller reporting company.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Additional audit and legal costs associated with periodic reporting requirements of the Securities Exchange Act of 1934, as amended
(the &#8220;Exchange Act&#8221;) will negatively affect our ability to earn a profit.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Because we do not intend to pay any cash dividends on our Common Stock, our stockholders will not be able to receive a return on their
shares unless they sell them.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>We are authorized to issue &#8220;blank check&#8221; preferred stock without stockholder approval, which could adversely impact the
rights of holders of our securities.</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.5in"/><td style="width: 0.5in"><span style="font-family: Symbol">&#183;</span></td><td>Provisions in our Articles of Incorporation, our Bylaws, and Nevada law might discourage, delay or prevent a change in control of
our company or changes in our management and, therefore, depress the trading price of our Common Stock.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Relating to Our Business and Industry</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We rely and will continue to rely on third parties
to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines
or do not successfully perform and comply with regulatory requirements, we may not be able to obtain regulatory approval of or commercialize
our product candidates.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">We depend, and will
continue to depend, on third parties, including, but not limited to, contract research organizations (&#8220;CROs&#8221;), clinical
trial sites and clinical trial principal investigators, contract laboratories, IRBs, manufacturers, suppliers, and other third
parties to conduct our clinical trials, including those for our drug candidates bezisterim (NE3107) and BIV201. We rely heavily on
these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless,
we retain ultimate responsibility for ensuring that each of our studies is conducted in accordance with the protocol and applicable
legal, regulatory, and scientific standards and regulations, and our reliance on third parties does not relieve us of our regulatory
responsibilities. We and these third parties are required to comply with cGCPs, which are regulations and guidelines enforced by the
FDA and comparable foreign regulatory authorities for the conduct of clinical trials on product candidates in clinical development.
Regulatory authorities enforce cGCPs through periodic inspections and for-cause inspections of clinical trial principal
investigators and trial sites. If, due to the failure of either the Company or a third party, a clinical trial fails to comply with
applicable cGCPs, FDA&#8217;s IND requirements, other applicable regulatory requirements, or requirements set forth in the
applicable IRB-approved protocol, the Company may be required to conduct additional clinical trials to support our marketing
applications, which would delay the regulatory approval process. For example, our drug product candidate bezisterim (NE3107) was
cleared by FDA for use in a Phase 3, randomized, double blind, placebo controlled, parallel group, multicenter study in subjects who
have mild to moderate AD. Enrollment in that trial began in August 2021, with a planned primary completion in late 2022/early 2023.
On November 29, 2023, the Company announced topline efficacy data from its Phase 3 clinical trial (NCT04669028) of bezisterim
(NE3107) in the treatment of mild to moderate AD. Upon trial completion, as the Company began the process of analyzing the trial
data, the Company found significant deviations from the protocol and cGCP violations at 15 study sites (virtually all of which were
from one geographic area). This highly unusual level of suspected improprieties led the Company to exclude all patients from these
sites. We subsequently notified FDA&#8217;s OSI of such significant deviations from study protocol, the suspected improprieties, and
the study sites involved. The identification of significant deviations from study protocol and numerous GCP violations at multiple
study sites raised questions regarding the validity and robustness of data from these study sites. The unplanned exclusion of so
many patients left the trial underpowered for its primary endpoints. However, based on the remaining dataset from those other sites
determined to be in compliance with the protocol and GCP&#8217;s, a preliminary signal of efficacy was detected. The Company is
considering: (1) employing the adaptive trial feature of the protocol to continue enrolling patients to achieve statistical
significance; and/or (2) designing a new Phase 3 study of bezisterim (NE3107) that leverages the most recent scientific literature
relating to AD along with the company's understanding regarding the effects of bezisterim (NE3107) in persons with mild-moderate
AD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">Although we design the clinical
trials for our product candidates, our CROs are tasked with facilitating and monitoring these trials. As a result, many aspects
of our clinical development programs, including site and investigator selection, and the conduct, timing, and monitoring of the study,
is outside our direct control, either partially or in whole. Our reliance on third parties to conduct clinical trials also results
in less direct control over the collection, management, and quality of data developed through clinical trials than would be the case if
we were relying entirely upon our own employees. Communicating with third parties can also be challenging, potentially leading to mistakes
as well as difficulties in coordinating activities. Our business may be impacted if any of these third parties violates applicable federal, state, or foreign laws and/or regulations, including
but not limited to FDA&#8217;s IND regulations, cGCPs, fraud and abuse or false claims laws, healthcare privacy and data security laws,
or provide us or government agencies with inaccurate, misleading, or incomplete data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Successful development of biopharmaceuticals
is highly uncertain and is dependent on numerous factors, many of which are beyond our control.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Product candidates that appear promising in the early
phases of development may fail to reach the market for several reasons. Pre-clinical study results may show the product candidate to be
less effective than desired (e.g., the study failed to meet its primary endpoints) or to have harmful or problematic side effects. Product
candidates may fail to receive the necessary regulatory approvals or may be delayed in receiving such approvals. Among other things, such
delays may be caused by slow enrollment in clinical studies; length of time to achieve study endpoints; additional time requirements for
data analysis; IND and later new drug application preparation; discussions with the FDA; an FDA request for additional pre-clinical or
clinical data; unexpected safety or manufacturing issues; manufacturing costs; pricing or reimbursement issues; clinical sites deviating
from the trial protocol, committing scientific misconduct, or other violations of regulatory requirements - which can render data from
those sites unusable in support of regulatory approval; or other factors that make the product not economical. Proprietary rights of others
and their competing products and technologies may also prevent the product from being commercialized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Success in pre-clinical and early clinical studies
does not ensure that large-scale clinical studies will be successful. Clinical results are frequently susceptible to varying interpretations
that may delay, limit or prevent regulatory approvals. The length of time necessary to complete clinical studies and to submit an application
for marketing approval for a final decision by a regulatory authority varies significantly from one product to the next, and may be difficult
to predict. There can be no assurance that any of our products will develop successfully, and the failure to develop our products will
have a materially adverse effect on our business and will cause you to lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The concentration of our assets within a
certain financial institution could have a material adverse effect on its business, financial condition and results of
operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of August 30, 2024, the Company had cash
deposited in a certain financial institution in excess of federally insured levels. The Company regularly monitors the financial
stability of these financial institutions and believes that it is not exposed to any significant credit risk in cash and cash
equivalents. Bank failures, events involving limited liquidity, defaults, non-performance, or other adverse developments that affect
financial institutions, or concerns or rumors about such events, may lead to liquidity constraints. In 2023, certain U.S. government
banking regulators took steps to intervene in the operations of certain financial institutions due to liquidity concerns, which
caused general heightened uncertainties in financial markets. While previous bank failures have not had a material direct impact on
the Company&#8217;s operations, if further liquidity and financial stability concerns arise with respect to banks and financial
institutions, either nationally or in specific regions, the Company&#8217;s ability to access cash or enter into new financing
arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of
operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are currently subject to securities class
action litigation and may be subject to similar or other litigation in the future, all of which will require significant management time
and attention, result in significant legal expenses and may result in unfavorable outcomes, which may have a material adverse effect on
our business, operating results and financial condition, and negatively affect the price of our Common Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are, and may in the future become, subject to
various legal proceedings and claims that arise in or outside the ordinary course of business. For example, On January 19, 2024, a
purported shareholder class action complaint, captioned&#160;<i>Eric Olmstead v. BioVie Inc. et al.</i>, No. 3:24-cv-00035, was
filed in the U.S. District Court for the District of Nevada, naming the Company and certain of its officers as defendants. On
February 22, 2024, a second, related putative securities class action was filed in the same court asserting similar claims against
the same defendants, captioned <i>Way v. BioVie Inc. et al.</i>, No. 2:24-cv-00361. On April 15, 2024, the court consolidated these
two actions under the caption <i>In re BioVie Inc. Securities Litigation</i>, No. 3:24-cv-00035, appointed the lead plaintiff, and
approved selection of the lead counsel. On June 21, 2024, the lead plaintiff filed an amended complaint, alleging that the
defendants made material misrepresentations and/or omissions of material fact relating to the Company&#8217;s business, operations,
compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to
moderate probable Alzheimer&#8217;s Disease,&#160;<span style="background-color: white">in violation of Sections 10(b) and 20(a) of
the Exchange Act, and&#160;Rule 10b-5&#160;promulgated thereunder. The class action is on behalf of purchasers of the
Company&#8217;s securities during the period from December 7, 2022 through November 28, 2023 and seeks unspecified monetary damages
on behalf of the putative class and an award of costs and expenses, including attorney&#8217;s fees. The defendants filed a motion
to dismiss the amended complaint on August 21, 2024. The defendants believe that the claims are without merit and intend to
defend vigorously against them, but there can be no assurances as to the outcome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">It is possible that additional lawsuits will be filed,
or allegations received from stockholders, with respect to these same or other matters and also naming us and/or our officers and directors
as defendants. Such lawsuits and any other related lawsuits are subject to inherent uncertainties, and the actual defense and disposition
costs will depend upon many unknown factors. The outcome of such lawsuits is necessarily uncertain. We could be forced to expend significant
resources in the defense of the pending lawsuit and any additional lawsuits, and we may not prevail. In addition, we may incur substantial
legal fees and costs in connection with such lawsuits. We currently are not able to estimate the possible cost to us from this matter,
as the pending lawsuit is currently at an early stage, and we cannot be certain how long it may take to resolve the pending lawsuit or
the possible amount of any damages that we may be required to pay. Monitoring, initiating and defending against legal actions is time-consuming
for our management, is likely to be expensive and may detract from our ability to fully focus our internal resources on our business activities.
We could be forced to expend significant resources in the settlement or defense of the pending lawsuit and any potential future lawsuits,
and we may not prevail in such lawsuits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although we have insurance coverage that we believe
applies to these actions, the coverage is subject to a $2 million deductible. That means that we are responsible for the first $2 million
of loss arising from these actions, which includes both defense costs and damages, before any insurance coverage will apply. Furthermore,
our insurance coverage may be insufficient, and our assets may be insufficient to cover any amounts that exceed our insurance coverage,
and we may have to pay damage awards or otherwise may enter into a settlement arrangement in connection with such claim. A decision adverse
to our interests in the pending lawsuit, or in similar or related litigation, could result in the payment of substantial damages, or possibly
fines, and could have a material adverse effect on our business, our stock price, cash flow, results of operations and financial condition.
We have not established any reserve for any potential liability relating to the pending lawsuit or any potential future lawsuits. Any
such payments or settlement arrangements in current or future litigation could have a material adverse effect on our business, operating
results or financial condition. In addition, such lawsuits may make it more difficult to finance our operations and affect our ability
to make payments for damages.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have no products approved for commercial
sale, have never generated any revenues and may never achieve revenues or profitability, which could cause us to cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no products approved for commercial sale and,
to date, we have not generated any revenue. Our ability to generate revenue depends heavily on (a) successful completion of one or more
development programs demonstrating in human clinical trials that BIV201 and bezisterim (NE3107), our product candidates, are safe and
effective; (b) our ability to seek and obtain regulatory approvals, including, without limitation, with respect to the indications we
are seeking; (c) successful commercialization of our product candidates; and (d) market acceptance of our products. There are no assurances
that we will achieve any of the forgoing objectives. Furthermore, our product candidates are in the development stage, and have not been
fully evaluated in human clinical trials. If we do not successfully develop and commercialize our product candidates we will not achieve
revenues or profitability in the foreseeable future, if at all. If we are unable to generate revenues or achieve profitability, we may
be unable to continue our operations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are a development stage company with a limited
operating history, making it difficult for you to evaluate our business and your investment.&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although our Company was incorporated on April 10,
2013, we are a development stage biopharmaceutical company with potential therapies that have not been fully evaluated in clinical trials,
and our operations are subject to all of the risks inherent in the establishment of a new business enterprise, including but not limited
to the absence of an operating history, the lack of commercialized products, insufficient capital, expected substantial and continual
losses for the foreseeable future, limited experience in dealing with regulatory issues, the lack of manufacturing experience and limited
marketing experience, possible reliance on third parties for the development and commercialization of our proposed products, a competitive
environment characterized by numerous, well-established and well capitalized competitors and reliance on key personnel.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since inception, we have not established any revenues
or operations that would provide financial stability in the long term, and there can be no assurance that we will realize our plans on
our projected timetable in order to reach sustainable or profitable operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investors are subject to all the risks incident to
the creation and development of a new business and each investor should be prepared to withstand a complete loss of his, her or its investment.
Furthermore, the accompanying financial statements have been prepared assuming that we will continue as a going concern. We have not emerged
from the development stage, and may be unable to raise further equity. These factors raise substantial doubt about our ability to continue
as a going concern. The financial statements included elsewhere in this Form 10-K do not include any adjustments that might result from
the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because we are subject to these risks, you may have
a difficult time evaluating our business and your investment in our Company. Our ability to become profitable depends primarily on our
ability to develop drugs, to obtain approval for such drugs, and if approved, to successfully commercialize our drugs, our research and
development (&#8220;R&amp;D&#8221;) efforts, including the timing and cost of clinical trials; and our ability to enter into favorable
alliances with third-parties who can provide substantial capabilities in clinical development, regulatory affairs, sales, marketing and
distribution.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if we successfully develop and market BIV201
and/or bezisterim (NE3107), we may not generate sufficient or sustainable revenue to achieve or sustain profitability, which could cause
us to cease operations and cause you to lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>If the FDA or comparable foreign regulatory
authorities approve generic versions of any of our product candidates that receive marketing approval, or such authorities do not grant
our products sufficient, or any, periods of exclusivity before approving generic versions of our products, the sales of our products could
be adversely affected.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Once a NDA is approved, the product covered thereby
becomes a &#8220;reference listed drug&#8221; (&#8220;RLD&#8221;), in the FDA&#8217;s publication, &#8220;Approved Drug Products with
Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. Other manufacturers may seek approval of generic versions
of reference listed drugs through submission of abbreviated new drug applications (&#8220;ANDAs&#8221;) in the United States. In support
of an ANDA, a generic manufacturer need not conduct clinical trials. Rather, the applicant generally must show that its product has the
same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference listed drug
and that the generic version is bioequivalent to the reference listed drug, meaning it is absorbed in the body at the same rate and to
the same extent as the RLD. Generic products may be significantly less costly to bring to market than the reference listed drug and companies
that produce generic products are generally able to offer them at lower prices. Moreover, generic versions of RLDs are often automatically
substituted for the RLD by pharmacies when dispensing a prescription written for the RLD. Thus, following the introduction of a generic
drug, a significant percentage of the sales of any branded product or reference listed drug is typically lost to the generic product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA may not approve an ANDA for a generic product
until any applicable period of non-patent exclusivity for the reference listed drug has expired. The FDCA provides a period of five years
of non-patent exclusivity for a new drug containing a new chemical entity (&#8220;NCE&#8221;). An NCE is an active ingredient that has
not previously been approved by FDA in any other NDA. Specifically, in cases where such exclusivity has been granted, an ANDA may not
be submitted to the FDA until the expiration of five years unless the submission is accompanied by a Paragraph&#160;IV certification that
a patent covering the reference listed drug is either invalid or will not be infringed by the generic product, in which case the applicant
may submit its application four years following approval of the reference listed drug. If an ANDA is submitted to FDA with a Paragraph
IV Certification, the generic applicant must also provide a &#8220;Paragraph IV Notification&#8221; to the holder of the NDA for the RLD
and to the owner of the listed patent(s) being challenged by the ANDA applicant, providing a detailed written statement of the basis for
the ANDA applicant&#8217;s position that the relevant patent(s) is invalid or would not be infringed. If the patent owner brings a patent
infringement lawsuit against the ANDA applicant within 45 days of the Paragraph IV Notification, FDA approval of the ANDA will be automatically
stayed for 30 months, or until 7-1/2 years after the NDA approval if the generic application was filed between 4 years and 5 years after
the NDA approval. Any such stay will be terminated earlier if the court rules that the patent is invalid or would not be infringed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Competition that our products may face from generic
versions of our products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit
our ability to obtain a return on the investments we have made in those product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>If we fail to obtain
or maintain Orphan Drug exclusivity for BIV201, we will have to rely on other potential marketing exclusivity, and on our intellectual
property rights, which may reduce the length of time that we can prevent competitors from selling generic versions of BIV201.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have obtained Orphan Drug Designation for BIV201
(terlipressin) in the U.S. for the treatment of hepatorenal syndrome on November 21, 2018 and treatment of ascites due to all etiologies
except cancer on September 8, 2016. Under the Orphan Drug Act, the FDA may designate a product as an Orphan Drug if it is a drug intended
to treat a rare disease or condition, defined, in part, as a patient population of fewer than 200,000 in the U.S. In the European Union
(&#8220;EU&#8221;), Orphan Drug designation may be granted to drugs intended to treat, diagnose or prevent a life-threatening or chronically
debilitating disease having a prevalence of no more than five in 10,000 people in the EU, and which meet other specified criteria. The
company that first obtains FDA approval for a designated Orphan Drug for the associated rare disease may receive a seven-year period of
marketing exclusivity during which time FDA may not approve another application for the same drug for the same orphan disease or condition.
Orphan Drug Exclusivity does not prevent FDA approval of another application for the same drug for a different disease or condition, or
of an application for a different drug for the same rare disease or condition. Orphan Drug exclusive marketing rights may be lost under
several circumstances, including a later determination by the FDA that the request for designation was materially defective or if the
manufacturer is unable to assure sufficient quantity of the drug. Similar regulations are available in the EU with a ten-year period of
market exclusivity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even though BioVie has obtained two Orphan Drug Designations
for its lead product candidate, terlipressin, for treatment of ascites and for treatment of hepatorenal syndrome, and may seek other Orphan
Drug Designations for BIV201, and Orphan Drug Designation for other product candidates, there is no assurance that BioVie will be the
first to obtain marketing approval for any particular rare indication. Further, even though BioVie has obtained Orphan Drug Designations
for its lead product candidate, or even if BioVie obtains Orphan Drug Designation for other potential product candidates, such designation
may not effectively protect BioVie from competition because different drugs can be approved for the same condition and the same drug can
be approved for different conditions and potentially used off-label in the Orphan indication. Even after an Orphan Drug is approved, the
FDA can subsequently approve another competing drug with the same active ingredient for the same condition for several reasons, including,
if the FDA concludes that the later drug is clinically superior due to being safer or more effective or because it makes a major contribution
to patient care. Orphan Drug Designation neither shortens the development time or regulatory review time of a drug, nor gives the drug
any advantage in the regulatory review or approval process.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, other companies have received Orphan
Drug designations for terlipressin. Mallinckrodt Hospital Products IP Limited received Orphan Drug designation in 2004 for terlipressin
for the treatment of Hepatorenal Syndrome. Mallinckrodt has already gained FDA approval for its product, lyophilized terlipressin acetate
for bolus intravenous administration for the treatment of hepatorenal syndrome Type 1 in September 2022. PharmaIN Corporation received
Orphan Drug Designation in 2012 for PGC-C12E-terlipressin for treatment of ascites due to all etiologies except cancer. In addition, Ferring
Pharmaceuticals Inc. received Orphan Drug designation in 1986 for terlipressin for the treatment of bleeding esophageal varices. If one
of those or any other company with Orphan Drug Designation for the same drug as ours for the same proposed disease or condition receives
FDA approval and Orphan Drug Exclusivity before our product is approved, approval of our drug(s) for the orphan indication may be blocked
for seven years by the other company&#8217;s Orphan Exclusivity and they may obtain a competitive advantage even after the exclusivity
period expires associated with being the first to market.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We will need to raise substantial additional
capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could
have a materially adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Developing biopharmaceutical products, including conducting
pre-clinical studies and clinical trials and establishing manufacturing capabilities, requires substantial funding. Additional financing
will be required to fund the research and development of our product candidates. We have not generated any product revenues, and do not
expect to generate any revenues until, and only if, we develop, and receive approval to sell our product candidates from the FDA and other
regulatory authorities for our product candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We may not have the resources to complete the development
and commercialization of any of our proposed product candidates. We will require additional financing to further the clinical development
of our product candidates. In the event that we cannot obtain the required financing, we will be unable to complete the development necessary
to file an NDA with the FDA for BIV201 or bezisterim (NE3107). This will delay or require termination of research and development programs,
preclinical studies and clinical trials, material characterization studies, regulatory processes, the establishment of our own laboratory
or a search for third party marketing partners to market our products for us, which could have a materially adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount of capital we may need will depend on many
factors, including the progress, timing and scope of our research and development programs, the progress, timing and scope of our preclinical
studies and clinical trials, the time and cost necessary to obtain regulatory approvals, the time and cost necessary to establish our
own marketing capabilities or to seek marketing partners, the time and cost necessary to respond to technological and market developments,
changes made or new developments in our existing collaborative, licensing and other commercial relationships, and new collaborative, licensing
and other commercial relationships that we may establish.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Until we can generate a sufficient amount of product
revenue, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings, or corporate collaboration
and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If
adequate funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development
programs or our commercialization efforts. In addition, we could be forced to discontinue product development and reduce or forego attractive
business opportunities. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional
significant dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds
through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or our product candidates
or grant licenses on terms that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions
are favorable, even if we do not have an immediate need for additional capital at that time.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our fixed expenses, such as rent and other contractual
commitments, will likely increase in the future, as we may enter into leases for new facilities and capital equipment and/or enter into
additional licenses and collaborative agreements. Therefore, if we fail to raise substantial additional capital to fund these expenses,
we could be forced to cease operations, which could cause you to lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have limited experience in drug development
and may not be able to successfully develop any drugs, which would cause us to cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never successfully developed a new drug and
brought it to market. Our management and clinical teams have experience in drug development but they may not be able to successfully
develop any drugs. Our ability to achieve revenues and profitability in our business will depend on, among other things, our ability
to develop products internally or to obtain rights to them from others on favorable terms; complete laboratory testing and human studies;
obtain and maintain necessary intellectual property rights to our products;&#160;successfully complete regulatory review to obtain requisite
governmental agency approvals;&#160;enter into arrangements with third parties to manufacture our products on our behalf; and&#160;enter
into arrangements with third parties to provide sales and marketing functions. If we are unable to achieve these objectives we will be
forced to cease operations and you will lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Development of pharmaceutical products is a
time-consuming process, subject to a number of risks, many of which are outside of our control. Consequently, we can provide no assurance
that our product candidates will obtain regulatory approval, and if we are unsuccessful or fail to timely develop new drugs, we could
be forced to discontinue our operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Development and extensive testing will be required
to determine the technical feasibility and commercial viability of BIV201 and bezisterim (NE3107). Our success will depend on our ability
to achieve scientific and technological advances and to translate such advances into reliable, commercially competitive drugs on a timely
basis. Drugs that we may develop are not likely to be commercially available, at a minimum, for several years, if ever. Our drug product
candidate, BIV201 (continuous infusion terlipressin), was cleared by the FDA to undergo testing in a mid-stage (Phase 2b) clinical trial
for the treatment of refractory ascites due to cirrhosis. On June 24, 2021, we announced that the first patient has been enrolled in this
study. In March 2023, the open-label trial was stopped after 15 of the planned 30 patients were enrolled, and an evaluation of those completed
patients assessed. Encouraging data from these patients appeared to show that treatment with BIV201 plus SOC resulted in a reduction in
ascites fluid accumulation during treatment versus pre-treatment. In June 2023, the Company requested and subsequently received guidance
from the FDA regarding the design and endpoints for definitive clinical testing of BIV201 for the treatment of ascites due to chronic
liver cirrhosis. Over three years since the initial enrollment of this clinical trial, the Company is continuing to finalize protocol
designs for the Phase 3 study of BIV201 for the treatment of ascites due to chronic liver cirrhosis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The proposed development schedules for our product
candidates may be affected by a variety of factors, including technological difficulties, proprietary technology of others, and changes
in government regulation, many of which will not be within our control. In June 2021, FDA approved the drug aducanumab for treatment of
Alzheimer&#8217;s despite a strong recommendation against approval from an FDA advisory committee. That FDA approval has generated significant
medical and political controversy, including a Congressional investigation, announced on June 25, 2021, into the basis for FDA&#8217;s
approval decision. That investigation, other potential investigations, and negative publicity of FDA&#8217;s approval decision could adversely
impact the agency&#8217;s oversight of our clinical development program, how the agency may view and act upon any NDA we may file for
bezisterim (NE3107), and the commercial viability of bezisterim (NE3107) if it were to be approved and marketed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Any delay or further delay in the development, introduction
or marketing of our product candidates could result either in such drugs being marketed at a time when their cost and performance characteristics
would not be competitive in the marketplace or in the shortening of their commercial lives. In light of the long-term nature of our projects
and other risk factors described elsewhere in this document, we may not be able to successfully complete the development or marketing
of any drugs, which could cause us to cease operations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, the FDA may have feedback on
our clinical trial designs, including for example certain of our endpoints and outcome measures. As a result, we may consider
revisions to our protocols which may delay progress in implementing our trials. We may fail to successfully develop and
commercialize our product candidate(s) if it is found to be unsafe or ineffective in clinical trials; does not receive necessary
approval from the FDA or foreign regulatory agencies; fails to conform to a changing standard of care for the disease it seeks to
treat; or is less effective or more expensive than current or alternative treatment methods.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Drug development failure can occur at any stage of
clinical trials and as a result of many factors, there can be no assurance that we or our collaborators will reach our anticipated clinical
targets. Even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and
we cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret the results as we do, and more trials could
be required before we submit our product candidates for approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities
will view our product candidates as having efficacy even if positive results are observed in clinical trials. In some instances, there
can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous
factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes
in and adherence to the clinical trial protocols, and the rate of dropout among clinical trial participants. If the results of our ongoing
or future clinical trials are inconclusive with respect to the efficacy of our product candidates, if we do not meet the clinical endpoints
with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may
be delayed in obtaining marketing approval, if at all. Additionally, any safety concerns observed in any one of our clinical trials in
our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications. We
also do not know what the long-term effects of exposure to our product candidates will be. Furthermore, our product candidates may be
used in combination with other treatments and there can be no assurance that such use will not lead to unique or unexpected safety issues.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Failure to complete clinical trials or to prove that
our product candidates are safe and effective would have a material adverse effect on our ability to generate revenue and could require
us to reduce the scope of or discontinue our operations, which could cause you to lose all of your investment.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may expend our limited resources to pursue
a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may be more profitable or for
which there is a greater likelihood of success.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Because we have limited human capital and financial
resources, we focus on research programs and drug candidates that we identify for specific indications. As a result, we may forego or
delay pursuit of opportunities with other drug candidates or for other indications that later prove to have greater commercial potential.
Our resource allocation decisions may cause us to fail to capitalize on viable commercial drugs or profitable market opportunities. Our
spending on current and future research and development programs and drug candidates for specific indications may not yield any commercially
viable drugs. If we do not accurately evaluate the commercial potential or target market for a particular drug candidate, we may relinquish
valuable rights to that drug candidate through collaboration, licensing or other royalty arrangements in cases in which it would have
been more advantageous for us to retain sole development and commercialization rights to such drug candidate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At any time and for any reason, we may determine that
one or more of our discovery programs or preclinical or clinical drug candidates or programs does not have sufficient potential to warrant
the allocation of resources toward such program or drug candidate. Accordingly, we may choose not to develop a potential drug candidate
or elect to suspend, deprioritize or terminate one or more of our discovery programs or preclinical or clinical drug candidates or programs.
For example, BIV201 has received Orphan Drug designation for HRS. On June 23, 2021, we announced that FDA has provided guidance on our
planned Phase 3 clinical trial of BIV201 in (HRS-AKI) and have since reached agreement on the key elements of the trial design. Thereafter,
we deprioritized HRS-AKI program to focus on bezisterim (NE3107). When we suspend, deprioritize or terminate a program or drug candidate
in which we have invested significant resources, we will have expended resources on a program that will not provide a full return on our
investment and may have missed the opportunity to have allocated those resources to potentially more productive uses, including existing
or future programs or drug candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We have no manufacturing experience, and the
failure to comply with all applicable manufacturing regulations and requirements could have a materially adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have never manufactured products in the highly
regulated environment of pharmaceutical manufacturing, and our team has limited experience in the manufacture of drug therapies. There
are numerous regulations and requirements that must be maintained to obtain licensure and permitting required prior to the commencement
of manufacturing, as well as additional requirements to continue manufacturing pharmaceutical products. We currently do not own or lease
facilities that could be used to manufacture any products that might be developed by us, and have contracted with an experienced Contract
Manufacturing Organization (&#8220;CMO&#8221;) to perform the manufacturing of our new product candidates BIV201 and bezisterim (NE3107).
In addition, we do not have the resources at this time to acquire or lease suitable facilities. If we or our CMO fail to comply with regulations,
to obtain the necessary licenses and knowhow or to obtain the requisite financing in order to comply with all applicable regulations and
to own or lease the required facilities in order to manufacture our products, we could be forced to cease operations, which would cause
you to lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, the FDA and other regulatory authorities
require that product candidates and drug products be manufactured according to cGMP. Any failure by our third-party manufacturers to comply
with cGMP could lead to a shortage of BIV201 and NE3107. In addition, such failure could be the basis for action by the FDA to withdraw
approval, if granted to us, and for other regulatory enforcement action, including Warning Letters, product seizure, injunction or other
civil or criminal penalties.<span style="font-size: 10pt">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BIV201 and bezisterim (NE3107) and any other product
candidates that we develop may have to compete with other products and product candidates for access to manufacturing facilities. There
are a limited number of manufacturers that operate under cGMP regulations and that are both capable of manufacturing for us and willing
to do so. If we need to find another source of drug substance or drug product manufacturing for BIV201 and bezisterim (NE3107), we may
not be able to identify, or reach agreement with, commercial-scale manufacturers on commercially reasonably terms, or at all. If we are
unable to do so, we will need to develop our own commercial-scale manufacturing capabilities, which would: impact commercialization of
BIV201 and bezisterim (NE3107) in the U.S. and other countries where it may be approved; require a capital investment by us that could
be quite costly; and increase our operating expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If our existing third-party manufacturers, or the
third parties that we engage in the future to manufacture a product for commercial sale or for our clinical trials, should cease to continue
to do so for any reason, we likely would experience significant delays in obtaining sufficient quantities of product for us to meet commercial
demand or to advance our clinical trials while we identify and qualify replacement suppliers. If for any reason we are unable to obtain
adequate supplies of BIV201 or any other product candidate that we develop, or the drug substances used to manufacture it, it will be
more difficult for us to compete effectively, generate revenue, and further develop our products. In addition, if we are unable to assure
a sufficient quantity of the drug for patients with rare diseases or conditions, we may lose any Orphan Drug exclusivity to which the
product otherwise would be entitled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We do not currently have the sales and marketing
personnel necessary to sell products, and the failure to hire and retain such staff could have a materially adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are an early stage development company with limited
resources. Even if we had products available for sale, which we currently do not, we have not secured sales and marketing staff at this
early stage of operations to sell products. We cannot generate sales without sales or marketing staff and must rely on others to provide
any sales or marketing services until such personnel are secured, if ever. If we fail to hire and retain the requisite expertise in order
to market and sell our products or fail to raise sufficient capital in order to afford to pay such sales or marketing staff, then we could
be forced to cease operations and you could lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Even if we were to successfully develop approvable
drugs, we will not be able to sell these drugs if we or our third-party manufacturers fail to comply with manufacturing regulations, which
could have a materially adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we were to successfully develop approvable drugs,
before we can begin selling these drugs, we must obtain regulatory approval of our manufacturing facility and process or the manufacturing
facility and process of the third party or parties with whom we may outsource our manufacturing activities. In addition, the manufacture
of our products must comply with the FDA&#8217;s current Good Manufacturing Practices regulations, commonly known as GMP regulations.
The GMP regulations govern quality control and documentation policies and procedures. Our manufacturing facilities, if any in the future,
and the manufacturing facilities of our third-party manufacturers will be continually subject to inspection by the FDA and other state,
local and foreign regulatory authorities, before and after product approval. We cannot guarantee that we, or any potential third-party
manufacturer of our products, will be able to comply with the GMP regulations or other applicable manufacturing regulations. The failure
to comply with all necessary regulations would have a materially adverse effect on our business and could force us to cease operations
and you could lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We must comply with significant and complex
government regulations, compliance with which may delay or prevent the commercialization of our product candidates, which could have a
materially adverse effect on our business.&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The R&amp;D, manufacture and marketing of drug product
candidates are subject to regulation, primarily by the FDA in the United States and by comparable authorities in other countries. These
national agencies and other federal, state, local and foreign entities regulate, among other things, R&amp;D activities (including testing
in animals and in humans) and the testing, manufacturing, handling, labeling, storage, record keeping, approval, advertising and promotion
of the product that we are developing. Noncompliance with applicable requirements can result in various adverse consequences, including
approval delays or refusals to approve drug licenses or other applications, suspension or termination of clinical investigations, revocation
of approvals previously granted, warning letters, fines, criminal prosecution, recalls or seizures of products, injunctions against shipping
drugs and total or partial suspension of production and/or refusal to allow a company to enter into governmental supply contracts.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
   <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The process of obtaining FDA approval is costly and
time consuming. Current FDA requirements for a new human drug or biological product to be marketed in the United States include, among
other things: (a) the successful conclusion of pre-clinical laboratory and animal tests, if appropriate, to gain preliminary information
on the product&#8217;s safety; (b) filing with the FDA of an IND application to conduct human clinical trials for drugs or biologics;
(c) the successful completion of adequate and well-controlled human clinical investigations to establish the safety and efficacy of the
product for its recommended use; and (d) filing by a company and acceptance and approval by the FDA of a NDA for a drug product or a BLA
for a biological product to allow commercial distribution of the drug or biologic. A delay in one or more of the procedural steps outlined
above could be harmful to us in terms of getting our product candidates through clinical testing and to market, which could have a materially
adverse effect on our business.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The FDA, clinical investigators, Data Safety Monitoring
Boards, and IRBs review the ongoing conduct of, and emerging safety information from, clinical trials and may order the temporary or permanent
discontinuation of clinical trials at any time if it believes the product candidate exposes clinical subjects to an unacceptable health
risk. Investigational drugs used in clinical studies must be produced in compliance with cGMP rules pursuant to FDA regulations.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Development, approval, and sales outside the United
States of products that we develop will also be subject to regulatory requirements governing human clinical trials and marketing for drugs
and biological products and devices. The requirements vary widely from country to country, but typically the registration and approval
process takes several years and requires significant resources.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If we experience delays or discontinuations of our
clinical trials by the FDA or comparable authorities in other countries, or if we fail to obtain registration or other approvals of our
products or devices then we could be forced to cease our operations and you will lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Even if we are successful in developing BIV201 and
bezisterim (NE3107), our product candidates, we have limited experience in conducting or supervising clinical trials that must be performed
to obtain data to submit in concert with applications for approval by the FDA. The regulatory process to obtain approval for drugs for
commercial sale involves numerous steps. Drugs are subjected to clinical trials that allow development of case studies to examine safety,
efficacy, and other issues to ensure that sale of drugs meets the requirements set forth by various governmental agencies, including the
FDA. In the event that our protocols do not meet standards set forth by the FDA, or that our data is not sufficient to allow such trials
to validate our drugs in the face of such examination, we might not be able to meet the requirements that allow our drugs to be approved
for sale which could have a materially adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We depend upon our management and their loss
or unavailability could put us at a competitive disadvantage which could have a material adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We currently depend upon the efforts and abilities
of our executive management team of Cuong Do, our Chief Executive Officer&#8211;President; Wendy Kim, our Chief Financial Officer; Dr
Joseph Palumbo, our Executive Vice President&#8211;Chief Medical Officer; Penelope Markham, our Senior Vice Ascites Programs &amp; Strategic
Initiatives&#8211;; Chris Reading, our Senior Vice President&#8211;Alzheimer&#8217;s Disease Program; Clarence Ahlem, our Senior Vice
President &#8211; Operations President&#8211;Operations, Discovery and Parkinson&#8217;s Disease Program; ; and David Morse, our Senior
Vice President&#8211;Chief Regulatory Officer; who all serve the Company full-time. The loss or unavailability of the services of any
of these individuals for any significant period of time could have a material adverse effect on our business, prospects, financial condition
and results of operations which may cause you to lose all of your investment. We have not obtained, do not own, nor are we the beneficiary
of key-person life insurance.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to attract and retain highly
skilled personnel, which could have a materially adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to attract and retain highly skilled personnel
is critical to our operations and expansion. We face competition for these types of personnel from other pharmaceutical companies and
more established organizations, many of which have significantly larger operations and greater financial, technical, human and other resources
than us. We may not be successful in attracting and retaining qualified personnel on a timely basis, on competitive terms, or at all.
If we are not successful in attracting and retaining these personnel, our business, prospects, financial condition and results of operations
will be materially and adversely affected.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The biotechnology and biopharmaceutical industries
are characterized by rapid technological developments and a high degree of competition. We may be unable to compete with enterprises equipped
with more substantial resources than us, which could cause us to curtail or cease operations.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The biotechnology and biopharmaceutical industries
are characterized by rapid technological developments and a high degree of competition based primarily on scientific and technological
factors. These factors include the availability of patent and other protection for technology and products, the ability to commercialize
technological developments and the ability to obtain government approval for testing, manufacturing and marketing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We compete with biopharmaceutical firms in the United
States, Europe and elsewhere, as well as a growing number of large pharmaceutical companies that are applying biotechnology to their operations.
Many biopharmaceutical companies have focused their development efforts in the human therapeutics area. Many major pharmaceutical companies
have developed or acquired internal biotechnology capabilities or made commercial arrangements with other biopharmaceutical companies.
These companies, as well as academic institutions, government agencies and private research organizations, also compete with us in recruiting
and retaining highly qualified scientific personnel and consultants. Our ability to compete successfully with other companies in the pharmaceutical
field will also depend to a considerable degree on the continuing availability of capital to us.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although there are not currently any therapies approved
by the FDA specifically for the treatment of ascites due to liver cirrhosis, we still face significant competitive and market risk. Other
companies, such as Ocelot Bio, are developing therapies for severe complications of advanced liver cirrhosis, which may in the future
be developed for the treatment of ascites, and these therapies could compete indirectly or directly with our product candidate. Similarly,
other companies, such as Biogen and Eli Lilly, are developing treatments for AD and PD, which could compete indirectly or directly with
our product candidate. There may be other competitive development programs of which we are unaware. Even if our product candidates are
ultimately approved by the FDA, there is no guarantee that once it is on the market doctors will adopt them in favor of current ascites
treatment procedures such as diuretics and paracentesis with respect to BIV201 and AD and PD with respect to bezisterim (NE3107). These
competitive and market risks could have a material adverse effect on our business, prospects, financial condition and results of operations
which may cause you to lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our competition will be determined in part by the
potential indications for which drugs are developed and ultimately approved by regulatory authorities. Additionally, the timing of the
market introduction of some of our potential product candidate or of competitors&#8217; products may be an important competitive factor.
Accordingly, the relative speed with which we can develop drugs, complete pre-clinical testing, clinical trials, approval processes and
supply commercial quantities to market are important competitive factors. We expect that competition among drugs approved for sale will
be based on various factors, including product efficacy, safety, reliability, availability, price and patent protection.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The successful development of biopharmaceuticals is
highly uncertain. A variety of factors including, pre-clinical study results or regulatory approvals, could cause us to abandon the development
of our product candidates.<span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>There may be conflicts of interest among our
officers, directors and stockholders. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Certain of our executive officers and directors and
their affiliates are engaged in other activities and have interests in other entities on their own behalf or on behalf of other persons.
Neither we nor any of our shareholders will have any rights in these ventures or their income or profits. In particular, our executive
officers or directors or their affiliates may have an economic interest in or other business relationship with partner companies that
invest in us or are engaged in competing drug development. Our executive officers or directors may have conflicting fiduciary duties to
us and third parties. The terms of transactions with third parties may not be subject to arm&#8217;s length negotiations and therefore
may be on terms less favorable to us than those that could be procured through arm&#8217;s length negotiations. Although we have established
an audit committee comprised solely of independent directors to oversee transactions between us and our insiders, we do not have any formal
policies in place to deal with such conflicting fiduciary duties should such a conflict arise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We indemnify our officers and directors against
liability to us and our security holders, and such indemnification could increase our operating costs.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Articles of Incorporation and Bylaws require us
to indemnify our officers and directors against claims associated with carrying out the duties of their offices. We are also required
to advance the costs of certain legal defenses upon the indemnitee undertaking to repay such expenses to the extent it is determined that
such person was not entitled to indemnification of such expenses. Insofar as indemnification for liabilities arising under the&#160;Securities
Act&#160;may be permitted to our officers, directors, or control persons, the Commission has advised that such indemnification is against
public policy and is therefore unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Relating to Our Intellectual Property</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be unable to obtain or protect intellectual
property rights relating to our product candidates, which could have a materially adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our ability to compete effectively will depend
on our ability to maintain the proprietary nature of our technologies. We cannot assure investors that we will continue to innovate and
file new patent applications, or that if filed any future patent applications will result in granted patents with respect to the technology
owned by us or licensed to us. Further, we cannot predict how long it will take for such patents to issue, if at all. The patent position
of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations
and, therefore, validity and enforceability cannot be predicted with certainty. Patents may be challenged, deemed unenforceable, invalidated
or circumvented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have pending patent applications for our
liquid formulations of terlipressen the following jurisdictions which claim priority to PCT/US2020/034269 filed on May 22, 2020 and published
as WO2020/237170: US, Europe, China, and Japan and 6 other jurisdictions. In two jurisdictions, we have patents for our liquid formulations
of terlipressen which claim priority to PCT/US2020/034269 filed on May 22, 2020 and published as WO2020/237170. We also have thirteen
(13) issued U.S. patents, six (6) pending U.S. applications, three (3) pending Patent Cooperation Treaty applications, six (6) issued
foreign patents, and six (6) pending foreign patent applications directed to protecting bezisterm (NE3107) and related compounds and
methods of making and using thereof. However, there can be no assurance that our pending patent applications will result in issued patents,
or that any issued patent claims from pending or future patent applications will be sufficiently broad to protect BIV201, bezisterim
(NE3107), or any other product candidates or to provide us with competitive advantages.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We can provide no assurance
that any issued patents will provide us with any competitive advantage. We cannot be certain that there is no invalidating prior art of
which we and the patent examiner are unaware or that our interpretation of the relevance of prior art is correct. If a third-party patent
or patent application is determined to have an earlier priority date, it may prevent our patent applications from issuing at all or issuing
in a form that provides any competitive advantage for our drug candidates. Failure to obtain additional issued patents could have a material
adverse effect on our ability to develop and commercialize our drug candidates. Even if our patent applications do issue as patents, third
parties may be able to challenge the validity and enforceability of our patents on a variety of grounds, including that such third party&#8217;s
patents and patent applications have an earlier priority date, and if such challenges are successful, we may be required to obtain one
or more licenses from such third parties, if available on commercially reasonable terms, or be prohibited from commercializing our drug
candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We seek to protect our proprietary
positions by, among other things, filing patent applications in the United States and abroad related to our current drug candidates and
other drug candidates that we may identify. Obtaining, maintaining, defending and enforcing pharmaceutical patents is costly, time-consuming
and complex, and we may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license
any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will
fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover,
under certain of our license or collaboration agreements, we may not have the right to control the preparation, filing, prosecution and
maintenance of patent applications, or to maintain the rights to patents licensed to or from third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We currently are the assignee
of a number of U.S. provisional patent applications. U.S. provisional patent applications are not eligible to become issued patents until,
among other things, we file a non-provisional patent application within 12 months of filing one or more of our related provisional patent
applications. With regard to such U.S. provisional patent applications, if we do not timely file any non-provisional patent applications,
we may lose our priority dates with respect to our provisional patent applications and any patent protection on the inventions disclosed
in our provisional patent applications. Further, in the event that we do timely file non-provisional patent applications relating to our
provisional patent applications, we cannot predict whether any such patent applications will result in the issuance of patents or if such
issued patents will provide us with any competitive advantage.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As to our material inventions,
trade secrets, and intellectual property, our employees, consultants, and advisors execute confidentiality agreements and agree to disclose
and assign to us all inventions conceived during the workday, using our property, or which relate to our business. However, any of these
parties may breach these agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to
seek patent protection. Further, we may not be aware of all third-party intellectual property rights potentially relating to our drug
candidates. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications
in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore,
we cannot know with certainty whether we were the first to make the inventions claimed in our patents or pending patent applications,
or that we were the first to file for patent protection of such inventions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The patent position of pharmaceutical
companies generally is highly uncertain, involves complex legal, technological and factual questions and has, in recent years, been the
subject of much debate and litigation throughout the world. In addition, the laws of foreign countries may not protect our rights to the
same extent as the laws of the United States, or vice versa. The standards that the United States Patent and Trademark Office (the &#8220;USPTO&#8221;)
(and foreign countries) use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform,
worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or biotechnology patents. Accordingly,
we do not know the degree of future protection for our proprietary rights or the breadth of claims that will be allowed in any patents
issued to us or to others. The issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain.
The subject matter claimed in a patent application can be significantly reduced or eliminated before the patent issues, if at all, and
its scope can be reinterpreted or narrowed after issuance. Therefore, our pending and future patent applications may not result in patents
being issued in relevant jurisdictions that protect our drug candidates, in whole or in part, or that effectively prevent others from
commercializing competitive drug candidates, and even if our patent applications issue as patents in relevant jurisdictions, they may
not issue in a form that will provide us with any meaningful protection for our drug candidates or technology, prevent competitors from
competing with us or otherwise provide us with any competitive advantage. Additionally, our competitors may be able to circumvent our
patents by challenging their validity or by developing similar or alternative drug candidates or technologies in a non-infringing manner.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The issuance of a patent is
not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices
in the United States and abroad. We may be subject to a third-party preissuance submission of prior art to the USPTO, or become involved
in opposition, derivation, reexamination, <i>inter partes</i> review, post-grant review or interference proceedings challenging our patent
rights or the patent rights of others, or other proceedings in the USPTO or applicable foreign offices that challenge priority of invention
or other features of patentability. An adverse determination in any such submission, proceeding or litigation could result in loss of
exclusivity or ability to sell our products free from infringing the patents of third parties, patent claims being narrowed, invalidated
or held unenforceable, in whole or in part, and limitation of the scope or duration of the patents directed to our drug candidates, all
of which could limit our ability to stop others from using or commercializing similar or identical drug candidates or technology to compete
directly with us, without payment to us, or result in our inability to manufacture or commercialize drug candidates or approved products
(if any) without infringing third-party patent rights. In addition, if the breadth or strength of the claims of our patents and patent
applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize
current or future drug candidates, or could have a material adverse effect on our ability to raise funds necessary to continue our research
programs or clinical trials. Such proceedings also may result in substantial cost and require significant time from our scientists and
management, even if the eventual outcome is favorable to us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition, given the amount
of time required for the development, testing and regulatory review of new drug candidates, patents protecting such candidates might expire
before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights
to exclude others from commercializing products or technology similar or identical to ours for a meaningful amount of time, or at all.
Moreover, some of our licensed patents and owned or licensed patent applications may in the future be co-owned with third parties. If
we are unable to obtain exclusive licenses to any such co-owners&#8217; interest in such patents or patent applications, such co-owners
may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products
and technology. In addition, we may need the cooperation of any such co-owners in order to enforce such patents against third parties,
and such cooperation may not be provided to us. Any of the foregoing could harm our competitive position, business, financial condition,
results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Further,
we rely on a combination of trade secrets, know-how, technology and nondisclosure, and other contractual agreements and technical measures
to protect our rights in the technology. If any trade secret, know-how or other technology not protected by a patent were to be disclosed
to or independently developed by a competitor, our business and financial condition could be materially and adversely affected. The laws
of some foreign countries do not protect our proprietary rights to the same extent as the laws of the U.S., and we may encounter significant
problems in protecting our proprietary rights in these countries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our success
depends in significant part on our ability to obtain, maintain, enforce and defend patents and other intellectual property rights with
respect to our drug candidates and technology and to operate our business without infringing, misappropriating, or otherwise violating
the intellectual property rights of others. If we are unable to obtain and maintain sufficient intellectual property protection for our
drug candidates or other drug candidates that we may identify, or if the scope of the intellectual property protection obtained is not
sufficiently broad, our competitors and other third parties could develop and commercialize drug candidates similar or identical to ours,
and our ability to successfully commercialize our drug candidates and other drug candidates that we may pursue may be impaired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Confidentiality agreements with employees and
others may not adequately prevent disclosure of trade secrets and other proprietary information and disclosure of our trade secrets or
proprietary information could compromise any competitive advantage that we have, which could have a materially adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our success depends, in part,
on our ability to protect our proprietary rights to the technologies used in our product candidates. We depend heavily upon confidentiality
agreements with our officers, employees, consultants and subcontractors to maintain the proprietary nature of our technology. These measures
may not afford us complete or even sufficient protection, and may not afford an adequate remedy in the event of an unauthorized disclosure
of confidential information. If we fail to protect and/or maintain our intellectual property, third parties may be able to compete more
effectively against us, we may lose our technological or competitive advantage, and/or we may incur substantial litigation costs in our
attempts to recover or restrict use of our intellectual property. In addition, others may independently develop technology similar to
ours, otherwise avoiding the confidentiality agreements, or produce patents that would materially and adversely affect our business, prospects,
financial condition and results of operations, in which event you could lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may enter into licensing and collaboration
agreements with third parties. If we fail to comply with our obligations in the agreements under which we license intellectual property
rights to or from third parties, or these agreements are terminated, or we otherwise experience disruptions to our business relationships
with our licensors or licensees, our competitive position, business, financial condition, results of operations and prospects could be
harmed. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">It may be necessary for us to
use the patented or proprietary technology of third parties to commercialize our products (if approved), in which case we would be required
to obtain a license from these third parties. The licensing of third-party intellectual property rights is a competitive area, and more
established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive
or necessary. More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical
development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign
or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow
us to make an appropriate return on our investment or at all. If we are unable to license such technology, or if we are forced to license
such technology on unfavorable terms, our business could be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We may fail to obtain any of
these licenses or intellectual property rights on commercially reasonable terms. Even if we are able to obtain a license, it may be non-exclusive,
thereby giving our competitors access to the same technologies licensed to us. Licenses may not provide us with exclusive rights to use
the applicable intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop
or commercialize our drug candidates, products (if approved) and technology in the future. In that event, we may be required to expend
significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or
commercialize the affected products, which could materially harm our business and the third parties owning such intellectual property
rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties
and/or other forms of compensation. Conversely, we may not always be able to successfully pursue our claims against others that infringe
upon our technology. Thus, the proprietary nature of our technology or technology licensed by us may not provide adequate protection against
competitors, and we may not be able to prevent competitors from developing and commercializing competitive products or technologies.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition, in some circumstances,
we may not have the right to control the preparation, filing and prosecution of patent applications or to maintain, defend and enforce
the patents that we license to or from third parties, and we may have to rely on our partners to fulfill these responsibilities. If our
current or future licensors, licensees or collaborators fail to prepare, file, prosecute, maintain, enforce, and defend licensed patents
and other intellectual property rights, such rights may be reduced or eliminated, and our right to develop and commercialize any of our
drug candidates or technology that are the subject of such licensed rights could be adversely affected. In addition, our licensors may
own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their
merit, that we are infringing or otherwise violating the licensor&#8217;s rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If we fail to comply with our
obligations, including the obligation to make various milestone payments and royalty payments, under any of the agreements under which
we license intellectual property rights from third parties, the licensor may have the right to terminate the license. If any of our license
agreements is terminated, the underlying licensed patents fail to provide the intended exclusivity or we otherwise experience disruptions
to our business relationships with our licensors, we could lose intellectual property rights that are important to our business or be
prevented from developing and commercializing our drug candidates, and competitors could have the freedom to seek regulatory approval
of, and to market, products identical to ours. Termination of these agreements or reduction or elimination of our rights under these agreements
may also result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these
agreements, including our rights to important intellectual property or technology, or impede, delay or prohibit the further development
or commercialization of one or more drug candidates that rely on such agreements. It is possible that we may be unable to obtain any additional
licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources
to redesign our drug candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may
not be feasible on a technical or commercial basis</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Licensing of intellectual property
is of critical importance to our business and involves complex legal, business and scientific issues and certain provisions in intellectual
property license agreements may be susceptible to multiple interpretations. Disputes may arise between us and our licensing partners regarding
intellectual property subject to a license agreement, including:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the scope of rights granted under the license agreement and other interpretation-related issues;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">whether and the extent to which technology and processes of one party infringe intellectual property of
the other party that are not subject to the licensing agreement;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">rights to sublicense patent and other rights to third parties;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">any diligence obligations with respect to the use of the licensed technology in relation to development
and commercialization of our drug candidates, and what activities satisfy those diligence obligations;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">rights to transfer or assign the license; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 18pt"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the effects of termination.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The resolution of any contract
interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property
or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could
harm our business, financial condition, results of operations and prospects. If disputes over intellectual property that we have licensed
prevent or impair our ability to maintain our current licensing arrangements on acceptable terms or at all, we may be unable to successfully
develop and commercialize the affected drug candidates. Moreover, any dispute or disagreement with our licensing partners may result in
the delay or termination of the research, development or commercialization of our drug candidates or any future drug candidates, and may
result in costly litigation or arbitration that diverts management attention and resources away from our day-to-day activities, which
may adversely affect our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Furthermore, current and future
collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the
products or potential products that are the subject of these collaborations. Competing products, either developed by our collaborators
or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support
for our drug candidates. Any of these developments could harm our product development efforts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition, if our licensors
fail to abide by the terms of the license, if the licensors fail to prevent infringement by third parties or if the licensed patents or
other rights are found to be invalid or unenforceable, our business, competitive position, financial condition, results of operations
and prospects could be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Some of our intellectual property may be subject
to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies
if it is determined that our intellectual property has been discovered through government-funded programs. Compliance with such regulations
may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.75pt; background-color: white">&#160;</p>
<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Some of the intellectual property
rights we have acquired or licensed or may acquire or license in the future may have been generated through the use of U.S. government
funding and may therefore be subject to certain federal regulations. These U.S. government rights include a non-exclusive, non-transferable,
irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under certain
limited circumstances, to require us to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to
a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is
necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal
regulations (also referred to as &#8220;march-in rights&#8221;). The U.S. government also has the right to take title to these inventions
if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual
property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting
requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any
products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the
United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee
of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential
licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture
is not commercially feasible. This preference for U.S. industry may limit our ability to contract with non-U.S. product manufacturers
for products relating to such intellectual property. To the extent any of our future intellectual property is also generated through the
use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Patent terms may be inadequate to establish
our competitive position on our drug candidates for an adequate amount of time. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Patents have a limited lifespan.
In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest
U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited.
Even if patents directed to our drug candidates are obtained, once the patent life has expired for a drug candidate, we may be open to
competition from competitive medications, including generic versions. Given the amount of time required for the development, testing and
regulatory review of new drug candidates, patents directed towards such drug candidates might expire before or shortly after such drug
candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude
others from commercializing drug candidates similar or identical to ours for a meaningful amount of time, or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Depending upon the timing, duration
and conditions of any FDA marketing approval of our drug candidates, one or more of our owned or licensed U.S. patents may be eligible
for limited patent term extension under the Hatch-Waxman Act, and similar legislation in the EU and certain other countries. The Hatch-Waxman
Act permits a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent
term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to exercise
due diligence during the testing phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to
expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less
than we request. Only one patent per approved product can be extended, the extension cannot extend the total patent term beyond 14 years
from approval and only those claims for the approved drug, a method for using it or a method for manufacturing it may be extended. If
we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can
enforce our patent rights for the applicable drug candidate will be shortened and our competitors may obtain approval to market competing
products sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take
advantage of our investment in development and trials by referencing our clinical and nonclinical data and launch their product earlier
than might otherwise be the case, and our competitive position, business, financial condition, results of operations and prospects could
be materially harmed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Filing, prosecuting, maintaining,
defending and enforcing patents on our drug candidates in all countries throughout the world would be prohibitively expensive, and consequently
our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In
addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws
in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside
the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions.
Competitors may use our technologies in jurisdictions where we have not obtained patents to develop their own products and may export
otherwise infringing products to territories where we have patents, but enforcement rights are not as strong as those in the United States.
These products may compete with our drug candidates and our patents or other intellectual property rights may not be effective or sufficient
to prevent them from competing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Many companies have encountered
significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries
do not favor the enforcement or protection of patents, trade secrets and other intellectual property, which could make it difficult for
us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary
rights generally. Proceedings to enforce our intellectual property rights in foreign jurisdictions could result in substantial costs and
divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted
narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail
in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Many foreign countries, including
some EU countries, India, Japan and China, have compulsory licensing laws under which a patent owner may be compelled under specified
circumstances to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies
or government contractors. In those countries, we may have limited remedies if patents are infringed or if we are compelled to grant a
license to a third party, which could materially diminish the value of the applicable patents and limit our potential revenue opportunities.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license, which could adversely affect our business, financial condition, results
of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In 2012, the European Patent
Package, or EU Patent Package, regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European
Unified Patent Court (&#8220;UPC&#8221;), for litigation involving European patents. Implementation of the EU Patent Package occurred
in 2023. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, will by default
automatically fall under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European
patents, and allow for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand
the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU
Patent Package as currently proposed, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s
existence, but doing so may preclude us from realizing the benefits of the new unified court.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Changes in patent law could diminish the value
of patents in general, thereby impairing our ability to protect our drug candidates. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Obtaining and enforcing patents
in the pharmaceutical industry is inherently uncertain, due in part to ongoing changes in the patent laws. For example, in the United
States, depending on decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents, and interpretation
thereof, could change in unpredictable ways that could weaken our and our collaborators&#8217; or licensors&#8217; ability to obtain new
patents or to enforce existing or future patents. For example, the U.S. Supreme Court has ruled on several patent cases in recent years,
either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain
situations. Therefore, there is increased uncertainty with regard to our and our collaborators&#8217; or licensors&#8217; ability to obtain
patents in the future, as well as uncertainty with respect to the value of patents once obtained.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Patent reform legislation could
increase the uncertainties and costs surrounding the prosecution of our and our collaborators&#8217; or licensors&#8217; patent applications
and the enforcement or defense of our or our collaborators&#8217; or licensors&#8217; issued patents. For example, assuming that other
requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled
to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under
the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;), enacted in September 2011, the United States transitioned to
a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent
application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention.
The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications are prosecuted and may also
affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional
procedures to challenge the validity of a patent by USPTO-administered post-grant proceedings, including post-grant review, <i>inter partes</i>
review and derivation proceedings. The USPTO has developed regulations and procedures to govern administration of the Leahy-Smith Act,
and many of the substantive changes to patent law associated with the Leahy-Smith Act, particularly the first inventor-to-file provisions.
Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith
Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors&#8217; patent
applications and the enforcement or defense of our or our licensors&#8217; issued patents. Similarly, statutory or judicial changes to
the patent laws of other countries may increase the uncertainties and costs surrounding the prosecution of patent applications and the
enforcement or defense of issued patents. Any of the foregoing could harm our business, financial condition, results of operations and
prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may become involved in lawsuits to protect
or enforce our patents or other intellectual property, which could be expensive, time-consuming and unsuccessful, and issued patents directed
towards our technology and drug candidates could be found invalid or unenforceable if challenged. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>
<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We are not aware that our patents
directed to either BIV201 or bezisterim (NE3107), the product candidates we are currently developing, are infringed by third parties.
However, there can be no assurance that our patents will not be found in the future to be infringed by others. Any patents we do obtain
may be challenged by reexamination or otherwise invalidated or eventually found unenforceable. Both the patent application process and
the process of managing patent disputes can be time-consuming and expensive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Significantly, our pending patent
applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until a patent
issues from such applications. Our ability to enforce patent rights also depends on our ability to identify infringement. It may be difficult
to identify infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover,
it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or
service. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that
we infringe their patents or that our patents are invalid or unenforceable. In a patent infringement proceeding, a court may decide that
a patent of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other
party from using the technology at issue on the grounds that our patents do not cover the technology. An adverse result in any litigation
proceeding could put one or more of our owned or licensed patents at risk of being invalidated, held unenforceable or interpreted narrowly.
We may find it impractical or undesirable to enforce our intellectual property against some third parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If we were to initiate legal
proceedings against a third party to enforce a patent directed to our drug candidates, or one of our future drug candidates, the defendant
could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging
invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory
requirements, including lack of novelty, obviousness, non-enablement or insufficient written description. Grounds for a presentability
assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO or
made a misleading statement during prosecution. Third parties may also raise similar claims before the USPTO or an equivalent foreign
body, even outside the context of litigation. Potential proceedings include reexamination, post-grant review, <i>inter partes</i> review,
interference proceedings, derivation proceedings and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such
proceedings could result in the revocation of, cancellation of, or amendment to our patents in such a way that they no longer cover our
technology or any drug candidates that we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we and the patent
examiner were unaware during prosecution. These assertions may also be based on information known to us or the USPTO. If a defendant were
to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent rights
directed towards the applicable drug candidates or technology related to the patent rendered invalid or unenforceable. Such a loss of
patent rights would materially harm our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Interference proceedings provoked
by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our
patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license
rights to it from the prevailing party. Our business could be materially harmed if the prevailing party does not offer us a license on
commercially reasonable terms or at all.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential
information could be compromised by disclosure during this type of litigation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The pharmaceutical industry
is characterized by extensive litigation regarding patents and other intellectual property rights. Moreover, the cost to us of any litigation
or other proceeding relating to our patents and other intellectual property rights, even if resolved in our favor, could be substantial,
and the litigation would divert our management&#8217;s efforts. We may not have sufficient resources to bring any such action to a successful
conclusion. Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations
and you could lose all of your investment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Some of our competitors are
larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent
litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual
property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or
otherwise violating our intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual
property claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the
uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue
our internal research programs, or in-license needed technology or other drug candidates. There could also be public announcements of
the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those
results to be negative, it could cause the price of shares of our Common Stock to decline. Any of the foregoing events could harm our
business, financial condition, results of operation and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>
<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may not identify relevant third-party patents
or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims
or adversely affect our ability to develop and market our drug candidates. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We cannot guarantee that any
of our or our licensors&#8217; patent searches or analyses, including the identification of relevant patents, the scope of patent claims
or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party
patent and pending patent application in the United States and abroad that is relevant to or necessary for the commercialization of our
drug candidates in any jurisdiction. For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications
filed after that date that will not be filed outside the United States remain confidential until patents issue. As mentioned above, patent
applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority is
claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our drug
candidates could have been filed by third parties without our knowledge. Additionally, pending patent applications that have been published
can, subject to certain limitations, be later amended in a manner that could cover our drug candidates or the use of our drug candidates.
The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution
history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively
impact our ability to market our drug candidates. We may incorrectly determine that our drug candidates are not covered by a third-party
patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination
of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, which may negatively impact
our ability to develop and market our drug candidates. Our failure to identify and correctly interpret relevant patents may negatively
impact our ability to develop and market our drug candidates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In addition, if we fail to identify
and correctly interpret relevant patents, we may be subject to infringement claims. We cannot guarantee that we will be able to successfully
settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay damages, which
may be significant, we may be temporarily or permanently prohibited from commercializing any of our drug candidates that are held to be
infringing. We might, if possible, also be forced to redesign drug candidates so that they no longer infringe the third-party intellectual
property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management
resources that we would otherwise be able to devote to our business and could adversely affect our business, financial condition, results
of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Third parties may initiate legal proceedings
alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would
be uncertain and could negatively impact the success of our business. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our commercial success depends
upon our ability to develop, manufacture, market and sell our drug candidates and use our proprietary technologies without infringing,
misappropriating or otherwise violating the intellectual property and other proprietary rights of third parties. There is considerable
intellectual property litigation in the pharmaceutical industry. We may become party to, or be threatened with, future adversarial proceedings
or litigation regarding intellectual property rights with respect to our drug candidates and their manufacture and our other technology,
including reexamination, interference, post-grant review, <i>inter partes</i> review or derivation proceedings before the USPTO or an
equivalent foreign body. Numerous U.S.- and foreign-issued patents and pending patent applications owned by third parties exist in the
fields in which we are developing our drug candidates. Third parties may assert infringement claims against us based on existing patents
or patents that may be granted in the future, regardless of their merit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We do not believe that either
BIV201 or bezisterim (NE3107), the product candidates we are currently developing, infringe the patents of any third parties. However,
there can be no assurance that our technology will not be found in the future to infringe the patents of others. Moreover, patent applications
are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature
frequently occurs substantially later than the date on which the underlying discoveries were made and patent applications were filed.
Because patents can take many years to issue, there may be currently pending applications of which we are unaware that may later result
in issued patents that our products or product candidates infringe. For example, pending applications may exist that provide support or
can be amended to provide support for a claim that results in an issued patent that our product infringes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Even if we believe third-party
intellectual property claims are without merit, there is no assurance that a court would find in our favor on questions of claim scope,
infringement, validity, enforceability or priority. A court of competent jurisdiction could hold that third-party patents asserted against
us are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any drug candidates
we may develop and any other drug candidates or technologies covered by the asserted third-party patents. In order to successfully challenge
the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one
requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a
court of competent jurisdiction would invalidate the claims of any such U.S. patent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If we are found to infringe,
misappropriate or otherwise violate a third party&#8217;s intellectual property rights, and we are unsuccessful in demonstrating that
such rights are invalid or unenforceable, we could be required to obtain a license from such a third party in order to continue developing
and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms
or at all. Even if we were able to obtain a license, it could be or may become non-exclusive, thereby giving our competitors access to
the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology
or product. A finding of infringement could prevent us from commercializing our drug candidates or force us to cease some of our business
operations. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages
and attorneys&#8217; fees for willful infringement, pay royalties and other fees, redesign our infringing drug candidate or obtain one
or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure. Claims that we have
misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. Any
of the foregoing events would harm our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims by third parties
asserting that we or our employees have infringed, misappropriated or otherwise violated their intellectual property rights, or claiming
ownership of what we regard as our own intellectual property. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Many of our employees were previously
employed at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do
not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals
have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s
former employer. We may also be subject to claims that patents and applications we have filed to protect inventions made on our behalf
by our employees, consultants and advisors, even those related to one or more of our drug candidates, are rightfully owned by their former
or concurrent employer. Litigation may be necessary to defend against these claims</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If we fail in prosecuting or
defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even
if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs, delay development
of our drug candidates and be a distraction to management. Any of the foregoing events would harm our business, financial condition, results
of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We may be subject to claims challenging the
inventorship of our patents and other intellectual property. </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">We or our licensors may be subject
to claims that former employees, collaborators or other third parties have an interest (including co-ownership or ownership) in our owned
or in-licensed patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors
or collaborators may have inventorship disputes arising from conflicting obligations of employees, consultants or others who are involved
in developing our drug candidates. While it is our policy to require our employees and contractors who may be involved in the development
of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an
agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may
not be self-executing or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship
or our or our licensors&#8217; or collaborators&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual
property. If we or our licensors or collaborators fail in defending any such claims, in addition to paying monetary damages, we may lose
valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our
drug candidates. Even if we are successful in defending against such claims, these claims may create considerable distraction to management
and other employees of the company. Any of the foregoing could have a material adverse effect on our business, financial condition, results
of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Intellectual property rights do not necessarily
address all potential threats.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The degree of future protection,
if any, afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately
protect our business or permit us to maintain our competitive advantage. For example:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">others may be able to make products that are similar to any drug candidates we may develop or utilize
similar technology but that are not covered by the claims of the patents that we license or may own in the future;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we, or our current or future licensors or collaborators, might not have been the first to make the inventions
covered by the issued patent or pending patent application that we license or may own in the future;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we, or our current or future licensors or collaborators might not have been the first to file patent applications
covering certain of our or their inventions;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our owned or licensed intellectual property rights;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">it is possible that our pending owned or licensed patent applications or those that we may own or license
in the future will not lead to issued patents;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal
challenges by our competitors;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">our competitors might conduct research and development activities in countries where we do not have patent
rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we may not develop additional proprietary technologies that are patentable;</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">the intellectual property rights of others may harm our business; and</td></tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="vertical-align: top">
<td style="width: 0"/><td style="width: 0.25in"><span style="font-family: Symbol">&#183;</span></td><td style="text-align: justify">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third
party may subsequently file a patent directed to such intellectual property.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Should any of these events occur,
they could harm our business, financial condition, results of operations and prospects.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><b><i>Intellectual property
litigation may lead to unfavorable publicity that harms our reputation and causes the market price of shares of our Common Stock to decline.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.75pt; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in; background-color: white">During
the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as
results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these
announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly,
the market price of shares of our Common Stock may decline. Such announcements could also harm our reputation or the market for our future
products, which could have a material adverse effect on our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Risks Relating to Our Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Our stock price is and may continue to be volatile
and you may not be able to resell our Common Stock at or above the price you paid.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The market price for our Common
Stock is volatile and may fluctuate significantly in response to a number of factors, many of which we cannot control, such as quarterly
fluctuations in financial results, the timing and our ability to advance the development of our product candidates or changes in securities
analysts&#8217; recommendations could cause the price of our stock to fluctuate substantially. In addition, stock markets generally have
recently experienced volatility. Our stock price is likely to experience significant volatility in the future. The price of our Common
Stock may decline and the value of any investment in our Common Stock may be reduced regardless of our performance. Further, the daily
trading volume of our Common Stock has historically been relatively low. As a result of the historically low volume, our shareholders
may be unable to sell significant quantities of Common Stock in the public trading markets without a significant reduction in the price
of our shares of Common Stock. Each of these factors, among others, could harm your investment in our Common Stock and could result in
your being unable to resell the shares of our Common Stock that you purchase at a price equal to or above the price you paid.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In the past, when the market price
of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If
any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention
of our management would be diverted from the operation of our business.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>You may experience future dilution as a result
of future equity offerings or if we issue shares subject to options, warrants, stock awards or other arrangements.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of June 30, 2024, our Articles
of Incorporation, as amended, authorize the issuance of 800,000,000 shares of Common Stock, and we had&#160;6,216,398 shares of Common
Stock issued and 6,190,072 issued and outstanding. Accordingly, we may issue up to an additional 793,783,602&#160;shares of Common Stock.
The future issuance of Common Stock may result in substantial dilution in the percentage of our Common Stock held by our then existing
stockholders. We may value any Common Stock in the future on an arbitrary basis. The issuance of Common Stock for future services or acquisitions
or other corporate actions may have the effect of diluting the value of the shares held by our investors, might have an adverse effect
on any trading market for our Common Stock and could impair our ability to raise capital in the future through the sale of equity securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">In order to raise additional capital,
we may in the future offer additional shares of our Common Stock or other securities convertible into or exchangeable for our Common Stock,
including under the Controlled Equity Offering Sales Agreement (the &#8220;ATM Agreement&#8221;), dated as of August 31, 2022, between
the Company and Cantor Fitzgerald &amp; Co. (the &#8220;Cantor&#8221;), pursuant to which the Company may issue and sell from time to
time shares of our Common Stock through Cantor. We may sell shares or other securities in any other offering at a price per share that
is less than the current market price of our securities, and investors purchasing shares or other securities in the future could have
rights superior to existing stockholders. The sale of additional shares of our Common Stock or other securities convertible into or exchangeable
for our Common Stock would dilute all of our stockholders, and if such sales of convertible securities into or exchangeable into our Common
Stock occur at a deemed issuance price that is lower than the current exercise price of our outstanding warrants sold to Acuitas Group
Holdings, LLC (&#8220;Acuitas&#8221;) in August 2022, the exercise price for those warrants would adjust downward to the deemed issuance
price pursuant to price adjustment protection contained within those warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">As of June 30, 2024, there were
warrants outstanding to purchase an aggregate of 1,932,029 shares of our Common Stock at exercise prices ranging from $10.00 to $125.00
per share and 518,076 shares issuable upon exercise of outstanding options at exercise prices ranging from $4.74 to $420.90 per share
and restricted stock units totaling 40,291. In addition, pursuant to the Loan and Security Agreement and the Supplement to the Loan and
Security Agreement, each entered into on November 30, 2021, with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities
Fund, L.P., the lenders have the option to convert up to $5 million of the outstanding loan amount into shares of our Common Stock at
a conversion price of $58.20 per share. We may also grant additional options, warrants or equity awards. To the extent such shares are
issued, the interest of holders of our Common Stock will be diluted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Moreover, we are obligated to
issue shares of our Common Stock upon achievement of certain clinical, regulatory and commercial milestones with respect to certain of
our drug candidates (i.e., bezisterim (NE3107), NE3291, NE3413, and NE3789) pursuant to the asset purchase agreement, dated April 27,
2021, by and among the Company, NeurMedix and Acuitas, as amended on May 9, 2021. The achievement of these milestones could result in
the issuance of up to 1.8 million shares of our Common Stock, further diluting the interest of holders of our Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Certain stockholder of the Company may have
significant control over our Company.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">As of August 30, 2024, Acuitas beneficially owns 3,050,397
shares of our Common Stock, which includes warrants to purchase 727,273 shares of our Common Stock and options to purchase 6,500 shares
of our Common Stock that are exercisable within 60 days of August 30, 2024 and currently constitutes 43.2% of our issued and outstanding
Common Stock. As a result, Acuitas has substantially influence over the management and affairs of our Company, as well as the ability
to control the outcome of matters submitted to our stockholders for approval, including the election of directors, the approval of significant
corporate transactions, including any merger, consolidation or sale of all or substantially all of our assets, the issuance or redemption
of equity interests in certain circumstances, and any other significant transaction. The interests of Acuitas may not always align with,
and in some cases may conflict with, our interests or the interests of our other stockholders. For instance, this concentration of ownership
may have the effect of delaying or preventing a change of control otherwise favored by our other stockholders and could deprive our other
stockholders of an opportunity to receive a premium for their Common Stock. This concentration of ownership may also negatively affect
the prevailing market price of our Common Stock due to investors&#8217; perceptions that conflicts of interest may exist or arise. As
a result, this concentration of ownership may not be in your best interests.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We effected a reverse stock split on August
6, 2024, and we cannot predict the effect that such reverse stock split will have on the market price for shares of our Common Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our board of directors approved
a one-for-ten (1:10) reverse stock split of our Common Stock, which became effective at 12:01 a.m. Eastern Time on August 6, 2024. We
cannot predict the effect that the reverse stock split will have on the market price for shares of our Common Stock, and the history of
similar reverse stock splits for companies in like circumstances has varied. Some investors may have a negative view of a reverse stock
split. Even if the reverse stock split has a positive effect on the market price for shares of our Common Stock, performance of our business
and financial results, general economic conditions and the market perception of our business, and other adverse factors which may not
be in our control could lead to a decrease in the price of our Common Stock following the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Furthermore, even if the reverse
stock split does result in an increased market price per share of our Common Stock, the market price per share following the reverse stock
split may not increase in proportion to the reduction of the number of shares of our Common Stock outstanding before the implementation
of the reverse stock split. Accordingly, even with an increased market price per share, the total market capitalization of shares of our
Common Stock after a reverse stock split could be lower than the total market capitalization before the reverse stock split. Also, even
if there is an initial increase in the market price per share of our Common Stock after a reverse stock split, the market price many not
remain at that level.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If the market price of shares
of our Common Stock declines following the reverse stock split, the percentage decline as an absolute number and as a percentage of our
overall market capitalization may be greater than would occur in the absence of the reverse stock split due to decreased liquidity in
the market for our Common Stock. Accordingly, the total market capitalization of our Common Stock following the reverse stock split could
be lower than the total market capitalization before the reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The market price and trading volume of our Common
Stock may be volatile.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">The market price and trading volume
of our Common Stock has been volatile. We expect that the market price of our Common Stock will continue to fluctuate significantly for
many reasons, including in response to the risk factors described in this prospectus or for reasons unrelated to our specific performance.
In recent years, the stock market has experienced extreme price and volume fluctuations. This volatility has affected the market prices
of securities issued by many companies for reasons unrelated to their operating performance and may adversely affect the market price
and trading volume of our Common Stock. Prices for our Common Stock may also be influenced by the depth and liquidity of the market for
our Common Stock, investor perceptions about us and our business, our future financial results, the absence of cash dividends on our Common
Stock and general economic and market conditions. In the past, securities class action litigation has often been instituted against companies
following periods of volatility in their stock price. This type of litigation could result in substantial costs and could divert our management
and other resources.&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Any failure to maintain effective internal control
over financial reporting could harm us.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is a process
designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). Under standards established by the Public Company
Accounting Oversight Board (&#8220;PCAOB&#8221;), a deficiency in internal control over financial reporting exists when the design or
operation of a control does not allow management or personnel, in the normal course of performing their assigned functions, to prevent
or detect misstatements on a timely basis. The PCAOB defines a material weakness as a deficiency, or combination of deficiencies, in internal
control over financial reporting, such that there is a reasonable possibility that a material misstatement of annual or interim financial
statements will not be prevented, or detected and corrected, on a timely basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 38; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">If we are unable to assert that
our internal control over financial reporting is effective, or when required in the future, if our independent registered public accounting
firm is unable to express an unqualified opinion as to the effectiveness of our internal control over financial reporting, investors may
lose confidence in the accuracy and completeness of our financial reports, the market price of our Common Stock could be adversely affected
and we could become subject to litigation or investigations by the stock exchange on which our securities are listed, the Commission or
other regulatory authorities, which could require additional financial and management resources.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><b><i>There is a limited trading market for our
Common Stock, which could make it difficult to liquidate an investment in our Common Stock, in a timely manner.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our Common Stock is currently
traded on the Nasdaq Capital Market. Because there is a limited public market for our Common Stock, investors may not be able to liquidate
their investment whenever desired. We cannot assure that there will be an active trading market for our Common Stock and the lack of an
active public trading market could mean that investors may be exposed to increased risk. In addition, if we failed to meet the criteria
set forth in the regulations of the Commission, various requirements would be imposed by law on broker dealers who sell our securities
to persons other than established customers and accredited investors. Consequently, such regulations may deter broker-dealers from recommending
or selling our Common Stock, which may further affect its liquidity.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>The lack of public company experience of our
management team could adversely impact our ability to comply with the reporting requirements of U.S. securities laws, which could have
a materially adverse effect on our business.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Our officers have limited public
company experience, which could impair our ability to comply with legal and regulatory requirements such as those imposed by Sarbanes-Oxley
Act of 2002. Such responsibilities include complying with federal securities laws and making required disclosures on a timely basis. Any
such deficiencies, weaknesses or lack of compliance could have a materially adverse effect on our ability to comply with the reporting
requirements of the Exchange Act, which is necessary to maintain our public company status. If we were to fail to fulfill those obligations,
our ability to continue as a U.S. public company would be in jeopardy in which event you could lose your entire investment in our Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are considered a smaller reporting company
that is exempt from certain disclosure requirements, which could make our stock less attractive to potential investors.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Rule 12b-2 of the Exchange Act
defines a &#8220;smaller reporting company&#8221; as an issuer that is not an investment company, an asset-backed issuer, or a majority-owned
subsidiary of a parent that is not a smaller reporting company and that:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10pt; text-align: justify">&#160;</td>
    <td style="width: 10pt; text-align: justify">&#9679;</td>
    <td style="text-align: justify">Had a public float of less than $250 million as of the last business day of its most recently completed fiscal quarter, computed by multiplying the aggregate number of worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principle market for the common equity; or</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10pt; text-align: justify">&#160;</td>
    <td style="width: 10pt; text-align: justify">&#9679;</td>
    <td style="text-align: justify">In the case of an initial registration statement under the Securities Act or the Exchange Act for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated public offering price of the shares; or</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10pt; text-align: justify">&#160;</td>
    <td style="width: 10pt; text-align: justify">&#9679;</td>
    <td style="text-align: justify">In the case of an issuer who had annual revenue of less than $100 million during the most recently completed fiscal year for which audit financial statements are available, had a public float as calculated under paragraph (1) or (2) of this definition that was either zero or less than $700 million.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a &#8220;smaller reporting
company&#8221; we are not required and may not include a Compensation Discussion and Analysis section in our proxy statements; we provide
only 3 years of business development information; and have other &#8220;scaled&#8221; disclosure requirements that are less comprehensive
than issuers that are not &#8220;smaller reporting companies&#8221; which could make our stock less attractive to potential investors,
which could make it more difficult for you to sell your shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 39; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are subject to the periodic reporting requirements
of the Exchange Act, which require us to incur audit fees and legal fees in connection with the preparation of such reports. These additional
costs will negatively affect our ability to earn a profit.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are required to file periodic
reports with the Commission pursuant to the Exchange Act and the rules and regulations thereunder. In order to comply with such requirements,
our independent registered auditors have to review our financial statements on a quarterly basis and audit our financial statements on&#160;an
annual basis. Moreover, our legal counsel has to review and assist in the preparation of such reports. Factors such as the number and
type of transactions that we engage in and the complexity of our reports cannot accurately be determined at this time and may have a major
negative effect on the cost and amount of time to be spent by our auditors and attorneys. However, the incurrence of such costs is an
expense to our operations and thus has a negative effect on our ability to meet our overhead requirements and earn a profit.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Because we do not intend to pay any cash dividends
on our Common Stock, our stockholders will not be able to receive a return on their shares unless they sell them.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We intend to retain any future
earnings to finance the development and expansion of our business. We do not anticipate paying any cash dividends on our Common Stock
in the foreseeable future. Unless we pay dividends, our stockholders will not be able to receive a return on their shares unless they
sell them. There is no assurance that stockholders will be able to sell shares when desired.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>We are authorized to issue &#8220;blank check&#8221;
preferred stock without stockholder approval, which could adversely impact the rights of holders of our securities.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our Articles of Incorporation
authorize us to issue up to 10,000,000 shares of blank check preferred stock. Any preferred stock that we issue in the future may rank
ahead of our Common Stock in terms of dividend priority or liquidation premiums and may have greater voting rights than our Common Stock.
Any preferred stock issued may contain provisions allowing those shares to be converted into shares of Common Stock, which could dilute
the value of our Common Stock to current stockholders and could adversely affect the market price, if any, of our Common Stock. The preferred
stock could be utilized, under certain circumstances, as a method of discouraging, delaying, or preventing a change in control of our
company. Although we have no present intention to issue any shares of our authorized preferred stock, there can be no assurance that we
will not do so in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Provisions in our Articles of Incorporation,
our Bylaws, and Nevada law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore,
depress the trading price of our Common Stock.</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Provisions of our Articles of
Incorporation, our Bylaws, and Nevada law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in
control of our company or changes in our management, including transactions in which our stockholders might otherwise receive a premium
for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions
that they may deem to be in their best interests. These provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">the inability of stockholders to call special meetings; </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">the &#8220;business combinations&#8221; and &#8220;control share acquisitions&#8221; provisions of Nevada law, to the extent applicable, could discourage attempts to acquire our stockholders stock even on terms above the prevailing market price; and </td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in; text-align: justify">&#9679;</td>
    <td style="text-align: justify">the ability of our board of directors to designate the terms of and issue new series of preferred stock without stockholder approval, which could include the right to approve an acquisition or other change in our control or could be used to institute a rights plan, also known as a poison pill, that would dilute the stock ownership of a potential hostile acquirer, likely preventing acquisitions that have not been approved by our board of directors.</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The existence of the forgoing
provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our Common
Stock. They could also deter potential acquirers of our company, thereby reducing the likelihood that you could receive a premium for
your Common Stock in an acquisition.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 40; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_004"></span>ITEM 1B.</b></td>
    <td style="width: 90%; text-align: justify"><b>UNRESOLVED STAFF COMMENTS</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_008"></span>ITEM 1C.</b></td>
    <td style="width: 90%; text-align: justify"><b>CYBERSECURITY</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We maintain an information technology and security
program appropriate for a company our size, taking into account our operations and risks. The Company recognizes the critical importance
of maintaining the trust and confidence of our investors, employees, and vendors. The Company's cybersecurity policies and processes are
integrated into the Company's enterprise risk management program and are informed by recognized frameworks established by the National
Institute of Standards and Technology, and other applicable industry standards.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the ordinary course of our business, we collect,
use, store, and transmit digitally confidential, sensitive, proprietary, and personal information. The secure maintenance of this information
and our information technology systems is important to our operations and business strategy. To this end, we have implemented processes
designed to assess, identify, and manage risks from potential unauthorized occurrences on or through our information technology systems
that may result in adverse effects on the confidentiality, integrity, and availability of these systems and the data residing therein.
These processes are managed and monitored by an outside information technology vendor under the supervision of our Chief Financial Officer,
and include mechanisms, controls, technologies, systems, and other processes designed to prevent or mitigate data loss, theft, misuse,
or other security incidents or vulnerabilities affecting the data and maintain a stable and secure information technology environment.
For example, we conduct ongoing monitoring of critical systems for any compromised or potentially compromised accounts. We conduct regular
trainings on cyber and information security, along with phishing simulations, among other topics. In addition, we consult with our outside
information technology vendor on a regular basis to assist with assessing, identifying, and managing cybersecurity risks, including to
anticipate future threats and trends, and their impact on the Company&#8217;s risk environment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the last fiscal year, we have not identified any
risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us,
including our operations, business strategy, results of operations, or financial condition. If we were to experience a material cybersecurity
incident in the future, such incidents are reasonably likely to materially affect us, including our operations, business strategy, results
of operations, or financial condition. The Company's Board of Directors, as a whole and at the committee level, has oversight for the
most significant risks facing us and for our processes to identify, prioritize, assess, manage, and mitigate those risks. The Audit Committee,
which is composed solely of independent directors, has been designated by our Board to oversee cybersecurity risks. The Board receives
updates from the Company's management on cybersecurity risks on at least an annual basis.</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_005"></span>ITEM 2.</b></td>
    <td style="width: 90%; text-align: justify"><b>PROPERTIES</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company pays an annual rent of $2,200 for its
headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 89703. The rental agreement was for a one-year term commenced on October
1, 2022 and has been subsequently renewed for another year at the same rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 26, 2022, the Company&#8217;s San Diego
office relocated to Suite 206 at 5090 Shoreham Place, San Diego, CA 92122. The amended lease entered into on February 12, 2024, increased
the base rate to $9,685 per month for the larger space, with an annual increase of 4%; and a new term of 60 months.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_006"></span>ITEM 3.</b></td>
    <td style="width: 90%; text-align: justify"><b>LEGAL PROCEEDINGS</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To our knowledge, other than described below, neither
the Company nor any of our officers or directors is a party to any material legal proceeding or litigation and such persons know of no
material legal proceeding or contemplated or threatened litigation, other than as described below. There are no judgments against us or
our officers or directors. None of our officers or directors has been convicted of a felony or misdemeanor relating to securities or performance
in corporate office.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 19, 2024, a purported shareholder
class action complaint, captioned&#160;<i>Eric Olmstead v. BioVie Inc. et al.</i>, No. 3:24-cv-00035, was filed in the U.S. District
Court for the District of Nevada, naming the Company and certain of its officers as defendants. On February 22, 2024, a second,
related putative securities class action was filed in the same court asserting similar claims against the same defendants, captioned <i>Way
v. BioVie Inc. et al.</i>, No. 2:24-cv-00361. On April 15, 2024, the court consolidated these two actions under the caption <i>In re
BioVie Inc. Securities Litigation</i>, No. 3:24-cv-00035, appointed the lead plaintiff, and approved selection of the lead counsel.
On June 21, 2024, the lead plaintiff filed an amended complaint, alleging that the defendants made material misrepresentations
and/or omissions of material fact relating to the Company&#8217;s business, operations, compliance, and prospects, including
information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable AD,&#160;<span style="background-color: white">in
violation of Sections 10(b) and 20(a) of the&#160; Exchange Act, and&#160;Rule 10b-5&#160;promulgated thereunder. The class action
is on behalf of purchasers of the Company&#8217;s securities during the period from December 7, 2022 through November 28, 2023 and
seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including attorney&#8217;s
fees. The defendants filed a motion to dismiss the amended complaint on August 21, 2024. The defendants believe that the
claims are without merit and intend to defend vigorously against them, but there can be no assurances as to the outcome.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_007"></span>ITEM 4.</b></td>
    <td style="width: 90%; text-align: justify"><b>MINE SAFETY DISCLOSURES</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">None.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 42; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_009"></span><b>PART II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%"><span id="a_010"></span><b>ITEM 5.</b></td>
    <td style="width: 90%; text-align: justify"><b>MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Unregistered Sales of Securities</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">All sales of unregistered securities during the year
ended June 30, 2024 were previously disclosed in a Quarterly Report on Form 10-Q or Current Report on Form 8-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Issuer Purchases of Common Stock</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the year ended June 30, 2024, there were no
issuer repurchases of shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_011"></span>ITEM 6.</b></td>
    <td style="width: 90%; text-align: justify"><b>[Reserved]</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_012"></span>ITEM 7.</b></td>
    <td style="width: 90%; text-align: justify"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>The following discussion of the Company&#8217;s
financial condition and the results of operations should be read in conjunction with the Financial Statements and Notes thereto appearing
elsewhere in this report.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Overview</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a clinical-stage company developing innovative
drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Neurodegenerative Disease Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acquired the biopharmaceutical assets
of NeurMedix a privately held clinical-stage pharmaceutical company and a related party in June 2021<i>.</i> The acquired assets included
NE3107. In April 2024, the Company announced that the United States Adopted Names Council, and the World Health Organization International
Nonproprietary Names expert committee had approved &#8220;bezisterim&#8221; as the non-proprietary (generic) name for NE3107. Bezisterim
(NE3107) is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven insulin resistance
and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus that both inflammation
and insulin resistance may play fundamental roles in the development of AD and PD, and bezisterim (NE3107) could, if approved by FDA,
represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering
from AD and 1 million Americans suffering from PD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In neurodegenerative disease, bezisterim (NE3107)
inhibits activation of inflammatory ERK and nuclear factor kappa-light-chain-enhancer of activated B cells (&#8220;NF&#954;B&#8221;)
(including interactions with TNF signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance.
Bezisterim (NE3107) does not interfere with their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both
inflammation and insulin resistance are drivers of AD and PD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>About Inflammation and Bezisterim&#8217;s (NE3107&#8217;s)
Mechanism of Action</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Neuroinflammation, insulin resistance, and oxidative
stress are common features in the major neurodegenerative diseases, including AD, PD, frontotemporal lobar dementia, and ALS. Bezisterim
(NE3107) is an orally bioavailable, blood-brain permeable, small molecule, with potential anti-inflammatory, insulin sensitizing, and
ERK-binding properties that may allow it to selectively inhibit ERK-, NF&#954;B- and TNF-stimulated inflammation. Bezisterim&#8217;s
(NE3107&#8217;s) potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company&#8217;s work testing the
molecule in AD and PD patients.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parallels exist between AD and PD, among them activated
microglia driving inflammation, involvement of TNF&#945;, oxidative stress, protein misfolding, mitochondrial dysfunction, and insulin
resistance. In preclinical and clinical studies, bezisterim (NE3107) reduced inflammation and enhanced insulin sensitivity, both of which
are important to PD pathology. Preclinical studies in marmoset monkeys have shown bezisterim (NE3107) administered alone to be as pro-motoric
as levodopa, underscoring the apparently critical role of inflammation in expression of PD motor symptoms. When bezisterim (NE3107) was
administered with levodopa, the combination improved motor control better than either drug alone. Furthermore, in the marmoset study,
bezisterim (NE3107) reduced the severity of LID concurrent with pro-motoric benefit and decreased neurodegeneration, preserving twice
as many dopaminergic neurons compared to control.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 43; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Parkinson&#8217;s Disease</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Parkinson&#8217;s disease (PD), which affects an estimated
1 million Americans, is driven in large part by neuroinflammation and activation of brain microglia, leading to increased proinflammatory
cytokines (particularly TNF). Multiple daily administrations of levodopa (converted to dopamine in the brain) is the current standard
of care treatment for this movement disorder, but levodopa effectiveness diminishes over time necessitating increased dosage and prolonged
daily administration leads to side effects of uncontrolled movements called levodopa-induced dyskinesia, commonly referred to as LID,
which is exacerbated by high dose levodopa. Although levodopa provides symptomatic benefit, it does not slow PD progression.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Long COVID Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2024, the Company announced the grant of
a clinical trial award of up to $13.1 million from the U.S. Department of Defense, awarded through the Peer Reviewed Medical Research
Program of the Congressionally Directed Medical Research Programs. The award can provide up to 2 years of non-dilutive funding for a Phase
2 clinical trial that will assess bezisterim (NE3107) for the treatment of neurological symptoms that are associated with long COVID.
The Company anticipates the trial to commence by early 2025. The study protocol has been finalized and submitted to the FDA for regulatory
review in July 2024. The FDA notified the Company that the study can proceed on August 22, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long COVID is a condition in which symptoms of COVID-19,
the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more.
The Centers for Disease Control recently reported that 6.8% of adults in the United States (more than 17 million individuals) currently
or previously had long COVID. Symptoms, which include fatigue, cognitive dysfunction and sleep disturbances, are debilitating. The loss
in quality of life and earnings and increased medical costs has an enormous economic impact estimated to be 3.7 trillion dollars. To date
there are no therapies proven effective for treatment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chronic inflammation is one of the main hypotheses
that researchers have proposed to explain the persistence of symptoms in long COVID. Specifically in individuals with &#8220;brain fog,&#8221;
sustained systemic inflammation and persistent localized blood-brain-barrier (&#8220;BBB&#8221;) dysfunction are key physiological features.
Bezisterim (NE3107) permeates the BBB and has been shown to modulate inflammation via the inhibition of NF-kB activation, thus representing
a novel oral treatment targeting an underlying cause of long COVID symptoms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Chronic neuroinflammation, insulin resistance, and
oxidative stress are common features in the major neurodegenerative diseases, including AD, PD, frontotemporal lobar dementia, and Amyotrophic
lateral sclerosis. Bezisterim (NE3107) is an investigational oral small molecule, blood-brain permeable, compound with potential anti-inflammatory,
insulin sensitizing, and ERK-binding properties that may allow it to selectively inhibit ERK-, NF&#954;B- and TNF-stimulated inflammation.
Bezisterim&#8217;s (NE3107) potential to inhibit neuroinflammation and insulin resistance forms the basis for the Company&#8217;s work
testing the molecule in AD, PD, and long COVID patients. Bezisterim (NE3107) is patented in the United States, Australia, Canada, Europe
and South Korea.<b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 44; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Results of Operations</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Comparison of the Year Ended June 30, 2024 to
the Year Ended June 30, 2023</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;<b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Net loss</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The net loss was approximately $33.0 million and $50.3
million for the years ended June 30, 2024 and 2023, respectively. The decrease in net loss of approximately $17.3 million was comprised
of a net decrease in research and development expenses of approximately $10.2 million and selling, general and administrative expenses
of approximately $2.7 million, and further reduced by an increase in interest income of approximately $574,000, a reduction in interest
expense of approximately $1.4 million and the reduction in the fair value of derivative liabilities of approximately $3.3 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating expenses were approximately $32.2
million and $45.1 million for the year ended June 30, 2024, and 2023, respectively.&#160;The net decrease of approximately $12.9 million
for the year ended June 30, 2024, was comprised of a decrease in research and development expenses of approximately $10.2 million and
a decrease in selling, general and administrative expenses of approximately $2.7 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and Development Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses were approximately $23.1 million
and $33.3 million for the year ended June 30, 2024, and 2023, respectively. The net decrease of approximately $10.2 million for the year
ended June 30, 2024, was primarily attributed to a reduction in expenses totaling approximately $13.8 million due to the completion of
clinical studies, offset by increased expenses of approximately $3.6 million primarily comprised of the planning and development of new
studies of approximately $836,000 which included the development of Sunrise 1 PD PH2b and Radiance 1 AD MCI Ph2b/3 studies which have
been put on hold in the first quarter of the fiscal year ended June 30,2024 pending financing and were designed to be large potentially
registrational studies. an increase in Chemistry, Manufacturing and Controls (&#8220;CMC&#8221;) expense of approximately $1.0 million
for drug production and development, an increase in clinical team compensation from the clinical team expansion and the use of consultants
totaling approximately $732,000 and $474,000, respectively, and other increases in regulatory and other consultants of approximately $362,000
and publications and travel of approximately $187,000. The decreased expenses from completed clinical studies of approximately $13.8 million
were comprised of approximately $2.7 million from Ascites BIV201 Phase 2b study, approximately $2.1 million from the PD Phase 2 study,
both studies were completed in the prior fiscal year ended June 30, 2023, approximately $238,000 from the Investigator-Initiated Trial
in MCI and Mild Alzheimer&#8217;s Disease, and approximately $8.8 million from the AD pivotal Phase 3 clinical study that completed on
December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following summarizes the expenses incurred during the fiscal years
ending June 30, 2024 and 2023 for new developmental studies and the completed studies:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Increase<br/>
 (Decrease)</td><td style="padding-bottom: 1pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-left: 0pt">New Development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 61%; text-align: left; padding-left: 0pt">Sunrise PD Phase 2</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">181,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">-</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">181,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Long Covid Program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">106,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">Sunrise 1 PD PH2b (On hold)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">822,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">600,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">222,000</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Radiance 1 AD MCI-301 Ph2b/3 (On hold)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">778,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">451,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">327,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,887,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,051,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">836,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-left: 0pt">Completed Studies</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">Ascites BIV201 Phase 2b</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">672,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,377,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(2,705,000</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0pt">AD mild to moderate pivotal Phase 3</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,888,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,630,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,742,000</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">PD Phase 2</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">612,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,747,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,135,000</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt">Investigator-Initiated studies</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">73,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">311,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(238,000</td><td style="white-space: nowrap; padding-bottom: 1pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 0pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">9,245,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">23,065,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(13,820,000</td><td style="white-space: nowrap; padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Selling, General and Administrative Expenses</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Selling, general and administrative expenses were
approximately $8.8 million and $11.6 million for the year ended June 30, 2024 and 2023, respectively. The net decrease of approximately
$2.7 million was primarily attributed to decreased stock and cash compensation of approximately $2.8 million of the executives and directors,
and a decline in investor relations fees of approximately $396,000, offset by insurance expense of approximately $248,000 and legal fees
of approximately $306,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Other Income and Expense</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Other income, net was approximately $59,000 compared
to other expense, net of $5.2 million, for the year ended June 30, 2024 and 2023, respectively. The net increase in other income of approximately
$5.2 million was primarily driven by the change in fair value of the derivative liabilities of approximately $3.3 million, reduction in
interest expense of approximately $1.4 million due to amortization and accretion of the financing costs, unearned discount, and premium
relating to the note payable, and an increase in interest income of approximately $574,000 from the investment in U.S. Treasury Bills.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Capital Resources and Liquidity</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2024, the Company had working capital
of approximately $14.7 million, cash and cash equivalents of approximately $23.8 million, stockholders&#8217; equity of approximately
$15.5 million, and an accumulated deficit of approximately $334.2 million. Additionally, the Company had a net loss of approximately $32.1 million and net cash used in operating activities of approximately $27.9
million during the year ended June 30, 2024. In addition, the Company has not generated any revenues to
date and no revenues are expected in the foreseeable future. The Company&#8217;s future operations are dependent on the success of the
Company&#8217;s ongoing development and commercialization efforts, as well as its ability to secure additional financing as needed. Projected
cash flows could be extended if further measures are taken to delay planned expenditures in our research protocols and slow the progress
in the Company&#8217;s development and launch of next phase clinical programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The future viability of the Company is largely dependent
upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include
sales of equity, obtaining loans, or other strategic transactions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although management continues to pursue the Company&#8217;s
strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the
Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&#8217;s ability to continue
as a going concern. The financial statements included elsewhere in this Form 10-K do not include any adjustments that might result from
the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>At-The-Market Facility</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 31, 2022, the Company entered into a Sales
Agreement with Cantor, pursuant to which the Company may issue and sell from time-to-time shares of the Company&#8217;s Common Stock through
Cantor, subject to the terms and conditions of the Sales Agreement. During the year ended June 30, 2024, the Company sold 333,749 shares
of its Common Stock under the ATM Agreement with Cantor for total net proceeds of approximately $9.3 million after 3% commissions and
cost totaling approximately $377,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>Underwritten Offering</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 6, 2024, the Company closed the best efforts
public offering (the &#8220;March 2024 Offering&#8221;) of 1,500,000 shares (the &#8220;Shares&#8221;) of Common Stock, pre-funded warrants
(the &#8220;Pre-funded Warrants&#8221;) to purchase 600,000 shares of Common Stock, and warrants to purchase up to 1,050,000 shares of
Common Stock (the &#8220;Common Warrants&#8221;) (CUSIP 09074F132) at a combined public offering price of $10.00 per Share, or Pre-funded
Warrant, and the associated Common Warrant. The gross proceeds to the Company from the March 2024 Offering were approximately $21 million,
before deducting placement agent fees and offering expenses of approximately $2.5 million. Upon closing of the March 2024 Offering, the
Company issued the placement agent a warrant (&#8220;Placement Agent&#8217;s Warrant&#8221;) to purchase 105,000 shares of Common Stock
exercisable at a per share price of $12.50, which was equal to 125% of the public offering price per Share. The Placement Agent&#8217;s
Warrant is exercisable during a five-year period commencing 180 days from March 6, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Off-Balance Sheet Arrangements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The term &#8220;off-balance sheet arrangement&#8221; generally means any
transaction, agreement or other contractual arrangement to which an entity unconsolidated with the Company is a party, under which the
Company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent
interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such
assets. The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change
on the Company&#8217;s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources
that are material to investors.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Critical Accounting Policies and Estimates</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Cash and cash equivalents </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents consisted of cash deposits
and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S.
Treasury Bills with original maturities of three months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Concentration of Credit Risk in the Financial Service
Industry</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2024, the Company had cash deposited
in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these
financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March
and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions
due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material
direct impact on the Company&#8217;s operations, if further liquidity and financial stability concerns arise with respect to banks and
financial institutions, either nationally or in specific regions, the Company&#8217;s ability to access cash or enter into new financing
arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Investments in U.S. Treasury Bills</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in U.S. Treasury Bills with maturities
greater than three months, are accounted for as available for sale and are recorded at fair value. Unrealized gains were included in other
comprehensive income in the accompanying statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<!-- Field: Page; Sequence: 46; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and Development</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses consist primarily of costs associated with the preclinical and/or clinical
trials of drug candidates, compensation and other expenses for research and development, personnel, supplies and development materials,
costs for consultants and related contract research and facility costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Accounting for Stock-based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company follows the provision of Accounting Standards
Codification (&#8220;ASC&#8221;) Topic 718 - Stock Compensation (&#8220;ASC 718&#8221;), which requires the measurement of compensation
expense for all share-based payment awards made to employees and non-employee director, including employee stock options. Share-based
compensation expense is based on the grant date fair value estimated in accordance with the provisions of ASC 718 and is generally recognized
as an expense over the requisite service period, net of forfeitures which are recorded as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fair value measurement of assets and liabilities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We determine the fair values of our financial instruments
based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the
asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the
fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset
or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant
to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active
markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - Inputs are quoted prices for similar assets
and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market
corroboration, for substantially the full term of the financial instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - Inputs are unobservable inputs based on
our assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_013"></span>ITEM 7A.</b></td>
    <td style="width: 90%; text-align: justify"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_014"></span>ITEM 8.</b></td>
    <td style="width: 90%; text-align: justify"><b>FINANCIAL STATEMENTS</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial information required to be filed hereunder
are indexed under Item 15 of this report and are incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_015"></span>ITEM 9.</b></td>
    <td style="width: 90%; text-align: justify"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_016"></span>ITEM 9A.</b></td>
    <td style="width: 90%; text-align: justify"><b>CONTROLS AND PROCEDURES</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Evaluation of Disclosure Controls and Procedures</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have evaluated, with the participation of our principal
executive and our principle financial officer, the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e)
and 15(d)-15(e) under the Exchange Act as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation,
our principal executive officer and our principal financial officer have concluded that our disclosure controls and procedures were effective
to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the Commission&#8217;s rules and forms, and is accumulated and communicated
to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span style="text-decoration: underline">Management&#8217;s Report on Internal Control
Over Financial Reporting</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our management is responsible for establishing and
maintaining adequate internal control over financial reporting as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act. Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation
of the effectiveness of internal control to future periods are subject to the risk that controls may become inadequate because of changes
in conditions, or that the degree of compliance with policies or procedures may deteriorate.&#160; Under the supervision and with the
participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the
effectiveness of our internal control over financial reporting as of June 30, 2024 using the criteria established in Internal Control
Integrated Framework issued by the Committee of Sponsoring Organization of the Treadway Commission. Based on our evaluation using those
criteria, our management has concluded that, as of June 30, 2024, our internal control over financial reporting was effective to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes
in accordance with generally accepted accounting principles for the reasons discussed above.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Changes in Internal Control Over Financial Reporting</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">There were no changes in our internal controls over
financial reporting during the quarter ended June 30, 2024, that materially affected, or are reasonably likely to materially affect our
internal controls over financial reporting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_017"></span>ITEM 9B.</b></td>
    <td style="width: 90%; text-align: justify"><b>OTHER INFORMATION</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_908_eecd--Rule10b51ArrAdoptedFlag_dbF_c20230701__20240630_zoh58WAhhEz2" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_903_eecd--NonRule10b51ArrAdoptedFlag_dbF_c20230701__20240630_zzBcx9GUHffa" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_904_eecd--Rule10b51ArrTrmntdFlag_dbF_c20230701__20240630_zFU7jvCdhWle" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><span id="xdx_906_eecd--NonRule10b51ArrTrmntdFlag_dbF_c20230701__20240630_z4irSO8AgZn5" class="xdx_phnt_RGlzY2xvc3VyZSAtIEluc2lkZXIgVHJhZGluZyBBcnJhbmdlbWVudHMA"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000042" name="ecd:Rule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000043" name="ecd:NonRule10b51ArrAdoptedFlag"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000044" name="ecd:Rule10b51ArrTrmntdFlag"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" format="ixt:booleanfalse" id="Fact000045" name="ecd:NonRule10b51ArrTrmntdFlag">None.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></span></span></span>&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_018"></span>ITEM 9C.</b></td>
    <td style="width: 90%; text-align: justify"><b>DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Not applicable.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="a_019"></span><b>PART III.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_020"></span>ITEM 10.</b></td>
    <td style="width: 90%; text-align: justify"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required by this item is
included in our 2024 Proxy Statement and is
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_021"></span>ITEM 11.</b></td>
    <td style="width: 90%; text-align: justify"><b>EXECUTIVE COMPENSATION</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The information required by this item is
included in our 2024 Proxy Statement and is
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_022"></span>ITEM 12.</b></td>
    <td style="width: 90%; text-align: justify"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required by this item is
included in our 2024 Proxy Statement and is
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_023"></span>ITEM 13.</b></td>
    <td style="width: 90%; text-align: justify"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required by this item is
included in our 2024 Proxy Statement and is
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><b><span id="a_024"></span>ITEM 14.</b></td>
    <td style="width: 90%; text-align: justify"><b>PRINCIPAL ACCOUNTANT FEES AND SERVICES</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information required by this item is
included in our 2024 Proxy Statement and is
incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b><span id="a_025"></span>PART IV</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 10%; text-align: justify"><span id="a_026"></span><b>ITEM 15.</b></td>
    <td style="width: 90%; text-align: justify"><b>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>(a)(1),(2) Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Financial Statements listed on page F-1 of this
document are filed as part of this filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(a)(3) <b>Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a list of exhibits filed as a part
of this report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: justify"><b>Exhibit</b><br/>
<b>Number</b></td>
    <td style="width: 2%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: justify"><b>Description of Document</b></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013816000847/nnab-20160415_8kex2z1.htm" style="-sec-extract: exhibit">2.1</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013816000847/nnab-20160415_8kex2z1.htm" style="-sec-extract: exhibit">Agreement and Plan of Merger, dated April 11, 2016, among the Company, LAT Acquisition Corp and LAT Pharma, LLC (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on April 15, 2016).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000154823313000011/nano0813ex-3.1.htm">3.1</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000154823313000011/nano0813ex-3.1.htm">Articles of Incorporation of the Company as filed with the Secretary of State of Nevada (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Registration Statement on Form S-1 filed on August 15, 2013, File No. 333-190635).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013816001063/nnab-20160722_8kex3z1.htm">3.2</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013816001063/nnab-20160722_8kex3z1.htm">Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on July 22, 2016).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000151/bivi-20180713_def14c.htm">3.3</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000151/bivi-20180713_def14c.htm">Certificate of Amendment to Articles of Incorporation (incorporated by reference to Appendix A to the Company&#8217;s Information Statement on Schedule 14C filed on July 13, 2018).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000134/biovie-20180703_8kex3z1.htm">3.4</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013818000134/biovie-20180703_8kex3z1.htm">Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on July 3, 2018).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000485/bivi-20191122_s1a8ex3z6.htm">3.5</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000485/bivi-20191122_s1a8ex3z6.htm">Certificate of Amendment to Articles of Incorporation (incorporated by reference to Exhibit 3.6 to the Company&#8217;s Registration Statement on Form S-1 filed on November 22, 2019, File No. 333-231136).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex3z5.htm">3.6</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex3z5.htm">Amended and Restated Bylaws of the Company, dated June 16, 2020 (incorporated by reference to Exhibit 3.5 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2021).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013823000131/bivi-20230313_8kex3z1.htm">3.7</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013823000131/bivi-20230313_8kex3z1.htm">First Amendment to the Amended and Restated Bylaws of the Company, dated March 12, 2023 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on March 13, 2023).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000254/bivi-20240729_8kex3z1.htm">3.8</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000254/bivi-20240729_8kex3z1.htm">Certificate of Change (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on August 1, 2024)</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000263/bivi-20240802_8kex3z1.htm">3.9</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000263/bivi-20240802_8kex3z1.htm">Termination of Amendment/Certificate (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report, as amended, on Form 8-K/A filed on August 6, 2024)</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000263/bivi-20240802_8kex3z2.htm">3.10</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000263/bivi-20240802_8kex3z2.htm">Certificate of Amendment (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report, as amended, on Form 8-K/A filed on August 6, 2024)</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1ex4z1.htm">4.1</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000127/bivi-20190426_s1ex4z1.htm">Specimen Certificate representing shares of Class A Common Stock (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Registration Statement on Form S-1 filed on April 26, 2019, File No. 333-231136).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000330/bivi-20190924_8kex4z2.htm">4.2</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000330/bivi-20190924_8kex4z2.htm">Form of Warrant (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on September 25, 2019).</a></td></tr>
    <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000330/bivi-20190924_8kex4z2.htm">4.3</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000330/bivi-20190924_8kex4z2.htm">Form of Warrant (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on September 25, 2019).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000330/bivi-20190924_8kex4z2.htm">4.4</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000330/bivi-20190924_8kex4z2.htm">Form of 10% OID Convertible Delayed Draw Debenture (incorporated by reference to Exhibit 4.1 the Company&#8217;s Current Report on Form 8-K filed on September 25, 2019).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013822000313/bivi-20220715_8ka1ex4z1.htm">4.5</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013822000313/bivi-20220715_8ka1ex4z1.htm">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form 8-K/A filed on July 18, 2022).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000754/bivi-20211130_8kex10z3.htm">4.6</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000754/bivi-20211130_8kex10z3.htm">Form of Warrant to Purchase Shares of Class A Common Stock of the Company (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Current Report on Form 8-K filed on December 1, 2021).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000086/bivi-20240304_8kex4z2.htm">4.7</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000086/bivi-20240304_8kex4z2.htm">Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 to the Company&#8217;s Current Report on Form 8-K filed on March 4, 2024).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000086/bivi-20240304_8kex10z1.htm">4.8</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1580149/000152013824000086/bivi-20240304_8kex10z1.htm">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.3 to the Company&#8217;s Current Report on Form 8-K filed on March 4, 2024).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000134/bivi_14cdef.htm">10.1#</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000134/bivi_14cdef.htm">BioVie Inc. 2019 Omnibus Equity Incentive Plan (incorporated by reference to Appendix D to the Definitive Information Statement on Schedule 14C, filed on May 8, 2019).</a></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 50; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; width: 8%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000221/bivi-20210427_8kex2z1.htm">10.2</a></td>
    <td style="vertical-align: bottom; width: 2%; text-align: justify">&#160;</td>
    <td style="vertical-align: top; width: 90%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000221/bivi-20210427_8kex2z1.htm">Asset Purchase Agreement, dated April 27, 2021, among the Company, NeurMedix, Inc. and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2021).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000249/bivi-20210509_8kex2z2.htm">10.3</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000249/bivi-20210509_8kex2z2.htm">Amendment No. 1 of the Asset Purchase Agreement, dated May 9, 2021, among the Company, NeurMedix, Inc. and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 2.2 to the Company&#8217;s Current Report on Form 8-K filed on May 10, 2021).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013823000087/bivi-20221231_10qex10z1.htm">10.4</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013823000087/bivi-20221231_10qex10z1.htm">Amendment No. 2 to the Asset Purchase Agreement, dated January 13, 2023, among the Company, Acuitas Group Holdings, LLC and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 12, 2023).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z14.htm">10.5#</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z14.htm">Employment Offer &amp; Agreement, between Chris Reading and the Company, dated June 18, 2021 (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2021).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z15.htm">10.6#</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z15.htm">Employment Offer &amp; Agreement, between Clarence Ahlem and the Company, dated June 18, 2021 (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2021).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z16.htm">10.7#</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z16.htm">Employment Offer &amp; Agreement, between Joanne Wendy Kim and the Company, dated June 26, 2021 (incorporated by reference to Exhibit 10.16 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2021).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z18.htm">10.8#</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z18.htm">Employment Offer &amp; Agreement, between Penelope Markham and the Company, dated September 7, 2021 (incorporated by reference to Exhibit 10.18 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2021).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z19.htm">10.9#</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000706/bivi-20210930_10qex10z19.htm">Employment Offer &amp; Agreement, between Joseph Palumbo and the Company, dated September 3, 2021 (incorporated by reference to Exhibit 10.19 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 10, 2021).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000754/bivi-20211130_8kex10z1.htm">10.10</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000754/bivi-20211130_8kex10z1.htm">Loan and Security Agreement, dated November 30, 2021, among the Company, Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Form 8-K filed on December 1, 2021).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000754/bivi-20211130_8kex10z2.htm">10.11</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013821000754/bivi-20211130_8kex10z2.htm">Supplement to Loan and Security Agreement, dated November 30, 2021, among the Company, Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Form 8-K filed on December 1, 2021).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013822000313/bivi-20220715_8ka1ex10z1.htm">10.12</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013822000313/bivi-20220715_8ka1ex10z1.htm">Securities Purchase Agreement, dated July 15, 2022, by and between the Company and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K/A filed on July 18, 2022).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013822000388/bivi-20220831_8kex1z1.htm">10.13</a></td>
    <td style="vertical-align: bottom; padding-bottom: 8pt">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013822000388/bivi-20220831_8kex1z1.htm">Controlled Equity Offering<sup>SM</sup> Sales Agreement, dated August 31, 2022, among the Company, Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed on August 31, 2022).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013822000502/bivi-20220930_10qex10z2.htm">10.14</a></td>
    <td style="vertical-align: bottom; padding-bottom: 8pt">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013822000502/bivi-20220930_10qex10z2.htm">Amended and Restated Registration Rights Agreement, dated August 15, 2022, by and between BioVie Inc. and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 4, 2022).</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000217/bivi-20190628_s1ex14z1.htm">14.1</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1580149/000152013819000217/bivi-20190628_s1ex14z1.htm">Code of Conduct and Ethics of BioVie Inc. (incorporated by reference to Exhibit 14.1 to the Company&#8217;s Registration Statement on Form S-1, File No. 333-231136).</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">19.1</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Insider Trading Policy</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex23z1.htm" style="-sec-extract: exhibit">23.1*</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex23z1.htm" style="-sec-extract: exhibit">Consent of Independent Registered Public Accounting Firm - EisnerAmper LLP</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">24.1*</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Power of Attorney (included on signature page to this registration statement)</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex31z1.htm">31.1*</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex31z1.htm">Rule 13a-14(a) Certification</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex31z2.htm">31.2*</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex31z2.htm">Rule 13a-14(a) Certification</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex32z1.htm">32.1**</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex32z1.htm">Certification Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex32z2.htm">32.2**</a></td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify"><a href="bivi-20240630_10kex32z2.htm">Certification Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to section 906 of the Sarbanes-Oxley Act of 2002</a></td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">97.1</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Clawback Policy</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">101.INS</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">XBRL Instance Document</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">101.SCH</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">XBRL Taxonomy Extension Schema Document</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">101.CAL</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">XBRL Taxonomy Calculation Linkbase Document</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">101.LAB</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">XBRL Taxonomy Label Linkbase Document</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">101.PRE</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">XBRL Taxonomy Presentation Linkbase Document</td></tr>
  <tr style="background-color: White">
    <td style="white-space: nowrap; vertical-align: top; text-align: justify">101.DEF</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="vertical-align: top; text-align: justify">XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"># Indicates a management contract or compensatory
plan or arrangement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">* Filed herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">** Furnished herewith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 51; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of Section 13 or 15(d)
of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>Date: September 30, 2024</td>
    <td colspan="3"><b>BIOVIE INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>By:</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid">/s/ Cuong Do</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 64%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 5%">Name:</td>
    <td style="width: 30%">Cuong Do</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Title:</td>
    <td>Chief Executive Officer<br/>
(Principal Executive Officer)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>POWER OF ATTORNEY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Each person whose signature appears below constitutes
and appoints Cuong Do and Joanne Wendy Kim, and each of them acting individually and without the other, as his or her true and lawful
attorneys-in-fact and agents, with full power of substitution and re-substitution, for him or her and in his or her name, place, and stead,
in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in
connection therewith) to this Report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with
the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and
every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might
or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them individually, or
their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the requirements of the Securities Exchange
Act of 1934, this report has been signed by the following persons in the capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 28%"><b>Person</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 48%; text-align: center"><b>Capacity</b></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 20%; text-align: center"><b>Date</b></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom">/s/ Cuong Do</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Chief Executive Officer</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: top">
    <td>Cuong Do</td>
    <td>&#160;</td>
    <td style="text-align: justify">(Principal Executive Officer)</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom">/s/ Joanne Wendy Kim</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: justify">Chief Financial Officer</td>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: top; text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: top">
    <td>Joanne Wendy Kim</td>
    <td>&#160;</td>
    <td style="text-align: justify">(Principal Financial Officer)</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid">/s/ Jim Lang</td>
    <td>&#160;</td>
    <td style="text-align: justify">Director</td>
    <td>&#160;</td>
    <td style="text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: top">
    <td>Jim Lang</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid">/s/ Michael Sherman</td>
    <td>&#160;</td>
    <td style="text-align: justify">Director</td>
    <td>&#160;</td>
    <td style="text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: top">
    <td>Michael Sherman</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid">/s/ Richard J. Berman</td>
    <td>&#160;</td>
    <td style="text-align: justify">Director</td>
    <td>&#160;</td>
    <td style="text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: top">
    <td>Richard J. Berman</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid">/s/ Robert Hariri</td>
    <td>&#160;</td>
    <td style="text-align: justify">Director</td>
    <td>&#160;</td>
    <td style="text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: top">
    <td>Robert Hariri</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid">/s/ Sigmund Rogich</td>
    <td>&#160;</td>
    <td style="text-align: justify">Director</td>
    <td>&#160;</td>
    <td style="text-align: center">September 30, 2024</td></tr>
  <tr style="vertical-align: top">
    <td>Sigmund Rogich</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 52; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>BioVie Inc. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Index to Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 93%"><a href="#a_027">Report of Independent Registered Public Accounting Firm &#8211; <span>EisnerAmper LLP</span> (PCAOB Number <span id="xdx_90F_edei--AuditorFirmId_c20230701__20240630_ztSSw5WSGKd1"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000046" name="dei:AuditorFirmId">274</ix:nonNumeric></span>)</a></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="width: 5%; text-align: right">F-2</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top">Financial Statements:</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_028">Balance Sheets</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">F-4</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#a_029">Statements of Operations and Comprehensive Loss</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">F-5</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_030">Statements of Changes in Stockholders&#8217; Equity</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">F-6</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top"><a href="#a_031">Statements of Cash Flows</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">F-7</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top"><a href="#a_032">Notes to Financial Statements</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="text-align: right">F-8</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 53; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="a_027"></span><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">To the Board of Directors and Stockholders of</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Opinion on the Financial Statements </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have audited the accompanying balance sheets of
BioVie, Inc. (the &#8220;Company&#8221;) as of June 30, 2024 and 2023, and the related statements of operations and comprehensive loss,
changes in stockholders&#8217; equity, and cash flows for each of the years then ended, and the related notes (collectively referred to
as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company as of June 30, 2024 and 2023, and the results of its operations and its cash flows for of the years then ended,
in conformity with accounting principles generally accepted in the United States of America.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Going Concern </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying financial statements have been prepared
assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company&#8216;s recurring
losses from operations and negative cash flows from operating activities raise substantial doubt about its ability to continue as a going
concern. Management&#8217;s plans regarding these matters are also described in Note 2. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Basis for Opinion </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We conducted our audits in accordance with the standards
of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements
are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform,
an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal
control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal
control over financial reporting. Accordingly, we express no such opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Critical Audit Matter</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The critical audit matter communicated below is a
matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit
committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially
challenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on
the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion
on the critical audit matter or on the accounts or disclosures to which it relates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Research and development expenses and related accruals</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As described in Note 3 to the accompanying financial
statements, research and development expenses consist primarily of costs associated with the preclinical and/or clinical trials of drug
candidates, compensation and other expenses for research and development, personnel, supplies and development materials, costs for consultants
and related contract research and third-party facility costs. The amounts recorded for clinical trial expenses represent the Company&#8217;s
estimates of clinical trial expenses based on facts and circumstances known to the Company at that time, and are dependent upon the timely
and accurate reporting of contract research organizations and other third-party vendors.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We identified the accounting for the research and
development expenses and related accruals to be a critical audit matter due to the degree of management judgement in ensuring they are
complete, accurate and classified correctly, their significance, and the risk of material misstatement due to the nature and timing of
these costs and accruals. This in turn led to a high degree of auditor judgment, subjectivity, and effort in applying the procedures related
to their accounting.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Addressing the matter involved performing procedures
and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included, obtaining
an understanding of management&#8217;s process and evaluating the design of controls over research and development expense classification
and the completeness and accuracy of related accruals, independently researching vendors, testing a selection of research and development
expense transactions to determine, based on the underlying supporting documents, the mathematical accuracy of the expense and the appropriateness
of the expense classification. In addition, we made inquiries of management and reviewed subsequent payments, invoices and agreements
relating to certain research and development expenses to ensure that accruals were properly recorded as of June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ <span><span id="xdx_901_edei--AuditorName_c20230701__20240630_z8HL7MYEz0P6"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000047" name="dei:AuditorName">EisnerAmper LLP</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have served as the Company&#8217;s auditor since
2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EISNERAMPER LLP</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span id="xdx_90E_edei--AuditorLocation_c20230701__20240630_z4uix6wKyTBh"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact000048" name="dei:AuditorLocation">Iselin</ix:nonNumeric></span>, New Jersey</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">September 30, 2024</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>


<!-- Field: Page; Sequence: 55; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="a_028"></span><b>BioVie Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Balance Sheets</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>&#160;</b></p>

<table cellpadding="0" cellspacing="0" summary="xdx: Statement - Balance Sheets" id="xdx_302_zrR7fpPOseU7" style="font: 11pt Calibri, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_493_20240630_zkculGDNh5xh" style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" id="xdx_49F_20230630_zZ9GW7e5DJw1" style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
    30,</span></td><td style="font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zd5pXjJX1p3d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASSETS</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrentAbstract_i01B_zHkE24DMgnS1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
    ASSETS:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzIGy_zy2KRbthtS32" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000056" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,843,798</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2023-06-30" id="Fact000057" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,460,883</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--InvestmentsInU.s.TreasuryBills_i02I_pp0p0_maCzIGy_zeDIBAu5F5h4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investments
    in U.S. Treasury Bills (available-for-sale)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0059">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="bivi:InvestmentsInU.s.TreasuryBills" contextRef="AsOf2023-06-30" id="Fact000060" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,477,726</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--PrepaidExpenseAndOtherAssets_i02I_pp0p0_maCzIGy_zf9mWZ9g6309" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    and other current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2024-06-30" id="Fact000062" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">204,392</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssets" contextRef="AsOf2023-06-30" id="Fact000063" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">102,526</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsCurrent_i01TI_mtCzIGy_maCzlCc_z6M3Cww741Jl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2024-06-30" id="Fact000065" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,048,190</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2023-06-30" id="Fact000066" format="ixt:numdotdecimal" decimals="0" unitRef="USD">34,041,135</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzlCc_z7U0BEG7zyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease right-of-use assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" id="Fact000068" format="ixt:numdotdecimal" decimals="0" unitRef="USD">406,726</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" id="Fact000069" format="ixt:numdotdecimal" decimals="0" unitRef="USD">80,789</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maCzlCc_zg8SWuUEvPzc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intangible
    assets, net</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2024-06-30" id="Fact000071" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,718</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2023-06-30" id="Fact000072" format="ixt:numdotdecimal" decimals="0" unitRef="USD">637,095</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--Goodwill_i01I_maCzlCc_zc3iYWaqq3s8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2024-06-30" id="Fact000074" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,711</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Goodwill" contextRef="AsOf2023-06-30" id="Fact000075" format="ixt:numdotdecimal" decimals="0" unitRef="USD">345,711</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--Assets_iTI_mtCzlCc_zgFASpZCH3Jh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    ASSETS</span></td><td style="padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2024-06-30" id="Fact000077" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,208,345</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2023-06-30" id="Fact000078" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,104,730</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zUDKYR9OYoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">LIABILITIES
    AND STOCKHOLDERS' EQUITY</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--LiabilitiesCurrentAbstract_i01B_zv6waoPIEI05" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CURRENT
    LIABILITIES:</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--AccountsPayableCurrent_i02I_maCzOPY_zEWzP3mVpbB8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable and accrued expenses</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2024-06-30" id="Fact000086" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,586,912</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2023-06-30" id="Fact000087" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,476,259</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzOPY_zXcsHbWwCjLj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    current liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0089">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2023-06-30" id="Fact000090" format="ixt:numdotdecimal" decimals="0" unitRef="USD">48,385</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_402_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzOPY_zK50vqI3LySh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of operating lease liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact000092" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,343</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-06-30" id="Fact000093" format="ixt:numdotdecimal" decimals="0" unitRef="USD">44,909</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NotesPayableCurrent_i02I_maCzOPY_zvo8r52Zk2fc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of note payable, net of financing cost, unearned premium and discount of $<span id="xdx_90E_ecustom--UnearnedPremiumAnddiscountCurrent_c20240630_pp0p0" title="Unearned premium and discount current"><ix:nonFraction name="bivi:UnearnedPremiumAnddiscountCurrent" contextRef="AsOf2024-06-30" id="Fact000098" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">701,210</ix:nonFraction></span> at June 30, 2024 and $<span id="xdx_90F_ecustom--UnearnedPremiumAnddiscountCurrent_c20230630_pp0p0" title="Unearned premium and discount current"><ix:nonFraction name="bivi:UnearnedPremiumAnddiscountCurrent" contextRef="AsOf2023-06-30" id="Fact000100" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">894,926</ix:nonFraction></span> at June 30,
    2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-06-30" id="Fact000095" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,701,210</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-06-30" id="Fact000096" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,105,074</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--WarrantLiabilities_i02I_pp0p0_maCzOPY_z84jYgsw2Mnb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liability</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="bivi:WarrantLiabilities" contextRef="AsOf2024-06-30" id="Fact000102" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,771</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="bivi:WarrantLiabilities" contextRef="AsOf2023-06-30" id="Fact000103" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">894,280</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40A_eus-gaap--EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_i02I_maCzOPY_z00QLwE1PhG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Embedded
    derivative liability</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0105">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" contextRef="AsOf2023-06-30" id="Fact000106" format="ixt:numdotdecimal" decimals="0" unitRef="USD">925,762</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LiabilitiesCurrent_i01TI_mtCzOPY_maCzuuS_zh87BZ2nsD3k" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2024-06-30" id="Fact000108" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,352,236</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2023-06-30" id="Fact000109" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,494,669</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCzuuS_zXdSvVZ4yeHd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
    lease liabilities, net of current portion</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact000111" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,894</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30" id="Fact000112" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,505</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--LongTermNotesPayable_i01I_maCzuuS_zcBwrcaJWV74" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; text-align: left; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Note payable,
    net of current portion, financing cost, unearned premium and&#160;&#160;discount of $<span id="xdx_904_ecustom--UnearnedPremiumAndDiscount_c20240630_pp0p0" title="Unearned premium and discount"><ix:nonFraction name="bivi:UnearnedPremiumAndDiscount" contextRef="AsOf2024-06-30" id="Fact000117" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_907_ecustom--UnearnedPremiumAndDiscount_c20230630_pp0p0" title="Unearned premium and discount"><ix:nonFraction name="bivi:UnearnedPremiumAndDiscount" contextRef="AsOf2023-06-30" id="Fact000119" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">227,268</ix:nonFraction></span> at June 30, 2024 and June 30,
    2023, respectively.</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0114">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2023-06-30" id="Fact000115" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,227,270</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--Liabilities_i01TI_mtCzuuS_maCzh6C_zpZybJgu1Hx4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LIABILITIES</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2024-06-30" id="Fact000121" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,702,130</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2023-06-30" id="Fact000122" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,764,444</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--CommitmentsAndContingencies_i01I_zuQUnA5nXNF7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and contingencies
    (Note 11)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockholdersEquityAbstract_i01B_zmbhjyTD8rt9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">STOCKHOLDERS'
    EQUITY :</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--PreferredStockValue_i02I_maCzmJX_z0gGCOrupOL2" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    stock; $<span id="xdx_90E_eus-gaap--PreferredStockParOrStatedValuePerShare_c20240630_pdd" title="Preferred stock, par value"><span id="xdx_90F_eus-gaap--PreferredStockParOrStatedValuePerShare_c20230630_pdd" title="Preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000133" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" id="Fact000135" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_c20240630_pdd" title="Preferred stock, shares authorized"><span id="xdx_907_eus-gaap--PreferredStockSharesAuthorized_c20230630_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000137" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2023-06-30" id="Fact000139" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_c20240630_pdd" title="Preferred stock, shares issued"><span id="xdx_900_eus-gaap--PreferredStockSharesOutstanding_c20240630_pdd" title="Preferred stock, shares outstanding"><span id="xdx_90C_eus-gaap--PreferredStockSharesIssued_c20230630_pdd" title="Preferred stock, shares issued"><span id="xdx_901_eus-gaap--PreferredStockSharesOutstanding_c20230630_pdd" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000141" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000143" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2023-06-30" id="Fact000145" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2023-06-30" id="Fact000147" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0130">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0131">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--CommonStockValue_i02I_pp0p0_maCzmJX_zxKQLiY4ha75" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common stock, $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240630_pdd" title="Common stock, par value"><span id="xdx_904_eus-gaap--CommonStockParOrStatedValuePerShare_c20230630_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-06-30" id="Fact000152" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2023-06-30" id="Fact000154" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> par
    value; <span id="xdx_902_eus-gaap--CommonStockSharesAuthorized_c20240630_pdd" title="Common stock, shares authorized"><span id="xdx_901_eus-gaap--CommonStockSharesAuthorized_c20230630_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2024-06-30" id="Fact000156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2023-06-30" id="Fact000158" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized at June 30, 2024 and June 30, 2023, respectively; <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_c20240630_pdd" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-06-30" id="Fact000160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,216,398</ix:nonFraction></span> shares issued of which <span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_c20240630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2024-06-30" id="Fact000162" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,190,072</ix:nonFraction></span>
    shares are outstanding at June 30, 2024; and <span id="xdx_905_eus-gaap--CommonStockSharesIssued_c20230630_pdd" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2023-06-30" id="Fact000164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,645,183</ix:nonFraction></span> shares issued of which <span id="xdx_90D_eus-gaap--CommonStockSharesOutstanding_c20230630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2023-06-30" id="Fact000166" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,642,895</ix:nonFraction></span> shares outstanding at June 30, 2023</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2024-06-30" id="Fact000149" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,229</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2023-06-30" id="Fact000150" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,643</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maCzmJX_zHTFsBSJRJEg" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid in capital</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2024-06-30" id="Fact000168" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,732,674</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2023-06-30" id="Fact000169" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,385,759</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_maCzmJX_zB31BDuAs1vb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    other comprehensive income</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0171">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-06-30" id="Fact000172" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,591</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzmJX_zrLWdy2fW1ag" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000174" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">334,232,661</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2023-06-30" id="Fact000175" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">301,225,705</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40E_eus-gaap--TreasuryStockValue_i02NI_di_msCzmJX_z3vDUbybtP59" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 30pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Treasury
    stock</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2024-06-30" id="Fact000177" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2023-06-30" id="Fact000178" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr id="xdx_40F_eus-gaap--StockholdersEquity_i01TI_mtCzmJX_maCzh6C_zo7tFH4JNP6f" style="vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; text-align: left; padding-bottom: 1.5pt; padding-left: 50pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders' equity</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000180" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,506,215</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000181" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,340,286</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--LiabilitiesAndStockholdersEquity_iTI_mtCzh6C_zuMQZFnAaaOe" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TOTAL
    LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td style="padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000183" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25,208,345</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 3.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000184" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,104,730</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>The accompanying notes are an integral part of the
financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 56; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_029"></span>BioVie Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Statements of Operations and Comprehensive Loss</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_309_zgB3nA32U225" summary="xdx: Statement - Statements of Operations and Comprehensive Loss" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_49D_20230701_20240630" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_496_20220701__20230630_zImpKlNG3Jyk" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OperatingExpensesAbstract_iB_zpm2HVkufn2a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OPERATING EXPENSES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AmortizationOfIntangibleAssets_i01_maCzctK_zhbugTP719Pa" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 10pt">Amortization of intangible assets</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-07-01to2024-06-30" id="Fact000189" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,377</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-07-012023-06-30" id="Fact000190" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,377</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzctK_zSnTg4NMD8si" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000192" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,100,394</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2022-07-012023-06-30" id="Fact000193" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,299,503</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCzctK_znAMBETiQ3o" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Selling, general and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000195" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,849,814</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2022-07-012023-06-30" id="Fact000196" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,551,568</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingExpenses_iT_mtCzctK_msCzdVf_zC6rFFFZETQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">TOTAL OPERATING EXPENSES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2023-07-01to2024-06-30" id="Fact000198" format="ixt:numdotdecimal" decimals="0" unitRef="USD">32,179,585</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2022-07-012023-06-30" id="Fact000199" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,080,448</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--OperatingIncomeLoss_iT_mtCzdVf_maCz9yP_z2PsDE4jy6yi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">LOSS FROM OPERATIONS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000201" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,179,585</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2022-07-012023-06-30" id="Fact000202" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">45,080,448</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zsinVgaH98Wi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">OTHER (INCOME) EXPENSE:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GainLossOnSaleOfDerivatives_i01N_di_maCztJD_z8nwj1YpUQQ2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2023-07-01to2024-06-30" id="Fact000207" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,816,271</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainLossOnSaleOfDerivatives" contextRef="From2022-07-012023-06-30" id="Fact000208" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,437,481</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--InterestExpense_i01_msCztJD_zT76l4T56inf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000210" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,893,922</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2022-07-012023-06-30" id="Fact000211" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,300,150</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InterestIncomeOther_i01N_di_maCztJD_zprzuK7LSDj3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Interest income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2023-07-01to2024-06-30" id="Fact000213" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,136,703</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeOther" contextRef="From2022-07-012023-06-30" id="Fact000214" format="ixt:numdotdecimal" decimals="0" unitRef="USD">562,264</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40E_eus-gaap--NonoperatingIncomeExpense_iNT_di_mtCztJD_maCz9yP_zRVJBsM35ux9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">TOTAL OTHER (INCOME) EXPENSE, NET</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2023-07-01to2024-06-30" id="Fact000216" format="ixt:numdotdecimal" decimals="0" unitRef="USD">59,052</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2022-07-012023-06-30" id="Fact000217" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,175,367</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--ProfitLoss_iT_mtCz9yP_maCzEKi_zBpBWQZEdlj3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 3.5pt">NET LOSS</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000219" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,120,533</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012023-06-30" id="Fact000220" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,255,815</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--DividendsSharebasedCompensationStock_msCzEKi_zSEB6917JUrb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Deemed dividend related to ratchet adjustment to warrants</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DividendsSharebasedCompensationStock" contextRef="From2023-07-01to2024-06-30" id="Fact000222" format="ixt:numdotdecimal" decimals="0" unitRef="USD">886,423</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0223">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--IncomeLossAttributableToParent_iT_mtCzEKi_zUGW1T3bvtMh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 3.5pt">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossAttributableToParent" contextRef="From2023-07-01to2024-06-30" id="Fact000225" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,006,956</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossAttributableToParent" contextRef="From2022-07-012023-06-30" id="Fact000226" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,255,815</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--EarningsPerShareAbstract_iB_zNaxEUdwRCi6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">NET LOSS PER COMMON SHARE</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--EarningsPerShareBasic_zeZ0CvQ87rx1" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt; padding-left: 10pt">- Basic</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2023-07-01to2024-06-30" id="Fact000231" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.30</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2022-07-012023-06-30" id="Fact000232" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">15.47</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--EarningsPerShareDiluted_zfpD1akV1fWa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt; padding-left: 10pt">- Diluted</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2023-07-01to2024-06-30" id="Fact000234" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">7.30</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2022-07-012023-06-30" id="Fact000235" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">15.47</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--WeightedAverageNumberOfSharesOutstandingAbstract_iB_zjaIJI6orhg7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">WEIGHTED AVERAGE NUMBER OF COMMON&#160;&#160;SHARES OUTSTANDING</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">- Basic</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2023-07-01to2024-06-30" id="Fact000240" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,518,533</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2022-07-012023-06-30" id="Fact000241" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,248,349</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">- Diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2023-07-01to2024-06-30" id="Fact000243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,518,533</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2022-07-012023-06-30" id="Fact000244" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,248,349</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_maCzJXr_zajjLb6cTSLg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2023-07-01to2024-06-30" id="Fact000246" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,006,956</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2022-07-012023-06-30" id="Fact000247" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,255,815</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract_iB_z9AayxwOLlhj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other comprehensive (loss) income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--UnrealizedGainOnInvestmentsForAvailableforsale_i01_maCzEmi_zCvJSm0mbbcb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Unrealized gain on available-for-sale investments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0252">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:UnrealizedGainOnInvestmentsForAvailableforsale" contextRef="From2022-07-012023-06-30" id="Fact000253" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,591</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_i01_maCzEmi_zQh2tagWrHbe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Reclassification of unrealized gains on available-for-sale investments upon settlement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2023-07-01to2024-06-30" id="Fact000255" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,591</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0256">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherComprehensiveIncomeLossNetOfTax_iT_mtCzEmi_maCzJXr_zsqmCllcvu53" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total other comprehensive (loss) income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2023-07-01to2024-06-30" id="Fact000258" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,591</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="From2022-07-012023-06-30" id="Fact000259" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,591</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--ComprehensiveIncomeNetOfTax_iT_mtCzJXr_zozPqmwMAu9h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Comprehensive loss</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2023-07-01to2024-06-30" id="Fact000261" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,183,547</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2022-07-012023-06-30" id="Fact000262" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,079,224</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>The accompanying notes are an integral part of the
financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 57; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_030"></span>BioVie Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Statements of Changes in Stockholders&#8217; Equity<br/>
For the Years Ended June 30, 2024 and 2023</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_307_z7PjLQ6LC8G7" summary="xdx: Statement - Statements of Changes in Stockholders' Equity" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_4B6_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zOVV3fnaBdsa" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_ztjZgMI2EbO4" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_custom--TreasuryStocksMember_z9LlrpaT0fij" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_4B8_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_zf675cQrAyNk" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_4B5_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zsyGRdOQauui" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_4B4_zxPgdMo69nyf" style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
<tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td>&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Accumulated</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td>&#160;</td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Additional</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Other</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Total</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Common Stock</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Common Stock</span></td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Paid in</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Treasury Stock</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Treasury Stock</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Comprehensive</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Accumulated</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Stockholders'</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Income</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Equity</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td>&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="white-space: nowrap"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_435_c20220701__20230630_eus-gaap--StockholdersEquity_iS_zTsar1cmq5sd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-size: 8pt">Balance, June 30, 2022</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zxJ35Y4qDr0c" title="Beginning balance, shares" style="width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" id="Fact000271" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,498,408</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_CommonStockMember" id="Fact000264" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,496</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000265" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,638,329</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStocksMember_zco4fpWDeDz6" style="width: 6%; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0272">-</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0266">-</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0267">-</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 6%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember" id="Fact000268" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">250,969,890</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 6%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2022-06-30" id="Fact000269" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,670,935</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Stock option-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0274">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000275" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,222,845</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0276">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0277">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0278">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2022-07-012023-06-30" id="Fact000279" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,222,845</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zRjfQ6FK4LZj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Stock-based compensation - restricted stock units</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbu5edprw716" title="Stock-based compensation - restricted stock units, Shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000288" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,518</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000281" format="ixt:numdotdecimal" decimals="0" unitRef="USD">21</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000282" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,780,028</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStocksMember_zqx4mObyLPba" style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="Fact000289" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,288</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember" id="Fact000283" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0284">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0285">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2022-07-012023-06-30" id="Fact000286" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,780,047</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--StockbasedCompensationIssuanceOfCommonStockForServicesRendered_zRpOPBKLQRri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Stock-based compensation - issuance of common stock for services rendered</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_983_ecustom--StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdjNVu2zTC14" title="Stock-based compensation - issuance of common stock for services rendered, Shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000298" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000291" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000292" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,495</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_988_ecustom--StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStocksMember_z7nlM42lmau8" style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0299">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0293">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0294">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0295">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2022-07-012023-06-30" id="Fact000296" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,500</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--CashlessExerciseOfOptions_z3sB0Cnbhlh3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 8pt">Cashless exercise of options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_989_ecustom--CashlessExerciseOfOptionsShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zYQlq2BhuCBb" title="Cashless exercise of options, Shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:CashlessExerciseOfOptionsShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000308" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,256</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:CashlessExerciseOfOptions" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000301" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="bivi:CashlessExerciseOfOptions" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000302" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0303">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0304">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0305">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0306">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--CashlessExerciseOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 8pt">Cashless exercise of warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_98A_ecustom--CashlessExerciseOfWarrantsShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zMxB49VoRH0h" title="Cashless exercise of warrants, Shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:CashlessExerciseOfWarrantsShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000317" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">359</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0310">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0311">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0312">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0313">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0314">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0315">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 8pt">Proceeds from exercise of options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zS4bBzvhCB8i" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000325" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0319">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000320" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,240</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0321">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0322">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0323">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2022-07-012023-06-30" id="Fact000324" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,240</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromIssuanceOfCommonStockNetCosts_zAUyKG6xkpW2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Proceeds from issuance of common stock, net costs of $2,008,898</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_989_ecustom--ProceedsFromIssuanceOfCommonStockNetCostsShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeUkE3OKWCy6" title="Proceeds from issuance of common stock, net costs, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCostsShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000334" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">753,925</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000327" format="ixt:numdotdecimal" decimals="0" unitRef="USD">754</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000328" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,464,349</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0329">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0330">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0331">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2022-07-012023-06-30" id="Fact000332" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,465,103</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Proceeds from issuance of common stock, net of costs of&#160;&#160;$94,160
    - Related Party</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_98B_ecustom--ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zknPfnhwotP" title="Proceeds from issuance of common stock, net of costs of Related Party, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000343" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">363,636</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember" id="Fact000336" format="ixt:numdotdecimal" decimals="0" unitRef="USD">364</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000337" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,905,476</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0338">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0339">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0340">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" contextRef="From2022-07-012023-06-30" id="Fact000341" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,905,840</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40A_ecustom--UnrealizedGainOnAvailableforsaleInvestments_zk1ZrG0TapX7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Unrealized gain on available-for-sale investments</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0345">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0346">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0347">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:UnrealizedGainOnAvailableforsaleInvestments" contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000348" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,591</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0349">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:UnrealizedGainOnAvailableforsaleInvestments" contextRef="From2022-07-012023-06-30" id="Fact000350" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,591</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 8pt">Net loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0352">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0353">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0354">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0355">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember" id="Fact000356" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,255,815</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2022-07-012023-06-30" id="Fact000357" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,255,815</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_439_c20230701__20240630_eus-gaap--StockholdersEquity_iS_z0gkr0wgs9qj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-size: 8pt">Balance, June 30, 2023</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZ1DyXyWELGj" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000365" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,645,183</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_CommonStockMember" id="Fact000359" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,643</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000360" format="ixt:numdotdecimal" decimals="0" unitRef="USD">316,385,759</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStocksMember_zdxV7urK2Dr1" style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2023-06-30_custom_TreasuryStocksMember" id="Fact000366" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,288</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_custom_TreasuryStocksMember" id="Fact000361" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000362" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,591</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember" id="Fact000363" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">301,225,705</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2023-06-30" id="Fact000364" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,340,286</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--StockIssuedDuringPeriodValueShareBasedCompensation_zp154PvFMPQl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Stock - based compensation - stock options</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0368">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000369" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,823,764</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0370">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0371">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0372">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="From2023-07-01to2024-06-30" id="Fact000373" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,823,764</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zykOPtpq6vZe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Stock-based compensation - restricted stock units</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z8u9Oc0GxSEf" title="Stock-based compensation - restricted stock units, Shares" style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0382">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0375">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000376" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,763,450</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStocksMember_z0EUUNgCUGNh" style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0383">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0377">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0378">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0379">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2023-07-01to2024-06-30" id="Fact000380" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,763,450</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_405_ecustom--ProceedsFromIssuanceOfCommonStockNetCosts_iP3us-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_zhJehKwzjaj8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Proceeds from issuance of common stock, net of costs of&#160;&#160;$2,908,141</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_981_ecustom--ProceedsFromIssuanceOfCommonStockNetCostsShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z3QEzRUBzgs1" title="Proceeds from issuance of common stock, net of costs, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCostsShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000392" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,433,749</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000385" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,449</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000386" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,800,490</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0387">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0388">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0389">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:ProceedsFromIssuanceOfCommonStockNetCosts" contextRef="From2023-07-01to2024-06-30" id="Fact000390" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,802,939</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--IssuanceOfCommonStockFromVestingOfRestrictedStockUnits_zATfjlGMUwub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Issuance of common stock from vesting of restricted stock units</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_98E_ecustom--IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares_iP3custom--IssuanceOfCommonStockFromVestingOfRestrictedStockUnits_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzTdVDIaBoi6" title="Issuance of common stock from vesting of restricted stock units, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000401" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,395</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000394" format="ixt:numdotdecimal" decimals="0" unitRef="USD">122</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000395" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">97</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_981_ecustom--IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStocksMember_zBu0GuZCOa7h" style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="Fact000402" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">24,038</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember" id="Fact000396" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">25</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0397">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0398">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0399">-</span></td><td style="white-space: nowrap; text-align: left"/></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--StockbasedCompensationIssuanceOfCommonStockForServicesRendered_zXp7eK2GENFb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Stock-based compensation - issuance of common stock for services rendered</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_989_ecustom--StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6HsIUetsAl1" title="Stock-based compensation - issuance of common stock for services rendered, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000411" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000404" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000405" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,885</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_982_ecustom--StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStocksMember_zcrdYZaKYNJ8" style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0412">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0406">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0407">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0408">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered" contextRef="From2023-07-01to2024-06-30" id="Fact000409" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,900</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_406_ecustom--DeemedDividendForRatchetAdjustmentToWarrants_iP3custom--StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_zgQKkbqq9rg4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Deemed dividend for ratchet adjustment to warrants</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0414">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:DeemedDividendForRatchetAdjustmentToWarrants" contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000415" format="ixt:numdotdecimal" decimals="0" unitRef="USD">886,423</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0416">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0417">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="bivi:DeemedDividendForRatchetAdjustmentToWarrants" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000418" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">886,423</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0419">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_iP3custom--DeemedDividendForRatchetAdjustmentToWarrants_zjkv6jmun461" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Relcassification of unrealized gains on available-for-sale investments
    upon settlement</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0421">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0422">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0423">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="Fact000424" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,591</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0425">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2023-07-01to2024-06-30" id="Fact000426" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,591</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit_iP3custom--RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_zwehdCCDXsfi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 8pt">Issuance of additional shares for fractional shares effected by the reverse
    split</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_98D_ecustom--IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares_iP3custom--IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqBpnO6tzoke" title="Issuance of additional shares for fractional shares effected by the reverse split, shares" style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember" id="Fact000435" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0428">-</span></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0429">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0430">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0431">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0432">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0433">-</span></span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_zUpYBaih6wU4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 8pt">Net Loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0437">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0438">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0439">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0440">-</span></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember" id="Fact000441" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,120,533</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000442" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,120,533</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="white-space: nowrap; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr id="xdx_431_c20230701__20240630_eus-gaap--StockholdersEquity_iE_zAmqgqDCKOki" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">Balance, June 30, 2024</span></td><td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zWUYTLx4iQh" title="Ending balance, shares" style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000451" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,216,398</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_CommonStockMember" id="Fact000444" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,229</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember" id="Fact000445" format="ixt:numdotdecimal" decimals="0" unitRef="USD">349,732,674</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__custom--TreasuryStocksMember_zcCf0mrpCFKe" style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2024-06-30_custom_TreasuryStocksMember" id="Fact000452" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">26,326</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_custom_TreasuryStocksMember" id="Fact000446" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-size: 8pt"><span style="-sec-ix-hidden: xdx2ixbrl0447">-</span></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember" id="Fact000448" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">334,232,661</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 3.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 3.5pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2024-06-30" id="Fact000449" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,506,215</ix:nonFraction></span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>The accompanying notes are an integral part of the
financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 58; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b><span id="a_031"></span>BioVie Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Statements of Cash Flows</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_30C_zngcrrz9U4a8" summary="xdx: Statement - Statements of Cash Flows" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20230701__20240630_z9PbVpwEbpS2" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20220701__20230630_z6FeoY01n41c" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year ended</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_zfszaOKa5Xq2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--ProfitLoss_i01_maCzXTV_zR5I7xKI5qje" style="vertical-align: bottom; background-color: White">
    <td style="width: 74%; text-align: left; padding-left: 10pt">Net loss</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2023-07-01to2024-06-30" id="Fact000457" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">32,120,533</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 8%; text-align: right">(<ix:nonFraction name="us-gaap:ProfitLoss" contextRef="From2022-07-012023-06-30" id="Fact000458" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">50,255,815</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zQIeNz9dTitd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AmortizationOfIntangibleAssets_i02_maCzXTV_zMAwadpwlOn1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Amortization of intangible assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-07-01to2024-06-30" id="Fact000463" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,377</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-07-012023-06-30" id="Fact000464" format="ixt:numdotdecimal" decimals="0" unitRef="USD">229,377</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--StockBasedCompensationRestrictedStock_i02_maCzXTV_zjESBUg0OoH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Stock based compensation - restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:StockBasedCompensationRestrictedStock" contextRef="From2023-07-01to2024-06-30" id="Fact000466" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,763,450</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:StockBasedCompensationRestrictedStock" contextRef="From2022-07-012023-06-30" id="Fact000467" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,780,047</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ShareBasedCompensation_i02_maCzXTV_zVLhAyL3Rlif" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Stock based compensation expense - stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-01to2024-06-30" id="Fact000469" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,823,764</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30" id="Fact000470" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,222,845</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--StockBasedCompensationExpenseStockIssued_i02_maCzXTV_z1EK40sxmMHh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Stock based compensation expense - stock issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:StockBasedCompensationExpenseStockIssued" contextRef="From2023-07-01to2024-06-30" id="Fact000472" format="ixt:numdotdecimal" decimals="0" unitRef="USD">72,900</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:StockBasedCompensationExpenseStockIssued" contextRef="From2022-07-012023-06-30" id="Fact000473" format="ixt:numdotdecimal" decimals="0" unitRef="USD">372,500</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--AmortizationOfDebtDiscountPremium_i02_maCzXTV_zRkajNeMJde6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Amortization of financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2023-07-01to2024-06-30" id="Fact000475" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,751</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" contextRef="From2022-07-012023-06-30" id="Fact000476" format="ixt:numdotdecimal" decimals="0" unitRef="USD">170,219</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_ecustom--AccretionOfUnearnedLoanDiscount_i02N_di_msCzXTV_zS23OZfdAE9g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accretion of unearned loan discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:AccretionOfUnearnedLoanDiscount" contextRef="From2023-07-01to2024-06-30" id="Fact000478" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,023,145</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:AccretionOfUnearnedLoanDiscount" contextRef="From2022-07-012023-06-30" id="Fact000479" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,601,445</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AccretionOfLoanPremium_i02_maCzXTV_zXYJcTKc5Cng" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accretion of loan premium</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:AccretionOfLoanPremium" contextRef="From2023-07-01to2024-06-30" id="Fact000481" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,970</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:AccretionOfLoanPremium" contextRef="From2022-07-012023-06-30" id="Fact000482" format="ixt:numdotdecimal" decimals="0" unitRef="USD">421,994</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--RealizedGainOnMaturityOfAvailableforSale_i02N_di_msCzXTV_zUNGICpQKMn5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Realized gain on maturity of available-for sale</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="bivi:RealizedGainOnMaturityOfAvailableforSale" contextRef="From2023-07-01to2024-06-30" id="Fact000484" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,865</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--NoncashLeaseExpenseFromRightofuseAssets_i02_maCzXTV_z78recgI72N4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Non-cash lease expense from right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:NoncashLeaseExpenseFromRightofuseAssets" contextRef="From2023-07-01to2024-06-30" id="Fact000487" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,346</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="bivi:NoncashLeaseExpenseFromRightofuseAssets" contextRef="From2022-07-012023-06-30" id="Fact000488" format="ixt:numdotdecimal" decimals="0" unitRef="USD">37,465</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GainLossOnSaleOfLeasedAssetsNetOperatingLeases_i02N_di_msCzXTV_zS7yELwXDwL7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Gain on termination of operating lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases" contextRef="From2023-07-01to2024-06-30" id="Fact000490" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,215</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0491">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--DerivativeGainLossOnDerivativeNet_i02N_di_msCzXTV_z3wiet2uZ9s7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of derivative liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2023-07-01to2024-06-30" id="Fact000493" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,816,271</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="From2022-07-012023-06-30" id="Fact000494" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,437,481</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_zhgrUtEY2uEh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_pp0p0_di_msCzXTV_zB8AdSL174e3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;&#160;&#160;Prepaid and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2023-07-01to2024-06-30" id="Fact000499" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">101,866</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2022-07-012023-06-30" id="Fact000500" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">39,915</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_maCzXTV_z9JisGMeN8S3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">&#160;&#160;&#160;Accounts payable and accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2023-07-01to2024-06-30" id="Fact000502" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,653</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2022-07-012023-06-30" id="Fact000503" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,033,455</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_i02_maCzXTV_zotzVcjVRxA3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;&#160;&#160;Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2023-07-01to2024-06-30" id="Fact000505" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,245</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="From2022-07-012023-06-30" id="Fact000506" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38,884</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInOtherOperatingLiabilities_i02_maCzXTV_z0AkLzVYeGoc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">&#160;&#160;&#160;Other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="From2023-07-01to2024-06-30" id="Fact000508" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">48,385</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="From2022-07-012023-06-30" id="Fact000509" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,304,925</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInOperatingActivities_iT_mtCzXTV_maCzrER_zx96Uy3E72Aj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2023-07-01to2024-06-30" id="Fact000511" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">27,945,024</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2022-07-012023-06-30" id="Fact000512" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,252,881</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zxomJfJwwoe2" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ProceedsFromMaturityOfU.s.TreasuryBills_iN_di_msCzMbL_zGwR9HMdTudb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Proceeds from (purchases of) U.S. Treasury Bills (available-for-sale)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:ProceedsFromMaturityOfU.s.TreasuryBills" contextRef="From2023-07-01to2024-06-30" id="Fact000517" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,525,000</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="bivi:ProceedsFromMaturityOfU.s.TreasuryBills" contextRef="From2022-07-012023-06-30" id="Fact000518" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,301,135</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--NetCashProvidedByUsedInInvestingActivities_iT_mtCzMbL_maCzrER_zOMFbnrmv8la" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2023-07-01to2024-06-30" id="Fact000520" format="ixt:numdotdecimal" decimals="0" unitRef="USD">14,525,000</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2022-07-012023-06-30" id="Fact000521" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">14,301,135</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zdgxMwCiQSXl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maCzVWw_za086Fn6sg1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net proceeds from issuance of common stock</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2023-07-01to2024-06-30" id="Fact000526" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,802,939</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2022-07-012023-06-30" id="Fact000527" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,465,103</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--RepaymentsOfNotesPayable_i01N_pp0p0_di_msCzVWw_zPOW9VFEt8i7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Payments of note payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-07-01to2024-06-30" id="Fact000529" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0530">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--ProceedsFromStockOptionsExercised_i01_maCzVWw_zYb5GOaEBzlf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from exercise of stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0532">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2022-07-012023-06-30" id="Fact000533" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,240</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--NetProceedsFromIssuanceOfCommonStockRelatedParty_i01_maCzVWw_zSWy9Pka4DGj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net proceeds from issuance of common stock - Related Party</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0535">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:NetProceedsFromIssuanceOfCommonStockRelatedParty" contextRef="From2022-07-012023-06-30" id="Fact000536" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,905,840</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivities_iT_mtCzVWw_maCzrER_zlp2rHNnbGUe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2023-07-01to2024-06-30" id="Fact000538" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,802,939</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2022-07-012023-06-30" id="Fact000539" format="ixt:numdotdecimal" decimals="0" unitRef="USD">55,373,183</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCzrER_zK023aM3Gk3f" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net increase in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2023-07-01to2024-06-30" id="Fact000541" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,382,915</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2022-07-012023-06-30" id="Fact000542" format="ixt:numdotdecimal" decimals="0" unitRef="USD">819,167</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_z7fjGWdkkXG7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents, beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" id="Fact000544" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,460,883</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2022-06-30" id="Fact000545" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,641,716</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zVBh5tqSV4g4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 3.5pt">Cash and cash equivalents, end of period</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2024-06-30" id="Fact000547" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,843,798</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2023-06-30" id="Fact000548" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,460,883</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--SupplementalCashFlowInformationAbstract_iB_z9riaNpradWk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestPaidNet_i01_zvge04tUxQ41" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">&#160;&#160;Cash paid for interest</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2023-07-01to2024-06-30" id="Fact000553" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,525,056</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2022-07-012023-06-30" id="Fact000554" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,106,491</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zaaZ3B0bypyf" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--RightOfUseAssetsObtainedInExchangeForLeaseObligations_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">Right-of-use assets obtained in exchange for lease obligations</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="bivi:RightOfUseAssetsObtainedInExchangeForLeaseObligations" contextRef="From2023-07-01to2024-06-30" id="Fact000559" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">432,192</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0560">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--UnrealizedGainOnU.s.TreasuryBills_i01_zEr3qCNIPTDd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">Unrealized gain on U.S. Treasury Bills (available-for-sale)</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0562">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="bivi:UnrealizedGainOnU.s.TreasuryBills" contextRef="From2022-07-012023-06-30" id="Fact000563" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,591</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_i01N_di_zfggeZ9ObKUc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">Reclassification of unrealized gains on U.S. Treasury Bills (available-for-sale investments) upon settlement</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" contextRef="From2023-07-01to2024-06-30" id="Fact000565" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">176,591</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0566">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--DeemedDividendOfRatchetAdjustmentsToWarrants_i01_zeVi6we5tNik" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 10pt">Deemed dividend of ratchet adjustment to warrants</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="bivi:DeemedDividendOfRatchetAdjustmentsToWarrants" contextRef="From2023-07-01to2024-06-30" id="Fact000568" format="ixt:numdotdecimal" decimals="0" unitRef="USD">886,423</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0569">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>The accompanying notes are an integral part of the
financial statements.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><i>&#160;</i></p>


<!-- Field: Page; Sequence: 59; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span id="a_032"></span><b>BioVie Inc.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><b>Notes to Financial Statements</b></p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000571" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5Wckacr5b3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>1.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_828_zoUWD0geoEd7">Background Information</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;
or &#8220;our&#8221;) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including
neurological and neuro-degenerative disorders and liver disease.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acquired the biopharmaceutical assets
of NeurMedix, Inc. (&#8220;NeurMedix&#8221;) a privately held clinical-stage pharmaceutical company and a related party in June 2021<i>.</i>&#160;The
acquired assets included NE3107. NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven
insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus
that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer&#8217;s disease (&#8220;AD&#8221;)
and Parkinson&#8217;s disease (&#8220;PD&#8221;), and NE3107 could, if approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;),
represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering
from AD and 1 million Americans suffering from PD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Neurodengenerative Disease Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In neurodegenerative disease, the Company&#8217;s
drug candidate NE3107 inhibits activation of inflammatory actions extracellular single-regulated kinase (&#8220;ERK&#8221;) and nuclear
factor kappa-light-chain-enhancer of activated B cells (&#8220;NF&#954;B&#8221;) (including interactions with tumor necrosis factor (&#8220;TNF&#8221;)
signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. NE3107 does not interfere with
their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers
of AD and PD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease (NCT05083260)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 29, 2023, the Company announced the analysis
of its unblinded, topline efficacy data from its Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate AD.
The study has co-primary endpoints looking at cognition using the Alzheimer&#8217;s Disease Assessment Scale-Cognitive Scale (ADAS-Cog
12) and function using the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Patients were randomly assigned, 1:1 versus placebo, to receive
sequentially 5 mg of NE3107 orally twice a day for 14 days, then 10 mg orally twice a day for 14 days, followed by 26 weeks of 20 mg orally
twice daily.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon trial completion, as the Company began the
process of unblinding the trial data, the Company found significant deviation from protocol and current good clinical practices
(&#8220;cGCPs&#8221;) violations at 15 study sites (virtually all of which were from one geographic area). This highly unusual level
of suspected improprieties led the Company to exclude all patients from these sites and to refer the sites to the FDA Office of
Scientific Investigations (&#8220;OSI&#8221;) for potential further action. After the patient exclusions, 81 patients remained in
the Modified Intent to Treat population, 57 of whom were in the Per-Protocol population which included those who completed the trial
and were verified to take study drug from pharmacokinetic data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial was originally designed to be 80% powered
with 125 patients in each of the treatment and placebo arms. The unplanned exclusion of so many patients has left the trial underpowered
for the primary endpoints. In the Per-Protocol population, which included those patients who completed the trial and who were further
verified to have taken the study drug (based on pharmacokinetic data), an observed descriptive change from baseline appeared to suggest
a slowing of cognitive loss; these same patients experienced an advantage in age deceleration vs. placebo as measured by DNA epigenetic
change. Age deceleration is used by longevity researchers to measure the difference between the patient&#8217;s biological age, in this
case as measured by the Horvath DNA methylation Skin Blood Clock, relative to the patient&#8217;s actual chronological age. This test
was a non-primary/secondary endpoint, other-outcome measure, done via blood test collected at week 30 (end of study). Additional DNA methylation
data continues to be collected and analyzed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease (NCT05083260)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Phase 2 study of bezisterim (NE3107) for the treatment
of PD (NCT05083260), completed in December 2022, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study
in PD participants treated with carbidopa/levodopa and bezisterim (NE3107). Forty-five patients with a defined L-dopa &#8220;off state&#8221;
were randomized 1:1 to placebo: bezisterim (NE3107) 20 mg twice daily for 28 days. This trial was launched with two design objectives:
1) the primary objective was safety and a drug-drug interaction study as requested by the FDA to measure the potential for adverse interactions
of bezisterim (NE3107) with carbidopa/ levodopa; and 2) the secondary objective was to determine if preclinical indications of promotoric
activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met.</p>

<ix:exclude><p id="xdx_23F_zhcXnlWnvO07" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 60; Value: 1 -->
    <div id="xdx_23C_zN8NalXuk3i6" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23A_zVxDbzzyDCr" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_23A_zMKTAwYWo6Cb" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>1.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span>Background Information (continued)</span></b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Long COVID Program</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2024, the Company announced the grant of
a clinical trial award of up to $13.1 million from the DOD, awarded through the Peer Reviewed
Medical Research Program (&#8220;PRMRP&#8221;) of the Congressionally Directed Medical Research Programs (&#8220;CDMRP&#8221;). The award
can provide up to 2 years of non-dilutive funding for a Phase 2b clinical trial that will assess bezisterim (NE3107) for the treatment
of neurological symptoms that are associated with long COVID. The Company anticipates the trial to commence by early 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liver Disease Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In liver disease, our investigational drug candidate
BIV201 (continuous infusion terlipressin), which has been granted both FDA Fast Track designation status and FDA Orphan Drug status, is
being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the
treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2021, the Company initiated a Phase 2 study
(NCT04112199) designed to evaluate the efficacy of BIV201 (terlipressin, administered by continuous infusion for two 28-day treatment
cycles) combined with standard-of-care (&#8220;SOC&#8221;), compared to SOC alone, for the treatment of refractory ascites. The primary
endpoints of the study are the incidence of ascites-related complications and change in ascites fluid accumulation during treatment compared
to a pre-treatment period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, the Company announced enrollment was
paused and that data from the first 15 patients treated with BIV201 plus SOC appeared to show at least a 30% reduction in ascites fluid
during the 28 days after treatment initiation compared to the 28 days prior to treatment. The change in ascites volume was significantly
different from those patients receiving SOC treatment. Patients who completed the treatment with BIV201 experienced a 53% reduction in
ascites fluid, which was sustained (43% reduction) during the three months after treatment initiation as compared to the three-month pre-treatment
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2023, the Company requested and subsequently
received guidance from the FDA regarding the design and endpoints for definitive clinical testing of BIV201 for the treatment of ascites
due to chronic liver cirrhosis. The Company is currently finalizing protocol designs for the Phase 3 study of BIV201 for the treatment
of ascites due to chronic liver cirrhosis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BIV201 development program was initiated by LAT
Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently
owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11,
2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty
on net sales of BIV201 (continuous infusion terlipressin). to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett
Edge, Inc.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000575" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zhHeG4Y54gD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt; text-align: justify"><b>2.</b></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><b><span id="xdx_826_z3bQ4oJ8lxTl">Liquidity and Going Concern</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s operations are subject to a number
of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of
clinical testing and trial activities of the Company&#8217;s products, the Company&#8217;s ability to obtain regulatory approval to market
its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company
products; the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products;
and the Company&#8217;s ability to raise capital. The Company&#8217;s financial statements have been prepared assuming the Company will
continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of
business. As of June 30, 2024, the Company had working capital of approximately $<span id="xdx_90F_ecustom--WorkingCapital_iI_pp0n3_dm_c20240630_zbAgiTsGFtJ7" title="Working capital"><ix:nonFraction name="bivi:WorkingCapital" contextRef="AsOf2024-06-30" id="Fact000577" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">14.7</ix:nonFraction></span> million, cash and cash equivalents of approximately
$<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0n3_dm_c20240630_zPJfCMM9XJo9" title="Cash and cash equivalent"><ix:nonFraction name="us-gaap:CashEquivalentsAtCarryingValue" contextRef="AsOf2024-06-30" id="Fact000579" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">23.8</ix:nonFraction></span> million, stockholders&#8217; equity of approximately $<span id="xdx_908_ecustom--StockholderEquities_iI_pp0n3_dm_c20240630_zS3WOvYfCG18" title="Stockholders' equity"><ix:nonFraction name="bivi:StockholderEquities" contextRef="AsOf2024-06-30" id="Fact000581" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">15.5</ix:nonFraction></span> million, and an accumulated deficit of approximately $<span id="xdx_907_ecustom--AccumulatedDeficit_iI_pp0n3_dm_c20240630_zu3kN9EV3Fia" title="Accumulated deficit"><ix:nonFraction name="bivi:AccumulatedDeficit" contextRef="AsOf2024-06-30" id="Fact000583" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">334.2</ix:nonFraction></span> million.
The Company is in the pre-revenue stage and no revenues are expected in the foreseeable future. The Company&#8217;s future operations
are dependent on the success of the Company&#8217;s ongoing development and commercialization efforts, as well as its ability to secure
additional financing as needed. Projected cash flows could be extended if further measures are taken to delay planned expenditures in
our research protocols and slow the progress in the Company&#8217;s development and launch of next phase clinical programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The future viability of the Company is largely dependent
upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include
sales of equity, obtaining loans, or other strategic transactions.</p>

<ix:exclude><p id="xdx_231_zXcGO7AB5F39" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 61; Value: 1 -->
    <div id="xdx_23E_zuuDAWWHMNtj" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zpKlVCqaVZtd" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_23A_z6tAb8P3jasg" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt; text-align: justify"><b>2.</b></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><b><span>Liquidity and Going Concern (continued)</span></b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although management continues to pursue the Company&#8217;s
strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the
Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&#8217;s ability to continue
as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000587" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zll1CrPAPwzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt; text-align: justify"><b>3.</b></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><b><span id="xdx_822_zbCcGWc1ytec">Significant Accounting Policies</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000589" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zebyfefaqk47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zuLVlMJvL9b2">Basis of Presentation</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial statements have been
prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and include all adjustments
necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000591" name="us-gaap:UseOfEstimates"><p id="xdx_843_eus-gaap--UseOfEstimates_zkYmHk6pRTDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zXVFq7dHQ0oc">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying
notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the
circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses reported
for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which
are used for, but not limited to, accounting for clinical accruals, share-based compensation, accounting for derivatives, assumptions
used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and
accounting for income taxes. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000593" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1bk7qiimWe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zUQkDpl4k1ya">Cash and cash equivalents</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents consisted of cash deposits
and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S.
Treasury Bills with original maturities of three months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000595" name="bivi:InvestmentsUSTreasuryBillsPolicyTextBlock"><p id="xdx_84D_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_z3aqWr0boaMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_862_zUelhoMtJqfg">Investments in U.S. Treasury Bills</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in U.S. Treasury Bills with maturities
greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other
comprehensive income in the accompanying statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000597" name="bivi:ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock"><p id="xdx_842_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zV9UO2YnPgge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zSuBbiWxmaLd">Concentration of Credit Risk in the Financial Service
Industry</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2024, the Company had cash deposited
in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these
financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March
and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions
due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material
direct impact on the Company&#8217;s operations, if further liquidity and financial stability concerns arise with respect to banks and
financial institutions, either nationally or in specific regions, the Company&#8217;s ability to access cash or enter into new financing
arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</p>

<ix:exclude><p id="xdx_235_zYNFHSAEwo93" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 62; Value: 1 -->
    <div id="xdx_232_zQwICdj250c4" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zf7rdd6EfVo6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_238_zzoddg9CoyQ" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt; text-align: justify"><b>3.</b></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><b>Significant Accounting Policies (continued)</b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000601" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zU1VURvQxAR" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zzS4ULT1Zzhg">Fair value measurement of assets and liabilities</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We determine the fair values of our financial instruments
based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the
asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the
fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset
or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant
to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active
markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - Inputs are quoted prices for similar assets
and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market
corroboration, for substantially the full term of the financial instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - Inputs are unobservable inputs based on
our assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial instruments include
cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts
payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating
lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000603" name="bivi:PrepaidAndOtherAssetsPolicyTextBlock"><p id="xdx_849_ecustom--PrepaidAndOtherAssetsPolicyTextBlock_zPIGiac7r2vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_zOA3YHVhTic4">Prepaid and other assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid and other assets consist of prepayments of
certain expenses and a security deposit paid in connection with a lease agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000605" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zXUyPYrjc8n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zFXQIjiZ4lIg">Leases</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines whether an arrangement contains
a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current portion of operating
lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from
the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease
term at the commencement date. As the Company&#8217;s leases do not provide an implicit rate, an incremental borrowing rate is used based
on the information available at the commencement date in determining the present value of lease payments. The Company does not include
options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such
options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets
or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease
payments as expense on a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000607" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zw5dMpI2O1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_zWnYoZSIavae">Research and Development</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses consist primarily
of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development,
personnel, supplies and development materials, costs for consultants and related contract research and facility costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000609" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zqRMfBsKS5pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zWAOugpoWc7l">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method of
accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards
and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a
valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company
decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses.</p>

<ix:exclude><p id="xdx_237_z5QUEs3PW5Ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 63; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_235_z5VMPFMDCoxd" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_233_z5EwB7IdOmij" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_236_zopTsrRz3Fy1" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt; text-align: justify"><b>3.</b></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><b>Significant Accounting Policies (continued)</b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes uncertainty in income taxes
in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in
a tax return. The Company applies the &#8220;more-likely-than-not&#8221; recognition threshold to all tax positions, commencing at the
adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there
have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,
if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive
Loss. For the years ended June 30, 2024 and 2023, there was no such interest or penalty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000613" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zzafBczj30B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zP0T8FTTKfDd">Net Loss per Common Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed by dividing
the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period.
Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number
of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution
that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30,
2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for
the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below shows the potential shares of common stock, presented based on amounts outstanding
at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including
them would have had an anti-dilutive effect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000615" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z4xX8a8Ld4Eh" summary="xdx: Disclosure - Significant Accounting Policies (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B0_zzRmJdp8450j" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" title="Total" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012024-06-30_us-gaap_StockOptionMember" id="Fact000617" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">518,076</ix:nonFraction></td><td style="white-space: nowrap; width: 8%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" title="Total" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012023-06-30_us-gaap_StockOptionMember" id="Fact000619" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">395,286</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember" id="Fact000621" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,932,029</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember" id="Fact000623" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">777,029</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000625" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,291</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember" id="Fact000627" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,646</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes payable conversion option</p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td title="Total" id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-012024-06-30_custom_NotespayableConversionOptionMember" id="Fact000629" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,633</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td title="Total" id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012023-06-30_custom_NotespayableConversionOptionMember" id="Fact000631" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,633</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 3.5pt">Total</td><td style="font-weight: bold; padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" title="Total" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2023-07-01to2024-06-30" id="Fact000633" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,562,029</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z7TsdxVTmiRa" title="Total" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2022-07-012023-06-30" id="Fact000635" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,303,594</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000637" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zGNGGaqFFrIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_860_zXhPFYOTD7x">Stock-based Compensation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has accounted for stock-based compensation
under the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718 &#8211; &#8220;Stock Compensation&#8221; (&#8220;ASC
718&#8221;) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees
and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees
awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses
assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. For non-employees, the Company
utilizes the graded vesting attribution method under which the entity treats each separately vesting portion (tranche) as a separate award
and recognizes compensation cost for each tranche over its separate vesting schedule. Expected volatilities are based on historical volatility
of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected
term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of
the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for
the period of the expected term. The Company recognizes forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000639" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy"><p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zpHNQRK66eD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zVullYgQSaFe">Goodwill</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill is recorded when the purchase price paid
for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual
impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests.
The Company&#8217;s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill
related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an
asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make
certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each
time the Company tests goodwill for impairment and are typically developed as part of the Company&#8217;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce
materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2024 and 2023.</p>

<ix:exclude><p id="xdx_235_zLQsljHFjuo" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 64; Value: 1 -->
    <div id="xdx_23C_zV0DXncVWMbk" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zxWRIRlg7Km6" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_231_zM7IviPO2Iyi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt; text-align: justify"><b>3.</b></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><b>Significant Accounting Policies (continued)</b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000643" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxEExg1l3wa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_ztcdrcAsC2q2">Impairment of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, including intangible assets, are
reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted
estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying
amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected
discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities
of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance
sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000645" name="bivi:ReverseStockSpliteUpPolicyTextBlock"><p id="xdx_848_ecustom--ReverseStockSpliteUpPolicyTextBlock_zSThz6PT6ydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_860_z1RnzX1jpb0k">Reverse stock split up</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">The company effected a 1:10 reverse split of the issued and outstanding
shares of its Class A commons stock which was approved by the board of director after the approval obtained from shareholders at a special
meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders&#8217; approval was
obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split.<span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000647" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zuwhNodhFzFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_z4C4Pn21Svea">Recent Accounting Pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and impact
of all Accounting Standards Updates (&#8220;ASU&#8217;s&#8221;). There were no recent ASU&#8217;s that are expected to have a material
impact on our balance sheets or statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the Financial Accounting Standards Board
(&#8220;FASB&#8221;) issued ASU No. 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments&#8221; (&#8220;ASU 2016-13&#8221;). This amendment replaces the incurred loss impairment methodology in current
GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade receivables. This update
is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted
ASU 2016-13 effective July 1, 2023 and the adoption had an insignificant impact on the accompanying financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures," to enhance disclosures for significant segment expenses for all public entities required to report segment information
in accordance with ASC 280. The standard did not change the definition of a segment, the method for determining segments or the criteria
for aggregating operating segments into reportable segments. The amendments are effective for fiscal years beginning after December 15,
2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods
presented in the financial statements. The adoption is not expected to have a material impact to our financial statements or disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09, "Income
Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures.
This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information
for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount
of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions.
Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between
domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are
effective for annual periods beginning after December 15, 2024. We will adopt this standard on a prospective basis as allowed by the standard.
The adoption of this standard is not expected to have a material impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 65; Value: 1 -->
    <div id="xdx_236_z2ModISsysth" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23D_zRpb4qmuSGSe" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000649" name="bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock"><p id="xdx_80F_ecustom--InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock_zWKBbFyMy4ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>4. <span id="xdx_824_zeVATi7Qf5w6">Investments in U.S. Treasury Bills available-for-sale</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the U.S. Treasury Bills
held at June 30, 2023:&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000651" name="bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)" id="xdx_88F_ecustom--ScheduleOfUSTreasuryBillsHeldTableTextBlock_zFpMQIBDZYM9" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span id="xdx_8B9_zwPq9nbsxKK3" style="display: none">Schedule of U.S. treasury bills held</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized
    Cost Basis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Unrealized Gain</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Unrealized loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Accumulated Other Comprehensive Income</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Treasury
    Bills due in 3 - 6 months</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--AmortizedCostBasis_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" title="Amortized Cost Basis" style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="bivi:AmortizedCostBasis" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember" id="Fact000653" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,301,136</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--GrossUnrealizedGain_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" title="Gross Unrealized Gain" style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="bivi:GrossUnrealizedGain" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember" id="Fact000655" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">176,591</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--GrossUnrealizedLoss_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" title="Gross Unrealized loss" style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--InvestmentOwnedAtFairValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" title="Fair Value" style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:InvestmentOwnedAtFairValue" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember" id="Fact000659" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,477,726</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" title="Total Accumulated Other Comprehensive Income" style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember" id="Fact000661" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">176,591</ix:nonFraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended June 30, 2023, the Company
purchased a total of approximately $<span id="xdx_90B_ecustom--NumberOfStockPurchased_pp0n3_dm_c20220701__20230630_zfZ2Q4bI3lp6" title="Number of stock purchased"><ix:nonFraction name="bivi:NumberOfStockPurchased" contextRef="From2022-07-012023-06-30" id="Fact000663" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">46</ix:nonFraction></span> million of U.S. Treasury Bills. All outstanding investments in U.S. Treasury Bills available-for-sale
held at June 30, 2023 matured during the three months ended September 30, 2023 and were settled, resulting in a realized gain of $<span id="xdx_90A_ecustom--RealizedGainOnMaturityOfAvailableforSale_pp0p0_c20230701__20240630_zx89DfToRKVk" title="Realized gain on maturity of available-for sale"><ix:nonFraction name="bivi:RealizedGainOnMaturityOfAvailableforSale" contextRef="From2023-07-01to2024-06-30" id="Fact000665" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,865</ix:nonFraction></span>
recorded as a component of interest income on the accompanying statement of operations and comprehensive loss.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000667" name="us-gaap:IntangibleAssetsDisclosureTextBlock"><p id="xdx_80D_eus-gaap--IntangibleAssetsDisclosureTextBlock_z4PkRJory8Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>5.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_823_zzqLK3WsC4al">Intangible Assets</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s intangible assets consist of intellectual property
acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets
as of June 30, 2024 and 2023:&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000669" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zWlieL5r0Rt3" summary="xdx: Disclosure - Intangible Assets (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8BD_zVTU4dWRgoW7" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20240630" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20230630" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzbKJ_zQ2SOZ6MBv28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Intellectual Property</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2024-06-30" id="Fact000671" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,293,770</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2023-06-30" id="Fact000672" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,293,770</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzbKJ_zuLnqk5tPxO" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2024-06-30" id="Fact000674" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,886,052</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2023-06-30" id="Fact000675" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,656,675</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzbKJ_z7X64uOB06K4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Intellectual Property, Net</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-06-30" id="Fact000677" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">407,718</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2023-06-30" id="Fact000678" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">637,095</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zk22UgZk5o54" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense amounted to $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20240630_pp0p0" title="Amortization expenses"><span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20220701__20230630_pp0p0" title="Amortization expenses"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2023-07-01to2024-06-30" id="Fact000680" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2022-07-012023-06-30" id="Fact000682" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,377</ix:nonFraction></ix:nonFraction></span></span> for each
of the years ended June 30, 2024 and 2023, respectively. The Company amortizes intellectual property over the expected original useful
lives of <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630_zD3NORzx3dJc" title="Useful life"><ix:nonNumeric contextRef="AsOf2024-06-30" format="ixt-sec:duryear" id="Fact000684" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">10</ix:nonNumeric> </span>years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Estimated future amortization expense is as follows:&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000686" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOWvmnVxiYid" summary="xdx: Disclosure - Intangible Assets (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_8B6_zPn29iP1C7w3" style="display: none">Schedule of future amortization expense</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20240630_zTK62UB8coMi" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">Year ending June 30,</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: center">2025</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 48%; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2024-06-30" id="Fact000690" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">229,377</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2024-06-30" id="Fact000692" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">178,341</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); padding-bottom: 3.5pt">&#160;Finite lived intangible assets, net</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2024-06-30" id="Fact000694" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">407,718</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000696" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOOirCY2eeze" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>6.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_82A_zMseLmUjNa1g">Related Party Transactions</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Equity Transactions with Acuitas</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 15, 2022, the Company entered into a securities
purchase agreement with Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;), the Company&#8217;s largest stockholder, pursuant to which
Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_c20220715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_pdd" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2022-07-15_custom_AcuitasGroupHoldingsLLCMember" id="Fact000698" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">363,636</ix:nonFraction></span> shares of the Company&#8217;s Common
Stock, at a price of $16.50 per share (the &#8220;PIPE Shares&#8221;), and (ii) a warrant to purchase 727,273 shares of Common Stock (&#8220;PIPE
Warrant Shares&#8221;), at an exercise price of $18.20, with a term of exercise of five years. The down round feature reduced the exercise
price of the PIPE Warrant Shares to $10.00 per share on March 6, 2024 in connection with the offering further described in Note 9 as the
Company sold stock at a price lower than its initial exercise price. The Company calculated the difference in fair value of the PIPE Warrant
Shares between the stated exercise price and the reduced exercise price and recorded $<span id="xdx_904_eus-gaap--Dividends_c20230701__20240630_pp0p0" title="Deemed dividend"><ix:nonFraction name="us-gaap:Dividends" contextRef="From2023-07-01to2024-06-30" id="Fact000700" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">886,423</ix:nonFraction></span> as a deemed dividend. The fair value of
the PIPE Warrant Shares were estimated using the Black Scholes Method with the following inputs, the stock price of $<span id="xdx_90A_eus-gaap--SharePrice_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Stock price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_WarrantsMember" id="Fact000702" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.65</ix:nonFraction></span>, exercise price
of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_custom_WarrantsMember_srt_MinimumMember" id="Fact000704" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.20</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-06-30_custom_WarrantsMember_srt_MaximumMember" id="Fact000706" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span>, remaining term of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zaQw6QcEbdm" title="Remaining term"><ix:nonNumeric contextRef="AsOf2024-06-30_custom_WarrantsMember" format="ixt-sec:duryear" id="Fact000708" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.5</ix:nonNumeric></span> years, risk free rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Risk free rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_custom_WarrantsMember" id="Fact000710" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.4</ix:nonFraction>%</span> and volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_custom_WarrantsMember" id="Fact000712" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.0</ix:nonFraction>%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 15, 2022, the Company received net proceeds of approximately
$5.9 million, net of costs of approximately $94,000, and entered into an amended and restated registration agreement with Acuitas, which
amended and restated that certain registration rights agreement, dated as of June 10, 2021, by and between the Company and Acuitas (the
&#8220;Existing Registration Rights Agreement&#8221;), to amend the definition of &#8220;Registrable Securities&#8221; in the Existing
Registration Rights Agreement to include the PIPE Shares and the PIPE Warrant Shares as Registrable Securities thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 66; Value: 1 -->
    <div id="xdx_23A_zXdGsRy0LQYh" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zUjlRK7AYCd8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000714" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_znaQgGUTiJn8" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>7.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_822_zvK1J4NAbR1g">Notes Payable</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 30, 2021 (the &#8220;Closing
Date&#8221;), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and
Promissory Notes (together, the &#8220;Loan Agreement&#8221;) with Avenue Venture Opportunities Fund, L.P. (&#8220;AVOPI&#8221;) and
Avenue Venture Opportunities Fund II, L.P. (&#8220;AVOPII,&#8221; and together with AVOPI, &#8220;Avenue&#8221;) for growth capital
loans in an aggregate commitment amount of up to $20 million (the &#8220;Loan&#8221;). On the Closing Date, $15 million of the Loan
was funded (&#8220;Tranche 1&#8221;). The Loan provided for an additional $5 million to be available to the Company on or prior to
September 15, 2022, subject to the Company&#8217;s achievement of certain milestones with respect to certain of its ongoing clinical
trials, which were not achieved. The Loan bears interest at an annual rate equal to the greater of (a) the sum of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230701__20240630__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_pdd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-07-012024-06-30_us-gaap_PrimeRateMember" id="Fact000716" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7.00</ix:nonFraction>%</span>
plus the prime rate as reported in The Wall Street Journal and (b) 10.75%. The prime rate at June 30, 2024 was <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230701__20240630_pdd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateDuringPeriod" contextRef="From2023-07-01to2024-06-30" id="Fact000718" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.50</ix:nonFraction>%</span>.
The Loan is secured by a lien upon and security interest in all of the Company&#8217;s assets, including intellectual property,
subject to agreed exceptions. The maturity date of the Loan is December 1, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Loan Agreement required monthly interest-only
payments during the first eighteen months of the term of the Loan. Following the interest-only period, on July 1, 2023, the Company pays
equal monthly payments of principal, plus accrued interest, until the Loan&#8217;s maturity date when all remaining principal and accrued
interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal
amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal
amount of the Loan that is prepaid after the interest-only period. At the Loan&#8217;s maturity date, or on the date of the prepayment
of the Loan, the Company will be obligated to pay a final payment equal to 4.25% of the Loan commitment amount, the sum of Tranche 1 and
Tranche 2, which amounts to $850,000 (the &#8220;Loan Premium&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Loan Agreement includes a conversion option to
convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company&#8217;s
Common Stock at a conversion price of $69.80 per share (the &#8220;Conversion Option&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the Closing Date, the Company issued to Avenue
warrants to purchase 36,101 shares of Common Stock of the Company (the &#8220;Avenue Warrants&#8221;) at an exercise price per share equal
to $58.20. The Avenue Warrants are exercisable until November 30, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount of the carrying value of the notes payable
was determined by allocating portions of the outstanding principal of the notes, approximately $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pp0n3_dm_c20230701__20240630_zFRfQ2xyaobl" title="Fair value of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2023-07-01to2024-06-30" id="Fact000720" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million, to the fair value of the
Avenue Warrants, and approximately $<span id="xdx_90F_ecustom--FairValueOfEmbeddedConversionOption_pp0n3_dm_c20230701__20240630_ztNYMpDOfJRk" title="Fair value of embedded conversion option"><ix:nonFraction name="bivi:FairValueOfEmbeddedConversionOption" contextRef="From2023-07-01to2024-06-30" id="Fact000722" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.2</ix:nonFraction></span> million to the fair value of the embedded Conversion Option. Accordingly, the total amount of
unearned discount of approximately $<span id="xdx_904_ecustom--UnearnedDiscount_pp0n3_dm_c20220701__20230630_zIYUU4ek7Ahh" title="Unearned discount"><ix:nonFraction name="bivi:UnearnedDiscount" contextRef="From2022-07-012023-06-30" id="Fact000724" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.6</ix:nonFraction></span> million, the total direct financing cost of approximately $<span id="xdx_909_ecustom--DirectFinancingCost_c20230701__20240630_pp0n3" title="Direct financing cost"><ix:nonFraction name="bivi:DirectFinancingCost" contextRef="From2023-07-01to2024-06-30" id="Fact000726" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">390,000</ix:nonFraction></span> and the Loan Premium of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedPremium_c20240630_pp0n3" title="Unamortized premium recognized"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedPremium" contextRef="AsOf2024-06-30" id="Fact000728" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">850,000</ix:nonFraction></span>
are being amortized using the effective interest method over the term of the Loan. The adjusted effective interest rate is 27%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total interest expense for the year ended June 30,
2024 was approximately $<span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0n3_dm_c20230701__20240630_zDAd1oZx9sk3" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2023-07-01to2024-06-30" id="Fact000730" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million on the accompanying statement of operations and comprehensive loss. Interest expense was comprised
of interest incurred on the outstanding principal of the loan of approximately $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0n3_dm_c20230701__20240630_zNX3xfmqKgI8" title="Interest payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentInterest" contextRef="From2023-07-01to2024-06-30" id="Fact000732" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.5</ix:nonFraction></span> million, amortization of financing costs of approximately
$<span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20230701__20240630_pp0n3" title="Amortization of financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2023-07-01to2024-06-30" id="Fact000734" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">109,000</ix:nonFraction></span>, amortization of the unearned discount of $<span id="xdx_90B_ecustom--UnearnedDiscount_pp0n3_dm_c20230701__20240630_znFjNVsItFQ7" title="Unearned discount"><ix:nonFraction name="bivi:UnearnedDiscount" contextRef="From2023-07-01to2024-06-30" id="Fact000736" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million, and the accretion of the Loan Premium of approximately $<span id="xdx_909_ecustom--AccretionsOfLoanPremium_c20230701__20240630_pp0n3" title="Accretion of loan premium"><ix:nonFraction name="bivi:AccretionsOfLoanPremium" contextRef="From2023-07-01to2024-06-30" id="Fact000738" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">237,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total interest expense for the year ended June 30,
2023 was approximately $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_pp0n3_dm_c20220701__20230630_zugWQm0wDE3a" title="Interest expense"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2022-07-012023-06-30" id="Fact000740" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million on the accompanying statement of operations and comprehensive loss. Interest expense was comprised
of interest incurred on the outstanding principal of the loan of approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0n3_dm_c20220701__20230630_zNQipDEkbQM4" title="Interest payment"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentInterest" contextRef="From2022-07-012023-06-30" id="Fact000742" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million, amortization of financing costs of approximately
$<span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20220701__20230630_pp0n3" title="Amortization of financing costs"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2022-07-012023-06-30" id="Fact000744" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">170,000</ix:nonFraction></span>, amortization of the unearned discount of $1.6 million, and the accretion of the Loan Premium of approximately $<span id="xdx_90F_ecustom--AccretionsOfLoanPremium_c20220701__20230630_pp0n3" title="Accretion of loan premium"><ix:nonFraction name="bivi:AccretionsOfLoanPremium" contextRef="From2022-07-012023-06-30" id="Fact000746" format="ixt:numdotdecimal" decimals="0" scale="3" unitRef="USD">422,000</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2024, the remaining principal balance
of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pp0n3_dm_c20240630_zKQgvFHSSVDl" title="Remaining principal balance"><ix:nonFraction name="us-gaap:NotesPayable" contextRef="AsOf2024-06-30" id="Fact000748" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million under the Loan is payable in 6 monthly equal installments. For the year ended June 30, 2024, the Company paid back $<span id="xdx_904_eus-gaap--RepaymentsOfNotesPayable_pp0n3_dm_c20230701__20240630_zGIzTAghBM65" title="Repayments of notes payable"><ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2023-07-01to2024-06-30" id="Fact000750" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">10</ix:nonFraction></span>
million, of the original loan of $15 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<ix:exclude><!-- Field: Page; Sequence: 67; Value: 1 -->
    <div id="xdx_233_zzG6wxLDwZZc" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_237_zzPzmkdVRTz4" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_23F_zLJodEhIzcl5" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>7.</b></td>
    <td style="width: 95%; font-size: 10pt"><b>Notes Payable (continued)</b></td></tr>
  </table></ix:exclude>
<ix:exclude><p id="xdx_23B_ze6dDMULPPNd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following is a summary of the Notes Payable as of June 30, 2024 and
2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Current portion of Notes Payable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000754" name="us-gaap:ScheduleOfDebtTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zaRglNHc3gAk" summary="xdx: Disclosure - Notes Payable (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B8_zWvDsDKpNXFg" style="display: none">Schedule of note payable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20240630_znFsMdOQI535" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230630_zoW9eLTsQjYl" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Current portion of Notes Payable</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="bivi:CurrentPortionOfNotesPayable" contextRef="AsOf2024-06-30" id="Fact000756" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="bivi:CurrentPortionOfNotesPayable" contextRef="AsOf2023-06-30" id="Fact000757" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000,000</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: debt financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="bivi:DebtFinancingCosts" contextRef="AsOf2024-06-30" id="Fact000759" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">11,820</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="bivi:DebtFinancingCosts" contextRef="AsOf2023-06-30" id="Fact000760" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">108,751</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_zZTwYjN6FXja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unearned discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" contextRef="AsOf2024-06-30" id="Fact000762" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,212</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" contextRef="AsOf2023-06-30" id="Fact000763" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,023,145</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: accretion of Loan Premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:AccretionOfLoanPremiums" contextRef="AsOf2024-06-30" id="Fact000765" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">824,242</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:AccretionOfLoanPremiums" contextRef="AsOf2023-06-30" id="Fact000766" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">236,970</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Current portion of Notes Payable, net of financing costs, unearned premium and discount</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2024-06-30" id="Fact000768" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,701,210</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2023-06-30" id="Fact000769" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,105,074</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Non-current portion of Notes Payable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zVy4JaB1LlEb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230630_zeXJplCcT4mb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--NotesPayableNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Notes Payable</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="bivi:NotesPayableNoncurrent" contextRef="AsOf2023-06-30" id="Fact000772" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LongtermDebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: debt financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="bivi:LongtermDebtFinancingCosts" contextRef="AsOf2023-06-30" id="Fact000775" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">11,820</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_z02kJbl99M2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unearned discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="bivi:LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" contextRef="AsOf2023-06-30" id="Fact000778" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,212</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--LongTermAccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: accretion of Loan Premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0780">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:LongTermAccretionOfLoanPremiums" contextRef="AsOf2023-06-30" id="Fact000781" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,302</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Notes Payable, net of the current portion financing costs, unearned premium and discount</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="bivi:LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" contextRef="AsOf2023-06-30" id="Fact000784" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,227,270</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zjQrjBvFwAL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Estimated future amortization expense and accretion of Loan Premium is
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000786" name="bivi:ScheduleofFutureAmortizationExpenseTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleofFutureAmortizationExpenseTableTextBlock_zfupwuvlLAFb" summary="xdx: Disclosure - Notes Payable (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B0_zxxq948tcl1c" style="display: none">Schedule of estimated future amortization expense and accretion of premium</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Unearned Discount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Debt Financing Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Loan Premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Year ending June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; text-align: center; padding-bottom: 1.5pt">2025</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" title="2025" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right"><ix:nonFraction name="bivi:AmortizationExpenseNextRollingTwoYears" contextRef="AsOf2024-06-30_custom_UnearnedDiscountMember" id="Fact000788" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,212</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" title="2025" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right"><ix:nonFraction name="bivi:AmortizationExpenseNextRollingTwoYears" contextRef="AsOf2024-06-30_us-gaap_FinanceReceivablesMember" id="Fact000790" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,820</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" title="2025" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right"><ix:nonFraction name="bivi:AmortizationExpenseNextRollingTwoYears" contextRef="AsOf2024-06-30_custom_LoanAccretionPremiumMember" id="Fact000792" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,758</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="bivi:AmortizationExpenseTotal" contextRef="AsOf2024-06-30_custom_UnearnedDiscountMember" id="Fact000794" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,212</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="bivi:AmortizationExpenseTotal" contextRef="AsOf2024-06-30_us-gaap_FinanceReceivablesMember" id="Fact000796" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,820</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="bivi:AmortizationExpenseTotal" contextRef="AsOf2024-06-30_custom_LoanAccretionPremiumMember" id="Fact000798" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,758</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z1BXfF6KpXTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 68; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_230_zou3JwYBnRm4" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_z1yuciHr0Y8c" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000800" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock"><p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zEa3bFnfv26i" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>8.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_827_z0cT4uPXKInc">Fair Value Measurements</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At June 30, 2024 and 2023, the estimated fair value of derivative liabilities
measured on a recurring basis are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000802" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zs1275pMAXB1" summary="xdx: Disclosure - Fair Value Measurements (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"><span id="xdx_8BC_ztGBkgtbqqxb" style="display: none">Schedule of derivative liabilities at fair value</span>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Derivative liability - Warrants</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total derivatives" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total derivatives" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0806">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total derivatives" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000808" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,771</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" title="Total derivatives" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember" id="Fact000810" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,771</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - Conversion Option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total derivatives" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total derivatives" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total derivatives" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" title="Total derivatives" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total derivative liabilities</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total derivatives" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total derivatives" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total derivatives" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000824" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,771</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630_pp0p0" title="Total derivatives" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30" id="Fact000826" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,771</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Derivative liability - Warrants</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total derivatives" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total derivatives" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total derivatives" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000832" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">894,280</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" title="Total derivatives" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember" id="Fact000834" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">894,280</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - Conversion option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total derivatives" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total derivatives" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total derivatives" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact000840" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">925,762</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" title="Total derivatives" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember" id="Fact000842" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">925,762</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total derivative liabilities</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total derivatives" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total derivatives" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total derivatives" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member" id="Fact000848" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,820,042</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630_pp0p0" title="Total derivatives" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30" id="Fact000850" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,820,042</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zDfjHjwYnFUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents the activity for level 3 liabilities measured
at fair value using unobservable inputs for the years ended June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000852" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z9w664WrOIM5" summary="xdx: Disclosure - Fair Value Measurements (Details 1)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BB_zwMPaIlLuXg" style="display: none">Fair value, liabilities measured on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liability - Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liability - Conversion Option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance at June 30, 2022</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUgcP89KKABf" title="Balance at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000854" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,531</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zblXPAVgAYlb" title="Balance at beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2022-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact000856" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">188,030</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions to level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Additions to level 3 liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Additions to level 3 liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in in fair value of level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Change in in fair value of level 3 liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000862" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">699,749</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Change in in fair value of level 3 liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact000864" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">737,732</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Transfer in and/or out of level 3</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Transfer in and/or out of Level 3" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Transfer in and/or out of Level 3" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0868">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0lABtpPOqxk" title="Balance at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000870" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">894,280</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCdd2q8kxlk5" title="Balance at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact000872" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">925,762</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions to level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Additions to level 3 liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Additions to level 3 liabilities" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in in fair value of level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Change in in fair value of level 3 liabilities" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000878" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">890,509</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Change in in fair value of level 3 liabilities" style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact000880" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">925,762</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Transfer in and/or out of level 3</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Transfer in and/or out of Level 3" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Transfer in and/or out of Level 3" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkkQVIkbkN86" title="Balance at ending" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DerivativeLiabilities" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000886" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,771</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwKr3rlPQmJ6" title="Balance at ending" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_ztmqNF8QSJvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair values of derivative liabilities for the
Avenue Warrants and Conversion Option at June 30, 2024 in the accompanying balance sheet, were approximately $3,800 and approximately
zero, respectively. The total change in the fair value of the derivative liabilities totaled approximately $(1.8) million and $1.4 million
for the years ended June 30, 2024, and 2023, respectively; and accordingly, was recorded in the accompanying statements of operations
and comprehensive loss. The assumptions used in the Black Scholes model to value the derivative liabilities at June 30, 2024 included
the closing stock price of $<span id="xdx_908_eus-gaap--SharePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Share Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000890" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.00</ix:nonFraction></span> per share; for the Avenue Warrants, the exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Exercise Price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000892" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.20</ix:nonFraction></span>, remaining term <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zQfz58nmCpci" title="Term"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" format="ixt-sec:duryear" id="Fact000894" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">2.4</ix:nonNumeric></span> year, risk free
rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Risk Free Interest Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000896" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.6</ix:nonFraction>%</span> and volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Volatility Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member" id="Fact000898" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">82.0</ix:nonFraction>%</span>; and for the Conversion Option, the conversion price of $<span id="xdx_903_eus-gaap--SharePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Share Price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member" id="Fact000900" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">69.80</ix:nonFraction></span>; remaining term of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtM_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z80P3yszfRQ1" title="Term"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" format="ixt-sec:durmonth" id="Fact000902" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5</ix:nonNumeric></span> months, risk
free rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Risk Free Interest Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact000904" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.38</ix:nonFraction>%</span> and volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Volatility Rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member" id="Fact000906" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">91.0</ix:nonFraction>%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Derivative liability &#8211; Avenue Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Avenue Warrants were not considered to be indexed
to the Company&#8217;s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompanying balance sheets
at June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Black Scholes model was used to calculate the
fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue Loan amount funded. The Avenue Warrants
are recorded at their fair values at the date of issuance and remeasured at each subsequent reporting period end date.</p>

<ix:exclude><p id="xdx_238_zL2IagkR8SCh" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 69; Value: 1 -->
    <div id="xdx_23F_zL1tYh7mOg7" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_231_zMw3SBwL0R5e" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_232_z6bVmPRzrD7c" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>8.</b></td>
    <td style="width: 95%; font-size: 10pt"><b>Fair Value Measurements (continued)</b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Embedded derivative liability &#8211; Conversion
Option</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Conversion Option is accounted for as an embedded
derivative liability and required bifurcation from the Loan amount. The Black Scholes model was used to calculate the fair value of the
Conversion Option to bifurcate it from the Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Financial assets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2024, investments in U.S. Treasury Bills were valued through
use of quoted prices and are classified as Level 1. The following table presents information about our assets that are measured at fair
value on a recurring basis using the above input categories.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000910" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znrCtiblFEj" summary="xdx: Disclosure - Fair Value Measurements (Details 2)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B5_zEnnMqJ0iX13" style="display: none">Measured at fair value on a recurring basis</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Cash</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel1Member" id="Fact000912" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,763,941</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" title="Total" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_CashMember" id="Fact000918" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,763,941</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel1Member" id="Fact000920" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,079,857</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember" id="Fact000926" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,079,857</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000928" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,843,798</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2024-06-30" id="Fact000934" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,843,798</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Cash</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel1Member" id="Fact000936" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,304,543</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total" style="width: 8%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" title="Total" style="width: 8%; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_CashMember" id="Fact000942" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,304,543</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel1Member" id="Fact000944" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,156,340</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0946">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember" id="Fact000950" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,156,340</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">U.S. Treasury Bills due in 3 - 6 months at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel1Member" id="Fact000952" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,477,726</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0954">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0956">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member" id="Fact000958" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,477,726</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member" id="Fact000960" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,938,609</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630_pp0p0" title="Total" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" contextRef="AsOf2023-06-30" id="Fact000966" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,938,609</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zKu2HKcCU3Th" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact000968" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zAP4FJUoa5K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>9.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_823_z2M2FnXZNpOb">Equity Transactions</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance of common stock for cash</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 31, 2022, the Company entered into a Controlled
Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (collectively,
the &#8220;Agents&#8221;), pursuant to which the Company may issue and sell from time-to-time shares of the Company&#8217;s common stock
through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities,
Inc. mutually agreed to terminate B. Riley Securities, Inc.&#8217;s role as a sales agent under the Sales Agreement. During the year ended
June 30, 2024, the Company sold <span id="xdx_90C_ecustom--IssuanceOfCommonStockForCashShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Issuance of common stock for cash, shares"><ix:nonFraction name="bivi:IssuanceOfCommonStockForCashShares" contextRef="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember" id="Fact000970" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">333,749</ix:nonFraction></span> shares of common stock under the Sales Agreement for total net proceeds of approximately $<span id="xdx_902_ecustom--IssuanceOfCommonStockForCash_pp0n3_dm_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z6dmYsKkbBx8" title="Issuance of common stock for cash"><ix:nonFraction name="bivi:IssuanceOfCommonStockForCash" contextRef="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember" id="Fact000972" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">9.3</ix:nonFraction></span>
million after deducting <span id="xdx_90E_ecustom--CommissionsPercentage_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Commissions percentage"><ix:nonFraction name="bivi:CommissionsPercentage" contextRef="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember" id="Fact000974" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span> commissions and expenses of approximately $<span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember" id="Fact000976" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">377,000</ix:nonFraction></span>. During the year ended June 30, 2023, the Company sold <span id="xdx_903_ecustom--IssuanceOfCommonStockForCashShares_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Issuance of common stock for cash, shares"><ix:nonFraction name="bivi:IssuanceOfCommonStockForCashShares" contextRef="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember" id="Fact000978" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">753,925</ix:nonFraction></span>
shares of common stock under the Sales Agreement for total net proceeds of approximately $<span id="xdx_908_ecustom--IssuanceOfCommonStockForCash_pp0n3_dm_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zyp1vsbfxDa1" title="Issuance of common stock for cash"><ix:nonFraction name="bivi:IssuanceOfCommonStockForCash" contextRef="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember" id="Fact000980" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">49.5</ix:nonFraction></span> million after <span id="xdx_90C_ecustom--CommissionsPercentage_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Commissions percentage"><ix:nonFraction name="bivi:CommissionsPercentage" contextRef="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember" id="Fact000982" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3</ix:nonFraction>%</span> commissions and expenses
of approximately $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_pp0n3_dm_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zvNIe5WdZ8cg" title="Issuance costs"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember" id="Fact000984" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.0</ix:nonFraction></span> million.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 6, 2024, the Company closed a best efforts
public offering (the &#8220;Offering&#8221;) of <span id="xdx_904_eus-gaap--PartnersCapitalAccountUnitsSoldInPublicOffering_c20240301__20240306_pdd" title="Public offering"><ix:nonFraction name="us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering" contextRef="From2024-03-012024-03-06" id="Fact000986" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,500,000</ix:nonFraction></span> shares (the &#8220;Shares&#8221;) of its common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240306_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-03-06" id="Fact000988" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per
share (the &#8220;Common Stock&#8221;), pre-funded warrants (the &#8220;Pre-funded Warrants&#8221;) to purchase <span id="xdx_90D_eus-gaap--StockRepurchasedDuringPeriodShares_c20240301__20240306__us-gaap--AwardTypeAxis__custom--PrefundedWarrantsMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-03-012024-03-06_custom_PrefundedWarrantsMember" id="Fact000990" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span> shares of Common
Stock, and warrants to purchase up to <span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodShares_c20240301__20240306__us-gaap--AwardTypeAxis__custom--CommonWarrantMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-03-012024-03-06_custom_CommonWarrantMember" id="Fact000992" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,050,000</ix:nonFraction></span> shares of Common Stock (the &#8220;Common Warrants&#8221;) at a combined public offering
price of $<span id="xdx_90B_eus-gaap--SharePrice_c20240306_pdd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-03-06" id="Fact000994" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></span> per Share, or Pre-funded Warrant, and the associated Common Warrant. <span style="background-color: white">The Common
Warrants have an exercise price of $15.00 per share and are immediately exercisable upon issuance for a period of five years following
the date of issuance. </span>The gross proceeds to the Company from the Offering were approximately $21.0 million, before deducting placement
agent fees and offering expenses of approximately $2.5 million, resulting in net proceeds of approximately $18.5 million. Additionally,
upon closing the Company issued the placement agent warrants (&#8220;Placement Agent&#8217;s warrants&#8221;) to purchase 105,000 shares
of Common Stock exercisable at a per share price of $12.50, which was equal to 125% of the public offering price per share. The Placement
Agent&#8217;s Warrants are exercisable during a five-year period commencing 180 days from March 6, 2024. The Pre-Funded Warrants were
exercised shortly after issuance and the <span id="xdx_90B_ecustom--StockExercised_c20230701__20240630__us-gaap--AwardTypeAxis__custom--PrefundedWarrantsMember_pdd" title="Number of stock exercised"><ix:nonFraction name="bivi:StockExercised" contextRef="From2023-07-012024-06-30_custom_PrefundedWarrantsMember" id="Fact000996" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span> shares of Common Stock were issued during the year ended June 30, 2024.</p>

<ix:exclude><p id="xdx_23A_z5xq8tzMx7p9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 70; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_23B_znffWQ4zaoDh" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_z8gZQ1LIw3Z8" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_23E_zTccnhbngRWd" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>9.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span>Equity Transactions (continued)</span></b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance of common stock for services</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 6, 2023, the Company awarded <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230401__20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Stock issued during period for service"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2023-04-012023-04-06_custom_VendorMember" id="Fact001000" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,000</ix:nonFraction></span> shares
of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance
was $<span id="xdx_901_eus-gaap--SharePrice_c20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-04-06_custom_VendorMember" id="Fact001002" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.50</ix:nonFraction></span> per share. The stock-based compensation expense related to this Common Stock issuance was $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230401__20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-04-012023-04-06_custom_VendorMember" id="Fact001004" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">372,500</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 10, 2024, the Company awarded <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240501__20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Stock issued during period for service"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2024-05-012024-05-10_custom_VendorMember" id="Fact001006" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,000</ix:nonFraction></span> shares
of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance
was $<span id="xdx_906_eus-gaap--SharePrice_c20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2024-05-10_custom_VendorMember" id="Fact001008" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.86</ix:nonFraction></span> per share. The stock-based compensation expense related to this Common Stock issuance was $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20240501__20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pp0p0" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2024-05-012024-05-10_custom_VendorMember" id="Fact001010" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">72,900</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the activity relating to the Company&#8217;s
stock options for the years ended June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001012" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY0PIa7Edy1a" summary="xdx: Disclosure - Equity Transactions (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BD_zyi9QO5BLXFj" style="display: none">Schedule of summarizes the activity relating to the Company&#8217;s stock options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%">Outstanding at June 30, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ6IjrYM0PK9" title="Options outstanding at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2022-06-30_custom_StockOptionsMember" id="Fact001014" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">339,876</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2LEuzgLVgc4" title="Weighted average exercise price, Options outstanding at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2022-06-30_custom_StockOptionsMember" id="Fact001016" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">74.20</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zniHPECSvOCf" title="Weighted remaining average contractual term, beginning" style="width: 10%; text-align: right"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001018" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">5.5</ix:nonNumeric></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJIMoPDiXiJ" title="Aggregate intrinsic value, outstanding at beginning of period" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001022" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">71,467</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001024" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">59.00</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zeuQ0zrcLVll" title="Weighted remaining average contractual term, granted" style="text-align: right"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001026" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">8.6</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AggregateIntrinsicValueGranted_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" title="Aggregate intrinsic value, granted" style="text-align: right"><ix:nonFraction name="bivi:AggregateIntrinsicValueGranted" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001028" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,610</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zOM87jFIn4xc" title="Options expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001030" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001032" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">286.90</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options Canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zv5I3FpYfVmb" title="Options canceled" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001034" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,967</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, canceled" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001036" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">77.40</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ztPM0sj37AFk" title="Options exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001038" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,090</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001040" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">81.20</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zUsCjdBEk1W8" title="Options outstanding at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2023-06-30_custom_StockOptionsMember" id="Fact001042" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">395,286</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4TQEKtO9GCi" title="Weighted average exercise price, options outstanding at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2023-06-30_custom_StockOptionsMember" id="Fact001044" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">71.00</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zTWfj23gEGsg" title="Weighted remaining average contractual term, beginning" style="text-align: right"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001046" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">6.3</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zacnml1ySyfj" title="Aggregate intrinsic value, outstanding at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2023-06-30_custom_StockOptionsMember" id="Fact001048" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,067,966</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Options granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001050" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">155,242</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001052" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.70</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zAmwB4FxAfqd" title="Weighted remaining average contractual term, granted" style="text-align: right"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001054" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">9.8</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z8npO4KRiGsc" title="Options expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001056" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">640</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001058" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">46.09</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2FzqrTWIjs9" title="Options canceled" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001060" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">31,812</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, canceled" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001062" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.19</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt">Outstanding at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zMmw4UMIeX61" title="Options outstanding at ending" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact001064" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">518,076</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ7GNFLcHTX6" title="Weighted average exercise price, options outstanding at ending" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact001066" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">54.11</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zBrYJHdSj1B2" title="Weighted remaining average contractual term, ending" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001068" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">6.1</ix:nonNumeric></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJUmTKoX9mMk" title="Aggregate intrinsic value, outstanding at ending" style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt">Exercisable at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Options exercisable" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact001072" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">296,934</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Weighted average exercise price, options exercisable" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2024-06-30_custom_StockOptionsMember" id="Fact001074" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">66.65</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4EOjftFLtG8" title="Weighted average remaining contractual term, options exercisable" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001076" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">4.9</ix:nonNumeric></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_z4i4Td2KuGA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option grant on the date of
grant is estimated using the Black-Scholes model. The following weighted-average assumptions were utilized for the years ended:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001078" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table border="0" cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Equity Transactions (Details 1)" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z2KR87Z44i4f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B8_zxtZOoPchiGa" style="display: none">Schedule of assumptions used</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 48%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"><b>June 30, 2024</b></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 4%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"><b>June 30, 2023</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">Expected life of options (in years)</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zCpnCMzVDOij" title="Expected life of options (In years)"><ix:nonNumeric contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001080" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zL9h2R6UTHG2" title="Expected life of options (In years)"><ix:nonNumeric contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" format="ixt-sec:duryear" id="Fact001082" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt">Expected volatility</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001084" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">86.28</ix:nonFraction>%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001086" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">81.65</ix:nonFraction>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">Risk free interest rate</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001088" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.40</ix:nonFraction>%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001090" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.82</ix:nonFraction>%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt">Dividend Yield</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001092" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction>%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001094" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction>%</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zQWkfr6n66x5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock based compensation expense
relating to the vesting of stock options of approximately $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0n3_dm_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zjq8SAOcHyG8" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2023-07-012024-06-30_custom_StockOptionsMember" id="Fact001096" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">2.8</ix:nonFraction></span> million and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0n3_dm_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zLp8INhuZr61" title="Stock-based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2022-07-012023-06-30_custom_StockOptionsMember" id="Fact001098" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">4.2</ix:nonFraction></span> million for the years ended June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance and modification of restricted stock units and options:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 21, 2022, the Company awarded <span id="xdx_903_ecustom--RsuGranted_c20220601__20220621__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2022-06-012022-06-21_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001100" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,452</ix:nonFraction></span> restricted
stock units (&#8220;RSUs&#8221;) to the President and CEO under the Company&#8217;s 2019 Omnibus Plan. Each RSU awarded to the CEO entitles
him to receive one share of Common Stock upon vesting. The RSUs vest in three equal annual installments beginning on the first anniversary
grant date. <span id="xdx_908_ecustom--RsuGranted_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001102" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,151</ix:nonFraction></span> and <span id="xdx_901_ecustom--RsuGranted_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001104" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,151</ix:nonFraction></span> RSUs vested in June 2023 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 23, 2022, the Company awarded <span id="xdx_909_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001106" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,198</ix:nonFraction></span> RSUs
to certain employees and a consultant, with a grant date fair value of $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted, grant date fair value"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001108" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.20</ix:nonFraction></span> per share. 25% of these RSUs vested on the grant date and
the remaining RSUs vest in three equal installments over three years beginning on the first anniversary of the grant date. During the
year ended June 30, 2023, <span id="xdx_908_ecustom--SharesIssuedOverVestingPeriod_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares issued over the vesting period"><ix:nonFraction name="bivi:SharesIssuedOverVestingPeriod" contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001110" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,550</ix:nonFraction></span> of these RSUs vested, of which <span id="xdx_90D_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares for tax withholdings"><ix:nonFraction name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001112" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,288</ix:nonFraction></span> shares were withheld in Treasury stock in exchange for payment of
withholding tax on behalf of the employees.</p>

<ix:exclude><p id="xdx_23E_zgAaNiP4lqEe" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>
<ix:exclude><!-- Field: Page; Sequence: 71; Value: 1 -->
    <div id="xdx_23A_zNhOSJSBCypl" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23E_zf9uHrnIJBbk" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>


<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_238_zNrvFmJYmNQ5" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>9.</b></td>
    <td style="width: 95%; font-size: 10pt"><b>Equity Transactions (continued)</b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 23, 2022, the Company issued equity awards
for the board of directors&#8217; annual compensation. Four directors received <span id="xdx_90A_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorsMember" id="Fact001116" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,564</ix:nonFraction></span> RSUs with a grant date fair value of $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pdd" title="Rsu granted, grant date fair value"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorsMember" id="Fact001118" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.20</ix:nonFraction></span> per
share. In addition, three directors received stock options to purchase <span id="xdx_90D_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_ThreeDirectorsMember" id="Fact001120" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">19,500</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pdd" title="Rsu granted, grant date fair value"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_ThreeDirectorsMember" id="Fact001122" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.20</ix:nonFraction></span> per
share with a grant date fair value of $40.60 per share. The equity awards vest quarterly on February 23, 2023, May 23, 2023, August 23,
2023 and earlier of November 23, 2023 or the next annual shareholders&#8217; meeting. During the year ended June 30, 2024, 7,746 of these
RSUs vested. These RSUs and options contain certain contractual vesting terms where the vesting can be accelerated outside the Company&#8217;s
control and as a result, for accounting purposes, are assumed to have been fully vested on the grant date, and accordingly, the Company
recognized the total compensation cost of $<span id="xdx_90F_ecustom--TotalCompensationCost_c20221123_pp0p0" title="Total compensation cost"><ix:nonFraction name="bivi:TotalCompensationCost" contextRef="AsOf2022-11-23" id="Fact001124" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,744,192</ix:nonFraction></span> on November 23, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 9, 2023, the Company issued equity awards
for the board of directors&#8217; annual compensation. Four directors received <span id="xdx_906_ecustom--RsuGranted_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember" id="Fact001126" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,270</ix:nonFraction></span> RSUs with a grant date fair value of $<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Rsu granted, grant date fair value"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" contextRef="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember" id="Fact001128" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.10</ix:nonFraction></span> per
share. In addition, two directors received stock options to purchase <span id="xdx_908_ecustom--RsuGranted_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_TwoDirectorsMember" id="Fact001130" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">18,325</ix:nonFraction></span> shares of common stock at an exercise price of $<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_pdd" title="Rsu granted, grant date fair value"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" contextRef="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_TwoDirectorsMember" id="Fact001132" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">30.10</ix:nonFraction></span> per
share with a grant date fair value of $18.30 per share. The equity awards vest quarterly on February 9, 2024, May 9, 2024, August 9, 2024
and earlier of November 9, 2024 or the next annual shareholders&#8217; meeting. During the year ended June 30, 2024, <span id="xdx_906_ecustom--SharesIssuedOverVestingPeriod_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Shares issued over the vesting period"><ix:nonFraction name="bivi:SharesIssuedOverVestingPeriod" contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember" id="Fact001134" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,568</ix:nonFraction> </span>of these RSUs
vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the Company terminated five employees
and as part of their severance agreement modified their equity awards that had been granted pursuant to the 2019 Omnibus Plan. The modifications
included the acceleration of certain stock option awards to purchase a total of 5,623 shares of common stock (&#8220;Accelerated Options&#8221;),
effective on the December Separation Date, as defined in severance agreement (&#8220;Separation Date&#8221;), and extended the expiration
date for one year from the Separation Date for both the Accelerated Options and any vested and unexercised stock options held by the terminated
employees as of the Separation Date. Accordingly, the Company remeasured the Accelerated Options based on the stock price of $15.40 per
share at the close on the Separation Date and a one-year extension of the term. The net adjustment for the modification was a net credit
of $127,199 and was recognized as an adjustment to stock compensation expense during the year ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, 1,030 vesting RSUs were accelerated
as of the Separation date. The modified RSUs were remeasured based on the stock price of $15.40 per share at close on the Separation Date
and $15,865, was recorded to additional in stock-based compensation for the year ended June 30, 2024 as a result of the modification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the separation, the Company canceled
18,396 unvested stock options and 1,030 unvested RSUs. Additionally, the Company canceled an additional 13,416 unvested stock options
for employees that voluntarily left the company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2023, the Company issued <span id="xdx_901_ecustom--RsuGranted_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001136" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,950</ix:nonFraction></span> RSUs with
a grant date fair value of $<span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted, grant date fair value"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" contextRef="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001138" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">41.10</ix:nonFraction></span> per share to the President and CEO under the Company&#8217;s 2019 Omnibus Plan. The RSUs vest in three
equal annual installments beginning on the first anniversary grant date. <span id="xdx_908_ecustom--SharesIssuedOverVestingPeriod_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares issued over the vesting period"><ix:nonFraction name="bivi:SharesIssuedOverVestingPeriod" contextRef="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember" id="Fact001140" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,983</ix:nonFraction></span> RSUs vested in June 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2024, the Company issued <span id="xdx_90B_ecustom--RsuGranted_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Rsu granted"><ix:nonFraction name="bivi:RsuGranted" contextRef="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" id="Fact001142" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,800</ix:nonFraction></span> RSUs to employees,
with a grant date fair value of $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Rsu granted, grant date fair value"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" contextRef="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" id="Fact001144" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.74</ix:nonFraction></span> per share. The RSUs vested on the grant date. The Company delivered the vested portion of the RSU&#8217;s
and issued <span id="xdx_90B_ecustom--SharesIssuedOverVestingPeriod_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Shares issued over the vesting period"><ix:nonFraction name="bivi:SharesIssuedOverVestingPeriod" contextRef="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" id="Fact001146" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,800</ix:nonFraction></span> shares of Common Stock, of which <span id="xdx_908_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Shares for tax withholdings"><ix:nonFraction name="us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" contextRef="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember" id="Fact001148" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,450</ix:nonFraction></span> shares were withheld in Treasury stock in exchange for payment of withholding
tax on behalf of the employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes vesting of restricted
stock units:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001150" name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Equity Transactions (Details 2)" id="xdx_89A_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zrLBdRIFCXO8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B2_zC55HbHlC8ej" style="display: none">Schedule of vesting of restricted common stock</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%">Unvested at June 30, 2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20220701__20230630_z3ZKAo78GOw7" title="Number of shares unvested at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2022-06-30" id="Fact001152" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,452</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220701__20230630_zxA1UuJE8s8e" title="Weighted average grant date fair value per share unvested at beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2022-06-30" id="Fact001154" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.90</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630_pdd" title="Number of shares, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2022-07-012023-06-30" id="Fact001156" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">68,711</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_zCIA6ZODyD7" title="Weighted average grant date fair value per share, Granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-012023-06-30" id="Fact001158" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">58.87</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20220701__20230630_z4lrSnhJp953" title="Number of shares, Vested" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2022-07-012023-06-30" id="Fact001160" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,518</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_pdd" title="Weighted average grant date fair value per share, Vested" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-012023-06-30" id="Fact001162" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">52.70</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20230701__20240630_z2tDKpwQiWM4" title="Number of shares unvested at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2023-06-30" id="Fact001164" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">59,646</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20240630_zkqNLQRgqHfb" title="Weighted average grant date fair value per share unvested at beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2023-06-30" id="Fact001166" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">52.40</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20230701__20240630_zuN0yG7i20bj" title="Number of shares, Issued" style="text-align: right"><ix:nonFraction name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" contextRef="From2023-07-01to2024-06-30" id="Fact001168" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">104,070</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_iP3custom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630_zSFOWi8SKBfl" title="Weighted average grant date fair value per share, Issued" style="text-align: right"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-07-01to2024-06-30" id="Fact001170" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">9.16</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20240630_zkIik14Oktj" title="Number of shares, Vested" style="text-align: right">(<ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="From2023-07-01to2024-06-30" id="Fact001172" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">122,395</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" title="Weighted average grant date fair value per share, Vested" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-07-01to2024-06-30" id="Fact001174" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">16.94</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230701__20240630_zeUdZqg5kC4b" title="Number of shares, Canceled" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2023-07-01to2024-06-30" id="Fact001176" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,030</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" title="Weighted average grant date fair value per share, Canceled" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2023-07-01to2024-06-30" id="Fact001178" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.20</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt">Unvested at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230701__20240630_ztxPtNap2pG3" title="Number of shares unvested at ending" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2024-06-30" id="Fact001180" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">40,291</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230701__20240630_zKNDqoCY15xh" title="Weighted average grant date fair value per share unvested at ending" style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="AsOf2024-06-30" id="Fact001182" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">44.59</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zuUMjSIs6ua6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>
<ix:exclude><!-- Field: Page; Sequence: 72; Value: 1 -->
    <div id="xdx_232_zRXH7nNXZa6" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_238_zb2Qfrdvsqp" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>
<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_232_zL2nzNV5Dy2" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>9.</b></td>
    <td style="width: 95%; font-size: 10pt"><b>Equity Transactions (continued)</b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total stock-based compensation expense from restricted
stock units for the year ended June 30, 2024 and 2023 was approximately $<span id="xdx_900_ecustom--StockBasedCompensationRestrictedStockUnits_pn3n3_dm_c20230701__20240630_z5KTM1s3ZZBi" title="Stock based compensation - restricted stock units"><ix:nonFraction name="bivi:StockBasedCompensationRestrictedStockUnits" contextRef="From2023-07-01to2024-06-30" id="Fact001185" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million and $<span id="xdx_90A_ecustom--StockBasedCompensationRestrictedStockUnits_pn3n3_dm_c20220701__20230630_zAuEvnV1p2U6" title="Stock based compensation - restricted stock units"><ix:nonFraction name="bivi:StockBasedCompensationRestrictedStockUnits" contextRef="From2022-07-012023-06-30" id="Fact001187" format="ixt:numdotdecimal" decimals="-3" scale="6" unitRef="USD">1.8</ix:nonFraction></span> million, respectively.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance of Common Stock through exercise of Stock Options and Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2022, the Company issued <span id="xdx_909_ecustom--IssuanceOfCommonStockForCashShares_c20221201__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares"><ix:nonFraction name="bivi:IssuanceOfCommonStockForCashShares" contextRef="From2022-12-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001189" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,209</ix:nonFraction></span> shares
of Common Stock pursuant to a cashless exercise of stock options to purchase <span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_c20221201__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-12-012022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001191" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,930</ix:nonFraction> </span>shares at an average exercise price of $<span id="xdx_900_eus-gaap--SharePrice_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember" id="Fact001193" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">76.40</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2022, the Company issued <span id="xdx_907_ecustom--IssuanceOfCommonStockForCashShares_c20221101__20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares"><ix:nonFraction name="bivi:IssuanceOfCommonStockForCashShares" contextRef="From2022-11-012022-11-30_us-gaap_EmployeeStockOptionMember" id="Fact001195" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80</ix:nonFraction></span> shares of
Common Stock pursuant to a cash exercise of stock options to purchase <span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_c20221101__20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-11-012022-11-30_us-gaap_EmployeeStockOptionMember" id="Fact001197" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80</ix:nonFraction></span> shares at an average exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_c20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-11-30_us-gaap_EmployeeStockOptionMember" id="Fact001199" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">28.00</ix:nonFraction></span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2022, the Company issued <span id="xdx_903_ecustom--IssuanceOfCommonStockForCashShares_c20221001__20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Issuance of common stock for cash, shares"><ix:nonFraction name="bivi:IssuanceOfCommonStockForCashShares" contextRef="From2022-10-012022-10-31_custom_WarrantsMember" id="Fact001201" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">359</ix:nonFraction></span> shares of
Common Stock pursuant to a cashless exercise of warrants to purchase <span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_c20221001__20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2022-10-012022-10-31_custom_WarrantsMember" id="Fact001203" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">800</ix:nonFraction></span> shares at an average exercise price of $<span id="xdx_90C_eus-gaap--SharePrice_c20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2022-10-31_custom_WarrantsMember" id="Fact001205" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.50</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2023, the Company issued <span id="xdx_90F_ecustom--IssuanceOfCommonStockForCashShares_c20230501__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares"><ix:nonFraction name="bivi:IssuanceOfCommonStockForCashShares" contextRef="From2023-05-012023-05-31_us-gaap_EmployeeStockOptionMember" id="Fact001207" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">48</ix:nonFraction></span> shares of Common
Stock pursuant to a cashless exercise of stock options to purchase <span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20230501__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2023-05-012023-05-31_us-gaap_EmployeeStockOptionMember" id="Fact001209" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">80</ix:nonFraction></span> shares at an average exercise price of $<span id="xdx_905_eus-gaap--SharePrice_c20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2023-05-31_us-gaap_EmployeeStockOptionMember" id="Fact001211" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">31.30</ix:nonFraction></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance of Stock Options under the 2019 Omnibus Plan.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a former employee&#8217;s Separation Agreement,
dated April 11, 2022, the Company modified their stock option award granted on August 20, 2021, pursuant to the 2019 Omnibus Plan (&#8220;2021
Options Grant&#8221;). Pursuant to the terms of the Separation Agreement, effective July 8, 2022 (the &#8220;Separation Date&#8221;),
the Company accelerated the vesting of options scheduled to vest on the first and second anniversary of the grant date as deemed vested
(&#8220;Accelerated Options&#8221;) and after giving effect to the Accelerated Options, extended the exercise period of the total vested
outstanding and unexercised options (totaling 7,450 options) to one year following the Separation Date. The unvested portion of the 2021
Option Grant (totaling 4,967 options) was canceled. The modification was remeasured as of July 8, 2022, and the incremental difference
in fair value resulted in a net credit to stock based compensation expense of $181,154, due to the original exercise price of $77.40 being
greater than the stock price of $18.00 on the remeasurement date, and accordingly was recognized on July 8, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 7, 2023, the Company granted stock options
to purchase <span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_CertainEmployeesMember" id="Fact001213" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">14,800</ix:nonFraction></span> shares of Common Stock to certain employees. <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember" id="Fact001215" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction>%</span> of the shares underlying the options awarded vested on the grant date,
and the remaining <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember" id="Fact001217" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction>%</span> will vest in four equal annual installments beginning, on the first grant date anniversary. The exercise price of
the options is $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_pdd" title="Weighted average exercise price, options grants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_CertainEmployeesMember" id="Fact001219" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">57.80</ix:nonFraction></span> per share, the grant date fair value and the options terminate on the earlier of the tenth grant date anniversary
or the date of which the options are fully exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended June 30, 2023, the Company
granted stock options to purchase a total of 28,617 shares of Common Stock in connection with compensation packages of three new employees.
The exercise prices were set at the grant date fair value with vesting terms over a five year period and the options terminate on the
earlier of tenth grant date anniversary or the date of which the options are fully exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 3, 2023, the Company granted stock options
to purchase <span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodShares_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember" id="Fact001221" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">21,117</ix:nonFraction></span> shares of Common Stock to new hire employees. <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember" id="Fact001223" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction>%</span> of the shares underlying the options awarded vest on the one-year
anniversary of the grant date, and the remaining <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember" id="Fact001225" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">80</ix:nonFraction>%</span> will vest in equal monthly installments over 48 months each month thereafter. The
exercise price of the options is $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_pdd" title="Weighted average exercise price, options grants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember" id="Fact001227" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">34.10</ix:nonFraction></span>, the grant date fair value, and the options terminate on the earlier of the tenth grant date anniversary
or the date of which the options are fully exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2024, the Company granted stock options to
purchase <span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodShares_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Stock option to purchase"><ix:nonFraction name="us-gaap:StockRepurchasedDuringPeriodShares" contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_EmployeesMember" id="Fact001229" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">115,800</ix:nonFraction></span> shares of Common Stock to employees. <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember" id="Fact001231" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">33</ix:nonFraction>%</span> of the shares underlying the options awarded vest on the grant date, and the
remaining <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember" id="Fact001233" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">67</ix:nonFraction>%</span> will vest over <span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dtY_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zEaDaznUB7S7" title="Weighted average contractual term, granted (in years)"><ix:nonNumeric contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_EmployeesMember" format="ixt-sec:duryear" id="Fact001235" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1">2</ix:nonNumeric> </span>years on first and second anniversary of the grant date. The exercise price of the options is $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Weighted average exercise price, options grants"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_EmployeesMember" id="Fact001237" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.70</ix:nonFraction></span>, the
grant date fair value, and the options terminate on the earlier of the tenth grant date anniversary or the date of which the options are
fully exercised.</p>

<ix:exclude><p id="xdx_235_zmGZ9v5CrQb3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 73; Value: 1 -->
    <div id="xdx_237_zz4eo6tlxaWb" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23B_zLd9qMxzFece" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_237_zUTcmEF6Y0vi" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>9.</b></td>
    <td style="width: 95%; font-size: 10pt"><b>Equity Transactions (continued)</b></td></tr>
  </table></ix:exclude>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the warrants activity during the years ended
June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001241" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Equity Transactions (Details 3)" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zTxLQfBk4QFf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BE_zXcxLU8Mrww2" style="display: none">Summary of warrants activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding and exercisable at June 30, 2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFt3UdaFHjA7" title="Number of shares, beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2022-06-30_us-gaap_WarrantMember" id="Fact001243" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">51,037</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezeOitS5oye" title="Weighted average exercise price, beginning" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="AsOf2022-06-30_us-gaap_WarrantMember" id="Fact001245" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">61.70</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4MlrRIkQenj" title="Weighted average remaining life (Years)" style="width: 10%; text-align: right"><ix:nonNumeric contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031" format="ixt-sec:duryear" id="Fact001247" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.8</ix:nonNumeric></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS0ffXNfJew2" title="Aggregate intrinsic value, beginning" style="width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031" id="Fact001251" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">727,273</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031" id="Fact001253" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">18.20</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6MduR83yFX6" title="Weighted average remaining life (Years), granted" style="text-align: right"><ix:nonNumeric contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031" format="ixt-sec:duryear" id="Fact001255" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">5.0</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of shares, expired" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031" id="Fact001257" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">482</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Weighted average exercise price, expired" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031" id="Fact001259" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">750.00</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of shares, exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031" id="Fact001261" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">800</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031" id="Fact001263" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">22.50</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and exercisable at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhqqbkU5vptj" title="Number of shares, beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2023-06-30_us-gaap_WarrantMember" id="Fact001265" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">777,029</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJE3Rq0QYL0h" title="Weighted average exercise price, beginning" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="AsOf2023-06-30_us-gaap_WarrantMember" id="Fact001267" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">20.60</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhG5LlwdbFaf" title="Weighted average remaining life (Years)" style="text-align: right"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062" format="ixt-sec:duryear" id="Fact001269" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">4.0</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeO5eZu6Onwk" title="Aggregate intrinsic value, beginning" style="text-align: right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2023-06-30_us-gaap_WarrantMember" id="Fact001271" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,318,954</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of shares, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062" id="Fact001273" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,755,000</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Weighted average exercise price, granted" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062" id="Fact001275" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">13.14</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsjwHYw3163d" title="Weighted average remaining life (Years), granted" style="text-align: right"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062" format="ixt-sec:duryear" id="Fact001277" name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">5.0</ix:nonNumeric></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Number of shares, exercised" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062" id="Fact001279" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">600,000</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Weighted average exercise price, exercised" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062" id="Fact001281" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">10.00</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and exercisable at June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCdB34JCMxi8" title="Number of shares, ending" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2024-06-30_us-gaap_WarrantMember" id="Fact001283" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,932,029</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1WDknVwxva4" title="Weighted average exercise price, ending" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="AsOf2024-06-30_us-gaap_WarrantMember" id="Fact001285" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">14.03</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8LHwB4BZkm7" title="Weighted average remaining life (Years)" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonNumeric contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062" format="ixt-sec:duryear" id="Fact001287" name="bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1">4.0</ix:nonNumeric></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR0yUbLulZtk" title="Aggregate intrinsic value, ending" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A6_zJDt286aOWy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Of the above warrants outstanding at June 30, 2024,
10,138 expire in the fiscal year ending June 30, 2025, 3,518 expire in the fiscal year ending June 30, 2026, 763,373 expire in the fiscal
year ending June 30, 2027 and 1,155,000 expire in the fiscal year ending June 30, 2029.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001291" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_z4gKA1pzvARi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 5%; text-align: left"><b>10.</b></td><td style="text-align: justify; width: 95%"><b><span id="xdx_821_znv0a0RRpg31">Leases</span></b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Office Leases&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company pays an annual rent of $2,200 for its
headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 89703. The rental agreement was for a one-year term, commenced on October
1, 2022 and has been subsequently renewed for another year at the same rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s San Diego office lease at 5090
Shoreham Place Suite 212, San Diego, CA 92122 which commenced on March 1, 2022, was for a term of 38 months with a base monthly rate of
$4,300, and annual increases of three percent. In February 2024, the Company amended the lease agreement which allowed the Company to
vacate the then current space and move to a larger space at Suite 206. The current monthly base rate for the new office space is $9,685,
with an annual increase of four percent. The term for the new office lease is 60 months and commenced on February 12, 2024. The lease
that was in place for the 5090 Shoreham Place Suite 212 office was effectively extinguished upon the commencement of the new office space
lease on February 12, 2024, resulting in the write off of the corresponding remaining right-of-use asset and operating lease liability
of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_c20240212_pp0p0" title="Right-of-use Asset"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-02-12" id="Fact001293" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,909</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_c20240212_pp0p0" title="Operating Lease Liability"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-02-12" id="Fact001295" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,124</ix:nonFraction></span>, respectively, and a gain to selling, general and administrative expenses of $<span id="xdx_908_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_c20230701__20240630_pp0p0" title="Selling, general and administrative expenses"><ix:nonFraction name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" contextRef="From2023-07-01to2024-06-30" id="Fact001297" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,215</ix:nonFraction></span> for the year ended June 30,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating lease expense for the years ended
June 30, 2024 and 2023 of approximately $<span id="xdx_900_eus-gaap--OperatingLeaseCost_c20230701__20240630_pp0p0" title="Operating lease cost"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2023-07-01to2024-06-30" id="Fact001299" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--OperatingLeaseCost_c20220701__20230630_pp0p0" title="Operating lease cost"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="From2022-07-012023-06-30" id="Fact001301" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">52,000</ix:nonFraction></span>, respectively were included in the accompanying statements of operations and
comprehensive loss as a component of selling, general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The right-of-use asset, net and current and non-current
portion of the operating lease liabilities included in the accompanying balance sheets are as follows:</p>

<ix:exclude><p id="xdx_23C_zQThKh9WNBSi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p></ix:exclude>


<ix:exclude><!-- Field: Page; Sequence: 74; Value: 1 -->
    <div id="xdx_237_zoBW9PP9pvAa" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23C_zRD1q4sEuwgi" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>


<ix:exclude><table cellspacing="0" cellpadding="0" id="xdx_238_zBoRKZCWYZ69" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>10.</b></td>
    <td style="width: 95%; font-size: 10pt"><b>Leases (continued)</b></td></tr>
  </table></ix:exclude>
<ix:exclude><p id="xdx_237_zyXPYZltiAy1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p></ix:exclude>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001306" name="bivi:LesseeOperatingLeaseLiabilityTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Leases (Details)" id="xdx_89C_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zK0mHEbrKgPk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span id="xdx_8BE_zfGb1g5Gxjca" style="display: none">Schedule of deferred tax assets</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20240630_zzJ7squRbxUd" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230630_zdOKjRFMiaj4" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 9pt">Operating lease, right-of-use asset, net</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2024-06-30" id="Fact001308" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">406,726</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2023-06-30" id="Fact001309" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,789</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzaZ2_zvpYfD8gWgH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Current portion of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact001311" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,343</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2023-06-30" id="Fact001312" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,909</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzaZ2_zrVGBZuBz8Q9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact001314" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">349,894</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2023-06-30" id="Fact001315" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">42,505</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzaZ2_zbGaMu8tGe2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-06-30" id="Fact001317" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">410,237</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2023-06-30" id="Fact001318" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,414</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A0_zqGo0In8Uesk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At June 30, 2024, the future estimated minimum lease payments under non-cancelable
operating leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001320" name="bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Leases (Details 1)" id="xdx_893_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_zjAniu6OFTM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap"><span id="xdx_8BB_zjR5t82sClE8" style="display: none">Schedule of future estimated minimum lease payments
under non-cancelable operating leases</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240630_ztH27BtOyWHk" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zqZ2B95jdEpg" style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">Year ending June 30,</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_z4Qw1VBlo9X1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">2025</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2024-06-30" id="Fact001324" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">117,915</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zHcktjtcrraj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2024-06-30" id="Fact001326" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,042</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zGrtVgFrWpw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2024-06-30" id="Fact001328" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">126,313</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_zC0ZhKUiCrDi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2024-06-30" id="Fact001330" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">130,734</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_zHDJjQ95KTtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2029</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2024-06-30" id="Fact001332" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,796</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_zlw86PDVV9oi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2024-06-30" id="Fact001334" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">574,800</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zCTd8MmOeJKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2024-06-30" id="Fact001336" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">164,563</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zphvj0jiWCak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2024-06-30" id="Fact001338" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">410,237</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_znbDQIyLJHmf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion of operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2024-06-30" id="Fact001340" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,343</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zmcpWkaywI88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2024-06-30" id="Fact001342" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">349,894</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zZTUpyEQNv8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total cash paid for amounts included in the measurement of lease liabilities
were $<span id="xdx_902_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20230701__20240630_pp0p0" title="Cash paid for amounts included in measurement of operating lease liabilities"><ix:nonFraction name="bivi:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" contextRef="From2023-07-01to2024-06-30" id="Fact001344" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,910</ix:nonFraction></span> and $<span id="xdx_904_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20220701__20230630_pp0p0" title="Cash paid for amounts included in measurement of operating lease liabilities"><ix:nonFraction name="bivi:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" contextRef="From2022-07-012023-06-30" id="Fact001346" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,600</ix:nonFraction></span> for the years ended June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average remaining lease term and discount
rate as of June 30, 2024 and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001348" name="bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Leases (Details 2)" id="xdx_89E_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zLzLUdGsL4C" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B0_zxPSCX2JvfVj" style="display: none">Schedule of weighted average remaining lease term and discount rate</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average remaining lease term (Years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 9pt">Operating lease</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zkd3G27WweUa" title="Weighted average remaining lease term (Years) Operating leases" style="width: 12%; text-align: right"><ix:nonNumeric contextRef="AsOf2024-06-30" format="ixt-sec:duryear" id="Fact001350" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.6</ix:nonNumeric></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630_zfttVefLI08j" title="Weighted average remaining lease term (Years) Operating leases" style="width: 12%; text-align: right"><ix:nonNumeric contextRef="AsOf2023-06-30" format="ixt-sec:duryear" id="Fact001352" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.8</ix:nonNumeric></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Operating lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zOCoMOiyaRXe" title="Weighted average discount rate Operating leases" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2024-06-30" id="Fact001354" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">15.00</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630_zxig8joGQCI7" title="Weighted average discount rate Operating leases" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2023-06-30" id="Fact001356" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10.75</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zTnRyaO6nrv" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<ix:exclude><!-- Field: Page; Sequence: 75; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" id="xdx_232_zpQI0edaa8Y6" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_23F_zkUwTgbkk1M5" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001358" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOdRkpzwL0e1" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>11.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_827_z8OY9MklOqL2">Commitments and Contingencies</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Royalty Agreements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered
into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay
a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members,
PharmaIn Corporation, and The Barrett Edge, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Technology Transfer Agreement entered
into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit
royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum
of $200,000 per year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Shareholder class action complaint</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 19, 2024, a purported shareholder class action complaint,
captioned&#160;<i>Eric Olmstead v. BioVie Inc. et al.</i>, No. 3:24-cv-00035, was filed in the U.S. District Court for the District of
Nevada, naming the Company and certain of its officers as defendants. On February 22, 2024, a second, related putative securities class
action was filed in the same court asserting similar claims against the same defendants, captioned <i>Way v. BioVie Inc. et al.</i>, No.
2:24-cv-00361. On April 15, 2024, the court consolidated these two actions under the caption <i>In re BioVie Inc. Securities Litigation</i>,
No. 3:24-cv-00035, appointed the lead plaintiff, and approved selection of the lead counsel. On June 21, 2024, the lead plaintiff filed
an amended complaint, alleging that the defendants made material misrepresentations and/or omissions of material fact relating to the
Company&#8217;s business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of
bezisterim (NE3107) in mild to moderate probable AD,&#160;<span style="background-color: white">in violation of Sections 10(b) and 20(a)
of the&#160; Exchange Act, and&#160;Rule 10b-5&#160;promulgated thereunder. The class action is on behalf of purchasers of the Company&#8217;s
securities during the period from December 7, 2022 through November 28, 2023 and seeks unspecified monetary damages on behalf of the putative
class and an award of costs and expenses, including attorney&#8217;s fees. The defendants filed a motion to dismiss the amended complaint
on August 21, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes the lawsuit is without merit
and intends to defend the case vigorously. At this early stage of the proceedings, the Company is unable to make any prediction regarding
the outcome of the litigation. No adjustment or accruals have been reflected in the accompanying financial statements.</p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001360" name="bivi:EmployeeBenefitPlanTextBlock"><p id="xdx_807_ecustom--EmployeeBenefitPlanTextBlock_zGZxSFtZCZ2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>12.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_82D_zLAjPhzflXqh">Employee Benefit Plan</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2021, the Company began sponsoring an
employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the &#8220;401K Plan&#8221;) pursuant to which,
all employees meeting eligibility requirements are able to participate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to certain limitations in the Internal Revenue Code, eligible employees
are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5%
of an employee&#8217;s contributions to the 401K Plan. The Company made contributions into the plan of approximately $<span id="xdx_903_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230701__20240630_pp0p0" title="Defined benefit plan, plan assets, contributions by employer"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2023-07-01to2024-06-30" id="Fact001362" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">153,200</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20220701__20230630_pp0p0" title="Defined benefit plan, plan assets, contributions by employer"><ix:nonFraction name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="From2022-07-012023-06-30" id="Fact001364" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">171,900</ix:nonFraction></span>,
for the years ended June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:exclude><!-- Field: Page; Sequence: 76; Value: 1 -->
    <div id="xdx_235_zC99Wcrm901a" style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div id="xdx_236_zk583pvy0C6l" style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --></ix:exclude>



</ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001366" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_z4N8PjsQUVik" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>13.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_828_zGs5FBxm8q4b">Income Taxes</span> </b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Significant components of the Company&#8217;s deferred tax assets (liabilities)
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001368" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Income Taxes (Details)" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTJXLAdEWMl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B0_za50uHnoA4Q1" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20240630_zWePO7pGDJld" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20230630_zQ70IyjVtpn7" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0p0_maDTANzRXI_zPq7iRYtFpkc" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Tax loss carryforward</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2024-06-30" id="Fact001373" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,429,074</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" contextRef="AsOf2023-06-30" id="Fact001374" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,080,664</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pp0p0_maDTANzRXI_zDpzXAwXpk3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2024-06-30" id="Fact001376" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">114,161</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="AsOf2023-06-30" id="Fact001377" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">189,854</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTANzRXI_zxuHC2mnaSAk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2024-06-30" id="Fact001379" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,860,272</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="AsOf2023-06-30" id="Fact001380" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,575,852</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTANzRXI_z8nmJRJah3Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D capitalized</td><td>&#160;</td>
    <td style="text-align: left"/><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2024-06-30" id="Fact001382" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,467,969</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="AsOf2023-06-30" id="Fact001383" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,171,276</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzRXI_zPKEQEoQ3QMd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"/><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2024-06-30" id="Fact001385" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">69,643,154</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="AsOf2023-06-30" id="Fact001386" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,637,938</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzRXI_zH8YMZ7CdXEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zhDwX9DMosy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At June 30, 2024 and 2023, the Company has recorded a full valuation
against its net deferred tax assets of approximately $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0n3_dm_c20240630_znkIDB2w2fzi"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2024-06-30" id="Fact001390" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">69.6</ix:nonFraction> </span>million
and $<span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0n3_dm_c20230630_zvALIByr1F3g"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" contextRef="AsOf2023-06-30" id="Fact001391" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">60.6</ix:nonFraction> </span>million,
respectively, since in the judgement of management, these assets are not more than likely to be realized. The increase in the
valuation allowance during the year ended June 30, 2024 was approximately $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n3_dm_c20230701__20240630_zJw54XjfI9r9"><ix:nonFraction name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" contextRef="From2023-07-01to2024-06-30" id="Fact001392" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">9.0</ix:nonFraction> </span>million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2024, the Company had a Net Operating
Loss (&#8220;NOL&#8221;) carryforward of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20240630_zfCD5CBcdSLb" title="Net Operating Loss carryforward"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="AsOf2024-06-30" id="Fact001394" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">184</ix:nonFraction></span> million. NOL&#8217;s generated prior to 2018 have expiration dates ranging
from <span id="xdx_90D_ecustom--ExpirationsDates_c20230701__20240630" title="Expirations dates"><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" id="Fact001396" name="bivi:ExpirationsDates">2032 to 2037</ix:nonNumeric></span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has no current tax expense due to its net losses and a full
valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reconciliation of the differences between income tax
benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2024
and 2023 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001398" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" summary="xdx: Disclosure - Income Taxes (Details 1)" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCYnObkGJGza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B1_zYNz8P5C7rqe" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20240630_zk1mL1B9jQt2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220701__20230630_zWwzEFvfLif2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zqiRUeC8q535" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Income tax expense at federal statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2023-07-01to2024-06-30" id="Fact001400" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="From2022-07-012023-06-30" id="Fact001401" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">21</ix:nonFraction></td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zoVUd8Dkb00d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2023-07-01to2024-06-30" id="Fact001403" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="From2022-07-012023-06-30" id="Fact001404" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">7</ix:nonFraction></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zmTGy9d4mR3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2023-07-01to2024-06-30" id="Fact001406" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">28</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="From2022-07-012023-06-30" id="Fact001407" format="ixt:numdotdecimal" decimals="INF" scale="-2" sign="-" unitRef="Pure">28</ix:nonFraction></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z1RlQ5vwLO89" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt">Effective tax rate</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2023-07-01to2024-06-30" escape="true" id="Fact001412" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zAWE7Lc3n62a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>14.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_822_zqES6tIa3ZV6">Subsequent Events</span></b></td></tr>
  </table>
  <p id="xdx_ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2024, the Company closed a best
efforts public offering (the &#8220;September 2024 Offering&#8221;) of <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_c20240925_pdd" title="Common stock shares"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2024-09-25" id="Fact001414" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,360,800</ix:nonFraction></span>
shares of its common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20240925_pdd" title="Common stock per value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-25" id="Fact001416" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></span>
per share, pre-funded warrants (the &#8220;September Pre-funded Warrants&#8221;) to purchase <span id="xdx_901_ecustom--PurchaseOfCommonStockShares_c20240925__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of shares"><ix:nonFraction name="bivi:PurchaseOfCommonStockShares" contextRef="AsOf2024-09-25_custom_PrefundedWarrantsMember" id="Fact001418" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">600,000</ix:nonFraction></span>
shares of Common Stock, and warrants to purchase up to <span id="xdx_908_ecustom--PurchaseOfCommonStockShares_c20240925__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pdd" title="Purchase of shares"><ix:nonFraction name="bivi:PurchaseOfCommonStockShares" contextRef="AsOf2024-09-25_custom_CommonWarrantsMember" id="Fact001420" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,960,800</ix:nonFraction></span>
shares of Common Stock (the &#8220;September Common Warrants&#8221;) at a combined public offering price of $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20240925__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pdd" title="Common stock per value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2024-09-25_custom_CommonWarrantsMember" id="Fact001422" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></span>
per Share, or September Pre-funded Warrant, and the associated September Common Warrant. <span style="background-color: white">The <span style="background-color: white">September </span>Common
Warrants have an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240925_pdd" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-25" id="Fact001424" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.53</ix:nonFraction></span>
per share and are immediately exercisable upon issuance and will expire on the fifth anniversary date of the original issuance date. </span>The
gross proceeds to the Company from the September 2024 Offering were approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0n3_dm_c20240901__20240925_zY5EFVFcB3Q2" title="Proceeds from public offering"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" contextRef="From2024-09-012024-09-25" id="Fact001426" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.0</ix:nonFraction></span>
million, before deducting placement agent fees and offering expenses of approximately $<span id="xdx_904_ecustom--AgentFeesAndOfferingExpenses_c20240901__20240925_pn3p0" title="Agent fees and offering expenses"><ix:nonFraction name="bivi:AgentFeesAndOfferingExpenses" contextRef="From2024-09-012024-09-25" id="Fact001428" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">560,000</ix:nonFraction></span>.
Additionally, upon closing the Company issued the placement agent warrants (&#8220;September Placement Agent&#8217;s
Warrants&#8221;) to purchase <span id="xdx_906_eus-gaap--TemporaryEquitySharesIssued_c20240925__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pdd" title="Warrant issued"><ix:nonFraction name="us-gaap:TemporaryEquitySharesIssued" contextRef="AsOf2024-09-25_custom_PlacementAgentsWarrantsMember" id="Fact001430" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">98,040</ix:nonFraction></span>
shares of Common Stock exercisable at a per share price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240925__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pdd" title="Warrants exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2024-09-25_custom_PlacementAgentsWarrantsMember" id="Fact001432" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.91</ix:nonFraction></span>,
which was equal to 125% of the public offering price per share. The September Placement Agent&#8217;s Warrants are exercisable
during a five-year period commencing 180 days from September 25, 2024.&#160;</p>

</ix:nonNumeric><p id="xdx_81A_z0UAeJeWh9Ei" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<!-- Field: Page; Sequence: 77; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>bivi-20240630_10kex23z1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<Center><DIV STYLE="width:8.5in" align="left">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>CONSENT OF INDEPENDENT REGISTERED
PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">We
consent to the incorporation by reference in the Registration Statements of BioVie Inc. on Form S-3 (Nos. 333-274083 and 333-271054) and
Form S-8 (No. 333-260019), of our report dated September 30, 2024, on our audits of the financial
statements as of June 30, 2024 and 2023, and for each of the years then ended, which
report is included in this Annual Report on Form 10-K to be filed on or about September 30, 2024.
Our report includes an explanatory paragraph about the existence of substantial doubt concerning the Company&rsquo;s ability to continue
as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">/s/ EisnerAmper LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">EISNERAMPER LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Iselin, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">September 30, 2024</P>
</div></center>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>bivi-20240630_10kex31z1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right">&nbsp;<B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RULE&nbsp;13-a-14(a) and 15d-14(a) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 OF THE SARBANES OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I, Cuong Do, certify that:</FONT></TD></TR>
<TR>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 96%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Biovie Inc.;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a &ndash; 15(f) and 15d &ndash; 15(f)) for the registrant and have:</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date:  September 30, 2024</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="color: White">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Cuong Do</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 21%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
Cuong Do<BR>
Chief Executive Officer <BR>
<I>(Principal Executive Officer)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>bivi-20240630_10kex31z2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>RULE&nbsp;13-a-14(a) and 15d-14(a) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>AS ADOPTED PURSUANT TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 302 OF THE SARBANES OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I, Joanne Wendy Kim, certify that:</FONT></TD></TR>
<TR>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 96%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this annual report on Form 10-K of Biovie Inc.;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a &ndash; 15(f) and 15d &ndash; 15(f)) for the registrant and have:</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of the annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: September 30, 2024&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="color: White">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/Joanne Wendy Kim</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 21%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 37%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Joanne Wendy Kim</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>(Principal Financial and Accounting Officer)</I></p></td></tr></table>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>bivi-20240630_10kex32z1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S. C. SECTION
1350 AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Biovie
Inc., (the &ldquo;Company&rdquo;) on Form 10-K for the year ended June 30, 2024, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Cuong Do, Chief Executive Officer and Chairman of the Board of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 98%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m (a) or 78o(d)); and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date: September 30, 2024</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Cuong Do</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 21%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 37%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cuong Do</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
<FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT><BR>
<FONT STYLE="font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: white">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>bivi-20240630_10kex32z2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO 18 U.S. C. SECTION
1350 AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Biovie
Inc., (the &ldquo;Company&rdquo;) on Form 10-K for the year ended June 30, 2024, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Joanne Wendy Kim, Chief Financial Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002, that, to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; background-color: white; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="width: 98%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Report fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m (a) or 78o(d)); and</FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date:  September 30, 2024</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Joanne Wendy Kim</I></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; width: 21%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 32%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 37%; padding-bottom: 8pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Joanne Wendy Kim</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Chief Financial Officer<BR>
        <I>(Principal Financial and Accounting Officer)</I></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; color: white">&nbsp;</P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>bivi-20240630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TreasuryStocksMember" xlink:label="bivi_TreasuryStocksMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_TreasuryStocksMember" xlink:to="bivi_TreasuryStocksMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_TreasuryStocksMember_lbl" xml:lang="en-US">Treasury Stocks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NotespayableConversionOptionMember" xlink:label="bivi_NotespayableConversionOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NotespayableConversionOptionMember" xlink:to="bivi_NotespayableConversionOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_NotespayableConversionOptionMember_lbl" xml:lang="en-US">Notespayable Conversion Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="us-gaap_USTreasuryBillSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasuryBillSecuritiesMember" xlink:to="us-gaap_USTreasuryBillSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USTreasuryBillSecuritiesMember_lbl" xml:lang="en-US">US Treasury Bill Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AcuitasGroupHoldingsLLCMember" xlink:label="bivi_AcuitasGroupHoldingsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AcuitasGroupHoldingsLLCMember" xlink:to="bivi_AcuitasGroupHoldingsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AcuitasGroupHoldingsLLCMember_lbl" xml:lang="en-US">Acuitas Group Holdings, LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantsMember" xlink:label="bivi_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WarrantsMember" xlink:to="bivi_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_WarrantsMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedDiscountMember" xlink:label="bivi_UnearnedDiscountMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnearnedDiscountMember" xlink:to="bivi_UnearnedDiscountMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_UnearnedDiscountMember_lbl" xml:lang="en-US">Unearned Discount [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="us-gaap_FinanceReceivablesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceReceivablesMember" xlink:to="us-gaap_FinanceReceivablesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceReceivablesMember_lbl" xml:lang="en-US">Financing Receivable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LoanAccretionPremiumMember" xlink:label="bivi_LoanAccretionPremiumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LoanAccretionPremiumMember" xlink:to="bivi_LoanAccretionPremiumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LoanAccretionPremiumMember_lbl" xml:lang="en-US">Loan Accretion Premium [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="bivi_DerivativeLiabilityWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilityWarrantsMember" xlink:to="bivi_DerivativeLiabilityWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DerivativeLiabilityWarrantsMember_lbl" xml:lang="en-US">Derivative liability - Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionMember" xlink:label="bivi_DerivativeLiabilityConversionOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilityConversionOptionMember" xlink:to="bivi_DerivativeLiabilityConversionOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DerivativeLiabilityConversionOptionMember_lbl" xml:lang="en-US">Derivative Liability Conversion Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:label="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:to="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_lbl" xml:lang="en-US">Derivative liability - Conversion Option on Convertible Debenture [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashMember_lbl" xml:lang="en-US">Cash [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_USTreasuryBillSecurities1Member" xlink:label="bivi_USTreasuryBillSecurities1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_USTreasuryBillSecurities1Member" xlink:to="bivi_USTreasuryBillSecurities1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_USTreasuryBillSecurities1Member_lbl" xml:lang="en-US">U.S. Treasury Bills due in 3 months or less at purchase [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="us-gaap_CommonClassAMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassAMember" xlink:to="us-gaap_CommonClassAMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassAMember_lbl" xml:lang="en-US">Common Class A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SalesAgreementMember" xlink:label="bivi_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SalesAgreementMember" xlink:to="bivi_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PrefundedWarrantsMember" xlink:label="bivi_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_PrefundedWarrantsMember" xlink:to="bivi_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_PrefundedWarrantsMember_lbl" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommonWarrantMember" xlink:label="bivi_CommonWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CommonWarrantMember" xlink:to="bivi_CommonWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CommonWarrantMember_lbl" xml:lang="en-US">Common Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_VendorMember" xlink:label="bivi_VendorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_VendorMember" xlink:to="bivi_VendorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_VendorMember_lbl" xml:lang="en-US">Vendor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockOptionsMember" xlink:label="bivi_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockOptionsMember" xlink:to="bivi_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_N2019OmnibusIncentiveEquityPlanMember" xlink:label="bivi_N2019OmnibusIncentiveEquityPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_N2019OmnibusIncentiveEquityPlanMember" xlink:to="bivi_N2019OmnibusIncentiveEquityPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_N2019OmnibusIncentiveEquityPlanMember_lbl" xml:lang="en-US">N2019 Omnibus Incentive Equity Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PresidentAndCEOMember" xlink:label="bivi_PresidentAndCEOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_PresidentAndCEOMember" xlink:to="bivi_PresidentAndCEOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_PresidentAndCEOMember_lbl" xml:lang="en-US">President And C E O [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FourDirectorsMember" xlink:label="bivi_FourDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_FourDirectorsMember" xlink:to="bivi_FourDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_FourDirectorsMember_lbl" xml:lang="en-US">Four Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ThreeDirectorsMember" xlink:label="bivi_ThreeDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ThreeDirectorsMember" xlink:to="bivi_ThreeDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ThreeDirectorsMember_lbl" xml:lang="en-US">Three Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FourDirectorMember" xlink:label="bivi_FourDirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_FourDirectorMember" xlink:to="bivi_FourDirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_FourDirectorMember_lbl" xml:lang="en-US">Four Director [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TwoDirectorsMember" xlink:label="bivi_TwoDirectorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_TwoDirectorsMember" xlink:to="bivi_TwoDirectorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_TwoDirectorsMember_lbl" xml:lang="en-US">Two Directors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_EmployeesMember" xlink:label="bivi_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_EmployeesMember" xlink:to="bivi_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CertainEmployeesMember" xlink:label="bivi_CertainEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CertainEmployeesMember" xlink:to="bivi_CertainEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CertainEmployeesMember_lbl" xml:lang="en-US">Certain Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NewEmployeeMember" xlink:label="bivi_NewEmployeeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NewEmployeeMember" xlink:to="bivi_NewEmployeeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_NewEmployeeMember_lbl" xml:lang="en-US">New Employee [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommonWarrantsMember" xlink:label="bivi_CommonWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CommonWarrantsMember" xlink:to="bivi_CommonWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CommonWarrantsMember_lbl" xml:lang="en-US">Common Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PlacementAgentsWarrantsMember" xlink:label="bivi_PlacementAgentsWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_PlacementAgentsWarrantsMember" xlink:to="bivi_PlacementAgentsWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_PlacementAgentsWarrantsMember_lbl" xml:lang="en-US">Placement Agents Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag_lbl" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_InvestmentsInU.s.TreasuryBills" xlink:label="bivi_InvestmentsInU.s.TreasuryBills" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_InvestmentsInU.s.TreasuryBills" xlink:to="bivi_InvestmentsInU.s.TreasuryBills_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_InvestmentsInU.s.TreasuryBills_lbl" xml:lang="en-US">Investments in U.S. Treasury Bills (available-for-sale)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Goodwill_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Current portion of note payable, net of financing cost, unearned premium and discount of $701,210 at June 30, 2024 and $894,926 at June 30, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantLiabilities" xlink:label="bivi_WarrantLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WarrantLiabilities" xlink:to="bivi_WarrantLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_WarrantLiabilities_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xml:lang="en-US">Embedded derivative liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Note payable, net of current portion, financing cost, unearned premium and&#160;&#160;discount of $0 and $227,268 at June 30, 2024 and June 30, 2023, respectively.</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY :</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 800,000,000 shares authorized at June 30, 2024 and June 30, 2023, respectively; 6,216,398 shares issued of which 6,190,072 shares are outstanding at June 30, 2024; and 3,645,183 shares issued of which 3,642,895 shares outstanding at June 30, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedPremiumAnddiscountCurrent" xlink:label="bivi_UnearnedPremiumAnddiscountCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnearnedPremiumAnddiscountCurrent" xlink:to="bivi_UnearnedPremiumAnddiscountCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_UnearnedPremiumAnddiscountCurrent_lbl" xml:lang="en-US">Unearned premium and discount current</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedPremiumAndDiscount" xlink:label="bivi_UnearnedPremiumAndDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnearnedPremiumAndDiscount" xlink:to="bivi_UnearnedPremiumAndDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_UnearnedPremiumAndDiscount_lbl" xml:lang="en-US">Unearned premium and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">OPERATING EXPENSES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">TOTAL OPERATING EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER (INCOME) EXPENSE:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="us-gaap_GainLossOnSaleOfDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="us-gaap_InterestIncomeOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeOther_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">TOTAL OTHER (INCOME) EXPENSE, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsSharebasedCompensationStock" xlink:label="us-gaap_DividendsSharebasedCompensationStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsSharebasedCompensationStock" xlink:to="us-gaap_DividendsSharebasedCompensationStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsSharebasedCompensationStock_lbl" xml:lang="en-US">Deemed dividend related to ratchet adjustment to warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="us-gaap_IncomeLossAttributableToParent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossAttributableToParent_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">NET LOSS PER COMMON SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">- Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">- Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON&#160;&#160;SHARES OUTSTANDING</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">- Basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">- Diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract_lbl" xml:lang="en-US">Other comprehensive (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnrealizedGainOnInvestmentsForAvailableforsale" xlink:label="bivi_UnrealizedGainOnInvestmentsForAvailableforsale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnrealizedGainOnInvestmentsForAvailableforsale" xlink:to="bivi_UnrealizedGainOnInvestmentsForAvailableforsale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_UnrealizedGainOnInvestmentsForAvailableforsale_lbl" xml:lang="en-US">Unrealized gain on available-for-sale investments</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:label="bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:to="bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_lbl" xml:lang="en-US">Reclassification of unrealized gains on available-for-sale investments upon settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Total other comprehensive (loss) income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock - based compensation - stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock-based compensation - restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Stock-based compensation - restricted stock units, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" xlink:label="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" xlink:to="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits_lbl" xml:lang="en-US">Issuance of common stock from vesting of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" xlink:label="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" xlink:to="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares_lbl" xml:lang="en-US">Issuance of common stock from vesting of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered" xlink:label="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered" xlink:to="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered_lbl" xml:lang="en-US">Stock-based compensation - issuance of common stock for services rendered</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" xlink:label="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" xlink:to="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_lbl" xml:lang="en-US">Stock-based compensation - issuance of common stock for services rendered, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DeemedDividendForRatchetAdjustmentToWarrants" xlink:label="bivi_DeemedDividendForRatchetAdjustmentToWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendForRatchetAdjustmentToWarrants" xlink:to="bivi_DeemedDividendForRatchetAdjustmentToWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividendForRatchetAdjustmentToWarrants_lbl" xml:lang="en-US">Deemed dividend for ratchet adjustment to warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:label="bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:to="bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_lbl" xml:lang="en-US">Relcassification of unrealized gains on available-for-sale investments upon settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" xlink:label="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" xlink:to="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit_lbl" xml:lang="en-US">Issuance of additional shares for fractional shares effected by the reverse split</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" xlink:label="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" xlink:to="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares_lbl" xml:lang="en-US">Issuance of additional shares for fractional shares effected by the reverse split, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfOptions" xlink:label="bivi_CashlessExerciseOfOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfOptions" xlink:to="bivi_CashlessExerciseOfOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashlessExerciseOfOptions_lbl" xml:lang="en-US">Cashless exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfOptionsShares" xlink:label="bivi_CashlessExerciseOfOptionsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfOptionsShares" xlink:to="bivi_CashlessExerciseOfOptionsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashlessExerciseOfOptionsShares_lbl" xml:lang="en-US">Cashless exercise of options, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="bivi_CashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrants" xlink:to="bivi_CashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="bivi_CashlessExerciseOfWarrantsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashlessExerciseOfWarrantsShares" xlink:to="bivi_CashlessExerciseOfWarrantsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashlessExerciseOfWarrantsShares_lbl" xml:lang="en-US">Cashless exercise of warrants, Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetCosts" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromIssuanceOfCommonStockNetCosts" xlink:to="bivi_ProceedsFromIssuanceOfCommonStockNetCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetCosts_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of costs of&#160;&#160;$2,908,141</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares" xlink:to="bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" xlink:to="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of costs of&#160;&#160;$94,160 - Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" xlink:to="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares_lbl" xml:lang="en-US">Proceeds from issuance of common stock, net of costs of Related Party, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnrealizedGainOnAvailableforsaleInvestments" xlink:label="bivi_UnrealizedGainOnAvailableforsaleInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnrealizedGainOnAvailableforsaleInvestments" xlink:to="bivi_UnrealizedGainOnAvailableforsaleInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_UnrealizedGainOnAvailableforsaleInvestments_lbl" xml:lang="en-US">Unrealized gain on available-for-sale investments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationRestrictedStock" xlink:label="bivi_StockBasedCompensationRestrictedStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockBasedCompensationRestrictedStock" xlink:to="bivi_StockBasedCompensationRestrictedStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockBasedCompensationRestrictedStock_lbl" xml:lang="en-US">Stock based compensation - restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation expense - stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationExpenseStockIssued" xlink:label="bivi_StockBasedCompensationExpenseStockIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockBasedCompensationExpenseStockIssued" xlink:to="bivi_StockBasedCompensationExpenseStockIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockBasedCompensationExpenseStockIssued_lbl" xml:lang="en-US">Stock based compensation expense - stock issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionOfUnearnedLoanDiscount" xlink:label="bivi_AccretionOfUnearnedLoanDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AccretionOfUnearnedLoanDiscount" xlink:to="bivi_AccretionOfUnearnedLoanDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bivi_AccretionOfUnearnedLoanDiscount_lbl" xml:lang="en-US">Accretion of unearned loan discount</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionOfLoanPremium" xlink:label="bivi_AccretionOfLoanPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AccretionOfLoanPremium" xlink:to="bivi_AccretionOfLoanPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AccretionOfLoanPremium_lbl" xml:lang="en-US">Accretion of loan premium</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RealizedGainOnMaturityOfAvailableforSale" xlink:label="bivi_RealizedGainOnMaturityOfAvailableforSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_RealizedGainOnMaturityOfAvailableforSale" xlink:to="bivi_RealizedGainOnMaturityOfAvailableforSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bivi_RealizedGainOnMaturityOfAvailableforSale_lbl" xml:lang="en-US">Realized gain on maturity of available-for sale</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NoncashLeaseExpenseFromRightofuseAssets" xlink:label="bivi_NoncashLeaseExpenseFromRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NoncashLeaseExpenseFromRightofuseAssets" xlink:to="bivi_NoncashLeaseExpenseFromRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_NoncashLeaseExpenseFromRightofuseAssets_lbl" xml:lang="en-US">Non-cash lease expense from right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:to="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_lbl" xml:lang="en-US">Gain on termination of operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xml:lang="en-US">Change in fair value of derivative liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">&#160;&#160;&#160;Prepaid and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">&#160;&#160;&#160;Accounts payable and accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">&#160;&#160;&#160;Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">&#160;&#160;&#160;Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromMaturityOfU.s.TreasuryBills" xlink:label="bivi_ProceedsFromMaturityOfU.s.TreasuryBills" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromMaturityOfU.s.TreasuryBills" xlink:to="bivi_ProceedsFromMaturityOfU.s.TreasuryBills_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bivi_ProceedsFromMaturityOfU.s.TreasuryBills_lbl" xml:lang="en-US">Proceeds from (purchases of) U.S. Treasury Bills (available-for-sale)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments of note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty" xlink:label="bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty" xlink:to="bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty_lbl" xml:lang="en-US">Net proceeds from issuance of common stock - Related Party</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">&#160;&#160;Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xlink:label="bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xlink:to="bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations_lbl" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnrealizedGainOnU.s.TreasuryBills" xlink:label="bivi_UnrealizedGainOnU.s.TreasuryBills" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnrealizedGainOnU.s.TreasuryBills" xlink:to="bivi_UnrealizedGainOnU.s.TreasuryBills_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_UnrealizedGainOnU.s.TreasuryBills_lbl" xml:lang="en-US">Unrealized gain on U.S. Treasury Bills (available-for-sale)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:to="bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_2_lbl" xml:lang="en-US">Reclassification of unrealized gains on U.S. Treasury Bills (available-for-sale investments) upon settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DeemedDividendOfRatchetAdjustmentsToWarrants" xlink:label="bivi_DeemedDividendOfRatchetAdjustmentsToWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DeemedDividendOfRatchetAdjustmentsToWarrants" xlink:to="bivi_DeemedDividendOfRatchetAdjustmentsToWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DeemedDividendOfRatchetAdjustmentsToWarrants_lbl" xml:lang="en-US">Deemed dividend of ratchet adjustment to warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="ecd_PvpTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTable" xlink:to="ecd_PvpTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTable_lbl" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="ecd_ExecutiveCategoryAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ExecutiveCategoryAxis" xlink:to="ecd_ExecutiveCategoryAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ExecutiveCategoryAxis_lbl" xml:lang="en-US">Executive Category [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="ecd_IndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_IndividualAxis" xlink:to="ecd_IndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_IndividualAxis_lbl" xml:lang="en-US">Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="ecd_AdjToCompAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAxis" xlink:to="ecd_AdjToCompAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAxis_lbl" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="ecd_MeasureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureAxis" xlink:to="ecd_MeasureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureAxis_lbl" xml:lang="en-US">Measure [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="ecd_PvpTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PvpTableTextBlock" xlink:to="ecd_PvpTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PvpTableTextBlock_lbl" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="ecd_CoSelectedMeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureName" xlink:to="ecd_CoSelectedMeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureName_lbl" xml:lang="en-US">Company Selected Measure Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NamedExecutiveOfficersFnTextBlock_lbl" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="ecd_PeerGroupIssuersFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupIssuersFnTextBlock" xlink:to="ecd_PeerGroupIssuersFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupIssuersFnTextBlock_lbl" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="ecd_ChangedPeerGroupFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ChangedPeerGroupFnTextBlock" xlink:to="ecd_ChangedPeerGroupFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ChangedPeerGroupFnTextBlock_lbl" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="ecd_PeoTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoTotalCompAmt" xlink:to="ecd_PeoTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoTotalCompAmt_lbl" xml:lang="en-US">PEO Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="ecd_PeoActuallyPaidCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoActuallyPaidCompAmt" xlink:to="ecd_PeoActuallyPaidCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoActuallyPaidCompAmt_lbl" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="ecd_AdjToPeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToPeoCompFnTextBlock" xlink:to="ecd_AdjToPeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToPeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgTotalCompAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonPeoNeoAvgCompActuallyPaidAmt_lbl" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToNonPeoNeoCompFnTextBlock_lbl" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_EquityValuationAssumptionDifferenceFnTextBlock_lbl" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsNetIncomeTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnVsPeerGroupTextBlock_lbl" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CompActuallyPaidVsOtherMeasureTextBlock_lbl" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="ecd_TabularListTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TabularListTableTextBlock" xlink:to="ecd_TabularListTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TabularListTableTextBlock_lbl" xml:lang="en-US">Tabular List, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="ecd_TotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TotalShareholderRtnAmt" xlink:to="ecd_TotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TotalShareholderRtnAmt_lbl" xml:lang="en-US">Total Shareholder Return Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeerGroupTotalShareholderRtnAmt_lbl" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Income (Loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="ecd_CoSelectedMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_CoSelectedMeasureAmt" xlink:to="ecd_CoSelectedMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_CoSelectedMeasureAmt_lbl" xml:lang="en-US">Company Selected Measure Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="ecd_OtherPerfMeasureAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OtherPerfMeasureAmt" xlink:to="ecd_OtherPerfMeasureAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OtherPerfMeasureAmt_lbl" xml:lang="en-US">Other Performance Measure, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="ecd_AdjToCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AdjToCompAmt" xlink:to="ecd_AdjToCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AdjToCompAmt_lbl" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="ecd_PeoName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PeoName" xlink:to="ecd_PeoName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PeoName_lbl" xml:lang="en-US">PEO Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="ecd_MeasureName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MeasureName" xlink:to="ecd_MeasureName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MeasureName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonGaapMeasureDescriptionTextBlock_lbl" xml:lang="en-US">Non-GAAP Measure Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="ecd_Additional402vDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Additional402vDisclosureTextBlock" xlink:to="ecd_Additional402vDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Additional402vDisclosureTextBlock_lbl" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="ecd_PnsnBnftsAdjFnTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_PnsnBnftsAdjFnTextBlock" xlink:to="ecd_PnsnBnftsAdjFnTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_PnsnBnftsAdjFnTextBlock_lbl" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="ecd_ErrCompRecoveryTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompRecoveryTable" xlink:to="ecd_ErrCompRecoveryTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompRecoveryTable_lbl" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="ecd_RestatementDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDateAxis" xlink:to="ecd_RestatementDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDateAxis_lbl" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="ecd_RestatementDeterminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDeterminationDate" xlink:to="ecd_RestatementDeterminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDeterminationDate_lbl" xml:lang="en-US">Restatement Determination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="ecd_AggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompAmt" xlink:to="ecd_AggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompAmt_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="ecd_ErrCompAnalysisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ErrCompAnalysisTextBlock" xlink:to="ecd_ErrCompAnalysisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ErrCompAnalysisTextBlock_lbl" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_StkPrcOrTsrEstimationMethodTextBlock_lbl" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="ecd_OutstandingAggtErrCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingAggtErrCompAmt" xlink:to="ecd_OutstandingAggtErrCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingAggtErrCompAmt_lbl" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AggtErrCompNotYetDeterminedTextBlock_lbl" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="ecd_ForgoneRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_ForgoneRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_lbl" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_lbl" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_lbl" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_lbl" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="ecd_OutstandingRecoveryIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_OutstandingRecoveryIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="ecd_OutstandingRecoveryCompAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryCompAmt" xlink:to="ecd_OutstandingRecoveryCompAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryCompAmt_lbl" xml:lang="en-US">Compensation Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_RestatementDoesNotRequireRecoveryTextBlock_lbl" xml:lang="en-US">Restatement does not require Recovery</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="ecd_AwardsCloseToMnpiDiscTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTable" xlink:to="ecd_AwardsCloseToMnpiDiscTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTable_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="ecd_AwardTmgMnpiDiscTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiDiscTextBlock" xlink:to="ecd_AwardTmgMnpiDiscTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiDiscTextBlock_lbl" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="ecd_AwardTmgMethodTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMethodTextBlock" xlink:to="ecd_AwardTmgMethodTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMethodTextBlock_lbl" xml:lang="en-US">Award Timing Method</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="ecd_AwardTmgPredtrmndFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgPredtrmndFlag" xlink:to="ecd_AwardTmgPredtrmndFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgPredtrmndFlag_lbl" xml:lang="en-US">Award Timing Predetermined</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgMnpiCnsdrdFlag_lbl" xml:lang="en-US">Award Timing MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardTmgHowMnpiCnsdrdTextBlock_lbl" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="ecd_MnpiDiscTimedForCompValFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MnpiDiscTimedForCompValFlag" xlink:to="ecd_MnpiDiscTimedForCompValFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MnpiDiscTimedForCompValFlag_lbl" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscTableTextBlock_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="ecd_AwardsCloseToMnpiDiscIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="ecd_AwardUndrlygSecuritiesAmt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardUndrlygSecuritiesAmt" xlink:to="ecd_AwardUndrlygSecuritiesAmt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardUndrlygSecuritiesAmt_lbl" xml:lang="en-US">Underlying Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="ecd_AwardExrcPrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardExrcPrice" xlink:to="ecd_AwardExrcPrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardExrcPrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="ecd_AwardGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardGrantDateFairValue" xlink:to="ecd_AwardGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardGrantDateFairValue_lbl" xml:lang="en-US">Fair Value as of Grant Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="ecd_UndrlygSecurityMktPriceChngPct" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_UndrlygSecurityMktPriceChngPct" xlink:to="ecd_UndrlygSecurityMktPriceChngPct_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_UndrlygSecurityMktPriceChngPct_lbl" xml:lang="en-US">Underlying Security Market Price Change</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingArrLineItems_lbl" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="ecd_TrdArrIndName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ecd_TrdArrIndName_lbl" xml:lang="en-US">Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="ecd_TrdArrIndTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndTitle_lbl" xml:lang="en-US">Title</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="ecd_TrdArrAdoptionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrAdoptionDate_lbl" xml:lang="en-US">Adoption Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="ecd_TrdArrTerminationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrTerminationDate" xlink:to="ecd_TrdArrTerminationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrTerminationDate_lbl" xml:lang="en-US">Termination Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="ecd_TrdArrExpirationDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrExpirationDate_lbl" xml:lang="en-US">Expiration Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="ecd_TrdArrDuration" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrDuration_lbl" xml:lang="en-US">Arrangement Duration</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="ecd_InsiderTradingPoliciesProcLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTradingPoliciesProcLineItems" xlink:to="ecd_InsiderTradingPoliciesProcLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTradingPoliciesProcLineItems_lbl" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcAdoptedFlag_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_lbl" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Background Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity and Going Concern</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:label="bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:to="bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract_lbl" xml:lang="en-US">Investments In U.s. Treasury Bills Available-for-sale</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock" xlink:label="bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock" xlink:to="bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock_lbl" xml:lang="en-US">Investments in U.S. Treasury Bills available-for-sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementInputsDisclosureTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureLeasesAbstract" xlink:label="bivi_DisclosureLeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureLeasesAbstract" xlink:to="bivi_DisclosureLeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureLeasesAbstract_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureEmployeeBenefitPlanAbstract" xlink:label="bivi_DisclosureEmployeeBenefitPlanAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DisclosureEmployeeBenefitPlanAbstract" xlink:to="bivi_DisclosureEmployeeBenefitPlanAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DisclosureEmployeeBenefitPlanAbstract_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_EmployeeBenefitPlanTextBlock" xlink:label="bivi_EmployeeBenefitPlanTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_EmployeeBenefitPlanTextBlock" xlink:to="bivi_EmployeeBenefitPlanTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_EmployeeBenefitPlanTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_InvestmentsUSTreasuryBillsPolicyTextBlock" xlink:label="bivi_InvestmentsUSTreasuryBillsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_InvestmentsUSTreasuryBillsPolicyTextBlock" xlink:to="bivi_InvestmentsUSTreasuryBillsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_InvestmentsUSTreasuryBillsPolicyTextBlock_lbl" xml:lang="en-US">Investments in U.S. Treasury Bills</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock" xlink:label="bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock" xlink:to="bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_lbl" xml:lang="en-US">Concentration of Credit Risk in the Financial Service Industry</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement of assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PrepaidAndOtherAssetsPolicyTextBlock" xlink:label="bivi_PrepaidAndOtherAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_PrepaidAndOtherAssetsPolicyTextBlock" xlink:to="bivi_PrepaidAndOtherAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_PrepaidAndOtherAssetsPolicyTextBlock_lbl" xml:lang="en-US">Prepaid and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xml:lang="en-US">Goodwill</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ReverseStockSpliteUpPolicyTextBlock" xlink:label="bivi_ReverseStockSpliteUpPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ReverseStockSpliteUpPolicyTextBlock" xlink:to="bivi_ReverseStockSpliteUpPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ReverseStockSpliteUpPolicyTextBlock_lbl" xml:lang="en-US">Reverse stock split up</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of dilutive securities were excluded from the computation of diluted loss per share</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock" xlink:label="bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock" xlink:to="bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock_lbl" xml:lang="en-US">Schedule of U.S. treasury bills held</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of future amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of note payable</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ScheduleofFutureAmortizationExpenseTableTextBlock" xlink:label="bivi_ScheduleofFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ScheduleofFutureAmortizationExpenseTableTextBlock" xlink:to="bivi_ScheduleofFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ScheduleofFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated future amortization expense and accretion of premium</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_lbl" xml:lang="en-US">Schedule of derivative liabilities at fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xml:lang="en-US">Fair value, liabilities measured on recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Measured at fair value on a recurring basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of summarizes the activity relating to the Company&#8217;s stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of vesting of restricted common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Summary of warrants activity</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LesseeOperatingLeaseLiabilityTableTextBlock" xlink:label="bivi_LesseeOperatingLeaseLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LesseeOperatingLeaseLiabilityTableTextBlock" xlink:to="bivi_LesseeOperatingLeaseLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LesseeOperatingLeaseLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases" xlink:label="bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases" xlink:to="bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_lbl" xml:lang="en-US">Schedule of future estimated minimum lease payments under non-cancelable operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:to="bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average remaining lease term and discount rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of effective income tax rate reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WorkingCapital" xlink:label="bivi_WorkingCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_WorkingCapital" xlink:to="bivi_WorkingCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_WorkingCapital_lbl" xml:lang="en-US">Working capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockholderEquities" xlink:label="bivi_StockholderEquities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockholderEquities" xlink:to="bivi_StockholderEquities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockholderEquities_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccumulatedDeficit" xlink:label="bivi_AccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AccumulatedDeficit" xlink:to="bivi_AccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_AccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="us-gaap_ScheduleOfInvestmentsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsTable" xlink:to="us-gaap_ScheduleOfInvestmentsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsTable_lbl" xml:lang="en-US">Schedule of Investments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInvestmentsLineItems_lbl" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizedCostBasis" xlink:label="bivi_AmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AmortizedCostBasis" xlink:to="bivi_AmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_GrossUnrealizedGain" xlink:label="bivi_GrossUnrealizedGain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_GrossUnrealizedGain" xlink:to="bivi_GrossUnrealizedGain_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_GrossUnrealizedGain_lbl" xml:lang="en-US">Gross Unrealized Gain</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_GrossUnrealizedLoss" xlink:label="bivi_GrossUnrealizedLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_GrossUnrealizedLoss" xlink:to="bivi_GrossUnrealizedLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_GrossUnrealizedLoss_lbl" xml:lang="en-US">Gross Unrealized loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="us-gaap_InvestmentOwnedAtFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedAtFairValue" xlink:to="us-gaap_InvestmentOwnedAtFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedAtFairValue_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Total Accumulated Other Comprehensive Income</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NumberOfStockPurchased" xlink:label="bivi_NumberOfStockPurchased" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NumberOfStockPurchased" xlink:to="bivi_NumberOfStockPurchased_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_NumberOfStockPurchased_lbl" xml:lang="en-US">Number of stock purchased</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_RealizedGainOnMaturityOfAvailableforSale" xlink:to="bivi_RealizedGainOnMaturityOfAvailableforSale_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_RealizedGainOnMaturityOfAvailableforSale_2_lbl" xml:lang="en-US">Realized gain on maturity of available-for sale</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Intellectual Property</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Less: Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Intellectual Property, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Year ending June 30,</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">&#160;Finite lived intangible assets, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Related Party Transaction [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Dividends_lbl" xml:lang="en-US">Deemed dividend</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Remaining term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CurrentPortionOfNotesPayable" xlink:label="bivi_CurrentPortionOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CurrentPortionOfNotesPayable" xlink:to="bivi_CurrentPortionOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CurrentPortionOfNotesPayable_lbl" xml:lang="en-US">Current portion of Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DebtFinancingCosts" xlink:label="bivi_DebtFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DebtFinancingCosts" xlink:to="bivi_DebtFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DebtFinancingCosts_lbl" xml:lang="en-US">Less: debt financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:label="us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:to="us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_lbl" xml:lang="en-US">Less: unearned discount</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionOfLoanPremiums" xlink:label="bivi_AccretionOfLoanPremiums" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AccretionOfLoanPremiums" xlink:to="bivi_AccretionOfLoanPremiums_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AccretionOfLoanPremiums_lbl" xml:lang="en-US">Plus: accretion of Loan Premium</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayableCurrent_2_lbl" xml:lang="en-US">Current portion of Notes Payable, net of financing costs, unearned premium and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NotesPayableNoncurrent" xlink:label="bivi_NotesPayableNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NotesPayableNoncurrent" xlink:to="bivi_NotesPayableNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_NotesPayableNoncurrent_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LongtermDebtFinancingCosts" xlink:label="bivi_LongtermDebtFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LongtermDebtFinancingCosts" xlink:to="bivi_LongtermDebtFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_LongtermDebtFinancingCosts_lbl" xml:lang="en-US">Less: debt financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:label="bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:to="bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_lbl" xml:lang="en-US">Less: unearned discount</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LongTermAccretionOfLoanPremiums" xlink:label="bivi_LongTermAccretionOfLoanPremiums" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LongTermAccretionOfLoanPremiums" xlink:to="bivi_LongTermAccretionOfLoanPremiums_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_LongTermAccretionOfLoanPremiums_lbl" xml:lang="en-US">Plus: accretion of Loan Premium</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" xlink:label="bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" xlink:to="bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_lbl" xml:lang="en-US">Notes Payable, net of the current portion financing costs, unearned premium and discount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Accounts and Financing Receivables [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizationExpenseNextRollingTwoYears" xlink:label="bivi_AmortizationExpenseNextRollingTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AmortizationExpenseNextRollingTwoYears" xlink:to="bivi_AmortizationExpenseNextRollingTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_AmortizationExpenseNextRollingTwoYears_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizationExpenseTotal" xlink:label="bivi_AmortizationExpenseTotal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AmortizationExpenseTotal" xlink:to="bivi_AmortizationExpenseTotal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_AmortizationExpenseTotal_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FairValueOfEmbeddedConversionOption" xlink:label="bivi_FairValueOfEmbeddedConversionOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_FairValueOfEmbeddedConversionOption" xlink:to="bivi_FairValueOfEmbeddedConversionOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_FairValueOfEmbeddedConversionOption_lbl" xml:lang="en-US">Fair value of embedded conversion option</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedDiscount" xlink:label="bivi_UnearnedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnearnedDiscount" xlink:to="bivi_UnearnedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_UnearnedDiscount_lbl" xml:lang="en-US">Unearned discount</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DirectFinancingCost" xlink:label="bivi_DirectFinancingCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_DirectFinancingCost" xlink:to="bivi_DirectFinancingCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_DirectFinancingCost_lbl" xml:lang="en-US">Direct financing cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl" xml:lang="en-US">Unamortized premium recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest_lbl" xml:lang="en-US">Interest payment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionsOfLoanPremium" xlink:label="bivi_AccretionsOfLoanPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AccretionsOfLoanPremium" xlink:to="bivi_AccretionsOfLoanPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_AccretionsOfLoanPremium_lbl" xml:lang="en-US">Accretion of loan premium</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="us-gaap_NotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Remaining principal balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilities_lbl" xml:lang="en-US">Total derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DerivativeLiabilities_2_lbl" xml:lang="en-US">Balance at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_lbl" xml:lang="en-US">Additions to level 3 liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_lbl" xml:lang="en-US">Change in in fair value of level 3 liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_lbl" xml:lang="en-US">Transfer in and/or out of Level 3</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DerivativeLiabilities_3_lbl" xml:lang="en-US">Balance at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk Free Interest Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="us-gaap_OffsettingAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsTable" xlink:to="us-gaap_OffsettingAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsTable_lbl" xml:lang="en-US">Offsetting Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="us-gaap_OffsettingAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OffsettingAssetsLineItems" xlink:to="us-gaap_OffsettingAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OffsettingAssetsLineItems_lbl" xml:lang="en-US">Offsetting Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted remaining average contractual term, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate intrinsic value, outstanding at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted remaining average contractual term, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AggregateIntrinsicValueGranted" xlink:label="bivi_AggregateIntrinsicValueGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AggregateIntrinsicValueGranted" xlink:to="bivi_AggregateIntrinsicValueGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AggregateIntrinsicValueGranted_lbl" xml:lang="en-US">Aggregate intrinsic value, granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Options expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options canceled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, canceled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted remaining average contractual term, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, options outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted remaining average contractual term, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Aggregate intrinsic value, outstanding at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted average remaining contractual term, options exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected life of options (In years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_3_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_3_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend Yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Number of shares unvested at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value per share unvested at beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_lbl" xml:lang="en-US">Number of shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value per share, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value per share, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Number of shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value per share, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of shares, Canceled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value per share, Canceled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares unvested at ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average grant date fair value per share unvested at ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US">Weighted average exercise price, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining life (Years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Number of shares, granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_2_lbl" xml:lang="en-US">Weighted average remaining life (Years), granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of shares, expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, expired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_2_lbl" xml:lang="en-US">Number of shares, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted average exercise price, exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2_lbl" xml:lang="en-US">Number of shares, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2_lbl" xml:lang="en-US">Weighted average exercise price, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_lbl" xml:lang="en-US">Weighted average remaining life (Years)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockForCashShares" xlink:label="bivi_IssuanceOfCommonStockForCashShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfCommonStockForCashShares" xlink:to="bivi_IssuanceOfCommonStockForCashShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfCommonStockForCashShares_lbl" xml:lang="en-US">Issuance of common stock for cash, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockForCash" xlink:label="bivi_IssuanceOfCommonStockForCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_IssuanceOfCommonStockForCash" xlink:to="bivi_IssuanceOfCommonStockForCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_IssuanceOfCommonStockForCash_lbl" xml:lang="en-US">Issuance of common stock for cash</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommissionsPercentage" xlink:label="bivi_CommissionsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CommissionsPercentage" xlink:to="bivi_CommissionsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CommissionsPercentage_lbl" xml:lang="en-US">Commissions percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl" xml:lang="en-US">Public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Stock option to purchase</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_3_lbl" xml:lang="en-US">Share price</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockExercised" xlink:label="bivi_StockExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockExercised" xlink:to="bivi_StockExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockExercised_lbl" xml:lang="en-US">Number of stock exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued during period for service</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RsuGranted" xlink:label="bivi_RsuGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_RsuGranted" xlink:to="bivi_RsuGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_RsuGranted_lbl" xml:lang="en-US">Rsu granted</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_lbl" xml:lang="en-US">Rsu granted, grant date fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharesIssuedOverVestingPeriod" xlink:label="bivi_SharesIssuedOverVestingPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharesIssuedOverVestingPeriod" xlink:to="bivi_SharesIssuedOverVestingPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharesIssuedOverVestingPeriod_lbl" xml:lang="en-US">Shares issued over the vesting period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:to="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_lbl" xml:lang="en-US">Shares for tax withholdings</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TotalCompensationCost" xlink:label="bivi_TotalCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_TotalCompensationCost" xlink:to="bivi_TotalCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_TotalCompensationCost_lbl" xml:lang="en-US">Total compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationRestrictedStockUnits" xlink:label="bivi_StockBasedCompensationRestrictedStockUnits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockBasedCompensationRestrictedStockUnits" xlink:to="bivi_StockBasedCompensationRestrictedStockUnits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="bivi_StockBasedCompensationRestrictedStockUnits_lbl" xml:lang="en-US">Stock based compensation - restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Awarded Vested rights, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, options grants</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_lbl" xml:lang="en-US">Weighted average contractual term, granted (in years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease, right-of-use asset, net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current portion of operating lease liability</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Total operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Year ending June 30,</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">2029</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less amount representing interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of future minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_3_lbl" xml:lang="en-US">Less current portion of operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (Years) Operating leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate Operating leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xml:lang="en-US">Right-of-use Asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, general and administrative expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xlink:label="bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xlink:to="bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_lbl" xml:lang="en-US">Cash paid for amounts included in measurement of operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Defined benefit plan, plan assets, contributions by employer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax assets (liabilities):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Tax loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D capitalized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation Allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Income tax expense at federal statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net Operating Loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ExpirationsDates" xlink:label="bivi_ExpirationsDates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ExpirationsDates" xlink:to="bivi_ExpirationsDates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ExpirationsDates_lbl" xml:lang="en-US">Expirations dates</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_2_lbl" xml:lang="en-US">Common stock shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_2_lbl" xml:lang="en-US">Common stock per value</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PurchaseOfCommonStockShares" xlink:label="bivi_PurchaseOfCommonStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_PurchaseOfCommonStockShares" xlink:to="bivi_PurchaseOfCommonStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_PurchaseOfCommonStockShares_lbl" xml:lang="en-US">Purchase of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrants exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US">Proceeds from public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AgentFeesAndOfferingExpenses" xlink:label="bivi_AgentFeesAndOfferingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AgentFeesAndOfferingExpenses" xlink:to="bivi_AgentFeesAndOfferingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AgentFeesAndOfferingExpenses_lbl" xml:lang="en-US">Agent fees and offering expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Warrant issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfDerivatives" xlink:to="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfDerivatives_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeOther" xlink:to="us-gaap_InterestIncomeOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeOther_2_lbl" xml:lang="en-US">Interest Income, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossAttributableToParent" xlink:to="us-gaap_IncomeLossAttributableToParent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossAttributableToParent_2_lbl" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_2_lbl" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_UnrealizedGainOnAvailableforsaleInvestments" xlink:to="bivi_UnrealizedGainOnAvailableforsaleInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_UnrealizedGainOnAvailableforsaleInvestments_2_lbl" xml:lang="en-US">UnrealizedGainOnAvailableforsaleInvestments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AccretionOfUnearnedLoanDiscount" xlink:to="bivi_AccretionOfUnearnedLoanDiscount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AccretionOfUnearnedLoanDiscount_2_lbl" xml:lang="en-US">AccretionOfUnearnedLoanDiscount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:to="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases_2_lbl" xml:lang="en-US">Gain (Loss) on Sale of Leased Assets, Net, Operating Leases</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_2_lbl" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ProceedsFromMaturityOfU.s.TreasuryBills" xlink:to="bivi_ProceedsFromMaturityOfU.s.TreasuryBills_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ProceedsFromMaturityOfU.s.TreasuryBills_2_lbl" xml:lang="en-US">ProceedsFromMaturityOfU.s.TreasuryBills</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_ForgoneRecoveryIndName" xlink:to="ecd_ForgoneRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_ForgoneRecoveryIndName_2_lbl" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_OutstandingRecoveryIndName" xlink:to="ecd_OutstandingRecoveryIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_OutstandingRecoveryIndName_2_lbl" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_AwardsCloseToMnpiDiscIndName" xlink:to="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_AwardsCloseToMnpiDiscIndName_2_lbl" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ecd_TrdArrIndName" xlink:to="ecd_TrdArrIndName_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ecd_TrdArrIndName_2_lbl" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_2_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_EmployeeBenefitPlanTextBlock" xlink:to="bivi_EmployeeBenefitPlanTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_EmployeeBenefitPlanTextBlock_2_lbl" xml:lang="en-US">EmployeeBenefitPlanTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_2_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_2_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AccumulatedDeficit" xlink:to="bivi_AccumulatedDeficit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AccumulatedDeficit_2_lbl" xml:lang="en-US">AccumulatedDeficit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:to="us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_2_lbl" xml:lang="en-US">Deferred Discounts, Finance Charges and Interest Included in Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_NotesPayableNoncurrent" xlink:to="bivi_NotesPayableNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_NotesPayableNoncurrent_2_lbl" xml:lang="en-US">NotesPayableNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LongtermDebtFinancingCosts" xlink:to="bivi_LongtermDebtFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LongtermDebtFinancingCosts_2_lbl" xml:lang="en-US">LongtermDebtFinancingCosts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:to="bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_2_lbl" xml:lang="en-US">LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_LongTermAccretionOfLoanPremiums" xlink:to="bivi_LongTermAccretionOfLoanPremiums_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_LongTermAccretionOfLoanPremiums_2_lbl" xml:lang="en-US">LongTermAccretionOfLoanPremiums</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AmortizationExpenseNextRollingTwoYears" xlink:to="bivi_AmortizationExpenseNextRollingTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AmortizationExpenseNextRollingTwoYears_2_lbl" xml:lang="en-US">AmortizationExpenseNextRollingTwoYears</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AmortizationExpenseTotal" xlink:to="bivi_AmortizationExpenseTotal_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AmortizationExpenseTotal_2_lbl" xml:lang="en-US">AmortizationExpenseTotal</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_2_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_2_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_AccretionsOfLoanPremium" xlink:to="bivi_AccretionsOfLoanPremium_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_AccretionsOfLoanPremium_2_lbl" xml:lang="en-US">AccretionsOfLoanPremium</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_2_lbl" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_2_lbl" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_2_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bivi_StockBasedCompensationRestrictedStockUnits" xlink:to="bivi_StockBasedCompensationRestrictedStockUnits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bivi_StockBasedCompensationRestrictedStockUnits_2_lbl" xml:lang="en-US">StockBasedCompensationRestrictedStockUnits</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherSellingGeneralAndAdministrativeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherSellingGeneralAndAdministrativeExpense_2_lbl" xml:lang="en-US">Other Selling, General and Administrative Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>bivi-20240630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://bioviepharma.com/role/Cover" xlink:href="bivi-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BalanceSheets" xlink:href="bivi-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="bivi-20240630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="bivi-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfCashFlows" xlink:href="bivi-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BackgroundInformation" xlink:href="bivi-20240630.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LiquidityAndGoingConcern" xlink:href="bivi-20240630.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPolicies" xlink:href="bivi-20240630.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssets" xlink:href="bivi-20240630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/RelatedPartyTransactions" xlink:href="bivi-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayable" xlink:href="bivi-20240630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurements" xlink:href="bivi-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactions" xlink:href="bivi-20240630.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/Leases" xlink:href="bivi-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/CommitmentsAndContingencies" xlink:href="bivi-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EmployeeBenefitPlan" xlink:href="bivi-20240630.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxes" xlink:href="bivi-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SubsequentEvents" xlink:href="bivi-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsTables" xlink:href="bivi-20240630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableTables" xlink:href="bivi-20240630.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsTables" xlink:href="bivi-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsTables" xlink:href="bivi-20240630.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesTables" xlink:href="bivi-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesTables" xlink:href="bivi-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="bivi-20240630.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetails" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetails1" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="bivi-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetails" xlink:href="bivi-20240630.xsd#NotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetails1" xlink:href="bivi-20240630.xsd#NotesPayableDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetailsNarrative" xlink:href="bivi-20240630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails1" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails2" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails1" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails2" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails3" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" xlink:href="bivi-20240630.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails" xlink:href="bivi-20240630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails1" xlink:href="bivi-20240630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails2" xlink:href="bivi-20240630.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetailsNarrative" xlink:href="bivi-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="bivi-20240630.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetails" xlink:href="bivi-20240630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetails1" xlink:href="bivi-20240630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="bivi-20240630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="bivi-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="loc_deiDocumentFinStmtErrorCorrectionFlag" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFinStmtErrorCorrectionFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="loc_deiAuditorFirmId" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorFirmId" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="loc_deiAuditorName" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="loc_deiAuditorLocation" />
      <link:presentationArc order="610" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditorLocation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_InvestmentsInU.s.TreasuryBills" xlink:label="loc_biviInvestmentsInU.s.TreasuryBills" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_biviInvestmentsInU.s.TreasuryBills" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantLiabilities" xlink:label="loc_biviWarrantLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_biviWarrantLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedPremiumAnddiscountCurrent" xlink:label="loc_biviUnearnedPremiumAnddiscountCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_biviUnearnedPremiumAnddiscountCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedPremiumAndDiscount" xlink:label="loc_biviUnearnedPremiumAndDiscount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_biviUnearnedPremiumAndDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsSharebasedCompensationStock" xlink:label="loc_us-gaapDividendsSharebasedCompensationStock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapDividendsSharebasedCompensationStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaapIncomeLossAttributableToParent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossAttributableToParent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract" xlink:label="loc_us-gaapOtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnrealizedGainOnInvestmentsForAvailableforsale" xlink:label="loc_biviUnrealizedGainOnInvestmentsForAvailableforsale" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract" xlink:to="loc_biviUnrealizedGainOnInvestmentsForAvailableforsale" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:label="loc_biviReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract" xlink:to="loc_biviReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TreasuryStocksMember" xlink:label="loc_biviTreasuryStocksMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_biviTreasuryStocksMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" xlink:label="loc_biviIssuanceOfCommonStockFromVestingOfRestrictedStockUnits" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfCommonStockFromVestingOfRestrictedStockUnits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" xlink:label="loc_biviIssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered" xlink:label="loc_biviStockbasedCompensationIssuanceOfCommonStockForServicesRendered" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviStockbasedCompensationIssuanceOfCommonStockForServicesRendered" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" xlink:label="loc_biviStockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviStockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DeemedDividendForRatchetAdjustmentToWarrants" xlink:label="loc_biviDeemedDividendForRatchetAdjustmentToWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendForRatchetAdjustmentToWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:label="loc_biviRelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviRelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" xlink:label="loc_biviIssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" xlink:label="loc_biviIssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfOptions" xlink:label="loc_biviCashlessExerciseOfOptions" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfOptionsShares" xlink:label="loc_biviCashlessExerciseOfOptionsShares" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfOptionsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="loc_biviCashlessExerciseOfWarrants" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="loc_biviCashlessExerciseOfWarrantsShares" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrantsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetCosts" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetCosts" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetCostsShares" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetCostsShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnrealizedGainOnAvailableforsaleInvestments" xlink:label="loc_biviUnrealizedGainOnAvailableforsaleInvestments" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviUnrealizedGainOnAvailableforsaleInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationRestrictedStock" xlink:label="loc_biviStockBasedCompensationRestrictedStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_biviStockBasedCompensationRestrictedStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationExpenseStockIssued" xlink:label="loc_biviStockBasedCompensationExpenseStockIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_biviStockBasedCompensationExpenseStockIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionOfUnearnedLoanDiscount" xlink:label="loc_biviAccretionOfUnearnedLoanDiscount" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_biviAccretionOfUnearnedLoanDiscount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionOfLoanPremium" xlink:label="loc_biviAccretionOfLoanPremium" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_biviAccretionOfLoanPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RealizedGainOnMaturityOfAvailableforSale" xlink:label="loc_biviRealizedGainOnMaturityOfAvailableforSale" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_biviRealizedGainOnMaturityOfAvailableforSale" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NoncashLeaseExpenseFromRightofuseAssets" xlink:label="loc_biviNoncashLeaseExpenseFromRightofuseAssets" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_biviNoncashLeaseExpenseFromRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="loc_us-gaapGainLossOnSaleOfLeasedAssetsNetOperatingLeases" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromMaturityOfU.s.TreasuryBills" xlink:label="loc_biviProceedsFromMaturityOfU.s.TreasuryBills" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_biviProceedsFromMaturityOfU.s.TreasuryBills" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty" xlink:label="loc_biviNetProceedsFromIssuanceOfCommonStockRelatedParty" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_biviNetProceedsFromIssuanceOfCommonStockRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations" xlink:label="loc_biviRightOfUseAssetsObtainedInExchangeForLeaseObligations" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_biviRightOfUseAssetsObtainedInExchangeForLeaseObligations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnrealizedGainOnU.s.TreasuryBills" xlink:label="loc_biviUnrealizedGainOnU.s.TreasuryBills" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_biviUnrealizedGainOnU.s.TreasuryBills" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:label="loc_biviReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_biviReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DeemedDividendOfRatchetAdjustmentsToWarrants" xlink:label="loc_biviDeemedDividendOfRatchetAdjustmentsToWarrants" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_biviDeemedDividendOfRatchetAdjustmentsToWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:title="995410 - Disclosure - Pay vs Performance Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems" xlink:label="loc_ecdPayVsPerformanceDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable" xlink:label="loc_ecdPvpTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis" xlink:label="loc_ecdExecutiveCategoryAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdExecutiveCategoryAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember" xlink:label="loc_ecdAllExecutiveCategoriesMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdExecutiveCategoryAxis" xlink:to="loc_ecdAllExecutiveCategoriesMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis" xlink:label="loc_ecdAdjToCompAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdAdjToCompAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember" xlink:label="loc_ecdAllAdjToCompMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAdjToCompAxis" xlink:to="loc_ecdAllAdjToCompMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis" xlink:label="loc_ecdMeasureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTable" xlink:to="loc_ecdMeasureAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock" xlink:label="loc_ecdPvpTableTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPvpTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName" xlink:label="loc_ecdCoSelectedMeasureName" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdCoSelectedMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock" xlink:label="loc_ecdNamedExecutiveOfficersFnTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdNamedExecutiveOfficersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock" xlink:label="loc_ecdPeerGroupIssuersFnTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeerGroupIssuersFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock" xlink:label="loc_ecdChangedPeerGroupFnTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdChangedPeerGroupFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt" xlink:label="loc_ecdPeoTotalCompAmt" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt" xlink:label="loc_ecdPeoActuallyPaidCompAmt" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdPeoActuallyPaidCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock" xlink:label="loc_ecdAdjToPeoCompFnTextBlock" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdCoSelectedMeasureName" xlink:to="loc_ecdAdjToPeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt" xlink:label="loc_ecdNonPeoNeoAvgTotalCompAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgTotalCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:label="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:label="loc_ecdAdjToNonPeoNeoCompFnTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdAdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:label="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdEquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:label="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:label="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" />
      <link:presentationArc order="2140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:label="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" />
      <link:presentationArc order="2150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:label="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" />
      <link:presentationArc order="2160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdCompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock" xlink:label="loc_ecdTabularListTableTextBlock" />
      <link:presentationArc order="2170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTabularListTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt" xlink:label="loc_ecdTotalShareholderRtnAmt" />
      <link:presentationArc order="2180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt" xlink:label="loc_ecdPeerGroupTotalShareholderRtnAmt" />
      <link:presentationArc order="2190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdNonPeoNeoAvgCompActuallyPaidAmt" xlink:to="loc_ecdPeerGroupTotalShareholderRtnAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="2200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPvpTableTextBlock" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt" xlink:label="loc_ecdCoSelectedMeasureAmt" />
      <link:presentationArc order="2210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdCoSelectedMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt" xlink:label="loc_ecdOtherPerfMeasureAmt" />
      <link:presentationArc order="2220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdOtherPerfMeasureAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt" xlink:label="loc_ecdAdjToCompAmt" />
      <link:presentationArc order="2230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdAdjToCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName" xlink:label="loc_ecdPeoName" />
      <link:presentationArc order="2240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_ecdPeoName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName" xlink:label="loc_ecdMeasureName" />
      <link:presentationArc order="2250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdMeasureName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock" xlink:label="loc_ecdNonGaapMeasureDescriptionTextBlock" />
      <link:presentationArc order="2260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdMeasureName" xlink:to="loc_ecdNonGaapMeasureDescriptionTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock" xlink:label="loc_ecdAdditional402vDisclosureTextBlock" />
      <link:presentationArc order="2270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdAdditional402vDisclosureTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock" xlink:label="loc_ecdPnsnBnftsAdjFnTextBlock" />
      <link:presentationArc order="2280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdPayVsPerformanceDisclosureLineItems" xlink:to="loc_ecdPnsnBnftsAdjFnTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:title="995440 - Disclosure - Recovery of Erroneously Awarded Compensation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems" xlink:label="loc_ecdRecoveryOfErrCompDisclosureLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable" xlink:label="loc_ecdErrCompRecoveryTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdErrCompRecoveryTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis" xlink:label="loc_ecdRestatementDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdRestatementDateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdErrCompRecoveryTable" xlink:to="loc_ecdIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate" xlink:label="loc_ecdRestatementDeterminationDate" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecdRestatementDeterminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt" xlink:label="loc_ecdAggtErrCompAmt" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock" xlink:label="loc_ecdErrCompAnalysisTextBlock" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdErrCompAnalysisTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:label="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdStkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt" xlink:label="loc_ecdOutstandingAggtErrCompAmt" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdOutstandingAggtErrCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:label="loc_ecdAggtErrCompNotYetDeterminedTextBlock" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdAggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName" xlink:label="loc_ecdForgoneRecoveryIndName" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:label="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAggtErrCompAmt" xlink:to="loc_ecdForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:label="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:label="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdRestatementDeterminationDate" xlink:to="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:label="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName" xlink:label="loc_ecdOutstandingRecoveryIndName" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt" xlink:label="loc_ecdOutstandingRecoveryCompAmt" />
      <link:presentationArc order="2120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdOutstandingRecoveryCompAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:label="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" />
      <link:presentationArc order="2130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="loc_ecdRestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:title="995443 - Disclosure - Award Timing Disclosure">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems" xlink:label="loc_ecdAwardTmgDiscLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable" xlink:label="loc_ecdAwardsCloseToMnpiDiscTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="loc_ecdIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_ecdIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="loc_ecdAllIndividualsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdIndividualAxis" xlink:to="loc_ecdAllIndividualsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock" xlink:label="loc_ecdAwardTmgMnpiDiscTextBlock" />
      <link:presentationArc order="2000" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiDiscTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock" xlink:label="loc_ecdAwardTmgMethodTextBlock" />
      <link:presentationArc order="2010" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMethodTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag" xlink:label="loc_ecdAwardTmgPredtrmndFlag" />
      <link:presentationArc order="2020" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgPredtrmndFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag" xlink:label="loc_ecdAwardTmgMnpiCnsdrdFlag" />
      <link:presentationArc order="2030" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgMnpiCnsdrdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:label="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" />
      <link:presentationArc order="2040" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag" xlink:label="loc_ecdMnpiDiscTimedForCompValFlag" />
      <link:presentationArc order="2050" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdMnpiDiscTimedForCompValFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:label="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" />
      <link:presentationArc order="2060" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName" xlink:label="loc_ecdAwardsCloseToMnpiDiscIndName" />
      <link:presentationArc order="2070" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt" xlink:label="loc_ecdAwardUndrlygSecuritiesAmt" />
      <link:presentationArc order="2080" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardUndrlygSecuritiesAmt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice" xlink:label="loc_ecdAwardExrcPrice" />
      <link:presentationArc order="2090" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardExrcPrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue" xlink:label="loc_ecdAwardGrantDateFairValue" />
      <link:presentationArc order="2100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdAwardGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct" xlink:label="loc_ecdUndrlygSecurityMktPriceChngPct" />
      <link:presentationArc order="2110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdAwardTmgDiscLineItems" xlink:to="loc_ecdUndrlygSecurityMktPriceChngPct" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:title="995445 - Disclosure - Insider Trading Arrangements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="loc_ecdInsiderTradingArrLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="loc_ecdMtrlTermsOfTrdArrTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdMtrlTermsOfTrdArrTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="loc_ecdTrdArrIndName" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="loc_ecdTrdArrIndTitle" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrIndTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="loc_ecdRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="loc_ecdNonRule10b51ArrAdoptedFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="loc_ecdTrdArrAdoptionDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrAdoptionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="loc_ecdRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="loc_ecdNonRule10b51ArrTrmntdFlag" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdNonRule10b51ArrTrmntdFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate" xlink:label="loc_ecdTrdArrTerminationDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrTerminationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="loc_ecdTrdArrExpirationDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrExpirationDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="loc_ecdTrdArrDuration" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingArrLineItems" xlink:to="loc_ecdTrdArrDuration" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:title="995447 - Disclosure - Insider Trading Policies and Procedures">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems" xlink:label="loc_ecdInsiderTradingPoliciesProcLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:label="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:label="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecdInsiderTradingPoliciesProcLineItems" xlink:to="loc_ecdInsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BackgroundInformation" xlink:title="995612 - Disclosure - Background Information">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LiquidityAndGoingConcern" xlink:title="995613 - Disclosure - Liquidity and Going Concern">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPolicies" xlink:title="995614 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:title="995615 - Disclosure - Investments in U.S. Treasury Bills available-for-sale">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:label="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock" xlink:label="loc_biviInvestmentsInUSTreasuryBillsAvailableForSaleTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:to="loc_biviInvestmentsInUSTreasuryBillsAvailableForSaleTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssets" xlink:title="995616 - Disclosure - Intangible Assets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/RelatedPartyTransactions" xlink:title="995617 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayable" xlink:title="995618 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurements" xlink:title="995619 - Disclosure - Fair Value Measurements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:label="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactions" xlink:title="995620 - Disclosure - Equity Transactions">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/Leases" xlink:title="995621 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureLeasesAbstract" xlink:label="loc_biviDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/CommitmentsAndContingencies" xlink:title="995622 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EmployeeBenefitPlan" xlink:title="995623 - Disclosure - Employee Benefit Plan">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureEmployeeBenefitPlanAbstract" xlink:label="loc_biviDisclosureEmployeeBenefitPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_EmployeeBenefitPlanTextBlock" xlink:label="loc_biviEmployeeBenefitPlanTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureEmployeeBenefitPlanAbstract" xlink:to="loc_biviEmployeeBenefitPlanTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxes" xlink:title="995624 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SubsequentEvents" xlink:title="995625 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="995626 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_InvestmentsUSTreasuryBillsPolicyTextBlock" xlink:label="loc_biviInvestmentsUSTreasuryBillsPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_biviInvestmentsUSTreasuryBillsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock" xlink:label="loc_biviConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_biviConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PrepaidAndOtherAssetsPolicyTextBlock" xlink:label="loc_biviPrepaidAndOtherAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_biviPrepaidAndOtherAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ReverseStockSpliteUpPolicyTextBlock" xlink:label="loc_biviReverseStockSpliteUpPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_biviReverseStockSpliteUpPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesTables" xlink:title="995627 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:title="995628 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:label="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock" xlink:label="loc_biviScheduleOfUSTreasuryBillsHeldTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:to="loc_biviScheduleOfUSTreasuryBillsHeldTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsTables" xlink:title="995629 - Disclosure - Intangible Assets (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableTables" xlink:title="995630 - Disclosure - Notes Payable (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ScheduleofFutureAmortizationExpenseTableTextBlock" xlink:label="loc_biviScheduleofFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviScheduleofFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsTables" xlink:title="995631 - Disclosure - Fair Value Measurements (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsTables" xlink:title="995632 - Disclosure - Equity Transactions (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:label="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesTables" xlink:title="995633 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureLeasesAbstract" xlink:label="loc_biviDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LesseeOperatingLeaseLiabilityTableTextBlock" xlink:label="loc_biviLesseeOperatingLeaseLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_biviLesseeOperatingLeaseLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases" xlink:label="loc_biviScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_biviScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:label="loc_biviScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_biviScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesTables" xlink:title="995634 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="995635 - Disclosure - Liquidity and Going Concern (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WorkingCapital" xlink:label="loc_biviWorkingCapital" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_biviWorkingCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockholderEquities" xlink:label="loc_biviStockholderEquities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_biviStockholderEquities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccumulatedDeficit" xlink:label="loc_biviAccumulatedDeficit" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_biviAccumulatedDeficit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" xlink:title="995636 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NotespayableConversionOptionMember" xlink:label="loc_biviNotespayableConversionOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_biviNotespayableConversionOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:title="995637 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:label="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaapScheduleOfInvestmentsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:to="loc_us-gaapScheduleOfInvestmentsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaapScheduleOfInvestmentsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_us-gaapScheduleOfInvestmentsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="loc_us-gaapUSTreasuryBillSecuritiesMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapUSTreasuryBillSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizedCostBasis" xlink:label="loc_biviAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_biviAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_GrossUnrealizedGain" xlink:label="loc_biviGrossUnrealizedGain" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_biviGrossUnrealizedGain" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_GrossUnrealizedLoss" xlink:label="loc_biviGrossUnrealizedLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_biviGrossUnrealizedLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:title="995638 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:label="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NumberOfStockPurchased" xlink:label="loc_biviNumberOfStockPurchased" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:to="loc_biviNumberOfStockPurchased" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RealizedGainOnMaturityOfAvailableforSale" xlink:label="loc_biviRealizedGainOnMaturityOfAvailableforSale" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" xlink:to="loc_biviRealizedGainOnMaturityOfAvailableforSale" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetails" xlink:title="995639 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetails1" xlink:title="995640 - Disclosure - Intangible Assets (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" xlink:title="995641 - Disclosure - Intangible Assets (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995642 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AcuitasGroupHoldingsLLCMember" xlink:label="loc_biviAcuitasGroupHoldingsLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_biviAcuitasGroupHoldingsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantsMember" xlink:label="loc_biviWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDividends" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetails" xlink:title="995643 - Disclosure - Notes Payable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CurrentPortionOfNotesPayable" xlink:label="loc_biviCurrentPortionOfNotesPayable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviCurrentPortionOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DebtFinancingCosts" xlink:label="loc_biviDebtFinancingCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviDebtFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:label="loc_us-gaapDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionOfLoanPremiums" xlink:label="loc_biviAccretionOfLoanPremiums" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviAccretionOfLoanPremiums" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NotesPayableNoncurrent" xlink:label="loc_biviNotesPayableNoncurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviNotesPayableNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LongtermDebtFinancingCosts" xlink:label="loc_biviLongtermDebtFinancingCosts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviLongtermDebtFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:label="loc_biviLongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviLongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LongTermAccretionOfLoanPremiums" xlink:label="loc_biviLongTermAccretionOfLoanPremiums" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviLongTermAccretionOfLoanPremiums" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" xlink:label="loc_biviLongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_biviLongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetails1" xlink:title="995644 - Disclosure - Notes Payable (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaapReceivableTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="loc_us-gaapReceivableTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedDiscountMember" xlink:label="loc_biviUnearnedDiscountMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_biviUnearnedDiscountMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="loc_us-gaapFinanceReceivablesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_us-gaapFinanceReceivablesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LoanAccretionPremiumMember" xlink:label="loc_biviLoanAccretionPremiumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_biviLoanAccretionPremiumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizationExpenseNextRollingTwoYears" xlink:label="loc_biviAmortizationExpenseNextRollingTwoYears" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_biviAmortizationExpenseNextRollingTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizationExpenseTotal" xlink:label="loc_biviAmortizationExpenseTotal" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_biviAmortizationExpenseTotal" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetailsNarrative" xlink:title="995645 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FairValueOfEmbeddedConversionOption" xlink:label="loc_biviFairValueOfEmbeddedConversionOption" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_biviFairValueOfEmbeddedConversionOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedDiscount" xlink:label="loc_biviUnearnedDiscount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_biviUnearnedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DirectFinancingCost" xlink:label="loc_biviDirectFinancingCost" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_biviDirectFinancingCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="loc_us-gaapDebtInstrumentUnamortizedPremium" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentInterest" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionsOfLoanPremium" xlink:label="loc_biviAccretionsOfLoanPremium" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_biviAccretionsOfLoanPremium" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails" xlink:title="995646 - Disclosure - Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails1" xlink:title="995647 - Disclosure - Fair Value Measurements (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails2" xlink:title="995648 - Disclosure - Fair Value Measurements (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="loc_us-gaapCashMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapCashMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapInvestmentTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="loc_us-gaapUSTreasuryBillSecuritiesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapUSTreasuryBillSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_USTreasuryBillSecurities1Member" xlink:label="loc_biviUSTreasuryBillSecurities1Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_biviUSTreasuryBillSecurities1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="995649 - Disclosure - Fair Value Measurements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails" xlink:title="995650 - Disclosure - Equity Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockOptionsMember" xlink:label="loc_biviStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AggregateIntrinsicValueGranted" xlink:label="loc_biviAggregateIntrinsicValueGranted" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviAggregateIntrinsicValueGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails1" xlink:title="995651 - Disclosure - Equity Transactions (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOffsettingAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapOffsettingAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockOptionsMember" xlink:label="loc_biviStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails2" xlink:title="995652 - Disclosure - Equity Transactions (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails3" xlink:title="995653 - Disclosure - Equity Transactions (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" xlink:title="995654 - Disclosure - Equity Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SalesAgreementMember" xlink:label="loc_biviSalesAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_biviSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PrefundedWarrantsMember" xlink:label="loc_biviPrefundedWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommonWarrantMember" xlink:label="loc_biviCommonWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviCommonWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantsMember" xlink:label="loc_biviWarrantsMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_VendorMember" xlink:label="loc_biviVendorMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviVendorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PresidentAndCEOMember" xlink:label="loc_biviPresidentAndCEOMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviPresidentAndCEOMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FourDirectorsMember" xlink:label="loc_biviFourDirectorsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviFourDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ThreeDirectorsMember" xlink:label="loc_biviThreeDirectorsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviThreeDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FourDirectorMember" xlink:label="loc_biviFourDirectorMember" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviFourDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TwoDirectorsMember" xlink:label="loc_biviTwoDirectorsMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviTwoDirectorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_EmployeesMember" xlink:label="loc_biviEmployeesMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CertainEmployeesMember" xlink:label="loc_biviCertainEmployeesMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviCertainEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NewEmployeeMember" xlink:label="loc_biviNewEmployeeMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviNewEmployeeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockOptionsMember" xlink:label="loc_biviStockOptionsMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_N2019OmnibusIncentiveEquityPlanMember" xlink:label="loc_biviN2019OmnibusIncentiveEquityPlanMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_biviN2019OmnibusIncentiveEquityPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockForCashShares" xlink:label="loc_biviIssuanceOfCommonStockForCashShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviIssuanceOfCommonStockForCashShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockForCash" xlink:label="loc_biviIssuanceOfCommonStockForCash" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviIssuanceOfCommonStockForCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommissionsPercentage" xlink:label="loc_biviCommissionsPercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviCommissionsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:label="loc_us-gaapPartnersCapitalAccountUnitsSoldInPublicOffering" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPartnersCapitalAccountUnitsSoldInPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockExercised" xlink:label="loc_biviStockExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviStockExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RsuGranted" xlink:label="loc_biviRsuGranted" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviRsuGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharesIssuedOverVestingPeriod" xlink:label="loc_biviSharesIssuedOverVestingPeriod" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviSharesIssuedOverVestingPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TotalCompensationCost" xlink:label="loc_biviTotalCompensationCost" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviTotalCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationRestrictedStockUnits" xlink:label="loc_biviStockBasedCompensationRestrictedStockUnits" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviStockBasedCompensationRestrictedStockUnits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails" xlink:title="995655 - Disclosure - Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureLeasesAbstract" xlink:label="loc_biviDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails1" xlink:title="995656 - Disclosure - Leases (Details 1)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureLeasesAbstract" xlink:label="loc_biviDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails2" xlink:title="995657 - Disclosure - Leases (Details 2)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureLeasesAbstract" xlink:label="loc_biviDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetailsNarrative" xlink:title="995658 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureLeasesAbstract" xlink:label="loc_biviDisclosureLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapOtherSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOtherSellingGeneralAndAdministrativeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaapOperatingLeaseCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xlink:label="loc_biviCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureLeasesAbstract" xlink:to="loc_biviCashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="995659 - Disclosure - Employee Benefit Plan (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DisclosureEmployeeBenefitPlanAbstract" xlink:label="loc_biviDisclosureEmployeeBenefitPlanAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biviDisclosureEmployeeBenefitPlanAbstract" xlink:to="loc_us-gaapDefinedBenefitPlanContributionsByEmployer" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetails" xlink:title="995660 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetails1" xlink:title="995661 - Disclosure - Income Taxes (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="995662 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsLiabilitiesNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ExpirationsDates" xlink:label="loc_biviExpirationsDates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_biviExpirationsDates" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="995663 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PrefundedWarrantsMember" xlink:label="loc_biviPrefundedWarrantsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_biviPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommonWarrantsMember" xlink:label="loc_biviCommonWarrantsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_biviCommonWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PlacementAgentsWarrantsMember" xlink:label="loc_biviPlacementAgentsWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviPlacementAgentsWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PurchaseOfCommonStockShares" xlink:label="loc_biviPurchaseOfCommonStockShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviPurchaseOfCommonStockShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AgentFeesAndOfferingExpenses" xlink:label="loc_biviAgentFeesAndOfferingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviAgentFeesAndOfferingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>bivi-20240630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Qpo7xRiXgOn8uPaXcsSaiLibP9xpJ7OZkhtGl8fblKTygsUpsJfifmUkoW8bkK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:bivi="http://bioviepharma.com/20240630" elementFormDefault="qualified" targetNamespace="http://bioviepharma.com/20240630">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://bioviepharma.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/BalanceSheets" id="BalanceSheets">
          <link:definition>00000002 - Statement - Balance Sheets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
          <link:definition>00000003 - Statement - Balance Sheets (Parenthetical)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
          <link:definition>00000004 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
          <link:definition>00000005 - Statement - Statements of Changes in Stockholders' Equity</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
          <link:definition>00000006 - Statement - Statements of Cash Flows</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/BackgroundInformation" id="BackgroundInformation">
          <link:definition>995612 - Disclosure - Background Information</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/LiquidityAndGoingConcern" id="LiquidityAndGoingConcern">
          <link:definition>995613 - Disclosure - Liquidity and Going Concern</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
          <link:definition>995614 - Disclosure - Significant Accounting Policies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale" id="InvestmentsInU.s.TreasuryBillsAvailable-for-sale">
          <link:definition>995615 - Disclosure - Investments in U.S. Treasury Bills available-for-sale</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IntangibleAssets" id="IntangibleAssets">
          <link:definition>995616 - Disclosure - Intangible Assets</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
          <link:definition>995617 - Disclosure - Related Party Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/NotesPayable" id="NotesPayable">
          <link:definition>995618 - Disclosure - Notes Payable</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/FairValueMeasurements" id="FairValueMeasurements">
          <link:definition>995619 - Disclosure - Fair Value Measurements</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EquityTransactions" id="EquityTransactions">
          <link:definition>995620 - Disclosure - Equity Transactions</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/Leases" id="Leases">
          <link:definition>995621 - Disclosure - Leases</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
          <link:definition>995622 - Disclosure - Commitments and Contingencies</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EmployeeBenefitPlan" id="EmployeeBenefitPlan">
          <link:definition>995623 - Disclosure - Employee Benefit Plan</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IncomeTaxes" id="IncomeTaxes">
          <link:definition>995624 - Disclosure - Income Taxes</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/SubsequentEvents" id="SubsequentEvents">
          <link:definition>995625 - Disclosure - Subsequent Events</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
          <link:definition>995626 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
          <link:definition>995627 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" id="InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables">
          <link:definition>995628 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
          <link:definition>995629 - Disclosure - Intangible Assets (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/NotesPayableTables" id="NotesPayableTables">
          <link:definition>995630 - Disclosure - Notes Payable (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/FairValueMeasurementsTables" id="FairValueMeasurementsTables">
          <link:definition>995631 - Disclosure - Fair Value Measurements (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EquityTransactionsTables" id="EquityTransactionsTables">
          <link:definition>995632 - Disclosure - Equity Transactions (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/LeasesTables" id="LeasesTables">
          <link:definition>995633 - Disclosure - Leases (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
          <link:definition>995634 - Disclosure - Income Taxes (Tables)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" id="LiquidityAndGoingConcernDetailsNarrative">
          <link:definition>995635 - Disclosure - Liquidity and Going Concern (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" id="SignificantAccountingPoliciesDetails">
          <link:definition>995636 - Disclosure - Significant Accounting Policies (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" id="InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails">
          <link:definition>995637 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" id="InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative">
          <link:definition>995638 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
          <link:definition>995639 - Disclosure - Intangible Assets (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
          <link:definition>995640 - Disclosure - Intangible Assets (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
          <link:definition>995641 - Disclosure - Intangible Assets (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
          <link:definition>995642 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/NotesPayableDetails" id="NotesPayableDetails">
          <link:definition>995643 - Disclosure - Notes Payable (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/NotesPayableDetails1" id="NotesPayableDetails1">
          <link:definition>995644 - Disclosure - Notes Payable (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
          <link:definition>995645 - Disclosure - Notes Payable (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails" id="FairValueMeasurementsDetails">
          <link:definition>995646 - Disclosure - Fair Value Measurements (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails1" id="FairValueMeasurementsDetails1">
          <link:definition>995647 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails2" id="FairValueMeasurementsDetails2">
          <link:definition>995648 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" id="FairValueMeasurementsDetailsNarrative">
          <link:definition>995649 - Disclosure - Fair Value Measurements (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EquityTransactionsDetails" id="EquityTransactionsDetails">
          <link:definition>995650 - Disclosure - Equity Transactions (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EquityTransactionsDetails1" id="EquityTransactionsDetails1">
          <link:definition>995651 - Disclosure - Equity Transactions (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EquityTransactionsDetails2" id="EquityTransactionsDetails2">
          <link:definition>995652 - Disclosure - Equity Transactions (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EquityTransactionsDetails3" id="EquityTransactionsDetails3">
          <link:definition>995653 - Disclosure - Equity Transactions (Details 3)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" id="EquityTransactionsDetailsNarrative">
          <link:definition>995654 - Disclosure - Equity Transactions (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/LeasesDetails" id="LeasesDetails">
          <link:definition>995655 - Disclosure - Leases (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/LeasesDetails1" id="LeasesDetails1">
          <link:definition>995656 - Disclosure - Leases (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/LeasesDetails2" id="LeasesDetails2">
          <link:definition>995657 - Disclosure - Leases (Details 2)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
          <link:definition>995658 - Disclosure - Leases (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" id="EmployeeBenefitPlanDetailsNarrative">
          <link:definition>995659 - Disclosure - Employee Benefit Plan (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
          <link:definition>995660 - Disclosure - Income Taxes (Details)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
          <link:definition>995661 - Disclosure - Income Taxes (Details 1)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
          <link:definition>995662 - Disclosure - Income Taxes (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:roleType roleURI="http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
          <link:definition>995663 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="bivi-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bivi-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bivi-20240630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="bivi-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
    <import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
    <import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
    <import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
    <import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
    <element id="bivi_TreasuryStocksMember" name="TreasuryStocksMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_NotespayableConversionOptionMember" name="NotespayableConversionOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AcuitasGroupHoldingsLLCMember" name="AcuitasGroupHoldingsLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_UnearnedDiscountMember" name="UnearnedDiscountMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LoanAccretionPremiumMember" name="LoanAccretionPremiumMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DerivativeLiabilityWarrantsMember" name="DerivativeLiabilityWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DerivativeLiabilityConversionOptionMember" name="DerivativeLiabilityConversionOptionMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" name="DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_USTreasuryBillSecurities1Member" name="USTreasuryBillSecurities1Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CommonWarrantMember" name="CommonWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_VendorMember" name="VendorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_N2019OmnibusIncentiveEquityPlanMember" name="N2019OmnibusIncentiveEquityPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_PresidentAndCEOMember" name="PresidentAndCEOMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_FourDirectorsMember" name="FourDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ThreeDirectorsMember" name="ThreeDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_FourDirectorMember" name="FourDirectorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_TwoDirectorsMember" name="TwoDirectorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CertainEmployeesMember" name="CertainEmployeesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_NewEmployeeMember" name="NewEmployeeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CommonWarrantsMember" name="CommonWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_PlacementAgentsWarrantsMember" name="PlacementAgentsWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_InvestmentsInU.s.TreasuryBills" name="InvestmentsInU.s.TreasuryBills" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_WarrantLiabilities" name="WarrantLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_UnearnedPremiumAnddiscountCurrent" name="UnearnedPremiumAnddiscountCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_UnearnedPremiumAndDiscount" name="UnearnedPremiumAndDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_UnrealizedGainOnInvestmentsForAvailableforsale" name="UnrealizedGainOnInvestmentsForAvailableforsale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" name="ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" name="IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" name="IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered" name="StockbasedCompensationIssuanceOfCommonStockForServicesRendered" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" name="StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividendForRatchetAdjustmentToWarrants" name="DeemedDividendForRatchetAdjustmentToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" name="RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" name="IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" name="IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashlessExerciseOfOptions" name="CashlessExerciseOfOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashlessExerciseOfOptionsShares" name="CashlessExerciseOfOptionsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashlessExerciseOfWarrantsShares" name="CashlessExerciseOfWarrantsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromIssuanceOfCommonStockNetCosts" name="ProceedsFromIssuanceOfCommonStockNetCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares" name="ProceedsFromIssuanceOfCommonStockNetCostsShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" name="ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" name="ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_UnrealizedGainOnAvailableforsaleInvestments" name="UnrealizedGainOnAvailableforsaleInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockBasedCompensationRestrictedStock" name="StockBasedCompensationRestrictedStock" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockBasedCompensationExpenseStockIssued" name="StockBasedCompensationExpenseStockIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AccretionOfUnearnedLoanDiscount" name="AccretionOfUnearnedLoanDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AccretionOfLoanPremium" name="AccretionOfLoanPremium" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_RealizedGainOnMaturityOfAvailableforSale" name="RealizedGainOnMaturityOfAvailableforSale" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_NoncashLeaseExpenseFromRightofuseAssets" name="NoncashLeaseExpenseFromRightofuseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ProceedsFromMaturityOfU.s.TreasuryBills" name="ProceedsFromMaturityOfU.s.TreasuryBills" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty" name="NetProceedsFromIssuanceOfCommonStockRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations" name="RightOfUseAssetsObtainedInExchangeForLeaseObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_UnrealizedGainOnU.s.TreasuryBills" name="UnrealizedGainOnU.s.TreasuryBills" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DeemedDividendOfRatchetAdjustmentsToWarrants" name="DeemedDividendOfRatchetAdjustmentsToWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" name="DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock" name="InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureLeasesAbstract" name="DisclosureLeasesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DisclosureEmployeeBenefitPlanAbstract" name="DisclosureEmployeeBenefitPlanAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_EmployeeBenefitPlanTextBlock" name="EmployeeBenefitPlanTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_InvestmentsUSTreasuryBillsPolicyTextBlock" name="InvestmentsUSTreasuryBillsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock" name="ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_PrepaidAndOtherAssetsPolicyTextBlock" name="PrepaidAndOtherAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ReverseStockSpliteUpPolicyTextBlock" name="ReverseStockSpliteUpPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock" name="ScheduleOfUSTreasuryBillsHeldTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ScheduleofFutureAmortizationExpenseTableTextBlock" name="ScheduleofFutureAmortizationExpenseTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LesseeOperatingLeaseLiabilityTableTextBlock" name="LesseeOperatingLeaseLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases" name="ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" name="ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_WorkingCapital" name="WorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockholderEquities" name="StockholderEquities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AccumulatedDeficit" name="AccumulatedDeficit" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AmortizedCostBasis" name="AmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_GrossUnrealizedGain" name="GrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_GrossUnrealizedLoss" name="GrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_NumberOfStockPurchased" name="NumberOfStockPurchased" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CurrentPortionOfNotesPayable" name="CurrentPortionOfNotesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DebtFinancingCosts" name="DebtFinancingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AccretionOfLoanPremiums" name="AccretionOfLoanPremiums" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_NotesPayableNoncurrent" name="NotesPayableNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LongtermDebtFinancingCosts" name="LongtermDebtFinancingCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" name="LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LongTermAccretionOfLoanPremiums" name="LongTermAccretionOfLoanPremiums" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" name="LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AmortizationExpenseNextRollingTwoYears" name="AmortizationExpenseNextRollingTwoYears" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AmortizationExpenseTotal" name="AmortizationExpenseTotal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_FairValueOfEmbeddedConversionOption" name="FairValueOfEmbeddedConversionOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_UnearnedDiscount" name="UnearnedDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_DirectFinancingCost" name="DirectFinancingCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AccretionsOfLoanPremium" name="AccretionsOfLoanPremium" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AggregateIntrinsicValueGranted" name="AggregateIntrinsicValueGranted" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfCommonStockForCashShares" name="IssuanceOfCommonStockForCashShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_IssuanceOfCommonStockForCash" name="IssuanceOfCommonStockForCash" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CommissionsPercentage" name="CommissionsPercentage" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockExercised" name="StockExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_RsuGranted" name="RsuGranted" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharesIssuedOverVestingPeriod" name="SharesIssuedOverVestingPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_TotalCompensationCost" name="TotalCompensationCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_StockBasedCompensationRestrictedStockUnits" name="StockBasedCompensationRestrictedStockUnits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" name="CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_ExpirationsDates" name="ExpirationsDates" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_PurchaseOfCommonStockShares" name="PurchaseOfCommonStockShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="bivi_AgentFeesAndOfferingExpenses" name="AgentFeesAndOfferingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>bivi-20240630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://bioviepharma.com/role/Cover" xlink:href="bivi-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BalanceSheets" xlink:href="bivi-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="bivi-20240630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="bivi-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfCashFlows" xlink:href="bivi-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BackgroundInformation" xlink:href="bivi-20240630.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LiquidityAndGoingConcern" xlink:href="bivi-20240630.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPolicies" xlink:href="bivi-20240630.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssets" xlink:href="bivi-20240630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/RelatedPartyTransactions" xlink:href="bivi-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayable" xlink:href="bivi-20240630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurements" xlink:href="bivi-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactions" xlink:href="bivi-20240630.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/Leases" xlink:href="bivi-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/CommitmentsAndContingencies" xlink:href="bivi-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EmployeeBenefitPlan" xlink:href="bivi-20240630.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxes" xlink:href="bivi-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SubsequentEvents" xlink:href="bivi-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsTables" xlink:href="bivi-20240630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableTables" xlink:href="bivi-20240630.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsTables" xlink:href="bivi-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsTables" xlink:href="bivi-20240630.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesTables" xlink:href="bivi-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesTables" xlink:href="bivi-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="bivi-20240630.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetails" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetails1" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="bivi-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetails" xlink:href="bivi-20240630.xsd#NotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetails1" xlink:href="bivi-20240630.xsd#NotesPayableDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetailsNarrative" xlink:href="bivi-20240630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails1" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails2" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails1" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails2" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails3" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" xlink:href="bivi-20240630.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails" xlink:href="bivi-20240630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails1" xlink:href="bivi-20240630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails2" xlink:href="bivi-20240630.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetailsNarrative" xlink:href="bivi-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="bivi-20240630.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetails" xlink:href="bivi-20240630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetails1" xlink:href="bivi-20240630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="bivi-20240630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="bivi-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_InvestmentsInU.s.TreasuryBills" xlink:label="loc_biviInvestmentsInU.s.TreasuryBills" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_biviInvestmentsInU.s.TreasuryBills" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaapGoodwill" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantLiabilities" xlink:label="loc_biviWarrantLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_biviWarrantLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapEmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaapGainLossOnSaleOfDerivatives" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainLossOnSaleOfDerivatives" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaapInterestIncomeOther" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapProfitLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossAttributableToParent" xlink:label="loc_us-gaapIncomeLossAttributableToParent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossAttributableToParent" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DividendsSharebasedCompensationStock" xlink:label="loc_us-gaapDividendsSharebasedCompensationStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossAttributableToParent" xlink:to="loc_us-gaapDividendsSharebasedCompensationStock" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnrealizedGainOnInvestmentsForAvailableforsale" xlink:label="loc_biviUnrealizedGainOnInvestmentsForAvailableforsale" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_biviUnrealizedGainOnInvestmentsForAvailableforsale" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:label="loc_biviReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_biviReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaapProfitLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProfitLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationRestrictedStock" xlink:label="loc_biviStockBasedCompensationRestrictedStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_biviStockBasedCompensationRestrictedStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationExpenseStockIssued" xlink:label="loc_biviStockBasedCompensationExpenseStockIssued" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_biviStockBasedCompensationExpenseStockIssued" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionOfUnearnedLoanDiscount" xlink:label="loc_biviAccretionOfUnearnedLoanDiscount" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_biviAccretionOfUnearnedLoanDiscount" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionOfLoanPremium" xlink:label="loc_biviAccretionOfLoanPremium" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_biviAccretionOfLoanPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RealizedGainOnMaturityOfAvailableforSale" xlink:label="loc_biviRealizedGainOnMaturityOfAvailableforSale" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_biviRealizedGainOnMaturityOfAvailableforSale" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NoncashLeaseExpenseFromRightofuseAssets" xlink:label="loc_biviNoncashLeaseExpenseFromRightofuseAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_biviNoncashLeaseExpenseFromRightofuseAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:label="loc_us-gaapGainLossOnSaleOfLeasedAssetsNetOperatingLeases" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainLossOnSaleOfLeasedAssetsNetOperatingLeases" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaapDerivativeGainLossOnDerivativeNet" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDerivativeGainLossOnDerivativeNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromMaturityOfU.s.TreasuryBills" xlink:label="loc_biviProceedsFromMaturityOfU.s.TreasuryBills" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_biviProceedsFromMaturityOfU.s.TreasuryBills" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty" xlink:label="loc_biviNetProceedsFromIssuanceOfCommonStockRelatedParty" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_biviNetProceedsFromIssuanceOfCommonStockRelatedParty" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BackgroundInformation" xlink:title="995612 - Disclosure - Background Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LiquidityAndGoingConcern" xlink:title="995613 - Disclosure - Liquidity and Going Concern" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPolicies" xlink:title="995614 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:title="995615 - Disclosure - Investments in U.S. Treasury Bills available-for-sale" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssets" xlink:title="995616 - Disclosure - Intangible Assets" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/RelatedPartyTransactions" xlink:title="995617 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayable" xlink:title="995618 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurements" xlink:title="995619 - Disclosure - Fair Value Measurements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactions" xlink:title="995620 - Disclosure - Equity Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/Leases" xlink:title="995621 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/CommitmentsAndContingencies" xlink:title="995622 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EmployeeBenefitPlan" xlink:title="995623 - Disclosure - Employee Benefit Plan" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxes" xlink:title="995624 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SubsequentEvents" xlink:title="995625 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="995626 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesTables" xlink:title="995627 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:title="995628 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsTables" xlink:title="995629 - Disclosure - Intangible Assets (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableTables" xlink:title="995630 - Disclosure - Notes Payable (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsTables" xlink:title="995631 - Disclosure - Fair Value Measurements (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsTables" xlink:title="995632 - Disclosure - Equity Transactions (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesTables" xlink:title="995633 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesTables" xlink:title="995634 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="995635 - Disclosure - Liquidity and Going Concern (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" xlink:title="995636 - Disclosure - Significant Accounting Policies (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:title="995637 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:title="995638 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetails" xlink:title="995639 - Disclosure - Intangible Assets (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetails1" xlink:title="995640 - Disclosure - Intangible Assets (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" xlink:title="995641 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995642 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetails" xlink:title="995643 - Disclosure - Notes Payable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetails1" xlink:title="995644 - Disclosure - Notes Payable (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetailsNarrative" xlink:title="995645 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails" xlink:title="995646 - Disclosure - Fair Value Measurements (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails1" xlink:title="995647 - Disclosure - Fair Value Measurements (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails2" xlink:title="995648 - Disclosure - Fair Value Measurements (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="995649 - Disclosure - Fair Value Measurements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails" xlink:title="995650 - Disclosure - Equity Transactions (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails1" xlink:title="995651 - Disclosure - Equity Transactions (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails2" xlink:title="995652 - Disclosure - Equity Transactions (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails3" xlink:title="995653 - Disclosure - Equity Transactions (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" xlink:title="995654 - Disclosure - Equity Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails" xlink:title="995655 - Disclosure - Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails1" xlink:title="995656 - Disclosure - Leases (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails2" xlink:title="995657 - Disclosure - Leases (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetailsNarrative" xlink:title="995658 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="995659 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetails" xlink:title="995660 - Disclosure - Income Taxes (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsCapitalLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetails1" xlink:title="995661 - Disclosure - Income Taxes (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="995662 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="995663 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>bivi-20240630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.24a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://bioviepharma.com/role/Cover" xlink:href="bivi-20240630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BalanceSheets" xlink:href="bivi-20240630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BalanceSheetsParenthetical" xlink:href="bivi-20240630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="bivi-20240630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="bivi-20240630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/StatementsOfCashFlows" xlink:href="bivi-20240630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/BackgroundInformation" xlink:href="bivi-20240630.xsd#BackgroundInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LiquidityAndGoingConcern" xlink:href="bivi-20240630.xsd#LiquidityAndGoingConcern" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPolicies" xlink:href="bivi-20240630.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssets" xlink:href="bivi-20240630.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/RelatedPartyTransactions" xlink:href="bivi-20240630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayable" xlink:href="bivi-20240630.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurements" xlink:href="bivi-20240630.xsd#FairValueMeasurements" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactions" xlink:href="bivi-20240630.xsd#EquityTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/Leases" xlink:href="bivi-20240630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/CommitmentsAndContingencies" xlink:href="bivi-20240630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EmployeeBenefitPlan" xlink:href="bivi-20240630.xsd#EmployeeBenefitPlan" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxes" xlink:href="bivi-20240630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SubsequentEvents" xlink:href="bivi-20240630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesTables" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsTables" xlink:href="bivi-20240630.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableTables" xlink:href="bivi-20240630.xsd#NotesPayableTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsTables" xlink:href="bivi-20240630.xsd#FairValueMeasurementsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsTables" xlink:href="bivi-20240630.xsd#EquityTransactionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesTables" xlink:href="bivi-20240630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesTables" xlink:href="bivi-20240630.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:href="bivi-20240630.xsd#LiquidityAndGoingConcernDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" xlink:href="bivi-20240630.xsd#SignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:href="bivi-20240630.xsd#InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetails" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetails1" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" xlink:href="bivi-20240630.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="bivi-20240630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetails" xlink:href="bivi-20240630.xsd#NotesPayableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetails1" xlink:href="bivi-20240630.xsd#NotesPayableDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/NotesPayableDetailsNarrative" xlink:href="bivi-20240630.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails1" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetails2" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:href="bivi-20240630.xsd#FairValueMeasurementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails1" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails2" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetails3" xlink:href="bivi-20240630.xsd#EquityTransactionsDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" xlink:href="bivi-20240630.xsd#EquityTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails" xlink:href="bivi-20240630.xsd#LeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails1" xlink:href="bivi-20240630.xsd#LeasesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetails2" xlink:href="bivi-20240630.xsd#LeasesDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/LeasesDetailsNarrative" xlink:href="bivi-20240630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:href="bivi-20240630.xsd#EmployeeBenefitPlanDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetails" xlink:href="bivi-20240630.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetails1" xlink:href="bivi-20240630.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="bivi-20240630.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="bivi-20240630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosureWithAdditionalMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosureWithAdditionalMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpTable" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsToCompensation" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsToCompensation" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListsByExecutiveCategory" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListsByExecutiveCategory" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TabularListMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TabularListMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpMeasures" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpMeasures" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpExecutiveCategoriesOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpAdjustmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTypeOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ForgoneRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ForgoneRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/OutstandingRecoveries" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#OutstandingRecoveries" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardsCloseToMnpiDisc" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardsCloseToMnpiDisc" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsByInd" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangemenstByInd" xlink:type="simple" />
    <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/Defaults" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#Defaults" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Statements of Operations and Comprehensive Loss" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Statements of Changes in Stockholders&apos; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TreasuryStocksMember" xlink:label="loc_biviTreasuryStocksMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_biviTreasuryStocksMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueShareBasedCompensation_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits" xlink:label="loc_biviIssuanceOfCommonStockFromVestingOfRestrictedStockUnits_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfCommonStockFromVestingOfRestrictedStockUnits_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares" xlink:label="loc_biviIssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered" xlink:label="loc_biviStockbasedCompensationIssuanceOfCommonStockForServicesRendered_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviStockbasedCompensationIssuanceOfCommonStockForServicesRendered_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares" xlink:label="loc_biviStockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviStockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DeemedDividendForRatchetAdjustmentToWarrants" xlink:label="loc_biviDeemedDividendForRatchetAdjustmentToWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviDeemedDividendForRatchetAdjustmentToWarrants_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement" xlink:label="loc_biviRelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviRelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit" xlink:label="loc_biviIssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares" xlink:label="loc_biviIssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviIssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfOptions" xlink:label="loc_biviCashlessExerciseOfOptions_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfOptions_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfOptionsShares" xlink:label="loc_biviCashlessExerciseOfOptionsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfOptionsShares_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfWarrants" xlink:label="loc_biviCashlessExerciseOfWarrants_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrants_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CashlessExerciseOfWarrantsShares" xlink:label="loc_biviCashlessExerciseOfWarrantsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviCashlessExerciseOfWarrantsShares_70" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetCosts" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetCosts_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetCosts_70" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetCostsShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetCostsShares_70" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty_70" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares" xlink:label="loc_biviProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares_70" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnrealizedGainOnAvailableforsaleInvestments" xlink:label="loc_biviUnrealizedGainOnAvailableforsaleInvestments_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviUnrealizedGainOnAvailableforsaleInvestments_70" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/BackgroundInformation" xlink:title="995612 - Disclosure - Background Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LiquidityAndGoingConcern" xlink:title="995613 - Disclosure - Liquidity and Going Concern" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPolicies" xlink:title="995614 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale" xlink:title="995615 - Disclosure - Investments in U.S. Treasury Bills available-for-sale" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssets" xlink:title="995616 - Disclosure - Intangible Assets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/RelatedPartyTransactions" xlink:title="995617 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayable" xlink:title="995618 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurements" xlink:title="995619 - Disclosure - Fair Value Measurements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactions" xlink:title="995620 - Disclosure - Equity Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/Leases" xlink:title="995621 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/CommitmentsAndContingencies" xlink:title="995622 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EmployeeBenefitPlan" xlink:title="995623 - Disclosure - Employee Benefit Plan" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxes" xlink:title="995624 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SubsequentEvents" xlink:title="995625 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="995626 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesTables" xlink:title="995627 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables" xlink:title="995628 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsTables" xlink:title="995629 - Disclosure - Intangible Assets (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableTables" xlink:title="995630 - Disclosure - Notes Payable (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsTables" xlink:title="995631 - Disclosure - Fair Value Measurements (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsTables" xlink:title="995632 - Disclosure - Equity Transactions (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesTables" xlink:title="995633 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesTables" xlink:title="995634 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative" xlink:title="995635 - Disclosure - Liquidity and Going Concern (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SignificantAccountingPoliciesDetails" xlink:title="995636 - Disclosure - Significant Accounting Policies (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NotespayableConversionOptionMember" xlink:label="loc_biviNotespayableConversionOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_biviNotespayableConversionOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_110" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails" xlink:title="995637 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems" xlink:label="loc_us-gaapScheduleOfInvestmentsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable" xlink:label="loc_us-gaapScheduleOfInvestmentsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapScheduleOfInvestmentsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfInvestmentsTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="loc_us-gaapUSTreasuryBillSecuritiesMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapUSTreasuryBillSecuritiesMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizedCostBasis" xlink:label="loc_biviAmortizedCostBasis_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_biviAmortizedCostBasis_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_GrossUnrealizedGain" xlink:label="loc_biviGrossUnrealizedGain_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_biviGrossUnrealizedGain_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_GrossUnrealizedLoss" xlink:label="loc_biviGrossUnrealizedLoss_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_biviGrossUnrealizedLoss_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentOwnedAtFairValue" xlink:label="loc_us-gaapInvestmentOwnedAtFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapInvestmentOwnedAtFairValue_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScheduleOfInvestmentsLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative" xlink:title="995638 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetails" xlink:title="995639 - Disclosure - Intangible Assets (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetails1" xlink:title="995640 - Disclosure - Intangible Assets (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative" xlink:title="995641 - Disclosure - Intangible Assets (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="995642 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AcuitasGroupHoldingsLLCMember" xlink:label="loc_biviAcuitasGroupHoldingsLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_biviAcuitasGroupHoldingsLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantsMember" xlink:label="loc_biviWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="loc_us-gaapDividends_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapDividends_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharePrice_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetails" xlink:title="995643 - Disclosure - Notes Payable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetails1" xlink:title="995644 - Disclosure - Notes Payable (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaapReceivableTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="loc_us-gaapReceivableTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableTypeDomain" xlink:label="loc_us-gaapReceivableTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="loc_us-gaapReceivableTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedDiscountMember" xlink:label="loc_biviUnearnedDiscountMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_biviUnearnedDiscountMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceReceivablesMember" xlink:label="loc_us-gaapFinanceReceivablesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_us-gaapFinanceReceivablesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_LoanAccretionPremiumMember" xlink:label="loc_biviLoanAccretionPremiumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapReceivableTypeDomain" xlink:to="loc_biviLoanAccretionPremiumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizationExpenseNextRollingTwoYears" xlink:label="loc_biviAmortizationExpenseNextRollingTwoYears_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_biviAmortizationExpenseNextRollingTwoYears_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AmortizationExpenseTotal" xlink:label="loc_biviAmortizationExpenseTotal_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccountsNotesAndLoansReceivableLineItems" xlink:to="loc_biviAmortizationExpenseTotal_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/NotesPayableDetailsNarrative" xlink:title="995645 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:label="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateDuringPeriod_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FairValueOfEmbeddedConversionOption" xlink:label="loc_biviFairValueOfEmbeddedConversionOption_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_biviFairValueOfEmbeddedConversionOption_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_UnearnedDiscount" xlink:label="loc_biviUnearnedDiscount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_biviUnearnedDiscount_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DirectFinancingCost" xlink:label="loc_biviDirectFinancingCost_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_biviDirectFinancingCost_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="loc_us-gaapDebtInstrumentUnamortizedPremium_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedPremium_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentInterest_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentInterest_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AccretionsOfLoanPremium" xlink:label="loc_biviAccretionsOfLoanPremium_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_biviAccretionsOfLoanPremium_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaapNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapNotesPayable_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfNotesPayable_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails" xlink:title="995646 - Disclosure - Fair Value Measurements (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_250" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails1" xlink:title="995647 - Disclosure - Fair Value Measurements (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaapDerivativeLiabilities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapDerivativeLiabilities_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetails2" xlink:title="995648 - Disclosure - Fair Value Measurements (Details 2)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashMember" xlink:label="loc_us-gaapCashMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapCashMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaapInvestmentTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapInvestmentTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaapInvestmentTypeCategorizationMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapInvestmentTypeAxis" xlink:to="loc_us-gaapInvestmentTypeCategorizationMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USTreasuryBillSecuritiesMember" xlink:label="loc_us-gaapUSTreasuryBillSecuritiesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_us-gaapUSTreasuryBillSecuritiesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_USTreasuryBillSecurities1Member" xlink:label="loc_biviUSTreasuryBillSecurities1Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapInvestmentTypeCategorizationMember" xlink:to="loc_biviUSTreasuryBillSecurities1Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_290" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative" xlink:title="995649 - Disclosure - Fair Value Measurements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityWarrantsMember" xlink:label="loc_biviDerivativeLiabilityWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionOnConvertibleDebentureMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_DerivativeLiabilityConversionOptionMember" xlink:label="loc_biviDerivativeLiabilityConversionOptionMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_biviDerivativeLiabilityConversionOptionMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapSharePrice_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails" xlink:title="995650 - Disclosure - Equity Transactions (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockOptionsMember" xlink:label="loc_biviStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AggregateIntrinsicValueGranted" xlink:label="loc_biviAggregateIntrinsicValueGranted_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviAggregateIntrinsicValueGranted_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_60" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails1" xlink:title="995651 - Disclosure - Equity Transactions (Details 1)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsLineItems" xlink:label="loc_us-gaapOffsettingAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OffsettingAssetsTable" xlink:label="loc_us-gaapOffsettingAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapOffsettingAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOffsettingAssetsTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockOptionsMember" xlink:label="loc_biviStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOffsettingAssetsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails2" xlink:title="995652 - Disclosure - Equity Transactions (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetails3" xlink:title="995653 - Disclosure - Equity Transactions (Details 3)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_60" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EquityTransactionsDetailsNarrative" xlink:title="995654 - Disclosure - Equity Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaapCommonClassAMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonClassAMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SalesAgreementMember" xlink:label="loc_biviSalesAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_biviSalesAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PrefundedWarrantsMember" xlink:label="loc_biviPrefundedWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviPrefundedWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommonWarrantMember" xlink:label="loc_biviCommonWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviCommonWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantsMember" xlink:label="loc_biviWarrantsMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviWarrantsMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_VendorMember" xlink:label="loc_biviVendorMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviVendorMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PresidentAndCEOMember" xlink:label="loc_biviPresidentAndCEOMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviPresidentAndCEOMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FourDirectorsMember" xlink:label="loc_biviFourDirectorsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviFourDirectorsMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ThreeDirectorsMember" xlink:label="loc_biviThreeDirectorsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviThreeDirectorsMember_180" xlink:type="arc" order="183" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_FourDirectorMember" xlink:label="loc_biviFourDirectorMember_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviFourDirectorMember_200" xlink:type="arc" order="203" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TwoDirectorsMember" xlink:label="loc_biviTwoDirectorsMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviTwoDirectorsMember_210" xlink:type="arc" order="213" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_EmployeesMember" xlink:label="loc_biviEmployeesMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviEmployeesMember_240" xlink:type="arc" order="242" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CertainEmployeesMember" xlink:label="loc_biviCertainEmployeesMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviCertainEmployeesMember_350" xlink:type="arc" order="352" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_NewEmployeeMember" xlink:label="loc_biviNewEmployeeMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_biviNewEmployeeMember_360" xlink:type="arc" order="362" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockOptionsMember" xlink:label="loc_biviStockOptionsMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_biviStockOptionsMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_N2019OmnibusIncentiveEquityPlanMember" xlink:label="loc_biviN2019OmnibusIncentiveEquityPlanMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_biviN2019OmnibusIncentiveEquityPlanMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_360" xlink:type="arc" order="363" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_370" xlink:type="arc" order="373" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockForCashShares" xlink:label="loc_biviIssuanceOfCommonStockForCashShares_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviIssuanceOfCommonStockForCashShares_450" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_IssuanceOfCommonStockForCash" xlink:label="loc_biviIssuanceOfCommonStockForCash_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviIssuanceOfCommonStockForCash_450" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommissionsPercentage" xlink:label="loc_biviCommissionsPercentage_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviCommissionsPercentage_450" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_450" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:label="loc_us-gaapPartnersCapitalAccountUnitsSoldInPublicOffering_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapPartnersCapitalAccountUnitsSoldInPublicOffering_450" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_450" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="loc_us-gaapStockRepurchasedDuringPeriodShares_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockRepurchasedDuringPeriodShares_450" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharePrice_450" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockExercised" xlink:label="loc_biviStockExercised_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviStockExercised_450" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_450" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensation_450" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_RsuGranted" xlink:label="loc_biviRsuGranted_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviRsuGranted_450" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1" xlink:label="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_450" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharesIssuedOverVestingPeriod" xlink:label="loc_biviSharesIssuedOverVestingPeriod_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviSharesIssuedOverVestingPeriod_450" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings" xlink:label="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapRestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_450" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_TotalCompensationCost" xlink:label="loc_biviTotalCompensationCost_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviTotalCompensationCost_450" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_StockBasedCompensationRestrictedStockUnits" xlink:label="loc_biviStockBasedCompensationRestrictedStockUnits_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviStockBasedCompensationRestrictedStockUnits_450" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_450" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_450" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1" xlink:label="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_450" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_biviSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_450" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails" xlink:title="995655 - Disclosure - Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails1" xlink:title="995656 - Disclosure - Leases (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetails2" xlink:title="995657 - Disclosure - Leases (Details 2)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/LeasesDetailsNarrative" xlink:title="995658 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative" xlink:title="995659 - Disclosure - Employee Benefit Plan (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetails" xlink:title="995660 - Disclosure - Income Taxes (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetails1" xlink:title="995661 - Disclosure - Income Taxes (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="995662 - Disclosure - Income Taxes (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bioviepharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="995663 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PrefundedWarrantsMember" xlink:label="loc_biviPrefundedWarrantsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_biviPrefundedWarrantsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommonWarrantsMember" xlink:label="loc_biviCommonWarrantsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_biviCommonWarrantsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PlacementAgentsWarrantsMember" xlink:label="loc_biviPlacementAgentsWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviPlacementAgentsWarrantsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PurchaseOfCommonStockShares" xlink:label="loc_biviPurchaseOfCommonStockShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviPurchaseOfCommonStockShares_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceInitialPublicOffering_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_AgentFeesAndOfferingExpenses" xlink:label="loc_biviAgentFeesAndOfferingExpenses_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_biviAgentFeesAndOfferingExpenses_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaapTemporaryEquitySharesIssued_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapTemporaryEquitySharesIssued_60" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpExecutiveCategoriesOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" />
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_WarrantsMember" xlink:label="loc_biviWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviWarrantsMember" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PrefundedWarrantsMember" xlink:label="loc_biviPrefundedWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviPrefundedWarrantsMember" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_CommonWarrantMember" xlink:label="loc_biviCommonWarrantMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviCommonWarrantMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="bivi-20240630.xsd#bivi_PlacementAgentsWarrantsMember" xlink:label="loc_biviPlacementAgentsWarrantsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_biviPlacementAgentsWarrantsMember" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (0 I0# 2(  A$! Q$!_\0
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MCR[OX<>U ';Z=JNJW6I:6S75HMK-9B66%N)=V.3C^M:J>)M%::"W34H#+/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY>&2+'=?6NJ!R.GYTHSGD@CTH <G2G5$", #GWJ1>E "T444 %%%% !1110
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M?:N(TS5->U7P[8W=O<RRN;JXWN@XV8&T4 >I*=O6CY@W<]_I61H@OD\,V_\
M:#%K[R2SL?[V#BN6\'>-+9],A@U>_#7TURZ#/;!P 30!Z#FG@Y%95GKEC>O=
M)!.C/:L1.!_#@9J?3=3M=6M!=6<GF0L2 XZ'% %^BFCI2@YH 6BBB@ HHHH
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M%O$8;:*+.=BJN?7 %2@<4 /HH%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 QC@9->
M<7EX=(^*EQ?W%K<FV:SV"2.,MS7I!/N*C8#/;/\ 2@#SXL=5^)>D:E%9SFSD
ML9$=GC(V^F?K65'HVHKKH\)M:3?V2MY]L\_'R;"<[<UZFLB[M@9-X&=@Z@>E
M.STR!TP3Z4 >8W%D+75/$%KJ4MW#'>N#%Y$'F"2,C  /J*GAT.-?&>@Q&SFG
MLH+1E62=<@<\9KT-S%&R^8Z*"2!NQU]JD..3T/<T <9\1K.6;P<8+:W9W$\>
MV.%>V?2L;Q):_8M535--DN(]7^S)&;8P;TF&!Q[5Z9]X8QD>_I2D#>IP..Q'
M- %#1WGETFUDNX5@G:,&2(#[I^E<_P#$6QO+_0(/LT#SI#<)+/ AY= >:ZWS
M$9F7>A<?> /('O2YQ@D^U '#ZI?V6J>%-2ATS39TE^S $B#;GD?**H11MI/C
M&+4M3LY9+*73HXXY5C+B)L<@CL:]% "9& ,GH!2ODKC (]Q0!X_>6CIH6KW;
M6;VL-WJ*R:?;MP2P[[?2M&!-(73_ !&FI32IJMW;;KB-T\O:@'&WTKT#6-&L
MM<LA;WT9958.A4X*'U!K/M/!VCP6]S%+&]T;E#%))<-N9E/;/M0!Q&@_9_M7
MA^XU]I;>2"+R;!&@VJS%<#)'7MS26^F0'3;G1M9DU".7[6SM#%!G?ELJP;TK
MM++P9I-E<QS2/<3_ &=M\27$I98C["NB4ABKHRLN.",<CZ^E 'G-G$NB^.M<
M?5+":Y%W"@LYC%O#*,@K[9.*V?AK;SVWA$QW%L\#-=RL(W&#M)&*Z[C /''>
MG*1R>F* (Y5#02A@2&0\8]J\9MK61_!']CKI-R=6EU NA,6,#=][=Z=:]L)!
M& >33-O(XP.P H \M\56M]HFMQ1::%,FNVZVLZCAE8=7_*O1]&TR'1])M=/@
M 6.! O'<]ZAGT2UGUF+5G1FN8EVQDG@9ZUIJ3USSWH > <^U.I 2>U+0 444
M4 %%%% !1110 444A.* %HINZC(H 0CGK3 ..M/)!J*26.)<R2H@']XXH 48
M&1D8IRD[>0#61=>)]%M%8RW\0QU"G)K%G^).D1']W%-(?4# Q0!V/4D8/N:0
MCH.N.]>?S?$X XBTMG7U9JK-\2[]O]7IT:CW- 'I0';'UH ]1UKS#_A8^KGD
MV$-*GQ'U88W6$/YT >FD8&.V.*"./E&:\Y7XFW:@>9IBGUPU6H/B=;'_ (^M
M.FC'8H<T =X1@]<TN,J.E<I!\0="F S+)"2<?.M;5IKNEWGRV]] Y'0;L&@#
M1(Q@T;>_;K2HRLF001ZCFER* $ W4\#%-##I2AA0 ZBBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH A^O-<IJOBZ>#6I-*TC39+^Y@7=<$'"H/\:ZPCE<]O2N(NM"U
M[1_$U_JWA]+6XCOT DBN#M\MQ_%GO0!':W]I_P )Y?W1MKA+^/2TGD#O\@&,
MXQZT^V^($EWI,VK+I,ZZ?%&6:9N,XZXIT/AK5CXEU+4[IX#]LTU;8A!P)-I_
M3I1'X9U)?AL= )B^VE"!@_* 3WH P?%.OS:KI>D:C]AGMHOMT;0J#@S#'2NH
MT[Q?YVKW=AJ=D]C+!$;@;CD%.]0ZQX<U'4-(\/6<7E![&2-ISGIM&#C]:EU/
MPS/J7BV6^<J+*6R:W8@\Y- %6V\>_:)[>6XTV2WTNZE\F"[8]6SQD>E6!XQE
MNM>N-.TVP^TQ6KA)WW@-SZ#N*QU\)^(KJUL="O6M4TJSF$HN$8[W .0/:K&O
M>&=8U?4PL5I9P()5:._B8K(J#LP[T 0S:[I/A[Q%X@OWAN/-@B3S,ME26/
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M7-".<[MVW'Y5-I7BZ[O-<BTJ[TIH9Y(A<!U8,HC/0G\*Y_Q#I=WHUKXPU.=
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MA/7+<5'%.DORD@-CI4I Z'CZ4 0BVB'.P''<U)M /'MT%.QT[^U&,<XQ0 W
MSWQFE90<T=0*,D\"@ QS2X&1QS1T'2@'TH :0,#C\J7 [BG&C *]1B@"-D5C
MR ,]\4SR$5MR$JW8@XJ4\#/7 HYY!';- %BUU75M/P;?4)!_LL<BM^Q^(FI0
M,!>P+/$/O%.M<SQC/I[4$9''I0!ZIIOC;1K]1F;R'/\ #)6_'(LB;HV5P>ZG
M->#M$K?PYJ6WNKVQD$UI=21G(.PL<4 >\YY-*#FO-M)^)+1E(]7MQCH9X_\
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M<#W Y+8(W'MD#K]: .._LJWU;XG_ &/53]K":3&7PYV2M_>Z\?6L:RT>:_\
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M;_6@#WI&# $'((R#V-/^HR*\W\$>*6@E&E:G-N!'[B5O_037HN<#/!.,X]J
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M35_P9X2^R(NI:E&&N6_U41'"#_&N[ZCI^E $5O!';PK%#&L<:]$08 JQBF\
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MH*1R']_;'8>>H]:ZD-GZT /HH%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4449Q0 TYI-P .3BE-8_B#
M6K?0-,EO[DCY!A$[NW8?G0!6\4>*;/PW9;Y65KAQ^ZBSU/J:^=_$OC'6_$M^
M[0QR3#>0"%)51Z"N@U47GB5+B]OI9%,_R1C/W>>U:&EV,>EVJ0P)@CDX'4^I
MH \N32+YY'DFM;EG/))0\_2MWPOI5K-XBMTU53'!$IF\IN"S#D*1^%=_+<W
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MCZ4 6A2T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ IK=*=36QCF@"-FPI9L;1R2>PKQ+Q=XAB\2>(1$
M\Z164#;54M]XYZXKT[QGJ?\ 9GABZ</B21?+3MU[UX1X<L]&\6:XNF/(]MJ4
M1W)*>DN.2!^5 '4/L=U(7$,7"#N>.34\5S' Q8C)QQGTJ&[B>RN);2<8EAP,
M5G2S;LX.1ZT :%WJ22X!3YAZ>E8-S*'W;<KELCGO0\V=N <]ZSYI@[$8X;G)
M[4 =C<7T'BW0()9)HX=9T\>41(<><GM7'S179R/LDK8XRJY'X&MWPWX*;Q1I
M4U[<S?9;593B0G!:,#)(/TK6;XH>'O#\B:7IVFR7=K;*%$IP=QZ$T <#+!=X
M(^R7''8(375_#G3X?^$G6ZOR!-;H7CMB/F)'0FM5OC/ITK970V '(( K6\-)
MX=\3ZC_PD&DJ\-ZBLEQ%C[Q- 'D/BW6)_$7BZ\O9V^XYCB0]%4<56@GAA7(7
M/;&.]1:S UGXAU&!QAHIV_4U5P,?>]Z +,LPD;..#VSQ44,SVUS#<QDK+%('
M5AUX/2F*.0>/I4D4+S7"0QC,CN%4>I)XH ]4\576FW,=C=2SI;7L\0E"XZFM
MOPWK7]J6!C<J+F(?-]*Y?QGJF@Z#J5A;36/]HZK:VJQNI.(XSC^=9'ACQ*TV
MK?:3$L)+[9(TZ;2>* /8=-M1=W84 ^7'\W-=63\V%P "*R]$A$=F9L$F0Y'T
MK37@ \<'- &5K.K+IMMLBP]Q(,8]JXO.X[\?,?O9JQJ<PNM6NI-Q.U\+[57'
M3&>M #LYR<8H"YIHZ^HIX)Z8XH 7;ZFGH!R3T[>]- [>IK-UK7;71(-\F&G;
M[L6>1[T 7-2U.VT:R:YNCD _(@^\U>=ZUKL^L2KYI*P?PPCH/<UFW^K7FJ7;
M7$\A_P!E3_#5/S05&WCGGW- %EG  &/;I4$C*2>F*89.K$G!J+?NS@\T *S;
M>3^=0OE\MLSBD9P,Y/\ ]>F&9U3 ^Z>E  PD=2W1>V:CE4QL """*53++^[0
MY IA4%3N;D<8H &B<1[\@"FL\:PD,#NI2S>2!N_"HVP_  &!S0 ^"-KIF0/M
M &2"*UO"5LEUXJTZ&7/EF;G)XXK'.X .1M[8!ZUT_P /+=)_&5BC_-C+*/0T
M >V>-M4CT;P7*[@J7C*1KW)/%?-<(1_OD@D'&><5[A\:[M(?#UI:_P#+229=
MN.P'6O$E$C6V1MV)R?\ :H 8&+8 7)0\D"GI)\V\@L!ZTZ-9EB>6- $/6G"V
M LI)_, *_P - $1<DF1?E]LT;OFPQ<$_W13"H"G>IW=14Z[X"LQPP88 H 8"
M!(VUB$'?%.@20PR%#\G<FFY94*,PZY--_>QQ9S\K<B@!%8A.>@/44]?]:IWC
MGOCI3,*FS:P.>U6K&SDO;Q;:-D_>G)/H* .K\)872[E1M;$_WAWXK>W=""?Q
MJCIUG%IUH+:#[HZ^YJP67.,\T 2E^>3Q32_R]<<5"7_+UII<>M $WF=ST--,
MC'CL:A,F<TPR$8QUH F8AE*X/0CZUZS\/;W[5X<6!F)>U;RVS^E>6PPM''DG
MG&:['X;W)AUJ_LR?]:@D ]Q0!ZCFBF9Z4\'- !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UC@4ZFM0!Y+\
M8M6,-O%9*1\D9D;/3/:O"M-GN-.GM[ZV<I<POYB,.N>N/I7I?Q?NGEUR\7)P
MN$%><I]W/&>,#N: /9Y[U/&/A:VU^V"?VC;CRKN->IQ_%7(37 QUP0><\5-X
M$TC5;[P_KDNF AI2L<:$X!/<UT2Z9X/TFWBM_$6KI)J &9O*;(4GMQ0!Q$UT
MH&0V&]Z32]+N?$&IQZ=:C"N<R2#H$'6N]>T^&3JI_M/&?5C1:>%IX/$-EK'A
MVYAGT;S"A6-OF"'J3^M !\3O$=OX9\.VGA71QLFECVL0/NQ8P?Q->1V5M%&@
M#GY>_')KIOBQ%/!\1+B:4'R)8=T+ ?PC'2N0\UMO4CZT 79EA!RA)P..U=#\
M/?$2>&_%,<K$_9KD>3,.V>QKDLD@Y!.33CE< <$,""/6@#U7XD>!Y=3U,:UH
M:+*\JKYUN"%W=]PSUKR^:RN[21H;BTGA93A@\9X->R:SI6JZMX=T1[>_6Q6W
MB#37+-@Q\5=MO&/A1%CAU+58+V:)0KS-']\^OUH \/MK2ZN9%2VM9WD/'RH>
M?I7<Z/X5?PO:OXF\2*;=;,;[*V8@L\N/ER/K7>3>+O#=T_V?1=1L[>[?_5NZ
M8!/I7GWBK2_$">%)Y-8>29Q>>826RI3L1[4 <!<7%S?W4U[=MON9V+RLW<GT
MJQI4IM[\C)VR*1QUS5;N3N)&.*<GRW$,A/W6YH ^K?#UTMUX?L)1T\I0?KBK
ME_=1Z?92SNP'8 US/P]N#/X7B4G_ %;E:N>+RQM+<$9C+X/U[4 <ODO(SGJY
M+&E.*:@.[G[WM3CD>]  ,GD"G 9)QU]!2 ' QT[^U<;XK\9):;]/TLDS;?GE
MSD"@#4\1^++;0X3! RS7S<*@Y"^YKS6>ZGNYVN+J0S3-R6/\/T]JH[VD<R2'
M+-R7;DM3PQ\IG,F#G&WVH G$F29 >3USTI&E P5;KU&*KDK@!6('I3I)$*A1
MG<* 'F3)/M3=XPQP01Z5#OZ$'!IWFM&,Y!W<'VH 7"B,-G)[9IKR%MN[&!Z5
M&.F2.:,MT( STH E#![C]SE>.:BD 7*E?G!]:;C.=K8QUI\7EK(3+TQU- #<
M$!#@$MP/:DP0C(05D[TY%\R<>0<%3D5()(U,OV@9D/>@",QMY08X(STS79_"
MR.)O'UCLR66-B1Z5QRVY-LLP8!=W2NX^$**WC^%TZ_9V)H U?C1=NWBFTM8U
M#)#%N8'N37EP23R';.(P<D5Z#\9"P^("JK[081NKSR4!)#&)<J>30!*LTX0Q
M1GY6["H_+(+1N67:1CGK1N"+&Z.?,^M/57N;@;O]9@-G/8?_ *Z $9GE)9W^
MZ,!<4*%E<*[E .F::<13EC\Q!J0L)K@,^U5Q0 ((O+EW(SMG[WM2JK2P@C&Q
M> I-,#21B1$.Y?3%"1M(1&GWCZ] : $C#2.GEQ[B6 55ZG/2O5K#X=W.A>#S
MK%['MU"1MQB4Y$:FCX,^$8+^[O-<OXA(MM((8 1P6')/YU[+K5LMYHMW ZGF
M,G% 'AWEMM!&#^-1LQ#8(('N*LVR[593V)_#FIC@YW?,N>_6@#++YSTQ32^.
M_%7I+.-\E!M-4Y;66/G&X>W2@",MR!QSTJ]:6P!$KKSC@9J&SM29 [C!'K6A
MG.?RH  %P.HR<5H^&+G['XML92VT.WEM[YK/&!QZU&LA@OK68<>5,I_6@#WH
M<,,5(.E0QNKQQN#PR@Y_"I^U !13-U+NSTH =13=W6C=QUH =12 YI3TH **
M9NQUHW9- #Z*!R** "BD)Q2;Q^- #J*9O/<4N^@!U% Z44 %%%% !1110 44
M44 %%%% !1110 4G>EIIH ^;?BCN;Q!?LQ(42C.#7'V5C=:E,EO96\EQ,V!^
MZ0DJ#W)Z5Z5\0[N#1/&%S>7MB+NV)4F,CK[U2;XB&[^S6/A?3(=.@WKYFU0)
M)#GH#Z4 =5XDF3X<_#2.QL90NI3$+D'#AB.3BO&+>P,[N\K[BQ),CG);OFNN
M^+'VO_A,X7N0P1K53%N/3N1]:XU;D[<#C_&@"2:QB3&T(?K6SX1\57WA75(C
M%+OTZ5@DT+' ()P<?A7/EF8@YYILJ!H7W+GCIZT ?0/Q*\+P>+?#HN;0@7EH
MIF@(Y\Q2 =O%?/9)CD,<T1BE4E61@05^N:]XU,:Q_P ('IHTH2/J*HNU%XP3
MMR?<8J[#X=BN+.!O%=KILFKD_O9$PN4[9]Z /GS='U+)@=BW%=AX!\--KVMQ
MS3K*NG6QWO(8SM9L_=STQ[UZS-X9\+M<>7;V%D[$#@$'FLO3UU^'5M:MM1MU
MM[&WLB+-(DQ&Q[-]: ./^*?B7[=>KH-D?W$&#*T3X#GT-<1#IL)0 X'IWJJ9
M#Y\TC$F1W.['<YI_G$!0 ?K0 3VL:!E4+G/!QTKUCX<ZI;^)?#M[X8U61'F2
M)DB:5N77&.I[]*\E)9EP<]>M;W@M7_X3?2BO4R@$=PO>@#'OM*N-&U&73[L?
MO86V@L-H([$>M5V& G0C<.@KT_7KRVO/%ES;^([2/^R(Y,+<L0LJKVQZU0U+
M3_AP(B=,U*X:XZHA8X)].E 'H?PV)_X1X@_\],G\JZG788Y]'E\P_<^=:YSX
M>0F/PS&QXWN6^HKJ[ZW-UIEQ".I3(H X!%_=*V[FAF4+N9MJCJ[' %0W-S!8
M0--=2B-8P=Q/?VQ7F7B7Q;-KLGD6P:"Q4X"YP7- &QXN\6Y;^S])GQ%C,TP.
M2WL*X665)"$PR@=<]3^- 2)4;JO8?6JZN3&021SUH G!(D )#*#Q]*5F7<[[
M<J>G%1QJTN4 &$&=V<$TGG2+'M'(]?2@"0\!6*?*?2F,5\W* _C0P"PJ5;<>
MN*)),HFQ &[B@ W,[;N,#DCUI5E(?<(^O #4QB#%\JL-K8W&G,DK0K,R$IS@
MC\?_ *U #2"_R[=K9Z"FE6#C=GY>U2X(B7*D,>0U(B22AR""0>3ZT ,P'?@[
M4/7-/,7(2/#J.<TW.YAN4;3^E.;"2E8F.T\4 -1I<N\9VGOQ4D>PR'SV))YR
M!398-CJBG/<FFA7.6DQA>.!0 !!YQ8;O)4^M=W\(I(H_B'"B$",Q, <]3Z5P
MF]Q%M481SS73_#YV@\=:4/++;9#]WT(H ZGXUVR+XKT^5L#SX]I)%>8QE(VE
M4KOZJK>E>N?'B'9)IEWU&2N#VKR%H?*CC(DSN["@!$A=H]X*A5^]D=:4,\C*
M4 # 8X]*:W  5FPWI3B!&5*.02<?6@!8S&K*[\\\CUI9VB>8>6C>7_$.XIH4
MQ3@$!F7GGO3FED<M+'A')V!?:@!!(L,SF')3_:IT,<TQ6"""5[B<A8MJYZU-
M86=Q?7$=G9VQN9YVQ&BC)'KFO=OAU\,F\.S)JFKS+/?JN(HA]V$'^M '5>"O
M#X\,^$[#3"2TH3S)F]7;DUT)&Y2K#[PP:=CGO@GF@<8H \+O(1;:Q>PX("3'
M IH')/>M#Q/%Y7BV_7/5@U9_8'WH 0GIG)H4XR>W2C/2C&* '')[_7VI!R#S
M2YY.>W?UIN?8T *QJ"YX /N"/PJ;CK@TR8 JPQU'Y?YYH ]NTF03:/9.#PT2
MG]*OYXK#\*L7\,6!(Y\O%:[.$4LY&S!W'T'>@"E+K6GP:C%I\U]$EW,-T<+M
MAF'L*O@C.*\'O-6TW6!K?B"XN0-62Z!T]=IX2-N #COG]*[BY\0:GKUYH>FZ
M3>K:"^M/M,MQMR<C@@4 =Y)/%"I>61(U'!WG%59]5LK34+:PFGVW-SDQ1@??
MQ7 ^.].U6T\(6D%YJYN)!=(H;9C<">^.]6VBU;2_%NEZ7)JKW,5W;R;"Z8>(
M@<8/XT >AAN]!.>]>8GQ;JH\*&R\Q6U_[;]B[Y//W\=^*L>*]4U'1D\Z+Q I
MEM(TS:*F?,;N6/:@#OY)8Q(J&5 [?<4G!/T%58=8L9M6ETQ+C-Y$H=XRO('\
MJ\]U*&^U3Q[HKIJ,D,ES9^8I1<^42.<#TI\>MZKHFJ^)(I[M;V2RM5:%W4!@
M6./F..: /4=WUHW5YLU[XA\-RZ/J%YJ8OK;4)4CF@9-NS=T*XZU"M]XCU$^(
MYH-7\F#2Y&:!"GS-@9PWM0!Z<6]Q3&&1SGU'%9%OJKMX535I4#2?91*ZKT)Q
MVKAFU'Q.WA=_&,>J1E(_WGV+'R&,'!!/KB@#O[K6]-L+N.TN[Z*.YD^Y""2Q
M]R.WXUHJVX DY!'!%>6Z7:W&H_$RXO8]0>)I+2*Y.Y0<(PX0 BO400%&6))[
MGO0!,.!2TB]*6@ HHHH **** "BBB@ HHHH **** "FM[TZD89% 'BWQKT_<
MJ787<LD6,YZ8KQBWDD0Q2P2,DT9S&X_A-?4OCS2TU7PI=*4R\(\Q>!T[BOEY
MX'M+Y[9BP&25..@H ]78?\+'^&KW#;3KFE#[W=U]_P!:\G4ED! '4@\8Y'\J
MZ;P7JL^@:M-JD".Z1QYDA.=LF>,$=Z]!7X=:-XOL&U:Q@NM%N;CYS&_*Y]0/
M>@#QU4)^9?F'?%:_AC1)M?\ $EEI\()"OYDI(X51S7IUK\%M/MUC;4-5GED_
MNI\HI-!FT3PWXN7PIIUO<)--(5EO+CJP'.%(H WO'>NQ^$=!:[M'(GE7R;50
M><XQGZ5X0&U'4R\UW?7#RLQ+.9&Q]*Z#XGR7I\>7$5]N$5MC[*A/RX[L!Z]3
M_P "KF/M#*H53@$9.3CF@"7_ $FPD\ZVO9HY000PD)/'I7J'P]\<W6NWZ:#K
M+DRE,02\_/ZJ:\D>1VSNYJUIEP]GJUE=1LP>*4,&!/3/:@#;\>^''\-^*YD!
M M;HF6(XX!]*YL#YB,'\NM>V^,-1\/W:V6F>)(WQ=()()8OO1OC[P]JR;?X.
M6]UAHM?D,)7*[U&<=OZ4 >68/)YP/7C%>A_"[0BEU=>*+Y/+L+"%F0M_$0,Y
M]Q5V3X366ESFYO\ 4WN;2#YGCAC7<X]*P_%?C%+WPZ=,TFS;3M-$OE!#PSIZ
M&@#D=?UNX\2:U<ZE-N:.1CY49(VA>W%0:;;K)?JQ  C&XX JN. ,8'/ ]!76
M^"]$;4-2BB*9\Q@S?04 >[>%[8VN@6<+ AO+!.<5OA@,%NRY/N*JVD/RA%X5
M0%P?8=JO^6A1D8?>4J?I0!\L>*?$=SK&NWRR$"TCE=8XA]<9/O6*48()01CC
M@GI5G5U%GXBU>V@*M;K=NL;8SQG-4R0$P 30 Q_W\A!8<<\&G0R1*C)*N7]:
M9(PD5 B;<=?>E'EK"Q(99 >#0 1Q22,RQ @]*$9U1D6/=GKQ2P"5O,99=K!,
MELXI$/EQ'RI2'R<Y[_YYH %C C,F\;U/W:#M6-C-'\[?=YQ2+%N196X1C\QS
M@TJJ3<D0.Q"]"PS0 +(\L:P,0B>M2F69PUK$6(!R,5%)EWWSG<<\\8ILL@$I
M:'<@^Z #0 KRR,P23.!Q4\R1)/''%(0K#DU6"NOL&/+,:5XU214$@/O0!+=0
M^0ZHK*Z[<GFH0,QA I!/.:5=JR/A-ZXZTZ)8L,969>/EH (PC,$+LF.I-!",
MS([-L4\$=Z"S_9E!12C'&>XIK%58QJ#M[Y[T *%D>(D',8/%=-\.%A/CS2C)
M*Z#>3QZ]JYV6+R5"))E&&=HK:\!SB+QSI#;?NS %>] 'I?QP#26.F.P'D"YQ
M(:\9N5@27,&67H!Z5[M\:T$G@H%23Y<X8\= :\()M_LWF)+F3KC'3_.: &1Q
ML5+8R!2+N&9-@XZ+SFB$M)YACDXQDY/7Z5+!9W%QB%(I6GD;;%!M^=_<9% #
M%217!V,,C[S5&71(I2^,KR2.PKJ8/ /B.9/-BT"X:)L#$O!#>O:O2?#WP3BM
MS97>L7\EP4(DEL]@$;$'(4GK0!6^"7AZ2&>]U>>S=(V15MY)5QGU*U[&@Y./
MQ/K1%'Y2"(!1&N H48 'IBI,9[8Q^M #L<4F,XIW&*8?2@#Q_P : 'QC=8XR
M%S6/_#D=S6QXQ=9/%]V< @* ?K6.!P*  \?3-+[^]'?FCG/H* #&1G&:.IY.
M3ZT9(/6C.X9]* #\ZAF/[MOPJ;/>HIS^[;I0![#X..?"MB,_\LZMZQI[ZGI%
MS8)<M ;A#'YJ#E0>M4_"''A2PS_SSK9WA3QPH[GI0!DZ9X;TW2]'@TY+>*18
M8O*,KQKN;W/YFN>3X<Q6MI;KIVHRVUW:2NUM<*N2D;<E#[9KM$N8)2JK-$S,
MNY0#U%#W5O$R++,D9?[NYMN: .:N?!S:AX9?2[[5)I[AY!(+EARK#T'I4EMX
M7F34=*U&]U*2YNK!&3<5^]N'3BNC\V-9A'O42,,A>YI#/%DCS%.UMIYZ-0!S
MH\&6*^-/^$DW.9]FWR?X<\_-]:I7O@%;R_U*2/4I(;;4,&9!&&8$>A/05UYG
MAVLWFH A^8[N :R_$&LC2] N=5M0EP8E!"JV1G\* ,O4?!KW=UI=[9:G+:7=
MC$(1(%!W(.QJ=_!]M/J6IW<]P\JZC (98\8 Q_$*U]-U".]T^WG=HUGEC5VC
M5@<9JP]Q!$R!YHXF?[JL<$_2@#DK#P&\5]93:EK-QJ$%BVZW@D  0]L^N*T+
M/PI%:0:U$;J20ZHS%OE^YD8XKH&EB3(=T7')R><>M--S"J@M/'M/<L.E %6Q
MTN*ST6'36)DBCB\LYXW#%<FWPY/D?V<NM72Z*SES9 #USMSZ5VWGP&7RO,0R
M]?+#9/Y4LEQ#&RK-+'&S<*K, 30!C6GAJ&Q\2SZQ'.W[R!(!!@;55>!6YM&W
MGMR*;YT:'+.J@#/)ZCUH6:*5"\<B.O3*'(H D!^6@,2>*H7NH10:;>7=NR3F
MWC9L*X() SBJ7A76IO$/AZVU.6W$3RDY0'I@T ;NX>M%"+A>@HH ?1110 44
M44 %%%% !1110 4A.*6D(H @D1)8GBD&Y'!4C'4&OF[XB^%Y-&U>78C,J$M&
M1_%&>WX5]+XKG?%?ABU\3Z:T,H*7$8)AD'9O0^HH \K^'L%EX>\(:IXFUN%9
M(I& BC(R6P.!7':OXVU_7]7ENXK^>SMCS%;Q' C Z5+XTN-=AMH-)O,+:VAP
M\"C&X@]:YNWG"1@1D9*D$D]/:@#6GU3Q$0&EUFY)'^W6_P" ]?N;GQ?;6NJR
M+=$J5MY91\R/[$=:XV2\EE)RPP2:;#--;W,-S;/LN8SYD+=E(]: /8OB;X4U
M'Q%;P:G8QH]S8[UFA;[[KZBO%U!&0R[6R00>V.M>VZ9\1M.GT2#5+\2QOYGD
M7"J> 1S^((K+O?AQI&M:I_:&FZW';V-T [1[1D-[9H \I''<#V]:Z+P9X<D\
M4>(H;13B"/$D\G8+D<5V-Y\);*WPUOXE4\9.]5/]:V/"7]C^'=4?0-):2>Z^
MSM+<WS$8<#!" 4 7O%*66F30SBVBFU )Y4'F@,J)Z_6N;@L-<U#?-#=S^N Q
M 'L/:I=0O9-0OFN;C!9CA?8"A_$4UC%Y4!V+C!(- &%J;:W82ADU"X\Q3SEB
M0?KQ5ZT2+QMX4U2RGCCCUBR0SQLG D YZ5D:CK4]RQ)P<]>O2LO2=7N='UJV
MU&UQYP<?(1PZ]"K#TQ0!A6<!NY$0*-O5P1]VO<_AWH)M;+[9(H$DH 0]U6L'
MPGX1@UK6+K4I+<VUB93)L7C<W7 ]J]@M;9(X@D:A$4?*H'2@"S#$$48Y/KZT
M7$1FBDBW[2ZE<CMFI5 /MCK61XJUM?#OAN^U3 +0QDJ#T+=J /E>]LYK'6M0
MM'S(UK<2(6/\1S529FDPR\8J9M0N;N>XNYF#2W4K2N<<98YJI)N7A@>: %#'
M)<<L.WM3E.297&X'M3'V>4%12''5O6C*NRI'&Q(ZX-  P+(7&,GC;3Y,O, 8
MP#C@"D9,;V6,[.ASVJ1V,#1F*?<=F<$9H 82S#[OR*<%:<9MLX:%3'@?=J/+
MNV26W'DXJ3][>RG:JY7Y?Q_SG\A0 AD95D62,L[_ ,784,Z[%B*<YQNII 2-
MHV5O-!^]G@4!]I$H(9N#B@  9\1[L@>M/BMV>$R(5.,\&HRY>0.P*Y/I3RIB
M8JTHP1VXS0 0JSS;5<*>XI5")*1,,X/%'D 0"4.22>!GI3"T+0[2S^8.] "Q
MHLGF'<P5>56E4((F9R=_8'K06'E*IAY'4XR?RKH/"/A*^\9Z@MK:J\=NAQ<7
MG50/0>] &K\./ 2>,[NXN+UI8=,ML*<'F1SV!]J]TT3P5X?T!(_L&G1"10/W
MSC+?7)J?PUX=L?"^B0Z7IZLT,?)9C\S-ZFMT 8Z4 4KRPM=0MG@N[:.:)_O(
MXS7+?\*L\&^;O_L=22=Q&XXR:[?:/2C'.<4 <J?A]X6,<:#1K<"(@KC/ZUL#
M1M,%S%<BPMUGA_U4@C&4^E:6!Z48'I0!$ 00<G/<YZ_A3U48XQ^5.VCTH Q0
M FVC%.HH 0CBF8RU/;A<U6FE^SVTLN>$4M0!XSK\OG>*-0<#)\S%5!T'TI'E
M^T7MU<D\R2LWZTHY.: #/%+U%&>#BDYH .^:,9 %)C\*<?8_I0 F,#BHKC_5
MG'?%2YY%5YPSNJ+U8[1^)% 'M'AN/R_#%BN/^60XJ?5V9-$O&!*D0L01U%3Z
M?%]GTZUB'18U'Z5)+"DT4B2@,CC:P/<4 >.PZ5#:?#W0M>CN9QJ'VB,&82GE
M2YRI'2M6\LKG7?$&NI/' \\2I'"9;@Q&%=HPX'U_E7=_V!IG]D0Z8;4?8X"K
M+%GH0<Y_.J^L>$]%UJZ%S?69DF "-()"A91R <=?2@#D+8W-EXZ\*IJ5ZKR#
M3W5I4;Y),#C)[GWK)U6;S].\3^5>-AM5A0.DGW1W KTK4?"^C:K96UM=62O#
M;?ZD*Q4QC'8]<4U/"VBI;26Z6*K [AW4?Q,.AH XC7]'M]*U'0=%6XF33K^?
M?>.TA_>-CU[53UB"WTG4=?TS2Y]^FMIXEDC:0LL<F>Q[&O3]3T?3]7LQ;7]N
MDT((*J>"OT-4;+PGH=C87%G#9+Y5S_K<MN9_QH XAM'MM&'A._LYYEN+F14E
M=G)\Q2.F.E0)!;:Q_P )7J>KW;IJ-E,PMP)"IA4#Y2%KTJXT;3[J.TCDM5=;
M0AH,'[A'3%4[_P )Z)J>H_;;K3XWN,C<X8KOQ_>'>@#@?)E\2ZSX7@U&XFC\
M^R8R^6^TRX]:L3Z-:W7C36-/>246]I8;HD$I^4@<&O1#I&GOJ,-\;5/M$"[(
MG'&U?0"@:-I_V^XOQ;+]IN(_*E?/++Z4 >46\(@T'PUX@6YF.HRW:Q/+O.&0
MG!&/I6O9V=IX@UWQ#+K]S(DEJQ$*F39Y:8X85W \-Z0-/M[+["HM[9]\*$_=
M;UJOJW@_1=8NQ=7]COG*X9HW*[@.Q'>@#@[=9-8E\'6]]<S%)8I$.UR#*JDX
M)_"K5E)8>'KSQ18SW$\>DPE %1B74GD!3V_^O7?C1-/-Q:W"VBJ]HH2VQP(Q
M["H[CP]I-T;WSK)'%Z!YX8\'' /UH \^TO9:Z_J%E;6[V=C<:.9Q#)-YF3EL
M.??C.*ZKX9MGP'8G/.7S_P!]5I6?AC1['S&AM#N>+R6=V))3LO/;FM#3].M=
M*LDL[.(0P(,A <XH O*>.M%(H %% #Z*** "BBB@ HHHH **** "BBB@ IA3
M)I]% '(^,/"%OXDMC*@5+U%(1\<,/0U\X:SH%WHUW*GE'Y'(:/'*^]?7)7IZ
MCI6!XA\)Z;XAA_TF,)<+]V=%&X?7UH ^58V5TXR>,CCH:DVG<53)DD^4 =<^
MPKT;Q+\)-2T\-<V[+<1@$F2)>?Q%4/ D%AH6OS7>N1I,L*GRD*\AO7% &LGA
M^ST?P7807]N#J-T_V@HPZ #N*QKCY/W:LP&,C!P /2MG5]<_MG4)KV9]A<$*
MK'A1G&!^%8MRZ/\ ,K C'7- &?,SCG>_XN:U/!>H6VG^)56<96XC\KS">A/%
M94K+S\U9\[IPJN P/RD=C0!W^J6TMC>36\PY3D$_Q ]Q6#<J<MUK9/B6W\0^
M%;=KC,>IV/[MO,/^M7L<UCV^GZCKUP(;2W.UB2Q[#GO0!CS-E]D8+MCG'0?6
MNH\'>"[C5KH3S@I"&!=\8S["NKT#X:16K)-J<PD;@^2BG'YUZ+:V"01)!$JI
M&G10,9H ;9V,5M;QQ(FV%!@*.E:2@8!QQ35CY P,"I,8X XH :>.AQQ7GWQD
MO(X/ $T<IVF:14&:[]NWU_2OG7XO>+8_$&OKI=HS&TL6*NQ/#O0!P(V1!#$V
MX #[U)//).X9MHQVHE01*C<'<. *1$1)/WI.#TQ0 CO&+8!5.\')/:I#.3(K
M1KM"C!.*CSM#1H-RL<Y-2>>PMFB"#.>N* (R[E&!8[6.3BG0,@E0R<KC& *%
MD: $[?E8=2.E#Q%(T<D$/R,=1_GC\J '2.!,6B! [9]*;%-+%(6BR689..QH
MB\L%A*23CCFDAN3 2=HY[4 ,+N=Y).YC@T\KM WJ03R,T*&ED) &>N*65WD;
MY\L%'..U ";FEVC  !ZTW(\T N2,\YIRKO/[L;4]">M+M#1!-H!)X- "LJ&9
MD61@HZ9ISR#:APHV<$CH?K1$DUU<BWM;>2XF_N1*237J_@CX1/=HNH>)(S%
MQREAW^IH XWP=X&U'QO?K+&IM].C8>;<$$!AZ+ZU](:'HECH&G)8:="(H5'.
M.K'U-6;'3[73K:.TLX$@MXAA8XUP!5M1SZF@!0OIQ3AQ0*6@ HHHH **** "
MBBB@ HHHS0 C=#7/^*[_ .P>&KJ3=AF&Q?QKH"1BO./B1J8;[-IB$$D[WYH
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M\*.M]XM\1ZG!GR"Z0J<<,PZ_SH [1?F4$$44!01SFB@"6BBB@ HHHH ****
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M'-/L;>ZU.&V19G;8C8^Z!Z5Z,N2,Y/?%9GARP_L_0[6VV[6V;FX[FM8+B@
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ME>4> 1XR_L_3?LXM?[%!Q\QPX7US5K4O%GB37_$EWHWA..*.*S;;-=OT)[T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4F*6B@!,4M%% ";11M%+10 F*,4M% "8HP*6B@! .:,<^U+10 F*,>
MU+10 F/:E%%% !1110 4F!2T4 )BDVTZB@!,"C%+10 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%!.!0 44G-!84 +1GVIF:-
MQH ?12;N*,\4 +12!@3BEH ***,T %%(6%)N/I0 ZBD# _6@M0 M%)DT@.30
M ZBBB@ HHHH **3=2CF@ HHHH **0G%&Z@!:*3-(6]!0 ZBFG.*3)]* 'T4S
M=3Z "BBB@ HI,T9H 6BDS1F@!:*,T4 %%%% !1110 4444 %%(3BC- "T444
M %%!Z4W.: '44W=B@-F@!U%%% !1110 44A^M)DCM0 ZBD!!HS0 M%%(6YZ4
M +129%&[VH 6BD!S2,V.G- #J*3)H- "T4F:6@ HHHH **** "BBB@ HHHH
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M+M)R.U '%MINMQ:GIE_)$+BZ2W:.20?PMV)JO!I>KW6H6-U=VD@DB219R[
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M\>G2C:/Z4 <+I>@R6CK9WNF33E)S(MRLOR'TS4ECH5]#H-U!):(MP]\)0/\
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<Q*5P-I   P3FK"FF]L4\#% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004246464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOVIE INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001580149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-2510769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">680 W Nye Lane Suite 204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carson City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">89703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(775)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">888-3162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Class A Common Stock, $0.0001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIVI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,590,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,956,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text">Portions of the Registrant&#8217;s definitive proxy
statement relating to its 2024 annual meeting of stockholders (the &#8220;2024 Proxy Statement&#8221;) are incorporated by reference into
Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement was filed with the U.S. Securities and Exchange
Commission on September 27, 2024.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">EisnerAmper LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Iselin<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004409872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 23,843,798<span></span>
</td>
<td class="nump">$ 19,460,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_InvestmentsInU.s.TreasuryBills', window );">Investments in U.S. Treasury Bills (available-for-sale)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">14,477,726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">204,392<span></span>
</td>
<td class="nump">102,526<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">24,048,190<span></span>
</td>
<td class="nump">34,041,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">406,726<span></span>
</td>
<td class="nump">80,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">407,718<span></span>
</td>
<td class="nump">637,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">345,711<span></span>
</td>
<td class="nump">345,711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">25,208,345<span></span>
</td>
<td class="nump">35,104,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">3,586,912<span></span>
</td>
<td class="nump">3,476,259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">48,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">60,343<span></span>
</td>
<td class="nump">44,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of note payable, net of financing cost, unearned premium and discount of $701,210 at June 30, 2024 and $894,926 at June 30, 2023</a></td>
<td class="nump">5,701,210<span></span>
</td>
<td class="nump">9,105,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_WarrantLiabilities', window );">Warrant liability</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">894,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">925,762<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,352,236<span></span>
</td>
<td class="nump">14,494,669<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">349,894<span></span>
</td>
<td class="nump">42,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net of current portion, financing cost, unearned premium and&#160;&#160;discount of $0 and $227,268 at June 30, 2024 and June 30, 2023, respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,227,270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">9,702,130<span></span>
</td>
<td class="nump">19,764,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY :</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 800,000,000 shares authorized at June 30, 2024 and June 30, 2023, respectively; 6,216,398 shares issued of which 6,190,072 shares are outstanding at June 30, 2024; and 3,645,183 shares issued of which 3,642,895 shares outstanding at June 30, 2023</a></td>
<td class="nump">6,229<span></span>
</td>
<td class="nump">3,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">349,732,674<span></span>
</td>
<td class="nump">316,385,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">176,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(334,232,661)<span></span>
</td>
<td class="num">(301,225,705)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">15,506,215<span></span>
</td>
<td class="nump">15,340,286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 25,208,345<span></span>
</td>
<td class="nump">$ 35,104,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_InvestmentsInU.s.TreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_InvestmentsInU.s.TreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_WarrantLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_WarrantLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073139771936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_UnearnedPremiumAnddiscountCurrent', window );">Unearned premium and discount current</a></td>
<td class="nump">$ 701,210<span></span>
</td>
<td class="nump">$ 894,926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_UnearnedPremiumAndDiscount', window );">Unearned premium and discount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 227,268<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,216,398<span></span>
</td>
<td class="nump">3,645,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">6,190,072<span></span>
</td>
<td class="nump">3,642,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_UnearnedPremiumAndDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_UnearnedPremiumAndDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_UnearnedPremiumAnddiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_UnearnedPremiumAnddiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004092896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 229,377<span></span>
</td>
<td class="nump">$ 229,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">23,100,394<span></span>
</td>
<td class="nump">33,299,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">8,849,814<span></span>
</td>
<td class="nump">11,551,568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">TOTAL OPERATING EXPENSES</a></td>
<td class="nump">32,179,585<span></span>
</td>
<td class="nump">45,080,448<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(32,179,585)<span></span>
</td>
<td class="num">(45,080,448)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER (INCOME) EXPENSE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(1,816,271)<span></span>
</td>
<td class="nump">1,437,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">2,893,922<span></span>
</td>
<td class="nump">4,300,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">(1,136,703)<span></span>
</td>
<td class="num">(562,264)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">TOTAL OTHER (INCOME) EXPENSE, NET</a></td>
<td class="num">(59,052)<span></span>
</td>
<td class="nump">5,175,367<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET LOSS</a></td>
<td class="num">(32,120,533)<span></span>
</td>
<td class="num">(50,255,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsSharebasedCompensationStock', window );">Deemed dividend related to ratchet adjustment to warrants</a></td>
<td class="nump">886,423<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (33,006,956)<span></span>
</td>
<td class="num">$ (50,255,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET LOSS PER COMMON SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">- Basic</a></td>
<td class="num">$ (7.30)<span></span>
</td>
<td class="num">$ (15.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">- Diluted</a></td>
<td class="num">$ (7.30)<span></span>
</td>
<td class="num">$ (15.47)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE NUMBER OF COMMON&#160;&#160;SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">- Basic</a></td>
<td class="nump">4,518,533<span></span>
</td>
<td class="nump">3,248,349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">- Diluted</a></td>
<td class="nump">4,518,533<span></span>
</td>
<td class="nump">3,248,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="num">$ (33,006,956)<span></span>
</td>
<td class="num">$ (50,255,815)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract', window );"><strong>Other comprehensive (loss) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_UnrealizedGainOnInvestmentsForAvailableforsale', window );">Unrealized gain on available-for-sale investments</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">176,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement', window );">Reclassification of unrealized gains on available-for-sale investments upon settlement</a></td>
<td class="num">(176,591)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Total other comprehensive (loss) income</a></td>
<td class="num">(176,591)<span></span>
</td>
<td class="nump">176,591<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (33,183,547)<span></span>
</td>
<td class="num">$ (50,079,224)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_UnrealizedGainOnInvestmentsForAvailableforsale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_UnrealizedGainOnInvestmentsForAvailableforsale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsSharebasedCompensationStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid stock dividends declared for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsSharebasedCompensationStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(a)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073001372960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Treasury Stocks [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Jun. 30, 2022</a></td>
<td class="nump">$ 2,496<span></span>
</td>
<td class="nump">$ 254,638,329<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (250,969,890)<span></span>
</td>
<td class="nump">$ 3,670,935<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2022</a></td>
<td class="nump">2,498,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock - based compensation - stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,222,845<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,222,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock-based compensation - restricted stock units</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">1,780,028<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,780,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock-based compensation - restricted stock units, Shares</a></td>
<td class="nump">21,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered', window );">Stock-based compensation - issuance of common stock for services rendered</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">372,495<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">372,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares', window );">Stock-based compensation - issuance of common stock for services rendered, shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_CashlessExerciseOfOptions', window );">Cashless exercise of options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_CashlessExerciseOfOptionsShares', window );">Cashless exercise of options, Shares</a></td>
<td class="nump">2,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_CashlessExerciseOfWarrantsShares', window );">Cashless exercise of warrants, Shares</a></td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,240<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ProceedsFromIssuanceOfCommonStockNetCosts', window );">Proceeds from issuance of common stock, net of costs of&#160;&#160;$2,908,141</a></td>
<td class="nump">$ 754<span></span>
</td>
<td class="nump">49,464,349<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">49,465,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares', window );">Proceeds from issuance of common stock, net of costs, shares</a></td>
<td class="nump">753,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty', window );">Proceeds from issuance of common stock, net of costs of&#160;&#160;$94,160 - Related Party</a></td>
<td class="nump">$ 364<span></span>
</td>
<td class="nump">5,905,476<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,905,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares', window );">Proceeds from issuance of common stock, net of costs of Related Party, shares</a></td>
<td class="nump">363,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_UnrealizedGainOnAvailableforsaleInvestments', window );">Unrealized gain on available-for-sale investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">176,591<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">176,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(50,255,815)<span></span>
</td>
<td class="num">(50,255,815)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2023</a></td>
<td class="nump">$ 3,643<span></span>
</td>
<td class="nump">316,385,759<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="nump">176,591<span></span>
</td>
<td class="num">(301,225,705)<span></span>
</td>
<td class="nump">15,340,286<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2023</a></td>
<td class="nump">3,645,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock - based compensation - stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,823,764<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,823,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Stock-based compensation - restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,763,450<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,763,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Stock-based compensation - restricted stock units, Shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits', window );">Issuance of common stock from vesting of restricted stock units</a></td>
<td class="nump">$ 122<span></span>
</td>
<td class="num">(97)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares', window );">Issuance of common stock from vesting of restricted stock units, shares</a></td>
<td class="nump">122,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24,038)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered', window );">Stock-based compensation - issuance of common stock for services rendered</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">72,885<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">72,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares', window );">Stock-based compensation - issuance of common stock for services rendered, shares</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DeemedDividendForRatchetAdjustmentToWarrants', window );">Deemed dividend for ratchet adjustment to warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">886,423<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(886,423)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement', window );">Relcassification of unrealized gains on available-for-sale investments upon settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(176,591)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(176,591)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit', window );">Issuance of additional shares for fractional shares effected by the reverse split</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares', window );">Issuance of additional shares for fractional shares effected by the reverse split, shares</a></td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ProceedsFromIssuanceOfCommonStockNetCosts', window );">Proceeds from issuance of common stock, net of costs of&#160;&#160;$2,908,141</a></td>
<td class="nump">$ 2,449<span></span>
</td>
<td class="nump">27,800,490<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">27,802,939<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares', window );">Proceeds from issuance of common stock, net of costs, shares</a></td>
<td class="nump">2,433,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(32,120,533)<span></span>
</td>
<td class="num">(32,120,533)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2024</a></td>
<td class="nump">$ 6,229<span></span>
</td>
<td class="nump">$ 349,732,674<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (334,232,661)<span></span>
</td>
<td class="nump">$ 15,506,215<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2024</a></td>
<td class="nump">6,216,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashlessExerciseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashlessExerciseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividendForRatchetAdjustmentToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividendForRatchetAdjustmentToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromIssuanceOfCommonStockNetCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromIssuanceOfCommonStockNetCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_UnrealizedGainOnAvailableforsaleInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_UnrealizedGainOnAvailableforsaleInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004322192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (32,120,533)<span></span>
</td>
<td class="num">$ (50,255,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">229,377<span></span>
</td>
<td class="nump">229,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockBasedCompensationRestrictedStock', window );">Stock based compensation - restricted stock units</a></td>
<td class="nump">1,763,450<span></span>
</td>
<td class="nump">1,780,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense - stock options</a></td>
<td class="nump">2,823,764<span></span>
</td>
<td class="nump">4,222,845<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockBasedCompensationExpenseStockIssued', window );">Stock based compensation expense - stock issued</a></td>
<td class="nump">72,900<span></span>
</td>
<td class="nump">372,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of financing costs</a></td>
<td class="nump">108,751<span></span>
</td>
<td class="nump">170,219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AccretionOfUnearnedLoanDiscount', window );">Accretion of unearned loan discount</a></td>
<td class="nump">1,023,145<span></span>
</td>
<td class="nump">1,601,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AccretionOfLoanPremium', window );">Accretion of loan premium</a></td>
<td class="nump">236,970<span></span>
</td>
<td class="nump">421,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RealizedGainOnMaturityOfAvailableforSale', window );">Realized gain on maturity of available-for sale</a></td>
<td class="num">(223,865)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_NoncashLeaseExpenseFromRightofuseAssets', window );">Non-cash lease expense from right-of-use assets</a></td>
<td class="nump">49,346<span></span>
</td>
<td class="nump">37,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases', window );">Gain on termination of operating lease</a></td>
<td class="num">(5,215)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(1,816,271)<span></span>
</td>
<td class="nump">1,437,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">&#160;&#160;&#160;Prepaid and other assets</a></td>
<td class="num">(101,866)<span></span>
</td>
<td class="nump">39,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">&#160;&#160;&#160;Accounts payable and accrued expenses</a></td>
<td class="nump">110,653<span></span>
</td>
<td class="nump">1,033,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">&#160;&#160;&#160;Operating lease liabilities</a></td>
<td class="num">(47,245)<span></span>
</td>
<td class="num">(38,884)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">&#160;&#160;&#160;Other current liabilities</a></td>
<td class="num">(48,385)<span></span>
</td>
<td class="num">(1,304,925)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(27,945,024)<span></span>
</td>
<td class="num">(40,252,881)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ProceedsFromMaturityOfU.s.TreasuryBills', window );">Proceeds from (purchases of) U.S. Treasury Bills (available-for-sale)</a></td>
<td class="nump">14,525,000<span></span>
</td>
<td class="num">(14,301,135)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">14,525,000<span></span>
</td>
<td class="num">(14,301,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">27,802,939<span></span>
</td>
<td class="nump">49,465,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of note payable</a></td>
<td class="num">(10,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty', window );">Net proceeds from issuance of common stock - Related Party</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,905,840<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">17,802,939<span></span>
</td>
<td class="nump">55,373,183<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">4,382,915<span></span>
</td>
<td class="nump">819,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">19,460,883<span></span>
</td>
<td class="nump">18,641,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">23,843,798<span></span>
</td>
<td class="nump">19,460,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">&#160;&#160;Cash paid for interest</a></td>
<td class="nump">1,525,056<span></span>
</td>
<td class="nump">2,106,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">432,192<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_UnrealizedGainOnU.s.TreasuryBills', window );">Unrealized gain on U.S. Treasury Bills (available-for-sale)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">176,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement', window );">Reclassification of unrealized gains on U.S. Treasury Bills (available-for-sale investments) upon settlement</a></td>
<td class="nump">176,591<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DeemedDividendOfRatchetAdjustmentsToWarrants', window );">Deemed dividend of ratchet adjustment to warrants</a></td>
<td class="nump">$ 886,423<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AccretionOfLoanPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AccretionOfLoanPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AccretionOfUnearnedLoanDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AccretionOfUnearnedLoanDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DeemedDividendOfRatchetAdjustmentsToWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DeemedDividendOfRatchetAdjustmentsToWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NoncashLeaseExpenseFromRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NoncashLeaseExpenseFromRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ProceedsFromMaturityOfU.s.TreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ProceedsFromMaturityOfU.s.TreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_RealizedGainOnMaturityOfAvailableforSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_RealizedGainOnMaturityOfAvailableforSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_StockBasedCompensationExpenseStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_StockBasedCompensationExpenseStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_StockBasedCompensationRestrictedStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_StockBasedCompensationRestrictedStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_UnrealizedGainOnU.s.TreasuryBills">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_UnrealizedGainOnU.s.TreasuryBills</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 840<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481222/840-30-40-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482161/360-10-40-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002399872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="num">$ (32,120,533)<span></span>
</td>
<td class="num">$ (50,255,815)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002144672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073094584464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Background Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Background Information</a></td>
<td class="text"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5Wckacr5b3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>1.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_828_zoUWD0geoEd7">Background Information</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">BioVie Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;
or &#8220;our&#8221;) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including
neurological and neuro-degenerative disorders and liver disease.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company acquired the biopharmaceutical assets
of NeurMedix, Inc. (&#8220;NeurMedix&#8221;) a privately held clinical-stage pharmaceutical company and a related party in June 2021<i>.</i>&#160;The
acquired assets included NE3107. NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven
insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus
that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer&#8217;s disease (&#8220;AD&#8221;)
and Parkinson&#8217;s disease (&#8220;PD&#8221;), and NE3107 could, if approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;),
represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering
from AD and 1 million Americans suffering from PD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Neurodengenerative Disease Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In neurodegenerative disease, the Company&#8217;s
drug candidate NE3107 inhibits activation of inflammatory actions extracellular single-regulated kinase (&#8220;ERK&#8221;) and nuclear
factor kappa-light-chain-enhancer of activated B cells (&#8220;NF&#954;B&#8221;) (including interactions with tumor necrosis factor (&#8220;TNF&#8221;)
signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. NE3107 does not interfere with
their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers
of AD and PD.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Alzheimer&#8217;s Disease (NCT05083260)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 29, 2023, the Company announced the analysis
of its unblinded, topline efficacy data from its Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate AD.
The study has co-primary endpoints looking at cognition using the Alzheimer&#8217;s Disease Assessment Scale-Cognitive Scale (ADAS-Cog
12) and function using the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Patients were randomly assigned, 1:1 versus placebo, to receive
sequentially 5 mg of NE3107 orally twice a day for 14 days, then 10 mg orally twice a day for 14 days, followed by 26 weeks of 20 mg orally
twice daily.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon trial completion, as the Company began the
process of unblinding the trial data, the Company found significant deviation from protocol and current good clinical practices
(&#8220;cGCPs&#8221;) violations at 15 study sites (virtually all of which were from one geographic area). This highly unusual level
of suspected improprieties led the Company to exclude all patients from these sites and to refer the sites to the FDA Office of
Scientific Investigations (&#8220;OSI&#8221;) for potential further action. After the patient exclusions, 81 patients remained in
the Modified Intent to Treat population, 57 of whom were in the Per-Protocol population which included those who completed the trial
and were verified to take study drug from pharmacokinetic data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The trial was originally designed to be 80% powered
with 125 patients in each of the treatment and placebo arms. The unplanned exclusion of so many patients has left the trial underpowered
for the primary endpoints. In the Per-Protocol population, which included those patients who completed the trial and who were further
verified to have taken the study drug (based on pharmacokinetic data), an observed descriptive change from baseline appeared to suggest
a slowing of cognitive loss; these same patients experienced an advantage in age deceleration vs. placebo as measured by DNA epigenetic
change. Age deceleration is used by longevity researchers to measure the difference between the patient&#8217;s biological age, in this
case as measured by the Horvath DNA methylation Skin Blood Clock, relative to the patient&#8217;s actual chronological age. This test
was a non-primary/secondary endpoint, other-outcome measure, done via blood test collected at week 30 (end of study). Additional DNA methylation
data continues to be collected and analyzed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Parkinson&#8217;s Disease (NCT05083260)</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Phase 2 study of bezisterim (NE3107) for the treatment
of PD (NCT05083260), completed in December 2022, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study
in PD participants treated with carbidopa/levodopa and bezisterim (NE3107). Forty-five patients with a defined L-dopa &#8220;off state&#8221;
were randomized 1:1 to placebo: bezisterim (NE3107) 20 mg twice daily for 28 days. This trial was launched with two design objectives:
1) the primary objective was safety and a drug-drug interaction study as requested by the FDA to measure the potential for adverse interactions
of bezisterim (NE3107) with carbidopa/ levodopa; and 2) the secondary objective was to determine if preclinical indications of promotoric
activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met.</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Long COVID Program</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In April 2024, the Company announced the grant of
a clinical trial award of up to $13.1 million from the DOD, awarded through the Peer Reviewed
Medical Research Program (&#8220;PRMRP&#8221;) of the Congressionally Directed Medical Research Programs (&#8220;CDMRP&#8221;). The award
can provide up to 2 years of non-dilutive funding for a Phase 2b clinical trial that will assess bezisterim (NE3107) for the treatment
of neurological symptoms that are associated with long COVID. The Company anticipates the trial to commence by early 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Liver Disease Program</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In liver disease, our investigational drug candidate
BIV201 (continuous infusion terlipressin), which has been granted both FDA Fast Track designation status and FDA Orphan Drug status, is
being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the
treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2021, the Company initiated a Phase 2 study
(NCT04112199) designed to evaluate the efficacy of BIV201 (terlipressin, administered by continuous infusion for two 28-day treatment
cycles) combined with standard-of-care (&#8220;SOC&#8221;), compared to SOC alone, for the treatment of refractory ascites. The primary
endpoints of the study are the incidence of ascites-related complications and change in ascites fluid accumulation during treatment compared
to a pre-treatment period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In March 2023, the Company announced enrollment was
paused and that data from the first 15 patients treated with BIV201 plus SOC appeared to show at least a 30% reduction in ascites fluid
during the 28 days after treatment initiation compared to the 28 days prior to treatment. The change in ascites volume was significantly
different from those patients receiving SOC treatment. Patients who completed the treatment with BIV201 experienced a 53% reduction in
ascites fluid, which was sustained (43% reduction) during the three months after treatment initiation as compared to the three-month pre-treatment
period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2023, the Company requested and subsequently
received guidance from the FDA regarding the design and endpoints for definitive clinical testing of BIV201 for the treatment of ascites
due to chronic liver cirrhosis. The Company is currently finalizing protocol designs for the Phase 3 study of BIV201 for the treatment
of ascites due to chronic liver cirrhosis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The BIV201 development program was initiated by LAT
Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently
owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11,
2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty
on net sales of BIV201 (continuous infusion terlipressin). to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett
Edge, Inc.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002337840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Going Concern<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text"><p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zhHeG4Y54gD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt; text-align: justify"><b>2.</b></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><b><span id="xdx_826_z3bQ4oJ8lxTl">Liquidity and Going Concern</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s operations are subject to a number
of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of
clinical testing and trial activities of the Company&#8217;s products, the Company&#8217;s ability to obtain regulatory approval to market
its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company
products; the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products;
and the Company&#8217;s ability to raise capital. The Company&#8217;s financial statements have been prepared assuming the Company will
continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of
business. As of June 30, 2024, the Company had working capital of approximately $<span id="xdx_90F_ecustom--WorkingCapital_iI_pp0n3_dm_c20240630_zbAgiTsGFtJ7" title="Working capital">14.7</span> million, cash and cash equivalents of approximately
$<span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0n3_dm_c20240630_zPJfCMM9XJo9" title="Cash and cash equivalent">23.8</span> million, stockholders&#8217; equity of approximately $<span id="xdx_908_ecustom--StockholderEquities_iI_pp0n3_dm_c20240630_zS3WOvYfCG18" title="Stockholders' equity">15.5</span> million, and an accumulated deficit of approximately $<span id="xdx_907_ecustom--AccumulatedDeficit_iI_pp0n3_dm_c20240630_zu3kN9EV3Fia" title="Accumulated deficit">334.2</span> million.
The Company is in the pre-revenue stage and no revenues are expected in the foreseeable future. The Company&#8217;s future operations
are dependent on the success of the Company&#8217;s ongoing development and commercialization efforts, as well as its ability to secure
additional financing as needed. Projected cash flows could be extended if further measures are taken to delay planned expenditures in
our research protocols and slow the progress in the Company&#8217;s development and launch of next phase clinical programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The future viability of the Company is largely dependent
upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include
sales of equity, obtaining loans, or other strategic transactions.</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Although management continues to pursue the Company&#8217;s
strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the
Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&#8217;s ability to continue
as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002468176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zll1CrPAPwzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt; text-align: justify"><b>3.</b></td>
    <td style="width: 95%; font-size: 10pt; text-align: justify"><b><span id="xdx_822_zbCcGWc1ytec">Significant Accounting Policies</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zebyfefaqk47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zuLVlMJvL9b2">Basis of Presentation</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial statements have been
prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and include all adjustments
necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_843_eus-gaap--UseOfEstimates_zkYmHk6pRTDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zXVFq7dHQ0oc">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying
notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the
circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses reported
for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which
are used for, but not limited to, accounting for clinical accruals, share-based compensation, accounting for derivatives, assumptions
used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and
accounting for income taxes. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1bk7qiimWe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zUQkDpl4k1ya">Cash and cash equivalents</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents consisted of cash deposits
and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S.
Treasury Bills with original maturities of three months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p id="xdx_84D_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_z3aqWr0boaMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_862_zUelhoMtJqfg">Investments in U.S. Treasury Bills</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in U.S. Treasury Bills with maturities
greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other
comprehensive income in the accompanying statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_842_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zV9UO2YnPgge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zSuBbiWxmaLd">Concentration of Credit Risk in the Financial Service
Industry</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2024, the Company had cash deposited
in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these
financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March
and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions
due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material
direct impact on the Company&#8217;s operations, if further liquidity and financial stability concerns arise with respect to banks and
financial institutions, either nationally or in specific regions, the Company&#8217;s ability to access cash or enter into new financing
arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
<p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zU1VURvQxAR" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zzS4ULT1Zzhg">Fair value measurement of assets and liabilities</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We determine the fair values of our financial instruments
based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the
asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the
fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset
or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant
to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active
markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - Inputs are quoted prices for similar assets
and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market
corroboration, for substantially the full term of the financial instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - Inputs are unobservable inputs based on
our assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial instruments include
cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts
payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating
lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_849_ecustom--PrepaidAndOtherAssetsPolicyTextBlock_zPIGiac7r2vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_zOA3YHVhTic4">Prepaid and other assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid and other assets consist of prepayments of
certain expenses and a security deposit paid in connection with a lease agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zXUyPYrjc8n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zFXQIjiZ4lIg">Leases</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines whether an arrangement contains
a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current portion of operating
lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from
the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease
term at the commencement date. As the Company&#8217;s leases do not provide an implicit rate, an incremental borrowing rate is used based
on the information available at the commencement date in determining the present value of lease payments. The Company does not include
options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such
options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets
or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease
payments as expense on a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zw5dMpI2O1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_zWnYoZSIavae">Research and Development</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses consist primarily
of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development,
personnel, supplies and development materials, costs for consultants and related contract research and facility costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zqRMfBsKS5pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zWAOugpoWc7l">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method of
accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards
and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a
valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company
decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes uncertainty in income taxes
in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in
a tax return. The Company applies the &#8220;more-likely-than-not&#8221; recognition threshold to all tax positions, commencing at the
adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there
have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,
if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive
Loss. For the years ended June 30, 2024 and 2023, there was no such interest or penalty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zzafBczj30B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zP0T8FTTKfDd">Net Loss per Common Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed by dividing
the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period.
Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number
of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution
that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30,
2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for
the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below shows the potential shares of common stock, presented based on amounts outstanding
at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including
them would have had an anti-dilutive effect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z4xX8a8Ld4Eh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B0_zzRmJdp8450j" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total">518,076</td><td style="white-space: nowrap; width: 8%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total">395,286</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">1,932,029</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">777,029</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">40,291</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">59,646</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes payable conversion option</p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">71,633</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">71,633</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 3.5pt">Total</td><td style="font-weight: bold; padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total">2,562,029</td><td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z7TsdxVTmiRa" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total">1,303,594</td><td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zGNGGaqFFrIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_860_zXhPFYOTD7x">Stock-based Compensation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has accounted for stock-based compensation
under the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718 &#8211; &#8220;Stock Compensation&#8221; (&#8220;ASC
718&#8221;) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees
and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees
awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses
assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. For non-employees, the Company
utilizes the graded vesting attribution method under which the entity treats each separately vesting portion (tranche) as a separate award
and recognizes compensation cost for each tranche over its separate vesting schedule. Expected volatilities are based on historical volatility
of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected
term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of
the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for
the period of the expected term. The Company recognizes forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zpHNQRK66eD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zVullYgQSaFe">Goodwill</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill is recorded when the purchase price paid
for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual
impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests.
The Company&#8217;s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill
related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an
asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make
certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each
time the Company tests goodwill for impairment and are typically developed as part of the Company&#8217;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce
materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2024 and 2023.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxEExg1l3wa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_ztcdrcAsC2q2">Impairment of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, including intangible assets, are
reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted
estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying
amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected
discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities
of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance
sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<p id="xdx_848_ecustom--ReverseStockSpliteUpPolicyTextBlock_zSThz6PT6ydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_860_z1RnzX1jpb0k">Reverse stock split up</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">The company effected a 1:10 reverse split of the issued and outstanding
shares of its Class A commons stock which was approved by the board of director after the approval obtained from shareholders at a special
meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders&#8217; approval was
obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split.<span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zuwhNodhFzFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_z4C4Pn21Svea">Recent Accounting Pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and impact
of all Accounting Standards Updates (&#8220;ASU&#8217;s&#8221;). There were no recent ASU&#8217;s that are expected to have a material
impact on our balance sheets or statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the Financial Accounting Standards Board
(&#8220;FASB&#8221;) issued ASU No. 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments&#8221; (&#8220;ASU 2016-13&#8221;). This amendment replaces the incurred loss impairment methodology in current
GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade receivables. This update
is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted
ASU 2016-13 effective July 1, 2023 and the adoption had an insignificant impact on the accompanying financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures," to enhance disclosures for significant segment expenses for all public entities required to report segment information
in accordance with ASC 280. The standard did not change the definition of a segment, the method for determining segments or the criteria
for aggregating operating segments into reportable segments. The amendments are effective for fiscal years beginning after December 15,
2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods
presented in the financial statements. The adoption is not expected to have a material impact to our financial statements or disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09, "Income
Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures.
This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information
for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount
of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions.
Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between
domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are
effective for annual periods beginning after December 15, 2024. We will adopt this standard on a prospective basis as allowed by the standard.
The adoption of this standard is not expected to have a material impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007816992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in U.S. Treasury Bills available-for-sale<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract', window );"><strong>Investments In U.s. Treasury Bills Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock', window );">Investments in U.S. Treasury Bills available-for-sale</a></td>
<td class="text"><p id="xdx_80F_ecustom--InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock_zWKBbFyMy4ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>4. <span id="xdx_824_zeVATi7Qf5w6">Investments in U.S. Treasury Bills available-for-sale</span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following is a summary of the U.S. Treasury Bills
held at June 30, 2023:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfUSTreasuryBillsHeldTableTextBlock_zFpMQIBDZYM9" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span id="xdx_8B9_zwPq9nbsxKK3" style="display: none">Schedule of U.S. treasury bills held</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized
    Cost Basis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Unrealized Gain</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Unrealized loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Accumulated Other Comprehensive Income</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Treasury
    Bills due in 3 - 6 months</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--AmortizedCostBasis_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Amortized Cost Basis"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,301,136</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--GrossUnrealizedGain_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Gross Unrealized Gain"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">176,591</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--GrossUnrealizedLoss_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Gross Unrealized loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--InvestmentOwnedAtFairValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,477,726</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Total Accumulated Other Comprehensive Income"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">176,591</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended June 30, 2023, the Company
purchased a total of approximately $<span id="xdx_90B_ecustom--NumberOfStockPurchased_pp0n3_dm_c20220701__20230630_zfZ2Q4bI3lp6" title="Number of stock purchased">46</span> million of U.S. Treasury Bills. All outstanding investments in U.S. Treasury Bills available-for-sale
held at June 30, 2023 matured during the three months ended September 30, 2023 and were settled, resulting in a realized gain of $<span id="xdx_90A_ecustom--RealizedGainOnMaturityOfAvailableforSale_pp0p0_c20230701__20240630_zx89DfToRKVk" title="Realized gain on maturity of available-for sale">223,865</span>
recorded as a component of interest income on the accompanying statement of operations and comprehensive loss.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002587632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--IntangibleAssetsDisclosureTextBlock_z4PkRJory8Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>5.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_823_zzqLK3WsC4al">Intangible Assets</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company&#8217;s intangible assets consist of intellectual property
acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets
as of June 30, 2024 and 2023:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zWlieL5r0Rt3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8BD_zVTU4dWRgoW7" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20240630" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20230630" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzbKJ_zQ2SOZ6MBv28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Intellectual Property</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzbKJ_zuLnqk5tPxO" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,886,052</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,656,675</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzbKJ_z7X64uOB06K4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Intellectual Property, Net</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">407,718</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">637,095</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zk22UgZk5o54" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Amortization expense amounted to $<span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20240630_pp0p0" title="Amortization expenses"><span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20220701__20230630_pp0p0" title="Amortization expenses">229,377</span></span> for each
of the years ended June 30, 2024 and 2023, respectively. The Company amortizes intellectual property over the expected original useful
lives of <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630_zD3NORzx3dJc" title="Useful life">10 </span>years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Estimated future amortization expense is as follows:&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOWvmnVxiYid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_8B6_zPn29iP1C7w3" style="display: none">Schedule of future amortization expense</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20240630_zTK62UB8coMi" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">Year ending June 30,</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: center">2025</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 48%; text-align: right">229,377</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,341</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); padding-bottom: 3.5pt">&#160;Finite lived intangible assets, net</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">407,718</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002408048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOOirCY2eeze" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>6.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_82A_zMseLmUjNa1g">Related Party Transactions</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Equity Transactions with Acuitas</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 15, 2022, the Company entered into a securities
purchase agreement with Acuitas Group Holdings, LLC (&#8220;Acuitas&#8221;), the Company&#8217;s largest stockholder, pursuant to which
Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of <span id="xdx_90F_eus-gaap--CommonStockSharesIssued_c20220715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_pdd" title="Common stock, shares issued">363,636</span> shares of the Company&#8217;s Common
Stock, at a price of $16.50 per share (the &#8220;PIPE Shares&#8221;), and (ii) a warrant to purchase 727,273 shares of Common Stock (&#8220;PIPE
Warrant Shares&#8221;), at an exercise price of $18.20, with a term of exercise of five years. The down round feature reduced the exercise
price of the PIPE Warrant Shares to $10.00 per share on March 6, 2024 in connection with the offering further described in Note 9 as the
Company sold stock at a price lower than its initial exercise price. The Company calculated the difference in fair value of the PIPE Warrant
Shares between the stated exercise price and the reduced exercise price and recorded $<span id="xdx_904_eus-gaap--Dividends_c20230701__20240630_pp0p0" title="Deemed dividend">886,423</span> as a deemed dividend. The fair value of
the PIPE Warrant Shares were estimated using the Black Scholes Method with the following inputs, the stock price of $<span id="xdx_90A_eus-gaap--SharePrice_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Stock price">10.65</span>, exercise price
of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price">18.20</span> and $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price">10.00</span>, remaining term of <span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zaQw6QcEbdm" title="Remaining term">3.5</span> years, risk free rate of <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Risk free rate">4.4%</span> and volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Volatility">95.0%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 15, 2022, the Company received net proceeds of approximately
$5.9 million, net of costs of approximately $94,000, and entered into an amended and restated registration agreement with Acuitas, which
amended and restated that certain registration rights agreement, dated as of June 10, 2021, by and between the Company and Acuitas (the
&#8220;Existing Registration Rights Agreement&#8221;), to amend the definition of &#8220;Registrable Securities&#8221; in the Existing
Registration Rights Agreement to include the PIPE Shares and the PIPE Warrant Shares as Registrable Securities thereunder.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007892336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_znaQgGUTiJn8" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>7.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_822_zvK1J4NAbR1g">Notes Payable</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 30, 2021 (the &#8220;Closing
Date&#8221;), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and
Promissory Notes (together, the &#8220;Loan Agreement&#8221;) with Avenue Venture Opportunities Fund, L.P. (&#8220;AVOPI&#8221;) and
Avenue Venture Opportunities Fund II, L.P. (&#8220;AVOPII,&#8221; and together with AVOPI, &#8220;Avenue&#8221;) for growth capital
loans in an aggregate commitment amount of up to $20 million (the &#8220;Loan&#8221;). On the Closing Date, $15 million of the Loan
was funded (&#8220;Tranche 1&#8221;). The Loan provided for an additional $5 million to be available to the Company on or prior to
September 15, 2022, subject to the Company&#8217;s achievement of certain milestones with respect to certain of its ongoing clinical
trials, which were not achieved. The Loan bears interest at an annual rate equal to the greater of (a) the sum of <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230701__20240630__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_pdd" title="Interest rate">7.00%</span>
plus the prime rate as reported in The Wall Street Journal and (b) 10.75%. The prime rate at June 30, 2024 was <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230701__20240630_pdd" title="Interest rate">8.50%</span>.
The Loan is secured by a lien upon and security interest in all of the Company&#8217;s assets, including intellectual property,
subject to agreed exceptions. The maturity date of the Loan is December 1, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Loan Agreement required monthly interest-only
payments during the first eighteen months of the term of the Loan. Following the interest-only period, on July 1, 2023, the Company pays
equal monthly payments of principal, plus accrued interest, until the Loan&#8217;s maturity date when all remaining principal and accrued
interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal
amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal
amount of the Loan that is prepaid after the interest-only period. At the Loan&#8217;s maturity date, or on the date of the prepayment
of the Loan, the Company will be obligated to pay a final payment equal to 4.25% of the Loan commitment amount, the sum of Tranche 1 and
Tranche 2, which amounts to $850,000 (the &#8220;Loan Premium&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Loan Agreement includes a conversion option to
convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company&#8217;s
Common Stock at a conversion price of $69.80 per share (the &#8220;Conversion Option&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On the Closing Date, the Company issued to Avenue
warrants to purchase 36,101 shares of Common Stock of the Company (the &#8220;Avenue Warrants&#8221;) at an exercise price per share equal
to $58.20. The Avenue Warrants are exercisable until November 30, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The amount of the carrying value of the notes payable
was determined by allocating portions of the outstanding principal of the notes, approximately $<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pp0n3_dm_c20230701__20240630_zFRfQ2xyaobl" title="Fair value of warrants">1.4</span> million, to the fair value of the
Avenue Warrants, and approximately $<span id="xdx_90F_ecustom--FairValueOfEmbeddedConversionOption_pp0n3_dm_c20230701__20240630_ztNYMpDOfJRk" title="Fair value of embedded conversion option">2.2</span> million to the fair value of the embedded Conversion Option. Accordingly, the total amount of
unearned discount of approximately $<span id="xdx_904_ecustom--UnearnedDiscount_pp0n3_dm_c20220701__20230630_zIYUU4ek7Ahh" title="Unearned discount">3.6</span> million, the total direct financing cost of approximately $<span id="xdx_909_ecustom--DirectFinancingCost_c20230701__20240630_pp0n3" title="Direct financing cost">390,000</span> and the Loan Premium of $<span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedPremium_c20240630_pp0n3" title="Unamortized premium recognized">850,000</span>
are being amortized using the effective interest method over the term of the Loan. The adjusted effective interest rate is 27%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total interest expense for the year ended June 30,
2024 was approximately $<span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0n3_dm_c20230701__20240630_zDAd1oZx9sk3" title="Interest expense">2.9</span> million on the accompanying statement of operations and comprehensive loss. Interest expense was comprised
of interest incurred on the outstanding principal of the loan of approximately $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0n3_dm_c20230701__20240630_zNX3xfmqKgI8" title="Interest payment">1.5</span> million, amortization of financing costs of approximately
$<span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20230701__20240630_pp0n3" title="Amortization of financing costs">109,000</span>, amortization of the unearned discount of $<span id="xdx_90B_ecustom--UnearnedDiscount_pp0n3_dm_c20230701__20240630_znFjNVsItFQ7" title="Unearned discount">1.0</span> million, and the accretion of the Loan Premium of approximately $<span id="xdx_909_ecustom--AccretionsOfLoanPremium_c20230701__20240630_pp0n3" title="Accretion of loan premium">237,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total interest expense for the year ended June 30,
2023 was approximately $<span id="xdx_90B_eus-gaap--InterestExpenseDebt_pp0n3_dm_c20220701__20230630_zugWQm0wDE3a" title="Interest expense">4.3</span> million on the accompanying statement of operations and comprehensive loss. Interest expense was comprised
of interest incurred on the outstanding principal of the loan of approximately $<span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0n3_dm_c20220701__20230630_zNQipDEkbQM4" title="Interest payment">2.1</span> million, amortization of financing costs of approximately
$<span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20220701__20230630_pp0n3" title="Amortization of financing costs">170,000</span>, amortization of the unearned discount of $1.6 million, and the accretion of the Loan Premium of approximately $<span id="xdx_90F_ecustom--AccretionsOfLoanPremium_c20220701__20230630_pp0n3" title="Accretion of loan premium">422,000</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2024, the remaining principal balance
of $<span id="xdx_90F_eus-gaap--NotesPayable_iI_pp0n3_dm_c20240630_zKQgvFHSSVDl" title="Remaining principal balance">5.0</span> million under the Loan is payable in 6 monthly equal installments. For the year ended June 30, 2024, the Company paid back $<span id="xdx_904_eus-gaap--RepaymentsOfNotesPayable_pp0n3_dm_c20230701__20240630_zGIzTAghBM65" title="Repayments of notes payable">10</span>
million, of the original loan of $15 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following is a summary of the Notes Payable as of June 30, 2024 and
2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Current portion of Notes Payable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zaRglNHc3gAk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B8_zWvDsDKpNXFg" style="display: none">Schedule of note payable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20240630_znFsMdOQI535" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230630_zoW9eLTsQjYl" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Current portion of Notes Payable</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: debt financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,820</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108,751</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_zZTwYjN6FXja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unearned discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111,212</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,023,145</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: accretion of Loan Premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">824,242</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">236,970</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Current portion of Notes Payable, net of financing costs, unearned premium and discount</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">5,701,210</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">9,105,074</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Non-current portion of Notes Payable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zVy4JaB1LlEb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230630_zeXJplCcT4mb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--NotesPayableNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Notes Payable</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LongtermDebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: debt financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,820</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_z02kJbl99M2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unearned discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111,212</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--LongTermAccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: accretion of Loan Premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0780">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">350,302</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Notes Payable, net of the current portion financing costs, unearned premium and discount</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">5,227,270</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zjQrjBvFwAL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Estimated future amortization expense and accretion of Loan Premium is
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleofFutureAmortizationExpenseTableTextBlock_zfupwuvlLAFb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B0_zxxq948tcl1c" style="display: none">Schedule of estimated future amortization expense and accretion of premium</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Unearned Discount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Debt Financing Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Loan Premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Year ending June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; text-align: center; padding-bottom: 1.5pt">2025</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025">111,212</td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025">11,820</td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025">25,758</td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">111,212</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">11,820</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">25,758</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z1BXfF6KpXTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007813552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zEa3bFnfv26i" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>8.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_827_z0cT4uPXKInc">Fair Value Measurements</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At June 30, 2024 and 2023, the estimated fair value of derivative liabilities
measured on a recurring basis are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zs1275pMAXB1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"><span id="xdx_8BC_ztGBkgtbqqxb" style="display: none">Schedule of derivative liabilities at fair value</span>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Derivative liability - Warrants</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0806">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">3,771</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">3,771</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - Conversion Option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total derivative liabilities</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives">3,771</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives">3,771</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Derivative liability - Warrants</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">894,280</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">894,280</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - Conversion option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives">925,762</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives">925,762</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total derivative liabilities</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives">1,820,042</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives">1,820,042</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zDfjHjwYnFUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table presents the activity for level 3 liabilities measured
at fair value using unobservable inputs for the years ended June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z9w664WrOIM5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BB_zwMPaIlLuXg" style="display: none">Fair value, liabilities measured on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liability - Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liability - Conversion Option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance at June 30, 2022</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUgcP89KKABf" style="width: 12%; text-align: right" title="Balance at beginning">194,531</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zblXPAVgAYlb" style="width: 12%; text-align: right" title="Balance at beginning">188,030</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions to level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in in fair value of level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities">699,749</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities">737,732</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Transfer in and/or out of level 3</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0868">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0lABtpPOqxk" style="text-align: right" title="Balance at beginning">894,280</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCdd2q8kxlk5" style="text-align: right" title="Balance at beginning">925,762</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions to level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in in fair value of level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities">(890,509</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities">(925,762</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Transfer in and/or out of level 3</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkkQVIkbkN86" style="border-bottom: Black 3.5pt double; text-align: right" title="Balance at ending">3,771</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwKr3rlPQmJ6" style="border-bottom: Black 3.5pt double; text-align: right" title="Balance at ending"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_ztmqNF8QSJvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair values of derivative liabilities for the
Avenue Warrants and Conversion Option at June 30, 2024 in the accompanying balance sheet, were approximately $3,800 and approximately
zero, respectively. The total change in the fair value of the derivative liabilities totaled approximately $(1.8) million and $1.4 million
for the years ended June 30, 2024, and 2023, respectively; and accordingly, was recorded in the accompanying statements of operations
and comprehensive loss. The assumptions used in the Black Scholes model to value the derivative liabilities at June 30, 2024 included
the closing stock price of $<span id="xdx_908_eus-gaap--SharePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Share Price">4.00</span> per share; for the Avenue Warrants, the exercise price of $<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Exercise Price">58.20</span>, remaining term <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zQfz58nmCpci" title="Term">2.4</span> year, risk free
rate of <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Risk Free Interest Rate">4.6%</span> and volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Volatility Rate">82.0%</span>; and for the Conversion Option, the conversion price of $<span id="xdx_903_eus-gaap--SharePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Share Price">69.80</span>; remaining term of <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtM_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z80P3yszfRQ1" title="Term">5</span> months, risk
free rate of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Risk Free Interest Rate">5.38%</span> and volatility of <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Volatility Rate">91.0%</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Derivative liability &#8211; Avenue Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Avenue Warrants were not considered to be indexed
to the Company&#8217;s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompanying balance sheets
at June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Black Scholes model was used to calculate the
fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue Loan amount funded. The Avenue Warrants
are recorded at their fair values at the date of issuance and remeasured at each subsequent reporting period end date.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Embedded derivative liability &#8211; Conversion
Option</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Conversion Option is accounted for as an embedded
derivative liability and required bifurcation from the Loan amount. The Black Scholes model was used to calculate the fair value of the
Conversion Option to bifurcate it from the Loan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Financial assets</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">As of June 30, 2024, investments in U.S. Treasury Bills were valued through
use of quoted prices and are classified as Level 1. The following table presents information about our assets that are measured at fair
value on a recurring basis using the above input categories.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znrCtiblFEj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B5_zEnnMqJ0iX13" style="display: none">Measured at fair value on a recurring basis</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Cash</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 8%; text-align: right" title="Total">12,763,941</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 8%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 8%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 8%; text-align: right" title="Total">12,763,941</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">11,079,857</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total">11,079,857</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">23,843,798</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">23,843,798</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Cash</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 8%; text-align: right" title="Total">6,304,543</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 8%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 8%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 8%; text-align: right" title="Total">6,304,543</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">13,156,340</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0946">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total">13,156,340</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">U.S. Treasury Bills due in 3 - 6 months at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">14,477,726</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0954">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0956">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" style="text-align: right" title="Total">14,477,726</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">33,938,609</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">33,938,609</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zKu2HKcCU3Th" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/820/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073092886032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity Transactions</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zAP4FJUoa5K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>9.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_823_z2M2FnXZNpOb">Equity Transactions</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance of common stock for cash</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 31, 2022, the Company entered into a Controlled
Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. and B. Riley Securities, Inc. (collectively,
the &#8220;Agents&#8221;), pursuant to which the Company may issue and sell from time-to-time shares of the Company&#8217;s common stock
through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities,
Inc. mutually agreed to terminate B. Riley Securities, Inc.&#8217;s role as a sales agent under the Sales Agreement. During the year ended
June 30, 2024, the Company sold <span id="xdx_90C_ecustom--IssuanceOfCommonStockForCashShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Issuance of common stock for cash, shares">333,749</span> shares of common stock under the Sales Agreement for total net proceeds of approximately $<span id="xdx_902_ecustom--IssuanceOfCommonStockForCash_pp0n3_dm_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z6dmYsKkbBx8" title="Issuance of common stock for cash">9.3</span>
million after deducting <span id="xdx_90E_ecustom--CommissionsPercentage_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Commissions percentage">3%</span> commissions and expenses of approximately $<span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Issuance costs">377,000</span>. During the year ended June 30, 2023, the Company sold <span id="xdx_903_ecustom--IssuanceOfCommonStockForCashShares_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Issuance of common stock for cash, shares">753,925</span>
shares of common stock under the Sales Agreement for total net proceeds of approximately $<span id="xdx_908_ecustom--IssuanceOfCommonStockForCash_pp0n3_dm_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zyp1vsbfxDa1" title="Issuance of common stock for cash">49.5</span> million after <span id="xdx_90C_ecustom--CommissionsPercentage_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Commissions percentage">3%</span> commissions and expenses
of approximately $<span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_pp0n3_dm_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zvNIe5WdZ8cg" title="Issuance costs">2.0</span> million.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On March 6, 2024, the Company closed a best efforts
public offering (the &#8220;Offering&#8221;) of <span id="xdx_904_eus-gaap--PartnersCapitalAccountUnitsSoldInPublicOffering_c20240301__20240306_pdd" title="Public offering">1,500,000</span> shares (the &#8220;Shares&#8221;) of its common stock, par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240306_pdd" title="Common stock, par value">0.001</span> per
share (the &#8220;Common Stock&#8221;), pre-funded warrants (the &#8220;Pre-funded Warrants&#8221;) to purchase <span id="xdx_90D_eus-gaap--StockRepurchasedDuringPeriodShares_c20240301__20240306__us-gaap--AwardTypeAxis__custom--PrefundedWarrantsMember_pdd" title="Stock option to purchase">600,000</span> shares of Common
Stock, and warrants to purchase up to <span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodShares_c20240301__20240306__us-gaap--AwardTypeAxis__custom--CommonWarrantMember_pdd" title="Stock option to purchase">1,050,000</span> shares of Common Stock (the &#8220;Common Warrants&#8221;) at a combined public offering
price of $<span id="xdx_90B_eus-gaap--SharePrice_c20240306_pdd" title="Share price">10.00</span> per Share, or Pre-funded Warrant, and the associated Common Warrant. <span style="background-color: white">The Common
Warrants have an exercise price of $15.00 per share and are immediately exercisable upon issuance for a period of five years following
the date of issuance. </span>The gross proceeds to the Company from the Offering were approximately $21.0 million, before deducting placement
agent fees and offering expenses of approximately $2.5 million, resulting in net proceeds of approximately $18.5 million. Additionally,
upon closing the Company issued the placement agent warrants (&#8220;Placement Agent&#8217;s warrants&#8221;) to purchase 105,000 shares
of Common Stock exercisable at a per share price of $12.50, which was equal to 125% of the public offering price per share. The Placement
Agent&#8217;s Warrants are exercisable during a five-year period commencing 180 days from March 6, 2024. The Pre-Funded Warrants were
exercised shortly after issuance and the <span id="xdx_90B_ecustom--StockExercised_c20230701__20240630__us-gaap--AwardTypeAxis__custom--PrefundedWarrantsMember_pdd" title="Number of stock exercised">600,000</span> shares of Common Stock were issued during the year ended June 30, 2024.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance of common stock for services</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 6, 2023, the Company awarded <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230401__20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Stock issued during period for service">5,000</span> shares
of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance
was $<span id="xdx_901_eus-gaap--SharePrice_c20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Share price">74.50</span> per share. The stock-based compensation expense related to this Common Stock issuance was $<span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230401__20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pp0p0" title="Stock-based compensation expense">372,500</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 10, 2024, the Company awarded <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240501__20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Stock issued during period for service">15,000</span> shares
of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance
was $<span id="xdx_906_eus-gaap--SharePrice_c20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Share price">4.86</span> per share. The stock-based compensation expense related to this Common Stock issuance was $<span id="xdx_908_eus-gaap--ShareBasedCompensation_c20240501__20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pp0p0" title="Stock-based compensation expense">72,900</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock Options</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the activity relating to the Company&#8217;s
stock options for the years ended June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY0PIa7Edy1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BD_zyi9QO5BLXFj" style="display: none">Schedule of summarizes the activity relating to the Company&#8217;s stock options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%">Outstanding at June 30, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ6IjrYM0PK9" style="width: 10%; text-align: right" title="Options outstanding at beginning">339,876</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2LEuzgLVgc4" style="width: 10%; text-align: right" title="Weighted average exercise price, Options outstanding at beginning">74.20</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zniHPECSvOCf" style="width: 10%; text-align: right" title="Weighted remaining average contractual term, beginning">5.5</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJIMoPDiXiJ" style="width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Options granted">71,467</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, granted">59.00</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zeuQ0zrcLVll" style="text-align: right" title="Weighted remaining average contractual term, granted">8.6</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AggregateIntrinsicValueGranted_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="text-align: right" title="Aggregate intrinsic value, granted">38,610</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zOM87jFIn4xc" style="text-align: right" title="Options expired">(1,000</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, expired">286.90</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options Canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zv5I3FpYfVmb" style="text-align: right" title="Options canceled">(4,967</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, canceled">77.40</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ztPM0sj37AFk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options exercised">(10,090</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">81.20</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zUsCjdBEk1W8" style="text-align: right" title="Options outstanding at beginning">395,286</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4TQEKtO9GCi" style="text-align: right" title="Weighted average exercise price, options outstanding at beginning">71.00</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zTWfj23gEGsg" style="text-align: right" title="Weighted remaining average contractual term, beginning">6.3</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zacnml1ySyfj" style="text-align: right" title="Aggregate intrinsic value, outstanding at beginning">1,067,966</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Options granted">155,242</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, granted">11.70</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zAmwB4FxAfqd" style="text-align: right" title="Weighted remaining average contractual term, granted">9.8</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z8npO4KRiGsc" style="text-align: right" title="Options expired">(640</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, expired">46.09</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2FzqrTWIjs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled">(31,812</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, canceled">57.19</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt">Outstanding at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zMmw4UMIeX61" style="border-bottom: Black 3.5pt double; text-align: right" title="Options outstanding at ending">518,076</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ7GNFLcHTX6" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average exercise price, options outstanding at ending">54.11</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zBrYJHdSj1B2" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted remaining average contractual term, ending">6.1</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJUmTKoX9mMk" style="border-bottom: Black 3.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt">Exercisable at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 3.5pt double; text-align: right" title="Options exercisable">296,934</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average exercise price, options exercisable">66.65</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4EOjftFLtG8" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average remaining contractual term, options exercisable">4.9</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_z4i4Td2KuGA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of each option grant on the date of
grant is estimated using the Black-Scholes model. The following weighted-average assumptions were utilized for the years ended:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table border="0" cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z2KR87Z44i4f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity Transactions (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B8_zxtZOoPchiGa" style="display: none">Schedule of assumptions used</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 48%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"><b>June 30, 2024</b></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 4%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"><b>June 30, 2023</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">Expected life of options (in years)</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zCpnCMzVDOij" title="Expected life of options (In years)">6</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zL9h2R6UTHG2" title="Expected life of options (In years)">6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt">Expected volatility</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility">86.28%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility">81.65%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">Risk free interest rate</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">4.40%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">3.82%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt">Dividend Yield</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield">0%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield">0%</span></td></tr>
  </table>
<p id="xdx_8AE_zQWkfr6n66x5" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recorded stock based compensation expense
relating to the vesting of stock options of approximately $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0n3_dm_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zjq8SAOcHyG8" title="Stock-based compensation expense">2.8</span> million and $<span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0n3_dm_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zLp8INhuZr61" title="Stock-based compensation expense">4.2</span> million for the years ended June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance and modification of restricted stock units and options:</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 21, 2022, the Company awarded <span id="xdx_903_ecustom--RsuGranted_c20220601__20220621__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted">12,452</span> restricted
stock units (&#8220;RSUs&#8221;) to the President and CEO under the Company&#8217;s 2019 Omnibus Plan. Each RSU awarded to the CEO entitles
him to receive one share of Common Stock upon vesting. The RSUs vest in three equal annual installments beginning on the first anniversary
grant date. <span id="xdx_908_ecustom--RsuGranted_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted">4,151</span> and <span id="xdx_901_ecustom--RsuGranted_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted">4,151</span> RSUs vested in June 2023 and 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 23, 2022, the Company awarded <span id="xdx_909_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted">38,198</span> RSUs
to certain employees and a consultant, with a grant date fair value of $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted, grant date fair value">61.20</span> per share. 25% of these RSUs vested on the grant date and
the remaining RSUs vest in three equal installments over three years beginning on the first anniversary of the grant date. During the
year ended June 30, 2023, <span id="xdx_908_ecustom--SharesIssuedOverVestingPeriod_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares issued over the vesting period">9,550</span> of these RSUs vested, of which <span id="xdx_90D_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares for tax withholdings">2,288</span> shares were withheld in Treasury stock in exchange for payment of
withholding tax on behalf of the employees.</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 23, 2022, the Company issued equity awards
for the board of directors&#8217; annual compensation. Four directors received <span id="xdx_90A_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pdd" title="Rsu granted">15,564</span> RSUs with a grant date fair value of $<span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pdd" title="Rsu granted, grant date fair value">61.20</span> per
share. In addition, three directors received stock options to purchase <span id="xdx_90D_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pdd" title="Rsu granted">19,500</span> shares of common stock at an exercise price of $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pdd" title="Rsu granted, grant date fair value">61.20</span> per
share with a grant date fair value of $40.60 per share. The equity awards vest quarterly on February 23, 2023, May 23, 2023, August 23,
2023 and earlier of November 23, 2023 or the next annual shareholders&#8217; meeting. During the year ended June 30, 2024, 7,746 of these
RSUs vested. These RSUs and options contain certain contractual vesting terms where the vesting can be accelerated outside the Company&#8217;s
control and as a result, for accounting purposes, are assumed to have been fully vested on the grant date, and accordingly, the Company
recognized the total compensation cost of $<span id="xdx_90F_ecustom--TotalCompensationCost_c20221123_pp0p0" title="Total compensation cost">1,744,192</span> on November 23, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On November 9, 2023, the Company issued equity awards
for the board of directors&#8217; annual compensation. Four directors received <span id="xdx_906_ecustom--RsuGranted_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Rsu granted">18,270</span> RSUs with a grant date fair value of $<span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Rsu granted, grant date fair value">30.10</span> per
share. In addition, two directors received stock options to purchase <span id="xdx_908_ecustom--RsuGranted_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_pdd" title="Rsu granted">18,325</span> shares of common stock at an exercise price of $<span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_pdd" title="Rsu granted, grant date fair value">30.10</span> per
share with a grant date fair value of $18.30 per share. The equity awards vest quarterly on February 9, 2024, May 9, 2024, August 9, 2024
and earlier of November 9, 2024 or the next annual shareholders&#8217; meeting. During the year ended June 30, 2024, <span id="xdx_906_ecustom--SharesIssuedOverVestingPeriod_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Shares issued over the vesting period">4,568 </span>of these RSUs
vested.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the Company terminated five employees
and as part of their severance agreement modified their equity awards that had been granted pursuant to the 2019 Omnibus Plan. The modifications
included the acceleration of certain stock option awards to purchase a total of 5,623 shares of common stock (&#8220;Accelerated Options&#8221;),
effective on the December Separation Date, as defined in severance agreement (&#8220;Separation Date&#8221;), and extended the expiration
date for one year from the Separation Date for both the Accelerated Options and any vested and unexercised stock options held by the terminated
employees as of the Separation Date. Accordingly, the Company remeasured the Accelerated Options based on the stock price of $15.40 per
share at the close on the Separation Date and a one-year extension of the term. The net adjustment for the modification was a net credit
of $127,199 and was recognized as an adjustment to stock compensation expense during the year ended June 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, 1,030 vesting RSUs were accelerated
as of the Separation date. The modified RSUs were remeasured based on the stock price of $15.40 per share at close on the Separation Date
and $15,865, was recorded to additional in stock-based compensation for the year ended June 30, 2024 as a result of the modification.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the separation, the Company canceled
18,396 unvested stock options and 1,030 unvested RSUs. Additionally, the Company canceled an additional 13,416 unvested stock options
for employees that voluntarily left the company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2023, the Company issued <span id="xdx_901_ecustom--RsuGranted_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted">14,950</span> RSUs with
a grant date fair value of $<span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted, grant date fair value">41.10</span> per share to the President and CEO under the Company&#8217;s 2019 Omnibus Plan. The RSUs vest in three
equal annual installments beginning on the first anniversary grant date. <span id="xdx_908_ecustom--SharesIssuedOverVestingPeriod_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares issued over the vesting period">4,983</span> RSUs vested in June 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2024, the Company issued <span id="xdx_90B_ecustom--RsuGranted_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Rsu granted">85,800</span> RSUs to employees,
with a grant date fair value of $<span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Rsu granted, grant date fair value">4.74</span> per share. The RSUs vested on the grant date. The Company delivered the vested portion of the RSU&#8217;s
and issued <span id="xdx_90B_ecustom--SharesIssuedOverVestingPeriod_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Shares issued over the vesting period">85,800</span> shares of Common Stock, of which <span id="xdx_908_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Shares for tax withholdings">21,450</span> shares were withheld in Treasury stock in exchange for payment of withholding
tax on behalf of the employees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes vesting of restricted
stock units:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zrLBdRIFCXO8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B2_zC55HbHlC8ej" style="display: none">Schedule of vesting of restricted common stock</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%">Unvested at June 30, 2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20220701__20230630_z3ZKAo78GOw7" style="width: 10%; text-align: right" title="Number of shares unvested at beginning">12,452</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220701__20230630_zxA1UuJE8s8e" style="width: 10%; text-align: right" title="Weighted average grant date fair value per share unvested at beginning">16.90</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630_pdd" style="text-align: right" title="Number of shares, Granted">68,711</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_zCIA6ZODyD7" style="text-align: right" title="Weighted average grant date fair value per share, Granted">58.87</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20220701__20230630_z4lrSnhJp953" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Vested">(21,518</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value per share, Vested">52.70</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20230701__20240630_z2tDKpwQiWM4" style="text-align: right" title="Number of shares unvested at beginning">59,646</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20240630_zkqNLQRgqHfb" style="text-align: right" title="Weighted average grant date fair value per share unvested at beginning">52.40</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20230701__20240630_zuN0yG7i20bj" style="text-align: right" title="Number of shares, Issued">104,070</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_iP3custom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630_zSFOWi8SKBfl" style="text-align: right" title="Weighted average grant date fair value per share, Issued">9.16</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20240630_zkIik14Oktj" style="text-align: right" title="Number of shares, Vested">(122,395</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" style="text-align: right" title="Weighted average grant date fair value per share, Vested">16.94</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230701__20240630_zeUdZqg5kC4b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Canceled">(1,030</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value per share, Canceled">61.20</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt">Unvested at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230701__20240630_ztxPtNap2pG3" style="border-bottom: Black 3.5pt double; text-align: right" title="Number of shares unvested at ending">40,291</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230701__20240630_zKNDqoCY15xh" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average grant date fair value per share unvested at ending">44.59</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zuUMjSIs6ua6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The total stock-based compensation expense from restricted
stock units for the year ended June 30, 2024 and 2023 was approximately $<span id="xdx_900_ecustom--StockBasedCompensationRestrictedStockUnits_pn3n3_dm_c20230701__20240630_z5KTM1s3ZZBi" title="Stock based compensation - restricted stock units">1.8</span> million and $<span id="xdx_90A_ecustom--StockBasedCompensationRestrictedStockUnits_pn3n3_dm_c20220701__20230630_zAuEvnV1p2U6" title="Stock based compensation - restricted stock units">1.8</span> million, respectively.&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance of Common Stock through exercise of Stock Options and Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2022, the Company issued <span id="xdx_909_ecustom--IssuanceOfCommonStockForCashShares_c20221201__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares">2,209</span> shares
of Common Stock pursuant to a cashless exercise of stock options to purchase <span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_c20221201__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase">9,930 </span>shares at an average exercise price of $<span id="xdx_900_eus-gaap--SharePrice_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price">76.40</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2022, the Company issued <span id="xdx_907_ecustom--IssuanceOfCommonStockForCashShares_c20221101__20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares">80</span> shares of
Common Stock pursuant to a cash exercise of stock options to purchase <span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_c20221101__20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase">80</span> shares at an average exercise price of $<span id="xdx_90E_eus-gaap--SharePrice_c20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price">28.00</span> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2022, the Company issued <span id="xdx_903_ecustom--IssuanceOfCommonStockForCashShares_c20221001__20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Issuance of common stock for cash, shares">359</span> shares of
Common Stock pursuant to a cashless exercise of warrants to purchase <span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_c20221001__20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Stock option to purchase">800</span> shares at an average exercise price of $<span id="xdx_90C_eus-gaap--SharePrice_c20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Share price">22.50</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2023, the Company issued <span id="xdx_90F_ecustom--IssuanceOfCommonStockForCashShares_c20230501__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares">48</span> shares of Common
Stock pursuant to a cashless exercise of stock options to purchase <span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20230501__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase">80</span> shares at an average exercise price of $<span id="xdx_905_eus-gaap--SharePrice_c20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price">31.30</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Issuance of Stock Options under the 2019 Omnibus Plan.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to a former employee&#8217;s Separation Agreement,
dated April 11, 2022, the Company modified their stock option award granted on August 20, 2021, pursuant to the 2019 Omnibus Plan (&#8220;2021
Options Grant&#8221;). Pursuant to the terms of the Separation Agreement, effective July 8, 2022 (the &#8220;Separation Date&#8221;),
the Company accelerated the vesting of options scheduled to vest on the first and second anniversary of the grant date as deemed vested
(&#8220;Accelerated Options&#8221;) and after giving effect to the Accelerated Options, extended the exercise period of the total vested
outstanding and unexercised options (totaling 7,450 options) to one year following the Separation Date. The unvested portion of the 2021
Option Grant (totaling 4,967 options) was canceled. The modification was remeasured as of July 8, 2022, and the incremental difference
in fair value resulted in a net credit to stock based compensation expense of $181,154, due to the original exercise price of $77.40 being
greater than the stock price of $18.00 on the remeasurement date, and accordingly was recognized on July 8, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On June 7, 2023, the Company granted stock options
to purchase <span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_pdd" title="Stock option to purchase">14,800</span> shares of Common Stock to certain employees. <span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage">20%</span> of the shares underlying the options awarded vested on the grant date,
and the remaining <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage">80%</span> will vest in four equal annual installments beginning, on the first grant date anniversary. The exercise price of
the options is $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_pdd" title="Weighted average exercise price, options grants">57.80</span> per share, the grant date fair value and the options terminate on the earlier of the tenth grant date anniversary
or the date of which the options are fully exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the fiscal year ended June 30, 2023, the Company
granted stock options to purchase a total of 28,617 shares of Common Stock in connection with compensation packages of three new employees.
The exercise prices were set at the grant date fair value with vesting terms over a five year period and the options terminate on the
earlier of tenth grant date anniversary or the date of which the options are fully exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On October 3, 2023, the Company granted stock options
to purchase <span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodShares_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_pdd" title="Stock option to purchase">21,117</span> shares of Common Stock to new hire employees. <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage">20%</span> of the shares underlying the options awarded vest on the one-year
anniversary of the grant date, and the remaining <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage">80%</span> will vest in equal monthly installments over 48 months each month thereafter. The
exercise price of the options is $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_pdd" title="Weighted average exercise price, options grants">34.10</span>, the grant date fair value, and the options terminate on the earlier of the tenth grant date anniversary
or the date of which the options are fully exercised.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2024, the Company granted stock options to
purchase <span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodShares_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Stock option to purchase">115,800</span> shares of Common Stock to employees. <span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage">33%</span> of the shares underlying the options awarded vest on the grant date, and the
remaining <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage">67%</span> will vest over <span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dtY_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zEaDaznUB7S7" title="Weighted average contractual term, granted (in years)">2 </span>years on first and second anniversary of the grant date. The exercise price of the options is $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Weighted average exercise price, options grants">4.70</span>, the
grant date fair value, and the options terminate on the earlier of the tenth grant date anniversary or the date of which the options are
fully exercised.</p>







<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Stock Warrants</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The following table summarizes the warrants activity during the years ended
June 30, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zTxLQfBk4QFf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BE_zXcxLU8Mrww2" style="display: none">Summary of warrants activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding and exercisable at June 30, 2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFt3UdaFHjA7" style="width: 10%; text-align: right" title="Number of shares, beginning">51,037</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezeOitS5oye" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning">61.70</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4MlrRIkQenj" style="width: 10%; text-align: right" title="Weighted average remaining life (Years)">3.8</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS0ffXNfJew2" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted">727,273</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, granted">18.20</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6MduR83yFX6" style="text-align: right" title="Weighted average remaining life (Years), granted">5.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, expired">(482</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, expired">750.00</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, exercised">(800</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">22.50</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and exercisable at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhqqbkU5vptj" style="text-align: right" title="Number of shares, beginning">777,029</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJE3Rq0QYL0h" style="text-align: right" title="Weighted average exercise price, beginning">20.60</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhG5LlwdbFaf" style="text-align: right" title="Weighted average remaining life (Years)">4.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeO5eZu6Onwk" style="text-align: right" title="Aggregate intrinsic value, beginning">18,318,954</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted">1,755,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, granted">13.14</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsjwHYw3163d" style="text-align: right" title="Weighted average remaining life (Years), granted">5.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, exercised">(600,000</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">10.00</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and exercisable at June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCdB34JCMxi8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, ending">1,932,029</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1WDknVwxva4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, ending">14.03</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8LHwB4BZkm7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average remaining life (Years)">4.0</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR0yUbLulZtk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A6_zJDt286aOWy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Of the above warrants outstanding at June 30, 2024,
10,138 expire in the fiscal year ending June 30, 2025, 3,518 expire in the fiscal year ending June 30, 2026, 763,373 expire in the fiscal
year ending June 30, 2027 and 1,155,000 expire in the fiscal year ending June 30, 2029.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007921664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_z4gKA1pzvARi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><tr style="vertical-align: top; text-align: justify">
<td style="width: 5%; text-align: left"><b>10.</b></td><td style="text-align: justify; width: 95%"><b><span id="xdx_821_znv0a0RRpg31">Leases</span></b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Office Leases&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company pays an annual rent of $2,200 for its
headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 89703. The rental agreement was for a one-year term, commenced on October
1, 2022 and has been subsequently renewed for another year at the same rate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s San Diego office lease at 5090
Shoreham Place Suite 212, San Diego, CA 92122 which commenced on March 1, 2022, was for a term of 38 months with a base monthly rate of
$4,300, and annual increases of three percent. In February 2024, the Company amended the lease agreement which allowed the Company to
vacate the then current space and move to a larger space at Suite 206. The current monthly base rate for the new office space is $9,685,
with an annual increase of four percent. The term for the new office lease is 60 months and commenced on February 12, 2024. The lease
that was in place for the 5090 Shoreham Place Suite 212 office was effectively extinguished upon the commencement of the new office space
lease on February 12, 2024, resulting in the write off of the corresponding remaining right-of-use asset and operating lease liability
of $<span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_c20240212_pp0p0" title="Right-of-use Asset">56,909</span> and $<span id="xdx_907_eus-gaap--OperatingLeaseLiability_c20240212_pp0p0" title="Operating Lease Liability">62,124</span>, respectively, and a gain to selling, general and administrative expenses of $<span id="xdx_908_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_c20230701__20240630_pp0p0" title="Selling, general and administrative expenses">5,215</span> for the year ended June 30,
2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total operating lease expense for the years ended
June 30, 2024 and 2023 of approximately $<span id="xdx_900_eus-gaap--OperatingLeaseCost_c20230701__20240630_pp0p0" title="Operating lease cost">78,000</span> and $<span id="xdx_909_eus-gaap--OperatingLeaseCost_c20220701__20230630_pp0p0" title="Operating lease cost">52,000</span>, respectively were included in the accompanying statements of operations and
comprehensive loss as a component of selling, general and administrative expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The right-of-use asset, net and current and non-current
portion of the operating lease liabilities included in the accompanying balance sheets are as follows:</p>










<table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zK0mHEbrKgPk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span id="xdx_8BE_zfGb1g5Gxjca" style="display: none">Schedule of deferred tax assets</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20240630_zzJ7squRbxUd" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230630_zdOKjRFMiaj4" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 9pt">Operating lease, right-of-use asset, net</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">406,726</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">80,789</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzaZ2_zvpYfD8gWgH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Current portion of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">60,343</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">44,909</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzaZ2_zrVGBZuBz8Q9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">349,894</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,505</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzaZ2_zbGaMu8tGe2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">410,237</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">87,414</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A0_zqGo0In8Uesk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At June 30, 2024, the future estimated minimum lease payments under non-cancelable
operating leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_zjAniu6OFTM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap"><span id="xdx_8BB_zjR5t82sClE8" style="display: none">Schedule of future estimated minimum lease payments
under non-cancelable operating leases</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240630_ztH27BtOyWHk" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zqZ2B95jdEpg" style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">Year ending June 30,</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_z4Qw1VBlo9X1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">2025</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">117,915</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zHcktjtcrraj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,042</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zGrtVgFrWpw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,313</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_zC0ZhKUiCrDi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,734</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_zHDJjQ95KTtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2029</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,796</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_zlw86PDVV9oi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">574,800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zCTd8MmOeJKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(164,563</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zphvj0jiWCak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410,237</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_znbDQIyLJHmf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion of operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,343</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zmcpWkaywI88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">349,894</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zZTUpyEQNv8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Total cash paid for amounts included in the measurement of lease liabilities
were $<span id="xdx_902_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20230701__20240630_pp0p0" title="Cash paid for amounts included in measurement of operating lease liabilities">83,910</span> and $<span id="xdx_904_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20220701__20230630_pp0p0" title="Cash paid for amounts included in measurement of operating lease liabilities">50,600</span> for the years ended June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average remaining lease term and discount
rate as of June 30, 2024 and 2023 were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zLzLUdGsL4C" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B0_zxPSCX2JvfVj" style="display: none">Schedule of weighted average remaining lease term and discount rate</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average remaining lease term (Years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 9pt">Operating lease</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zkd3G27WweUa" style="width: 12%; text-align: right" title="Weighted average remaining lease term (Years) Operating leases">4.6</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630_zfttVefLI08j" style="width: 12%; text-align: right" title="Weighted average remaining lease term (Years) Operating leases">1.8</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Operating lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zOCoMOiyaRXe" style="text-align: right" title="Weighted average discount rate Operating leases">15.00</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630_zxig8joGQCI7" style="text-align: right" title="Weighted average discount rate Operating leases">10.75</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  </table>

<p id="xdx_8AF_zTnRyaO6nrv" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>




<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007828000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOdRkpzwL0e1" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>11.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_827_z8OY9MklOqL2">Commitments and Contingencies</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Royalty Agreements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Agreement and Plan of Merger entered
into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay
a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members,
PharmaIn Corporation, and The Barrett Edge, Inc.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Pursuant to the Technology Transfer Agreement entered
into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit
royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum
of $200,000 per year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>Shareholder class action complaint</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 19, 2024, a purported shareholder class action complaint,
captioned&#160;<i>Eric Olmstead v. BioVie Inc. et al.</i>, No. 3:24-cv-00035, was filed in the U.S. District Court for the District of
Nevada, naming the Company and certain of its officers as defendants. On February 22, 2024, a second, related putative securities class
action was filed in the same court asserting similar claims against the same defendants, captioned <i>Way v. BioVie Inc. et al.</i>, No.
2:24-cv-00361. On April 15, 2024, the court consolidated these two actions under the caption <i>In re BioVie Inc. Securities Litigation</i>,
No. 3:24-cv-00035, appointed the lead plaintiff, and approved selection of the lead counsel. On June 21, 2024, the lead plaintiff filed
an amended complaint, alleging that the defendants made material misrepresentations and/or omissions of material fact relating to the
Company&#8217;s business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of
bezisterim (NE3107) in mild to moderate probable AD,&#160;<span style="background-color: white">in violation of Sections 10(b) and 20(a)
of the&#160; Exchange Act, and&#160;Rule 10b-5&#160;promulgated thereunder. The class action is on behalf of purchasers of the Company&#8217;s
securities during the period from December 7, 2022 through November 28, 2023 and seeks unspecified monetary damages on behalf of the putative
class and an award of costs and expenses, including attorney&#8217;s fees. The defendants filed a motion to dismiss the amended complaint
on August 21, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company believes the lawsuit is without merit
and intends to defend the case vigorously. At this early stage of the proceedings, the Company is unable to make any prediction regarding
the outcome of the litigation. No adjustment or accruals have been reflected in the accompanying financial statements.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002201536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureEmployeeBenefitPlanAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_EmployeeBenefitPlanTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p id="xdx_807_ecustom--EmployeeBenefitPlanTextBlock_zGZxSFtZCZ2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>12.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_82D_zLAjPhzflXqh">Employee Benefit Plan</span></b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2021, the Company began sponsoring an
employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the &#8220;401K Plan&#8221;) pursuant to which,
all employees meeting eligibility requirements are able to participate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Subject to certain limitations in the Internal Revenue Code, eligible employees
are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5%
of an employee&#8217;s contributions to the 401K Plan. The Company made contributions into the plan of approximately $<span id="xdx_903_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230701__20240630_pp0p0" title="Defined benefit plan, plan assets, contributions by employer">153,200</span> and $<span id="xdx_901_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20220701__20230630_pp0p0" title="Defined benefit plan, plan assets, contributions by employer">171,900</span>,
for the years ended June 30, 2024 and 2023, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>





<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureEmployeeBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureEmployeeBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_EmployeeBenefitPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_EmployeeBenefitPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007894832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_z4N8PjsQUVik" style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>13.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_828_zGs5FBxm8q4b">Income Taxes</span> </b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Significant components of the Company&#8217;s deferred tax assets (liabilities)
are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTJXLAdEWMl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B0_za50uHnoA4Q1" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20240630_zWePO7pGDJld" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20230630_zQ70IyjVtpn7" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0p0_maDTANzRXI_zPq7iRYtFpkc" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Tax loss carryforward</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">51,429,074</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,080,664</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pp0p0_maDTANzRXI_zDpzXAwXpk3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">(114,161</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(189,854</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTANzRXI_zxuHC2mnaSAk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">5,860,272</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,575,852</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTANzRXI_z8nmJRJah3Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D capitalized</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">12,467,969</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,171,276</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzRXI_zPKEQEoQ3QMd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,643,154</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,637,938</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzRXI_zH8YMZ7CdXEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zhDwX9DMosy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">At June 30, 2024 and 2023, the Company has recorded a full valuation
against its net deferred tax assets of approximately $<span id="xdx_90D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0n3_dm_c20240630_znkIDB2w2fzi">69.6 </span>million
and $<span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0n3_dm_c20230630_zvALIByr1F3g">60.6 </span>million,
respectively, since in the judgement of management, these assets are not more than likely to be realized. The increase in the
valuation allowance during the year ended June 30, 2024 was approximately $<span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n3_dm_c20230701__20240630_zJw54XjfI9r9">9.0 </span>million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At June 30, 2024, the Company had a Net Operating
Loss (&#8220;NOL&#8221;) carryforward of approximately $<span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20240630_zfCD5CBcdSLb" title="Net Operating Loss carryforward">184</span> million. NOL&#8217;s generated prior to 2018 have expiration dates ranging
from <span id="xdx_90D_ecustom--ExpirationsDates_c20230701__20240630" title="Expirations dates">2032 to 2037</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">The Company has no current tax expense due to its net losses and a full
valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Reconciliation of the differences between income tax
benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2024
and 2023 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCYnObkGJGza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B1_zYNz8P5C7rqe" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20240630_zk1mL1B9jQt2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220701__20230630_zWwzEFvfLif2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zqiRUeC8q535" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Income tax expense at federal statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zoVUd8Dkb00d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zmTGy9d4mR3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z1RlQ5vwLO89" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt">Effective tax rate</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007737376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zAWE7Lc3n62a" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 5%; font-size: 10pt"><b>14.</b></td>
    <td style="width: 95%; font-size: 10pt"><b><span id="xdx_822_zqES6tIa3ZV6">Subsequent Events</span></b></td></tr>
  </table>
  <p id="xdx_ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 25, 2024, the Company closed a best
efforts public offering (the &#8220;September 2024 Offering&#8221;) of <span id="xdx_90C_eus-gaap--CommonStockSharesIssued_c20240925_pdd" title="Common stock shares">1,360,800</span>
shares of its common stock, par value $<span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20240925_pdd" title="Common stock per value">0.0001</span>
per share, pre-funded warrants (the &#8220;September Pre-funded Warrants&#8221;) to purchase <span id="xdx_901_ecustom--PurchaseOfCommonStockShares_c20240925__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of shares">600,000</span>
shares of Common Stock, and warrants to purchase up to <span id="xdx_908_ecustom--PurchaseOfCommonStockShares_c20240925__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pdd" title="Purchase of shares">1,960,800</span>
shares of Common Stock (the &#8220;September Common Warrants&#8221;) at a combined public offering price of $<span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20240925__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pdd" title="Common stock per value">1.53</span>
per Share, or September Pre-funded Warrant, and the associated September Common Warrant. <span style="background-color: white">The <span style="background-color: white">September </span>Common
Warrants have an exercise price of $<span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240925_pdd" title="Warrants exercise price">1.53</span>
per share and are immediately exercisable upon issuance and will expire on the fifth anniversary date of the original issuance date. </span>The
gross proceeds to the Company from the September 2024 Offering were approximately $<span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0n3_dm_c20240901__20240925_zY5EFVFcB3Q2" title="Proceeds from public offering">3.0</span>
million, before deducting placement agent fees and offering expenses of approximately $<span id="xdx_904_ecustom--AgentFeesAndOfferingExpenses_c20240901__20240925_pn3p0" title="Agent fees and offering expenses">560,000</span>.
Additionally, upon closing the Company issued the placement agent warrants (&#8220;September Placement Agent&#8217;s
Warrants&#8221;) to purchase <span id="xdx_906_eus-gaap--TemporaryEquitySharesIssued_c20240925__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pdd" title="Warrant issued">98,040</span>
shares of Common Stock exercisable at a per share price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240925__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pdd" title="Warrants exercise price">1.91</span>,
which was equal to 125% of the public offering price per share. The September Placement Agent&#8217;s Warrants are exercisable
during a five-year period commencing 180 days from September 25, 2024.&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004646656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zebyfefaqk47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zuLVlMJvL9b2">Basis of Presentation</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial statements have been
prepared in accordance with accounting principles generally accepted in the United States (&#8220;GAAP&#8221;) and include all adjustments
necessary for the fair presentation of the Company&#8217;s financial position for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p id="xdx_843_eus-gaap--UseOfEstimates_zkYmHk6pRTDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_865_zXVFq7dHQ0oc">Use of Estimates</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying
notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the
circumstances. The amounts of assets and liabilities reported in the Company&#8217;s balance sheets and the amounts of expenses reported
for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which
are used for, but not limited to, accounting for clinical accruals, share-based compensation, accounting for derivatives, assumptions
used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and
accounting for income taxes. Actual results could differ from those estimates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1bk7qiimWe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zUQkDpl4k1ya">Cash and cash equivalents</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cash and cash equivalents consisted of cash deposits
and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S.
Treasury Bills with original maturities of three months or less.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_InvestmentsUSTreasuryBillsPolicyTextBlock', window );">Investments in U.S. Treasury Bills</a></td>
<td class="text"><p id="xdx_84D_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_z3aqWr0boaMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_862_zUelhoMtJqfg">Investments in U.S. Treasury Bills</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Investments in U.S. Treasury Bills with maturities
greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other
comprehensive income in the accompanying statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock', window );">Concentration of Credit Risk in the Financial Service Industry</a></td>
<td class="text"><p id="xdx_842_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zV9UO2YnPgge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zSuBbiWxmaLd">Concentration of Credit Risk in the Financial Service
Industry</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of June 30, 2024, the Company had cash deposited
in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these
financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March
and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions
due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material
direct impact on the Company&#8217;s operations, if further liquidity and financial stability concerns arise with respect to banks and
financial institutions, either nationally or in specific regions, the Company&#8217;s ability to access cash or enter into new financing
arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement of assets and liabilities</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zU1VURvQxAR" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zzS4ULT1Zzhg">Fair value measurement of assets and liabilities</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We determine the fair values of our financial instruments
based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the
asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the
fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset
or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant
to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 1 - Inputs are unadjusted quoted prices in active
markets for identical assets or liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 2 - Inputs are quoted prices for similar assets
and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market
corroboration, for substantially the full term of the financial instrument.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Level 3 - Inputs are unobservable inputs based on
our assumptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company&#8217;s financial instruments include
cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts
payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating
lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_PrepaidAndOtherAssetsPolicyTextBlock', window );">Prepaid and other assets</a></td>
<td class="text"><p id="xdx_849_ecustom--PrepaidAndOtherAssetsPolicyTextBlock_zPIGiac7r2vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_zOA3YHVhTic4">Prepaid and other assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid and other assets consist of prepayments of
certain expenses and a security deposit paid in connection with a lease agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>




<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zXUyPYrjc8n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_zFXQIjiZ4lIg">Leases</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company determines whether an arrangement contains
a lease at inception. Operating leases are included in operating lease right-of-use (&#8220;ROU&#8221;) assets, current portion of operating
lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company&#8217;s
right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from
the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease
term at the commencement date. As the Company&#8217;s leases do not provide an implicit rate, an incremental borrowing rate is used based
on the information available at the commencement date in determining the present value of lease payments. The Company does not include
options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such
options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets
or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease
payments as expense on a straight-line basis over the lease term.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zw5dMpI2O1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_zWnYoZSIavae">Research and Development</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses consist primarily
of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development,
personnel, supplies and development materials, costs for consultants and related contract research and facility costs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zqRMfBsKS5pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_867_zWAOugpoWc7l">Income Taxes</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the asset and liability method of
accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards
and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a
valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company
decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company recognizes uncertainty in income taxes
in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in
a tax return. The Company applies the &#8220;more-likely-than-not&#8221; recognition threshold to all tax positions, commencing at the
adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there
have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,
if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive
Loss. For the years ended June 30, 2024 and 2023, there was no such interest or penalty.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zzafBczj30B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_861_zP0T8FTTKfDd">Net Loss per Common Share</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per common share is computed by dividing
the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period.
Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number
of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution
that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30,
2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for
the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below shows the potential shares of common stock, presented based on amounts outstanding
at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including
them would have had an anti-dilutive effect:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z4xX8a8Ld4Eh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B0_zzRmJdp8450j" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total">518,076</td><td style="white-space: nowrap; width: 8%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total">395,286</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">1,932,029</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">777,029</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">40,291</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">59,646</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes payable conversion option</p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">71,633</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">71,633</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 3.5pt">Total</td><td style="font-weight: bold; padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total">2,562,029</td><td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z7TsdxVTmiRa" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total">1,303,594</td><td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zGNGGaqFFrIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i><span id="xdx_860_zXhPFYOTD7x">Stock-based Compensation</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company has accounted for stock-based compensation
under the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 718 &#8211; &#8220;Stock Compensation&#8221; (&#8220;ASC
718&#8221;) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees
and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees
awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses
assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. For non-employees, the Company
utilizes the graded vesting attribution method under which the entity treats each separately vesting portion (tranche) as a separate award
and recognizes compensation cost for each tranche over its separate vesting schedule. Expected volatilities are based on historical volatility
of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected
term of options granted is derived using the &#8220;simplified method&#8221; which computes expected term as the average of the sum of
the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for
the period of the expected term. The Company recognizes forfeitures as they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zpHNQRK66eD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_864_zVullYgQSaFe">Goodwill</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Goodwill is recorded when the purchase price paid
for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual
impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests.
The Company&#8217;s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill
related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an
asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make
certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each
time the Company tests goodwill for impairment and are typically developed as part of the Company&#8217;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce
materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2024 and 2023.</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxEExg1l3wa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_866_ztcdrcAsC2q2">Impairment of Long-Lived Assets</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Long-lived assets, including intangible assets, are
reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">If the carrying amount of an asset exceeds its undiscounted
estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying
amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected
discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities
of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance
sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ReverseStockSpliteUpPolicyTextBlock', window );">Reverse stock split up</a></td>
<td class="text"><p id="xdx_848_ecustom--ReverseStockSpliteUpPolicyTextBlock_zSThz6PT6ydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_860_z1RnzX1jpb0k">Reverse stock split up</span> </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt">The company effected a 1:10 reverse split of the issued and outstanding
shares of its Class A commons stock which was approved by the board of director after the approval obtained from shareholders at a special
meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders&#8217; approval was
obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split.<span style="font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zuwhNodhFzFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span id="xdx_868_z4C4Pn21Svea">Recent Accounting Pronouncements</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company considers the applicability and impact
of all Accounting Standards Updates (&#8220;ASU&#8217;s&#8221;). There were no recent ASU&#8217;s that are expected to have a material
impact on our balance sheets or statements of operations and comprehensive loss.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2016, the Financial Accounting Standards Board
(&#8220;FASB&#8221;) issued ASU No. 2016-13, &#8220;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments&#8221; (&#8220;ASU 2016-13&#8221;). This amendment replaces the incurred loss impairment methodology in current
GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade receivables. This update
is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted
ASU 2016-13 effective July 1, 2023 and the adoption had an insignificant impact on the accompanying financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>





<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures," to enhance disclosures for significant segment expenses for all public entities required to report segment information
in accordance with ASC 280. The standard did not change the definition of a segment, the method for determining segments or the criteria
for aggregating operating segments into reportable segments. The amendments are effective for fiscal years beginning after December 15,
2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods
presented in the financial statements. The adoption is not expected to have a material impact to our financial statements or disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2023, the FASB issued ASU 2023-09, "Income
Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures.
This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information
for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount
of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions.
Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between
domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are
effective for annual periods beginning after December 15, 2024. We will adopt this standard on a prospective basis as allowed by the standard.
The adoption of this standard is not expected to have a material impact on our financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_InvestmentsUSTreasuryBillsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_InvestmentsUSTreasuryBillsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_PrepaidAndOtherAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_PrepaidAndOtherAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ReverseStockSpliteUpPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ReverseStockSpliteUpPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007917488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of dilutive securities were excluded from the computation of diluted loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z4xX8a8Ld4Eh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B0_zzRmJdp8450j" style="display: none">Schedule of dilutive securities were excluded from the computation of diluted loss per share</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2024</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30, 2023</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Stock Options</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total">518,076</td><td style="white-space: nowrap; width: 8%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total">395,286</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">1,932,029</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total">777,029</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Restricted Stock Units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">40,291</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total">59,646</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Notes payable conversion option</p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">71,633</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">71,633</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 3.5pt">Total</td><td style="font-weight: bold; padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total">2,562,029</td><td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z7TsdxVTmiRa" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total">1,303,594</td><td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073091473936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in U.S. Treasury Bills available-for-sale (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract', window );"><strong>Investments In U.s. Treasury Bills Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock', window );">Schedule of U.S. treasury bills held</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfUSTreasuryBillsHeldTableTextBlock_zFpMQIBDZYM9" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span id="xdx_8B9_zwPq9nbsxKK3" style="display: none">Schedule of U.S. treasury bills held</span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amortized
    Cost Basis</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Unrealized Gain</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gross
    Unrealized loss</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair
    Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    Accumulated Other Comprehensive Income</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">U.S. Treasury
    Bills due in 3 - 6 months</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--AmortizedCostBasis_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Amortized Cost Basis"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,301,136</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_985_ecustom--GrossUnrealizedGain_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Gross Unrealized Gain"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">176,591</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_ecustom--GrossUnrealizedLoss_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Gross Unrealized loss"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#8212;</span></span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98D_eus-gaap--InvestmentOwnedAtFairValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Fair Value"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14,477,726</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td><td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Total Accumulated Other Comprehensive Income"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">176,591</span></td><td style="white-space: nowrap; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073093649296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zWlieL5r0Rt3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8BD_zVTU4dWRgoW7" style="display: none">Schedule of intangible assets</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_492_20240630" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_491_20230630" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzbKJ_zQ2SOZ6MBv28" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Intellectual Property</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">2,293,770</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzbKJ_zuLnqk5tPxO" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Amortization</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,886,052</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,656,675</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzbKJ_z7X64uOB06K4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Intellectual Property, Net</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">407,718</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">637,095</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of future amortization expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOWvmnVxiYid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt"><span id="xdx_8B6_zPn29iP1C7w3" style="display: none">Schedule of future amortization expense</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20240630_zTK62UB8coMi" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">Year ending June 30,</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: center">2025</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 48%; text-align: right">229,377</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 1.5pt">2026</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">178,341</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="color: rgb(204,238,255); padding-bottom: 3.5pt">&#160;Finite lived intangible assets, net</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">407,718</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007803104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of note payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zaRglNHc3gAk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B8_zWvDsDKpNXFg" style="display: none">Schedule of note payable</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20240630_znFsMdOQI535" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_491_20230630_zoW9eLTsQjYl" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Current portion of Notes Payable</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">10,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--DebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: debt financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,820</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108,751</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_zZTwYjN6FXja" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unearned discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111,212</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,023,145</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: accretion of Loan Premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">824,242</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">236,970</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Current portion of Notes Payable, net of financing costs, unearned premium and discount</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">5,701,210</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">9,105,074</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Non-current portion of Notes Payable</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20240630_zVy4JaB1LlEb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49B_20230630_zeXJplCcT4mb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_406_ecustom--NotesPayableNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Notes Payable</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0771">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">5,000,000</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--LongtermDebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Less: debt financing costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0774">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,820</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_401_ecustom--LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_z02kJbl99M2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: unearned discount</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0777">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(111,212</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_400_ecustom--LongTermAccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Plus: accretion of Loan Premium</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0780">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">350,302</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt">Notes Payable, net of the current portion financing costs, unearned premium and discount</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0783">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">5,227,270</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ScheduleofFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated future amortization expense and accretion of premium</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleofFutureAmortizationExpenseTableTextBlock_zfupwuvlLAFb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B0_zxxq948tcl1c" style="display: none">Schedule of estimated future amortization expense and accretion of premium</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Unearned Discount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Debt Financing Costs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">Loan Premium</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Year ending June 30,</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 22%; text-align: center; padding-bottom: 1.5pt">2025</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025">111,212</td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025">11,820</td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 5%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025">25,758</td><td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center; padding-bottom: 3.5pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">111,212</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">11,820</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">25,758</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ScheduleofFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ScheduleofFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002159280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of derivative liabilities at fair value</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zs1275pMAXB1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center"><span id="xdx_8BC_ztGBkgtbqqxb" style="display: none">Schedule of derivative liabilities at fair value</span>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Derivative liability - Warrants</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0806">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">3,771</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">3,771</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - Conversion Option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0812">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0814">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0816">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0818">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total derivative liabilities</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives">3,771</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives">3,771</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Derivative liability - Warrants</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">894,280</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives">894,280</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Derivative liability - Conversion option</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives">925,762</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives">925,762</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total derivative liabilities</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0844">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"><span style="-sec-ix-hidden: xdx2ixbrl0846">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives">1,820,042</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives">1,820,042</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value, liabilities measured on recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z9w664WrOIM5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8BB_zwMPaIlLuXg" style="display: none">Fair value, liabilities measured on recurring basis</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liability - Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Derivative liability - Conversion Option</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%">Balance at June 30, 2022</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUgcP89KKABf" style="width: 12%; text-align: right" title="Balance at beginning">194,531</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zblXPAVgAYlb" style="width: 12%; text-align: right" title="Balance at beginning">188,030</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions to level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0858">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0860">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in in fair value of level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities">699,749</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities">737,732</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Transfer in and/or out of level 3</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0866">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0868">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Balance at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0lABtpPOqxk" style="text-align: right" title="Balance at beginning">894,280</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCdd2q8kxlk5" style="text-align: right" title="Balance at beginning">925,762</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additions to level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0874">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"><span style="-sec-ix-hidden: xdx2ixbrl0876">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in in fair value of level 3 liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities">(890,509</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities">(925,762</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Transfer in and/or out of level 3</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0882">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"><span style="-sec-ix-hidden: xdx2ixbrl0884">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt">Balance at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkkQVIkbkN86" style="border-bottom: Black 3.5pt double; text-align: right" title="Balance at ending">3,771</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwKr3rlPQmJ6" style="border-bottom: Black 3.5pt double; text-align: right" title="Balance at ending"><span style="-sec-ix-hidden: xdx2ixbrl0888">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Measured at fair value on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znrCtiblFEj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B5_zEnnMqJ0iX13" style="display: none">Measured at fair value on a recurring basis</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Cash</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 8%; text-align: right" title="Total">12,763,941</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 8%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0914">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 8%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 8%; text-align: right" title="Total">12,763,941</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">11,079,857</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0924">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total">11,079,857</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">23,843,798</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0930">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0932">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">23,843,798</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center">Fair Value Measurements at</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 1</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 2</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Level 3</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center">Total</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 48%">Cash</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 8%; text-align: right" title="Total">6,304,543</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 8%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0938">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 8%; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0940">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 8%; text-align: right" title="Total">6,304,543</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">U.S. Treasury Bills due in 3 months or less at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">13,156,340</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0946">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0948">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total">13,156,340</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">U.S. Treasury Bills due in 3 - 6 months at purchase</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total">14,477,726</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0954">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0956">-</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" style="text-align: right" title="Total">14,477,726</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt; padding-left: 9pt">Total</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">33,938,609</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0962">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"><span style="-sec-ix-hidden: xdx2ixbrl0964">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total">33,938,609</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073092894480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summarizes the activity relating to the Company&#8217;s stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY0PIa7Edy1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BD_zyi9QO5BLXFj" style="display: none">Schedule of summarizes the activity relating to the Company&#8217;s stock options</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Remaining Average Contractual Term</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%">Outstanding at June 30, 2022</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ6IjrYM0PK9" style="width: 10%; text-align: right" title="Options outstanding at beginning">339,876</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2LEuzgLVgc4" style="width: 10%; text-align: right" title="Weighted average exercise price, Options outstanding at beginning">74.20</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zniHPECSvOCf" style="width: 10%; text-align: right" title="Weighted remaining average contractual term, beginning">5.5</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJIMoPDiXiJ" style="width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding at beginning of period"><span style="-sec-ix-hidden: xdx2ixbrl1020">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Options granted">71,467</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, granted">59.00</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zeuQ0zrcLVll" style="text-align: right" title="Weighted remaining average contractual term, granted">8.6</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_ecustom--AggregateIntrinsicValueGranted_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="text-align: right" title="Aggregate intrinsic value, granted">38,610</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zOM87jFIn4xc" style="text-align: right" title="Options expired">(1,000</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, expired">286.90</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options Canceled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zv5I3FpYfVmb" style="text-align: right" title="Options canceled">(4,967</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, canceled">77.40</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ztPM0sj37AFk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options exercised">(10,090</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">81.20</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Outstanding at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zUsCjdBEk1W8" style="text-align: right" title="Options outstanding at beginning">395,286</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4TQEKtO9GCi" style="text-align: right" title="Weighted average exercise price, options outstanding at beginning">71.00</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zTWfj23gEGsg" style="text-align: right" title="Weighted remaining average contractual term, beginning">6.3</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zacnml1ySyfj" style="text-align: right" title="Aggregate intrinsic value, outstanding at beginning">1,067,966</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Options granted">155,242</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, granted">11.70</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zAmwB4FxAfqd" style="text-align: right" title="Weighted remaining average contractual term, granted">9.8</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z8npO4KRiGsc" style="text-align: right" title="Options expired">(640</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, expired">46.09</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Options Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2FzqrTWIjs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled">(31,812</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, canceled">57.19</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt">Outstanding at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zMmw4UMIeX61" style="border-bottom: Black 3.5pt double; text-align: right" title="Options outstanding at ending">518,076</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ7GNFLcHTX6" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average exercise price, options outstanding at ending">54.11</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zBrYJHdSj1B2" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted remaining average contractual term, ending">6.1</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJUmTKoX9mMk" style="border-bottom: Black 3.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding at ending"><span style="-sec-ix-hidden: xdx2ixbrl1070">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 3.5pt">Exercisable at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 3.5pt double; text-align: right" title="Options exercisable">296,934</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average exercise price, options exercisable">66.65</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4EOjftFLtG8" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average remaining contractual term, options exercisable">4.9</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used</a></td>
<td class="text"><table border="0" cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z2KR87Z44i4f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity Transactions (Details 1)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8B8_zxtZOoPchiGa" style="display: none">Schedule of assumptions used</span></td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 48%; font-size: 10pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"><b>June 30, 2024</b></td>
    <td style="padding-bottom: 1.5pt; white-space: nowrap; width: 4%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"><b>June 30, 2023</b></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">Expected life of options (in years)</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zCpnCMzVDOij" title="Expected life of options (In years)">6</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zL9h2R6UTHG2" title="Expected life of options (In years)">6</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt">Expected volatility</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility">86.28%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility">81.65%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; font-size: 10pt">Risk free interest rate</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">4.40%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate">3.82%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="white-space: nowrap; font-size: 10pt">Dividend Yield</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield">0%</span></td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; font-size: 10pt; text-align: center"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield">0%</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of vesting of restricted common stock</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zrLBdRIFCXO8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8B2_zC55HbHlC8ej" style="display: none">Schedule of vesting of restricted common stock</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Grant Date Fair Value Per Share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%">Unvested at June 30, 2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20220701__20230630_z3ZKAo78GOw7" style="width: 10%; text-align: right" title="Number of shares unvested at beginning">12,452</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220701__20230630_zxA1UuJE8s8e" style="width: 10%; text-align: right" title="Weighted average grant date fair value per share unvested at beginning">16.90</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630_pdd" style="text-align: right" title="Number of shares, Granted">68,711</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_zCIA6ZODyD7" style="text-align: right" title="Weighted average grant date fair value per share, Granted">58.87</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Vested</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20220701__20230630_z4lrSnhJp953" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Vested">(21,518</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value per share, Vested">52.70</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Unvested at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20230701__20240630_z2tDKpwQiWM4" style="text-align: right" title="Number of shares unvested at beginning">59,646</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20240630_zkqNLQRgqHfb" style="text-align: right" title="Weighted average grant date fair value per share unvested at beginning">52.40</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20230701__20240630_zuN0yG7i20bj" style="text-align: right" title="Number of shares, Issued">104,070</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_iP3custom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630_zSFOWi8SKBfl" style="text-align: right" title="Weighted average grant date fair value per share, Issued">9.16</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20240630_zkIik14Oktj" style="text-align: right" title="Number of shares, Vested">(122,395</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" style="text-align: right" title="Weighted average grant date fair value per share, Vested">16.94</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Canceled</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230701__20240630_zeUdZqg5kC4b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Canceled">(1,030</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value per share, Canceled">61.20</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 3.5pt">Unvested at June 30, 2024</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230701__20240630_ztxPtNap2pG3" style="border-bottom: Black 3.5pt double; text-align: right" title="Number of shares unvested at ending">40,291</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230701__20240630_zKNDqoCY15xh" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average grant date fair value per share unvested at ending">44.59</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Summary of warrants activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zTxLQfBk4QFf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)">
  <tr style="vertical-align: bottom; background-color: White">
    <td><span id="xdx_8BE_zXcxLU8Mrww2" style="display: none">Summary of warrants activity</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Exercise Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life (Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left">Outstanding and exercisable at June 30, 2022</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFt3UdaFHjA7" style="width: 10%; text-align: right" title="Number of shares, beginning">51,037</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezeOitS5oye" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning">61.70</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4MlrRIkQenj" style="width: 10%; text-align: right" title="Weighted average remaining life (Years)">3.8</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS0ffXNfJew2" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning"><span style="-sec-ix-hidden: xdx2ixbrl1249">-</span></td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted">727,273</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, granted">18.20</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6MduR83yFX6" style="text-align: right" title="Weighted average remaining life (Years), granted">5.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, expired">(482</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, expired">750.00</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, exercised">(800</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">22.50</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Outstanding and exercisable at June 30, 2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhqqbkU5vptj" style="text-align: right" title="Number of shares, beginning">777,029</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJE3Rq0QYL0h" style="text-align: right" title="Weighted average exercise price, beginning">20.60</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhG5LlwdbFaf" style="text-align: right" title="Weighted average remaining life (Years)">4.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeO5eZu6Onwk" style="text-align: right" title="Aggregate intrinsic value, beginning">18,318,954</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted">1,755,000</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, granted">13.14</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsjwHYw3163d" style="text-align: right" title="Weighted average remaining life (Years), granted">5.0</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, exercised">(600,000</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised">10.00</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Outstanding and exercisable at June 30, 2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCdB34JCMxi8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, ending">1,932,029</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1WDknVwxva4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, ending">14.03</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8LHwB4BZkm7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average remaining life (Years)">4.0</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR0yUbLulZtk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value, ending"><span style="-sec-ix-hidden: xdx2ixbrl1289">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007784128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_LesseeOperatingLeaseLiabilityTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zK0mHEbrKgPk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span id="xdx_8BE_zfGb1g5Gxjca" style="display: none">Schedule of deferred tax assets</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20240630_zzJ7squRbxUd" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_493_20230630_zdOKjRFMiaj4" style="text-align: right">&#160;</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; font-weight: bold">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 9pt">Operating lease, right-of-use asset, net</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">406,726</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">80,789</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-decoration: underline; font-weight: bold">Liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzaZ2_zvpYfD8gWgH5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Current portion of operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">60,343</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">44,909</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzaZ2_zrVGBZuBz8Q9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">349,894</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">42,505</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzaZ2_zbGaMu8tGe2i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt">Total operating lease liability</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">410,237</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">87,414</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases', window );">Schedule of future estimated minimum lease payments under non-cancelable operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_zjAniu6OFTM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap"><span id="xdx_8BB_zjR5t82sClE8" style="display: none">Schedule of future estimated minimum lease payments
under non-cancelable operating leases</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20240630_ztH27BtOyWHk" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zqZ2B95jdEpg" style="vertical-align: bottom">
    <td style="text-align: left; white-space: nowrap">Year ending June 30,</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_z4Qw1VBlo9X1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: left">2025</td><td style="width: 10%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">117,915</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zHcktjtcrraj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">122,042</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zGrtVgFrWpw8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">2027</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,313</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_zC0ZhKUiCrDi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2028</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">130,734</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_zHDJjQ95KTtk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2029</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">77,796</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_zlw86PDVV9oi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">574,800</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zCTd8MmOeJKj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(164,563</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zphvj0jiWCak" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">410,237</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_znbDQIyLJHmf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less current portion of operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,343</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zmcpWkaywI88" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">$</td><td style="border-bottom: Black 3.5pt double; text-align: right">349,894</td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock', window );">Schedule of weighted average remaining lease term and discount rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zLzLUdGsL4C" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B0_zxPSCX2JvfVj" style="display: none">Schedule of weighted average remaining lease term and discount rate</span></td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Weighted average remaining lease term (Years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 9pt">Operating lease</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zkd3G27WweUa" style="width: 12%; text-align: right" title="Weighted average remaining lease term (Years) Operating leases">4.6</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630_zfttVefLI08j" style="width: 12%; text-align: right" title="Weighted average remaining lease term (Years) Operating leases">1.8</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Operating lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zOCoMOiyaRXe" style="text-align: right" title="Weighted average discount rate Operating leases">15.00</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630_zxig8joGQCI7" style="text-align: right" title="Weighted average discount rate Operating leases">10.75</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_LesseeOperatingLeaseLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_LesseeOperatingLeaseLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002226448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTJXLAdEWMl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)">
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span id="xdx_8B0_za50uHnoA4Q1" style="display: none">Schedule of deferred tax assets</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_497_20240630_zWePO7pGDJld" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20230630_zQ70IyjVtpn7" style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Deferred tax assets (liabilities):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0p0_maDTANzRXI_zPq7iRYtFpkc" style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left">Tax loss carryforward</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">51,429,074</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">48,080,664</td><td style="white-space: nowrap; width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pp0p0_maDTANzRXI_zDpzXAwXpk3c" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">(114,161</td><td style="white-space: nowrap; text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(189,854</td><td style="white-space: nowrap; text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTANzRXI_zxuHC2mnaSAk" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stock based compensation</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">5,860,272</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,575,852</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTANzRXI_z8nmJRJah3Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">R&amp;D capitalized</td><td>&#160;</td>
    <td style="text-align: left"></td><td style="text-align: right">12,467,969</td><td style="white-space: nowrap; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,171,276</td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzRXI_zPKEQEoQ3QMd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"></td><td style="border-bottom: Black 1.5pt solid; text-align: right">(69,643,154</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(60,637,938</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzRXI_zH8YMZ7CdXEe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1388">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1389">-</span></td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of effective income tax rate reconciliation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCYnObkGJGza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap"><span id="xdx_8B1_zYNz8P5C7rqe" style="display: none">Schedule of effective income tax rate reconciliation</span></td><td>&#160;</td>
    <td colspan="2" id="xdx_49C_20230701__20240630_zk1mL1B9jQt2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49F_20220701__20230630_zWwzEFvfLif2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="white-space: nowrap">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zqiRUeC8q535" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Income tax expense at federal statutory rate</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td><td style="width: 8%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">21</td><td style="white-space: nowrap; width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zoVUd8Dkb00d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">State taxes, net of federal benefit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="white-space: nowrap; text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7</td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zmTGy9d4mR3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(28</td><td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z1RlQ5vwLO89" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 3.5pt">Effective tax rate</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1409">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td><td style="padding-bottom: 3.5pt">&#160;</td>
    <td style="border-bottom: Black 3.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 3.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1410">-</span></td><td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004243680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity and Going Concern (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_WorkingCapital', window );">Working capital</a></td>
<td class="nump">$ 14,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalent</a></td>
<td class="nump">23,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockholderEquities', window );">Stockholders' equity</a></td>
<td class="nump">15,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 334,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_StockholderEquities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_StockholderEquities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004595248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,562,029<span></span>
</td>
<td class="nump">1,303,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">518,076<span></span>
</td>
<td class="nump">395,286<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">1,932,029<span></span>
</td>
<td class="nump">777,029<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">40,291<span></span>
</td>
<td class="nump">59,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bivi_NotespayableConversionOptionMember', window );">Notespayable Conversion Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">71,633<span></span>
</td>
<td class="nump">71,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bivi_NotespayableConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bivi_NotespayableConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073003850512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in U.S. Treasury Bills Available for Sale (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Total Accumulated Other Comprehensive Income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 176,591<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AmortizedCostBasis', window );">Amortized Cost Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,301,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_GrossUnrealizedGain', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_GrossUnrealizedLoss', window );">Gross Unrealized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtFairValue', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,477,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Total Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,591<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_GrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_GrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_GrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_GrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in security owned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073093606256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in U.S. Treasury Bills available-for-sale (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract', window );"><strong>Investments In U.s. Treasury Bills Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_NumberOfStockPurchased', window );">Number of stock purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RealizedGainOnMaturityOfAvailableforSale', window );">Realized gain on maturity of available-for sale</a></td>
<td class="nump">$ 223,865<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NumberOfStockPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NumberOfStockPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_RealizedGainOnMaturityOfAvailableforSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_RealizedGainOnMaturityOfAvailableforSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002468176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intellectual Property</a></td>
<td class="nump">$ 2,293,770<span></span>
</td>
<td class="nump">$ 2,293,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated Amortization</a></td>
<td class="num">(1,886,052)<span></span>
</td>
<td class="num">(1,656,675)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intellectual Property, Net</a></td>
<td class="nump">$ 407,718<span></span>
</td>
<td class="nump">$ 637,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007875840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">$ 229,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">178,341<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">&#160;Finite lived intangible assets, net</a></td>
<td class="nump">$ 407,718<span></span>
</td>
<td class="nump">$ 637,095<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073007586944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expenses</a></td>
<td class="nump">$ 229,377<span></span>
</td>
<td class="nump">$ 229,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004556160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Sep. 25, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">6,216,398<span></span>
</td>
<td class="nump">1,360,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,645,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed dividend</a></td>
<td class="nump">$ 886,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bivi_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 10.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Remaining term</a></td>
<td class="text">3 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bivi_WarrantsMember', window );">Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 18.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bivi_WarrantsMember', window );">Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bivi_AcuitasGroupHoldingsLLCMember', window );">Acuitas Group Holdings, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">363,636<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bivi_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bivi_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bivi_AcuitasGroupHoldingsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bivi_AcuitasGroupHoldingsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073006099936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_CurrentPortionOfNotesPayable', window );">Current portion of Notes Payable</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DebtFinancingCosts', window );">Less: debt financing costs</a></td>
<td class="num">(11,820)<span></span>
</td>
<td class="num">(108,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables', window );">Less: unearned discount</a></td>
<td class="num">(111,212)<span></span>
</td>
<td class="num">(1,023,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AccretionOfLoanPremiums', window );">Plus: accretion of Loan Premium</a></td>
<td class="nump">824,242<span></span>
</td>
<td class="nump">236,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of Notes Payable, net of financing costs, unearned premium and discount</a></td>
<td class="nump">5,701,210<span></span>
</td>
<td class="nump">9,105,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_NotesPayableNoncurrent', window );">Notes Payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_LongtermDebtFinancingCosts', window );">Less: debt financing costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(11,820)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables', window );">Less: unearned discount</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(111,212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_LongTermAccretionOfLoanPremiums', window );">Plus: accretion of Loan Premium</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">350,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount', window );">Notes Payable, net of the current portion financing costs, unearned premium and discount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,227,270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AccretionOfLoanPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AccretionOfLoanPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CurrentPortionOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CurrentPortionOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DebtFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DebtFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_LongTermAccretionOfLoanPremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_LongTermAccretionOfLoanPremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_LongtermDebtFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_LongtermDebtFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_NotesPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_NotesPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unearned discount, finance charge, and interest included in face amount of receivable. Excludes cash or quantity discount or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002267136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable (Details 1)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bivi_UnearnedDiscountMember', window );">Unearned Discount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AmortizationExpenseNextRollingTwoYears', window );">2025</a></td>
<td class="nump">$ 111,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AmortizationExpenseTotal', window );">Total</a></td>
<td class="nump">111,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AmortizationExpenseNextRollingTwoYears', window );">2025</a></td>
<td class="nump">11,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AmortizationExpenseTotal', window );">Total</a></td>
<td class="nump">11,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bivi_LoanAccretionPremiumMember', window );">Loan Accretion Premium [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AmortizationExpenseNextRollingTwoYears', window );">2025</a></td>
<td class="nump">25,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AmortizationExpenseTotal', window );">Total</a></td>
<td class="nump">$ 25,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AmortizationExpenseNextRollingTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AmortizationExpenseNextRollingTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AmortizationExpenseTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AmortizationExpenseTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 40<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481628/310-20-40-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bivi_UnearnedDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bivi_UnearnedDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bivi_LoanAccretionPremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=bivi_LoanAccretionPremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073005009728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_FairValueOfEmbeddedConversionOption', window );">Fair value of embedded conversion option</a></td>
<td class="nump">2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_UnearnedDiscount', window );">Unearned discount</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DirectFinancingCost', window );">Direct financing cost</a></td>
<td class="nump">390,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Unamortized premium recognized</a></td>
<td class="nump">850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest payment</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of financing costs</a></td>
<td class="nump">109,000,000<span></span>
</td>
<td class="nump">170,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AccretionsOfLoanPremium', window );">Accretion of loan premium</a></td>
<td class="nump">237,000,000<span></span>
</td>
<td class="nump">422,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Remaining principal balance</a></td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes payable</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember', window );">Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AccretionsOfLoanPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AccretionsOfLoanPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DirectFinancingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DirectFinancingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_FairValueOfEmbeddedConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_FairValueOfEmbeddedConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_UnearnedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_UnearnedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073003127696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">$ 3,771<span></span>
</td>
<td class="nump">$ 1,820,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">1,820,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">894,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">894,280<span></span>
</td>
<td class="nump">$ 194,531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember', window );">Derivative Liability Conversion Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">925,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember', window );">Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember', window );">Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember', window );">Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivatives</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 925,762<span></span>
</td>
<td class="nump">$ 188,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004262512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at beginning</a></td>
<td class="nump">$ 1,820,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at ending</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">$ 1,820,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at beginning</a></td>
<td class="nump">1,820,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at ending</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">1,820,042<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at beginning</a></td>
<td class="nump">894,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at ending</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">894,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at beginning</a></td>
<td class="nump">894,280<span></span>
</td>
<td class="nump">194,531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Additions to level 3 liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Change in in fair value of level 3 liabilities</a></td>
<td class="num">(890,509)<span></span>
</td>
<td class="nump">699,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfer in and/or out of Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at ending</a></td>
<td class="nump">3,771<span></span>
</td>
<td class="nump">894,280<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember', window );">Derivative Liability Conversion Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at beginning</a></td>
<td class="nump">925,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">925,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember', window );">Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at beginning</a></td>
<td class="nump">925,762<span></span>
</td>
<td class="nump">188,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Additions to level 3 liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease', window );">Change in in fair value of level 3 liabilities</a></td>
<td class="num">(925,762)<span></span>
</td>
<td class="nump">737,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet', window );">Transfer in and/or out of Level 3</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Balance at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 925,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(9)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column G))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002545264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="nump">$ 23,843,798<span></span>
</td>
<td class="nump">$ 33,938,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember', window );">US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="nump">11,079,857<span></span>
</td>
<td class="nump">13,156,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=bivi_USTreasuryBillSecurities1Member', window );">U.S. Treasury Bills due in 3 months or less at purchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,477,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="nump">23,843,798<span></span>
</td>
<td class="nump">33,938,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="nump">11,079,857<span></span>
</td>
<td class="nump">13,156,340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | U.S. Treasury Bills due in 3 months or less at purchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,477,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | U.S. Treasury Bills due in 3 months or less at purchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | US Treasury Bill Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | U.S. Treasury Bills due in 3 months or less at purchase [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="nump">12,763,941<span></span>
</td>
<td class="nump">6,304,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="nump">12,763,941<span></span>
</td>
<td class="nump">6,304,543<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasuryBillSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=bivi_USTreasuryBillSecurities1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=bivi_USTreasuryBillSecurities1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073003713632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember', window );">Derivative liability - Warrants [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 4.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise Price</a></td>
<td class="nump">$ 58.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility Rate</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember', window );">Derivative liability - Conversion Option on Convertible Debenture [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 69.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember', window );">Derivative Liability Conversion Option [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">5 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Interest Rate</a></td>
<td class="nump">5.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility Rate</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=bivi_DerivativeLiabilityConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073004622304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning | shares</a></td>
<td class="nump">395,286<span></span>
</td>
<td class="nump">339,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options outstanding at beginning | $ / shares</a></td>
<td class="nump">$ 71.00<span></span>
</td>
<td class="nump">$ 74.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted remaining average contractual term, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, outstanding at beginning | $</a></td>
<td class="nump">$ 1,067,966<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted | shares</a></td>
<td class="nump">155,242<span></span>
</td>
<td class="nump">71,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">$ 11.70<span></span>
</td>
<td class="nump">$ 59.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted remaining average contractual term, granted</a></td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AggregateIntrinsicValueGranted', window );">Aggregate intrinsic value, granted | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Options expired | shares</a></td>
<td class="num">(640)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired | $ / shares</a></td>
<td class="nump">$ 46.09<span></span>
</td>
<td class="nump">$ 286.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled | shares</a></td>
<td class="num">(31,812)<span></span>
</td>
<td class="num">(4,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, canceled | $ / shares</a></td>
<td class="nump">$ 57.19<span></span>
</td>
<td class="nump">$ 77.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Options exercised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted remaining average contractual term, beginning</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at ending | shares</a></td>
<td class="nump">518,076<span></span>
</td>
<td class="nump">395,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, options outstanding at ending | $ / shares</a></td>
<td class="nump">$ 54.11<span></span>
</td>
<td class="nump">$ 71.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted remaining average contractual term, ending</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, outstanding at ending | $</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,067,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Options exercisable | shares</a></td>
<td class="nump">296,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, options exercisable | $ / shares</a></td>
<td class="nump">$ 66.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, options exercisable</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AggregateIntrinsicValueGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AggregateIntrinsicValueGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073098412352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 1) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OffsettingAssetsLineItems', window );"><strong>Offsetting Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of options (In years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">86.28%<span></span>
</td>
<td class="nump">81.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.82%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OffsettingAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OffsettingAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073003555376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 2) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares unvested at beginning</a></td>
<td class="nump">59,646<span></span>
</td>
<td class="nump">12,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share unvested at beginning</a></td>
<td class="nump">$ 52.40<span></span>
</td>
<td class="nump">$ 16.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares', window );">Number of shares, Issued</a></td>
<td class="nump">104,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share, Issued</a></td>
<td class="nump">$ 9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 58.87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares, Vested</a></td>
<td class="num">(122,395)<span></span>
</td>
<td class="num">(21,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share, Vested</a></td>
<td class="nump">$ 16.94<span></span>
</td>
<td class="nump">$ 52.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of shares, Canceled</a></td>
<td class="num">(1,030)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share, Canceled</a></td>
<td class="nump">$ 61.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of shares unvested at ending</a></td>
<td class="nump">40,291<span></span>
</td>
<td class="nump">59,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share unvested at ending</a></td>
<td class="nump">$ 44.59<span></span>
</td>
<td class="nump">$ 52.40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073003199584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares', window );">Number of shares, exercised</a></td>
<td class="nump">104,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 9.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, beginning</a></td>
<td class="nump">777,029<span></span>
</td>
<td class="nump">51,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted average exercise price, beginning</a></td>
<td class="nump">$ 20.60<span></span>
</td>
<td class="nump">$ 61.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining life (Years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, outstanding at beginning</a></td>
<td class="nump">$ 18,318,954<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">1,755,000<span></span>
</td>
<td class="nump">727,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted</a></td>
<td class="nump">$ 13.14<span></span>
</td>
<td class="nump">$ 18.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life (Years), granted</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of shares, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(482)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares', window );">Number of shares, exercised</a></td>
<td class="num">(600,000)<span></span>
</td>
<td class="num">(800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average exercise price, exercised</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, ending</a></td>
<td class="nump">1,932,029<span></span>
</td>
<td class="nump">777,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted average exercise price, ending</a></td>
<td class="nump">$ 14.03<span></span>
</td>
<td class="nump">$ 20.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1', window );">Weighted average remaining life (Years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, outstanding at ending</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 18,318,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46072993219600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2024</div></th>
<th class="th"><div>May 10, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Nov. 09, 2023</div></th>
<th class="th"><div>Oct. 03, 2023</div></th>
<th class="th"><div>Apr. 06, 2023</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Nov. 23, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,823,764<span></span>
</td>
<td class="nump">$ 4,222,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_TotalCompensationCost', window );">Total compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,744,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockBasedCompensationRestrictedStockUnits', window );">Stock based compensation - restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.70<span></span>
</td>
<td class="nump">$ 59.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bivi_VendorMember', window );">Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued during period for service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bivi_EmployeesMember', window );">Employees [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1', window );">Weighted average contractual term, granted (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bivi_CertainEmployeesMember', window );">Certain Employees [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock option to purchase</a></td>
<td class="nump">14,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options grants</a></td>
<td class="nump">$ 57.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bivi_NewEmployeeMember', window );">New Employee [Member] | Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, options grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bivi_NewEmployeeMember', window );">New Employee [Member] | Equity Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Awarded Vested rights, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=bivi_NewEmployeeMember', window );">New Employee [Member] | Equity Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Awarded Vested rights, percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bivi_PrefundedWarrantsMember', window );">Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_StockExercised', window );">Number of stock exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bivi_CommonWarrantMember', window );">Common Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | President And C E O [Member] | N2019 Omnibus Incentive Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RsuGranted', window );">Rsu granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,452<span></span>
</td>
<td class="nump">4,151<span></span>
</td>
<td class="nump">4,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1', window );">Rsu granted, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharesIssuedOverVestingPeriod', window );">Shares issued over the vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares for tax withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Four Directors [Member] | N2019 Omnibus Incentive Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RsuGranted', window );">Rsu granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1', window );">Rsu granted, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Three Directors [Member] | N2019 Omnibus Incentive Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RsuGranted', window );">Rsu granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1', window );">Rsu granted, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Four Director [Member] | N2019 Omnibus Incentive Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RsuGranted', window );">Rsu granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1', window );">Rsu granted, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharesIssuedOverVestingPeriod', window );">Shares issued over the vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Two Directors [Member] | N2019 Omnibus Incentive Equity Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RsuGranted', window );">Rsu granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1', window );">Rsu granted, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_RsuGranted', window );">Rsu granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1', window );">Rsu granted, grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_SharesIssuedOverVestingPeriod', window );">Shares issued over the vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings', window );">Shares for tax withholdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_IssuanceOfCommonStockForCashShares', window );">Issuance of common stock for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">9,930<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.30<span></span>
</td>
<td class="nump">$ 76.40<span></span>
</td>
<td class="nump">$ 28.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bivi_WarrantsMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_IssuanceOfCommonStockForCashShares', window );">Issuance of common stock for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock option to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A [Member] | Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_IssuanceOfCommonStockForCashShares', window );">Issuance of common stock for cash, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">333,749<span></span>
</td>
<td class="nump">753,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_IssuanceOfCommonStockForCash', window );">Issuance of common stock for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,300,000<span></span>
</td>
<td class="nump">$ 49,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_CommissionsPercentage', window );">Commissions percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 377,000<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CommissionsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CommissionsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfCommonStockForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfCommonStockForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_IssuanceOfCommonStockForCashShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_IssuanceOfCommonStockForCashShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_RsuGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_RsuGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_SharesIssuedOverVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_SharesIssuedOverVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_StockBasedCompensationRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_StockBasedCompensationRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_StockExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_StockExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_TotalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_TotalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=bivi_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_VendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_VendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_CertainEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_CertainEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_NewEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_NewEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bivi_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bivi_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bivi_CommonWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bivi_CommonWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_PresidentAndCEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_PresidentAndCEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=bivi_N2019OmnibusIncentiveEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=bivi_N2019OmnibusIncentiveEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_FourDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_FourDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_ThreeDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_ThreeDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_FourDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_FourDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=bivi_TwoDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=bivi_TwoDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bivi_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bivi_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=bivi_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=bivi_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46072993338080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset, net</a></td>
<td class="nump">$ 406,726<span></span>
</td>
<td class="nump">$ 56,909<span></span>
</td>
<td class="nump">$ 80,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">60,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">349,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,505<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">$ 410,237<span></span>
</td>
<td class="nump">$ 62,124<span></span>
</td>
<td class="nump">$ 87,414<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002334992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">$ 117,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">122,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">126,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">130,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2029</a></td>
<td class="nump">77,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">574,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less amount representing interest</a></td>
<td class="num">(164,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="nump">410,237<span></span>
</td>
<td class="nump">$ 62,124<span></span>
</td>
<td class="nump">$ 87,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of operating lease liability</a></td>
<td class="num">(60,343)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 349,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,505<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073091473936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details 2)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (Years) Operating leases</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate Operating leases</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073094604160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Feb. 12, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureLeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use Asset</a></td>
<td class="nump">$ 406,726<span></span>
</td>
<td class="nump">$ 80,789<span></span>
</td>
<td class="nump">$ 56,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease Liability</a></td>
<td class="nump">410,237<span></span>
</td>
<td class="nump">87,414<span></span>
</td>
<td class="nump">$ 62,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">5,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">78,000<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities', window );">Cash paid for amounts included in measurement of operating lease liabilities</a></td>
<td class="nump">$ 83,910<span></span>
</td>
<td class="nump">$ 50,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of selling, general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002461792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_DisclosureEmployeeBenefitPlanAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Defined benefit plan, plan assets, contributions by employer</a></td>
<td class="nump">$ 153,200<span></span>
</td>
<td class="nump">$ 171,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_DisclosureEmployeeBenefitPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_DisclosureEmployeeBenefitPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002258816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract', window );"><strong>Deferred tax assets (liabilities):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Tax loss carryforward</a></td>
<td class="nump">$ 51,429,074<span></span>
</td>
<td class="nump">$ 48,080,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(114,161)<span></span>
</td>
<td class="num">(189,854)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">5,860,272<span></span>
</td>
<td class="nump">4,575,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D capitalized</a></td>
<td class="nump">12,467,969<span></span>
</td>
<td class="nump">8,171,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
<td class="num">(69,643,154)<span></span>
</td>
<td class="num">(60,637,938)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073002492752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details 1)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(28.00%)<span></span>
</td>
<td class="num">(28.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073092868976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred Tax Assets, Net</a></td>
<td class="nump">$ 69,600,000<span></span>
</td>
<td class="nump">$ 60,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net Operating Loss carryforward</a></td>
<td class="nump">$ 184,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_ExpirationsDates', window );">Expirations dates</a></td>
<td class="text">2032 to 2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_ExpirationsDates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_ExpirationsDates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm46073003517456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 25, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 06, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares</a></td>
<td class="nump">1,360,800<span></span>
</td>
<td class="nump">6,216,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,645,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock per value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from public offering</a></td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_AgentFeesAndOfferingExpenses', window );">Agent fees and offering expenses</a></td>
<td class="nump">$ 560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=bivi_PlacementAgentsWarrantsMember', window );">Placement Agents Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price</a></td>
<td class="nump">$ 1.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Warrant issued</a></td>
<td class="nump">98,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bivi_PrefundedWarrantsMember', window );">Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_PurchaseOfCommonStockShares', window );">Purchase of shares</a></td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=bivi_CommonWarrantsMember', window );">Common Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock per value</a></td>
<td class="nump">$ 1.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bivi_PurchaseOfCommonStockShares', window );">Purchase of shares</a></td>
<td class="nump">1,960,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_AgentFeesAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_AgentFeesAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bivi_PurchaseOfCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">bivi_PurchaseOfCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>bivi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=bivi_PlacementAgentsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=bivi_PlacementAgentsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bivi_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bivi_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=bivi_CommonWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=bivi_CommonWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M,/N% 7P_5R F-S?%BY3JQ=GX/U!+ P04    "  0B3Y9$$!OUS<#   V"P
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MIP+R]Q5CXOB0+E#^]Z#W+U!+ P04    "  0B3Y9;!#6F,<)    3@  &
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M&"NYVT3DS"%Q\"%Q<,?Q3G ^L<>\;)T1E:"@Y9Q=H"=:;!FB'/UE6WY Q+E
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MP;*F<_E;MERR;LKX\(+XBHFSQQ.K&X::39&;<P'H$=(I%&@&!4J@0"D4* ,
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MOEQ1,J=<"<C?%YG<YNR^J >4KTX-_P]02P,$%     @ $(D^65[V4X-, @
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M?8FN)703Q6M[J]9<Z3MJAZ7NHB!,@/Z^X5SM)V:#H2]GOP%02P,$%     @
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MR=*\3MDUP&ZB1>V:SD%HT\+<L#+_#) VP#POA-#'B=U@^ NE?P!02P,$%
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MH*A064EPM*HE ,=>T;#2S]=!)(M#VP1DG6HU'H#?(=9H%&+!:I% 1-:8B+J
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MF9#^F9EEEF60[<QWN"5,:#U$(W!QH1H,R#,LP0B!=7%'/D-I5\+YBD&&D^8
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M9&E_KCC+N:(%^/]"8LZT%[2!?UUX\U]02P,$%     @ $(D^6<LI([^F!@
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MRTC.Z8SG7'.FG,)"9P23$!(YK:7DY0*3B2M")2-4D;G(H3ZH$^<6RDY6YP<
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M?S,I7-"KJIAIF/*-9VS1)H/3ULMZQSXT#T?VF&@6L^PQAU>!E[R&KB;/C67
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M=-IA_3QH^EX'U$.A)\RCQL5T#7%J)T#M4>JDB?6+WOL4\@/64P_@HY<X2C1
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M..7_%TT^G_ZF9YV/G.RK&</1T;+/(H*3"4V6U1P\ #B;#?K1XOI)P)!-U&L
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MK&<7+^"\L#;<+>(#F]'\Z%]02P,$%     @ $(D^6>8D@HPH P  ' <  !D
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M807_EY2B.$C243!))S .HE%$*JGW@Q5U8^;<AH>)#.$XG01I,@@BZY=FA'-
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ME0SO!,BVKJEX7F'%=TO'=_8+]^6F4&;!BQ<-W> :U8_F3NB9-U"RLD8F2\Y
M8+YT+OV+563R;<+/$G?R8 RFDH3S!S/YFBT=8@QAA:DR!*I?6[S"JC(@;>.Q
M9SK#ED9X.-[3/]O:=2T)E7C%JU]EIHJE,W4@PYRVE;KGNR_8US,VO)17TCYA
MU^4&,P?25BI>]V+MH"Y9]Z9/_3D<"*;D%4'0"P+KN]O(NOQ$%8T7@N] F&Q-
M,P-;JE5K<R4S'V6MA(Z66J?B=9M(?&R1*;C>ZJ=<>$IC3=!+>\2J0P2O(/P
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M&Q>KSL*GSUKI> IRI?1@Z;=XB >ZE9TJETLPQ43#<H-RX&&WK749PT=!H<U
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MK405I!D&6&@<ZP*2" Z$=XL]<,%,V8U67?D5I>6ZZ@!= -%#_.!AR[ZI56V
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MATJ?@4_.8D0" EI@8XR7= 4T8DL1JR4JDQ@<D9"9TH9.:NETDDUR^0JW0'E
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M5M1.@?9KI>Q.< [ZQWK^ U!+ P04    "  0B3Y9EG1T(X "  #2!0  &0
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MRIVV:&[@K?IH*XX)EY2547:7V3B3?V,/#2N8>2(@"O)),K$E"RDH*D&.KM
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M"KP3Y'O^L <^>ST\.(2[VF#GTN]<^I8O>(;ODO.\)I0BS'+TU/*<R(QR60E
M/Z8KJ83^N7[VF6YV&?;O8@[<6)8X@XFC3Y0$L0,G??=F$'GO^TKPG\@."A)T
M!0E>8C>?79\<?90J3-%"Z*8@U'V?XX8FM#2F(^Q2WS\/XMA+W-V^F;_G'>@<
M=CJ'+^K\#%*.T33+JJ*B6$&.I@47BOS&I@GT"6[XHCTAIX/1*/)"_Y'BOL0H
MC*(X[)<<=I+#?R_M"?H*JD]N^*1N0R^.!Z-'8I^F14'LG3^6ZNXU M.$OV"Q
M(4PB"FL-],YBS2":QM8$BI>V-ZRXTIW&#K?Z+@!A$O3ZFG/U$)AVT]TNZ1]0
M2P,$%     @ $(D^6=W0$5YE @  J@8  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S<N>&ULK55=3]LP%/TK5C9-(#'RW4"71BJM8$R:A*C8'J8]N,EM:^'8
MF>TV[-_/=M*LT-"A:B^)KWW/\3DW]DU:<_$H5P */964R9&S4JH:NJ[,5U!B
M><XK8'IEP46)E0[%TI65 %Q84$G=P/,&;HD)<[+4SMV)+.5K10F#.X'DNBRQ
M^'T%E-<CQW>V$_=DN5)FPLW2"B]A!NJANA,Z<CN6@I3 ).$,"5B,G+$_G,0F
MWR9\(U#+G3$R3N:</YK@MA@YGA$$%')E&+!^;6 "E!HB+>-7R^ET6QK@[GC+
M?FV]:R]S+&'"Z7=2J-7(N7!0 0N\INJ>UY^A]6,%YIQ*^T1UDQN'#LK74O&R
M!6L%)6'-&S^U==@!^-$K@* %!&\%A"T@M$8;9=;6%"N<I8+72)ALS68&MC86
MK=T09K[B3 F]2C1.9;=,8;8D<PIH+"4HB4ZFH#"A$OFGZ"-ZF$W1R?O3U%5Z
M,P-Q\Y;XJB$.7B'^LF;G*/3.4. %40]\\G9X^!SN:HN=SZ#S&5B^\!6^&\Z+
MFE"*,"O0ONDID3GE<BT _1C/I1+Z>/WL,]WL$O7O8J[<4%8XAY&C[Y0$L0$G
M^_#.'WB?^DKPG\B>%23L"A(>8L]T7>,^@PTJMBC3 C99$%R&29*ZFUWI!\F/
ME!YUTJ-_21_T26]0@QWI?G(11OX+Z0?)CY0>=]+C8]FO"2,*$-5=K4#D[PG%
M]H2>(0:JSW2\][TB+TG\BQ>F]],&8>)=QEU:8\?=Z22FBW_%8DF81!06&NB=
M)YI!-)VQ"12O;'.9<Z5;E1VN],\$A$G0ZPO.U38P_:K[/65_ %!+ P04
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M0H16N[>K$YYORLW#=SGG>5H>K@F.""T:B._O\YR_G!0!FCWTB_\ 4$L#!!0
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MQ:JY-;4\2!M@GJ^%&:^F8ZO%]M]!_ ]02P,$%     @ $(D^6>1O4[*W @
MZ D  !D   !X;"]W;W)K<VAE971S+W-H965T-#$N>&ULO59;3]LP%/XK5C9-
M3$(D<9NVL#024$UC@JF"L3V@/;C):6OAV)GMM/#O9SLA5%.2;=7@I?'MNQR?
M4]OQ5LA[M0;0Z"%G7$V]M=;%B>^K= TY44>B &YFED+F1)NN7/FJD$ R!\J9
MCX-@Y.>$<B^)W=A<)K$H-:,<YA*I,L^)?#P#)K93+_2>!J[I:JWM@)_$!5G!
M#>C;8BY-SV]8,IH#5U1P)&$Y]4[#D[-P8 %NQ3<*6[731C:4A1#WMG.13;W
M.@(&J;84Q'PV< Z,62;CXV=-ZC6:%KC;?F+_Z((WP2R(@G/!OM-,KZ?>Q$,9
M+$G)]+78?H(ZH,CRI8(I]XNVU=J144Q+I45>@TT_I[SZDH=Z(W8 &'< < W
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MO,UVO[-R0(.<M\AB4?Q%N[*MYZ#%1L@L*8U5#Y(HW;_2KZ4C#@S\\#L&N#3
M30V"TB!H:A"6!F'AF?U0"C\0*NE\RK,=XGEK1<O?%,XLK-7PHS2/^YWDZMM(
MV<GY>QIQ])'&&X:N&14;SE10I4!O"),TBL5;]"OZ<$?0FY_?3EVI?C W<Q<E
M_'P/Q]^!_[%)3U'@G2#LX;#&_**Y>5!C3IJ;8]/<55ZJ7(4K5^&"%QQUU0EZ
M)P137J+I$EU%]#Z*(QDQ\>3")5(S^I8M-IQ'Z6/1ZL\LY=4'YU1$ GV^4C^
M+B5+Q#]UOMWW)JSO35X/SL2:+MC,40DO&-\R9_[+3_[0^ZW.TY P @0SHA!4
M40AL]/G?F:2QRFP>;6E>,D2=Z_:(08'(*]]V'HQ&_M3='KKD92-_K,IEB,UV
MQ-J?CJ,-J]&&UM$>SKG+=+V1X@1=L2V+D8\^7[/DGO':N6.EMIT[D# "!#.\
M.:B\.>A5!@\@HP )(T P(PK#*@K#UV>P%5'?053G-2 .Z< YZK!1Y;!1QR*
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M_0YR(&3[9B"5P)"Z3W4< '+P[$WSP)6:'2L#O:1;W6_BE()=J=G!VVJ M^V
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MB#-E(*B^K'"$86B0-(^O.:A3C&D"=^\WZ%>I>"UF2B6.>/B)!6HQ<+H.!/A
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MGF><9TGQN"9X06C>0/R^S#)^>,D#U']AF/T'4$L#!!0    ( !")/EF^A_'
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M]0#U_8(Q^?R@)ZAN*J?_ 5!+ P04    "  0B3Y9YDS3_G(9  "8XP$ &0
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M1?WTA]T$7XKRS_V/<_G_4$L#!!0    ( !")/EDE9$_NMP(  + (   9
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MZY-: ;E0"O20=PU'9#G,=7>;A5Z<!/'4O=UWI1^6>DEZ=ABUZ$=%\9GW-^I
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M6ZP*09H _+X60M]WS 1=G9G] 5!+ P04    "  0B3Y9E5;Q(5L"  #$!0
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M3_7)TXQ.T]B)G>B&%C -<"0UJ"T$^;LW\3CZ=$KC?R)[HGC4*QZ]QIXO4*:
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M*-I^UTX4KYN6,>5*-Z!FN-"?""!,@'X^XUR]3DP7ZCXZLC]02P,$%     @
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M0;/J= =D#4P9R.<;2L7[A7+0-KAG_P-02P,$%     @ $(D^62Q:NY(S P
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MV"I@M0/Y_7F@IOR<*()5Q;QA;S".) F&0"WZ:S2.D=F)X>-?'^PMB:(D\2.
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MHAVE?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%
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M4Q0CM^^;O%4\W_]-;/\7MR^_ 5!+ P04    "  0B3Y9F!M:GOL!  #+(P
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+;J- %(7AK5@L(.7[
M(DDKSJ@GF4;9 '+*#\4VB**59/=M.0/GH![T)*HS0@7B\H\^$/#PG _=M.]/
M9;<?RN+C>#B55;.;IN%72F6]R\>NW/1#/IV/;/KQV$WGY;A-0[=^Z[8YZ7+9
MIO'[C.;QX?O,Q<OGD/]G8K_9[-?Y=[_^<\RGZ1^#TWL_OI5=SE.S>.G&;9Y6
M3?HX7'>7=-G(S7ERLWAZ737CTZLTJ7:00I#6#S((LOI!#D%>/R@@*.H'M1#4
MU@^ZA:#;^D%W$'17/^@>@N[K!\D295P2),VP)M!:D&LA\%H0;"$06Y!L(3!;
M$&TA4%N0;2%P6Q!N(9!;D&XAL%L0;R'06U%O)=!;46\ET%MG#]L$>BOJK01Z
M*^JM!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z&^IM!'H;ZFT$>AOJ;01Z
MV^QE"8'>AGH;@=Z&>AN!WH9Z&X'>AGH;@=Z&>AN!WH9Z&X'>CGH[@=Z.>CN!
MWHYZ.X'>CGH[@=X^>]E-H+>CWDZ@MZ/>3J"WH]Y.H+>CWDZ@MZ/>3J!WH-Y!
MH'>@WD&@=Z#>0:!WH-Y!H'>@WD&@=\P^5A+H':AW$.@=J'<0Z!VH=Q#H':AW
M$.C=HM[M3^I=IL]#+M>>KS5>_R>IGL[GYNOE+\NOG7B_:"\X)_AWY_$O4$L#
M!!0    ( !")/EETTL9BW@$  %HC   3    6T-O;G1E;G1?5'EP97-=+GAM
M;,W:74_",!0&X+]"=FM8Z1=^!+A1;]4+_T#=#K"PK4U;$/Z]W0 3C1(-)KXW
M6[:VYSUKD^=JD^>=HS#8-G4;IMDR1G?#6"B6U)B06T=M&IE;WYB8'OV".5.L
MS(*8&(W&K+!MI#8.8U<CFTWN:&[6=1S<;]/K4-EVFGFJ0S:XW4_LLJ:9<:ZN
M"A/3.-NTY:>4X2$A3RO[.6%9N7"1)F3LRX1NY/N P[K'#7E?E31X,CX^F";-
M8MN:A;BK*>2G2WS1HYW/JX)*6ZR;M"0/SI,IPY(H-G6^+WIQ.CFF':;]E9^=
MWY<Y%9AF/GGK0CHQ3[^/.QY)MWKH4B'RL3K]B>^)J?39WT?=:9=4_C [;>^K
M]:O^/ +K;^?O\<<S?J__RSX$2!\2I \%TH<&Z6,,TL<E2!]7('U<@_3!1RB-
MH(C*44CE**9R%%0YBJH<A56.XBI'@96CR"I09!4HL@H4606*K )%5H$BJT"1
M5:#(*E!D%2BR2A19)8JL$D56B2*K1)%5HL@J4625*+)*%%DEBJP*15:%(JM"
MD56AR*I09%4HLBH4616*K I%5H4BJT:15:/(JE%DU2BR:A19-8JL&D56C2*K
M1I%5H\@Z_D]97ZQ=_?7?'MT];TS5'O-9_TO-[ U02P$"% ,4    "  0B3Y9
M!T%-8H$   "Q    $               @ $     9&]C4')O<',O87!P+GAM
M;%!+ 0(4 Q0    ( !")/EFTTIS-[P   "L"   1              "  :\
M  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !")/EF97)PC$ 8  )PG
M   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#
M%     @ $(D^6?D0NK=4"   43,  !@              ("!#@@  'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !")/EF>',!CTP8  $0;
M   8              " @9@0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"% ,4    "  0B3Y9$$!OUS<#   V"P  &               @(&A%P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ $(D^68=95/ %
M!@  21@  !@              ("!#AL  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( !")/EEL$-:8QPD   !.   8              "
M@4DA  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  0B3Y9
MM?&B G8(  !&)0  &               @(%&*P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ $(D^65[V4X-, @  HP4  !@
M     ("!\C,  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M !")/EF^A($^0P(  )$&   8              " @70V  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    "  0B3Y9-3T$HUH.  "1(@  &
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M970Q,RYX;6Q02P$"% ,4    "  0B3Y9O,%B/+X#  "@"   &0
M    @(&=;   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M !")/EGZ9KJCMP<  #H4   9              " @9)P  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ $(D^6<LI([^F!@  >!,  !D
M             ("!@'@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    "  0B3Y9G?\924$-  #K)   &0              @(%=?P  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !")/EF(,[5\( 8
M "X/   9              " @=6,  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ $(D^62$0[%!O!0  I@L  !D              ("!
M+),  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  0B3Y9
MYB2"C"@#   <!P  &0              @('2F   >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( !")/EGBJ0N92 0  (@)   9
M      " @3&<  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ $(D^64JOYKUR @  ;04  !D              ("!L*   'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  0B3Y930MY!2 :  "340
M&0              @(%9HP  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( !")/EG=?W-JR0(  $<&   9              " @;"]  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ $(D^69XRZ-ZN
M @  ^04  !D              ("!L,   'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    "  0B3Y9*##;)M@"  #7!@  &0
M@(&5PP  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !")
M/EG9 9_]8 ,   0)   9              " @:3&  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ $(D^60Y"I/?X P  N P  !D
M         ("!.\H  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    "  0B3Y9K%W]Q1P%  !?#0  &0              @(%JS@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !")/EENLP[HE0,   <*
M   9              " @;W3  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ $(D^67/^WH16 P  N <  !D              ("!B=<
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  0B3Y9EG1T
M(X "  #2!0  &0              @($6VP  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( !")/EDHN<YQK0,  .H0   9
M  " @<W=  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M$(D^6?\!8!4/ P  B L  !D              ("!L>$  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    "  0B3Y9/!PJI9X"  #J!@  &0
M            @('WY   >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( !")/EG."+PH>@(  &D&   9              " @<SG  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ $(D^6=W0$5YE @
MJ@8  !D              ("!?>H  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    "  0B3Y9^#.WJG\"  "-!@  &0              @($9
M[0  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !")/EFE
M$@6RA04  $\O   9              " @<_O  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ $(D^60:)>_X] P  *0P  !D
M     ("!B_4  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !")/EF8IF"GMP4  .DS   9              "
M@1D+ 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ $(D^
M6:Q4\4D;!   ?10  !D              ("!!Q$! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    "  0B3Y9K2!KE3,%  !M&   &0
M        @(%9%0$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( !")/EF^A_' R (  ,,'   9              " @<,: 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ $(D^6;B=+K22 P  N0X
M !D              ("!PAT! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    "  0B3Y9*4O?<9 $  "U%   &0              @(&+(0$
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !")/EGF3-/^
M<AD  )CC 0 9              " @5(F 0!X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ $(D^625D3^ZW @  L @  !D
M ("!^S\! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  0
MB3Y93W16_7@#  !G#P  &0              @('I0@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !")/EG$_Y@X0P(  /4%   9
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M970U."YX;6Q02P$"% ,4    "  0B3Y9B>S2=M@"  !""   &0
M    @($>50$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M !")/EG5(?'F&00  .P6   9              " @2U8 0!X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ $(D^62Q:NY(S P  3A,   T
M             ( !?5P! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  0B3Y9
MEXJ[',     3 @  "P              @ ';7P$ 7W)E;',O+G)E;'-02P$"
M% ,4    "  0B3Y9A0JI-JP$  !F)P  #P              @ '$8 $ >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ $(D^69@;6I[[ 0  RR,  !H
M         ( !G64! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ $(D^6732QF+> 0  6B,  !,              ( !T&<! %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     $0 1 "3$@  WVD!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>152</ContextCount>
  <ElementCount>333</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995612 - Disclosure - Background Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/BackgroundInformation</Role>
      <ShortName>Background Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995613 - Disclosure - Liquidity and Going Concern</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/LiquidityAndGoingConcern</Role>
      <ShortName>Liquidity and Going Concern</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995614 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995615 - Disclosure - Investments in U.S. Treasury Bills available-for-sale</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale</Role>
      <ShortName>Investments in U.S. Treasury Bills available-for-sale</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995616 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995617 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995618 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://bioviepharma.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995619 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995620 - Disclosure - Equity Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EquityTransactions</Role>
      <ShortName>Equity Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995621 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995622 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995623 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995624 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995625 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995626 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995627 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995628 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables</Role>
      <ShortName>Investments in U.S. Treasury Bills available-for-sale (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995629 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/IntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995630 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://bioviepharma.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/NotesPayable</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>995631 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/FairValueMeasurements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995632 - Disclosure - Equity Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EquityTransactionsTables</Role>
      <ShortName>Equity Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/EquityTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995633 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995634 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/IncomeTaxes</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995635 - Disclosure - Liquidity and Going Concern (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative</Role>
      <ShortName>Liquidity and Going Concern (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/LiquidityAndGoingConcern</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>995636 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>995637 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails</Role>
      <ShortName>Investments in U.S. Treasury Bills Available for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>995638 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative</Role>
      <ShortName>Investments in U.S. Treasury Bills available-for-sale (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>995639 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>995640 - Disclosure - Intangible Assets (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>Intangible Assets (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>995641 - Disclosure - Intangible Assets (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>Intangible Assets (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/IntangibleAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>995642 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>995643 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://bioviepharma.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/NotesPayableTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>995644 - Disclosure - Notes Payable (Details 1)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://bioviepharma.com/role/NotesPayableDetails1</Role>
      <ShortName>Notes Payable (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/NotesPayableTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>995645 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://bioviepharma.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/NotesPayableTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>995646 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>995647 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>995648 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>995649 - Disclosure - Fair Value Measurements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative</Role>
      <ShortName>Fair Value Measurements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>995650 - Disclosure - Equity Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EquityTransactionsDetails</Role>
      <ShortName>Equity Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/EquityTransactionsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>995651 - Disclosure - Equity Transactions (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EquityTransactionsDetails1</Role>
      <ShortName>Equity Transactions (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/EquityTransactionsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>995652 - Disclosure - Equity Transactions (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EquityTransactionsDetails2</Role>
      <ShortName>Equity Transactions (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/EquityTransactionsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>995653 - Disclosure - Equity Transactions (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EquityTransactionsDetails3</Role>
      <ShortName>Equity Transactions (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/EquityTransactionsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>995654 - Disclosure - Equity Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EquityTransactionsDetailsNarrative</Role>
      <ShortName>Equity Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/EquityTransactionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>995655 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/LeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>995656 - Disclosure - Leases (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/LeasesDetails1</Role>
      <ShortName>Leases (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/LeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>995657 - Disclosure - Leases (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/LeasesDetails2</Role>
      <ShortName>Leases (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/LeasesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>995658 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/LeasesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>995659 - Disclosure - Employee Benefit Plan (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative</Role>
      <ShortName>Employee Benefit Plan (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>995660 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>995661 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IncomeTaxesDetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>995662 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="bivi-20240630_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>995663 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bioviepharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://bioviepharma.com/role/SubsequentEvents</ParentRole>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>bivi-20240630.xsd</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="bivi-20240630_10k.htm">bivi-20240630_10k.htm</File>
    <File>bivi-20240630_cal.xml</File>
    <File>bivi-20240630_def.xml</File>
    <File>bivi-20240630_lab.xml</File>
    <File>bivi-20240630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_01.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="541">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "bivi-20240630_10k.htm": {
   "nsprefix": "bivi",
   "nsuri": "http://bioviepharma.com/20240630",
   "dts": {
    "schema": {
     "local": [
      "bivi-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "inline": {
     "local": [
      "bivi-20240630_10k.htm"
     ]
    },
    "calculationLink": {
     "local": [
      "bivi-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "bivi-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "bivi-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "bivi-20240630_pre.xml"
     ]
    }
   },
   "keyStandard": 246,
   "keyCustom": 87,
   "axisStandard": 16,
   "axisCustom": 0,
   "memberStandard": 18,
   "memberCustom": 26,
   "hidden": {
    "total": 154,
    "http://bioviepharma.com/20240630": 63,
    "http://fasb.org/us-gaap/2024": 87,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 152,
   "entityCount": 1,
   "segmentCount": 48,
   "elementCount": 572,
   "unitCount": 4,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 541,
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/ecd/2024": 4
   },
   "report": {
    "R1": {
     "role": "http://bioviepharma.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://bioviepharma.com/role/BalanceSheets",
     "longName": "00000002 - Statement - Balance Sheets",
     "shortName": "Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://bioviepharma.com/role/BalanceSheetsParenthetical",
     "longName": "00000003 - Statement - Balance Sheets (Parenthetical)",
     "shortName": "Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "bivi:UnearnedPremiumAnddiscountCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "bivi:UnearnedPremiumAnddiscountCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "longName": "00000004 - Statement - Statements of Operations and Comprehensive Loss",
     "shortName": "Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity",
     "longName": "00000005 - Statement - Statements of Changes in Stockholders' Equity",
     "shortName": "Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://bioviepharma.com/role/StatementsOfCashFlows",
     "longName": "00000006 - Statement - Statements of Cash Flows",
     "shortName": "Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:StockBasedCompensationRestrictedStock",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R8": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://bioviepharma.com/role/BackgroundInformation",
     "longName": "995612 - Disclosure - Background Information",
     "shortName": "Background Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://bioviepharma.com/role/LiquidityAndGoingConcern",
     "longName": "995613 - Disclosure - Liquidity and Going Concern",
     "shortName": "Liquidity and Going Concern",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://bioviepharma.com/role/SignificantAccountingPolicies",
     "longName": "995614 - Disclosure - Significant Accounting Policies",
     "shortName": "Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale",
     "longName": "995615 - Disclosure - Investments in U.S. Treasury Bills available-for-sale",
     "shortName": "Investments in U.S. Treasury Bills available-for-sale",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://bioviepharma.com/role/IntangibleAssets",
     "longName": "995616 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://bioviepharma.com/role/RelatedPartyTransactions",
     "longName": "995617 - Disclosure - Related Party Transactions",
     "shortName": "Related Party Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://bioviepharma.com/role/NotesPayable",
     "longName": "995618 - Disclosure - Notes Payable",
     "shortName": "Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://bioviepharma.com/role/FairValueMeasurements",
     "longName": "995619 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://bioviepharma.com/role/EquityTransactions",
     "longName": "995620 - Disclosure - Equity Transactions",
     "shortName": "Equity Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://bioviepharma.com/role/Leases",
     "longName": "995621 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://bioviepharma.com/role/CommitmentsAndContingencies",
     "longName": "995622 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://bioviepharma.com/role/EmployeeBenefitPlan",
     "longName": "995623 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:EmployeeBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:EmployeeBenefitPlanTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://bioviepharma.com/role/IncomeTaxes",
     "longName": "995624 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://bioviepharma.com/role/SubsequentEvents",
     "longName": "995625 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "995626 - Disclosure - Significant Accounting Policies (Policies)",
     "shortName": "Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "23",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesTables",
     "longName": "995627 - Disclosure - Significant Accounting Policies (Tables)",
     "shortName": "Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables",
     "longName": "995628 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Tables)",
     "shortName": "Investments in U.S. Treasury Bills available-for-sale (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://bioviepharma.com/role/IntangibleAssetsTables",
     "longName": "995629 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://bioviepharma.com/role/NotesPayableTables",
     "longName": "995630 - Disclosure - Notes Payable (Tables)",
     "shortName": "Notes Payable (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://bioviepharma.com/role/FairValueMeasurementsTables",
     "longName": "995631 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://bioviepharma.com/role/EquityTransactionsTables",
     "longName": "995632 - Disclosure - Equity Transactions (Tables)",
     "shortName": "Equity Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://bioviepharma.com/role/LeasesTables",
     "longName": "995633 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:LesseeOperatingLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:LesseeOperatingLeaseLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://bioviepharma.com/role/IncomeTaxesTables",
     "longName": "995634 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative",
     "longName": "995635 - Disclosure - Liquidity and Going Concern (Details Narrative)",
     "shortName": "Liquidity and Going Concern (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "bivi:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "bivi:WorkingCapital",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails",
     "longName": "995636 - Disclosure - Significant Accounting Policies (Details)",
     "shortName": "Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails",
     "longName": "995637 - Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)",
     "shortName": "Investments in U.S. Treasury Bills Available for Sale (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember",
      "name": "bivi:AmortizedCostBasis",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock",
       "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative",
     "longName": "995638 - Disclosure - Investments in U.S. Treasury Bills available-for-sale (Details Narrative)",
     "shortName": "Investments in U.S. Treasury Bills available-for-sale (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "From2022-07-012023-06-30",
      "name": "bivi:NumberOfStockPurchased",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2022-07-012023-06-30",
      "name": "bivi:NumberOfStockPurchased",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://bioviepharma.com/role/IntangibleAssetsDetails",
     "longName": "995639 - Disclosure - Intangible Assets (Details)",
     "shortName": "Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://bioviepharma.com/role/IntangibleAssetsDetails1",
     "longName": "995640 - Disclosure - Intangible Assets (Details 1)",
     "shortName": "Intangible Assets (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative",
     "longName": "995641 - Disclosure - Intangible Assets (Details Narrative)",
     "shortName": "Intangible Assets (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
     "longName": "995642 - Disclosure - Related Party Transactions (Details Narrative)",
     "shortName": "Related Party Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:Dividends",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://bioviepharma.com/role/NotesPayableDetails",
     "longName": "995643 - Disclosure - Notes Payable (Details)",
     "shortName": "Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "bivi:CurrentPortionOfNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "bivi:CurrentPortionOfNotesPayable",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://bioviepharma.com/role/NotesPayableDetails1",
     "longName": "995644 - Disclosure - Notes Payable (Details 1)",
     "shortName": "Notes Payable (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30_custom_UnearnedDiscountMember",
      "name": "bivi:AmortizationExpenseNextRollingTwoYears",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:ScheduleofFutureAmortizationExpenseTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_UnearnedDiscountMember",
      "name": "bivi:AmortizationExpenseNextRollingTwoYears",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:ScheduleofFutureAmortizationExpenseTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://bioviepharma.com/role/NotesPayableDetailsNarrative",
     "longName": "995645 - Disclosure - Notes Payable (Details Narrative)",
     "shortName": "Notes Payable (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails",
     "longName": "995646 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R44": {
     "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
     "longName": "995647 - Disclosure - Fair Value Measurements (Details 1)",
     "shortName": "Fair Value Measurements (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30",
      "name": "us-gaap:DerivativeLiabilities",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
     "longName": "995648 - Disclosure - Fair Value Measurements (Details 2)",
     "shortName": "Fair Value Measurements (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative",
     "longName": "995649 - Disclosure - Fair Value Measurements (Details Narrative)",
     "shortName": "Fair Value Measurements (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "AsOf2024-03-06",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member",
      "name": "us-gaap:SharePrice",
      "unitRef": "USDPShares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://bioviepharma.com/role/EquityTransactionsDetails",
     "longName": "995650 - Disclosure - Equity Transactions (Details)",
     "shortName": "Equity Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30_custom_StockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-30_custom_StockOptionsMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://bioviepharma.com/role/EquityTransactionsDetails1",
     "longName": "995651 - Disclosure - Equity Transactions (Details 1)",
     "shortName": "Equity Transactions (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_StockOptionsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-012024-06-30_custom_StockOptionsMember",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://bioviepharma.com/role/EquityTransactionsDetails2",
     "longName": "995652 - Disclosure - Equity Transactions (Details 2)",
     "shortName": "Equity Transactions (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "AsOf2023-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-30",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://bioviepharma.com/role/EquityTransactionsDetails3",
     "longName": "995653 - Disclosure - Equity Transactions (Details 3)",
     "shortName": "Equity Transactions (Details 3)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2022-06-30_us-gaap_WarrantMember",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
     "longName": "995654 - Disclosure - Equity Transactions (Details Narrative)",
     "shortName": "Equity Transactions (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "From2024-03-012024-03-06",
      "name": "us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-03-012024-03-06",
      "name": "us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://bioviepharma.com/role/LeasesDetails",
     "longName": "995655 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://bioviepharma.com/role/LeasesDetails1",
     "longName": "995656 - Disclosure - Leases (Details 1)",
     "shortName": "Leases (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://bioviepharma.com/role/LeasesDetails2",
     "longName": "995657 - Disclosure - Leases (Details 2)",
     "shortName": "Leases (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://bioviepharma.com/role/LeasesDetailsNarrative",
     "longName": "995658 - Disclosure - Leases (Details Narrative)",
     "shortName": "Leases (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:OtherSellingGeneralAndAdministrativeExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative",
     "longName": "995659 - Disclosure - Employee Benefit Plan (Details Narrative)",
     "shortName": "Employee Benefit Plan (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "bivi:EmployeeBenefitPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "bivi:EmployeeBenefitPlanTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://bioviepharma.com/role/IncomeTaxesDetails",
     "longName": "995660 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://bioviepharma.com/role/IncomeTaxesDetails1",
     "longName": "995661 - Disclosure - Income Taxes (Details 1)",
     "shortName": "Income Taxes (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "From2023-07-01to2024-06-30",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative",
     "longName": "995662 - Disclosure - Income Taxes (Details Narrative)",
     "shortName": "Income Taxes (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2024-06-30",
      "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative",
     "longName": "995663 - Disclosure - Subsequent Events (Details Narrative)",
     "shortName": "Subsequent Events (Details Narrative)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "AsOf2024-09-25",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "From2024-09-012024-09-25",
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "bivi-20240630_10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r799"
     ]
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r66"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r674"
     ]
    },
    "bivi_AccretionOfLoanPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AccretionOfLoanPremium",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accretion of loan premium"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_AccretionOfLoanPremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AccretionOfLoanPremiums",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plus: accretion of Loan Premium"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_AccretionOfUnearnedLoanDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AccretionOfUnearnedLoanDiscount",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accretion of unearned loan discount",
        "label": "AccretionOfUnearnedLoanDiscount"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_AccretionsOfLoanPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AccretionsOfLoanPremium",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accretion of loan premium",
        "label": "AccretionsOfLoanPremium"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_AccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AccumulatedDeficit",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "label": "AccumulatedDeficit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets",
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated other comprehensive income",
        "verboseLabel": "Total Accumulated Other Comprehensive Income",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r69",
      "r125",
      "r431",
      "r447",
      "r448"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r136",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r8",
      "r17",
      "r360",
      "r363",
      "r403",
      "r443",
      "r444",
      "r779",
      "r780",
      "r781",
      "r788",
      "r789",
      "r790",
      "r791"
     ]
    },
    "bivi_AcuitasGroupHoldingsLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AcuitasGroupHoldingsLLCMember",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Acuitas Group Holdings, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r734"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r788",
      "r789",
      "r790",
      "r791",
      "r844",
      "r880"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_AgentFeesAndOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AgentFeesAndOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agent fees and offering expenses"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_AggregateIntrinsicValueGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AggregateIntrinsicValueGranted",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate intrinsic value, granted"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r716",
      "r726",
      "r752"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r708",
      "r719",
      "r729",
      "r755"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r747"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r747",
      "r756",
      "r760",
      "r768"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_AmortizationExpenseNextRollingTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AmortizationExpenseNextRollingTwoYears",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "AmortizationExpenseNextRollingTwoYears"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_AmortizationExpenseTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AmortizationExpenseTotal",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "AmortizationExpenseTotal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of financing costs",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r73",
      "r255",
      "r861"
     ]
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of financing costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r255",
      "r783",
      "r861"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative",
      "http://bioviepharma.com/role/StatementsOfCashFlows",
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of intangible assets",
        "verboseLabel": "Amortization expenses",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r203",
      "r205",
      "r650"
     ]
    },
    "bivi_AmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "AmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortized Cost Basis"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r107",
      "r121",
      "r151",
      "r181",
      "r185",
      "r188",
      "r189",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r353",
      "r357",
      "r383",
      "r426",
      "r510",
      "r646",
      "r647",
      "r674",
      "r686",
      "r810",
      "r811",
      "r865"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r126",
      "r151",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r353",
      "r357",
      "r383",
      "r674",
      "r810",
      "r811",
      "r865"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r712"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r712"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r712"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r761"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r760"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r118",
      "r641"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r75",
      "r147"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r75"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalent",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r877"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashMember",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash [Member]",
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "bivi_CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for amounts included in measurement of operating lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_CashlessExerciseOfOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CashlessExerciseOfOptions",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of options"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_CashlessExerciseOfOptionsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CashlessExerciseOfOptionsShares",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of options, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_CashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CashlessExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_CashlessExerciseOfWarrantsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CashlessExerciseOfWarrantsShares",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cashless exercise of warrants, Shares"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_CertainEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CertainEmployeesMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Certain Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r122",
      "r123",
      "r124",
      "r151",
      "r171",
      "r172",
      "r175",
      "r177",
      "r183",
      "r184",
      "r194",
      "r224",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r262",
      "r263",
      "r266",
      "r269",
      "r276",
      "r383",
      "r455",
      "r456",
      "r457",
      "r458",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r498",
      "r519",
      "r541",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r776",
      "r784",
      "r792"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r124",
      "r183",
      "r262",
      "r263",
      "r264",
      "r266",
      "r269",
      "r274",
      "r276",
      "r455",
      "r456",
      "r457",
      "r458",
      "r656",
      "r776",
      "r784"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price",
        "verboseLabel": "Warrants exercise price",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "bivi_CommissionsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CommissionsPercentage",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commissions percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and contingencies (Note 11)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r102",
      "r428",
      "r497"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r216",
      "r217",
      "r636",
      "r807",
      "r809"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r880"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r678",
      "r680",
      "r681",
      "r682",
      "r683",
      "r788",
      "r789",
      "r791",
      "r844",
      "r878",
      "r880"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical",
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value",
        "verboseLabel": "Common stock per value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r498"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued",
        "verboseLabel": "Common stock shares",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r498",
      "r516",
      "r880",
      "r881"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, $0.0001 par value; 800,000,000 shares authorized at June 30, 2024 and June 30, 2023, respectively; 6,216,398 shares issued of which 6,190,072 shares are outstanding at June 30, 2024; and 3,645,183 shares issued of which 3,642,895 shares outstanding at June 30, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r430",
      "r674"
     ]
    },
    "bivi_CommonWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CommonWarrantMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrant [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_CommonWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CommonWarrantsMember",
     "presentation": [
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r743"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r93"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets (liabilities):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r131",
      "r133",
      "r139",
      "r423",
      "r438",
      "r439"
     ]
    },
    "bivi_ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration of Credit Risk in the Financial Service Industry"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r41",
      "r42",
      "r190",
      "r635"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r41",
      "r42",
      "r190",
      "r450",
      "r635"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_CurrentPortionOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "CurrentPortionOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of Notes Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r149",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r222",
      "r223",
      "r233",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r249",
      "r256",
      "r257",
      "r259",
      "r392"
     ]
    },
    "bivi_DebtFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DebtFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Less: debt financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r252",
      "r860"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r258",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r672",
      "r785",
      "r860",
      "r862"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payment",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r31",
      "r34",
      "r45",
      "r85",
      "r86",
      "r153",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r240",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r258",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r672",
      "r785",
      "r860",
      "r862"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized premium recognized",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r813",
      "r859",
      "r860",
      "r862"
     ]
    },
    "bivi_DeemedDividendForRatchetAdjustmentToWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DeemedDividendForRatchetAdjustmentToWarrants",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend for ratchet adjustment to warrants"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_DeemedDividendOfRatchetAdjustmentsToWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DeemedDividendOfRatchetAdjustmentsToWarrants",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend of ratchet adjustment to warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unearned discount",
        "label": "Deferred Discounts, Finance Charges and Interest Included in Receivables",
        "documentation": "Amount of unearned discount, finance charge, and interest included in face amount of receivable. Excludes cash or quantity discount or both."
       }
      }
     },
     "auth_ref": [
      "r193"
     ]
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax loss carryforward",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "R&amp;D capitalized",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/IncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/IncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation Allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r332"
     ]
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/EmployeeBenefitPlanDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined benefit plan, plan assets, contributions by employer",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r281",
      "r288",
      "r657",
      "r658",
      "r659",
      "r660"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails1",
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r485",
      "r488",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r597",
      "r598",
      "r601",
      "r603",
      "r676",
      "r678",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of derivative liabilities",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails1",
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r98",
      "r485",
      "r488",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r529",
      "r530",
      "r531",
      "r532",
      "r535",
      "r536",
      "r537",
      "r538",
      "r597",
      "r598",
      "r601",
      "r603",
      "r642",
      "r676",
      "r678",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857"
     ]
    },
    "us-gaap_DerivativeLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total derivatives",
        "periodStartLabel": "Balance at beginning",
        "periodEndLabel": "Balance at ending",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r128",
      "r370",
      "r371",
      "r379",
      "r382",
      "r477",
      "r478",
      "r479",
      "r481",
      "r483",
      "r484",
      "r485",
      "r487",
      "r488",
      "r511",
      "r513",
      "r514",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r642",
      "r847",
      "r848",
      "r849",
      "r879"
     ]
    },
    "bivi_DerivativeLiabilityConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DerivativeLiabilityConversionOptionMember",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liability Conversion Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DerivativeLiabilityConversionOptionOnConvertibleDebentureMember",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability - Conversion Option on Convertible Debenture [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_DerivativeLiabilityWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DerivativeLiabilityWarrantsMember",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative liability - Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_DirectFinancingCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DirectFinancingCost",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct financing cost"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_DisclosureEmployeeBenefitPlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DisclosureEmployeeBenefitPlanAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DisclosureInvestmentsInU.s.TreasuryBillsAvailableforsaleAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments In U.s. Treasury Bills Available-for-sale"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_DisclosureLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "DisclosureLeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r87"
     ]
    },
    "us-gaap_DividendsSharebasedCompensationStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DividendsSharebasedCompensationStock",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deemed dividend related to ratchet adjustment to warrants",
        "documentation": "Amount of paid and unpaid stock dividends declared for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r712"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r698",
      "r700",
      "r712",
      "r748"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r699"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r733"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r690"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER COMMON SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r168",
      "r171",
      "r175",
      "r176",
      "r177",
      "r180",
      "r347",
      "r350",
      "r367",
      "r368",
      "r424",
      "r440",
      "r643"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "- Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r171",
      "r175",
      "r176",
      "r177",
      "r180",
      "r347",
      "r350",
      "r367",
      "r368",
      "r424",
      "r440",
      "r643"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Common Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r179"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r662"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax expense at federal statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r322",
      "r339",
      "r662"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r662",
      "r787",
      "r840"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal benefit",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r324",
      "r662",
      "r787",
      "r840"
     ]
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Embedded derivative liability",
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r847",
      "r848",
      "r849"
     ]
    },
    "bivi_EmployeeBenefitPlanTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "EmployeeBenefitPlanTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee Benefit Plan",
        "label": "EmployeeBenefitPlanTextBlock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "EmployeesMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r689"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r773"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3",
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r114",
      "r135",
      "r136",
      "r137",
      "r154",
      "r155",
      "r156",
      "r158",
      "r163",
      "r165",
      "r167",
      "r182",
      "r195",
      "r196",
      "r209",
      "r278",
      "r337",
      "r338",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r395",
      "r403",
      "r437",
      "r443",
      "r444",
      "r445",
      "r465",
      "r541"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r705",
      "r716",
      "r726",
      "r752"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r702",
      "r713",
      "r723",
      "r749"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "bivi_ExpirationsDates": {
     "xbrltype": "stringItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ExpirationsDates",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expirations dates"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Extension",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r379",
      "r665"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r371",
      "r379",
      "r665"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measured at fair value on a recurring basis",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r845",
      "r846",
      "r856"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r378",
      "r379",
      "r381",
      "r412",
      "r413",
      "r414",
      "r652",
      "r653",
      "r657",
      "r658",
      "r659",
      "r665",
      "r668"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r281",
      "r286",
      "r371",
      "r379",
      "r412",
      "r657",
      "r658",
      "r659",
      "r665"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r281",
      "r286",
      "r371",
      "r372",
      "r379",
      "r413",
      "r652",
      "r653",
      "r657",
      "r658",
      "r659",
      "r665"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r371",
      "r372",
      "r373",
      "r374",
      "r379",
      "r414",
      "r652",
      "r653",
      "r657",
      "r658",
      "r659",
      "r665",
      "r668"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value, liabilities measured on recurring basis",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r377",
      "r380"
     ]
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements",
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value measurement of assets and liabilities",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in in fair value of level 3 liabilities",
        "documentation": "Amount of increase (decrease) of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r850",
      "r857"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additions to level 3 liabilities",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r380",
      "r667"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Transfer in and/or out of Level 3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r854",
      "r857"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r380",
      "r667"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r369",
      "r371",
      "r372",
      "r373",
      "r374",
      "r378",
      "r379",
      "r381",
      "r412",
      "r413",
      "r414",
      "r652",
      "r653",
      "r657",
      "r658",
      "r659",
      "r665",
      "r668"
     ]
    },
    "bivi_FairValueOfEmbeddedConversionOption": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "FairValueOfEmbeddedConversionOption",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of embedded conversion option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceReceivablesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceReceivablesMember",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable [Member]",
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/IntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r197",
      "r204",
      "r650"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year ending June 30,",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r640",
      "r650"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r640",
      "r650"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2025",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r640",
      "r650"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/IntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r204",
      "r420",
      "r650"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/IntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsDetails",
      "http://bioviepharma.com/role/IntangibleAssetsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intellectual Property, Net",
        "label": "Finite lived intangible assets, net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r804"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r756"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r756"
     ]
    },
    "bivi_FourDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "FourDirectorMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Director [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_FourDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "FourDirectorsMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Four Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of derivative liabilities",
        "label": "Gain (Loss) on Sale of Derivatives",
        "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r104",
      "r529",
      "r530",
      "r531",
      "r532"
     ]
    },
    "us-gaap_GainLossOnSaleOfLeasedAssetsNetOperatingLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfLeasedAssetsNetOperatingLeases",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on termination of operating lease",
        "label": "Gain (Loss) on Sale of Leased Assets, Net, Operating Leases",
        "documentation": "The net gain (loss) arising from the lessor's sale of assets held- or available-for-lease under contractual arrangements classified as operating leases."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r210"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r199",
      "r421",
      "r647",
      "r649",
      "r666",
      "r674",
      "r801",
      "r802"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r200",
      "r649"
     ]
    },
    "bivi_GrossUnrealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "GrossUnrealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Unrealized Gain"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_GrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "GrossUnrealizedLoss",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Unrealized loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r80"
     ]
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r137"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r319",
      "r322",
      "r326",
      "r327",
      "r328",
      "r329",
      "r334",
      "r340",
      "r341",
      "r342",
      "r343",
      "r460",
      "r662"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r320",
      "r321",
      "r329",
      "r330",
      "r333",
      "r336",
      "r454"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable and accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r782"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r709",
      "r720",
      "r730",
      "r747",
      "r756",
      "r760",
      "r768"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r766"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r771"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r771"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r701",
      "r771"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r201",
      "r207",
      "r208",
      "r639",
      "r640"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r202",
      "r804",
      "r806"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r185",
      "r186",
      "r187",
      "r189",
      "r391",
      "r646",
      "r647"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r253",
      "r260",
      "r654",
      "r655"
     ]
    },
    "us-gaap_InterestIncomeOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOther",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest income",
        "label": "Interest Income, Other",
        "documentation": "Amount of interest income earned from interest bearing assets classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r145",
      "r146"
     ]
    },
    "us-gaap_InvestmentOwnedAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentOwnedAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value",
        "documentation": "Fair value of investment in security owned."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r477",
      "r478",
      "r479",
      "r481",
      "r482",
      "r483",
      "r484",
      "r486",
      "r489",
      "r490",
      "r501",
      "r502",
      "r549",
      "r558",
      "r559",
      "r568",
      "r579",
      "r580",
      "r593",
      "r594",
      "r595",
      "r610",
      "r613",
      "r619",
      "r621",
      "r624",
      "r678",
      "r686",
      "r879"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r480",
      "r481",
      "r483",
      "r486",
      "r549",
      "r558",
      "r572",
      "r580",
      "r593",
      "r605",
      "r621",
      "r625",
      "r626",
      "r627",
      "r628",
      "r678"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r478",
      "r480",
      "r481",
      "r483",
      "r486",
      "r549",
      "r558",
      "r572",
      "r580",
      "r593",
      "r605",
      "r621",
      "r625",
      "r626",
      "r627",
      "r628",
      "r678"
     ]
    },
    "bivi_InvestmentsInU.s.TreasuryBills": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "InvestmentsInU.s.TreasuryBills",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in U.S. Treasury Bills (available-for-sale)"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-sale"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in U.S. Treasury Bills available-for-sale"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_InvestmentsUSTreasuryBillsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "InvestmentsUSTreasuryBillsPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in U.S. Treasury Bills"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of additional shares for fractional shares effected by the reverse split"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of additional shares for fractional shares effected by the reverse split, shares"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_IssuanceOfCommonStockForCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "IssuanceOfCommonStockForCash",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for cash"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_IssuanceOfCommonStockForCashShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "IssuanceOfCommonStockForCashShares",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock for cash, shares"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "IssuanceOfCommonStockFromVestingOfRestrictedStockUnits",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock from vesting of restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock from vesting of restricted stock units, shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r398"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year ending June 30,",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "bivi_LesseeOperatingLeaseLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "LesseeOperatingLeaseLiabilityTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less amount representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r402"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r49",
      "r50",
      "r51",
      "r53",
      "r54",
      "r55",
      "r56",
      "r151",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r354",
      "r357",
      "r358",
      "r383",
      "r496",
      "r644",
      "r686",
      "r810",
      "r865",
      "r866"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r103",
      "r433",
      "r674",
      "r786",
      "r800",
      "r858"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r117",
      "r151",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r354",
      "r357",
      "r358",
      "r383",
      "r674",
      "r810",
      "r865",
      "r866"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_LoanAccretionPremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "LoanAccretionPremiumMember",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loan Accretion Premium [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_LongTermAccretionOfLoanPremiums": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "LongTermAccretionOfLoanPremiums",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Plus: accretion of Loan Premium",
        "label": "LongTermAccretionOfLoanPremiums"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: unearned discount",
        "label": "LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note payable, net of current portion, financing cost, unearned premium and\u00a0\u00a0discount of $0 and $227,268 at June 30, 2024 and June 30, 2023, respectively.",
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "bivi_LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, net of the current portion financing costs, unearned premium and discount"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_LongtermDebtFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "LongtermDebtFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: debt financing costs",
        "label": "LongtermDebtFinancingCosts"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r289",
      "r316",
      "r374",
      "r417",
      "r441",
      "r442",
      "r449",
      "r487",
      "r488",
      "r552",
      "r571",
      "r576",
      "r577",
      "r615",
      "r637",
      "r638",
      "r648",
      "r656",
      "r661",
      "r668",
      "r669",
      "r670",
      "r671",
      "r675",
      "r812",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r289",
      "r316",
      "r374",
      "r417",
      "r441",
      "r442",
      "r449",
      "r487",
      "r488",
      "r552",
      "r571",
      "r576",
      "r577",
      "r615",
      "r637",
      "r638",
      "r648",
      "r656",
      "r661",
      "r668",
      "r669",
      "r670",
      "r675",
      "r812",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r759"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "bivi_N2019OmnibusIncentiveEquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "N2019OmnibusIncentiveEquityPlanMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "N2019 Omnibus Incentive Equity Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss",
        "verboseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r77",
      "r105",
      "r115",
      "r129",
      "r132",
      "r137",
      "r151",
      "r157",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r166",
      "r167",
      "r173",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r347",
      "r350",
      "r368",
      "r383",
      "r436",
      "r518",
      "r539",
      "r540",
      "r684",
      "r810"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r159",
      "r160",
      "r161",
      "r162",
      "r168",
      "r169",
      "r174",
      "r177",
      "r350"
     ]
    },
    "bivi_NetProceedsFromIssuanceOfCommonStockRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "NetProceedsFromIssuanceOfCommonStockRelatedParty",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of common stock - Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_NewEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "NewEmployeeMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Employee [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "bivi_NoncashLeaseExpenseFromRightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "NoncashLeaseExpenseFromRightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash lease expense from right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "TOTAL OTHER (INCOME) EXPENSE, NET",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER (INCOME) EXPENSE:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining principal balance",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r101",
      "r875",
      "r876"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets",
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of note payable, net of financing cost, unearned premium and discount of $701,210 at June 30, 2024 and $894,926 at June 30, 2023",
        "verboseLabel": "Current portion of Notes Payable, net of financing costs, unearned premium and discount",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50"
     ]
    },
    "bivi_NotesPayableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "NotesPayableNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes Payable",
        "label": "NotesPayableNoncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_NotespayableConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "NotespayableConversionOptionMember",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notespayable Conversion Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_NumberOfStockPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "NumberOfStockPurchased",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock purchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsLineItems",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OffsettingAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OffsettingAssetsTable",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Offsetting Assets [Table]",
        "documentation": "Disclosure of information about derivative and financial assets that are subject to offsetting, including enforceable master netting arrangements."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL OPERATING EXPENSES",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LOSS FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r645",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r673"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/LeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails",
      "http://bioviepharma.com/role/LeasesDetails1",
      "http://bioviepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating lease liability",
        "label": "Present value of future minimum lease payments",
        "verboseLabel": "Operating Lease Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/LeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets",
      "http://bioviepharma.com/role/LeasesDetails",
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of operating lease liabilities",
        "verboseLabel": "Current portion of operating lease liability",
        "negatedLabel": "Less current portion of operating lease liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      },
      "http://bioviepharma.com/role/LeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets",
      "http://bioviepharma.com/role/LeasesDetails",
      "http://bioviepharma.com/role/LeasesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Operating lease liability, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets",
      "http://bioviepharma.com/role/LeasesDetails",
      "http://bioviepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease right-of-use assets, net",
        "verboseLabel": "Operating lease, right-of-use asset, net",
        "terseLabel": "Right-of-use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r396"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average discount rate Operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r401",
      "r673"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining lease term (Years) Operating leases",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r673"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss carryforward",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/BackgroundInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Background Information",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r96",
      "r451",
      "r452"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive (loss) income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r14",
      "r130",
      "r133",
      "r138",
      "r163",
      "r384",
      "r385",
      "r390",
      "r422",
      "r437",
      "r779",
      "r780"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current liabilities",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r674"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "us-gaap_OtherSellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/LeasesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative expenses",
        "label": "Other Selling, General and Administrative Expense",
        "documentation": "Amount of selling, general and administrative expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r707",
      "r718",
      "r728",
      "r754"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r757"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r710",
      "r721",
      "r731",
      "r757"
     ]
    },
    "us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PartnersCapitalAccountUnitsSoldInPublicOffering",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering",
        "documentation": "The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r736"
     ]
    },
    "bivi_PlacementAgentsWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "PlacementAgentsWarrantsMember",
     "presentation": [
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Placement Agents Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r694"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r696"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r262"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r498"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r262"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r498",
      "r516",
      "r880",
      "r881"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock; $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r429",
      "r674"
     ]
    },
    "bivi_PrefundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "PrefundedWarrantsMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prefunded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_PrepaidAndOtherAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "PrepaidAndOtherAssetsPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_PresidentAndCEOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "PresidentAndCEOMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "President And C E O [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrimeRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrimeRateMember",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prime Rate [Member]",
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from public offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "bivi_ProceedsFromIssuanceOfCommonStockNetCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ProceedsFromIssuanceOfCommonStockNetCosts",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of costs of\u00a0\u00a0$2,908,141"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_ProceedsFromIssuanceOfCommonStockNetCostsShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ProceedsFromIssuanceOfCommonStockNetCostsShares",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of costs, shares"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of costs of Related Party, shares"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of costs of\u00a0\u00a0$94,160 - Related Party"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_ProceedsFromMaturityOfU.s.TreasuryBills": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ProceedsFromMaturityOfU.s.TreasuryBills",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Proceeds from (purchases of) U.S. Treasury Bills (available-for-sale)",
        "label": "ProceedsFromMaturityOfU.s.TreasuryBills"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of stock options",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r13"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows",
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET LOSS",
        "label": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r129",
      "r132",
      "r143",
      "r151",
      "r157",
      "r163",
      "r166",
      "r167",
      "r194",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r347",
      "r350",
      "r352",
      "r355",
      "r356",
      "r368",
      "r383",
      "r425",
      "r435",
      "r464",
      "r518",
      "r539",
      "r540",
      "r663",
      "r664",
      "r685",
      "r781",
      "r810"
     ]
    },
    "bivi_PurchaseOfCommonStockShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "PurchaseOfCommonStockShares",
     "presentation": [
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of shares"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r280",
      "r289",
      "r312",
      "r313",
      "r314",
      "r316",
      "r374",
      "r415",
      "r416",
      "r417",
      "r441",
      "r442",
      "r449",
      "r487",
      "r488",
      "r552",
      "r571",
      "r576",
      "r577",
      "r615",
      "r637",
      "r638",
      "r648",
      "r656",
      "r661",
      "r668",
      "r669",
      "r670",
      "r671",
      "r675",
      "r678",
      "r808",
      "r812",
      "r848",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r221",
      "r280",
      "r289",
      "r312",
      "r313",
      "r314",
      "r316",
      "r374",
      "r415",
      "r416",
      "r417",
      "r441",
      "r442",
      "r449",
      "r487",
      "r488",
      "r552",
      "r571",
      "r576",
      "r577",
      "r615",
      "r637",
      "r638",
      "r648",
      "r656",
      "r661",
      "r668",
      "r669",
      "r670",
      "r671",
      "r675",
      "r678",
      "r808",
      "r812",
      "r848",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872"
     ]
    },
    "bivi_RealizedGainOnMaturityOfAvailableforSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "RealizedGainOnMaturityOfAvailableforSale",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleDetailsNarrative",
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Realized gain on maturity of available-for sale",
        "label": "Realized gain on maturity of available-for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r66"
     ]
    },
    "bivi_ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows",
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reclassification of unrealized gains on available-for-sale investments upon settlement",
        "negatedLabel": "Reclassification of unrealized gains on U.S. Treasury Bills (available-for-sale investments) upon settlement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "auth_ref": [
      "r702",
      "r713",
      "r723",
      "r749"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r287",
      "r407",
      "r408",
      "r427",
      "r434",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r515",
      "r517",
      "r548"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r522",
      "r523",
      "r526"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r287",
      "r407",
      "r408",
      "r427",
      "r434",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r515",
      "r517",
      "r548",
      "r864"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r405",
      "r406",
      "r408",
      "r409",
      "r461",
      "r462",
      "r463",
      "r524",
      "r525",
      "r526",
      "r545",
      "r547"
     ]
    },
    "bivi_RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relcassification of unrealized gains on available-for-sale investments upon settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative",
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments of note payable",
        "label": "Repayments of notes payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r640",
      "r646",
      "r873"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r703",
      "r714",
      "r724",
      "r750"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r704",
      "r715",
      "r725",
      "r751"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r711",
      "r722",
      "r732",
      "r758"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares for tax withholdings",
        "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r87",
      "r432",
      "r446",
      "r448",
      "r459",
      "r499",
      "r674"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r154",
      "r155",
      "r156",
      "r158",
      "r163",
      "r165",
      "r167",
      "r195",
      "r196",
      "r209",
      "r337",
      "r338",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r359",
      "r361",
      "r362",
      "r364",
      "r366",
      "r393",
      "r395",
      "r443",
      "r445",
      "r465",
      "r880"
     ]
    },
    "bivi_ReverseStockSpliteUpPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ReverseStockSpliteUpPolicyTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse stock split up"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_RightOfUseAssetsObtainedInExchangeForLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_RsuGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "RsuGranted",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rsu granted"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "bivi_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts and Financing Receivables [Table]",
        "documentation": "Disclosure of information about accounts and financing receivables. Includes, but is not limited to, amount of receivable and allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r66",
      "r192",
      "r799"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of dilutive securities were excluded from the computation of diluted loss per share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of warrants activity",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of note payable",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of deferred tax assets",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of derivative liabilities at fair value",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of effective income tax rate reconciliation",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r662",
      "r840"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r803"
     ]
    },
    "bivi_ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases",
     "presentation": [
      "http://bioviepharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future estimated minimum lease payments under non-cancelable operating leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r606",
      "r607",
      "r608",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r522",
      "r523",
      "r526"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of summarizes the activity relating to the Company\u2019s stock options",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r12",
      "r90"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of assumptions used",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r34",
      "r83",
      "r85",
      "r86",
      "r87",
      "r122",
      "r123",
      "r124",
      "r183",
      "r262",
      "r263",
      "r264",
      "r266",
      "r269",
      "r274",
      "r276",
      "r455",
      "r456",
      "r457",
      "r458",
      "r656",
      "r776",
      "r784"
     ]
    },
    "bivi_ScheduleOfUSTreasuryBillsHeldTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ScheduleOfUSTreasuryBillsHeldTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailable-for-saleTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of U.S. treasury bills held"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of vesting of restricted common stock",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average remaining lease term and discount rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of future amortization expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r650",
      "r805"
     ]
    },
    "bivi_ScheduleofFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ScheduleofFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of estimated future amortization expense and accretion of premium"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12gTitle",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r697"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expenses",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation expense - stock options",
        "verboseLabel": "Stock-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rsu granted, grant date fair value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value per share, Canceled",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r306"
     ]
    },
    "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2",
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value per share, Issued",
        "verboseLabel": "Weighted average exercise price, exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, beginning",
        "periodEndLabel": "Weighted average exercise price, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares, beginning",
        "periodEndLabel": "Number of shares, ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average grant date fair value per share unvested at beginning",
        "periodEndLabel": "Weighted average grant date fair value per share unvested at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining life (Years)",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "bivi_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining life (Years)",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value per share, Vested",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend Yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r313"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "verboseLabel": "Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r312"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk free rate",
        "verboseLabel": "Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised",
        "documentation": "Number of non-option equity instruments exercised by participants."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures",
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, expired",
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average exercise price, expired",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Options canceled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options granted",
        "verboseLabel": "Number of shares, granted",
        "documentation": "Net number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average grant date fair value per share, Granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r307"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding at beginning",
        "periodEndLabel": "Options outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted average exercise price, options outstanding at beginning",
        "periodEndLabel": "Weighted average exercise price, options outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r294"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, options exercisable",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of shares unvested at beginning",
        "periodEndLabel": "Number of shares unvested at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r309"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, exercised",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r298"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, expired",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r300"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, canceled",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r299"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails3",
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average exercise price, granted",
        "verboseLabel": "Weighted average exercise price, options grants",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r297"
     ]
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharePrice",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock price",
        "verboseLabel": "Share Price",
        "terseLabel": "Share price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awarded Vested rights, percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Aggregate intrinsic value, outstanding at beginning",
        "periodEndLabel": "Aggregate intrinsic value, outstanding at ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails1",
      "http://bioviepharma.com/role/FairValueMeasurementsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term",
        "verboseLabel": "Expected life of options (In years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r311"
     ]
    },
    "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted remaining average contractual term, granted",
        "verboseLabel": "Weighted average remaining life (Years), granted"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2",
      "http://bioviepharma.com/role/EquityTransactionsDetails3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares, Issued",
        "verboseLabel": "Number of shares, exercised"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted remaining average contractual term, beginning",
        "label": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted remaining average contractual term, ending"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted remaining average contractual term, beginning",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual term, options exercisable",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r310"
     ]
    },
    "bivi_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average contractual term, granted (in years)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_SharesIssuedOverVestingPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "SharesIssuedOverVestingPeriod",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares issued over the vesting period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r148"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r695"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r122",
      "r123",
      "r124",
      "r151",
      "r171",
      "r172",
      "r175",
      "r177",
      "r183",
      "r184",
      "r194",
      "r224",
      "r226",
      "r227",
      "r228",
      "r231",
      "r232",
      "r262",
      "r263",
      "r266",
      "r269",
      "r276",
      "r383",
      "r455",
      "r456",
      "r457",
      "r458",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r498",
      "r519",
      "r541",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r776",
      "r784",
      "r792"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3",
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r63",
      "r64",
      "r114",
      "r135",
      "r136",
      "r137",
      "r154",
      "r155",
      "r156",
      "r158",
      "r163",
      "r165",
      "r167",
      "r182",
      "r195",
      "r196",
      "r209",
      "r278",
      "r337",
      "r338",
      "r344",
      "r345",
      "r346",
      "r348",
      "r349",
      "r350",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r366",
      "r384",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r393",
      "r395",
      "r403",
      "r437",
      "r443",
      "r444",
      "r445",
      "r465",
      "r541"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r182",
      "r395",
      "r418",
      "r453",
      "r476",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r520",
      "r521",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r679"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity",
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r182",
      "r191",
      "r395",
      "r418",
      "r453",
      "r476",
      "r489",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r498",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r520",
      "r521",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r541",
      "r679"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r706",
      "r717",
      "r727",
      "r753"
     ]
    },
    "bivi_StockBasedCompensationExpenseStockIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "StockBasedCompensationExpenseStockIssued",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation expense - stock issued"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_StockBasedCompensationRestrictedStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "StockBasedCompensationRestrictedStock",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock based compensation - restricted stock units"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_StockBasedCompensationRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "StockBasedCompensationRestrictedStockUnits",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock based compensation - restricted stock units",
        "label": "StockBasedCompensationRestrictedStockUnits"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_StockExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "StockExercised",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock exercised"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock issued during period for service",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation - restricted stock units, Shares",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r87",
      "r298"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation - restricted stock units",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock - based compensation - stock options",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r58",
      "r59",
      "r87"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from exercise of options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r59",
      "r63",
      "r64",
      "r87"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "bivi_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails",
      "http://bioviepharma.com/role/EquityTransactionsDetails1",
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock option to purchase",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r58",
      "r59",
      "r87",
      "r458",
      "r541",
      "r632"
     ]
    },
    "bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRendered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "StockbasedCompensationIssuanceOfCommonStockForServicesRendered",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation - issuance of common stock for services rendered"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation - issuance of common stock for services rendered, shares"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_StockholderEquities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "StockholderEquities",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets",
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance, value",
        "periodEndLabel": "Ending balance, value",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r63",
      "r64",
      "r79",
      "r500",
      "r516",
      "r542",
      "r543",
      "r674",
      "r686",
      "r786",
      "r800",
      "r858",
      "r880"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY :"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Transactions",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r150",
      "r261",
      "r263",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r275",
      "r278",
      "r365",
      "r544",
      "r546",
      "r634"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411"
     ]
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "presentation": [
      "http://bioviepharma.com/role/LiquidityAndGoingConcern"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liquidity and Going Concern",
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r746"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://bioviepharma.com/role/SubsequentEventsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "bivi_ThreeDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "ThreeDirectorsMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Three Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r863"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "auth_ref": []
    },
    "bivi_TotalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "TotalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total compensation cost"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title"
       }
      }
     },
     "auth_ref": [
      "r768"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r769"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r59",
      "r63"
     ]
    },
    "bivi_TreasuryStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "TreasuryStocksMember",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Stocks [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_TwoDirectorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "TwoDirectorsMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Directors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "bivi_USTreasuryBillSecurities1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "USTreasuryBillSecurities1Member",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "U.S. Treasury Bills due in 3 months or less at purchase [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryBillSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USTreasuryBillSecuritiesMember",
     "presentation": [
      "http://bioviepharma.com/role/FairValueMeasurementsDetails2",
      "http://bioviepharma.com/role/InvestmentsInU.s.TreasuryBillsAvailableForSaleDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "US Treasury Bill Securities [Member]",
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one year or less, are interest bearing, and are backed by the full faith and credit of the United States government."
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r765"
     ]
    },
    "bivi_UnearnedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "UnearnedDiscount",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unearned discount"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_UnearnedDiscountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "UnearnedDiscountMember",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unearned Discount [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_UnearnedPremiumAndDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "UnearnedPremiumAndDiscount",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unearned premium and discount"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_UnearnedPremiumAnddiscountCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "UnearnedPremiumAnddiscountCurrent",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unearned premium and discount current"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_UnrealizedGainOnAvailableforsaleInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "UnrealizedGainOnAvailableforsaleInvestments",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrealized gain on available-for-sale investments",
        "label": "UnrealizedGainOnAvailableforsaleInvestments"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_UnrealizedGainOnInvestmentsForAvailableforsale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "UnrealizedGainOnInvestmentsForAvailableforsale",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on available-for-sale investments"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_UnrealizedGainOnU.s.TreasuryBills": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "UnrealizedGainOnU.s.TreasuryBills",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized gain on U.S. Treasury Bills (available-for-sale)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://bioviepharma.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28",
      "r109",
      "r110",
      "r111",
      "r112"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://bioviepharma.com/role/IncomeTaxesDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://bioviepharma.com/role/NotesPayableDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "bivi_VendorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "VendorMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "bivi_WarrantLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "WarrantLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://bioviepharma.com/role/BalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://bioviepharma.com/role/BalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetails3",
      "http://bioviepharma.com/role/SignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r677",
      "r680",
      "r681",
      "r682",
      "r683"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r847",
      "r848",
      "r849"
     ]
    },
    "bivi_WarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "WarrantsMember",
     "presentation": [
      "http://bioviepharma.com/role/EquityTransactionsDetailsNarrative",
      "http://bioviepharma.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "- Diluted",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r177"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE NUMBER OF COMMON\u00a0\u00a0SHARES OUTSTANDING"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://bioviepharma.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "- Basic",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r177"
     ]
    },
    "bivi_WorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://bioviepharma.com/20240630",
     "localname": "WorkingCapital",
     "crdr": "debit",
     "presentation": [
      "http://bioviepharma.com/role/LiquidityAndGoingConcernDetailsNarrative"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Working capital"
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://bioviepharma.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-40/tableOfContent"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-4"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 4.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/820/tableOfContent"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "840",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481222/840-30-40-8"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482161/360-10-40-3A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-6"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-18"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "40",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481628/310-20-40-7"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001520138-24-000324-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001520138-24-000324-xbrl.zip
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M'.8AQTS16UY<($E\T@LR4Z0DE_0T("41J84S= R;!POZU(,,H#]Z%Q'ZK+M
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M0M'2@N=GZ2!T\*IN6MI,F@YB"I\U,"69/I&;HX/(=T>'_;/1RB$SGPT=$_+
M0 8'AOC.8<:M523603$>CR06)/'O<U^/I"&:FZF#X#?4=Z^(BTV/NIE>E)^E
M@]#3)1CJ JD+\G00.]F@Q4VME<C39UK4SGDY.H@<G4G(R"LGZR#L);A_P*E
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M5MAG/F=?PLTGG)51']>1B+;JYZNIG^M(+EOU=4W4UW4FKJWZ^VKJ[^J3S5,
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M"@S[M!HS"=2^-"#V.1SNF<W"%[R#'_P5(TW!N/0V"OV,KWT*RGQZ;P]R]O:
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MKU(!"? 5@36DTW&3QPT""N9$W#VSZ0W3TY9+4P6^R9K)[8)INX@,D2T1AJ=
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MQ7O$1?UULX]Z6FY,7F8ZR1 X=4+%Z[U<PW^&=-8>D!*-\,BC'1_3DUB3J1S
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M+QS@;5#1'<SG+5>,R49CXZ!1*Q^](=$L!6V,PO?!\316$\T^'^0KJ:Q(<+B
MA,(TPD8"2XEU0L*BO/($:VG4Y])W$':LZ6%250SW>=@CK4->3E;N!!.\KV2?
MF7*4>ILU58T)UURJ4$3%8:P65[ Z"4Z?)3,)QI?,^06,66[*3!/*H6#(K D8
MK!EU.P/GQ7C.$O< ["TA.])X4[:;;#(]P 1_-<%\J:IBM7VAD;$.\S=(HNC
M&T(*WN1B+!;U84H -JJ'$=SE596?$T =.X.UDY9Z[\C*$HDBIH@:MS>#XJ6
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M\S\JI3(5:6 Q%:-4=K@N&TC)=;C[1N(OU7<*V9!XQ6%2,%HL9VC6W@88H.7
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MK^&AM+%<CJ91N*H]HHEJ%\)(C8W:>: <!,K ]@GMGCX.:K38QMH+!DO$ LW
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M=&YGXNB7H995 $YM;/U4K^NG.OCQ_%3+DOIG%!TRK_PP=)#:I(0X3QK;K+G
M5UT5LTE!J=+<.RYZ<(2J@3#2":8H]53\+9MJ>H]Y72[U.<2(3K:XER+:J4PU
MWN54#A)% =F6S$EAD2XRG6 \EEA\(]J<69[$.17H52C],BEQB@%)TE\) DI*
M4EB ZZ;Z8(U@1C&&$<PU[ P-;8ASVT9E \O<+ZD'95&7Z!U]ACGT)-R(*F.^
M$QKWR>8&'AAK=_HBFS&MNDR&Z>H<@U^>[KRD+ASI=\PD@^5D).E4-=H-6>G,
M?I3TJ$Y'-LQ%$ \AG1CT*DY[W*":?&RE3@HNAI"O&/!AR7Z\%]H\>,U[1VI]
MF'#R$D>U=)'&U$LNO9!CSVEL7O8R<FY\8-G4V R4Q()FG-192W /S(.Z#\U=
MY4M$5J>B(]DH'GW6;XB-D5M<G^QX<AOT$QQ3'E[V[R66E=F1*N!-)H7.9J6\
M"R6*\ EN1"MP(S!'F<+O&B/5OL-.DRP('@0!?%&BL<T"EAJMZ?FPE]Y7C@W?
ME+,6,O,-E6G4I#%-S^6[P&.>QW8CG'^4*MQ!9!#;&A;@>96,JO:-,B)49AZ!
M^\CX?@N?!0F$,)68#R1((">;PSVV?2.]1?DGLWM^!5L?>PDH'><\"/;?6A$F
M.4<,I3? Q*:!ZH,I)\JYPUR"Y;<B!<P=D_M &\Z&;* CBV>0"E*9[6MLV4J%
MAMK"2!C0=&[92>*#5HDY#-296_>36_$,/'>!0-R4J,(I3T=,@GDU(O)&1\*#
M>YLPIC![!\RW 24)M6$4[,@-?]*0QA$G47&>4B:Q^OAVMG1I<^'ITL9CZ=+C
MN=)F-E?Z&>G1J@9!#LCU!D8&$ 4&1LW5PKX\]-(+?\^LUTI'Y2K/ZYBJB-+?
M'APU#NIOL&-KZ)-2AQEE1 'RH7*Y4#VH%2J'AQ(<B>;,W<GP^].K:K5V6*I6
M4AUB;04/2QE1V&E=P@>.!(G2U8>%=)[Y( ["F!Y,D$;E^^B894-[WD7:-KV9
MAERG9[V8K;R\BWM",\]TP1:"787+O]MY0FK=RWY;D_A4 I26ZP4)J7PO>S=$
MH+MC$\ER!6&FPABV@DA6<D;!#)T'<_?@C:%@<%+?9JR0@BQ+W:TBD%WJV1'A
MD@RIWH<V,-95ZE=RVAP_HX:2#QDY;\[PB)(-\!.)LIY[RO0I<Q/M3]_ZSD!W
MMKR;R=?F=]B,2.\( ;^I6>7-1@;V';HRO_'$Q ,AB%+1.KO2 Z$BJ]BDU?5?
MJH_/TUQ!L\]A-J?18WEI[.K(24WK@8PKX@1A9,^_#ZR!]#_=4[X]_M*U=S[<
M.I$K1CTW.<]-:],ZTZOR/5!2SC<3<GC?"O8_F!<QWK_/G!=L),S&^WFGLK/
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M^MU<N0KJT</VS$2YJ9(E.5%F;*DL3USWKUL@"79C1 (=@.PVY]/?L]=^G'T
MD-WR6-+TN"NI1&:3>)S'/ONQ]EJDHJMZLEGJD#9A3U]L*6]HY[G<^F3:468E
MR_@&=J!C]+CGDWO?T@KA9:?^ \N!BNK0NA'N;ZP> B,64(HT5"$C$P<5_SP_
MQW=8IA*L8'&=D>6"'<@#B;/@XY72[Y,G>+J3]H96(:6J.63ES).3QQ,H.\S_
M0=T).@#H[5<E!(%V)-S 0N;?LDEBUP/)[4( 1"@TRL"G%BG)@S),G2#;*P\(
MY]/"8^/CUKFJ>-R9B""7)-9Q#E9XU[ZQ='1X3XGV/"?_J1M+-G\<VGU+JG^7
M[+5PQ(+1/RO>1;=O$\^= Z2L*;^XQ%3PLT,(B?PWF'[9M5!6GWDIAE6EM&XS
MEY@GCY:G1T6P+ J:RVM+(AEY[:S!H.N#7'_B,Y,J%P0CJA&OAEO5NMBIX0P.
ML(S@72X\=:T"//"V$S]D"<4M.AK$%['4K#\:9B#%TJWAO^5$94@.>"\:DQ?U
MEF)X 6F@=D35K O2@Z32RD#:Y6H$9>*"31PEW*-K0?^?NE(VS=\((*^U3C(4
M.6C%^SA0 =MNZQ[=!]%7(?R(M'J.%Q:A6D8%DKC7PQ@1P[>U$DQUB=T3'Q[5
M@F''"0)^ /J% E06U2X.Q/@UY\M[\1^S/:+<X2A]*8:P<<)D;,1O!9/1!\&8
M3A[GK'ANTPHKX-J0K*74&BY-(\TE>^!51]/"2"9=.)/2%8>#\55933IAB4X.
MT*JKV6# Z3_O0F;*$%XVG=9323^/K-!P46_6R /=X?TL[9:D;_%#@CH\5]=)
M&BWK?X)6RQ]S!VFF2:S,^B!DB84I+HB"I@UM)NSS53TL^^8R*2)-\'>I]RRN
M_@-W';,WDY9MUXYLVQ'S52;4L891KJ>QCQOGJD+UU%G._N;:<!87P6J) 3 G
MFLK1B :",XA<+QP2,'9RJ6;P39]<[3ZH_^_Q'#&(H)[,>G@6K?%U!95*?"5Z
M(?2Q.O[< EFO M?S!>MA":METR_W6]'HOL/[4MU"+GRSNEP<5CXJX\ .;DI3
MCS@;+=1KM[#CZ\96"(V?3.RQ,S9:.#X=JE8NQ3_V$YJN>E:\:46L.:V T SR
M4TG0\W=33S-Z,0:N]C]<Q>]=*,9J#E9U5Z?O.<+H_'7\/CDR2J:.JM.N5_!)
MSGFZ!P\B,!-A?LN ($*[&*1O9JY+ :B4,+J87H/=:4<:,>M1P_%):%[."SE<
MKESP-C#<D/P+-C79EL"@?O#(^ $IZ>+RB-U.!<8=]!@I/*36 G &V<N7:MGQ
M3W@Q]8I1#1L2EZK)25"D,YT3<8T8E'K?SX^&*M6NK+0E_I4]Y/)P%EZG1 L2
M\G2F7;<R-&FS\9Y?IV:[Q,C*JGXS7I'7>3SU9QX5 6T4JX;2G_%P+?CHD,-0
M0M=X"4N/<JPH,IQ M,.,Q;FP$C+YXU4;'P_>F_BG@YS"@(FE(P])IEWT9>FE
M]/TE2ZLYHPH4):02O)(/ ;'Q"\.+% X7Z"'VS!^<KJ #YYH>*<DJIV7)(6=8
M4'RM^8_\MH.V<<^\^V)/H>T8(C3^_;*B)FLK+(IHV:I> FU'# X6LX1Q^BNM
M"F![6+%8=XZ-1<7YDM$ QJ>4IKV"_>ISUBO]X=5W[TJ\>4VWJ/K#:'73_ <5
M4Y[QPL^*UVM[+I),Y9EFW"8NSU>O5[3'L@3)^+3@6(!/10[HV ;219YA1.@>
M>&WR]+7U?G01LF 4:%;Z;FM+-?X#((N>W".+/B^RZ(_WR*)?1TI7B FP"2=.
M9C)5V*[2WQ3REJ <T.D.=L;0^H,Z&>G9[:^_W;<;RL4TNV07AY1 R&(ZY1/1
M=GCW5"BG39#ODVR0B%&GWB6QFBGMDQ%PY+4V22ZK90I:L%:BFCS9LOB0P4Z'
ML Q[#$T!>$$I,47'W!KC'EO?-]C[9L8]&]+LO"WGP^5BDHD;C3*F,65IFAV_
M0+3>I,Z%U;*JXZ!0!<K1L3DO'%X$@#+XY4QTI'DP\I13H/2IU' _7FB9!?O3
M#A>=@KB;I!D$GGAR\M1-=DXFG?*.TF:4!EC[67>4#W"#!!%OLSJ@Y;%A9UKC
MUJ;W&>1@*Q$E$B.5\+-4O+JJ42" +X7O,:M>BG@;%T?G;G-\RX;H8Z@B'S?7
MRJ42TWL%2QSR([/79^_CJ\]G)%E96?J":UIS96PLZ\UU=1C$(1H,#\T9D&$_
M(#2G48P#?A6]+K)(T-Z.[OBN4OH@&$?FPUG5&Y*=1Y8$M9P>E;8Y&JF1L02-
M:F%]QY;,CWX_>6*U(/"%>$C+)<+5PR/'(^36QBC,QPTG%Y8K2GYM47,.1 QA
M0NC,[/!XZ:#K3O2!LD(QWS#_9?J>\N$T;==S:W7]<T7/5LHR!,V2YMZ6%U5[
M+J7V;?77\4]"^HFS*J-I']OKW:GAH,?3C+V%!Q2A"->4K=+$6K4EER,0E 5%
MJ.@4UI.8!Z@O"VM&*_<U2G''GJA1KMUR?-_XJ'4CB4G>9B&?>B*(7+%X_+F?
MWF-S(Q/,-\:8*T?6^(7N<.X(H^WHNVHT(,WL5!MO+I@J0:1D0N-4CW%L@Z+@
MXO8<M.*<\!6<&" [#F V3=QU@T8OO6AN5(C.JV^6.UVP4A<+%#O6(Y?%=0?E
MYX8V^U%4+;E<9@QSSV7T9H/8KF6UYP=>U+H9;''(#4-"&;EDR?S=,XR,'OG\
MID9W-3;5/IVCX##ID*_&29V0DXAP^JW%5UUB%N.@:7>J=NW[JSJ:8#B1EX3\
MJ+:#;PO3 )N+;Y:KL P-!A5,:"A4IQFB#J$[O$&X9O6FOZ0\M7"#TF14S"1\
MUPM5?[%^1_^*SXDBQ"]>-+'&_4!?":LT #AH3V3N,K ?X%B4] %1KC1VHG&W
MU0TC^\!SP%6S7\5Z"Y4@@-?UM982GCQZ5#YZ]"AK:9OG1M8PXX-^IH1D*1JD
M8@@Y';[[C4$9E3VH&*T!A:A$$2P[\CT#8TZ,8G55-1OMJYL^$RMV-$.(\11L
MX>R(:=\A'>346"!NX5!M4F7?#*BLAE2X3%.>FBL1P5A-2)U;IE7.?*Y4H: %
MA<4TR&J:NT6900'TV3Q.CUP^(6:.5[HTT@6Y)ATK<9&%. [+#1<GP.L:EY/W
MS$Z\I/G:<?RNZ@/@3=6*RIV4JFC 4CE<=/U.6BY6^ZP#VI^@'/.$N9CG#MO%
MS'$0XS_HB/J13/RPFT,P#X/1&WU<24@2Z[BH]LSL D[;KN&[<:@U7C<N.X,%
MM&'KDR^W(#W25Z@%">%;77F?5FV?S^#0,L@(!<4/UGJU')/;60B([S/0[P6'
M.-6>G[8XU!4UW<1GC+%7<:SB7!H%>45K\1JY@[5+F^P! 41!1^OA+J>C(^)&
MXBP056.]:] T7\1K4@M2*5X#IBY#.%.,CK:BO'$I]_1R<SG>=#2/[@D07"-L
M#9-%@7'5WU$-@ZFHTD/\PGM.#('[6T#]@EW0Q:9;OL_1OD23W,+D=OL^'P0W
MDX!@(J;AH94W'"8L'S>LG% -B%;:'(I,^2)^@).XHV9(>;&5)"[)^^44@63Y
M-!SD![5"X6CI!CRH&V[F[$7["@=P)Y:_;EB*(U&;'QT$9B.F@'">\=;=.2SZ
MKEKIX8]Z63.X6Y3*FB\ VN,6879%P!L">XBY RSP$O\6S^#XYK!#C#@-M";I
M/GQRT3MKK_O\C^^P^6>W^%7T<U8P3)XPGTXZP7>]E4CB[CO*FJ>Z@+G]EG#L
M/_94\9)@2<K'"> 06.X'X^/(T+0)S6- V4-@,ALAZH-VPTPAG%N9Z]H%L)(
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M+YGQR4QEG?QS)/;J<NK*<&FOD313*V<)]8/*U24)N&<FO.Q/&(M5QTR.&9>
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MD=)=B_K0L:L<5-?Y?L9N,V,_<B\6Y7-2VSM.KNA@[09M)C6WR4)5)Z:A3AN
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M0-I5^5WVK6Y5:<Z5%^H"&']MABACD!9K_%G<")<=+1H6ZJ!=IYL]NM2774/
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M@&Q#/<5:;#Z"Z;%*M*P@N$I"-QX]HQZIN;%HU6#G7&KNW]25$AU!K*Q:JNO
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MTW>':D/X%@]I,V)_HZEO=NY("D FP.X8YP3A,;B1E(\7Y$&';G,;W=_T+E8
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M'(@K%X?4OT>[T?I5E!D"78STI8_N;'K T\?()Y_T!@1'<<A%%L),>EB3&Q8
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M1TT\I50NHMR2\SK2 5^*9Y+]FIJ:94,5I&RYLNR$5'0I1B$?AQE@24@B[94
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M33;[JBN&SC^$^Y-=.>1#@4F2$HY3U_/9BM%^GA:.$(=GIWAWW1KTX*33R'=
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M%:*+*_W$%80PV5&\]'@9J;E("TX%TYIE/J^0QB]5\X 19AI[6FP*P^JA,!%
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MSY"V 'Q;ZH 1P:=HF"4Y9>X.(''Y$NO(1:3_N.3.4,IZR9X$[ /+Y($'FD]
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MAY.6CI:\&!K9%F!%[TT,,JNX8\#DZ&'Q=>#ZUJ)1^O=HE"^,1GGV_:%1;E'
M5,%KET13ED;)8F?;WSA%\OS@-Q\\D##+'^BVY=/DP>'^SO;6[D/M;96. C$'
M4LW4U'70<.FURI]MRJI-9_V(.I-&A1)1 HN:=!):3TY^BDA-L DR>0REM#)W
MI=XN.MWT,AE 13DC(L5JM5>$18?85GD,;9-'"SZ!*+L%U5GPB2)+N)D\K]C=
MZX@@N4TED;J$_.R/3Z0D-$ZZ4E;R.'58?#T/[CBIVDF(JZ3X+.G5+@^/6UB&
MZN.-M=@? U ,WI9Z0?2H"Z$@TVO9ZR_*0N0WO-^6%R%X90D.@M^VO[>9',69
M?#GQXYH3AI>4/U:,M_D2M1A. K_^%-,+09%=<56NZ]-0KSNO!!>-=>]YSKXF
ME-JJ4C%6+!"CY(:+A@;$K[&2TZ,2N>2F(Q^!TEE]D8\B9E&7+S^A0)-%=$=S
MQAD4RS").(FA8(@*""5!%?2+>!D[_BZFJJH=/QOM?P8>@=DB))(L%!$3']N1
M:X.9$-^[#&8BH-\2I@G"\^Q,4B?N,I@E&4*3)6_;.;*=W<X586&T'=N.5PB$
M>SAPD#8GOLP1I;K\@P2HSH1Z5C$!O8H#$#-!P%Z 0#%\_1[V"<SKA6V*UJ'G
M<5 @&;;G318$:U' 'V4(*6.!VX>@Z:UMF1*X3(-28DYKEH>+U_=(RYY657=0
M"N##H/ 06::9%1<&SH+H;M)C>A.472\Y]V=_RT6.D7<Z8)M.!,AS#*5AQY#=
M(D)E2",V>2WM!==#<61%(O K/H*_O;(A:1(BV@23?804)%BLF>2P3^-TH1G0
M-!R\:[D">J3WI2MD%44QXA01XNN/-<<5.F,ZVHMZW;9$"["4'ER1,]>;MBT5
MFR?'=V'Y0'.CD,X%,%95HA+89O(+[T)J/=;OAN1@4)\MZ2Y 29#F!3MHR&;%
MR3,IXVDRI46/%!*$&'(AXM1[F! ,5\,+8(^@9 02AV$GJ.0Y_.R&CO_+.@<@
MK1^+9E3G,TJFQN\Q Y)J36([,NY1$ZZ\C>&/ACT%<\]GI"3W6MD9X_S!G]$6
M"(H/['=53]. \0U96G]Z8=M.FDSSILA2' =L2L*7#!W:<C,DY3$.3Y 23.'0
MEWYU7@ ,D;'WP[YL/_Y^4N$.#"1U0!#50T<WJIH 4-)O0GA%FZ1^8QF3=<-)
MTCIRK'LWS/O*WX@<7QB'HE1R=SJ8_.+P1O$3K4!L/\@VSS9["(AD'AKSM8=0
MEAZ=1\:D#?'&LC"R]/$2 ,G%$L+\\ L8;#^-8^+UKZ+C3-U0+!_@2O.7!.!R
M4E3@F_!)!SJKL1X\\KEW*2$R9I7C,\J2^[D<41^=%!*H?4#7?L.:)++%TSBZ
M(?N0-S&^P!]@W45CN@8V51-UL"T@4C.U(+.Y\BYO3E7RL@IG*BU\J6VH6L!E
M%EAAR$6GQ08XY8R:Q3$B[MXZ*,09WEUWCW\B(L5%&QNV*\BSE$2Y*/WEN)%(
M_]487KBWM&0!0P!J([;&NC74'9:8X&!!A-6/C3<*X+RB4X8UC:P^3V<-R0?$
MEH?"#;?$X])""Z\7(1<6];@P5T-3?IVM3@?2EH%WKC"X=7$(=-G&-7]*N8<O
M"T>X+51NMQ646&7LN@C"A]@7C"4Z6K ^*O#'@4$IXBG 45M$0*ETFIP(\AN/
M"W^FD;2-%0'K9&*<CAH%^N:+,NC3BD42@VH9$$=8) EQ@J[%R !"7.:/^ND,
M'T&4EXU<[3R<LKP=1=CBBB)VU=M<S5 N-(+M"_@X)*/R6S4!?2 ( I6:U4<9
M4<=)6R#VTU(#?2TB#\.,Q(;)&#G;_!2HD80F7$DO.Q,/W>%-\#P,H"JE6$Q]
M-''._24GE"-)H;\HF'*=:T@F^/61-[0MF*!T41L"&M#NOB($F7%[[O:<G:[&
M4@(-I/?M(0;U5_N#QB7T\)OX0^5=HYZ3ZQN:VW0XJ*+,Q^JD':EKC<R$[)85
M,LJBW.CV[-GF$U)EXK(=QG)@F'IA<9C5VU.4E1F 2P;_:BM?T)71_(CH7MB.
M-RR\6X(R59V!?'8MW*SD$XZ$\#8U8D#>M)1(FPR>S-NHB-RA'<=QL> ]P(_/
MRT6@^HM&G%]_)9%GCLU#D!N)I1ZNJH5\%;T5$HR^B@EA[OBV.8EL2^B1\*>J
M\T?K&6:CB$X(W$X8%IYKR]AZ!B)^B*M20M]3</=3!8D27C2POQI^B<8_2\HQ
M!V$%N$<6)*39"8Y5D*S#@+DM)1% U D]+E49K.W.:WW0X(P9?22 Q%1(M(X)
M$(+H"/BFFPM&6?O $[ X%A^GS_)Y9OO._@2_1N"$Z$$$C=Q)WG=)&81LV".X
M>UC),3HY9??76XEXD,GLD(]O!]R:JNY!X>C\1FW#9&L$[&54K'1>8M# DF.]
M3!WM6A"4%FYIR2Z$ [-M'"CI0,4YR+-$'F5D.938B;B@>OI7):&I2UIL*".F
MBB&L2+<A+A8PJR]YA#032ZT3IU1TI'Y CO*841WB4!@%%FDCY6(3:\"/Y_Y)
M:&%53-D9@3>@>FJGO:HC@22,$"'TK',&^J3%54-^,AE'L")2E$BP0<S)$]#^
M+S$1!=B/7(#\M%O90Z=J2N-G/--.\3U,XR4G\VKTCMQZ&/EL!?(G(T1JO'+<
MGPC)OIZ(;"T(9.<>!/)E02 [6]\?".2S$+1I65C9*RUB6% AK*22E_X@AB01
M<LES@4HB;O@V- ER#TV]1!*]?&$Y@8B)3Z01**:/BI=T\,%C=/9GFY/%ZEXR
M"^)WUA[WNZ9+SQ8I9,\S!LN M,.-4+()G:6BK0GG3T0408$"+1S3A=SF/^UU
MME2%J43H[5H&U9X2(A09J9#ZXPY355#6J=$319W9."TL/%[RB/[<SU*(CR#A
MC[D$LQ0EX4@Y4@LEB> XG=()B(@?UE7*LF=Y8[91A:HUZMA(6_,J75/7Q=[G
MSUY;?VAUUA@.XQB6 DCPL11Q#GWT3!T@SWI)?VMK*Z(?7G4-1]<@6FX21$5*
M!FUE%J05?FPUNU^=35-*V&AVA:$R6M& ,CX2DDXI70BW'5:D!;0,Z5DY$5G1
M9,3CA@T4"]0/@&N!;_\^ATR=MQK;3[U;5L[/&WVU3'GIA8(>IHH,DZ8S\\8Q
M$*AG].?:7\0AHA(_E46+J[:^3I0D):Y[T_;7-9G*W"QVS"V!;H.D",]\.\4+
MCUPQ]P^4)OR'SF#,M9L#(JO5JY\+1>$V.KKP++TN41O,":3L_P*](T:'6-:B
M\"B%F*24Q24! Y>N.FL-YRHKTV71L4%'C4T:F9N61.'PBKJ%(C%M4=U,+\EN
M:5TXI/ER@ZV):TD6721E(W>>@Z_.J>/NN^FQ*2^X_ )4@1;Z3V.1E"^%S^2>
M$0B2"*"X<MS9L21%O?IH9._ 'O8VR9]V?DUQI2+J"(/<96<[7 FN$';W:86A
M[1@#M$2$ \)=R0&R/4IP1&D.Y"TX6SAIGT"X?3G)I1"J#FL#4V*L_B66N\'^
MU>&V-YL=[KMQ?]*).5K4%CVAOAQE[I8]M26&\ANME1L^S;?G2;45? T3O0RU
MN^E06\T/8RX[O%S<@-T>W&6@!>\4?6^R^9S@8R%_Q2DID43JN-U!>#/V.4B&
M@U#%B/.38: $ Y^1(SK49H =()8UJW(.[QG NO;UH017U6F=$P00I W2,A-Z
M$Z0@!E10E^"&46OJA#* $4(,#3ZG"UD^LFHD5 @T7 PT[6E^)[R/-T89//FR
MND?5B;>PT,THQEE'<MU2R*9\2J@V"% -LO/LN 2,0"_IJH%R:<'F D,6AIL2
M.07H3!%!EA5>,>)"EQ7FMW_%9%RV!!HH_;Y%RJR/K<^O#;^7D5@Q&M&F!UT$
M%99JP37IZZ0K?4UY^O75KKF!_@3DC##5:_K73/[26<9-KR-I5HA3RM]NV'U$
M=1XV5SH"#-]WJ'G3?;#VC*A%UI,CEL#S4!E;00XMM-J&LS2FV!:GWRP6]P&+
M915F6 NG]L:!Z:3%S7@J=7=QD<"LN.OJ]4JVTUUW5A^5>RH%H=NC)B7_5:Q&
ME5R9Z GREBQ56K< B"XF?@NUZK4$AAV8ELYYHGUG11F%R8.&,90D ,,H*986
M%M*"&S\0&4D%ADX$9#?,TRW#/!. >6XFAPN_O$&6#=7@\3WX QNM!M+UV92&
MP?)+<2KR /'DNPDD1!LEG!#;%_K(NIWB#IPK=6-T.#^V)T-Q?$I&9+*?2D$/
M1IC]&)R K-5FUFMQ3_#L^_&_ZP7MWS/II1AF19Y=L$]*38+N%IH$(\=*T6(4
MGK6LC/0+NAOT"YH2X U:!E<]A+0.!GA*)]T.90V(:1MYJ$37@SO*@#9[=-7*
MB.&W<#\1&)=JCYHX$$A4'DC)&@2'@*]MX'3>I(%G!7*MDUJT*%BCIP4SH.P,
M:VYD' C+OB/R 6]""I0"MK=')Y6 Z.6X<Z/C)S KM>F>,VA WA.F"56BD2^#
M* AAR.'5!;$E'9B! 7$Y#=#$*%\#YM7M6@B* KKA\K+=[QX:+*1WK:J[UJNL
MAE8BMO.92(LBQU;#H#GL!Q[)= %DP,M4DF)$ A!]B/H/3!.(U%!S(KRQ;['T
M$OJTG\25_H*69S]$1<'TA,32"F%F-O!UIHX06F$#!5RV#](81^$0M5D9) ?L
M"0&I$Y@&9P933#UGSY>>HMI[2\33M2: ?13(-U3R>IC(B(25,[Q5,9;H<ZD\
MQP=<:&X%#GUX<7P&\P!%QMR W .]DCV:J'[65]HB2<ZN[@(7-Q;01<NK;M1%
MA";/L\;F$1&'+J_8\?Z(5,%B>#LC$CJ/7-1I8&7>; 4$^CXL#Z/!U0. !-T\
M_UCH=%)?T&(Z$[LL5\=:!F)!APO_4"6A3L^]UPC-8-S%!.9BP<0?V%W$M#P,
MNKO(2>M,VU]3526RG0 K7@.7Y?J%[JY;=Y=,RR.=BE2\TOQJUWT_EYE9"]5X
M= _5^,)0C>WO#ZIQJRVK8,G).S7^:"N4S[H"^6Q%)65]#@@LD+I1P9@FJ,\X
MQ?9NR1&D<X<VP.ABK6X7OS3=GXKEMQ3_ M4SG GV\?$D%B.O&,$0,+A0GY#8
M,&(BL'W?7?JS)N4ICU2:KH/0JY&L[=5PH5<CV6^E<]O7#Q($"M0;9E(AX]P&
MMJ^^1P#W119(H<_R"WG+"%U,62>F&$,!N^A4U=YTQ-!3J2'P-D$*W.(\AE?B
MGL"X]T*K33LO3^>2RJR%H7;!CP9G!SRJG+1ZXFB<Z10(K[M8(;>]HC!,3=FV
M$\CV=4CNT84\,TMW<-J=JJUFH9-3UW[$D"F(53ZX F+S[EH-,8@9/VF%JM$X
MUN^IZC*[4O#-),NHXQC"4MIQUJ&$N]3555HH_QLY4O"U7JA:$"Q6IZ*E*@M6
M@A8?N"+"8*#:*MP&8&)K6[>$>F;@Z*B4[3-Z>92;)\1W2;E!Y)[Q_HH/1#>3
M/?(@+$ZG9<G&#),Q@!';C@-^8B0YU<XY6DQ$JHW-DJ>6+#5G8T-F>D#HJ$Z<
MZ^6G(;K[2FH;GX'I+D*$<$MY*VDC;?2FLL&HM,P'U=55)GII)EII+Y2N,T\2
MKNL/N8I;W>'<(%+N\WQ&:01Z%B;73AOA]E@%_;_MBL9GDX9B>QE&GX19((E<
M+9KBRO%?P'*QZ1GF50RH;^7K5?G.;Z\"8O SS-#,:Z;30%2-IBWTSL0BX_=0
M*JED'XOF@%-,QI6#LSJ V4,)HF4D .:T<5Y=AF0=)\O\VKBLZG<L,[ZB+C^*
MS12A<Y#@RWN"^=@O@<;AZD0J),BP$TRHU<]B"!KM61"9K[JCG&+>I1=%6^'^
MJL\!G\QT]&JMC4AE>\5;V4Q]*V-'^XZ@9$9FPO3S8LI/3&CF8^P)M!7?<!*Y
MS$W2-J9MO(-39XDJ!5Q,W,,4WILR LPK#04<:]#S1BE#,S"O0HVGNY,9FO(-
M05BFFO5W.W\6 SR,S#0D(:VV-"\R>N<EX(=W0.!C>JX'T <M..SE P4 5DE8
M4SLCV$<#7;SL)KL@@!;''/'C&BE,)2^RC[S4@[2F2PIZR8J0GT)DQ IP"2Q?
MB ]@FZ, ' ])P%2L;Y3Y4P[$5PN.^#(.A*3R.-YP0GTM)_<'=/=^&Z?V[^HQ
M*8Z_-7JN9?/CHX)LM)%X"&=1[%"3*\V(68 [/PB'V:C:,/Y3G>@/#R5SCC;:
M1=UX6GAIR<>V.N4ZP =-X/FOL(W!WU]^;!5E+I>'ATX&^\8:QD6K20DUTSIO
MM#T:0I(B)U7>:EBPG4$_?\6I)V]#3(N<'L$&48?9E/6%[-]1BX)XVW%Q5_[N
MU#[)<5?LKTF_-@M4XCT5AAI(I[' %YN\%9*)WD5[CR($WM;6&?<\>K<=8'U
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M\=/-OIG!F&Z'./G-R; 4/**])5>#XD=_J%1LITA[$2TW/1FL$ I@>HE FY"
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MSY1(I#U7;*G6Y(-;!J1-AZ/3Y.9*6L\S!084$K7H ]=0Z?U=00L8@F36KQ-
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M940\KXD!0"'YD:L1O$O?N\.6CF'P2'H,782!7"WFX42NF@+D@WK.AX ]B-F
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M Y"31!UPRQ/K&.]Z_$$W/K9&1,<D&H*H.E<Y ]GB%(G?^EG*@,-Y35@KWGO
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MNV9@^SJP.T^V\<T&LSHODNW'\EJ4#8$G@O0G.%@IJ]=!J_1EE4A'0$BO\T/
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MV6%5FMXGOAH"MN<&J8Q"'U(-$Q8<K=X813FX-2CKV&L^P"68CQY";90:#64
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M__RT8G]&TM<$6M7[$LD.#!L*MN;XA.?*D.]GU(\>D A(1CV,Q;AJD&>:,.!
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MLKSB#Z#0H[(BG@R.3S;VJM\V^LE%7@.=#_2+0AJ >"5(' 'V&[?&L(AG+Z%
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MO^C"D%ETF"6;+;!=':CX]*S*:W]4,A^U2G8&"836ND%?!%CBL>Q$'7[\ZKA
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M^"O[<;M2449N PXP4/)(ZQIIB>SWWX2__\Y_UXO1J3W"V.=)_ A+]T&:*+Y
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M57@D3B:EWC.[R#;PE&&M$U; @;]N/]U*QND5<V9%QN-SB33>FA/E5\W&\[1
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M_!OA+>;B!T-[<.T/8O6I$-2 ()6F82U+Y IV"7\YBH?UQLAIZ F#7!FZ_$6
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M#OW+0A#6'I0_,'>S"3YBS<1RI?^!:6)IXV"B:0#,I>"7WGG?@K^L>K_X5ZB
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MQ/4LSQHWC_]</-Z4]Z@;KUR5:"-SK.I^!&E>AD-X?S\JT8MOQ(-T,BZO)DY
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MNJ^ +3U\ZQETNTTPD^%7:X;QFQ ^MLB-H4YT(S.U7.T98C-XB(9Z)LLBK^]
M-5&A[GP="U#R,_.F=E'KP&]/>,&171[_!9Y?]VY\05QF569NB:(N=*;$@CHW
MGC *W]0O;@N=<\Q^;?Q7,B#V$?C<Q$\UQF -6L#" &G^/<\ STTM,([ZJ&<
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M.RR7VG[0">>\3V (+Z G S<;VS@@<2280@L,2MU=YJJODJIYKMMW<./DFJ-
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MR2(&GJU%%<P^,7_>,1D)>)B?NZ,Z%%1[J*&=1P-YIB,P$F1RGW*<PF/A2&/
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MU+DW1G8'/$/$MJ-$U=;?83F(X6$Y*=@E%2%)['*+SSX[04S21-QB'/2MN&D
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M6B,WV&9(NKQ?%(8%?)[:D*'T#J[+NJ/Y4RWW%=B2X O>Z.6HRBXZ$,IU/!
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MB^*D!B"2RPWWO6D!$L4L<(CV]&1X_OGTX.B_'^?-*#IIH>S.*_#FHXZB 3
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M',+P5=#A<&59IT.,RW&,@W>" T[XR"#2^3O6(Y\7I"#NW5FVH3O[*8(VRZ%
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M3 ,5:6___ _N6KIU[P)J[6GC[K_/Q;/3I_)_#>\";%U]V&/2\!U8JHA.R3#
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M!.U?P[0HLLHMT.UO;_Y09#DL4;\%(Y\X!").LO[FF&;2'#4/(H(+$G)SVJK
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M5[CV=^#H2IGX=]@H(AFZ0- H9@6-BC(&K0+XY[@5V?%0UYO%:;J"30P5. S
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M$)W7P:J%GX_9AX5JK&RXVCNLOO44"*#J!=.YWABVQM-],J0EQII;P_Z$WSB
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MNN"CZ3'\UZ=8M5F*%\%=V^;9RK@F/)7"6/P1:DJX&8Q#2\148:(*FB!;,R:
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M2'!,05?B8*6]Z91 -!^) R=^7@UU;D:O 6[E9!.F,F7/-^&PB0%E&;*8=I
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M.HJ%D"HQ2PW!?\7Q6.!%LXC7(@5RCHR)LL9',V\'.-$=U9L*<"*\.<^]IP_
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M/[CE^$5YZ:V:Y*B;RN2)99;AC<I(?M-O5L/"1^F=7;S22S)-5I9#?=1;U ?
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M=F-V]\:\=_YA5VDTS?.CO1-HHP#?%]K;IX*U_?D?*=U&_M_+%U!+ P04
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MC["M/"D;^W:.SN085.T^ _$?GH?$>0FL)NN@:NAFXD./)M8A#V_ 7XR?89+
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M#M>T9SF2DKYJV/T5_M5>&7#10<K]2J\0Z!4IQA/_'_^<(_O-_P!02P,$%
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MQPF[M28TPO' ;JT)C?S>FTNE-99?V_CEN] 2=Y'>E$$4.E%);,5 $IVX:FS
MA*3Z3D[J@I6E;X(XS?Z*D??^";_L(F^<(;YY>3[S8R_ U(OZTT^FQ^.Q3U<
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MK^\&>TLLU.,>?WV71',&RRTK*+-M.I3)AHO>=7CU92R,3:94?4QG4Z2N52T
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M*V%6+2X4 M'Z*F1=)I2RJ"ULF1:W213Z81[&#Y_)XC,-/9%5(B%;A) #K-C
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M>P?]VDN7*4O-&#"'[QJG+-.]T?:[7-G=J8;.(/E!ATS3.0L'P=4<A\SV^]/
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MD[K3K"4Y*<LO+HD@=AY7:HJ &:/$N 1/)C&IRK\&0XIB6&57,C4&MB1=D$,
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MQLM2H@TH!T PD-Y,XRA/42'.^7LH\BZGK]/$QSC(BC/C"=RO:</<1B"TLB
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M34\_DUIY>\Q4G:]?A^'ELJO<75]?GG\^OUK-+U%]?H$65Q?+F\_SU6)YY?[
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MVJ4M_54M%S>RDO@3<39+;&<X\].0':@KKV09*%F,$S,TH!$JIM$ 01=CF**
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MW>(HOTF!]=$B#&Z3R8-84]J[V&SIPXX$\'T8A?FK:IDSL!Q'[.YGIH3>9H5
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M)1(M-R<F2A/$1R="%1 L,L>I.TRI=)$7!X@6@(/BQM>ELW.5VKB@:9AZN\1
MQSKM=/ YTLD48%%.@W(HX=QLJXBMNDKR$H[J2*^'KEON*<Q1<U"@")B+<K1#
M.4FS*D[!R[67W3-3RP=(2W)&>5;]9<_2ZHW29?K@Q>$_F"] KRT0R '[CWD<
M7!.PQ%<H,Z9<D#5#[(=>=%O=#<_F]UE.DYYTZG+DLFVP?)+J:#Y5.TK!SGO)
M%-9P.7$;9<]0J_2R(^W+IT?N]1?0_A/HU^HCXWH9UGN8_L6MZ3YS-/U.\Z[7
M5-_X.GJC^>MA'SW_MX<TV9$^N(C92[2C+R"']*_;W3U-K9,3J\Z2W7T^OT]V
M^:>$3,"GE'>I]'&Q(078[!/]#6NRW5P;#(][0^XR]#+\^RX,:"0HG2B8)BI5
MG=-T[OLTB5-C7:WQGE0*-FFH!]ZDG5P:#,VT$+E]LUIA[](#<C!NPX>8)=B,
M<]XT[>!GJ&QUX.ME4&O0,]($P\1><+E'1_;*2,#00VEY'SZ%C&MO?_CPEO&-
M_N5O>W=A$3_A\E'(17SW)GNS2MESM:\?PRC*YD]>&-$+I,11R+P(2P:[D<JT
MP<Y1S:>D':5 YUP>TPI^0Z4NC+B<B!:'JO(0*Q#5)9Z0(D]HF1,1OVW8K=BL
MBR2]]>0WY \IR!K%#S*TYO6@4F"0^1#H*@:'E,&W'(.]T1E\L$?Q*4F"9P*.
MK!\79.T8/X0$WCS+<'.YJ'%?>Y9AT[\89%[3S>A5@'-2'X*ZR^>J#+; VI>"
MBF*:J4P .<AR:W7>L9&F3>KV,*5)6 ,U,#0UQ\H/MAT^.F?>#8YHR-VUE^:O
MJ]2+,YHA/HEU2W^]FDW.F1K1))Q.!PS;#('R&9*9&F)ZJ*D(:>"3&6<^ /8J
M 0(I#0?$'NK@J6H^0,I9ZYRJ9_@^-_8M9<(V":@&W.2:6!(,K93PN@RBPD"]
MO+8=NH%-*NV.0\H!2R(*E$6Z@>@JR7%&AJ'7T5/,#6%.G;.FD?Y.,P*I56QR
MR 1\DT@J>3!L,@"I2"S4>F( S@!5&_69[?^PX_=%O-WU69#V+,,)$?N8)V2F
M20'PJ-H#M8*[C5+<.V7G?]^%^:MF*.P*V>2<&&"35&T),*P1PN(NYS A2$/8
M;4Y(_)A$ 4ZS AV=R<V'KQ[Z5@^<^YK5.G,V509#OKZ();P<<_VH/6V^)..B
MU"O3R#HX'1;#%9SZM@6=4\0$'1=UQ82<CTV7.,LP7FXQO=@6/Q2H= .23LGF
M*&1F0'/H46M 2:35"RU0<ITFFTU8G./.X^ T8;$V.*:!-L:[5CW+L$F]0>8U
MF=BK .>CW"&H!0]U5F6P0]%6*4"WRHSLU@V=?0L!QV?ET-JOA.-BM&[,55)Z
M<D_O?+.-DE>,RR?BKPDT,[=/J>C !S0P1. 0*K2<LZPW5&[E4&J@4@51G8D8
M)4"GC,M3RUOCCPGLFC8J82CNGRE0*UP9(9;(3S9XY;T8NWU*#;NQ0UKH[9@A
MJ;CS@<@<(Q\C1#4040'JFPE,TD>IJ50<4TP3ER:7ATPR?21:Q3( :U=ZK0[_
M?4?<N?,G@UO[<G';EQ]5H+M7'46R8!BD <C=[*G%42$/:7SJVF)RNU8B[Y)/
MVKNS0F&PC-)>%NM2RCF//GI9F"W7G7MOK\7_U9'*5-DFP_H9U*2;F288[O6"
MRR<1(,HT;4<S,8%S,MYE>+D^S_)PX^6XFX%.)F237&* 31*U)<"010B+>\LI
MPY02M9AS/IQZV2/=/R/_0P\[G[R(CIEF8Y.AKM7MT#[FM'9!312A;#0, <UM
M?1(EMN?ITW_@O?KTMTH[-PW59.NK[.+VJ)E!HANC:DWG8]L@N/UOADY$.980
M)<[3,B70:8J#,+\)L]_">/6(]QF"</H4^G@1!SNR]-#X96,6;(VJHU9$3>-1
M2H5!\3%-X<^8&F73R;\H'='B:7_('W$SLUOQ"51]P[F#((KZ[+. Z:'O.H;7
M>!ECK.R<W4,1"^-VGUC<[F9? F6S5]R'IIY$%'KW833*F]>2$9TLI;9>&!"?
M9TFZ35K<?348L,WTK(W'?<RHAUL3)>=\ZXNTR[-2E=$IH<HEOYP/@T5(5Q&C
M93;P*37L1]LIH?.A=D)Q:.L?/52@078W.,.DZNCB[0P_X2C9TN'T_&6+XPP7
MEDA,-M*T>SW9V)3VM62MFO/!K#]6_AIRH<G&LX:N<P+6)WUF8YE<W,F9J\$H
M)I.%-H1I<((^;CWWTCB,'[)KG-X^>BDVXY)6R^JU*C,36O>LU"I@1BTSG-Q]
M99RCRR3+T);X7C0\DJQ9F;ISMA$P=,!ER^@RO<-IDAGO59MJ6P[>[6-2)VK7
M1!4,&_OAY0YUZ3VNDWOBN]$8W7U)SDFIR#16_:1TYWKH \D;)S;+,&=<6QG:
M7-P7N"QEG'-6+C9D$9U21W.9GH79-LF\:+F^3.*'R_ )!R;;)H<59=4K/,#8
MEL<XH!PPP^L!X#D7LRZ*;N_1(DY8&2-EFI/L[-V0Q5&:83;0WVZC,,=W6X.-
M/2,U:_MZ/8RHM_4,=)RSK"=0?A7,-%%&55%&==%NZWR4O,+/C<B>-(G)/_TB
M'T6? X[^Q=@<'8<:V1P9^Y;AG*\' N?Y2P_P6JGG6V4Y9_*M_XB#7827ZSG!
M%X31+B<C]BWV=RD[C3E_\:-=@(,+0@WJ/N^J5W*Z:T1MB.L$'[(:&SM91;6"
M:D?_"I@>-9EIW(JO_!#U0:K/H*S^#GK&*4:X_!JBK<P.TOW]-VM-\GM4[6AD
M8VQE2%R8?=UTPF3^@J-@1?._*5V97NK67)H!1M6N30]=YP0?"%A%6Q;HE%>!
M3O<L!?XC*0C0='$1QL2/8^Y]=\6K).Q!);D9\'N;*A[1C8MQSNC#L:O('>XS
MD ,YH:_0)2H[+W8YO3FY2=*\?$:P/,;K1?=Q/N&B'XQ9.:(.,D;YX'K.B$:I
MNM2:E82\1E'$PV%E@>E<RS5-?]MS;A"IN)D$Y.#%HSTO#XZ<"I JLL5)CM%V
MG+3$&G^8=)]!H^[00JS[QKT-Y#QDXQ*<T^\@V"I"XO)*5* :!UD<C>?[*:Y6
M>-L4;\+=!M0 F89/'EVO7N[C8>=Y'8';>_#L5YRK@76(T;)!MT]9SGO$2 8H
M-T#J ILQULC+T;J.RW;> VKS&D:7T>;!,KZA6S=I&#^P:[%W<7*?X?2)5@1+
M(4U^)G0C6JR[&]\I&/533JX?3%!9PIL*(WX'3(^;T#CY_8=9JPN6ER$"1&:C
MM/H@NJ=?A-,ABX7*/ [4]40$KI(X;56;T60UQ8><=,;1*TK8%4?["KR..+9I
MW6Y8E=6>^FCG\\!UO[T_P X\/M+@M6;L&CM(7VZ+-]A\,KF'^6M/WW!XP6Z\
MQ$,K0NPO#BT53/<9S125#YGM-ALO#?]!)BUZ4.:5Y9!N$[$DU2A/V _TPU[\
M^B__].?W[_[T<U8&;21;&(^GB:KJVGNEQ_#S9R\-FE5%1R16?V14VFV*OPWN
M8(=\Q'5G.[R"=!UO^!= =\*#S5)U2&^OBW;D8X#ZUAW+V("#&_)_T] G_V+6
MW\5AGMTD4721I+1*>G:F@:6ZZ3T'58&XNPPJ$F#_.,0.58>@I=*)B/PSK8NF
M$1WT#@J;A@!UD>)J3#$H[/(L]^* 8!_>.7J7YZ9;##1;W"%Z%@:P*PRS@$]9
M2%VS5TI\HI-Z+!M]Z9]-=#8C>J&D6K.I5R']U:V=QPPPJCZ)Z:'KG(<# :MW
MF-<XI0OKW'L9*:!#&R57G!U5J?""SV$<;G8;9DCI>&5W<8#3JR0^]4C+1]2H
MSJ,ZZBBN<;[@(-9NS*H1A..-43R,7C")309!&OO3RDWQ(131$NB)>I'H;$>_
MA>(D/O'KKY%5=/FY0GKZ+O8+#A\>"<KY$_GP [[!&R^,*W-7.-W0E 9AQN+:
M;X@Y?:)4#RW;0;<:ISH$'>JP@J%UI5&L476BY_(#R"N^0/S]\A-E-\K)1]A9
M?U!^!I%^X_Z(LWG$6\R7*^]%M.?=^XR_5VFNCO@'F"P[X>]1%+1;PH>98=D)
M&Y'RY^LUIHL27*<LH7V_<XS:C_=#BG1#_N'&BWM __*<3Q(C&J&, ZL*16&1
MZX9V!CKZTP.^1L$3^4Z_).EO9!XZ];9A[@GGR:Z$-3]&#*WV1MH_.Z>+'%.W
M]4LAY!=2SH>\3CKM>7[JI>DK0<B.N"6]0J=D.PFZWH!N]G.YAG,N]8)IFNA\
MJL77_LEQ]GIX*-FD$(G96Q+)0>Y7-[R,<R)H@ G3!I7/O_\K:_K)-E3GOK_;
M[%A>(^(6AGXH?,)3)&6MT>40ZS;G1:!XWVIXW89O"%*OFDHZGU;&NSI-72JM
M<S;.1X[S<GZS@J:YF$^_X'PTG-0LKDLUBD9EV:\S5)6-SJ]OT:D7^;37T;L9
MO[+"W+_B=F"57(8Q7N1X(WLJ:;SB;7:UL2NEV<G&*AM,]QK9()..14/+SUO)
M+4[;B2VJCR#RE2(_)_J5?@BQ+QU]KYMOZ*;O-.U1E7U$_:U='2-VMJ+@KZ6G
MM:SI=K-5 F%O83]5-UY%,G/H> 4WSID,N-C1ZDJ#X9H6HFJ3LOFD%11'1VB0
MSGW1*3FGF-+54&O IIK.+9#2;<1I7K:74=R\+C(TL\LYPL6X0,K>7H84XGXO
M@Q-Q3@@U+LXQK 01E40?Q[C5)&GQ3VF297=QBKV(?O"3%\8BZ$(Q:VVN %DW
MND &1JO+@7%9I*DDVHLB*FNGW6GB?P/PA9BK=F^"E+4[E0'9[@U@VG:G20N=
M>Q7[J6?Y'..@D<5 ,MFI%.P^%J,#WGXN1B;MG$;&$(5WUK_H<D-,N>K=[\*S
MA^#HXBW%CSC.ZI@!VA^N<+Y<K[P7X?JV7Q%_>P_EO.)0 X3+5]0\UV#%H59Y
MJ"APHLGB:K>YQ^ERS4[5KDE=/=([<J)!3R9I;<I00ZUG#;&8\QZOQ\:]VL.$
MV35?=EUW6\E;[OEEHOB]C[.,/WLY.RI8KN=/7AC1M?(Z26^]]L9!+T7+O5S:
M1+WQ\HG%RZG^@91 LQALRC+8_="JE!-2#,J\P_.T'9Y11)X&D7DODC%0KV8U
MVX>A$:W<'1H=YWSL"91_5B['483]?$<FF>N4WE,X/%)B2KHU)L)F\KG^M2(M
M" @E-88:DE12BAW:_EC0-L8/]/LJ9VFP!?PSKUGV4\M;:BI!)C9Q!/M7#E,"
M0MB& 8;D)!I6Q\^<NM(#:;C':C2$SA!1@$PW0>;.*_R2KYYQ](0_)W'^.&!2
M-RH4"%U[5(#I6*LO\1C<!7,SNCWAK]A+$68WX=%_[&*,/KR='5D?H":LGI-1
M:JTN"R[C.^8.)WI9T)'RNXV^2VM"J3\>(XW)EV5[M8-+ T[EILD'DID6=<QT
M;N 7$/H'1SO#H_N/[G>$>@+M-L:__-.['][^7"BCB+VWR3VQ,D.QVIN<<B^_
MP2\:Q]"V3+AUK]0 N%-OAE=R2M]*4^_^V$[.PKL,KW?19;CN/RDT56', +PQ
M9F/&7N\(Q@T.;)>"A0 9-=;NMXCWL4[E*^_7'ED'KU(OSFA*JR3./KZV?C&*
M?>Q5EIN8M0'FBD/9>A0$AKR'H.</18H=.R:(&F6 B;24V'BIB;74J]EDKJD1
M39+J=,#PT1!H#^I= KI<<18^A0&. QG1&K_;9!0'JTF=^D<P'.DBZI+A#.,-
MO3Y:BCEO=7;%X3H-?>ETV1"P.@=RP%H36_TKF);G( GOC:,ME7#>[*<16?PM
MU[\4B4&7Z0U-G77^@E,_S HCZA^S\M?LG<3P@659S5UQB+FME!9#"@)#T4/0
M=]E<J0$A= 5['@<%[D;F7)I<3E(C>C6;-#4UHLE(G0X8\AD"Y;VG*HD?3=_G
MG&?BMS3FU+0'3,-H/[Z*,_TW7[.I,O3?A-EO%RG&])27)B>GB:Y4L\NTW[4^
MN]NH1LYIF/*C8/J:+4NYSDI$T9K( LFL.68UT/,/^G; EX3FHJ#YL&UU5]F7
MC[;#JJMRLBXK_NS7V6F5MG:[[5YHHB#_TUV:$K37]%"#GH-<)3G.KHMWHCNU
M82!O+>#?!'8=9ZX2=LXQ4X1<FKM"!6T+'1I!SK30]:2/?-/'QR_"V(M]FN<Q
MR7+A!4*1E#5NR"'6C.!%8/! BDL<\!H0<;2NY)%/%9Q/[566Y"IC>%88A$_)
M"/F Z2*C<E<6<9'H8T%?BL0A>ZM5NL=Y:*E6=T;'J8+6?NIA14*+_!['''&O
MV,782V.\3R8_70K(XEWZY?HR\>+KXF5Z<>X$F:C-9) JL,V,D"(Y&,.C&ER7
M#=?1CK#!JW3H#$FU4*GF*+"F.;67<[BHOPO$X(70J$#V]5=8L!-[<:4]G\WV
M_7E;-%SKH8BI[KXV++LBC=INJ"8G99+V[KXJH>[OO@K%H#!*#Y&[ FO!V;U,
MX@>ZMVGF]*JD[;V)IH6\?P)-*@J*%5J8]GQC!4U6#.&8GN^X15LEX(B5T6+K
M".5"<80GL,FM-US9TL,KUJI8)ZVIEZR1!S=^ZK&.Z#R/0**6)T!3I;0'_KN2
MTY4-C??)5#5P2*G6J7AX%7!L'5XDC.7?:'8H?<EZ(9(_8N1W5BUV%R=COD'@
M%S,+,Y7V9%HM=;WM)Q/#QP;ZE>;H58$A)DN>#^A3E//.,@Y^P1L;K S&\%H7
M-?P0, ';+7/I(WW4XCW02UV.?V-UJSG%>QK52:MFI N&NCT!R[@Z*_:89LQW
MD3/78I+=[OWZFR2*:)C5<T*O;ZH2[VHU;2?C-32EFZ!7HP;*=^X%>8H+Y.9D
M8@D##6TH95T2I@5711$F")T439 P'R*@NV>+.,O3'0U.47EY0DF[IZ=2J.T3
M44X,S/0EQZ9*^T[7-R=T@8.H/MH7 ,>S:ANF<Z2DTN[HI'23)*) ::5S@CHD
M G:GK65*,X#U;)>2N?4:IV'233;;5]D=S70&R5DGTP1*0@U<4=8T*@XC"GD?
MGAG\WUV9:[N^9B,Q7Z-C-4^""?Q6@@25 AB"F: 4YCY_HDIT(GTNA2?ROFN
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M"=/UK=;5@-YL4KQ<A''Q.]HF*5OW)6LRC;>:$D556;#:[HIH]FZ^O=+1M*
MLJ;S[5N,=3EVE:#=S,Y7\1);^]6,W96T!K(!^>R&Y-'=Q %T4VY.#AH:K!#J
M$I,I!DMLJJ+CSW;X"K_DJV<</>'/Q,5XE)W*#"_.)B4/-;K)V:%E01M%#[2C
MRWMZ,;W,BH'^8Q=C].'M[&C(3L&OGI,#:ZHN!2*U.R8.8719Q+$2N0V_RU_"
MG3\>%U_)-V7[\0/* <O9IIF#64L+.6K>-@P0,/>'HV+N!:G-$>JD* 8J;YM&
M#J4M+</YMMB!P 5L_=-QL35\&F.8+8H!R]:&D8/92LHX3K;N@0O8^N>C8>M\
MG>-T),IVRH+(6Z&Y0\C;*NCH&"Q"+Z#QCT=#XP/K R99#^'GT5%2N36V">-P
ML]N4&V/;4@LV.^_B(,S837P<T!#_+)MOZ'\-J2=Y66!XJS/7F,2R@NPP^L>"
MT3%^H"]%#UZ*:8SHLIR6A3PF@5*\)8@)O^FN6$@*H+&"L$Z'^FS+VST)4HU$
M.H1<0HRB&8H[-?2<9[VCCU0,&(R.Z>S54FX#\WYFB%?8I?R1#F ='-O)LL*R
M'T5!4L.+<7?09VZDG,'Z,H".0,; ^R3\99RF03U5VE_4.;]V[S4I:^&LG#9O
MR+!0!O,.J4QA,6!XKC#2F.>",HZ#YW+@6IY7/A5*Z877/L0^GI U8+F%S,!R
M=Y2;\6E,%$3C#')@[3;(\% F:6/L^PE30)=P/!YZ$_X61Z3,AT\X)C"C>1S,
M ^IA9SD%_83/BZ0CLKKH4X+5\;^_:2TRFJN#HV=OZ-R]N4)YAAX*=>3%9 YH
M%5#EHH'FS0CN^JH$W7DDW;N^<BF@7H7BKF\W8G/"B[XTV?2U%]*<5\4&3[:(
M_6@7T&0>G\G'=RF[ +!<BP?M4)R!?HQ2[>6,'JT*]@FF#R[2.6G'M8,++"<%
MHRTIF24V*#8.,Q26A9-_H,V^>-6N1PA@!#W#ZS#&P4<RV*_#_)H8RBZVA/<[
M=COFX^OY9ALEKU@6_]%#W^9XV]NLYC!LK.R<Z$,1=RE=ZJ/[H@"T);_.V/\M
M+KADL^+>4E4@NG]%N"S2.87IO:\D+G*$$T-PFN)@Y;VPE0]]U+C1H^?W&;M\
M):G&0259?;AFN*FM9VWZ%P.&ZL.Q"TC/M%ENFH+FZ-O&V/S=3\ZIS1E89AF_
M3#+RSS1])3,0O<LH"_;OH6]Y=.YG5F=T-E,&0]F^B+EC>,+/**$G*@UA>-S\
ME"3!<QC1!><BSHD!X7U4;%49TU-9A%.&&ABG)*E"'RY/]:"YIS=JL7)$A4=3
M\H_J;^5.2.OB>%QY49DX,X5BDV&:3SFE_8B5I>P>(WP';C<:SSC3)%?P>MTB
MODX3&HIS@S-,&N:1F'V&GW"4;#?R8\;^Q3CM+89&*GN"I@RX+#<#SAU6_8NW
MV?Y\1EP;YA*%_P#P@ )G&DT)7/35*$J>Z=-2II4BTG1*4;DI2E;R:M BE<PA
M=RE8"Z):$AX%K[#Q&,E$G9+L2GSV+I*#E3E @9![_P7G*.!W$)PSYWR]QCX]
MI5O$Q"/ Q!(:ZW&#:3N&45CTB/P"!_1P[S;W\AW!\-H2EE3.*"7;Y.6(5=&D
M\0C%@IG%Q[.%7PE2&=8SRN-BY.5H792$LJHH%DUT%)V&6H_I!B-!$-5RT@>4
M#BL26C?1&=^W?\C*.ZJ.H3&"7ZS1P+F<2M39BZK^4!Z\'$5'.'VDJ?46\7 W
M>?2O0.LN ZJH;P_J\8FCZE3][>+.YUD)]!S^J?;L/3">O;@.Z'%M&._"^*&,
M1DCB?A.+N #W_4)EF)[R(FW@;%9 [A*U+H!Y22 <(:[7-8Y3>RQ!NUI.5Z-B
M$Y0+T[8*&,:9X92><]-SQ'D9SG&EC@JW0C9^1.\:6$T&RLN[_8NQ2<>A1C;Y
MV;<,,(0="-Q@AVZ&>%K/$!F)4Q9B]^T9+O[UW0P513MG^S[,T#!X0Z7@)G;9
M)#Q#+@V&E5J(HKV^QD6.L4,Q).'-YR_;L'0@SHAO( Q6YF6LA1[+X-6!Q%T!
MY^VO0L7Y9GLQ]L*CJPMNI\EF0W<:.J^Q2:+Z1*+PTD'K@'(+.B9?OM64,0WW
MK7'MI<N4;>D$[,70:YPR8S0M(U,#W4I:T,H6(P/GI$^C7A/C'\E4OUQSQ!(-
M $IQ:Z.G >AZ(%7(PAA3]0"Y]!ZE!MT#==NC(R_+ENM?//I@2+Y,V>79UJM!
M]8]9^6LFS(LPJ"" O?X@,[A+Y*5DYT$EY[XXBU3!079!N$ G'[JB6,1D'>U%
MU[O[*/27:[*X(,Z>I)9ZZ-OTU'N;U22PL;+S,6<H8C['4*&/:"VB+5,A U*A
M,]%D-7_ <7Z!,;VJ4,$K@P*%LY5:WMIT90*[GJ]4PL[)8XJ0>[N0JJ UT6$W
MHBN:P+D+O<*;;9)ZZ6OQYKUHM=#I/TH-F^.6 ?3F2*40=TXO<XR2N;)\)-Z1
M.U3>3Y$G,&L) ,HO)\;%=>)R][N4<UK)\MH%5ZV:^G14C8W##P5A>2E U:L
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MSW=:]&MC#+[J7\7TGJW.0%8Z#8JWHYGJ6U_CV]OEP/)2=K-.WTE+ D\&H]!
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M+P' 46Y$6\AX1I='*8E%%R_6:(GW1D!;2<BX11?#V/>SJQTOG'J!?QV=>ZN
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M4]MP]4&'+KI&P ,C^HCF<BD-SD8<5^<83/R7L"3,YG'V_83Y*<=R)P.OLX(
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MU&(<FS""(I<I(?0SC=>KK&0D0"+*#F!9]'\#:2 + ,]#KT;9]<>>,*T4E!W
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MW@1)"KGI4C0'R\6*"Z+%7-)QCK_B20_#LK9@&5AQ1?2RGF$Z0+?KJ($DM)W
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M<'S0"ZDFXUB0#V5P#'5CGME(+>XAH&F5+\R)-NM[=V4OZP&5AR-^ 1WKCL2
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M&8R#7<7:> DSQ@A?M,*$"LW2)FB/7I+9>)V3,HU9^$^RZMTEZ^*I%,F*5VZ
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MJNP&.B23JB5*WX]F\'I5/>E&/M0AV6"MD?IN](/7U^I'/?*1#LF*:XL3^E6
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M" @+&QL/%X\<'Y^<FX&:@?O_N3RT D18:(_0$L @1@"-" 0F CUT G0  ,(
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M^<A0Y2^EK,'CO'2?7_69UTPF]R8$H&?]N)YVH#X>?!3'CQ?!C06U:U]B=J=
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M,I()+=;4%C;S6$S=/G'RS[-QE2/1_;6N[&OB*'9$ JJ H^3Y.#P5HQ6F3;^
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MF'2*WQ7QGY6]HW@ =,99_7.MP3OXC[#>"]$N^7MDTK4W?[@,]7OV8Y6JRFK
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M18WTU)"![C .&T*Q27I 1WDP1D<(@ST _0K/C&KW(+#CI\1\U;*+7WH? -L
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MZ.T!4_8X85>_][!SLL46"KITBKT4T7SN2:C -)0%EV[C1M1<]&L!BFMAH'.
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M$A&VTS)]'4-OWXL^,H$E,%TJE@PI1::.#PK8Z;'-:^/5S%A?>3>2L^U+6/T
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M1G6KWQ^ ='=J40.WX= <N6-'E-SPV7+F[P5KV&W@D9W?&RNX^O>+ZRO*$4W
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MNO$7NU]0_P'"3G/ZAW_E[X2G)AL:T&-?F6TR]:]>_04MA7Z:4GG&=M%JUC'
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M&^XP_4J03O=TOA<.EW@NR#I['*/$FT%).ISVK,SXGDNI)<;,PJAYEBEL6Z1
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M2Y%*_T%@#-BI7TVL*0][[[L<Z&C+4"(STM^5+M:2U^\QVR0H2>?X9'2<(@_
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M]\MX^Q.MCI8(/_)@1FDFWK7'-)1ZFIO+,4:K!#[3N>ORLHHJ'[OB+GL=))&
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MW&W-(1S^- '':?I]Y:^((SI]M-96!D?[1%( T;GKE>,@U=OM+N+CQ=#="/\
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MPM)>:K;/=WU^RNWE'#!4X0J>QQ7<2QH\960*4;[P(X--""-410%11MVKV]*
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MS6I$BC*2Q1&'=R"R'I[4V\L-3U1;R1M/, >W1%1VR20>?PKL_NCJ*4#'0^]
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M-C,P7S$P:RYH=&U02P$"% ,4    "  0B3Y9SCZ_G;$"   -"0  &P
M        @ 'UCP( 8FEV:2TR,#(T,#8S,%\Q,&ME>#(S>C$N:'1M4$L! A0#
M%     @ $(D^6=>%>KB.!P  &"<  !L              ( !WY(" &)I=FDM
M,C R-# V,S!?,3!K97@S,7HQ+FAT;5!+ 0(4 Q0    ( !")/ED3Y;[8C0<
M !XG   ;              "  ::: @!B:79I+3(P,C0P-C,P7S$P:V5X,S%Z
M,BYH=&U02P$"% ,4    "  0B3Y982QI\S$$  "$$0  &P
M@ %LH@( 8FEV:2TR,#(T,#8S,%\Q,&ME>#,R>C$N:'1M4$L! A0#%     @
M$(D^6:QPN5Y!!   &!$  !L              ( !UJ8" &)I=FDM,C R-# V
M,S!?,3!K97@S,GHR+FAT;5!+ 0(4 Q0    ( !")/EG;K$20QA   -37   5
M              "  5"K @!B:79I+3(P,C0P-C,P7V-A;"YX;6Q02P$"% ,4
M    "  0B3Y9HI.GEA\E  #ME@( %0              @ %)O ( 8FEV:2TR
M,#(T,#8S,%]D968N>&UL4$L! A0#%     @ $(D^67)ZY?A_;@  O' & !4
M             ( !F^$" &)I=FDM,C R-# V,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( !")/ED12$>=+DP  (@^!0 5              "  4U0 P!B:79I+3(P
M,C0P-C,P7W!R92YX;6Q02P$"% ,4    "  0B3Y9M&6NX86*  #CD@  #
M            @ &NG , :6UA9V5?,#$N:G!G4$L%!@     ,  P -0,  %TG
$!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>bivi-20240630_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:bivi="http://bioviepharma.com/20240630"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="bivi-20240630.xsd" xlink:type="simple"/>
    <context id="From2023-07-01to2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-09-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2024-09-25</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_TreasuryStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_TreasuryStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_TreasuryStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_TreasuryStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_TreasuryStocksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">bivi:TreasuryStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_NotespayableConversionOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bivi:NotespayableConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_NotespayableConversionOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bivi:NotespayableConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-07-15_custom_AcuitasGroupHoldingsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bivi:AcuitasGroupHoldingsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-15</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_WarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_UnearnedDiscountMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bivi:UnearnedDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FinanceReceivablesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_LoanAccretionPremiumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">bivi:LoanAccretionPremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">bivi:DerivativeLiabilityConversionOptionOnConvertibleDebentureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_CashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasuryBillSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bivi:USTreasuryBillSecurities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bivi:USTreasuryBillSecurities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bivi:USTreasuryBillSecurities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">bivi:USTreasuryBillSecurities1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bivi:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">bivi:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-03-012024-03-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="AsOf2024-03-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2024-03-06</instant>
        </period>
    </context>
    <context id="From2024-03-012024-03-06_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="From2024-03-012024-03-06_custom_CommonWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:CommonWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-06</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-04-012023-04-06_custom_VendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-04-06</endDate>
        </period>
    </context>
    <context id="AsOf2023-04-06_custom_VendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-04-06</instant>
        </period>
    </context>
    <context id="From2024-05-012024-05-10_custom_VendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-01</startDate>
            <endDate>2024-05-10</endDate>
        </period>
    </context>
    <context id="AsOf2024-05-10_custom_VendorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:VendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-10</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-06-012022-06-21_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-21</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-23</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:FourDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-23</endDate>
        </period>
    </context>
    <context id="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_ThreeDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:ThreeDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-23</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2022-11-23</instant>
        </period>
    </context>
    <context id="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:FourDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-09</endDate>
        </period>
    </context>
    <context id="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_TwoDirectorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:TwoDirectorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-09</endDate>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:FourDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:PresidentAndCEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">bivi:N2019OmnibusIncentiveEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2022-12-012022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="From2022-11-012022-11-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-11-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="From2022-10-012022-10-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-10-31_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="From2023-05-012023-05-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2023-05-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-31</instant>
        </period>
    </context>
    <context id="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_CertainEmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:CertainEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-07</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-07</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-07</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-03</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">bivi:NewEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2022-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="AsOf2023-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-06-30_custom_StockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">bivi:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2022-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="From2022-07-012023-06-30_us-gaap_WarrantMember53646031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2023-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="From2023-07-012024-06-30_us-gaap_WarrantMember53646062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2024-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="AsOf2024-02-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <instant>2024-02-12</instant>
        </period>
    </context>
    <context id="AsOf2024-09-25_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bivi:PrefundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-25</instant>
        </period>
    </context>
    <context id="AsOf2024-09-25_custom_CommonWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">bivi:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-25</instant>
        </period>
    </context>
    <context id="From2024-09-012024-09-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-25</endDate>
        </period>
    </context>
    <context id="AsOf2024-09-25_custom_PlacementAgentsWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001580149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">bivi:PlacementAgentsWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-25</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:AmendmentFlag contextRef="From2023-07-01to2024-06-30" id="Fact000003">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2023-07-01to2024-06-30" id="Fact000004">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2023-07-01to2024-06-30" id="Fact000005">2024</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey contextRef="From2023-07-01to2024-06-30" id="Fact000006">0001580149</dei:EntityCentralIndexKey>
    <bivi:InvestmentsInU.s.TreasuryBills
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0059"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0089"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0114"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0130"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl0131"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0171"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DividendsSharebasedCompensationStock
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0223"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:UnrealizedGainOnInvestmentsForAvailableforsale
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl0252"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0256"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0266"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0267"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0272"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0276"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0295"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0299"
      unitRef="Shares"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfOptions
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfOptions
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfOptions
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfOptions
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfWarrants
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0310"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfWarrants
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfWarrants
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfWarrants
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfWarrants
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:CashlessExerciseOfWarrants
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0321"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0323"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0338"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0339"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:UnrealizedGainOnAvailableforsaleInvestments
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0345"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:UnrealizedGainOnAvailableforsaleInvestments
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:UnrealizedGainOnAvailableforsaleInvestments
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0347"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:UnrealizedGainOnAvailableforsaleInvestments
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0349"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0353"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0354"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0370"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0375"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0378"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0379"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0382"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0383"
      unitRef="Shares"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0397"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl0399"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0406"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0407"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0408"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0412"
      unitRef="Shares"
      xsi:nil="true"/>
    <bivi:DeemedDividendForRatchetAdjustmentToWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0414"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:DeemedDividendForRatchetAdjustmentToWarrants
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0416"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:DeemedDividendForRatchetAdjustmentToWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:DeemedDividendForRatchetAdjustmentToWarrants
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl0419"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0422"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0423"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0425"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0428"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0431"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0432"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplit
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl0433"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0437"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0440"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0447"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:RealizedGainOnMaturityOfAvailableforSale
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0491"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0530"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:NetProceedsFromIssuanceOfCommonStockRelatedParty
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:RightOfUseAssetsObtainedInExchangeForLeaseObligations
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:UnrealizedGainOnU.s.TreasuryBills
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0566"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:DeemedDividendOfRatchetAdjustmentsToWarrants
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:GrossUnrealizedLoss
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:NotesPayableNoncurrent
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0771"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:LongtermDebtFinancingCosts
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0774"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:LongTermAccretionOfLoanPremiums
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0780"
      unitRef="USD"
      xsi:nil="true"/>
    <bivi:LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl0783"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0804"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0806"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0812"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0814"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0816"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember"
      id="xdx2ixbrl0818"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0822"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0830"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0836"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0838"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0844"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0846"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0858"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0860"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0866"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0868"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0874"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0876"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0882"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0884"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0888"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0914"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0922"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0924"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0930"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0932"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0938"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0940"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0946"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0948"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0954"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0956"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0962"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0964"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2022-06-30_custom_StockOptionsMember"
      id="xdx2ixbrl1020"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      id="xdx2ixbrl1070"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2022-06-30_us-gaap_WarrantMember"
      id="xdx2ixbrl1249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember"
      id="xdx2ixbrl1289"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2024-06-30"
      id="xdx2ixbrl1388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="AsOf2023-06-30"
      id="xdx2ixbrl1389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2023-07-01to2024-06-30"
      id="xdx2ixbrl1409"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="From2022-07-012023-06-30"
      id="xdx2ixbrl1410"
      unitRef="Pure"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2023-07-01to2024-06-30" id="Fact000012">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="From2023-07-01to2024-06-30" id="Fact000013">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="From2023-07-01to2024-06-30" id="Fact000014">2024-06-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-07-01to2024-06-30" id="Fact000015">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="From2023-07-01to2024-06-30" id="Fact000016">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2023-07-01to2024-06-30" id="Fact000017">001-39015</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2023-07-01to2024-06-30" id="Fact000018">BIOVIE INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-07-01to2024-06-30" id="Fact000019">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-07-01to2024-06-30" id="Fact000020">46-2510769</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-07-01to2024-06-30" id="Fact000021">680 W Nye Lane Suite 204</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2023-07-01to2024-06-30" id="Fact000022">Carson City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-07-01to2024-06-30" id="Fact000023">NV</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-07-01to2024-06-30" id="Fact000024">89703</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-07-01to2024-06-30" id="Fact000025">(775)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-07-01to2024-06-30" id="Fact000026">888-3162</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2023-07-01to2024-06-30" id="Fact000027">Class A Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-07-01to2024-06-30" id="Fact000028">BIVI</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-07-01to2024-06-30" id="Fact000029">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2023-07-01to2024-06-30" id="Fact000030">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2023-07-01to2024-06-30" id="Fact000031">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2023-07-01to2024-06-30" id="Fact000032">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2023-07-01to2024-06-30" id="Fact000033">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2023-07-01to2024-06-30" id="Fact000034">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2023-07-01to2024-06-30" id="Fact000035">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-07-01to2024-06-30" id="Fact000036">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="From2023-07-01to2024-06-30" id="Fact000037">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="From2023-07-01to2024-06-30" id="Fact000038">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000039"
      unitRef="USD">20590705</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="AsOf2024-09-25"
      decimals="INF"
      id="Fact000040"
      unitRef="Shares">7956660</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000041">Portions of the Registrant&#x2019;s definitive proxy
statement relating to its 2024 annual meeting of stockholders (the &#x201c;2024 Proxy Statement&#x201d;) are incorporated by reference into
Part III of this Annual Report on Form 10-K where indicated. The 2024 Proxy Statement was filed with the U.S. Securities and Exchange
Commission on September 27, 2024.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="From2023-07-01to2024-06-30" id="Fact000042">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="From2023-07-01to2024-06-30" id="Fact000043">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="From2023-07-01to2024-06-30" id="Fact000044">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="From2023-07-01to2024-06-30" id="Fact000045">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="From2023-07-01to2024-06-30" id="Fact000046">274</dei:AuditorFirmId>
    <dei:AuditorName contextRef="From2023-07-01to2024-06-30" id="Fact000047">EisnerAmper LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="From2023-07-01to2024-06-30" id="Fact000048">Iselin</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000056"
      unitRef="USD">23843798</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000057"
      unitRef="USD">19460883</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <bivi:InvestmentsInU.s.TreasuryBills
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000060"
      unitRef="USD">14477726</bivi:InvestmentsInU.s.TreasuryBills>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000062"
      unitRef="USD">204392</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000063"
      unitRef="USD">102526</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000065"
      unitRef="USD">24048190</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000066"
      unitRef="USD">34041135</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000068"
      unitRef="USD">406726</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000069"
      unitRef="USD">80789</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000071"
      unitRef="USD">407718</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000072"
      unitRef="USD">637095</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000074"
      unitRef="USD">345711</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000075"
      unitRef="USD">345711</us-gaap:Goodwill>
    <us-gaap:Assets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000077"
      unitRef="USD">25208345</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000078"
      unitRef="USD">35104730</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000086"
      unitRef="USD">3586912</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000087"
      unitRef="USD">3476259</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000090"
      unitRef="USD">48385</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000092"
      unitRef="USD">60343</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000093"
      unitRef="USD">44909</us-gaap:OperatingLeaseLiabilityCurrent>
    <bivi:UnearnedPremiumAnddiscountCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000098"
      unitRef="USD">701210</bivi:UnearnedPremiumAnddiscountCurrent>
    <bivi:UnearnedPremiumAnddiscountCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000100"
      unitRef="USD">894926</bivi:UnearnedPremiumAnddiscountCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000095"
      unitRef="USD">5701210</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000096"
      unitRef="USD">9105074</us-gaap:NotesPayableCurrent>
    <bivi:WarrantLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000102"
      unitRef="USD">3771</bivi:WarrantLiabilities>
    <bivi:WarrantLiabilities
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000103"
      unitRef="USD">894280</bivi:WarrantLiabilities>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000106"
      unitRef="USD">925762</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000108"
      unitRef="USD">9352236</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000109"
      unitRef="USD">14494669</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000111"
      unitRef="USD">349894</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000112"
      unitRef="USD">42505</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <bivi:UnearnedPremiumAndDiscount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000117"
      unitRef="USD">0</bivi:UnearnedPremiumAndDiscount>
    <bivi:UnearnedPremiumAndDiscount
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000119"
      unitRef="USD">227268</bivi:UnearnedPremiumAndDiscount>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000115"
      unitRef="USD">5227270</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000121"
      unitRef="USD">9702130</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000122"
      unitRef="USD">19764444</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000133"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000135"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000137"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000139"
      unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000141"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000143"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000145"
      unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000147"
      unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000152"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000154"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000156"
      unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000158"
      unitRef="Shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000160"
      unitRef="Shares">6216398</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact000162"
      unitRef="Shares">6190072</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000164"
      unitRef="Shares">3645183</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact000166"
      unitRef="Shares">3642895</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000149"
      unitRef="USD">6229</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000150"
      unitRef="USD">3643</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000168"
      unitRef="USD">349732674</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000169"
      unitRef="USD">316385759</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000172"
      unitRef="USD">176591</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000174"
      unitRef="USD">-334232661</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000175"
      unitRef="USD">-301225705</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000177"
      unitRef="USD">27</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000178"
      unitRef="USD">2</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000180"
      unitRef="USD">15506215</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000181"
      unitRef="USD">15340286</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000183"
      unitRef="USD">25208345</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000184"
      unitRef="USD">35104730</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000189"
      unitRef="USD">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000190"
      unitRef="USD">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000192"
      unitRef="USD">23100394</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000193"
      unitRef="USD">33299503</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000195"
      unitRef="USD">8849814</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000196"
      unitRef="USD">11551568</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000198"
      unitRef="USD">32179585</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000199"
      unitRef="USD">45080448</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000201"
      unitRef="USD">-32179585</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000202"
      unitRef="USD">-45080448</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000207"
      unitRef="USD">1816271</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:GainLossOnSaleOfDerivatives
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000208"
      unitRef="USD">-1437481</us-gaap:GainLossOnSaleOfDerivatives>
    <us-gaap:InterestExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000210"
      unitRef="USD">2893922</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000211"
      unitRef="USD">4300150</us-gaap:InterestExpense>
    <us-gaap:InterestIncomeOther
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000213"
      unitRef="USD">1136703</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000214"
      unitRef="USD">562264</us-gaap:InterestIncomeOther>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000216"
      unitRef="USD">59052</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000217"
      unitRef="USD">-5175367</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000219"
      unitRef="USD">-32120533</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000220"
      unitRef="USD">-50255815</us-gaap:ProfitLoss>
    <us-gaap:DividendsSharebasedCompensationStock
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000222"
      unitRef="USD">886423</us-gaap:DividendsSharebasedCompensationStock>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000225"
      unitRef="USD">-33006956</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000226"
      unitRef="USD">-50255815</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000231"
      unitRef="USDPShares">-7.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000232"
      unitRef="USDPShares">-15.47</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000234"
      unitRef="USDPShares">-7.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000235"
      unitRef="USDPShares">-15.47</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000240"
      unitRef="Shares">4518533</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000241"
      unitRef="Shares">3248349</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000243"
      unitRef="Shares">4518533</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000244"
      unitRef="Shares">3248349</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000246"
      unitRef="USD">-33006956</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000247"
      unitRef="USD">-50255815</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <bivi:UnrealizedGainOnInvestmentsForAvailableforsale
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000253"
      unitRef="USD">176591</bivi:UnrealizedGainOnInvestmentsForAvailableforsale>
    <bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000255"
      unitRef="USD">-176591</bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000258"
      unitRef="USD">-176591</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000259"
      unitRef="USD">176591</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000261"
      unitRef="USD">-33183547</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000262"
      unitRef="USD">-50079224</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000271"
      unitRef="Shares">2498408</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000264"
      unitRef="USD">2496</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000265"
      unitRef="USD">254638329</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000268"
      unitRef="USD">-250969890</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-06-30"
      decimals="0"
      id="Fact000269"
      unitRef="USD">3670935</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000275"
      unitRef="USD">4222845</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000279"
      unitRef="USD">4222845</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000288"
      unitRef="Shares">21518</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000281"
      unitRef="USD">21</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000282"
      unitRef="USD">1780028</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      decimals="INF"
      id="Fact000289"
      unitRef="Shares">-2288</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30_custom_TreasuryStocksMember"
      decimals="0"
      id="Fact000283"
      unitRef="USD">-2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000286"
      unitRef="USD">1780047</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000298"
      unitRef="Shares">5000</bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000291"
      unitRef="USD">5</bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000292"
      unitRef="USD">372495</bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000296"
      unitRef="USD">372500</bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered>
    <bivi:CashlessExerciseOfOptionsShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000308"
      unitRef="Shares">2256</bivi:CashlessExerciseOfOptionsShares>
    <bivi:CashlessExerciseOfOptions
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000301"
      unitRef="USD">3</bivi:CashlessExerciseOfOptions>
    <bivi:CashlessExerciseOfOptions
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000302"
      unitRef="USD">-3</bivi:CashlessExerciseOfOptions>
    <bivi:CashlessExerciseOfWarrantsShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000317"
      unitRef="Shares">359</bivi:CashlessExerciseOfWarrantsShares>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000325"
      unitRef="Shares">80</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000320"
      unitRef="USD">2240</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000324"
      unitRef="USD">2240</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCostsShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000334"
      unitRef="Shares">753925</bivi:ProceedsFromIssuanceOfCommonStockNetCostsShares>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000327"
      unitRef="USD">754</bivi:ProceedsFromIssuanceOfCommonStockNetCosts>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000328"
      unitRef="USD">49464349</bivi:ProceedsFromIssuanceOfCommonStockNetCosts>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000332"
      unitRef="USD">49465103</bivi:ProceedsFromIssuanceOfCommonStockNetCosts>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000343"
      unitRef="Shares">363636</bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsOfRelatedPartyShares>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty
      contextRef="From2022-07-012023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000336"
      unitRef="USD">364</bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty
      contextRef="From2022-07-012023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000337"
      unitRef="USD">5905476</bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty>
    <bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000341"
      unitRef="USD">5905840</bivi:ProceedsFromIssuanceOfCommonStockNetOfCostsRelatedParty>
    <bivi:UnrealizedGainOnAvailableforsaleInvestments
      contextRef="From2022-07-012023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000348"
      unitRef="USD">176591</bivi:UnrealizedGainOnAvailableforsaleInvestments>
    <bivi:UnrealizedGainOnAvailableforsaleInvestments
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000350"
      unitRef="USD">176591</bivi:UnrealizedGainOnAvailableforsaleInvestments>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000356"
      unitRef="USD">-50255815</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000357"
      unitRef="USD">-50255815</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000365"
      unitRef="Shares">3645183</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000359"
      unitRef="USD">3643</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000360"
      unitRef="USD">316385759</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2023-06-30_custom_TreasuryStocksMember"
      decimals="INF"
      id="Fact000366"
      unitRef="Shares">-2288</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_custom_TreasuryStocksMember"
      decimals="0"
      id="Fact000361"
      unitRef="USD">-2</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000362"
      unitRef="USD">176591</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000363"
      unitRef="USD">-301225705</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000364"
      unitRef="USD">15340286</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000369"
      unitRef="USD">2823764</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000373"
      unitRef="USD">2823764</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000376"
      unitRef="USD">1763450</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000380"
      unitRef="USD">1763450</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCostsShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000392"
      unitRef="Shares">2433749</bivi:ProceedsFromIssuanceOfCommonStockNetCostsShares>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000385"
      unitRef="USD">2449</bivi:ProceedsFromIssuanceOfCommonStockNetCosts>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000386"
      unitRef="USD">27800490</bivi:ProceedsFromIssuanceOfCommonStockNetCosts>
    <bivi:ProceedsFromIssuanceOfCommonStockNetCosts
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000390"
      unitRef="USD">27802939</bivi:ProceedsFromIssuanceOfCommonStockNetCosts>
    <bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000401"
      unitRef="Shares">122395</bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares>
    <bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000394"
      unitRef="USD">122</bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits>
    <bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000395"
      unitRef="USD">-97</bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits>
    <bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      decimals="INF"
      id="Fact000402"
      unitRef="Shares">-24038</bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnitsShares>
    <bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits
      contextRef="From2023-07-012024-06-30_custom_TreasuryStocksMember"
      decimals="0"
      id="Fact000396"
      unitRef="USD">-25</bivi:IssuanceOfCommonStockFromVestingOfRestrictedStockUnits>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000411"
      unitRef="Shares">15000</bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRenderedShares>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000404"
      unitRef="USD">15</bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000405"
      unitRef="USD">72885</bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered>
    <bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000409"
      unitRef="USD">72900</bivi:StockbasedCompensationIssuanceOfCommonStockForServicesRendered>
    <bivi:DeemedDividendForRatchetAdjustmentToWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000415"
      unitRef="USD">886423</bivi:DeemedDividendForRatchetAdjustmentToWarrants>
    <bivi:DeemedDividendForRatchetAdjustmentToWarrants
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000418"
      unitRef="USD">-886423</bivi:DeemedDividendForRatchetAdjustmentToWarrants>
    <bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2023-07-012024-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Fact000424"
      unitRef="USD">-176591</bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement>
    <bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000426"
      unitRef="USD">-176591</bivi:RelcassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement>
    <bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000435"
      unitRef="Shares">71</bivi:IssuanceOfAdditionalSharesForFractionalSharesEffectedByReverseSplitShares>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-012024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000441"
      unitRef="USD">-32120533</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000442"
      unitRef="USD">-32120533</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      id="Fact000451"
      unitRef="Shares">6216398</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_CommonStockMember"
      decimals="0"
      id="Fact000444"
      unitRef="USD">6229</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Fact000445"
      unitRef="USD">349732674</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2024-06-30_custom_TreasuryStocksMember"
      decimals="INF"
      id="Fact000452"
      unitRef="Shares">-26326</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_custom_TreasuryStocksMember"
      decimals="0"
      id="Fact000446"
      unitRef="USD">-27</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      id="Fact000448"
      unitRef="USD">-334232661</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000449"
      unitRef="USD">15506215</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000457"
      unitRef="USD">-32120533</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000458"
      unitRef="USD">-50255815</us-gaap:ProfitLoss>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000463"
      unitRef="USD">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000464"
      unitRef="USD">229377</us-gaap:AmortizationOfIntangibleAssets>
    <bivi:StockBasedCompensationRestrictedStock
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000466"
      unitRef="USD">1763450</bivi:StockBasedCompensationRestrictedStock>
    <bivi:StockBasedCompensationRestrictedStock
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000467"
      unitRef="USD">1780047</bivi:StockBasedCompensationRestrictedStock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000469"
      unitRef="USD">2823764</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000470"
      unitRef="USD">4222845</us-gaap:ShareBasedCompensation>
    <bivi:StockBasedCompensationExpenseStockIssued
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000472"
      unitRef="USD">72900</bivi:StockBasedCompensationExpenseStockIssued>
    <bivi:StockBasedCompensationExpenseStockIssued
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000473"
      unitRef="USD">372500</bivi:StockBasedCompensationExpenseStockIssued>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000475"
      unitRef="USD">108751</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000476"
      unitRef="USD">170219</us-gaap:AmortizationOfDebtDiscountPremium>
    <bivi:AccretionOfUnearnedLoanDiscount
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000478"
      unitRef="USD">-1023145</bivi:AccretionOfUnearnedLoanDiscount>
    <bivi:AccretionOfUnearnedLoanDiscount
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000479"
      unitRef="USD">-1601445</bivi:AccretionOfUnearnedLoanDiscount>
    <bivi:AccretionOfLoanPremium
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000481"
      unitRef="USD">236970</bivi:AccretionOfLoanPremium>
    <bivi:AccretionOfLoanPremium
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000482"
      unitRef="USD">421994</bivi:AccretionOfLoanPremium>
    <bivi:RealizedGainOnMaturityOfAvailableforSale
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000484"
      unitRef="USD">223865</bivi:RealizedGainOnMaturityOfAvailableforSale>
    <bivi:NoncashLeaseExpenseFromRightofuseAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000487"
      unitRef="USD">49346</bivi:NoncashLeaseExpenseFromRightofuseAssets>
    <bivi:NoncashLeaseExpenseFromRightofuseAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000488"
      unitRef="USD">37465</bivi:NoncashLeaseExpenseFromRightofuseAssets>
    <us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000490"
      unitRef="USD">5215</us-gaap:GainLossOnSaleOfLeasedAssetsNetOperatingLeases>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000493"
      unitRef="USD">1816271</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000494"
      unitRef="USD">-1437481</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000499"
      unitRef="USD">101866</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000500"
      unitRef="USD">-39915</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000502"
      unitRef="USD">110653</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000503"
      unitRef="USD">1033455</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000505"
      unitRef="USD">-47245</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000506"
      unitRef="USD">-38884</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000508"
      unitRef="USD">-48385</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000509"
      unitRef="USD">-1304925</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000511"
      unitRef="USD">-27945024</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000512"
      unitRef="USD">-40252881</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <bivi:ProceedsFromMaturityOfU.s.TreasuryBills
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000517"
      unitRef="USD">-14525000</bivi:ProceedsFromMaturityOfU.s.TreasuryBills>
    <bivi:ProceedsFromMaturityOfU.s.TreasuryBills
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000518"
      unitRef="USD">14301135</bivi:ProceedsFromMaturityOfU.s.TreasuryBills>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000520"
      unitRef="USD">14525000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000521"
      unitRef="USD">-14301135</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000526"
      unitRef="USD">27802939</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000527"
      unitRef="USD">49465103</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000529"
      unitRef="USD">10000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000533"
      unitRef="USD">2240</us-gaap:ProceedsFromStockOptionsExercised>
    <bivi:NetProceedsFromIssuanceOfCommonStockRelatedParty
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000536"
      unitRef="USD">5905840</bivi:NetProceedsFromIssuanceOfCommonStockRelatedParty>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000538"
      unitRef="USD">17802939</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000539"
      unitRef="USD">55373183</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000541"
      unitRef="USD">4382915</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000542"
      unitRef="USD">819167</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000544"
      unitRef="USD">19460883</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2022-06-30"
      decimals="0"
      id="Fact000545"
      unitRef="USD">18641716</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000547"
      unitRef="USD">23843798</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000548"
      unitRef="USD">19460883</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000553"
      unitRef="USD">1525056</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000554"
      unitRef="USD">2106491</us-gaap:InterestPaidNet>
    <bivi:RightOfUseAssetsObtainedInExchangeForLeaseObligations
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000559"
      unitRef="USD">432192</bivi:RightOfUseAssetsObtainedInExchangeForLeaseObligations>
    <bivi:UnrealizedGainOnU.s.TreasuryBills
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000563"
      unitRef="USD">176591</bivi:UnrealizedGainOnU.s.TreasuryBills>
    <bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000565"
      unitRef="USD">-176591</bivi:ReclassificationOfUnrealizedGainsOnAvailableforsaleInvestmentsUponSettlement>
    <bivi:DeemedDividendOfRatchetAdjustmentsToWarrants
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000568"
      unitRef="USD">886423</bivi:DeemedDividendOfRatchetAdjustmentsToWarrants>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000571">&lt;p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z5Wckacr5b3g" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zoUWD0geoEd7"&gt;Background Information&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;BioVie Inc. (the &#x201c;Company&#x201d; or &#x201c;we&#x201d;
or &#x201c;our&#x201d;) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including
neurological and neuro-degenerative disorders and liver disease.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company acquired the biopharmaceutical assets
of NeurMedix, Inc. (&#x201c;NeurMedix&#x201d;) a privately held clinical-stage pharmaceutical company and a related party in June 2021&lt;i&gt;.&lt;/i&gt;&#160;The
acquired assets included NE3107. NE3107 is an investigational, novel, orally administered small molecule that is thought to inhibit inflammation-driven
insulin resistance and major pathological inflammatory cascades with a novel mechanism of action. There is emerging scientific consensus
that both inflammation and insulin resistance may play fundamental roles in the development of Alzheimer&#x2019;s disease (&#x201c;AD&#x201d;)
and Parkinson&#x2019;s disease (&#x201c;PD&#x201d;), and NE3107 could, if approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;),
represent an entirely new medical approach to treating these devastating conditions affecting an estimated 6 million Americans suffering
from AD and 1 million Americans suffering from PD.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Neurodengenerative Disease Program&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In neurodegenerative disease, the Company&#x2019;s
drug candidate NE3107 inhibits activation of inflammatory actions extracellular single-regulated kinase (&#x201c;ERK&#x201d;) and nuclear
factor kappa-light-chain-enhancer of activated B cells (&#x201c;NF&#x3ba;B&#x201d;) (including interactions with tumor necrosis factor (&#x201c;TNF&#x201d;)
signaling and other relevant inflammatory pathways) that lead to neuroinflammation and insulin resistance. NE3107 does not interfere with
their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers
of AD and PD.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Alzheimer&#x2019;s Disease (NCT05083260)&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 29, 2023, the Company announced the analysis
of its unblinded, topline efficacy data from its Phase 3 clinical trial (NCT04669028) of NE3107 in the treatment of mild to moderate AD.
The study has co-primary endpoints looking at cognition using the Alzheimer&#x2019;s Disease Assessment Scale-Cognitive Scale (ADAS-Cog
12) and function using the Clinical Dementia Rating-Sum of Boxes (CDR-SB). Patients were randomly assigned, 1:1 versus placebo, to receive
sequentially 5 mg of NE3107 orally twice a day for 14 days, then 10 mg orally twice a day for 14 days, followed by 26 weeks of 20 mg orally
twice daily.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Upon trial completion, as the Company began the
process of unblinding the trial data, the Company found significant deviation from protocol and current good clinical practices
(&#x201c;cGCPs&#x201d;) violations at 15 study sites (virtually all of which were from one geographic area). This highly unusual level
of suspected improprieties led the Company to exclude all patients from these sites and to refer the sites to the FDA Office of
Scientific Investigations (&#x201c;OSI&#x201d;) for potential further action. After the patient exclusions, 81 patients remained in
the Modified Intent to Treat population, 57 of whom were in the Per-Protocol population which included those who completed the trial
and were verified to take study drug from pharmacokinetic data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The trial was originally designed to be 80% powered
with 125 patients in each of the treatment and placebo arms. The unplanned exclusion of so many patients has left the trial underpowered
for the primary endpoints. In the Per-Protocol population, which included those patients who completed the trial and who were further
verified to have taken the study drug (based on pharmacokinetic data), an observed descriptive change from baseline appeared to suggest
a slowing of cognitive loss; these same patients experienced an advantage in age deceleration vs. placebo as measured by DNA epigenetic
change. Age deceleration is used by longevity researchers to measure the difference between the patient&#x2019;s biological age, in this
case as measured by the Horvath DNA methylation Skin Blood Clock, relative to the patient&#x2019;s actual chronological age. This test
was a non-primary/secondary endpoint, other-outcome measure, done via blood test collected at week 30 (end of study). Additional DNA methylation
data continues to be collected and analyzed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Parkinson&#x2019;s Disease (NCT05083260)&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Phase 2 study of bezisterim (NE3107) for the treatment
of PD (NCT05083260), completed in December 2022, was a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study
in PD participants treated with carbidopa/levodopa and bezisterim (NE3107). Forty-five patients with a defined L-dopa &#x201c;off state&#x201d;
were randomized 1:1 to placebo: bezisterim (NE3107) 20 mg twice daily for 28 days. This trial was launched with two design objectives:
1) the primary objective was safety and a drug-drug interaction study as requested by the FDA to measure the potential for adverse interactions
of bezisterim (NE3107) with carbidopa/ levodopa; and 2) the secondary objective was to determine if preclinical indications of promotoric
activity and apparent enhancement of levodopa activity could be seen in humans. Both objectives were met.&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Long COVID Program&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In April 2024, the Company announced the grant of
a clinical trial award of up to $13.1 million from the DOD, awarded through the Peer Reviewed
Medical Research Program (&#x201c;PRMRP&#x201d;) of the Congressionally Directed Medical Research Programs (&#x201c;CDMRP&#x201d;). The award
can provide up to 2 years of non-dilutive funding for a Phase 2b clinical trial that will assess bezisterim (NE3107) for the treatment
of neurological symptoms that are associated with long COVID. The Company anticipates the trial to commence by early 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;Liver Disease Program&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In liver disease, our investigational drug candidate
BIV201 (continuous infusion terlipressin), which has been granted both FDA Fast Track designation status and FDA Orphan Drug status, is
being evaluated and discussed after receiving guidance from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the
treatment of ascites due to chronic liver cirrhosis. BIV201 is administered as a patent-pending liquid formulation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2021, the Company initiated a Phase 2 study
(NCT04112199) designed to evaluate the efficacy of BIV201 (terlipressin, administered by continuous infusion for two 28-day treatment
cycles) combined with standard-of-care (&#x201c;SOC&#x201d;), compared to SOC alone, for the treatment of refractory ascites. The primary
endpoints of the study are the incidence of ascites-related complications and change in ascites fluid accumulation during treatment compared
to a pre-treatment period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In March 2023, the Company announced enrollment was
paused and that data from the first 15 patients treated with BIV201 plus SOC appeared to show at least a 30% reduction in ascites fluid
during the 28 days after treatment initiation compared to the 28 days prior to treatment. The change in ascites volume was significantly
different from those patients receiving SOC treatment. Patients who completed the treatment with BIV201 experienced a 53% reduction in
ascites fluid, which was sustained (43% reduction) during the three months after treatment initiation as compared to the three-month pre-treatment
period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2023, the Company requested and subsequently
received guidance from the FDA regarding the design and endpoints for definitive clinical testing of BIV201 for the treatment of ascites
due to chronic liver cirrhosis. The Company is currently finalizing protocol designs for the Phase 3 study of BIV201 for the treatment
of ascites due to chronic liver cirrhosis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The BIV201 development program was initiated by LAT
Pharma LLC. On April 11, 2016, the Company acquired LAT Pharma LLC and the rights to its BIV201 development program. The Company currently
owns all development and marketing rights to this drug candidate. Pursuant to the Agreement and Plan of Merger entered into on April 11,
2016, between our predecessor entities, LAT Pharma LLC and NanoAntibiotics, Inc., BioVie is obligated to pay a low single digit royalty
on net sales of BIV201 (continuous infusion terlipressin). to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett
Edge, Inc.&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000575">&lt;p id="xdx_804_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zhHeG4Y54gD3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_826_z3bQ4oJ8lxTl"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s operations are subject to a number
of factors that can affect its operating results and financial conditions. Such factors include, but are not limited to: the results of
clinical testing and trial activities of the Company&#x2019;s products, the Company&#x2019;s ability to obtain regulatory approval to market
its products; competition from products manufactured and sold or being developed by other companies; the price of, and demand for, Company
products; the Company&#x2019;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products;
and the Company&#x2019;s ability to raise capital. The Company&#x2019;s financial statements have been prepared assuming the Company will
continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of
business. As of June 30, 2024, the Company had working capital of approximately $&lt;span id="xdx_90F_ecustom--WorkingCapital_iI_pp0n3_dm_c20240630_zbAgiTsGFtJ7" title="Working capital"&gt;14.7&lt;/span&gt; million, cash and cash equivalents of approximately
$&lt;span id="xdx_90C_eus-gaap--CashEquivalentsAtCarryingValue_iI_pp0n3_dm_c20240630_zPJfCMM9XJo9" title="Cash and cash equivalent"&gt;23.8&lt;/span&gt; million, stockholders&#x2019; equity of approximately $&lt;span id="xdx_908_ecustom--StockholderEquities_iI_pp0n3_dm_c20240630_zS3WOvYfCG18" title="Stockholders' equity"&gt;15.5&lt;/span&gt; million, and an accumulated deficit of approximately $&lt;span id="xdx_907_ecustom--AccumulatedDeficit_iI_pp0n3_dm_c20240630_zu3kN9EV3Fia" title="Accumulated deficit"&gt;334.2&lt;/span&gt; million.
The Company is in the pre-revenue stage and no revenues are expected in the foreseeable future. The Company&#x2019;s future operations
are dependent on the success of the Company&#x2019;s ongoing development and commercialization efforts, as well as its ability to secure
additional financing as needed. Projected cash flows could be extended if further measures are taken to delay planned expenditures in
our research protocols and slow the progress in the Company&#x2019;s development and launch of next phase clinical programs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The future viability of the Company is largely dependent
upon its ability to raise additional capital to finance its operations. Management expects that future sources of funding may include
sales of equity, obtaining loans, or other strategic transactions.&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Although management continues to pursue the Company&#x2019;s
strategic plans, there is no assurance that the Company will be successful in obtaining sufficient financing on terms acceptable to the
Company, if at all, to fund continuing operations. These circumstances raise substantial doubt on the Company&#x2019;s ability to continue
as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <bivi:WorkingCapital
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000577"
      unitRef="USD">14700000</bivi:WorkingCapital>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000579"
      unitRef="USD">23800000</us-gaap:CashEquivalentsAtCarryingValue>
    <bivi:StockholderEquities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000581"
      unitRef="USD">15500000</bivi:StockholderEquities>
    <bivi:AccumulatedDeficit
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000583"
      unitRef="USD">334200000</bivi:AccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000587">&lt;p id="xdx_80A_eus-gaap--SignificantAccountingPoliciesTextBlock_zll1CrPAPwzf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt; text-align: justify"&gt;&lt;b&gt;&lt;span id="xdx_822_zbCcGWc1ytec"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zebyfefaqk47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zuLVlMJvL9b2"&gt;Basis of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s financial statements have been
prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) and include all adjustments
necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zkYmHk6pRTDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_865_zXVFq7dHQ0oc"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying
notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the
circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses reported
for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which
are used for, but not limited to, accounting for clinical accruals, share-based compensation, accounting for derivatives, assumptions
used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and
accounting for income taxes. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1bk7qiimWe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zUQkDpl4k1ya"&gt;Cash and cash equivalents&lt;/span&gt; &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents consisted of cash deposits
and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S.
Treasury Bills with original maturities of three months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p id="xdx_84D_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_z3aqWr0boaMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_862_zUelhoMtJqfg"&gt;Investments in U.S. Treasury Bills&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investments in U.S. Treasury Bills with maturities
greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other
comprehensive income in the accompanying statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zV9UO2YnPgge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zSuBbiWxmaLd"&gt;Concentration of Credit Risk in the Financial Service
Industry&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2024, the Company had cash deposited
in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these
financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March
and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions
due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material
direct impact on the Company&#x2019;s operations, if further liquidity and financial stability concerns arise with respect to banks and
financial institutions, either nationally or in specific regions, the Company&#x2019;s ability to access cash or enter into new financing
arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;
&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zU1VURvQxAR" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zzS4ULT1Zzhg"&gt;Fair value measurement of assets and liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We determine the fair values of our financial instruments
based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the
asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the
fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset
or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant
to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - Inputs are unadjusted quoted prices in active
markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - Inputs are quoted prices for similar assets
and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market
corroboration, for substantially the full term of the financial instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - Inputs are unobservable inputs based on
our assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s financial instruments include
cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts
payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating
lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--PrepaidAndOtherAssetsPolicyTextBlock_zPIGiac7r2vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_zOA3YHVhTic4"&gt;Prepaid and other assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid and other assets consist of prepayments of
certain expenses and a security deposit paid in connection with a lease agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zXUyPYrjc8n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_868_zFXQIjiZ4lIg"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determines whether an arrangement contains
a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current portion of operating
lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from
the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease
term at the commencement date. As the Company&#x2019;s leases do not provide an implicit rate, an incremental borrowing rate is used based
on the information available at the commencement date in determining the present value of lease payments. The Company does not include
options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such
options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets
or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease
payments as expense on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zw5dMpI2O1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_zWnYoZSIavae"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenses consist primarily
of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development,
personnel, supplies and development materials, costs for consultants and related contract research and facility costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zqRMfBsKS5pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zWAOugpoWc7l"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the asset and liability method of
accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards
and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a
valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company
decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes uncertainty in income taxes
in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in
a tax return. The Company applies the &#x201c;more-likely-than-not&#x201d; recognition threshold to all tax positions, commencing at the
adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there
have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,
if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive
Loss. For the years ended June 30, 2024 and 2023, there was no such interest or penalty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zzafBczj30B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zP0T8FTTKfDd"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per common share is computed by dividing
the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period.
Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number
of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution
that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30,
2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for
the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below shows the potential shares of common stock, presented based on amounts outstanding
at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including
them would have had an anti-dilutive effect:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z4xX8a8Ld4Eh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zzRmJdp8450j" style="display: none"&gt;Schedule of dilutive securities were excluded from the computation of diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total"&gt;518,076&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total"&gt;395,286&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total"&gt;1,932,029&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total"&gt;777,029&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total"&gt;40,291&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total"&gt;59,646&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Notes payable conversion option&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;71,633&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;71,633&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total"&gt;2,562,029&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z7TsdxVTmiRa" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total"&gt;1,303,594&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zGNGGaqFFrIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_860_zXhPFYOTD7x"&gt;Stock-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has accounted for stock-based compensation
under the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 718 &#x2013; &#x201c;Stock Compensation&#x201d; (&#x201c;ASC
718&#x201d;) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees
and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees
awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses
assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. For non-employees, the Company
utilizes the graded vesting attribution method under which the entity treats each separately vesting portion (tranche) as a separate award
and recognizes compensation cost for each tranche over its separate vesting schedule. Expected volatilities are based on historical volatility
of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected
term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of
the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for
the period of the expected term. The Company recognizes forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zpHNQRK66eD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zVullYgQSaFe"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Goodwill is recorded when the purchase price paid
for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual
impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests.
The Company&#x2019;s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill
related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an
asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make
certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each
time the Company tests goodwill for impairment and are typically developed as part of the Company&#x2019;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce
materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2024 and 2023.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxEExg1l3wa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_ztcdrcAsC2q2"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets, including intangible assets, are
reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the carrying amount of an asset exceeds its undiscounted
estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying
amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected
discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities
of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance
sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_848_ecustom--ReverseStockSpliteUpPolicyTextBlock_zSThz6PT6ydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_860_z1RnzX1jpb0k"&gt;Reverse stock split up&lt;/span&gt; &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"&gt;The company effected a 1:10 reverse split of the issued and outstanding
shares of its Class A commons stock which was approved by the board of director after the approval obtained from shareholders at a special
meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders&#x2019; approval was
obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split.&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zuwhNodhFzFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_868_z4C4Pn21Svea"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers the applicability and impact
of all Accounting Standards Updates (&#x201c;ASU&#x2019;s&#x201d;). There were no recent ASU&#x2019;s that are expected to have a material
impact on our balance sheets or statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the Financial Accounting Standards Board
(&#x201c;FASB&#x201d;) issued ASU No. 2016-13, &#x201c;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments&#x201d; (&#x201c;ASU 2016-13&#x201d;). This amendment replaces the incurred loss impairment methodology in current
GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade receivables. This update
is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted
ASU 2016-13 effective July 1, 2023 and the adoption had an insignificant impact on the accompanying financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures," to enhance disclosures for significant segment expenses for all public entities required to report segment information
in accordance with ASC 280. The standard did not change the definition of a segment, the method for determining segments or the criteria
for aggregating operating segments into reportable segments. The amendments are effective for fiscal years beginning after December 15,
2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods
presented in the financial statements. The adoption is not expected to have a material impact to our financial statements or disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09, "Income
Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures.
This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information
for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount
of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions.
Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between
domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are
effective for annual periods beginning after December 15, 2024. We will adopt this standard on a prospective basis as allowed by the standard.
The adoption of this standard is not expected to have a material impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000589">&lt;p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zebyfefaqk47" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zuLVlMJvL9b2"&gt;Basis of Presentation&lt;/span&gt; &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s financial statements have been
prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) and include all adjustments
necessary for the fair presentation of the Company&#x2019;s financial position for the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2023-07-01to2024-06-30" id="Fact000591">&lt;p id="xdx_843_eus-gaap--UseOfEstimates_zkYmHk6pRTDa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_865_zXVFq7dHQ0oc"&gt;Use of Estimates&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The preparation of financial statements in conformity
with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying
notes. The Company bases its estimates on historical experience and on various assumptions that are believed to be reasonable under the
circumstances. The amounts of assets and liabilities reported in the Company&#x2019;s balance sheets and the amounts of expenses reported
for each of the periods presented in the statements of operations and comprehensive loss are affected by estimates and assumptions, which
are used for, but not limited to, accounting for clinical accruals, share-based compensation, accounting for derivatives, assumptions
used in recording leases, the inputs used in the valuation of goodwill and intangible assets in connection with impairment testing and
accounting for income taxes. Actual results could differ from those estimates.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000593">&lt;p id="xdx_84B_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_z1bk7qiimWe3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zUQkDpl4k1ya"&gt;Cash and cash equivalents&lt;/span&gt; &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Cash and cash equivalents consisted of cash deposits
and money market funds held at a bank and funds held in a brokerage account which included a U.S. treasury money market fund and U.S.
Treasury Bills with original maturities of three months or less.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <bivi:InvestmentsUSTreasuryBillsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000595">&lt;p id="xdx_84D_ecustom--InvestmentsUSTreasuryBillsPolicyTextBlock_z3aqWr0boaMd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_862_zUelhoMtJqfg"&gt;Investments in U.S. Treasury Bills&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Investments in U.S. Treasury Bills with maturities
greater than three months, are accounted for as available-for-sale and are recorded at fair value. Unrealized gains were included in other
comprehensive income in the accompanying statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</bivi:InvestmentsUSTreasuryBillsPolicyTextBlock>
    <bivi:ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000597">&lt;p id="xdx_842_ecustom--ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock_zV9UO2YnPgge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zSuBbiWxmaLd"&gt;Concentration of Credit Risk in the Financial Service
Industry&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2024, the Company had cash deposited
in certain financial institutions in excess of federally insured levels. The Company regularly monitors the financial stability of these
financial institutions and believes that it is not exposed to any significant credit risk in cash and cash equivalents. However, in March
and April 2023, certain U.S. government banking regulators took steps to intervene in the operations of certain financial institutions
due to liquidity concerns, which caused general heightened uncertainties in financial markets. While these events have not had a material
direct impact on the Company&#x2019;s operations, if further liquidity and financial stability concerns arise with respect to banks and
financial institutions, either nationally or in specific regions, the Company&#x2019;s ability to access cash or enter into new financing
arrangements may be threatened, which could have a material adverse effect on its business, financial condition and results of operations.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;
</bivi:ConcentrationOfCreditRiskinTheFinancialServiceIndustryPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000601">&lt;p id="xdx_846_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zU1VURvQxAR" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zzS4ULT1Zzhg"&gt;Fair value measurement of assets and liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We determine the fair values of our financial instruments
based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable
inputs when measuring fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability
in an orderly transaction between market participants at the measurement date. The fair value assumes that the transaction to sell the
asset or transfer the liability occurs in the principal or most advantageous market for the asset or liability and establishes that the
fair value of an asset or liability shall be determined based on the assumptions that market participants would use in pricing the asset
or liability. The classification of a financial asset or liability within the hierarchy is based upon the lowest level input that is significant
to the fair value measurement. The fair value hierarchy prioritizes the inputs into three levels that may be used to measure fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 1 - Inputs are unadjusted quoted prices in active
markets for identical assets or liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 2 - Inputs are quoted prices for similar assets
and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market
corroboration, for substantially the full term of the financial instrument.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Level 3 - Inputs are unobservable inputs based on
our assumptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s financial instruments include
cash, accounts payable, the carrying value of the operating lease liabilities and notes payable. The carrying amounts of cash and accounts
payable approximate their fair value, due to the short-term nature of these items. The carrying amounts of notes payable and operating
lease liabilities approximate their fair values since they bear interest at rates which approximate market rates for similar debt instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <bivi:PrepaidAndOtherAssetsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000603">&lt;p id="xdx_849_ecustom--PrepaidAndOtherAssetsPolicyTextBlock_zPIGiac7r2vk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_zOA3YHVhTic4"&gt;Prepaid and other assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid and other assets consist of prepayments of
certain expenses and a security deposit paid in connection with a lease agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




</bivi:PrepaidAndOtherAssetsPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000605">&lt;p id="xdx_84D_eus-gaap--LesseeLeasesPolicyTextBlock_zXUyPYrjc8n3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_868_zFXQIjiZ4lIg"&gt;Leases&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company determines whether an arrangement contains
a lease at inception. Operating leases are included in operating lease right-of-use (&#x201c;ROU&#x201d;) assets, current portion of operating
lease liabilities, and operating lease liabilities, net of current portion on our balance sheets. ROU assets represent the Company&#x2019;s
right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from
the lease. ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease
term at the commencement date. As the Company&#x2019;s leases do not provide an implicit rate, an incremental borrowing rate is used based
on the information available at the commencement date in determining the present value of lease payments. The Company does not include
options to extend or terminate the lease term in its calculation unless it is reasonably certain that the Company will exercise any such
options. Rent expense is recognized under the operating leases on a straight-line basis. The Company does not recognize right-of-use assets
or lease liabilities for short-term leases, which have a lease term of 12 months or less at inception, and instead will recognize lease
payments as expense on a straight-line basis over the lease term.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2023-07-01to2024-06-30" id="Fact000607">&lt;p id="xdx_847_eus-gaap--ResearchAndDevelopmentExpensePolicy_zw5dMpI2O1S" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_zWnYoZSIavae"&gt;Research and Development&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development expenses consist primarily
of costs associated with the preclinical and/or clinical trials of drug candidates, compensation and other expenses for research and development,
personnel, supplies and development materials, costs for consultants and related contract research and facility costs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000609">&lt;p id="xdx_840_eus-gaap--IncomeTaxPolicyTextBlock_zqRMfBsKS5pd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_867_zWAOugpoWc7l"&gt;Income Taxes&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company uses the asset and liability method of
accounting for deferred income taxes. Deferred income taxes are measured by applying enacted statutory rates to net operating loss carryforwards
and to the differences between the financial reporting and tax bases of assets and liabilities. Deferred tax assets are reduced, by a
valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. The Company
decided to apply a full valuation allowance against its deferred tax assets due to the continuing losses.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recognizes uncertainty in income taxes
in the financial statements using a recognition threshold and measurement attribute of a tax position taken or expected to be taken in
a tax return. The Company applies the &#x201c;more-likely-than-not&#x201d; recognition threshold to all tax positions, commencing at the
adoption date of the applicable accounting guidance, which resulted in no unrecognized tax benefits as of such date. Additionally, there
have been no unrecognized tax benefits subsequent to adoption. The Company has opted to classify interest and penalties that would accrue,
if any, according to the provisions of relevant tax law as general and administrative expenses, in the Statements of Operations and Comprehensive
Loss. For the years ended June 30, 2024 and 2023, there was no such interest or penalty.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000613">&lt;p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zzafBczj30B7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_861_zP0T8FTTKfDd"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per common share is computed by dividing
the net loss attributable to Common Stockholders by the weighted average number of shares of Common Stock outstanding during the period.
Diluted net loss per common share is computed by dividing the net loss attributable to Common Stockholders by the weighted average number
of shares of Common Stock outstanding and potentially outstanding shares of Common Stock during the period to reflect the potential dilution
that could occur from common shares issuable through stock options, warrants, and convertible debentures. For the years ended June 30,
2024 and 2023, such amounts were excluded from the diluted loss since their effect was considered anti-dilutive due to the net loss for
the periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The table below shows the potential shares of common stock, presented based on amounts outstanding
at each year end, that were excluded from the computation of diluted net loss per share attributable to common stockholders because including
them would have had an anti-dilutive effect:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z4xX8a8Ld4Eh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zzRmJdp8450j" style="display: none"&gt;Schedule of dilutive securities were excluded from the computation of diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total"&gt;518,076&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total"&gt;395,286&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total"&gt;1,932,029&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total"&gt;777,029&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total"&gt;40,291&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total"&gt;59,646&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Notes payable conversion option&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;71,633&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;71,633&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total"&gt;2,562,029&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z7TsdxVTmiRa" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total"&gt;1,303,594&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;



</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000615">&lt;table cellpadding="0" cellspacing="0" id="xdx_88A_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z4xX8a8Ld4Eh" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Significant Accounting Policies (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8B0_zzRmJdp8450j" style="display: none"&gt;Schedule of dilutive securities were excluded from the computation of diluted loss per share&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Stock Options&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total"&gt;518,076&lt;/td&gt;&lt;td style="white-space: nowrap; width: 8%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_pdd" style="width: 12%; text-align: right" title="Total"&gt;395,286&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total"&gt;1,932,029&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Total"&gt;777,029&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Restricted Stock Units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total"&gt;40,291&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_pdd" style="text-align: right" title="Total"&gt;59,646&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Notes payable conversion option&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;71,633&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630__us-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--NotespayableConversionOptionMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;71,633&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20230701__20240630_pdd" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total"&gt;2,562,029&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20220701__20230630_z7TsdxVTmiRa" style="border-bottom: Black 3.5pt double; font-weight: bold; text-align: right" title="Total"&gt;1,303,594&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012024-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000617"
      unitRef="Shares">518076</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012023-06-30_us-gaap_StockOptionMember"
      decimals="INF"
      id="Fact000619"
      unitRef="Shares">395286</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000621"
      unitRef="Shares">1932029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact000623"
      unitRef="Shares">777029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000625"
      unitRef="Shares">40291</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="Fact000627"
      unitRef="Shares">59646</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-012024-06-30_custom_NotespayableConversionOptionMember"
      decimals="INF"
      id="Fact000629"
      unitRef="Shares">71633</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012023-06-30_custom_NotespayableConversionOptionMember"
      decimals="INF"
      id="Fact000631"
      unitRef="Shares">71633</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000633"
      unitRef="Shares">2562029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact000635"
      unitRef="Shares">1303594</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000637">&lt;p id="xdx_84E_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zGNGGaqFFrIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span id="xdx_860_zXhPFYOTD7x"&gt;Stock-based Compensation&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has accounted for stock-based compensation
under the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 718 &#x2013; &#x201c;Stock Compensation&#x201d; (&#x201c;ASC
718&#x201d;) which requires the use of the fair-value based method to determine compensation for all arrangements under which employees
and others receive shares of stock or equity instruments (stock options and Common Stock purchase warrants). For employees and non-employees
awards, the fair value of each stock option award is estimated on the date of grant using the Black-Scholes valuation model that uses
assumptions for expected volatility, expected dividends, expected term, and the risk-free interest rate. For non-employees, the Company
utilizes the graded vesting attribution method under which the entity treats each separately vesting portion (tranche) as a separate award
and recognizes compensation cost for each tranche over its separate vesting schedule. Expected volatilities are based on historical volatility
of peer companies and other factors estimated over the expected term of the stock options. For employee and non-employee awards, the expected
term of options granted is derived using the &#x201c;simplified method&#x201d; which computes expected term as the average of the sum of
the vesting term plus the contract term. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for
the period of the expected term. The Company recognizes forfeitures as they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="From2023-07-01to2024-06-30" id="Fact000639">&lt;p id="xdx_846_eus-gaap--GoodwillAndIntangibleAssetsGoodwillPolicy_zpHNQRK66eD2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_864_zVullYgQSaFe"&gt;Goodwill&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Goodwill is recorded when the purchase price paid
for an acquisition exceeds the fair value of the net identified tangible and intangible assets acquired. The Company performs an annual
impairment test of goodwill and further periodic tests to the extent indicators of impairment develop between annual impairment tests.
The Company&#x2019;s impairment review process compares the fair value of the reporting unit to its carrying value, including the goodwill
related to the reporting unit. To determine the fair value of the reporting unit, the Company may use various approaches including an
asset or cost approach, market approach or income approach or any combination thereof. These approaches may require the Company to make
certain estimates and assumptions including future cash flows, revenue and expenses. These estimates and assumptions are reviewed each
time the Company tests goodwill for impairment and are typically developed as part of the Company&#x2019;s routine business planning and
forecasting process. While the Company believes its estimates and assumptions are reasonable, variations from those estimates could produce
materially different results. The Company did not recognize any goodwill impairments for the years ended June 30, 2024 and 2023.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000643">&lt;p id="xdx_843_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_zxEExg1l3wa4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_866_ztcdrcAsC2q2"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Long-lived assets, including intangible assets, are
reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted
future cash flows expected to be generated by the asset.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;If the carrying amount of an asset exceeds its undiscounted
estimated future cash flows, an impairment review is performed. An impairment charge is recognized in the amount by which the carrying
amount of the asset exceeds the fair value of the asset. Generally, fair value is determined using valuation techniques such as expected
discounted cash flows or appraisals, as appropriate. Assets to be disposed of would be separately presented in the balance sheet and reported
at the lower of the carrying amount or fair value less costs to sell, and are no longer depreciated or amortized. The assets and liabilities
of a disposed group classified as held for sale would be presented separately in the appropriate asset and liability sections of the balance
sheets. The Company did not recognize any long-lived asset impairments for the years ended June 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <bivi:ReverseStockSpliteUpPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000645">&lt;p id="xdx_848_ecustom--ReverseStockSpliteUpPolicyTextBlock_zSThz6PT6ydg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_860_z1RnzX1jpb0k"&gt;Reverse stock split up&lt;/span&gt; &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"&gt;The company effected a 1:10 reverse split of the issued and outstanding
shares of its Class A commons stock which was approved by the board of director after the approval obtained from shareholders at a special
meeting on July 29, 2024 which became effective on Nasdaq on August 6, 2024, 5 trading days after the shareholders&#x2019; approval was
obtained. All historical share and earnings per share amounts have been retroactively adjusted to reflect the split.&lt;span style="font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</bivi:ReverseStockSpliteUpPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000647">&lt;p id="xdx_845_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zuwhNodhFzFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span id="xdx_868_z4C4Pn21Svea"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company considers the applicability and impact
of all Accounting Standards Updates (&#x201c;ASU&#x2019;s&#x201d;). There were no recent ASU&#x2019;s that are expected to have a material
impact on our balance sheets or statements of operations and comprehensive loss.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2016, the Financial Accounting Standards Board
(&#x201c;FASB&#x201d;) issued ASU No. 2016-13, &#x201c;Financial Instruments - Credit Losses (Topic 326), Measurement of Credit Losses on
Financial Instruments&#x201d; (&#x201c;ASU 2016-13&#x201d;). This amendment replaces the incurred loss impairment methodology in current
GAAP with a methodology that reflects expected credit losses on instruments within its scope, including trade receivables. This update
is intended to provide financial statement users with more decision-useful information about the expected credit losses. The Company adopted
ASU 2016-13 effective July 1, 2023 and the adoption had an insignificant impact on the accompanying financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2023, the FASB issued Accounting Standards Update (ASU) 2023-07, "Segment Reporting (Topic 280): Improvements to Reportable
Segment Disclosures," to enhance disclosures for significant segment expenses for all public entities required to report segment information
in accordance with ASC 280. The standard did not change the definition of a segment, the method for determining segments or the criteria
for aggregating operating segments into reportable segments. The amendments are effective for fiscal years beginning after December 15,
2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods
presented in the financial statements. The adoption is not expected to have a material impact to our financial statements or disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the FASB issued ASU 2023-09, "Income
Taxes (Topic 740): Improvements in Income Tax Disclosures" to enhance the transparency and decision usefulness of income tax disclosures.
This amendment requires public companies to disclose specific categories in the rate reconciliation and provide additional information
for reconciling items that meet a quantitative threshold. Additionally, under the amendment entities are required to disclose the amount
of income taxes paid disaggregated by federal, state and foreign taxes, as well as disaggregated by material individual jurisdictions.
Finally, the amendment requires entities to disclose income from continuing operations before income tax expense disaggregated between
domestic and foreign and income tax expense from continuing operations disaggregated by federal, state and foreign. The new rules are
effective for annual periods beginning after December 15, 2024. We will adopt this standard on a prospective basis as allowed by the standard.
The adoption of this standard is not expected to have a material impact on our financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000649">&lt;p id="xdx_80F_ecustom--InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock_zWKBbFyMy4ab" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;4. &lt;span id="xdx_824_zeVATi7Qf5w6"&gt;Investments in U.S. Treasury Bills available-for-sale&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following is a summary of the U.S. Treasury Bills
held at June 30, 2023:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfUSTreasuryBillsHeldTableTextBlock_zFpMQIBDZYM9" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span id="xdx_8B9_zwPq9nbsxKK3" style="display: none"&gt;Schedule of U.S. treasury bills held&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortized
    Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross
    Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross
    Unrealized loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S. Treasury
    Bills due in 3 - 6 months&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AmortizedCostBasis_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Amortized Cost Basis"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,301,136&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--GrossUnrealizedGain_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;176,591&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--GrossUnrealizedLoss_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Gross Unrealized loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentOwnedAtFairValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,477,726&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Total Accumulated Other Comprehensive Income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;176,591&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the fiscal year ended June 30, 2023, the Company
purchased a total of approximately $&lt;span id="xdx_90B_ecustom--NumberOfStockPurchased_pp0n3_dm_c20220701__20230630_zfZ2Q4bI3lp6" title="Number of stock purchased"&gt;46&lt;/span&gt; million of U.S. Treasury Bills. All outstanding investments in U.S. Treasury Bills available-for-sale
held at June 30, 2023 matured during the three months ended September 30, 2023 and were settled, resulting in a realized gain of $&lt;span id="xdx_90A_ecustom--RealizedGainOnMaturityOfAvailableforSale_pp0p0_c20230701__20240630_zx89DfToRKVk" title="Realized gain on maturity of available-for sale"&gt;223,865&lt;/span&gt;
recorded as a component of interest income on the accompanying statement of operations and comprehensive loss.&lt;/p&gt;

</bivi:InvestmentsInUSTreasuryBillsAvailableForSaleTextBlock>
    <bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000651">&lt;table cellpadding="0" cellspacing="0" id="xdx_88F_ecustom--ScheduleOfUSTreasuryBillsHeldTableTextBlock_zFpMQIBDZYM9" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Investments in U.S. Treasury Bills Available for Sale (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span id="xdx_8B9_zwPq9nbsxKK3" style="display: none"&gt;Schedule of U.S. treasury bills held&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Amortized
    Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross
    Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Gross
    Unrealized loss&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair
    Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Total
    Accumulated Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 35%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;U.S. Treasury
    Bills due in 3 - 6 months&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--AmortizedCostBasis_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Amortized Cost Basis"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,301,136&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--GrossUnrealizedGain_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Gross Unrealized Gain"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;176,591&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_988_ecustom--GrossUnrealizedLoss_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Gross Unrealized loss"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0657"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--InvestmentOwnedAtFairValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Fair Value"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14,477,726&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 3%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="width: 8%; text-align: right" title="Total Accumulated Other Comprehensive Income"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;176,591&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</bivi:ScheduleOfUSTreasuryBillsHeldTableTextBlock>
    <bivi:AmortizedCostBasis
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember"
      decimals="0"
      id="Fact000653"
      unitRef="USD">14301136</bivi:AmortizedCostBasis>
    <bivi:GrossUnrealizedGain
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember"
      decimals="0"
      id="Fact000655"
      unitRef="USD">176591</bivi:GrossUnrealizedGain>
    <us-gaap:InvestmentOwnedAtFairValue
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember"
      decimals="0"
      id="Fact000659"
      unitRef="USD">14477726</us-gaap:InvestmentOwnedAtFairValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember"
      decimals="0"
      id="Fact000661"
      unitRef="USD">176591</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <bivi:NumberOfStockPurchased
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000663"
      unitRef="USD">46000000</bivi:NumberOfStockPurchased>
    <bivi:RealizedGainOnMaturityOfAvailableforSale
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000665"
      unitRef="USD">223865</bivi:RealizedGainOnMaturityOfAvailableforSale>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000667">&lt;p id="xdx_80D_eus-gaap--IntangibleAssetsDisclosureTextBlock_z4PkRJory8Rl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_823_zzqLK3WsC4al"&gt;Intangible Assets&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company&#x2019;s intangible assets consist of intellectual property
acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets
as of June 30, 2024 and 2023:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zWlieL5r0Rt3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8BD_zVTU4dWRgoW7" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240630" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230630" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzbKJ_zQ2SOZ6MBv28" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Intellectual Property&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzbKJ_zuLnqk5tPxO" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,886,052&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,656,675&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzbKJ_z7X64uOB06K4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Intellectual Property, Net&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;407,718&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;637,095&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zk22UgZk5o54" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Amortization expense amounted to $&lt;span id="xdx_900_eus-gaap--AmortizationOfIntangibleAssets_c20230701__20240630_pp0p0" title="Amortization expenses"&gt;&lt;span id="xdx_902_eus-gaap--AmortizationOfIntangibleAssets_c20220701__20230630_pp0p0" title="Amortization expenses"&gt;229,377&lt;/span&gt;&lt;/span&gt; for each
of the years ended June 30, 2024 and 2023, respectively. The Company amortizes intellectual property over the expected original useful
lives of &lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20240630_zD3NORzx3dJc" title="Useful life"&gt;10 &lt;/span&gt;years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Estimated future amortization expense is as follows:&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOWvmnVxiYid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_8B6_zPn29iP1C7w3" style="display: none"&gt;Schedule of future amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240630_zTK62UB8coMi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;Year ending June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 47%; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 48%; text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178,341&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); padding-bottom: 3.5pt"&gt;&#160;Finite lived intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;407,718&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000669">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zWlieL5r0Rt3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8BD_zVTU4dWRgoW7" style="display: none"&gt;Schedule of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20240630" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20230630" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_pp0p0_maFLIANzbKJ_zQ2SOZ6MBv28" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Intellectual Property&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;2,293,770&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_pp0p0_di_msFLIANzbKJ_zuLnqk5tPxO" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,886,052&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(1,656,675&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_pp0p0_mtFLIANzbKJ_z7X64uOB06K4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Intellectual Property, Net&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;407,718&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;637,095&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000671"
      unitRef="USD">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000672"
      unitRef="USD">2293770</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000674"
      unitRef="USD">1886052</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000675"
      unitRef="USD">1656675</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000677"
      unitRef="USD">407718</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000678"
      unitRef="USD">637095</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000680"
      unitRef="USD">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000682"
      unitRef="USD">229377</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="AsOf2024-06-30" id="Fact000684">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000686">&lt;table cellpadding="0" cellspacing="0" id="xdx_881_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zOWvmnVxiYid" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Intangible Assets (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;&lt;span id="xdx_8B6_zPn29iP1C7w3" style="display: none"&gt;Schedule of future amortization expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240630_zTK62UB8coMi" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_406_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0" style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;Year ending June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 47%; text-align: center"&gt;2025&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 48%; text-align: right"&gt;229,377&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center; padding-bottom: 1.5pt"&gt;2026&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;178,341&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="color: rgb(204,238,255); padding-bottom: 3.5pt"&gt;&#160;Finite lived intangible assets, net&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;407,718&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000690"
      unitRef="USD">229377</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000692"
      unitRef="USD">178341</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000694"
      unitRef="USD">407718</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000696">&lt;p id="xdx_802_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zOOirCY2eeze" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82A_zMseLmUjNa1g"&gt;Related Party Transactions&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Equity Transactions with Acuitas&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 15, 2022, the Company entered into a securities
purchase agreement with Acuitas Group Holdings, LLC (&#x201c;Acuitas&#x201d;), the Company&#x2019;s largest stockholder, pursuant to which
Acuitas agreed to purchase from the Company, in a private placement, (i) an aggregate of &lt;span id="xdx_90F_eus-gaap--CommonStockSharesIssued_c20220715__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--AcuitasGroupHoldingsLLCMember_pdd" title="Common stock, shares issued"&gt;363,636&lt;/span&gt; shares of the Company&#x2019;s Common
Stock, at a price of $16.50 per share (the &#x201c;PIPE Shares&#x201d;), and (ii) a warrant to purchase 727,273 shares of Common Stock (&#x201c;PIPE
Warrant Shares&#x201d;), at an exercise price of $18.20, with a term of exercise of five years. The down round feature reduced the exercise
price of the PIPE Warrant Shares to $10.00 per share on March 6, 2024 in connection with the offering further described in Note 9 as the
Company sold stock at a price lower than its initial exercise price. The Company calculated the difference in fair value of the PIPE Warrant
Shares between the stated exercise price and the reduced exercise price and recorded $&lt;span id="xdx_904_eus-gaap--Dividends_c20230701__20240630_pp0p0" title="Deemed dividend"&gt;886,423&lt;/span&gt; as a deemed dividend. The fair value of
the PIPE Warrant Shares were estimated using the Black Scholes Method with the following inputs, the stock price of $&lt;span id="xdx_90A_eus-gaap--SharePrice_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Stock price"&gt;10.65&lt;/span&gt;, exercise price
of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Exercise price"&gt;18.20&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Exercise price"&gt;10.00&lt;/span&gt;, remaining term of &lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_zaQw6QcEbdm" title="Remaining term"&gt;3.5&lt;/span&gt; years, risk free rate of &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Risk free rate"&gt;4.4%&lt;/span&gt; and volatility of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Volatility"&gt;95.0%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 15, 2022, the Company received net proceeds of approximately
$5.9 million, net of costs of approximately $94,000, and entered into an amended and restated registration agreement with Acuitas, which
amended and restated that certain registration rights agreement, dated as of June 10, 2021, by and between the Company and Acuitas (the
&#x201c;Existing Registration Rights Agreement&#x201d;), to amend the definition of &#x201c;Registrable Securities&#x201d; in the Existing
Registration Rights Agreement to include the PIPE Shares and the PIPE Warrant Shares as Registrable Securities thereunder.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2022-07-15_custom_AcuitasGroupHoldingsLLCMember"
      decimals="INF"
      id="Fact000698"
      unitRef="Shares">363636</us-gaap:CommonStockSharesIssued>
    <us-gaap:Dividends
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000700"
      unitRef="USD">886423</us-gaap:Dividends>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_WarrantsMember"
      decimals="INF"
      id="Fact000702"
      unitRef="USDPShares">10.65</us-gaap:SharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_custom_WarrantsMember_srt_MinimumMember"
      decimals="INF"
      id="Fact000704"
      unitRef="USDPShares">18.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-06-30_custom_WarrantsMember_srt_MaximumMember"
      decimals="INF"
      id="Fact000706"
      unitRef="USDPShares">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="AsOf2024-06-30_custom_WarrantsMember"
      id="Fact000708">P3Y6M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_custom_WarrantsMember"
      decimals="INF"
      id="Fact000710"
      unitRef="Pure">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_custom_WarrantsMember"
      decimals="INF"
      id="Fact000712"
      unitRef="Pure">0.950</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000714">&lt;p id="xdx_80C_eus-gaap--DebtDisclosureTextBlock_znaQgGUTiJn8" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_822_zvK1J4NAbR1g"&gt;Notes Payable&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 30, 2021 (the &#x201c;Closing
Date&#x201d;), the Company entered into a Loan and Security Agreement and the Supplement to the Loan and Security Agreement and
Promissory Notes (together, the &#x201c;Loan Agreement&#x201d;) with Avenue Venture Opportunities Fund, L.P. (&#x201c;AVOPI&#x201d;) and
Avenue Venture Opportunities Fund II, L.P. (&#x201c;AVOPII,&#x201d; and together with AVOPI, &#x201c;Avenue&#x201d;) for growth capital
loans in an aggregate commitment amount of up to $20 million (the &#x201c;Loan&#x201d;). On the Closing Date, $15 million of the Loan
was funded (&#x201c;Tranche 1&#x201d;). The Loan provided for an additional $5 million to be available to the Company on or prior to
September 15, 2022, subject to the Company&#x2019;s achievement of certain milestones with respect to certain of its ongoing clinical
trials, which were not achieved. The Loan bears interest at an annual rate equal to the greater of (a) the sum of &lt;span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230701__20240630__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_pdd" title="Interest rate"&gt;7.00%&lt;/span&gt;
plus the prime rate as reported in The Wall Street Journal and (b) 10.75%. The prime rate at June 30, 2024 was &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230701__20240630_pdd" title="Interest rate"&gt;8.50%&lt;/span&gt;.
The Loan is secured by a lien upon and security interest in all of the Company&#x2019;s assets, including intellectual property,
subject to agreed exceptions. The maturity date of the Loan is December 1, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Loan Agreement required monthly interest-only
payments during the first eighteen months of the term of the Loan. Following the interest-only period, on July 1, 2023, the Company pays
equal monthly payments of principal, plus accrued interest, until the Loan&#x2019;s maturity date when all remaining principal and accrued
interest is due. If the Company prepays the Loan, it will be required to pay (a) a prepayment fee in an amount equal to 3.0% of the principal
amount of the Loan that is prepaid during the interest-only period; and (b) a prepayment fee in an amount equal to 1.0% of the principal
amount of the Loan that is prepaid after the interest-only period. At the Loan&#x2019;s maturity date, or on the date of the prepayment
of the Loan, the Company will be obligated to pay a final payment equal to 4.25% of the Loan commitment amount, the sum of Tranche 1 and
Tranche 2, which amounts to $850,000 (the &#x201c;Loan Premium&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Loan Agreement includes a conversion option to
convert up to $5.0 million of the principal amount of the Loan outstanding at the option of Avenue, into shares of the Company&#x2019;s
Common Stock at a conversion price of $69.80 per share (the &#x201c;Conversion Option&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On the Closing Date, the Company issued to Avenue
warrants to purchase 36,101 shares of Common Stock of the Company (the &#x201c;Avenue Warrants&#x201d;) at an exercise price per share equal
to $58.20. The Avenue Warrants are exercisable until November 30, 2026.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The amount of the carrying value of the notes payable
was determined by allocating portions of the outstanding principal of the notes, approximately $&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pp0n3_dm_c20230701__20240630_zFRfQ2xyaobl" title="Fair value of warrants"&gt;1.4&lt;/span&gt; million, to the fair value of the
Avenue Warrants, and approximately $&lt;span id="xdx_90F_ecustom--FairValueOfEmbeddedConversionOption_pp0n3_dm_c20230701__20240630_ztNYMpDOfJRk" title="Fair value of embedded conversion option"&gt;2.2&lt;/span&gt; million to the fair value of the embedded Conversion Option. Accordingly, the total amount of
unearned discount of approximately $&lt;span id="xdx_904_ecustom--UnearnedDiscount_pp0n3_dm_c20220701__20230630_zIYUU4ek7Ahh" title="Unearned discount"&gt;3.6&lt;/span&gt; million, the total direct financing cost of approximately $&lt;span id="xdx_909_ecustom--DirectFinancingCost_c20230701__20240630_pp0n3" title="Direct financing cost"&gt;390,000&lt;/span&gt; and the Loan Premium of $&lt;span id="xdx_90B_eus-gaap--DebtInstrumentUnamortizedPremium_c20240630_pp0n3" title="Unamortized premium recognized"&gt;850,000&lt;/span&gt;
are being amortized using the effective interest method over the term of the Loan. The adjusted effective interest rate is 27%.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total interest expense for the year ended June 30,
2024 was approximately $&lt;span id="xdx_904_eus-gaap--InterestExpenseDebt_pp0n3_dm_c20230701__20240630_zDAd1oZx9sk3" title="Interest expense"&gt;2.9&lt;/span&gt; million on the accompanying statement of operations and comprehensive loss. Interest expense was comprised
of interest incurred on the outstanding principal of the loan of approximately $&lt;span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0n3_dm_c20230701__20240630_zNX3xfmqKgI8" title="Interest payment"&gt;1.5&lt;/span&gt; million, amortization of financing costs of approximately
$&lt;span id="xdx_90A_eus-gaap--AmortizationOfFinancingCosts_c20230701__20240630_pp0n3" title="Amortization of financing costs"&gt;109,000&lt;/span&gt;, amortization of the unearned discount of $&lt;span id="xdx_90B_ecustom--UnearnedDiscount_pp0n3_dm_c20230701__20240630_znFjNVsItFQ7" title="Unearned discount"&gt;1.0&lt;/span&gt; million, and the accretion of the Loan Premium of approximately $&lt;span id="xdx_909_ecustom--AccretionsOfLoanPremium_c20230701__20240630_pp0n3" title="Accretion of loan premium"&gt;237,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total interest expense for the year ended June 30,
2023 was approximately $&lt;span id="xdx_90B_eus-gaap--InterestExpenseDebt_pp0n3_dm_c20220701__20230630_zugWQm0wDE3a" title="Interest expense"&gt;4.3&lt;/span&gt; million on the accompanying statement of operations and comprehensive loss. Interest expense was comprised
of interest incurred on the outstanding principal of the loan of approximately $&lt;span id="xdx_90E_eus-gaap--DebtInstrumentPeriodicPaymentInterest_pp0n3_dm_c20220701__20230630_zNQipDEkbQM4" title="Interest payment"&gt;2.1&lt;/span&gt; million, amortization of financing costs of approximately
$&lt;span id="xdx_90C_eus-gaap--AmortizationOfFinancingCosts_c20220701__20230630_pp0n3" title="Amortization of financing costs"&gt;170,000&lt;/span&gt;, amortization of the unearned discount of $1.6 million, and the accretion of the Loan Premium of approximately $&lt;span id="xdx_90F_ecustom--AccretionsOfLoanPremium_c20220701__20230630_pp0n3" title="Accretion of loan premium"&gt;422,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of June 30, 2024, the remaining principal balance
of $&lt;span id="xdx_90F_eus-gaap--NotesPayable_iI_pp0n3_dm_c20240630_zKQgvFHSSVDl" title="Remaining principal balance"&gt;5.0&lt;/span&gt; million under the Loan is payable in 6 monthly equal installments. For the year ended June 30, 2024, the Company paid back $&lt;span id="xdx_904_eus-gaap--RepaymentsOfNotesPayable_pp0n3_dm_c20230701__20240630_zGIzTAghBM65" title="Repayments of notes payable"&gt;10&lt;/span&gt;
million, of the original loan of $15 million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following is a summary of the Notes Payable as of June 30, 2024 and
2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Current portion of Notes Payable&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zaRglNHc3gAk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zWvDsDKpNXFg" style="display: none"&gt;Schedule of note payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240630_znFsMdOQI535" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230630_zoW9eLTsQjYl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Current portion of Notes Payable&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: debt financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,820&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108,751&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_zZTwYjN6FXja" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: unearned discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111,212&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,023,145&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Plus: accretion of Loan Premium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;824,242&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;236,970&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Current portion of Notes Payable, net of financing costs, unearned premium and discount&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;5,701,210&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;9,105,074&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Non-current portion of Notes Payable&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_zVy4JaB1LlEb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230630_zeXJplCcT4mb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NotesPayableNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Notes Payable&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0771"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--LongtermDebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: debt financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0774"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,820&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_z02kJbl99M2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: unearned discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111,212&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--LongTermAccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Plus: accretion of Loan Premium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;350,302&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Notes Payable, net of the current portion financing costs, unearned premium and discount&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0783"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;5,227,270&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zjQrjBvFwAL5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Estimated future amortization expense and accretion of Loan Premium is
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleofFutureAmortizationExpenseTableTextBlock_zfupwuvlLAFb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8B0_zxxq948tcl1c" style="display: none"&gt;Schedule of estimated future amortization expense and accretion of premium&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Unearned Discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Debt Financing Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Loan Premium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Year ending June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 22%; text-align: center; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025"&gt;111,212&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025"&gt;11,820&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025"&gt;25,758&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 3.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;111,212&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;11,820&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;25,758&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z1BXfF6KpXTd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-07-012024-06-30_us-gaap_PrimeRateMember"
      decimals="INF"
      id="Fact000716"
      unitRef="Pure">0.0700</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact000718"
      unitRef="Pure">0.0850</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000720"
      unitRef="USD">1400000</us-gaap:FairValueAdjustmentOfWarrants>
    <bivi:FairValueOfEmbeddedConversionOption
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000722"
      unitRef="USD">2200000</bivi:FairValueOfEmbeddedConversionOption>
    <bivi:UnearnedDiscount
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000724"
      unitRef="USD">3600000</bivi:UnearnedDiscount>
    <bivi:DirectFinancingCost
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000726"
      unitRef="USD">390000000</bivi:DirectFinancingCost>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000728"
      unitRef="USD">850000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000730"
      unitRef="USD">2900000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000732"
      unitRef="USD">1500000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000734"
      unitRef="USD">109000000</us-gaap:AmortizationOfFinancingCosts>
    <bivi:UnearnedDiscount
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000736"
      unitRef="USD">1000000.0</bivi:UnearnedDiscount>
    <bivi:AccretionsOfLoanPremium
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000738"
      unitRef="USD">237000000</bivi:AccretionsOfLoanPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000740"
      unitRef="USD">4300000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000742"
      unitRef="USD">2100000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000744"
      unitRef="USD">170000000</us-gaap:AmortizationOfFinancingCosts>
    <bivi:AccretionsOfLoanPremium
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact000746"
      unitRef="USD">422000000</bivi:AccretionsOfLoanPremium>
    <us-gaap:NotesPayable
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000748"
      unitRef="USD">5000000.0</us-gaap:NotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact000750"
      unitRef="USD">10000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000754">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfDebtTableTextBlock_zaRglNHc3gAk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B8_zWvDsDKpNXFg" style="display: none"&gt;Schedule of note payable&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20240630_znFsMdOQI535" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_491_20230630_zoW9eLTsQjYl" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--CurrentPortionOfNotesPayable_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Current portion of Notes Payable&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--DebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: debt financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,820&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108,751&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_zZTwYjN6FXja" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: unearned discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111,212&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,023,145&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_ecustom--AccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Plus: accretion of Loan Premium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;824,242&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;236,970&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--NotesPayableCurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Current portion of Notes Payable, net of financing costs, unearned premium and discount&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;5,701,210&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;9,105,074&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Non-current portion of Notes Payable&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20240630_zVy4JaB1LlEb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49B_20230630_zeXJplCcT4mb" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--NotesPayableNoncurrent_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Notes Payable&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0771"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;5,000,000&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--LongtermDebtFinancingCosts_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Less: debt financing costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0774"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(11,820&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables_iNI_pp0p0_di_z02kJbl99M2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: unearned discount&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0777"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(111,212&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--LongTermAccretionOfLoanPremiums_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Plus: accretion of Loan Premium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0780"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;350,302&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount_iI_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Notes Payable, net of the current portion financing costs, unearned premium and discount&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0783"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;5,227,270&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDebtTableTextBlock>
    <bivi:CurrentPortionOfNotesPayable
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000756"
      unitRef="USD">5000000</bivi:CurrentPortionOfNotesPayable>
    <bivi:CurrentPortionOfNotesPayable
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000757"
      unitRef="USD">10000000</bivi:CurrentPortionOfNotesPayable>
    <bivi:DebtFinancingCosts
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000759"
      unitRef="USD">-11820</bivi:DebtFinancingCosts>
    <bivi:DebtFinancingCosts
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000760"
      unitRef="USD">-108751</bivi:DebtFinancingCosts>
    <us-gaap:DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000762"
      unitRef="USD">111212</us-gaap:DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables>
    <us-gaap:DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000763"
      unitRef="USD">1023145</us-gaap:DeferredDiscountsFinanceChargesAndInterestIncludedInReceivables>
    <bivi:AccretionOfLoanPremiums
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000765"
      unitRef="USD">824242</bivi:AccretionOfLoanPremiums>
    <bivi:AccretionOfLoanPremiums
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000766"
      unitRef="USD">236970</bivi:AccretionOfLoanPremiums>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000768"
      unitRef="USD">5701210</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000769"
      unitRef="USD">9105074</us-gaap:NotesPayableCurrent>
    <bivi:NotesPayableNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000772"
      unitRef="USD">5000000</bivi:NotesPayableNoncurrent>
    <bivi:LongtermDebtFinancingCosts
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000775"
      unitRef="USD">-11820</bivi:LongtermDebtFinancingCosts>
    <bivi:LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000778"
      unitRef="USD">111212</bivi:LongTermDeferredDiscountsFinanceChargesAndInterestIncludedInReceivables>
    <bivi:LongTermAccretionOfLoanPremiums
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000781"
      unitRef="USD">350302</bivi:LongTermAccretionOfLoanPremiums>
    <bivi:LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000784"
      unitRef="USD">5227270</bivi:LongTermNotesPayableNetOfFinancingCostsUnearnedPremiumsAndDiscount>
    <bivi:ScheduleofFutureAmortizationExpenseTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000786">&lt;table cellpadding="0" cellspacing="0" id="xdx_89B_ecustom--ScheduleofFutureAmortizationExpenseTableTextBlock_zfupwuvlLAFb" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Notes Payable (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8B0_zxxq948tcl1c" style="display: none"&gt;Schedule of estimated future amortization expense and accretion of premium&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Unearned Discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Debt Financing Costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;Loan Premium&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Year ending June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 22%; text-align: center; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025"&gt;111,212&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025"&gt;11,820&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--AmortizationExpenseNextRollingTwoYears_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 19%; text-align: right" title="2025"&gt;25,758&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center; padding-bottom: 3.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--UnearnedDiscountMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;111,212&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__us-gaap--FinanceReceivablesMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;11,820&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_ecustom--AmortizationExpenseTotal_c20240630__us-gaap--AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis__custom--LoanAccretionPremiumMember_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;25,758&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</bivi:ScheduleofFutureAmortizationExpenseTableTextBlock>
    <bivi:AmortizationExpenseNextRollingTwoYears
      contextRef="AsOf2024-06-30_custom_UnearnedDiscountMember"
      decimals="0"
      id="Fact000788"
      unitRef="USD">111212</bivi:AmortizationExpenseNextRollingTwoYears>
    <bivi:AmortizationExpenseNextRollingTwoYears
      contextRef="AsOf2024-06-30_us-gaap_FinanceReceivablesMember"
      decimals="0"
      id="Fact000790"
      unitRef="USD">11820</bivi:AmortizationExpenseNextRollingTwoYears>
    <bivi:AmortizationExpenseNextRollingTwoYears
      contextRef="AsOf2024-06-30_custom_LoanAccretionPremiumMember"
      decimals="0"
      id="Fact000792"
      unitRef="USD">25758</bivi:AmortizationExpenseNextRollingTwoYears>
    <bivi:AmortizationExpenseTotal
      contextRef="AsOf2024-06-30_custom_UnearnedDiscountMember"
      decimals="0"
      id="Fact000794"
      unitRef="USD">111212</bivi:AmortizationExpenseTotal>
    <bivi:AmortizationExpenseTotal
      contextRef="AsOf2024-06-30_us-gaap_FinanceReceivablesMember"
      decimals="0"
      id="Fact000796"
      unitRef="USD">11820</bivi:AmortizationExpenseTotal>
    <bivi:AmortizationExpenseTotal
      contextRef="AsOf2024-06-30_custom_LoanAccretionPremiumMember"
      decimals="0"
      id="Fact000798"
      unitRef="USD">25758</bivi:AmortizationExpenseTotal>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000800">&lt;p id="xdx_803_eus-gaap--FairValueMeasurementInputsDisclosureTextBlock_zEa3bFnfv26i" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_z0cT4uPXKInc"&gt;Fair Value Measurements&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At June 30, 2024 and 2023, the estimated fair value of derivative liabilities
measured on a recurring basis are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zs1275pMAXB1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span id="xdx_8BC_ztGBkgtbqqxb" style="display: none"&gt;Schedule of derivative liabilities at fair value&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Derivative liability - Warrants&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0806"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative liability - Conversion Option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0818"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Derivative liability - Warrants&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;894,280&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;894,280&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative liability - Conversion option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;925,762&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;925,762&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;1,820,042&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;1,820,042&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zDfjHjwYnFUi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table presents the activity for level 3 liabilities measured
at fair value using unobservable inputs for the years ended June 30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z9w664WrOIM5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zwMPaIlLuXg" style="display: none"&gt;Fair value, liabilities measured on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Derivative liability - Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Derivative liability - Conversion Option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Balance at June 30, 2022&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUgcP89KKABf" style="width: 12%; text-align: right" title="Balance at beginning"&gt;194,531&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zblXPAVgAYlb" style="width: 12%; text-align: right" title="Balance at beginning"&gt;188,030&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additions to level 3 liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in in fair value of level 3 liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities"&gt;699,749&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities"&gt;737,732&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Transfer in and/or out of level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0866"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0lABtpPOqxk" style="text-align: right" title="Balance at beginning"&gt;894,280&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCdd2q8kxlk5" style="text-align: right" title="Balance at beginning"&gt;925,762&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additions to level 3 liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in in fair value of level 3 liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities"&gt;(890,509&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities"&gt;(925,762&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Transfer in and/or out of level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0882"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 3.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkkQVIkbkN86" style="border-bottom: Black 3.5pt double; text-align: right" title="Balance at ending"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwKr3rlPQmJ6" style="border-bottom: Black 3.5pt double; text-align: right" title="Balance at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_ztmqNF8QSJvf" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair values of derivative liabilities for the
Avenue Warrants and Conversion Option at June 30, 2024 in the accompanying balance sheet, were approximately $3,800 and approximately
zero, respectively. The total change in the fair value of the derivative liabilities totaled approximately $(1.8) million and $1.4 million
for the years ended June 30, 2024, and 2023, respectively; and accordingly, was recorded in the accompanying statements of operations
and comprehensive loss. The assumptions used in the Black Scholes model to value the derivative liabilities at June 30, 2024 included
the closing stock price of $&lt;span id="xdx_908_eus-gaap--SharePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Share Price"&gt;4.00&lt;/span&gt; per share; for the Avenue Warrants, the exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Exercise Price"&gt;58.20&lt;/span&gt;, remaining term &lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zQfz58nmCpci" title="Term"&gt;2.4&lt;/span&gt; year, risk free
rate of &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Risk Free Interest Rate"&gt;4.6%&lt;/span&gt; and volatility of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Volatility Rate"&gt;82.0%&lt;/span&gt;; and for the Conversion Option, the conversion price of $&lt;span id="xdx_903_eus-gaap--SharePrice_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionOnConvertibleDebentureMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Share Price"&gt;69.80&lt;/span&gt;; remaining term of &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtM_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z80P3yszfRQ1" title="Term"&gt;5&lt;/span&gt; months, risk
free rate of &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Risk Free Interest Rate"&gt;5.38%&lt;/span&gt; and volatility of &lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pdd" title="Volatility Rate"&gt;91.0%&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Derivative liability &#x2013; Avenue Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Avenue Warrants were not considered to be indexed
to the Company&#x2019;s own stock, and accordingly, were recorded as a derivative liability at fair value in the accompanying balance sheets
at June 30, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Black Scholes model was used to calculate the
fair value of the warrant derivative to bifurcate the warrant derivative amount from the Avenue Loan amount funded. The Avenue Warrants
are recorded at their fair values at the date of issuance and remeasured at each subsequent reporting period end date.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Embedded derivative liability &#x2013; Conversion
Option&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Conversion Option is accounted for as an embedded
derivative liability and required bifurcation from the Loan amount. The Black Scholes model was used to calculate the fair value of the
Conversion Option to bifurcate it from the Loan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Financial assets&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;As of June 30, 2024, investments in U.S. Treasury Bills were valued through
use of quoted prices and are classified as Level 1. The following table presents information about our assets that are measured at fair
value on a recurring basis using the above input categories.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znrCtiblFEj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8B5_zEnnMqJ0iX13" style="display: none"&gt;Measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%"&gt;Cash&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;12,763,941&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;12,763,941&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;U.S. Treasury Bills due in 3 months or less at purchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total"&gt;11,079,857&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total"&gt;11,079,857&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;23,843,798&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;23,843,798&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%"&gt;Cash&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;6,304,543&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;6,304,543&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;U.S. Treasury Bills due in 3 months or less at purchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total"&gt;13,156,340&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0946"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total"&gt;13,156,340&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;U.S. Treasury Bills due in 3 - 6 months at purchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total"&gt;14,477,726&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0954"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0956"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" style="text-align: right" title="Total"&gt;14,477,726&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;33,938,609&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;33,938,609&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zKu2HKcCU3Th" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000802">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_zs1275pMAXB1" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&lt;span id="xdx_8BC_ztGBkgtbqqxb" style="display: none"&gt;Schedule of derivative liabilities at fair value&lt;/span&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Derivative liability - Warrants&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0804"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0806"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative liability - Conversion Option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0814"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0816"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0818"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--DerivativeLiabilities_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_c20240630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Derivative liability - Warrants&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0830"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;894,280&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember_pp0p0" style="width: 10%; text-align: right" title="Total derivatives"&gt;894,280&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Derivative liability - Conversion option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0836"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0838"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;925,762&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total derivatives"&gt;925,762&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total derivative liabilities&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0844"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0846"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;1,820,042&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--DerivativeLiabilities_c20230630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total derivatives"&gt;1,820,042&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000808"
      unitRef="USD">3771</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember"
      decimals="0"
      id="Fact000810"
      unitRef="USD">3771</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000824"
      unitRef="USD">3771</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000826"
      unitRef="USD">3771</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000832"
      unitRef="USD">894280</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember"
      decimals="0"
      id="Fact000834"
      unitRef="USD">894280</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000840"
      unitRef="USD">925762</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember"
      decimals="0"
      id="Fact000842"
      unitRef="USD">925762</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000848"
      unitRef="USD">1820042</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000850"
      unitRef="USD">1820042</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000852">&lt;table cellpadding="0" cellspacing="0" id="xdx_898_eus-gaap--FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_z9w664WrOIM5" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8BB_zwMPaIlLuXg" style="display: none"&gt;Fair value, liabilities measured on recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Derivative liability - Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Derivative liability - Conversion Option&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%"&gt;Balance at June 30, 2022&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zUgcP89KKABf" style="width: 12%; text-align: right" title="Balance at beginning"&gt;194,531&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zblXPAVgAYlb" style="width: 12%; text-align: right" title="Balance at beginning"&gt;188,030&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additions to level 3 liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0858"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0860"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in in fair value of level 3 liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities"&gt;699,749&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities"&gt;737,732&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Transfer in and/or out of level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0866"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20220701__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0868"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Balance at June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_z0lABtpPOqxk" style="text-align: right" title="Balance at beginning"&gt;894,280&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--DerivativeLiabilities_iS_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zCdd2q8kxlk5" style="text-align: right" title="Balance at beginning"&gt;925,762&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Additions to level 3 liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0874"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Additions to level 3 liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0876"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Change in in fair value of level 3 liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities"&gt;(890,509&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Change in in fair value of level 3 liabilities"&gt;(925,762&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Transfer in and/or out of level 3&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0882"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Transfer in and/or out of Level 3"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0884"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 3.5pt"&gt;Balance at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityWarrantsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zkkQVIkbkN86" style="border-bottom: Black 3.5pt double; text-align: right" title="Balance at ending"&gt;3,771&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--DerivativeLiabilities_iE_pp0p0_c20230701__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--DerivativeLiabilityConversionOptionMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zwKr3rlPQmJ6" style="border-bottom: Black 3.5pt double; text-align: right" title="Balance at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0888"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000854"
      unitRef="USD">194531</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2022-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000856"
      unitRef="USD">188030</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000862"
      unitRef="USD">699749</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2022-07-012023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000864"
      unitRef="USD">737732</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000870"
      unitRef="USD">894280</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2023-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000872"
      unitRef="USD">925762</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000878"
      unitRef="USD">-890509</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000880"
      unitRef="USD">-925762</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPeriodIncreaseDecrease>
    <us-gaap:DerivativeLiabilities
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      id="Fact000886"
      unitRef="USD">3771</us-gaap:DerivativeLiabilities>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact000890"
      unitRef="USDPShares">4.00</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact000892"
      unitRef="USDPShares">58.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact000894">P2Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact000896"
      unitRef="Pure">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityWarrantsMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact000898"
      unitRef="Pure">0.820</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharePrice
      contextRef="AsOf2024-06-30_custom_DerivativeLiabilityConversionOptionOnConvertibleDebentureMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact000900"
      unitRef="USDPShares">69.80</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      id="Fact000902">P5M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact000904"
      unitRef="Pure">0.0538</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_custom_DerivativeLiabilityConversionOptionMember_us-gaap_FairValueInputsLevel3Member"
      decimals="INF"
      id="Fact000906"
      unitRef="Pure">0.910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000910">&lt;table cellpadding="0" cellspacing="0" id="xdx_897_eus-gaap--FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_znrCtiblFEj" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Fair Value Measurements (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8B5_zEnnMqJ0iX13" style="display: none"&gt;Measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%"&gt;Cash&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;12,763,941&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0914"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;12,763,941&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;U.S. Treasury Bills due in 3 months or less at purchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total"&gt;11,079,857&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0924"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total"&gt;11,079,857&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;23,843,798&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0930"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0932"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20240630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;23,843,798&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Fair Value Measurements at&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 1&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 2&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Level 3&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 48%"&gt;Cash&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;6,304,543&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0938"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0940"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CashMember_pp0p0" style="width: 8%; text-align: right" title="Total"&gt;6,304,543&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;U.S. Treasury Bills due in 3 months or less at purchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total"&gt;13,156,340&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0946"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0948"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__us-gaap--USTreasuryBillSecuritiesMember_pp0p0" style="text-align: right" title="Total"&gt;13,156,340&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;U.S. Treasury Bills due in 3 - 6 months at purchase&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Total"&gt;14,477,726&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0954"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0956"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--InvestmentTypeAxis__custom--USTreasuryBillSecurities1Member_pp0p0" style="text-align: right" title="Total"&gt;14,477,726&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;33,938,609&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0962"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0964"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_c20230630_pp0p0" style="border-bottom: Black 3.5pt double; text-align: right" title="Total"&gt;33,938,609&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000912"
      unitRef="USD">12763941</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_CashMember"
      decimals="0"
      id="Fact000918"
      unitRef="USD">12763941</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000920"
      unitRef="USD">11079857</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_USTreasuryBillSecuritiesMember"
      decimals="0"
      id="Fact000926"
      unitRef="USD">11079857</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000928"
      unitRef="USD">23843798</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact000934"
      unitRef="USD">23843798</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_CashMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000936"
      unitRef="USD">6304543</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_CashMember"
      decimals="0"
      id="Fact000942"
      unitRef="USD">6304543</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000944"
      unitRef="USD">13156340</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_USTreasuryBillSecuritiesMember"
      decimals="0"
      id="Fact000950"
      unitRef="USD">13156340</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000952"
      unitRef="USD">14477726</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_custom_USTreasuryBillSecurities1Member"
      decimals="0"
      id="Fact000958"
      unitRef="USD">14477726</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      id="Fact000960"
      unitRef="USD">33938609</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact000966"
      unitRef="USD">33938609</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact000968">&lt;p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zAP4FJUoa5K4" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_823_z2M2FnXZNpOb"&gt;Equity Transactions&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Issuance of common stock for cash&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 31, 2022, the Company entered into a Controlled
Equity Offering Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. and B. Riley Securities, Inc. (collectively,
the &#x201c;Agents&#x201d;), pursuant to which the Company may issue and sell from time-to-time shares of the Company&#x2019;s common stock
through the Agents, subject to the terms and conditions of the Sales Agreement. On April 6, 2023, the Company and B. Riley Securities,
Inc. mutually agreed to terminate B. Riley Securities, Inc.&#x2019;s role as a sales agent under the Sales Agreement. During the year ended
June 30, 2024, the Company sold &lt;span id="xdx_90C_ecustom--IssuanceOfCommonStockForCashShares_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Issuance of common stock for cash, shares"&gt;333,749&lt;/span&gt; shares of common stock under the Sales Agreement for total net proceeds of approximately $&lt;span id="xdx_902_ecustom--IssuanceOfCommonStockForCash_pp0n3_dm_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_z6dmYsKkbBx8" title="Issuance of common stock for cash"&gt;9.3&lt;/span&gt;
million after deducting &lt;span id="xdx_90E_ecustom--CommissionsPercentage_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Commissions percentage"&gt;3%&lt;/span&gt; commissions and expenses of approximately $&lt;span id="xdx_902_eus-gaap--PaymentsOfStockIssuanceCosts_c20230701__20240630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pp0p0" title="Issuance costs"&gt;377,000&lt;/span&gt;. During the year ended June 30, 2023, the Company sold &lt;span id="xdx_903_ecustom--IssuanceOfCommonStockForCashShares_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Issuance of common stock for cash, shares"&gt;753,925&lt;/span&gt;
shares of common stock under the Sales Agreement for total net proceeds of approximately $&lt;span id="xdx_908_ecustom--IssuanceOfCommonStockForCash_pp0n3_dm_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zyp1vsbfxDa1" title="Issuance of common stock for cash"&gt;49.5&lt;/span&gt; million after &lt;span id="xdx_90C_ecustom--CommissionsPercentage_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_pdd" title="Commissions percentage"&gt;3%&lt;/span&gt; commissions and expenses
of approximately $&lt;span id="xdx_906_eus-gaap--PaymentsOfStockIssuanceCosts_pp0n3_dm_c20220701__20230630__us-gaap--StatementClassOfStockAxis__us-gaap--CommonClassAMember__us-gaap--TypeOfArrangementAxis__custom--SalesAgreementMember_zvNIe5WdZ8cg" title="Issuance costs"&gt;2.0&lt;/span&gt; million.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 6, 2024, the Company closed a best efforts
public offering (the &#x201c;Offering&#x201d;) of &lt;span id="xdx_904_eus-gaap--PartnersCapitalAccountUnitsSoldInPublicOffering_c20240301__20240306_pdd" title="Public offering"&gt;1,500,000&lt;/span&gt; shares (the &#x201c;Shares&#x201d;) of its common stock, par value $&lt;span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_c20240306_pdd" title="Common stock, par value"&gt;0.001&lt;/span&gt; per
share (the &#x201c;Common Stock&#x201d;), pre-funded warrants (the &#x201c;Pre-funded Warrants&#x201d;) to purchase &lt;span id="xdx_90D_eus-gaap--StockRepurchasedDuringPeriodShares_c20240301__20240306__us-gaap--AwardTypeAxis__custom--PrefundedWarrantsMember_pdd" title="Stock option to purchase"&gt;600,000&lt;/span&gt; shares of Common
Stock, and warrants to purchase up to &lt;span id="xdx_901_eus-gaap--StockRepurchasedDuringPeriodShares_c20240301__20240306__us-gaap--AwardTypeAxis__custom--CommonWarrantMember_pdd" title="Stock option to purchase"&gt;1,050,000&lt;/span&gt; shares of Common Stock (the &#x201c;Common Warrants&#x201d;) at a combined public offering
price of $&lt;span id="xdx_90B_eus-gaap--SharePrice_c20240306_pdd" title="Share price"&gt;10.00&lt;/span&gt; per Share, or Pre-funded Warrant, and the associated Common Warrant. &lt;span style="background-color: white"&gt;The Common
Warrants have an exercise price of $15.00 per share and are immediately exercisable upon issuance for a period of five years following
the date of issuance. &lt;/span&gt;The gross proceeds to the Company from the Offering were approximately $21.0 million, before deducting placement
agent fees and offering expenses of approximately $2.5 million, resulting in net proceeds of approximately $18.5 million. Additionally,
upon closing the Company issued the placement agent warrants (&#x201c;Placement Agent&#x2019;s warrants&#x201d;) to purchase 105,000 shares
of Common Stock exercisable at a per share price of $12.50, which was equal to 125% of the public offering price per share. The Placement
Agent&#x2019;s Warrants are exercisable during a five-year period commencing 180 days from March 6, 2024. The Pre-Funded Warrants were
exercised shortly after issuance and the &lt;span id="xdx_90B_ecustom--StockExercised_c20230701__20240630__us-gaap--AwardTypeAxis__custom--PrefundedWarrantsMember_pdd" title="Number of stock exercised"&gt;600,000&lt;/span&gt; shares of Common Stock were issued during the year ended June 30, 2024.&lt;/p&gt;





&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Issuance of common stock for services&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 6, 2023, the Company awarded &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20230401__20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Stock issued during period for service"&gt;5,000&lt;/span&gt; shares
of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance
was $&lt;span id="xdx_901_eus-gaap--SharePrice_c20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Share price"&gt;74.50&lt;/span&gt; per share. The stock-based compensation expense related to this Common Stock issuance was $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_c20230401__20230406__srt--TitleOfIndividualAxis__custom--VendorMember_pp0p0" title="Stock-based compensation expense"&gt;372,500&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 10, 2024, the Company awarded &lt;span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20240501__20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Stock issued during period for service"&gt;15,000&lt;/span&gt; shares
of Common Stock to a vendor as part of their fees in exchange for services. The fair value of the Common Stock at the date of issuance
was $&lt;span id="xdx_906_eus-gaap--SharePrice_c20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pdd" title="Share price"&gt;4.86&lt;/span&gt; per share. The stock-based compensation expense related to this Common Stock issuance was $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_c20240501__20240510__srt--TitleOfIndividualAxis__custom--VendorMember_pp0p0" title="Stock-based compensation expense"&gt;72,900&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the activity relating to the Company&#x2019;s
stock options for the years ended June 30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY0PIa7Edy1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_zyi9QO5BLXFj" style="display: none"&gt;Schedule of summarizes the activity relating to the Company&#x2019;s stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Remaining Average Contractual Term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;Outstanding at June 30, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ6IjrYM0PK9" style="width: 10%; text-align: right" title="Options outstanding at beginning"&gt;339,876&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2LEuzgLVgc4" style="width: 10%; text-align: right" title="Weighted average exercise price, Options outstanding at beginning"&gt;74.20&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zniHPECSvOCf" style="width: 10%; text-align: right" title="Weighted remaining average contractual term, beginning"&gt;5.5&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJIMoPDiXiJ" style="width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1020"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Options granted"&gt;71,467&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, granted"&gt;59.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zeuQ0zrcLVll" style="text-align: right" title="Weighted remaining average contractual term, granted"&gt;8.6&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AggregateIntrinsicValueGranted_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="text-align: right" title="Aggregate intrinsic value, granted"&gt;38,610&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zOM87jFIn4xc" style="text-align: right" title="Options expired"&gt;(1,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, expired"&gt;286.90&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options Canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zv5I3FpYfVmb" style="text-align: right" title="Options canceled"&gt;(4,967&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, canceled"&gt;77.40&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ztPM0sj37AFk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options exercised"&gt;(10,090&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;81.20&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding at June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zUsCjdBEk1W8" style="text-align: right" title="Options outstanding at beginning"&gt;395,286&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4TQEKtO9GCi" style="text-align: right" title="Weighted average exercise price, options outstanding at beginning"&gt;71.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zTWfj23gEGsg" style="text-align: right" title="Weighted remaining average contractual term, beginning"&gt;6.3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zacnml1ySyfj" style="text-align: right" title="Aggregate intrinsic value, outstanding at beginning"&gt;1,067,966&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Options granted"&gt;155,242&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, granted"&gt;11.70&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zAmwB4FxAfqd" style="text-align: right" title="Weighted remaining average contractual term, granted"&gt;9.8&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z8npO4KRiGsc" style="text-align: right" title="Options expired"&gt;(640&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, expired"&gt;46.09&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options Canceled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2FzqrTWIjs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled"&gt;(31,812&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, canceled"&gt;57.19&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 3.5pt"&gt;Outstanding at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zMmw4UMIeX61" style="border-bottom: Black 3.5pt double; text-align: right" title="Options outstanding at ending"&gt;518,076&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ7GNFLcHTX6" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average exercise price, options outstanding at ending"&gt;54.11&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zBrYJHdSj1B2" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted remaining average contractual term, ending"&gt;6.1&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJUmTKoX9mMk" style="border-bottom: Black 3.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 3.5pt"&gt;Exercisable at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 3.5pt double; text-align: right" title="Options exercisable"&gt;296,934&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average exercise price, options exercisable"&gt;66.65&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4EOjftFLtG8" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average remaining contractual term, options exercisable"&gt;4.9&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_z4i4Td2KuGA9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of each option grant on the date of
grant is estimated using the Black-Scholes model. The following weighted-average assumptions were utilized for the years ended:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z2KR87Z44i4f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity Transactions (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zxtZOoPchiGa" style="display: none"&gt;Schedule of assumptions used&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; width: 48%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"&gt;&lt;b&gt;June 30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"&gt;&lt;b&gt;June 30, 2023&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;Expected life of options (in years)&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zCpnCMzVDOij" title="Expected life of options (In years)"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zL9h2R6UTHG2" title="Expected life of options (In years)"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility"&gt;86.28%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility"&gt;81.65%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;Risk free interest rate&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;4.40%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;3.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;Dividend Yield&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield"&gt;0%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zQWkfr6n66x5" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company recorded stock based compensation expense
relating to the vesting of stock options of approximately $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0n3_dm_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zjq8SAOcHyG8" title="Stock-based compensation expense"&gt;2.8&lt;/span&gt; million and $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensation_pp0n3_dm_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zLp8INhuZr61" title="Stock-based compensation expense"&gt;4.2&lt;/span&gt; million for the years ended June 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Issuance and modification of restricted stock units and options:&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 21, 2022, the Company awarded &lt;span id="xdx_903_ecustom--RsuGranted_c20220601__20220621__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"&gt;12,452&lt;/span&gt; restricted
stock units (&#x201c;RSUs&#x201d;) to the President and CEO under the Company&#x2019;s 2019 Omnibus Plan. Each RSU awarded to the CEO entitles
him to receive one share of Common Stock upon vesting. The RSUs vest in three equal annual installments beginning on the first anniversary
grant date. &lt;span id="xdx_908_ecustom--RsuGranted_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"&gt;4,151&lt;/span&gt; and &lt;span id="xdx_901_ecustom--RsuGranted_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"&gt;4,151&lt;/span&gt; RSUs vested in June 2023 and 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 23, 2022, the Company awarded &lt;span id="xdx_909_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"&gt;38,198&lt;/span&gt; RSUs
to certain employees and a consultant, with a grant date fair value of $&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted, grant date fair value"&gt;61.20&lt;/span&gt; per share. 25% of these RSUs vested on the grant date and
the remaining RSUs vest in three equal installments over three years beginning on the first anniversary of the grant date. During the
year ended June 30, 2023, &lt;span id="xdx_908_ecustom--SharesIssuedOverVestingPeriod_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares issued over the vesting period"&gt;9,550&lt;/span&gt; of these RSUs vested, of which &lt;span id="xdx_90D_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20220701__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares for tax withholdings"&gt;2,288&lt;/span&gt; shares were withheld in Treasury stock in exchange for payment of
withholding tax on behalf of the employees.&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 23, 2022, the Company issued equity awards
for the board of directors&#x2019; annual compensation. Four directors received &lt;span id="xdx_90A_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pdd" title="Rsu granted"&gt;15,564&lt;/span&gt; RSUs with a grant date fair value of $&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorsMember_pdd" title="Rsu granted, grant date fair value"&gt;61.20&lt;/span&gt; per
share. In addition, three directors received stock options to purchase &lt;span id="xdx_90D_ecustom--RsuGranted_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pdd" title="Rsu granted"&gt;19,500&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20221101__20221123__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--ThreeDirectorsMember_pdd" title="Rsu granted, grant date fair value"&gt;61.20&lt;/span&gt; per
share with a grant date fair value of $40.60 per share. The equity awards vest quarterly on February 23, 2023, May 23, 2023, August 23,
2023 and earlier of November 23, 2023 or the next annual shareholders&#x2019; meeting. During the year ended June 30, 2024, 7,746 of these
RSUs vested. These RSUs and options contain certain contractual vesting terms where the vesting can be accelerated outside the Company&#x2019;s
control and as a result, for accounting purposes, are assumed to have been fully vested on the grant date, and accordingly, the Company
recognized the total compensation cost of $&lt;span id="xdx_90F_ecustom--TotalCompensationCost_c20221123_pp0p0" title="Total compensation cost"&gt;1,744,192&lt;/span&gt; on November 23, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November 9, 2023, the Company issued equity awards
for the board of directors&#x2019; annual compensation. Four directors received &lt;span id="xdx_906_ecustom--RsuGranted_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Rsu granted"&gt;18,270&lt;/span&gt; RSUs with a grant date fair value of $&lt;span id="xdx_909_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Rsu granted, grant date fair value"&gt;30.10&lt;/span&gt; per
share. In addition, two directors received stock options to purchase &lt;span id="xdx_908_ecustom--RsuGranted_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_pdd" title="Rsu granted"&gt;18,325&lt;/span&gt; shares of common stock at an exercise price of $&lt;span id="xdx_90F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20231101__20231109__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--TwoDirectorsMember_pdd" title="Rsu granted, grant date fair value"&gt;30.10&lt;/span&gt; per
share with a grant date fair value of $18.30 per share. The equity awards vest quarterly on February 9, 2024, May 9, 2024, August 9, 2024
and earlier of November 9, 2024 or the next annual shareholders&#x2019; meeting. During the year ended June 30, 2024, &lt;span id="xdx_906_ecustom--SharesIssuedOverVestingPeriod_c20230701__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--FourDirectorMember_pdd" title="Shares issued over the vesting period"&gt;4,568 &lt;/span&gt;of these RSUs
vested.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2023, the Company terminated five employees
and as part of their severance agreement modified their equity awards that had been granted pursuant to the 2019 Omnibus Plan. The modifications
included the acceleration of certain stock option awards to purchase a total of 5,623 shares of common stock (&#x201c;Accelerated Options&#x201d;),
effective on the December Separation Date, as defined in severance agreement (&#x201c;Separation Date&#x201d;), and extended the expiration
date for one year from the Separation Date for both the Accelerated Options and any vested and unexercised stock options held by the terminated
employees as of the Separation Date. Accordingly, the Company remeasured the Accelerated Options based on the stock price of $15.40 per
share at the close on the Separation Date and a one-year extension of the term. The net adjustment for the modification was a net credit
of $127,199 and was recognized as an adjustment to stock compensation expense during the year ended June 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Additionally, 1,030 vesting RSUs were accelerated
as of the Separation date. The modified RSUs were remeasured based on the stock price of $15.40 per share at close on the Separation Date
and $15,865, was recorded to additional in stock-based compensation for the year ended June 30, 2024 as a result of the modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In connection with the separation, the Company canceled
18,396 unvested stock options and 1,030 unvested RSUs. Additionally, the Company canceled an additional 13,416 unvested stock options
for employees that voluntarily left the company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2023, the Company issued &lt;span id="xdx_901_ecustom--RsuGranted_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted"&gt;14,950&lt;/span&gt; RSUs with
a grant date fair value of $&lt;span id="xdx_907_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Rsu granted, grant date fair value"&gt;41.10&lt;/span&gt; per share to the President and CEO under the Company&#x2019;s 2019 Omnibus Plan. The RSUs vest in three
equal annual installments beginning on the first anniversary grant date. &lt;span id="xdx_908_ecustom--SharesIssuedOverVestingPeriod_c20230601__20230630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__us-gaap--PlanNameAxis__custom--N2019OmnibusIncentiveEquityPlanMember__srt--TitleOfIndividualAxis__custom--PresidentAndCEOMember_pdd" title="Shares issued over the vesting period"&gt;4,983&lt;/span&gt; RSUs vested in June 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2024, the Company issued &lt;span id="xdx_90B_ecustom--RsuGranted_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Rsu granted"&gt;85,800&lt;/span&gt; RSUs to employees,
with a grant date fair value of $&lt;span id="xdx_90A_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Rsu granted, grant date fair value"&gt;4.74&lt;/span&gt; per share. The RSUs vested on the grant date. The Company delivered the vested portion of the RSU&#x2019;s
and issued &lt;span id="xdx_90B_ecustom--SharesIssuedOverVestingPeriod_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Shares issued over the vesting period"&gt;85,800&lt;/span&gt; shares of Common Stock, of which &lt;span id="xdx_908_eus-gaap--RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings_c20240601__20240630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Shares for tax withholdings"&gt;21,450&lt;/span&gt; shares were withheld in Treasury stock in exchange for payment of withholding
tax on behalf of the employees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table summarizes vesting of restricted
stock units:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zrLBdRIFCXO8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zC55HbHlC8ej" style="display: none"&gt;Schedule of vesting of restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;Unvested at June 30, 2022&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20220701__20230630_z3ZKAo78GOw7" style="width: 10%; text-align: right" title="Number of shares unvested at beginning"&gt;12,452&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220701__20230630_zxA1UuJE8s8e" style="width: 10%; text-align: right" title="Weighted average grant date fair value per share unvested at beginning"&gt;16.90&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630_pdd" style="text-align: right" title="Number of shares, Granted"&gt;68,711&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_zCIA6ZODyD7" style="text-align: right" title="Weighted average grant date fair value per share, Granted"&gt;58.87&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20220701__20230630_z4lrSnhJp953" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Vested"&gt;(21,518&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value per share, Vested"&gt;52.70&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20230701__20240630_z2tDKpwQiWM4" style="text-align: right" title="Number of shares unvested at beginning"&gt;59,646&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20240630_zkqNLQRgqHfb" style="text-align: right" title="Weighted average grant date fair value per share unvested at beginning"&gt;52.40&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20230701__20240630_zuN0yG7i20bj" style="text-align: right" title="Number of shares, Issued"&gt;104,070&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_iP3custom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630_zSFOWi8SKBfl" style="text-align: right" title="Weighted average grant date fair value per share, Issued"&gt;9.16&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20240630_zkIik14Oktj" style="text-align: right" title="Number of shares, Vested"&gt;(122,395&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" style="text-align: right" title="Weighted average grant date fair value per share, Vested"&gt;16.94&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Canceled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230701__20240630_zeUdZqg5kC4b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Canceled"&gt;(1,030&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value per share, Canceled"&gt;61.20&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 3.5pt"&gt;Unvested at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230701__20240630_ztxPtNap2pG3" style="border-bottom: Black 3.5pt double; text-align: right" title="Number of shares unvested at ending"&gt;40,291&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230701__20240630_zKNDqoCY15xh" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average grant date fair value per share unvested at ending"&gt;44.59&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zuUMjSIs6ua6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The total stock-based compensation expense from restricted
stock units for the year ended June 30, 2024 and 2023 was approximately $&lt;span id="xdx_900_ecustom--StockBasedCompensationRestrictedStockUnits_pn3n3_dm_c20230701__20240630_z5KTM1s3ZZBi" title="Stock based compensation - restricted stock units"&gt;1.8&lt;/span&gt; million and $&lt;span id="xdx_90A_ecustom--StockBasedCompensationRestrictedStockUnits_pn3n3_dm_c20220701__20230630_zAuEvnV1p2U6" title="Stock based compensation - restricted stock units"&gt;1.8&lt;/span&gt; million, respectively.&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Issuance of Common Stock through exercise of Stock Options and Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In December 2022, the Company issued &lt;span id="xdx_909_ecustom--IssuanceOfCommonStockForCashShares_c20221201__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares"&gt;2,209&lt;/span&gt; shares
of Common Stock pursuant to a cashless exercise of stock options to purchase &lt;span id="xdx_905_eus-gaap--StockRepurchasedDuringPeriodShares_c20221201__20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase"&gt;9,930 &lt;/span&gt;shares at an average exercise price of $&lt;span id="xdx_900_eus-gaap--SharePrice_c20221231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price"&gt;76.40&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In November 2022, the Company issued &lt;span id="xdx_907_ecustom--IssuanceOfCommonStockForCashShares_c20221101__20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares"&gt;80&lt;/span&gt; shares of
Common Stock pursuant to a cash exercise of stock options to purchase &lt;span id="xdx_906_eus-gaap--StockRepurchasedDuringPeriodShares_c20221101__20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase"&gt;80&lt;/span&gt; shares at an average exercise price of $&lt;span id="xdx_90E_eus-gaap--SharePrice_c20221130__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price"&gt;28.00&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In October 2022, the Company issued &lt;span id="xdx_903_ecustom--IssuanceOfCommonStockForCashShares_c20221001__20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Issuance of common stock for cash, shares"&gt;359&lt;/span&gt; shares of
Common Stock pursuant to a cashless exercise of warrants to purchase &lt;span id="xdx_903_eus-gaap--StockRepurchasedDuringPeriodShares_c20221001__20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Stock option to purchase"&gt;800&lt;/span&gt; shares at an average exercise price of $&lt;span id="xdx_90C_eus-gaap--SharePrice_c20221031__us-gaap--AwardTypeAxis__custom--WarrantsMember_pdd" title="Share price"&gt;22.50&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In May 2023, the Company issued &lt;span id="xdx_90F_ecustom--IssuanceOfCommonStockForCashShares_c20230501__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Issuance of common stock for cash, shares"&gt;48&lt;/span&gt; shares of Common
Stock pursuant to a cashless exercise of stock options to purchase &lt;span id="xdx_90F_eus-gaap--StockRepurchasedDuringPeriodShares_c20230501__20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Stock option to purchase"&gt;80&lt;/span&gt; shares at an average exercise price of $&lt;span id="xdx_905_eus-gaap--SharePrice_c20230531__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Share price"&gt;31.30&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Issuance of Stock Options under the 2019 Omnibus Plan.&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to a former employee&#x2019;s Separation Agreement,
dated April 11, 2022, the Company modified their stock option award granted on August 20, 2021, pursuant to the 2019 Omnibus Plan (&#x201c;2021
Options Grant&#x201d;). Pursuant to the terms of the Separation Agreement, effective July 8, 2022 (the &#x201c;Separation Date&#x201d;),
the Company accelerated the vesting of options scheduled to vest on the first and second anniversary of the grant date as deemed vested
(&#x201c;Accelerated Options&#x201d;) and after giving effect to the Accelerated Options, extended the exercise period of the total vested
outstanding and unexercised options (totaling 7,450 options) to one year following the Separation Date. The unvested portion of the 2021
Option Grant (totaling 4,967 options) was canceled. The modification was remeasured as of July 8, 2022, and the incremental difference
in fair value resulted in a net credit to stock based compensation expense of $181,154, due to the original exercise price of $77.40 being
greater than the stock price of $18.00 on the remeasurement date, and accordingly was recognized on July 8, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On June 7, 2023, the Company granted stock options
to purchase &lt;span id="xdx_90A_eus-gaap--StockRepurchasedDuringPeriodShares_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_pdd" title="Stock option to purchase"&gt;14,800&lt;/span&gt; shares of Common Stock to certain employees. &lt;span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage"&gt;20%&lt;/span&gt; of the shares underlying the options awarded vested on the grant date,
and the remaining &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage"&gt;80%&lt;/span&gt; will vest in four equal annual installments beginning, on the first grant date anniversary. The exercise price of
the options is $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240601__20240607__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--CertainEmployeesMember_pdd" title="Weighted average exercise price, options grants"&gt;57.80&lt;/span&gt; per share, the grant date fair value and the options terminate on the earlier of the tenth grant date anniversary
or the date of which the options are fully exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the fiscal year ended June 30, 2023, the Company
granted stock options to purchase a total of 28,617 shares of Common Stock in connection with compensation packages of three new employees.
The exercise prices were set at the grant date fair value with vesting terms over a five year period and the options terminate on the
earlier of tenth grant date anniversary or the date of which the options are fully exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On October 3, 2023, the Company granted stock options
to purchase &lt;span id="xdx_90B_eus-gaap--StockRepurchasedDuringPeriodShares_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_pdd" title="Stock option to purchase"&gt;21,117&lt;/span&gt; shares of Common Stock to new hire employees. &lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage"&gt;20%&lt;/span&gt; of the shares underlying the options awarded vest on the one-year
anniversary of the grant date, and the remaining &lt;span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage"&gt;80%&lt;/span&gt; will vest in equal monthly installments over 48 months each month thereafter. The
exercise price of the options is $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20231001__20231003__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember_pdd" title="Weighted average exercise price, options grants"&gt;34.10&lt;/span&gt;, the grant date fair value, and the options terminate on the earlier of the tenth grant date anniversary
or the date of which the options are fully exercised.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2024, the Company granted stock options to
purchase &lt;span id="xdx_90E_eus-gaap--StockRepurchasedDuringPeriodShares_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Stock option to purchase"&gt;115,800&lt;/span&gt; shares of Common Stock to employees. &lt;span id="xdx_901_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Awarded Vested rights, percentage"&gt;33%&lt;/span&gt; of the shares underlying the options awarded vest on the grant date, and the
remaining &lt;span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--NewEmployeeMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Awarded Vested rights, percentage"&gt;67%&lt;/span&gt; will vest over &lt;span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1_dtY_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_zEaDaznUB7S7" title="Weighted average contractual term, granted (in years)"&gt;2 &lt;/span&gt;years on first and second anniversary of the grant date. The exercise price of the options is $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20240601__20240630__us-gaap--DerivativeInstrumentRiskAxis__us-gaap--StockOptionMember__srt--TitleOfIndividualAxis__custom--EmployeesMember_pdd" title="Weighted average exercise price, options grants"&gt;4.70&lt;/span&gt;, the
grant date fair value, and the options terminate on the earlier of the tenth grant date anniversary or the date of which the options are
fully exercised.&lt;/p&gt;







&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Stock Warrants&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The following table summarizes the warrants activity during the years ended
June 30, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zTxLQfBk4QFf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zXcxLU8Mrww2" style="display: none"&gt;Summary of warrants activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Outstanding and exercisable at June 30, 2022&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFt3UdaFHjA7" style="width: 10%; text-align: right" title="Number of shares, beginning"&gt;51,037&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezeOitS5oye" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning"&gt;61.70&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4MlrRIkQenj" style="width: 10%; text-align: right" title="Weighted average remaining life (Years)"&gt;3.8&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS0ffXNfJew2" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted"&gt;727,273&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, granted"&gt;18.20&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6MduR83yFX6" style="text-align: right" title="Weighted average remaining life (Years), granted"&gt;5.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, expired"&gt;(482&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, expired"&gt;750.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, exercised"&gt;(800&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;22.50&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and exercisable at June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhqqbkU5vptj" style="text-align: right" title="Number of shares, beginning"&gt;777,029&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJE3Rq0QYL0h" style="text-align: right" title="Weighted average exercise price, beginning"&gt;20.60&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhG5LlwdbFaf" style="text-align: right" title="Weighted average remaining life (Years)"&gt;4.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeO5eZu6Onwk" style="text-align: right" title="Aggregate intrinsic value, beginning"&gt;18,318,954&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted"&gt;1,755,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, granted"&gt;13.14&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsjwHYw3163d" style="text-align: right" title="Weighted average remaining life (Years), granted"&gt;5.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, exercised"&gt;(600,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;10.00&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Outstanding and exercisable at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCdB34JCMxi8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, ending"&gt;1,932,029&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1WDknVwxva4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, ending"&gt;14.03&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8LHwB4BZkm7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average remaining life (Years)"&gt;4.0&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR0yUbLulZtk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A6_zJDt286aOWy8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Of the above warrants outstanding at June 30, 2024,
10,138 expire in the fiscal year ending June 30, 2025, 3,518 expire in the fiscal year ending June 30, 2026, 763,373 expire in the fiscal
year ending June 30, 2027 and 1,155,000 expire in the fiscal year ending June 30, 2029.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <bivi:IssuanceOfCommonStockForCashShares
      contextRef="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact000970"
      unitRef="Shares">333749</bivi:IssuanceOfCommonStockForCashShares>
    <bivi:IssuanceOfCommonStockForCash
      contextRef="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000972"
      unitRef="USD">9300000</bivi:IssuanceOfCommonStockForCash>
    <bivi:CommissionsPercentage
      contextRef="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact000974"
      unitRef="Pure">0.03</bivi:CommissionsPercentage>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2023-07-012024-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000976"
      unitRef="USD">377000</us-gaap:PaymentsOfStockIssuanceCosts>
    <bivi:IssuanceOfCommonStockForCashShares
      contextRef="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact000978"
      unitRef="Shares">753925</bivi:IssuanceOfCommonStockForCashShares>
    <bivi:IssuanceOfCommonStockForCash
      contextRef="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000980"
      unitRef="USD">49500000</bivi:IssuanceOfCommonStockForCash>
    <bivi:CommissionsPercentage
      contextRef="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember"
      decimals="INF"
      id="Fact000982"
      unitRef="Pure">0.03</bivi:CommissionsPercentage>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2022-07-012023-06-30_us-gaap_CommonClassAMember_custom_SalesAgreementMember"
      decimals="0"
      id="Fact000984"
      unitRef="USD">2000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering
      contextRef="From2024-03-012024-03-06"
      decimals="INF"
      id="Fact000986"
      unitRef="Shares">1500000</us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-03-06"
      decimals="INF"
      id="Fact000988"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-03-012024-03-06_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000990"
      unitRef="Shares">600000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-03-012024-03-06_custom_CommonWarrantMember"
      decimals="INF"
      id="Fact000992"
      unitRef="Shares">1050000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="AsOf2024-03-06"
      decimals="INF"
      id="Fact000994"
      unitRef="USDPShares">10.00</us-gaap:SharePrice>
    <bivi:StockExercised
      contextRef="From2023-07-012024-06-30_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact000996"
      unitRef="Shares">600000</bivi:StockExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2023-04-012023-04-06_custom_VendorMember"
      decimals="INF"
      id="Fact001000"
      unitRef="Shares">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2023-04-06_custom_VendorMember"
      decimals="INF"
      id="Fact001002"
      unitRef="USDPShares">74.50</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-04-012023-04-06_custom_VendorMember"
      decimals="0"
      id="Fact001004"
      unitRef="USD">372500</us-gaap:ShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2024-05-012024-05-10_custom_VendorMember"
      decimals="INF"
      id="Fact001006"
      unitRef="Shares">15000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:SharePrice
      contextRef="AsOf2024-05-10_custom_VendorMember"
      decimals="INF"
      id="Fact001008"
      unitRef="USDPShares">4.86</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensation
      contextRef="From2024-05-012024-05-10_custom_VendorMember"
      decimals="0"
      id="Fact001010"
      unitRef="USD">72900</us-gaap:ShareBasedCompensation>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001012">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY0PIa7Edy1a" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8BD_zyi9QO5BLXFj" style="display: none"&gt;Schedule of summarizes the activity relating to the Company&#x2019;s stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Remaining Average Contractual Term&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%"&gt;Outstanding at June 30, 2022&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ6IjrYM0PK9" style="width: 10%; text-align: right" title="Options outstanding at beginning"&gt;339,876&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2LEuzgLVgc4" style="width: 10%; text-align: right" title="Weighted average exercise price, Options outstanding at beginning"&gt;74.20&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zniHPECSvOCf" style="width: 10%; text-align: right" title="Weighted remaining average contractual term, beginning"&gt;5.5&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJIMoPDiXiJ" style="width: 10%; text-align: right" title="Aggregate intrinsic value, outstanding at beginning of period"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1020"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Options granted"&gt;71,467&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, granted"&gt;59.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zeuQ0zrcLVll" style="text-align: right" title="Weighted remaining average contractual term, granted"&gt;8.6&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--AggregateIntrinsicValueGranted_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pp0p0" style="text-align: right" title="Aggregate intrinsic value, granted"&gt;38,610&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zOM87jFIn4xc" style="text-align: right" title="Options expired"&gt;(1,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, expired"&gt;286.90&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options Canceled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zv5I3FpYfVmb" style="text-align: right" title="Options canceled"&gt;(4,967&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, canceled"&gt;77.40&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_ztPM0sj37AFk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options exercised"&gt;(10,090&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;81.20&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Outstanding at June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zUsCjdBEk1W8" style="text-align: right" title="Options outstanding at beginning"&gt;395,286&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4TQEKtO9GCi" style="text-align: right" title="Weighted average exercise price, options outstanding at beginning"&gt;71.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zTWfj23gEGsg" style="text-align: right" title="Weighted remaining average contractual term, beginning"&gt;6.3&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zacnml1ySyfj" style="text-align: right" title="Aggregate intrinsic value, outstanding at beginning"&gt;1,067,966&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Options granted"&gt;155,242&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, granted"&gt;11.70&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zAmwB4FxAfqd" style="text-align: right" title="Weighted remaining average contractual term, granted"&gt;9.8&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z8npO4KRiGsc" style="text-align: right" title="Options expired"&gt;(640&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="text-align: right" title="Weighted average exercise price, expired"&gt;46.09&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Options Canceled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z2FzqrTWIjs9" style="border-bottom: Black 1.5pt solid; text-align: right" title="Options canceled"&gt;(31,812&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, canceled"&gt;57.19&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 3.5pt"&gt;Outstanding at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zMmw4UMIeX61" style="border-bottom: Black 3.5pt double; text-align: right" title="Options outstanding at ending"&gt;518,076&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zZ7GNFLcHTX6" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average exercise price, options outstanding at ending"&gt;54.11&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zBrYJHdSj1B2" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted remaining average contractual term, ending"&gt;6.1&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zJUmTKoX9mMk" style="border-bottom: Black 3.5pt double; text-align: right" title="Aggregate intrinsic value, outstanding at ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1070"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 3.5pt"&gt;Exercisable at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 3.5pt double; text-align: right" title="Options exercisable"&gt;296,934&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_c20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average exercise price, options exercisable"&gt;66.65&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_z4EOjftFLtG8" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average remaining contractual term, options exercisable"&gt;4.9&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2022-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001014"
      unitRef="Shares">339876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001016"
      unitRef="USDPShares">74.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      id="Fact001018">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001022"
      unitRef="Shares">71467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001024"
      unitRef="USDPShares">59.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      id="Fact001026">P8Y7M6D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <bivi:AggregateIntrinsicValueGranted
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="0"
      id="Fact001028"
      unitRef="USD">38610</bivi:AggregateIntrinsicValueGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001030"
      unitRef="Shares">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001032"
      unitRef="USDPShares">286.90</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001034"
      unitRef="Shares">4967</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001036"
      unitRef="USDPShares">77.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001038"
      unitRef="Shares">10090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001040"
      unitRef="USDPShares">81.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001042"
      unitRef="Shares">395286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001044"
      unitRef="USDPShares">71.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      id="Fact001046">P6Y3M18D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-06-30_custom_StockOptionsMember"
      decimals="0"
      id="Fact001048"
      unitRef="USD">1067966</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001050"
      unitRef="Shares">155242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001052"
      unitRef="USDPShares">11.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      id="Fact001054">P9Y9M18D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001056"
      unitRef="Shares">640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001058"
      unitRef="USDPShares">46.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001060"
      unitRef="Shares">31812</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001062"
      unitRef="USDPShares">57.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001064"
      unitRef="Shares">518076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001066"
      unitRef="USDPShares">54.11</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      id="Fact001068">P6Y1M6D</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001072"
      unitRef="Shares">296934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001074"
      unitRef="USDPShares">66.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      id="Fact001076">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001078">&lt;table border="0" cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_z2KR87Z44i4f" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse" summary="xdx: Disclosure - Equity Transactions (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;&lt;span id="xdx_8B8_zxtZOoPchiGa" style="display: none"&gt;Schedule of assumptions used&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; width: 48%; font-size: 10pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"&gt;&lt;b&gt;June 30, 2024&lt;/b&gt;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; white-space: nowrap; width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; white-space: nowrap; width: 24%; font-size: 10pt; text-align: center"&gt;&lt;b&gt;June 30, 2023&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;Expected life of options (in years)&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zCpnCMzVDOij" title="Expected life of options (In years)"&gt;6&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_zL9h2R6UTHG2" title="Expected life of options (In years)"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility"&gt;86.28%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Expected volatility"&gt;81.65%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;Risk free interest rate&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;4.40%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Risk free interest rate"&gt;3.82%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt"&gt;Dividend Yield&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20230701__20240630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield"&gt;0%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; font-size: 10pt; text-align: center"&gt;&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_c20220701__20230630__us-gaap--DerivativeInstrumentRiskAxis__custom--StockOptionsMember_pdd" title="Dividend Yield"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      id="Fact001080">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      id="Fact001082">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001084"
      unitRef="Pure">0.8628</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001086"
      unitRef="Pure">0.8165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001088"
      unitRef="Pure">0.0440</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001090"
      unitRef="Pure">0.0382</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001092"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="INF"
      id="Fact001094"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensation
      contextRef="From2023-07-012024-06-30_custom_StockOptionsMember"
      decimals="0"
      id="Fact001096"
      unitRef="USD">2800000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-07-012023-06-30_custom_StockOptionsMember"
      decimals="0"
      id="Fact001098"
      unitRef="USD">4200000</us-gaap:ShareBasedCompensation>
    <bivi:RsuGranted
      contextRef="From2022-06-012022-06-21_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001100"
      unitRef="Shares">12452</bivi:RsuGranted>
    <bivi:RsuGranted
      contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001102"
      unitRef="Shares">4151</bivi:RsuGranted>
    <bivi:RsuGranted
      contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001104"
      unitRef="Shares">4151</bivi:RsuGranted>
    <bivi:RsuGranted
      contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001106"
      unitRef="Shares">38198</bivi:RsuGranted>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1
      contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001108"
      unitRef="USDPShares">61.20</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1>
    <bivi:SharesIssuedOverVestingPeriod
      contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001110"
      unitRef="Shares">9550</bivi:SharesIssuedOverVestingPeriod>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2022-07-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001112"
      unitRef="Shares">2288</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <bivi:RsuGranted
      contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorsMember"
      decimals="INF"
      id="Fact001116"
      unitRef="Shares">15564</bivi:RsuGranted>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1
      contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorsMember"
      decimals="INF"
      id="Fact001118"
      unitRef="USDPShares">61.20</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1>
    <bivi:RsuGranted
      contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_ThreeDirectorsMember"
      decimals="INF"
      id="Fact001120"
      unitRef="Shares">19500</bivi:RsuGranted>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1
      contextRef="From2022-11-012022-11-23_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_ThreeDirectorsMember"
      decimals="INF"
      id="Fact001122"
      unitRef="USDPShares">61.20</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1>
    <bivi:TotalCompensationCost
      contextRef="AsOf2022-11-23"
      decimals="0"
      id="Fact001124"
      unitRef="USD">1744192</bivi:TotalCompensationCost>
    <bivi:RsuGranted
      contextRef="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember"
      decimals="INF"
      id="Fact001126"
      unitRef="Shares">18270</bivi:RsuGranted>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1
      contextRef="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember"
      decimals="INF"
      id="Fact001128"
      unitRef="USDPShares">30.10</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1>
    <bivi:RsuGranted
      contextRef="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_TwoDirectorsMember"
      decimals="INF"
      id="Fact001130"
      unitRef="Shares">18325</bivi:RsuGranted>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1
      contextRef="From2023-11-012023-11-09_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_TwoDirectorsMember"
      decimals="INF"
      id="Fact001132"
      unitRef="USDPShares">30.10</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1>
    <bivi:SharesIssuedOverVestingPeriod
      contextRef="From2023-07-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_FourDirectorMember"
      decimals="INF"
      id="Fact001134"
      unitRef="Shares">4568</bivi:SharesIssuedOverVestingPeriod>
    <bivi:RsuGranted
      contextRef="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001136"
      unitRef="Shares">14950</bivi:RsuGranted>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1
      contextRef="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001138"
      unitRef="USDPShares">41.10</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1>
    <bivi:SharesIssuedOverVestingPeriod
      contextRef="From2023-06-012023-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_N2019OmnibusIncentiveEquityPlanMember_custom_PresidentAndCEOMember"
      decimals="INF"
      id="Fact001140"
      unitRef="Shares">4983</bivi:SharesIssuedOverVestingPeriod>
    <bivi:RsuGranted
      contextRef="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact001142"
      unitRef="Shares">85800</bivi:RsuGranted>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1
      contextRef="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact001144"
      unitRef="USDPShares">4.74</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExcersiedIntrinsicValue1>
    <bivi:SharesIssuedOverVestingPeriod
      contextRef="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact001146"
      unitRef="Shares">85800</bivi:SharesIssuedOverVestingPeriod>
    <us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
      contextRef="From2024-06-012024-06-30_us-gaap_RestrictedStockUnitsRSUMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact001148"
      unitRef="Shares">21450</us-gaap:RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001150">&lt;table cellpadding="0" cellspacing="0" id="xdx_89A_eus-gaap--ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_zrLBdRIFCXO8" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8B2_zC55HbHlC8ej" style="display: none"&gt;Schedule of vesting of restricted common stock&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Grant Date Fair Value Per Share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%"&gt;Unvested at June 30, 2022&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20220701__20230630_z3ZKAo78GOw7" style="width: 10%; text-align: right" title="Number of shares unvested at beginning"&gt;12,452&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20220701__20230630_zxA1UuJE8s8e" style="width: 10%; text-align: right" title="Weighted average grant date fair value per share unvested at beginning"&gt;16.90&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220701__20230630_pdd" style="text-align: right" title="Number of shares, Granted"&gt;68,711&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_zCIA6ZODyD7" style="text-align: right" title="Weighted average grant date fair value per share, Granted"&gt;58.87&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Vested&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20220701__20230630_z4lrSnhJp953" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Vested"&gt;(21,518&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value per share, Vested"&gt;52.70&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Unvested at June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iS_c20230701__20240630_z2tDKpwQiWM4" style="text-align: right" title="Number of shares unvested at beginning"&gt;59,646&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20230701__20240630_zkqNLQRgqHfb" style="text-align: right" title="Weighted average grant date fair value per share unvested at beginning"&gt;52.40&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_iP3us-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c20230701__20240630_zuN0yG7i20bj" style="text-align: right" title="Number of shares, Issued"&gt;104,070&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_iP3custom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630_zSFOWi8SKBfl" style="text-align: right" title="Weighted average grant date fair value per share, Issued"&gt;9.16&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_iN_di_c20230701__20240630_zkIik14Oktj" style="text-align: right" title="Number of shares, Vested"&gt;(122,395&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" style="text-align: right" title="Weighted average grant date fair value per share, Vested"&gt;16.94&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Canceled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_iN_di_c20230701__20240630_zeUdZqg5kC4b" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, Canceled"&gt;(1,030&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c20230701__20240630_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average grant date fair value per share, Canceled"&gt;61.20&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 3.5pt"&gt;Unvested at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20230701__20240630_ztxPtNap2pG3" style="border-bottom: Black 3.5pt double; text-align: right" title="Number of shares unvested at ending"&gt;40,291&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20230701__20240630_zKNDqoCY15xh" style="border-bottom: Black 3.5pt double; text-align: right" title="Weighted average grant date fair value per share unvested at ending"&gt;44.59&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2022-06-30"
      decimals="INF"
      id="Fact001152"
      unitRef="Shares">12452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2022-06-30"
      decimals="INF"
      id="Fact001154"
      unitRef="USDPShares">16.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact001156"
      unitRef="Shares">68711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact001158"
      unitRef="USDPShares">58.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact001160"
      unitRef="Shares">21518</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact001162"
      unitRef="USDPShares">52.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact001164"
      unitRef="Shares">59646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact001166"
      unitRef="USDPShares">52.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001168"
      unitRef="Shares">104070</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001170"
      unitRef="USDPShares">9.16</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001172"
      unitRef="Shares">122395</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001174"
      unitRef="USDPShares">16.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001176"
      unitRef="Shares">1030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001178"
      unitRef="USDPShares">61.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001180"
      unitRef="Shares">40291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001182"
      unitRef="USDPShares">44.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <bivi:StockBasedCompensationRestrictedStockUnits
      contextRef="From2023-07-01to2024-06-30"
      decimals="-3"
      id="Fact001185"
      unitRef="USD">1800000</bivi:StockBasedCompensationRestrictedStockUnits>
    <bivi:StockBasedCompensationRestrictedStockUnits
      contextRef="From2022-07-012023-06-30"
      decimals="-3"
      id="Fact001187"
      unitRef="USD">1800000</bivi:StockBasedCompensationRestrictedStockUnits>
    <bivi:IssuanceOfCommonStockForCashShares
      contextRef="From2022-12-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001189"
      unitRef="Shares">2209</bivi:IssuanceOfCommonStockForCashShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-12-012022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001191"
      unitRef="Shares">9930</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="AsOf2022-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001193"
      unitRef="USDPShares">76.40</us-gaap:SharePrice>
    <bivi:IssuanceOfCommonStockForCashShares
      contextRef="From2022-11-012022-11-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001195"
      unitRef="Shares">80</bivi:IssuanceOfCommonStockForCashShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-11-012022-11-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001197"
      unitRef="Shares">80</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="AsOf2022-11-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001199"
      unitRef="USDPShares">28.00</us-gaap:SharePrice>
    <bivi:IssuanceOfCommonStockForCashShares
      contextRef="From2022-10-012022-10-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact001201"
      unitRef="Shares">359</bivi:IssuanceOfCommonStockForCashShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2022-10-012022-10-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact001203"
      unitRef="Shares">800</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="AsOf2022-10-31_custom_WarrantsMember"
      decimals="INF"
      id="Fact001205"
      unitRef="USDPShares">22.50</us-gaap:SharePrice>
    <bivi:IssuanceOfCommonStockForCashShares
      contextRef="From2023-05-012023-05-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001207"
      unitRef="Shares">48</bivi:IssuanceOfCommonStockForCashShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2023-05-012023-05-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001209"
      unitRef="Shares">80</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharePrice
      contextRef="AsOf2023-05-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      id="Fact001211"
      unitRef="USDPShares">31.30</us-gaap:SharePrice>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_CertainEmployeesMember"
      decimals="INF"
      id="Fact001213"
      unitRef="Shares">14800</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001215"
      unitRef="Pure">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001217"
      unitRef="Pure">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-06-012024-06-07_us-gaap_StockOptionMember_custom_CertainEmployeesMember"
      decimals="INF"
      id="Fact001219"
      unitRef="USDPShares">57.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember"
      decimals="INF"
      id="Fact001221"
      unitRef="Shares">21117</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001223"
      unitRef="Pure">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001225"
      unitRef="Pure">0.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-10-012023-10-03_us-gaap_StockOptionMember_custom_NewEmployeeMember"
      decimals="INF"
      id="Fact001227"
      unitRef="USDPShares">34.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact001229"
      unitRef="Shares">115800</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MinimumMember"
      decimals="INF"
      id="Fact001231"
      unitRef="Pure">0.33</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_NewEmployeeMember_srt_MaximumMember"
      decimals="INF"
      id="Fact001233"
      unitRef="Pure">0.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1
      contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_EmployeesMember"
      id="Fact001235">P2Y</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantedContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2024-06-012024-06-30_us-gaap_StockOptionMember_custom_EmployeesMember"
      decimals="INF"
      id="Fact001237"
      unitRef="USDPShares">4.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001241">&lt;table cellpadding="0" cellspacing="0" id="xdx_891_eus-gaap--ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_zTxLQfBk4QFf" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Equity Transactions (Details 3)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span id="xdx_8BE_zXcxLU8Mrww2" style="display: none"&gt;Summary of warrants activity&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Exercise Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted Average Remaining Life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Aggregate Intrinsic Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; text-align: left"&gt;Outstanding and exercisable at June 30, 2022&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFt3UdaFHjA7" style="width: 10%; text-align: right" title="Number of shares, beginning"&gt;51,037&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezeOitS5oye" style="width: 10%; text-align: right" title="Weighted average exercise price, beginning"&gt;61.70&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z4MlrRIkQenj" style="width: 10%; text-align: right" title="Weighted average remaining life (Years)"&gt;3.8&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zS0ffXNfJew2" style="width: 10%; text-align: right" title="Aggregate intrinsic value, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1249"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted"&gt;727,273&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, granted"&gt;18.20&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6MduR83yFX6" style="text-align: right" title="Weighted average remaining life (Years), granted"&gt;5.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, expired"&gt;(482&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, expired"&gt;750.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, exercised"&gt;(800&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20220701__20230630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;22.50&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Outstanding and exercisable at June 30, 2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhqqbkU5vptj" style="text-align: right" title="Number of shares, beginning"&gt;777,029&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iS_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJE3Rq0QYL0h" style="text-align: right" title="Weighted average exercise price, beginning"&gt;20.60&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhG5LlwdbFaf" style="text-align: right" title="Weighted average remaining life (Years)"&gt;4.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iS_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeO5eZu6Onwk" style="text-align: right" title="Aggregate intrinsic value, beginning"&gt;18,318,954&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Number of shares, granted"&gt;1,755,000&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Weighted average exercise price, granted"&gt;13.14&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zsjwHYw3163d" style="text-align: right" title="Weighted average remaining life (Years), granted"&gt;5.0&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Exercised&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, exercised"&gt;(600,000&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, exercised"&gt;10.00&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;-&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Outstanding and exercisable at June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCdB34JCMxi8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of shares, ending"&gt;1,932,029&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_iE_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z1WDknVwxva4" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average exercise price, ending"&gt;14.03&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_dtY_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8LHwB4BZkm7" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted average remaining life (Years)"&gt;4.0&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iE_pp0p0_c20230701__20240630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zR0yUbLulZtk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Aggregate intrinsic value, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1289"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2022-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001243"
      unitRef="Shares">51037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="AsOf2022-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001245"
      unitRef="USDPShares">61.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031"
      id="Fact001247">P3Y9M18D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031"
      decimals="INF"
      id="Fact001251"
      unitRef="Shares">727273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031"
      decimals="INF"
      id="Fact001253"
      unitRef="USDPShares">18.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031"
      id="Fact001255">P5Y</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031"
      decimals="INF"
      id="Fact001257"
      unitRef="Shares">-482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031"
      decimals="INF"
      id="Fact001259"
      unitRef="USDPShares">750.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031"
      decimals="INF"
      id="Fact001261"
      unitRef="Shares">-800</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2022-07-012023-06-30_us-gaap_WarrantMember53646031"
      decimals="INF"
      id="Fact001263"
      unitRef="USDPShares">22.50</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001265"
      unitRef="Shares">777029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001267"
      unitRef="USDPShares">20.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062"
      id="Fact001269">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2023-06-30_us-gaap_WarrantMember"
      decimals="0"
      id="Fact001271"
      unitRef="USD">18318954</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062"
      decimals="INF"
      id="Fact001273"
      unitRef="Shares">1755000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062"
      decimals="INF"
      id="Fact001275"
      unitRef="USDPShares">13.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
      contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062"
      id="Fact001277">P5Y</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm>
    <bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares
      contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062"
      decimals="INF"
      id="Fact001279"
      unitRef="Shares">-600000</bivi:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsIssuedNumberOfShares>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062"
      decimals="INF"
      id="Fact001281"
      unitRef="USDPShares">10.00</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001283"
      unitRef="Shares">1932029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="AsOf2024-06-30_us-gaap_WarrantMember"
      decimals="INF"
      id="Fact001285"
      unitRef="USDPShares">14.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1
      contextRef="From2023-07-012024-06-30_us-gaap_WarrantMember53646062"
      id="Fact001287">P4Y</bivi:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001291">&lt;p id="xdx_800_eus-gaap--LesseeOperatingLeasesTextBlock_z4gKA1pzvARi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 5%; text-align: left"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; width: 95%"&gt;&lt;b&gt;&lt;span id="xdx_821_znv0a0RRpg31"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Office Leases&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company pays an annual rent of $2,200 for its
headquarters at 680 W Nye Lane, Suite 201, Carson City Nevada 89703. The rental agreement was for a one-year term, commenced on October
1, 2022 and has been subsequently renewed for another year at the same rate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s San Diego office lease at 5090
Shoreham Place Suite 212, San Diego, CA 92122 which commenced on March 1, 2022, was for a term of 38 months with a base monthly rate of
$4,300, and annual increases of three percent. In February 2024, the Company amended the lease agreement which allowed the Company to
vacate the then current space and move to a larger space at Suite 206. The current monthly base rate for the new office space is $9,685,
with an annual increase of four percent. The term for the new office lease is 60 months and commenced on February 12, 2024. The lease
that was in place for the 5090 Shoreham Place Suite 212 office was effectively extinguished upon the commencement of the new office space
lease on February 12, 2024, resulting in the write off of the corresponding remaining right-of-use asset and operating lease liability
of $&lt;span id="xdx_903_eus-gaap--OperatingLeaseRightOfUseAsset_c20240212_pp0p0" title="Right-of-use Asset"&gt;56,909&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--OperatingLeaseLiability_c20240212_pp0p0" title="Operating Lease Liability"&gt;62,124&lt;/span&gt;, respectively, and a gain to selling, general and administrative expenses of $&lt;span id="xdx_908_eus-gaap--OtherSellingGeneralAndAdministrativeExpense_c20230701__20240630_pp0p0" title="Selling, general and administrative expenses"&gt;5,215&lt;/span&gt; for the year ended June 30,
2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Total operating lease expense for the years ended
June 30, 2024 and 2023 of approximately $&lt;span id="xdx_900_eus-gaap--OperatingLeaseCost_c20230701__20240630_pp0p0" title="Operating lease cost"&gt;78,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OperatingLeaseCost_c20220701__20230630_pp0p0" title="Operating lease cost"&gt;52,000&lt;/span&gt;, respectively were included in the accompanying statements of operations and
comprehensive loss as a component of selling, general and administrative expenses.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The right-of-use asset, net and current and non-current
portion of the operating lease liabilities included in the accompanying balance sheets are as follows:&lt;/p&gt;










&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zK0mHEbrKgPk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span id="xdx_8BE_zfGb1g5Gxjca" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240630_zzJ7squRbxUd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20230630_zdOKjRFMiaj4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-left: 9pt"&gt;Operating lease, right-of-use asset, net&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;406,726&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;80,789&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzaZ2_zvpYfD8gWgH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Current portion of operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;60,343&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;44,909&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzaZ2_zrVGBZuBz8Q9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;349,894&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,505&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzaZ2_zbGaMu8tGe2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;410,237&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;87,414&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A0_zqGo0In8Uesk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At June 30, 2024, the future estimated minimum lease payments under non-cancelable
operating leases are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_zjAniu6OFTM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&lt;span id="xdx_8BB_zjR5t82sClE8" style="display: none"&gt;Schedule of future estimated minimum lease payments
under non-cancelable operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240630_ztH27BtOyWHk" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zqZ2B95jdEpg" style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;Year ending June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_z4Qw1VBlo9X1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;117,915&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zHcktjtcrraj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,042&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zGrtVgFrWpw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,313&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_zC0ZhKUiCrDi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130,734&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_zHDJjQ95KTtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,796&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_zlw86PDVV9oi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;574,800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zCTd8MmOeJKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(164,563&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zphvj0jiWCak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410,237&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_znbDQIyLJHmf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less current portion of operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60,343&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zmcpWkaywI88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;349,894&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zZTUpyEQNv8i" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Total cash paid for amounts included in the measurement of lease liabilities
were $&lt;span id="xdx_902_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20230701__20240630_pp0p0" title="Cash paid for amounts included in measurement of operating lease liabilities"&gt;83,910&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities_c20220701__20230630_pp0p0" title="Cash paid for amounts included in measurement of operating lease liabilities"&gt;50,600&lt;/span&gt; for the years ended June 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average remaining lease term and discount
rate as of June 30, 2024 and 2023 were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zLzLUdGsL4C" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8B0_zxPSCX2JvfVj" style="display: none"&gt;Schedule of weighted average remaining lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average remaining lease term (Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-left: 9pt"&gt;Operating lease&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zkd3G27WweUa" style="width: 12%; text-align: right" title="Weighted average remaining lease term (Years) Operating leases"&gt;4.6&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630_zfttVefLI08j" style="width: 12%; text-align: right" title="Weighted average remaining lease term (Years) Operating leases"&gt;1.8&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Operating lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zOCoMOiyaRXe" style="text-align: right" title="Weighted average discount rate Operating leases"&gt;15.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630_zxig8joGQCI7" style="text-align: right" title="Weighted average discount rate Operating leases"&gt;10.75&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zTnRyaO6nrv" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-02-12"
      decimals="0"
      id="Fact001293"
      unitRef="USD">56909</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-02-12"
      decimals="0"
      id="Fact001295"
      unitRef="USD">62124</us-gaap:OperatingLeaseLiability>
    <us-gaap:OtherSellingGeneralAndAdministrativeExpense
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001297"
      unitRef="USD">5215</us-gaap:OtherSellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingLeaseCost
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001299"
      unitRef="USD">78000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001301"
      unitRef="USD">52000</us-gaap:OperatingLeaseCost>
    <bivi:LesseeOperatingLeaseLiabilityTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001306">&lt;table cellpadding="0" cellspacing="0" id="xdx_89C_ecustom--LesseeOperatingLeaseLiabilityTableTextBlock_zK0mHEbrKgPk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;&lt;span id="xdx_8BE_zfGb1g5Gxjca" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20240630_zzJ7squRbxUd" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_493_20230630_zdOKjRFMiaj4" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-decoration: underline; font-weight: bold"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-left: 9pt"&gt;Operating lease, right-of-use asset, net&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;406,726&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;80,789&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-decoration: underline; font-weight: bold"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_maOLLzaZ2_zvpYfD8gWgH5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Current portion of operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;60,343&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;44,909&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_maOLLzaZ2_zrVGBZuBz8Q9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;349,894&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;42,505&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--OperatingLeaseLiability_iTI_pp0p0_mtOLLzaZ2_zbGaMu8tGe2i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt; padding-left: 9pt"&gt;Total operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;410,237&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;87,414&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</bivi:LesseeOperatingLeaseLiabilityTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001308"
      unitRef="USD">406726</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001309"
      unitRef="USD">80789</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001311"
      unitRef="USD">60343</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001312"
      unitRef="USD">44909</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001314"
      unitRef="USD">349894</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001315"
      unitRef="USD">42505</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001317"
      unitRef="USD">410237</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001318"
      unitRef="USD">87414</us-gaap:OperatingLeaseLiability>
    <bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases contextRef="From2023-07-01to2024-06-30" id="Fact001320">&lt;table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases_zjAniu6OFTM2" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;&lt;span id="xdx_8BB_zjR5t82sClE8" style="display: none"&gt;Schedule of future estimated minimum lease payments
under non-cancelable operating leases&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20240630_ztH27BtOyWHk" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_zqZ2B95jdEpg" style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left; white-space: nowrap"&gt;Year ending June 30,&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_z4Qw1VBlo9X1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: left"&gt;2025&lt;/td&gt;&lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;117,915&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_zHcktjtcrraj" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;122,042&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_pp0p0_zGrtVgFrWpw8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;2027&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,313&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_pp0p0_zC0ZhKUiCrDi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2028&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;130,734&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_pp0p0_zHDJjQ95KTtk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2029&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,796&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iI_pp0p0_zlw86PDVV9oi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;574,800&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_zCTd8MmOeJKj" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(164,563&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiability_iI_pp0p0_zphvj0jiWCak" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;410,237&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_pp0p0_di_znbDQIyLJHmf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less current portion of operating lease liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60,343&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zmcpWkaywI88" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Operating lease liability, net of current portion&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;349,894&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</bivi:ScheduleOfFutureEstimatedMinimumLeasePaymentsUnderNonCancelableOperatingLeases>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001324"
      unitRef="USD">117915</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001326"
      unitRef="USD">122042</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001328"
      unitRef="USD">126313</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001330"
      unitRef="USD">130734</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001332"
      unitRef="USD">77796</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001334"
      unitRef="USD">574800</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001336"
      unitRef="USD">164563</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001338"
      unitRef="USD">410237</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001340"
      unitRef="USD">60343</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001342"
      unitRef="USD">349894</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <bivi:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001344"
      unitRef="USD">83910</bivi:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities>
    <bivi:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001346"
      unitRef="USD">50600</bivi:CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities>
    <bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001348">&lt;table cellpadding="0" cellspacing="0" id="xdx_89E_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock_zLzLUdGsL4C" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Leases (Details 2)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8B0_zxPSCX2JvfVj" style="display: none"&gt;Schedule of weighted average remaining lease term and discount rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Weighted average remaining lease term (Years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-left: 9pt"&gt;Operating lease&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20240630_zkd3G27WweUa" style="width: 12%; text-align: right" title="Weighted average remaining lease term (Years) Operating leases"&gt;4.6&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20230630_zfttVefLI08j" style="width: 12%; text-align: right" title="Weighted average remaining lease term (Years) Operating leases"&gt;1.8&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 9pt"&gt;Operating lease&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20240630_zOCoMOiyaRXe" style="text-align: right" title="Weighted average discount rate Operating leases"&gt;15.00&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_c20230630_zxig8joGQCI7" style="text-align: right" title="Weighted average discount rate Operating leases"&gt;10.75&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</bivi:ScheduleOfWeightedAverageRemainingLeaseTermAndDiscountRateTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2024-06-30" id="Fact001350">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2023-06-30" id="Fact001352">P1Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2024-06-30"
      decimals="INF"
      id="Fact001354"
      unitRef="Pure">0.1500</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="AsOf2023-06-30"
      decimals="INF"
      id="Fact001356"
      unitRef="Pure">0.1075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001358">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zOdRkpzwL0e1" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_827_z8OY9MklOqL2"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Royalty Agreements&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Agreement and Plan of Merger entered
into on April 11, 2016, by and between our predecessor entities, LAT Pharma and NanoAntibiotics, Inc., the Company is obligated to pay
a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared by the members of LAT Pharma Members,
PharmaIn Corporation, and The Barrett Edge, Inc.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Pursuant to the Technology Transfer Agreement entered
into on July 25, 2016, by and between the Company and the University of Padova (Italy), the Company is obligated to pay a low single digit
royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum
of $200,000 per year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;Shareholder class action complaint&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 19, 2024, a purported shareholder class action complaint,
captioned&#160;&lt;i&gt;Eric Olmstead v. BioVie Inc. et al.&lt;/i&gt;, No. 3:24-cv-00035, was filed in the U.S. District Court for the District of
Nevada, naming the Company and certain of its officers as defendants. On February 22, 2024, a second, related putative securities class
action was filed in the same court asserting similar claims against the same defendants, captioned &lt;i&gt;Way v. BioVie Inc. et al.&lt;/i&gt;, No.
2:24-cv-00361. On April 15, 2024, the court consolidated these two actions under the caption &lt;i&gt;In re BioVie Inc. Securities Litigation&lt;/i&gt;,
No. 3:24-cv-00035, appointed the lead plaintiff, and approved selection of the lead counsel. On June 21, 2024, the lead plaintiff filed
an amended complaint, alleging that the defendants made material misrepresentations and/or omissions of material fact relating to the
Company&#x2019;s business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of
bezisterim (NE3107) in mild to moderate probable AD,&#160;&lt;span style="background-color: white"&gt;in violation of Sections 10(b) and 20(a)
of the&#160; Exchange Act, and&#160;Rule 10b-5&#160;promulgated thereunder. The class action is on behalf of purchasers of the Company&#x2019;s
securities during the period from December 7, 2022 through November 28, 2023 and seeks unspecified monetary damages on behalf of the putative
class and an award of costs and expenses, including attorney&#x2019;s fees. The defendants filed a motion to dismiss the amended complaint
on August 21, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company believes the lawsuit is without merit
and intends to defend the case vigorously. At this early stage of the proceedings, the Company is unable to make any prediction regarding
the outcome of the litigation. No adjustment or accruals have been reflected in the accompanying financial statements.&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <bivi:EmployeeBenefitPlanTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001360">&lt;p id="xdx_807_ecustom--EmployeeBenefitPlanTextBlock_zGZxSFtZCZ2j" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_82D_zLAjPhzflXqh"&gt;Employee Benefit Plan&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 1, 2021, the Company began sponsoring an
employee benefit plan subject to Section 401(K) of the Internal Revenue Service Code (the &#x201c;401K Plan&#x201d;) pursuant to which,
all employees meeting eligibility requirements are able to participate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Subject to certain limitations in the Internal Revenue Code, eligible employees
are permitted to make contributions to the 401K Plan on a pre-tax salary reduction basis and the Company will match 5% of the first 5%
of an employee&#x2019;s contributions to the 401K Plan. The Company made contributions into the plan of approximately $&lt;span id="xdx_903_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20230701__20240630_pp0p0" title="Defined benefit plan, plan assets, contributions by employer"&gt;153,200&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--DefinedBenefitPlanContributionsByEmployer_c20220701__20230630_pp0p0" title="Defined benefit plan, plan assets, contributions by employer"&gt;171,900&lt;/span&gt;,
for the years ended June 30, 2024 and 2023, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;





</bivi:EmployeeBenefitPlanTextBlock>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001362"
      unitRef="USD">153200</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="From2022-07-012023-06-30"
      decimals="0"
      id="Fact001364"
      unitRef="USD">171900</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001366">&lt;p id="xdx_80F_eus-gaap--IncomeTaxDisclosureTextBlock_z4N8PjsQUVik" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_828_zGs5FBxm8q4b"&gt;Income Taxes&lt;/span&gt; &lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Significant components of the Company&#x2019;s deferred tax assets (liabilities)
are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTJXLAdEWMl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_za50uHnoA4Q1" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20240630_zWePO7pGDJld" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20230630_zQ70IyjVtpn7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0p0_maDTANzRXI_zPq7iRYtFpkc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Tax loss carryforward&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;51,429,074&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;48,080,664&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pp0p0_maDTANzRXI_zDpzXAwXpk3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;(114,161&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(189,854&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTANzRXI_zxuHC2mnaSAk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,860,272&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,575,852&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTANzRXI_z8nmJRJah3Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D capitalized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,467,969&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,171,276&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzRXI_zPKEQEoQ3QMd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,643,154&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60,637,938&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzRXI_zH8YMZ7CdXEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1388"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zhDwX9DMosy3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;At June 30, 2024 and 2023, the Company has recorded a full valuation
against its net deferred tax assets of approximately $&lt;span id="xdx_90D_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0n3_dm_c20240630_znkIDB2w2fzi"&gt;69.6 &lt;/span&gt;million
and $&lt;span id="xdx_908_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pp0n3_dm_c20230630_zvALIByr1F3g"&gt;60.6 &lt;/span&gt;million,
respectively, since in the judgement of management, these assets are not more than likely to be realized. The increase in the
valuation allowance during the year ended June 30, 2024 was approximately $&lt;span id="xdx_90B_eus-gaap--ValuationAllowanceDeferredTaxAssetChangeInAmount_pp0n3_dm_c20230701__20240630_zJw54XjfI9r9"&gt;9.0 &lt;/span&gt;million.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At June 30, 2024, the Company had a Net Operating
Loss (&#x201c;NOL&#x201d;) carryforward of approximately $&lt;span id="xdx_908_eus-gaap--OperatingLossCarryforwards_iI_pp0n3_dm_c20240630_zfCD5CBcdSLb" title="Net Operating Loss carryforward"&gt;184&lt;/span&gt; million. NOL&#x2019;s generated prior to 2018 have expiration dates ranging
from &lt;span id="xdx_90D_ecustom--ExpirationsDates_c20230701__20240630" title="Expirations dates"&gt;2032 to 2037&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has no current tax expense due to its net losses and a full
valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Reconciliation of the differences between income tax
benefit computed at the federal and state statutory tax rates and the provision for income tax benefit for the years ended June 30, 2024
and 2023 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCYnObkGJGza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8B1_zYNz8P5C7rqe" style="display: none"&gt;Schedule of effective income tax rate reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230701__20240630_zk1mL1B9jQt2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220701__20230630_zWwzEFvfLif2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zqiRUeC8q535" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Income tax expense at federal statutory rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zoVUd8Dkb00d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zmTGy9d4mR3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z1RlQ5vwLO89" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1409"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1410"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001368">&lt;table cellpadding="0" cellspacing="0" id="xdx_899_eus-gaap--ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_zQTJXLAdEWMl" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details)"&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span id="xdx_8B0_za50uHnoA4Q1" style="display: none"&gt;Schedule of deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_497_20240630_zWePO7pGDJld" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_492_20230630_zQ70IyjVtpn7" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Deferred tax assets (liabilities):&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--DeferredTaxAssetsCapitalLossCarryforwards_i01I_pp0p0_maDTANzRXI_zPq7iRYtFpkc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Tax loss carryforward&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;51,429,074&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;48,080,664&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--DeferredTaxAssetsGoodwillAndIntangibleAssets_i01I_pp0p0_maDTANzRXI_zDpzXAwXpk3c" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Intangible assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;(114,161&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(189,854&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_i01I_pp0p0_maDTANzRXI_zxuHC2mnaSAk" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Stock based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,860,272&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,575,852&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--DeferredTaxAssetsInProcessResearchAndDevelopment_i01I_pp0p0_maDTANzRXI_z8nmJRJah3Jd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;R&amp;amp;D capitalized&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,467,969&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,171,276&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--DeferredTaxAssetsValuationAllowance_i01NI_pp0p0_di_msDTANzRXI_zPKEQEoQ3QMd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(69,643,154&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(60,637,938&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--DeferredTaxAssetsNet_i01TI_pp0p0_mtDTANzRXI_zH8YMZ7CdXEe" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Net deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1388"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1389"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001373"
      unitRef="USD">51429074</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001374"
      unitRef="USD">48080664</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001376"
      unitRef="USD">-114161</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001377"
      unitRef="USD">-189854</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001379"
      unitRef="USD">5860272</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001380"
      unitRef="USD">4575852</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001382"
      unitRef="USD">12467969</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001383"
      unitRef="USD">8171276</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001385"
      unitRef="USD">69643154</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001386"
      unitRef="USD">60637938</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001390"
      unitRef="USD">69600000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="AsOf2023-06-30"
      decimals="0"
      id="Fact001391"
      unitRef="USD">60600000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="From2023-07-01to2024-06-30"
      decimals="0"
      id="Fact001392"
      unitRef="USD">9000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="AsOf2024-06-30"
      decimals="0"
      id="Fact001394"
      unitRef="USD">184000000</us-gaap:OperatingLossCarryforwards>
    <bivi:ExpirationsDates contextRef="From2023-07-01to2024-06-30" id="Fact001396">2032 to 2037</bivi:ExpirationsDates>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001398">&lt;table cellpadding="0" cellspacing="0" id="xdx_89F_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_zCYnObkGJGza" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - Income Taxes (Details 1)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&lt;span id="xdx_8B1_zYNz8P5C7rqe" style="display: none"&gt;Schedule of effective income tax rate reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20230701__20240630_zk1mL1B9jQt2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49F_20220701__20230630_zWwzEFvfLif2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_dp_zqiRUeC8q535" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Income tax expense at federal statutory rate&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;21&lt;/td&gt;&lt;td style="white-space: nowrap; width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dp_zoVUd8Dkb00d" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;State taxes, net of federal benefit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_dp_zmTGy9d4mR3g" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(28&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; text-align: left"&gt;)%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_dp_z1RlQ5vwLO89" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 3.5pt"&gt;Effective tax rate&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1409"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 3.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 3.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 3.5pt double; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1410"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 3.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001400"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact001401"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001403"
      unitRef="Pure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact001404"
      unitRef="Pure">0.07</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2023-07-01to2024-06-30"
      decimals="INF"
      id="Fact001406"
      unitRef="Pure">-0.28</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="From2022-07-012023-06-30"
      decimals="INF"
      id="Fact001407"
      unitRef="Pure">-0.28</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2023-07-01to2024-06-30" id="Fact001412">&lt;p id="xdx_803_eus-gaap--SubsequentEventsTextBlock_zAWE7Lc3n62a" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 5%; font-size: 10pt"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/td&gt;
    &lt;td style="width: 95%; font-size: 10pt"&gt;&lt;b&gt;&lt;span id="xdx_822_zqES6tIa3ZV6"&gt;Subsequent Events&lt;/span&gt;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
  &lt;p id="xdx_ff" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 25, 2024, the Company closed a best
efforts public offering (the &#x201c;September 2024 Offering&#x201d;) of &lt;span id="xdx_90C_eus-gaap--CommonStockSharesIssued_c20240925_pdd" title="Common stock shares"&gt;1,360,800&lt;/span&gt;
shares of its common stock, par value $&lt;span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20240925_pdd" title="Common stock per value"&gt;0.0001&lt;/span&gt;
per share, pre-funded warrants (the &#x201c;September Pre-funded Warrants&#x201d;) to purchase &lt;span id="xdx_901_ecustom--PurchaseOfCommonStockShares_c20240925__us-gaap--StatementClassOfStockAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of shares"&gt;600,000&lt;/span&gt;
shares of Common Stock, and warrants to purchase up to &lt;span id="xdx_908_ecustom--PurchaseOfCommonStockShares_c20240925__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pdd" title="Purchase of shares"&gt;1,960,800&lt;/span&gt;
shares of Common Stock (the &#x201c;September Common Warrants&#x201d;) at a combined public offering price of $&lt;span id="xdx_901_eus-gaap--CommonStockParOrStatedValuePerShare_c20240925__us-gaap--StatementClassOfStockAxis__custom--CommonWarrantsMember_pdd" title="Common stock per value"&gt;1.53&lt;/span&gt;
per Share, or September Pre-funded Warrant, and the associated September Common Warrant. &lt;span style="background-color: white"&gt;The &lt;span style="background-color: white"&gt;September &lt;/span&gt;Common
Warrants have an exercise price of $&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240925_pdd" title="Warrants exercise price"&gt;1.53&lt;/span&gt;
per share and are immediately exercisable upon issuance and will expire on the fifth anniversary date of the original issuance date. &lt;/span&gt;The
gross proceeds to the Company from the September 2024 Offering were approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromIssuanceInitialPublicOffering_pp0n3_dm_c20240901__20240925_zY5EFVFcB3Q2" title="Proceeds from public offering"&gt;3.0&lt;/span&gt;
million, before deducting placement agent fees and offering expenses of approximately $&lt;span id="xdx_904_ecustom--AgentFeesAndOfferingExpenses_c20240901__20240925_pn3p0" title="Agent fees and offering expenses"&gt;560,000&lt;/span&gt;.
Additionally, upon closing the Company issued the placement agent warrants (&#x201c;September Placement Agent&#x2019;s
Warrants&#x201d;) to purchase &lt;span id="xdx_906_eus-gaap--TemporaryEquitySharesIssued_c20240925__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pdd" title="Warrant issued"&gt;98,040&lt;/span&gt;
shares of Common Stock exercisable at a per share price of $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20240925__us-gaap--AwardTypeAxis__custom--PlacementAgentsWarrantsMember_pdd" title="Warrants exercise price"&gt;1.91&lt;/span&gt;,
which was equal to 125% of the public offering price per share. The September Placement Agent&#x2019;s Warrants are exercisable
during a five-year period commencing 180 days from September 25, 2024.&#160;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="AsOf2024-09-25"
      decimals="INF"
      id="Fact001414"
      unitRef="Shares">1360800</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-25"
      decimals="INF"
      id="Fact001416"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <bivi:PurchaseOfCommonStockShares
      contextRef="AsOf2024-09-25_custom_PrefundedWarrantsMember"
      decimals="INF"
      id="Fact001418"
      unitRef="Shares">600000</bivi:PurchaseOfCommonStockShares>
    <bivi:PurchaseOfCommonStockShares
      contextRef="AsOf2024-09-25_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact001420"
      unitRef="Shares">1960800</bivi:PurchaseOfCommonStockShares>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2024-09-25_custom_CommonWarrantsMember"
      decimals="INF"
      id="Fact001422"
      unitRef="USDPShares">1.53</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-25"
      decimals="INF"
      id="Fact001424"
      unitRef="USDPShares">1.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="From2024-09-012024-09-25"
      decimals="0"
      id="Fact001426"
      unitRef="USD">3000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <bivi:AgentFeesAndOfferingExpenses
      contextRef="From2024-09-012024-09-25"
      decimals="-3"
      id="Fact001428"
      unitRef="USD">560000</bivi:AgentFeesAndOfferingExpenses>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="AsOf2024-09-25_custom_PlacementAgentsWarrantsMember"
      decimals="INF"
      id="Fact001430"
      unitRef="Shares">98040</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2024-09-25_custom_PlacementAgentsWarrantsMember"
      decimals="INF"
      id="Fact001432"
      unitRef="USDPShares">1.91</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
